PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hunter, DJ; Spiegelman, D; Adami, HO; Beeson, L; vandenBrandt, PA; Folsom, AR; Fraser, GE; Goldbohm, RA; Graham, S; Howe, GR; Kushi, LH; Marshall, JR; McDermott, A; Miller, AB; Speizer, FE; Wolk, A; Yaun, SS; Willett, W				Hunter, DJ; Spiegelman, D; Adami, HO; Beeson, L; vandenBrandt, PA; Folsom, AR; Fraser, GE; Goldbohm, RA; Graham, S; Howe, GR; Kushi, LH; Marshall, JR; McDermott, A; Miller, AB; Speizer, FE; Wolk, A; Yaun, SS; Willett, W			Cohort studies of fat intake and the risk of breast cancer - A pooled analysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; TOTAL ENERGY-INTAKE; DIETARY-FAT; EPIDEMIOLOGIC ANALYSES; CONFIDENCE-INTERVALS; DIFFERENT COUNTRIES; DISEASE PREVENTION; MEASUREMENT ERROR; FOLLOW-UP; REPRODUCIBILITY	Background. Experiments in animals, international correlation comparisons, and case-control studies support an association between dietary fat intake and the incidence of breast cancer. Most cohort studies do not corroborate the association, but they have been criticized for involving small numbers of cases, homogeneous fat intake, and measurement errors in estimates of fat intake. Methods. We identified seven prospective studies in four countries that met specific criteria and analyzed the primary data in a standardized manner. Pooled estimates of the relation of fat intake to the risk of breast cancer were calculated, and data from study-specific validation studies were used to adjust the results for measurement error. Results. Information about 4980 cases from studies including 337,819 women was available. When women in the highest quintile of energy-adjusted total fat intake were compared with women in the lowest quintile, the multivariate pooled relative risk of breast cancer was 1.05 (95 percent confidence interval, 0.94 to 1.16). Relative risks for saturated, monounsaturated, and polyunsaturated fat and for cholesterol, considered individually, were also close to unity. There was little overall association between the percentage of energy intake from fat and the risk of breast cancer, even among women whose energy intake from fat was less than 20 percent. Correcting for error in the measurement of nutrient intake did not materially alter these findings. Conclusions. We found no evidence of a positive association between total dietary fat intake and the risk of breast cancer. There was no reduction in risk even among women whose energy intake from fat was less than 20 percent of total energy intake. in the context of the Western lifestyle, lowering the total intake of fat in midlife is unlikely to reduce the risk of breast cancer substantially.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CTR CANC PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; LOMA LINDA UNIV, SCH MED, CTR HLTH RES, LOMA LINDA, CA USA; UNIV TORONTO, FAC MED, DEPT PREVENT MED & BIOSTAT, TORONTO, ON, CANADA; UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN USA; UNIV LIMBURG, DEPT EPIDEMIOL, 6200 MD MAASTRICHT, NETHERLANDS; TNO, FOOD & NUTR RES INST, DEPT NUTR, 3700 AJ ZEIST, NETHERLANDS; SUNY BUFFALO, DEPT SOCIAL & PREVENT MED, BUFFALO, NY USA; UNIV UPPSALA HOSP, DEPT CANC EPIDEMIOL, UPPSALA, SWEDEN	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Loma Linda University; University of Toronto; University of Minnesota System; University of Minnesota Twin Cities; Hasselt University; Netherlands Organization Applied Science Research; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Uppsala University; Uppsala University Hospital	Hunter, DJ (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.			Kushi, Lawrence/0000-0001-9136-1175; van den Brandt, Piet/0000-0001-8781-8099	NCI NIH HHS [CA55075, CA50597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075, R01CA050597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBEY DE, 1988, AM J EPIDEMIOL, V128, P934; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BEESON WL, 1989, CANCER, V64, P570, DOI 10.1002/1097-0142(19890801)64:3<570::AID-CNCR2820640303>3.0.CO;2-4; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; Byrne C., 1992, American Journal of Epidemiology, V136, P1024; COHEN LA, 1990, MED HYPOTHESES, V31, P83, DOI 10.1016/0306-9877(90)90002-V; COX DR, 1972, J R STAT SOC B, V34, P187; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Feskanich Diane, 1994, Annals of Epidemiology, V4, P181, DOI 10.1016/1047-2797(94)90095-7; FREEDMAN LS, 1993, J NATL CANCER I, V85, P764, DOI 10.1093/jnci/85.10.764; FRIEDENREICH CM, 1991, EPIDEMIOLOGY, V2, P424, DOI 10.1097/00001648-199111000-00006; GAARD M, 1994, CANCER CAUSE CONTROL, V5, P501, DOI 10.1007/BF01831377; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; GRAHAM S, 1992, AM J EPIDEMIOL, V136, P1327, DOI 10.1093/oxfordjournals.aje.a116445; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; HIATT RA, 1982, J NATL CANCER I, V68, P885; HOLMBERG L, 1994, ARCH INTERN MED, V154, P1805, DOI 10.1001/archinte.154.16.1805; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HOWE GR, 1986, AM J EPIDEMIOL, V124, P157, DOI 10.1093/oxfordjournals.aje.a114365; HOWE GR, 1994, CANCER, V74, P1078, DOI 10.1002/1097-0142(19940801)74:3+<1078::AID-CNCR2820741516>3.0.CO;2-H; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KAAKS R, 1994, AM J CLIN NUTR, V59, p245S, DOI 10.1093/ajcn/59.1.245S; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; LANGHOLZ B, 1990, AM J EPIDEMIOL, V131, P169, DOI 10.1093/oxfordjournals.aje.a115471; MARSHALL JR, 1992, EUR J CANCER, V28A, P1720, DOI 10.1016/0959-8049(92)90077-F; MCMICHAEL AJ, 1988, CANCER RES, V48, P751; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MUIR CS, 1987, IARC SCI PUBLICATION, V88; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Tannenbaum A, 1942, CANCER RES, V12, P468; TONIOLO P, 1994, EPIDEMIOLOGY, V5, P391, DOI 10.1097/00001648-199407000-00003; VANDENBRANDT PA, 1993, CANCER RES, V53, P75; WACHOLDER S, 1993, AM J EPIDEMIOL, V137, P1251, DOI 10.1093/oxfordjournals.aje.a116627; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1990, CANCER CAUSE CONTROL, V1, P103, DOI 10.1007/BF00053190; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WYNDER EL, 1994, J CLIN EPIDEMIOL, V47, P217, DOI 10.1016/0895-4356(94)90001-9; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263; 1991, SAS STAT SOFTWARE PH; 1993, EPICURE USERS GUIDE	55	480	487	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					356	361		10.1056/NEJM199602083340603	http://dx.doi.org/10.1056/NEJM199602083340603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538706	Green Published, Bronze			2022-12-28	WOS:A1996TT48700003
J	Rosenberg, SA				Rosenberg, SA			Secrecy in medical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Rosenberg, SA (corresponding author), NCI,BETHESDA,MD 20892, USA.							Blumenthal D, 1996, NEW ENGL J MED, V334, P368, DOI 10.1056/NEJM199602083340606; HAGGARD HW, 1929, DEVILS DRUGS DOCTORS, P49	2	57	58	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					392	394		10.1056/NEJM199602083340610	http://dx.doi.org/10.1056/NEJM199602083340610			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538713				2022-12-28	WOS:A1996TT48700010
J	Lamberts, SWJ; vanderLely, AJ; deHerder, WW; Hofland, LJ				Lamberts, SWJ; vanderLely, AJ; deHerder, WW; Hofland, LJ			Drug therapy - Octreotide	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANALOG SMS 201-995; GROWTH-HORMONE SECRETION; ACTING SOMATOSTATIN ANALOG; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; FUNCTIONAL-CHARACTERIZATION; ACROMEGALIC PATIENTS; MOLECULAR-CLONING; DOUBLE-BLIND; RECEPTORS		ERASMUS UNIV ROTTERDAM,DEPT MED,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			de+Herder, Wouter/AAN-8429-2021					AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; BASSI C, 1994, DIGESTION, V55, P41, DOI 10.1159/000201188; BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BINMOELLER KF, 1992, GUT, V33, P1129, DOI 10.1136/gut.33.8.1129; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BRUNS C, 1994, ANN NY ACAD SCI, V733, P138, DOI 10.1111/j.1749-6632.1994.tb17263.x; BUCHLER M, 1992, AM J SURG, V163, P125, DOI 10.1016/0002-9610(92)90264-R; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CELLO JP, 1991, ANN INTERN MED, V115, P705, DOI 10.7326/0003-4819-115-9-705; CHANSON P, 1993, ANN INTERN MED, V119, P236, DOI 10.7326/0003-4819-119-3-199308010-00010; CHRISTIANSEN J, 1989, GASTROENTEROLOGY, V97, P568, DOI 10.1016/0016-5085(89)90626-4; CREUTZFELDT W, 1987, AM J MED, V82, P49, DOI 10.1016/0002-9343(87)90426-8; DEBRUIN TWA, 1992, J CLIN ENDOCR METAB, V75, P1310, DOI 10.1210/jc.75.5.1310; DEHERDER WW, 1994, AM J MED, V96, P305, DOI 10.1016/0002-9343(94)90059-0; DELVALLE J, 1990, ANNU REV MED, V41, P447; DOWLING RH, 1992, METABOLISM, V41, P22, DOI 10.1016/0026-0495(92)90027-8; EZZAT S, 1992, ANN INTERN MED, V117, P711, DOI 10.7326/0003-4819-117-9-711; GREENMAN Y, 1994, J CLIN ENDOCR METAB, V78, P398, DOI 10.1210/jc.78.2.398; GREENMAN Y, 1994, J CLIN ENDOCR METAB, V79, P724, DOI 10.1210/jc.79.3.724; GUILLEMIN R, 1978, SCIENCE, V202, P390, DOI 10.1126/science.212832; HARRIS AG, 1992, DRUG INVEST, V4, P1; HERON I, 1993, J CLIN ENDOCR METAB, V76, P721, DOI 10.1210/jc.76.3.721; HOFLAND LJ, 1994, ENDOCRINOLOGY, V134, P301, DOI 10.1210/en.134.1.301; HOFLAND LJ, 1992, ENDOCRINOLOGY, V131, P571, DOI 10.1210/en.131.2.571; KAUPMANN K, 1993, FEBS LETT, V331, P53, DOI 10.1016/0014-5793(93)80296-7; KRENNING EP, 1989, LANCET, V1, P242; KRULICH L, 1968, ENDOCRINOLOGY, V83, P783, DOI 10.1210/endo-83-4-783; KUBOTA A, 1994, J CLIN INVEST, V93, P1321, DOI 10.1172/JCI117090; KVOLS LK, 1987, ANN INTERN MED, V107, P162, DOI 10.7326/0003-4819-107-2-162; KVOLS LK, 1994, ANN NY ACAD SCI, V733, P464, DOI 10.1111/j.1749-6632.1994.tb17296.x; KVOLS LK, 1986, NEW ENGL J MED, V315, P663, DOI 10.1056/NEJM198609113151102; LAMBERTS SWJ, 1985, J CLIN ENDOCR METAB, V60, P1161, DOI 10.1210/jcem-60-6-1161; LAMBERTS SWJ, 1988, ENDOCR REV, V9, P417, DOI 10.1210/edrv-9-4-417; LAMBERTS SWJ, 1985, NEW ENGL J MED, V313, P1576, DOI 10.1056/NEJM198512193132504; LAMBERTS SWJ, 1986, CLIN ENDOCRINOL, V25, P201, DOI 10.1111/j.1365-2265.1986.tb01683.x; LAMBERTS SWJ, 1988, ACTA ENDOCRINOL-COP, V119, P561, DOI 10.1530/acta.0.1190561; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LAMBERTS SWJ, 1988, CLIN ENDOCRINOL, V29, P411, DOI 10.1111/j.1365-2265.1988.tb02890.x; LAMBERTS SWJ, 1986, J CLIN ENDOCR METAB, V63, P16, DOI 10.1210/jcem-63-1-16; LANCRANJAN I, 1995, METABOLISM, V44, P18, DOI 10.1016/0026-0495(95)90306-2; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P20032; LONDONG W, 1989, GASTROENTEROLOGY, V96, P713; MCKAY CJ, 1993, GUT, V34, P1622, DOI 10.1136/gut.34.11.1622; OCARROLL AM, 1994, MOL PHARMACOL, V46, P291; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; OCARROLL AM, 1993, MOL PHARMACOL, V44, P1278; PANETTA R, 1994, MOL PHARMACOL, V45, P417; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; PATEL YC, 1990, METABOLISM, V39, P63, DOI 10.1016/0026-0495(90)90214-W; PATEL YC, 1994, ENDOCRINOLOGY, V135, P2814, DOI 10.1210/en.135.6.2814; PATEL YC, 1992, BASIC CLIN ASPECTS N, V4; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; REUBI JC, 1993, BLOOD, V82, P2143; REUBI JC, 1989, J CLIN ENDOCR METAB, V68, P844, DOI 10.1210/jcem-68-4-844; REUBI JC, 1994, CANCER RES, V54, P3455; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; REUBI JC, 1990, CANCER RES, V50, P5969; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; ROSSOWSKI WJ, 1994, BIOCHEM BIOPH RES CO, V205, P341, DOI 10.1006/bbrc.1994.2670; SCHALLY AV, 1988, CANCER RES, V48, P6977; SCHALLY AV, 1989, CANCER RES, V49, P1618; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; VALENZUELA JE, 1989, HEPATOLOGY, V10, P958, DOI 10.1002/hep.1840100611; VANDERLELY AJ, 1992, CLIN ENDOCRINOL, V37, P181; WAGENAAR AH, 1991, ACTA ENDOCRINOL-COP, V125, P637, DOI 10.1530/acta.0.1250637; WARNET A, 1989, J NEUROSURG, V71, P687, DOI 10.3171/jns.1989.71.5.0687; WYNICK D, 1989, CLIN ENDOCRINOL, V30, P385, DOI 10.1111/j.1365-2265.1989.tb00436.x; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422; 1994, AM J MED, V97, P468; 1986, AM J MED, V81, P1	79	888	936	0	41	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					246	254		10.1056/NEJM199601253340408	http://dx.doi.org/10.1056/NEJM199601253340408			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532003	Green Published			2022-12-28	WOS:A1996TQ75500008
J	Reimold, AM; Grusby, MJ; Kosaras, B; Fries, JWU; Mori, R; Maniwa, S; Clauss, IM; Collins, T; Sidman, RL; Glimcher, MJ; Glimcher, LH				Reimold, AM; Grusby, MJ; Kosaras, B; Fries, JWU; Mori, R; Maniwa, S; Clauss, IM; Collins, T; Sidman, RL; Glimcher, MJ; Glimcher, LH			Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice	NATURE			English	Article							AMP RESPONSE ELEMENT; NF-KAPPA-B; CYCLIC-AMP; E-SELECTIN; BINDING PROTEIN; C-FOS; GENE; TRANSCRIPTION; EXPRESSION; ACTIVATION	ACTIVATING transcription factor-2 (ATF-2) is a basic region leucine zipper protein whose DNA target sequence is the widely distributed cAMP response element (CRE). We report here that mice carrying a germline mutation in ATF-2 demonstrated unique actions of ATF-2 not duplicated by other ATF/CREB family members. Mutant mice had decreased postnatal viability and growth, with a defect in endochondral ossification at epiphyseal plates similar to human hypochondroplasia. The animals had ataxic gait, hyperactivity and decreased hearing. In the brain, there were reduced numbers of cerebellar Purkinje cells, atrophic vestibular sense organs and enlarged ventricles. Unlike CREB alpha/delta-deficient mice whose main defect is in longterm potentiation, the widespread abnormalities in ATF-2 mutant mice demonstrate its absolute requirement for skeletal and central nervous system development, and for maximal induction of select genes with CRE sites, such as E-selectin.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,DIV NEUROGENET,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,VASC RES DIV,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ORTHOPAED SURG,LAB STUDY SKELETAL DISORDERS & REHABIL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Reimold, AM (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Fries, Jochen/AAM-5999-2020	Fries, Jochen/0000-0003-2054-6345				BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRIES JWU, 1993, AM J PATHOL, V143, P725; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hayat MA, 1989, PRINCIPLES TECHNIQUE; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEMERRER M, 1994, NAT GENET, V6, P318; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MATSUURA S, 1990, BIOCHEM BIOPH RES CO, V168, P993, DOI 10.1016/0006-291X(90)91127-E; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAKEDA J, 1991, ONCOGENE, V6, P1009; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	29	236	246	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					262	265		10.1038/379262a0	http://dx.doi.org/10.1038/379262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538792				2022-12-28	WOS:A1996TQ16900048
J	Zuddas, A; Cianchetti, C				Zuddas, A; Cianchetti, C			Efficacy of risperidone in idiopathic segmental dystonia	LANCET			English	Letter											Zuddas, A (corresponding author), UNIV CAGLIARI,DEPT NEUROSCI,VIA OSPED 119,I-09124 CAGLIARI,ITALY.		Cianchetti, Carlo/ABD-9536-2021					ADITYANJEE, 1993, AM J PSYCHIAT, V150, P837; FERRE S, 1994, J NEUROSCI, V14, P4839; Lang A E, 1988, Adv Neurol, V50, P561; LIVINGSTON MG, 1994, LANCET, V343, P457, DOI 10.1016/S0140-6736(94)92696-4; TSUI JKC, 1986, LANCET, V2, P245	5	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					127	128		10.1016/S0140-6736(96)90257-3	http://dx.doi.org/10.1016/S0140-6736(96)90257-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538330				2022-12-28	WOS:A1996TP28100062
J	Mande, SC; Mehra, V; Bloom, BR; Hol, WGJ				Mande, SC; Mehra, V; Bloom, BR; Hol, WGJ			Structure of the heat shock protein chaperonin-10 of Mycobacterium leprae	SCIENCE			English	Article							GROES; BINDING; MODELS; CYCLE	Members of the chaperonin-10 (cpn10) protein family, also called heat shock protein 10 and in Escherichia coli GroES, play an important role in ensuring the proper folding of many proteins. The crystal structure of the Mycobacterium leprae cpn10 (MI-cpn10) oligomer has been elucidated at a resolution of 3.5 angstroms. The architecture of the MI-cpn10 heptamer resembles a dome with an oculus in its roof. The inner surface of the dome is hydrophilic and highly charged. A flexible region, known to interact with cpn60, extends from the lower rim of the dome. With the structure of a cpn10 heptamer now revealed and the structure of the E. coli GroEL previously known, models of cpn10:cpn60 and GroEL:GroES complexes are proposed.	UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,BIOMOLEC STRUCT CTR,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL & IMMUNOL,SEATTLE,WA 98195; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Mande, Shekhar/C-2136-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023545, R01AI023545] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23545, AI07118] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BOOM BR, 1992, SCIENCE, V257, P105; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, X PLOR USER MANUAL; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; COWTAN K, 1994, NEWSLETTER PROTEIN C, V31, P34; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FOSSATI G, 1995, J BIOL CHEM, V270, P26159, DOI 10.1074/jbc.270.44.26159; HARRIS JR, 1995, J STRUCT BIOL, V115, P68, DOI 10.1006/jsbi.1995.1031; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HUGHES AL, 1993, MOL BIOL EVOL, V10, P1343; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM J, UNPUB; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MAYERHARTL MK, 1995, SCIENCE, V269, P836; MEHRA V, 1992, J EXP MED, V175, P275, DOI 10.1084/jem.175.1.275; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURRAY CJL, 1994, GLOBAL COMP ASSESSME, P54; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	40	127	129	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					203	207		10.1126/science.271.5246.203	http://dx.doi.org/10.1126/science.271.5246.203			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539620				2022-12-28	WOS:A1996TP36400042
J	Shakhnovich, E; Abkevich, V; Ptitsyn, O				Shakhnovich, E; Abkevich, V; Ptitsyn, O			Conserved residues and the mechanism of protein folding	NATURE			English	Article							CHYMOTRYPSIN INHIBITOR-2; 3-DIMENSIONAL STRUCTURE; TRANSITION; SEQUENCES	EXPERIMENTAL(1-6) and simulation(7) studies show that small monomeric proteins fold in one kinetic step, which entails overcoming the free-energy barrier between the unfolded and the native protein through a transition state(8,9). Two models of transition state formation have been proposed: a 'nonspecific' one in which it depends on the formation of a sufficient number of native-like contacts regardless of what amino acids are involved(10-12) and a 'specific' one, in which it depends on formation of a specific subset of the native structure (a folding nucleus)(8,13,14). The latter requires that some amino acids form most of their contacts in the transition state, whereas others only do so on reaching the native conformation. If so, mutations affecting the stability of the transition state nucleus should have a greater effect on the folding kinetics than mutations elsewhere, and the residues involved should be evolutionarily conserved. Lattice-model simulations and experiments(8,13-16) suggest that such mutations exist. Here we present a method for determining the folding nucleus of a protein with known structure with two-state folding kinetics. This method is based on the alignment of many sequences designed to fold into the native conformation of a protein to identify the positions where amino acids are most conserved in designed sequences. The method is applied to chymotrypsin inhibitor 2 (CI2), a protein whose transition state has been previously studied by protein engineering(14-16). The involvement of residues in folding nucleus of CI2 is clearly correlated with their conservation in design, and the residues forming the nucleus are highly conserved in 23 natural sequences homologous to CI2.	RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,RUSSIA; NCI,MOLEC STRUCT SECT,LMMB,BETHESDA,MD	Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shakhnovich, E (corresponding author), HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138, USA.							ABKEVICH VI, 1994, J CHEM PHYS, V101, P6052, DOI 10.1063/1.467320; ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P7243, DOI 10.1021/bi00147a006; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P4918, DOI 10.1073/pnas.89.11.4918; GUO Z, 1995, BIOPOLYMERS, V35, P137; GUTIN AM, 1995, BIOCHEMISTRY-US, V34, P3066, DOI 10.1021/bi00009a038; GUTIN AM, 1995, P NATL ACAD SCI USA, V92, P1282, DOI 10.1073/pnas.92.5.1282; HAO MH, 1995, J CHEM PHYS, V102, P1334, DOI 10.1063/1.468920; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KOLINSKI A, 1993, J CHEM PHYS, V98, P7420, DOI 10.1063/1.464706; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MYAZAWA S, 1985, MACROMOLECULES, V18, P534; OLTSEN DE, 1994, P NATL ACAD SCI USA, V91, P10422; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SHAKHNOVICH E, 1991, PHYS REV LETT, V67, P1665, DOI 10.1103/PhysRevLett.67.1665; SHAKHNOVICH EI, 1993, PROTEIN ENG, V6, P793, DOI 10.1093/protein/6.8.793; SHAKHNOVICH EI, 1993, P NATL ACAD SCI USA, V90, P7195, DOI 10.1073/pnas.90.15.7195; SHAKHNOVICH EI, 1994, PHYS REV LETT, V72, P3907, DOI 10.1103/PhysRevLett.72.3907; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; [No title captured]	31	310	314	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					96	98		10.1038/379096a0	http://dx.doi.org/10.1038/379096a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538750				2022-12-28	WOS:A1996TN21600064
J	Cooper, BG; Matthews, JNS; Alberti, KGMM				Cooper, BG; Matthews, JNS; Alberti, KGMM			Resting energy expenditure, substrate use, and video tapes	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the effect of watching different types of video on energy expenditure. Design-Randomised study assessing ''pleasant,'' an ''amusing,'' an ''exciting,'' and no video film clips. Subjects-12 volunteers who did not know the purpose of the study. Main outcome measures-Changes in energy expenditure, substrate use, heart rate, and aural temperature during each film clip. Results-Energy expenditure was raised slightly (0 . 21 kJ/day) during the ''exciting'' film, Individual responses varied greatly. Conclusion-Watching different types of video seems to have little effect on resting metabolic rate.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK			Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Cooper, Brendan/0000-0003-0785-1038				CONSOLAZIO CF, 1963, PHYSL MEASUREMENTS M, P1; COOPER BG, 1991, CLIN PHYS PHYSIOL M, V12, P333, DOI 10.1088/0143-0815/12/4/003	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1664	1665		10.1136/bmj.311.7021.1664	http://dx.doi.org/10.1136/bmj.311.7021.1664			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541750	Green Published			2022-12-28	WOS:A1995TL94200009
J	SRIVASTAVA, D; CSERJESI, P; OLSON, EN				SRIVASTAVA, D; CSERJESI, P; OLSON, EN			A SUBCLASS OF BHLH PROTEINS REQUIRED FOR CARDIAC MORPHOGENESIS	SCIENCE			English	Article							LOOP-HELIX PROTEINS; MUSCLE TRANSCRIPTION; GENE-EXPRESSION; HEART; MYOCYTES	Skeletal muscle development is controlled by a family of muscle-specific basic helix-loop-helix (bHLH) transcription factors. Two bHLH genes, dHAND and eHAND, have now been isolated that are expressed in the bilateral heart primordia and subsequently throughout the primitive tubular heart and its derivatives during chick and mouse embryogenesis. Incubation of stage 8 chick embryos with dHAND and eHAND antisense oligonucleotides revealed that either oligonucleotide alone had no effect on embryonic development, whereas together they arrested development at the looping heart tube stage. Thus, dHAND and eHAND may play redundant roles in the regulation of the morphogenetic events of vertebrate heart development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARTH J, 1994, BIOTECHNIQUES, V17, P324; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EVANS SM, 1993, DEV BIOL, V159, P485, DOI 10.1006/dbio.1993.1258; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KIRBY ML, 1990, CIRCULATION, V83, P332; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27, DOI 10.1016/1050-1738(92)90041-P; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAYNE RM, 1995, CIRCULATION, V91, P494, DOI 10.1161/01.CIR.91.2.494; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RUDNICKI MA, 1985, BIOESSAYS, V17, P203; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHOENWOLF GC, 1989, LABORATORY STUDIES C; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SRIVASTAVA DK, UNPUB, P42502; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V142, P363; YOSH WJ, 1995, CELL, V82, P689; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	43	437	447	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1995	1999		10.1126/science.270.5244.1995	http://dx.doi.org/10.1126/science.270.5244.1995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533092				2022-12-28	WOS:A1995TL42000043
J	SCHALLER, GE; BLEECKER, AB				SCHALLER, GE; BLEECKER, AB			ETHYLENE-BINDING SITES GENERATED IN YEAST EXPRESSING THE ARABIDOPSIS ETR1 GENE	SCIENCE			English	Article							THALIANA	Mutations in the ETR1 gene of Arabidopsis thaliana confer insensitivity to ethylene, which indicates a role for the gene product in ethylene signal transduction. Saturable binding sites for [C-14]ethylene were detected in transgenic yeast expressing the ETR1 protein, whereas control yeast lacking ETR1 showed no detectable ethylene binding. Yeast expressing a mutant form of ETR1 (etr1-1) also showed no detectable ethylene binding, which provides an explanation for the ethylene-insensitive phenotype observed in plants carrying this mutation. Expression of truncated forms of ETR1 in yeast provided evidence that the amino-terminal hydrophobic domain of the protein is the site of ethylene binding. It was concluded from these results that ETR1 acts as an ethylene receptor in Arabidopsis.	UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								Abeles F, 1992, ETHYLENE PLANT BIOL; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; COLLMAN JP, 1967, PRINCIPLES APPLICATI; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SANDERS IO, 1991, ANN BOT-LONDON, V68, P97, DOI 10.1093/oxfordjournals.aob.a088242; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SISLER EC, 1979, PLANT PHYSIOL, V64, P538, DOI 10.1104/pp.64.4.538; SISLER EC, 1990, PLANT GROWTH REGUL, V9, P157, DOI 10.1007/BF00027443; SISLER EC, 1991, PLANT HORMONE ETHYLE, P81; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	19	444	488	6	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1809	1811		10.1126/science.270.5243.1809	http://dx.doi.org/10.1126/science.270.5243.1809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525372				2022-12-28	WOS:A1995TK47600042
J	TSUKIYAMA, T; WU, C				TSUKIYAMA, T; WU, C			PURIFICATION AND PROPERTIES OF AN ATP-DEPENDENT NUCLEOSOME REMODELING FACTOR	CELL			English	Article							HEAT-SHOCK GENES; HYPERSENSITIVE SITES; DROSOPHILA EMBRYOS; HISTONE OCTAMER; DNASE-I; CHROMATIN; TRANSCRIPTION; PROTEIN; INVITRO; RESOLUTION	We report the purification of an ATP-dependent nucleosome remodeling factor (NURF) from Drosophila embryo extracts. NURF is composed of at least four polypeptides that act in concert with the GAGA transcription factor to alter chromatin structure at the hsp70 promoter. The energy requirement is attributed to an ATPase activity that is stimulated by nucleosomes but not by free DNA or histones, suggesting that NURF acts directly on a nucleosome to perturb its structure. This finding and the physical properties of NURF contrast sharply with the multisubunit SW12/SNF2 complex, which has also been shown to alter nucleosomes in an ATP-dependent manner. The results suggest that two distinct systems may be involved in remodeling chromatin for transcription.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COSTLOW N, 1984, MOL CELL BIOL, V4, P1853, DOI 10.1128/MCB.4.9.1853; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KORNBERG RD, 1995, ANN REV CELL BIOL, V7, P371; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; NEUBAUER B, 1989, METHOD ENZYMOL, V170, P630; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; van Holde KE., 1989, SPRINGER SERIES MOL; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441	45	508	518	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1011	1020		10.1016/0092-8674(95)90216-3	http://dx.doi.org/10.1016/0092-8674(95)90216-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521501	Bronze			2022-12-28	WOS:A1995TK74500019
J	MACKIE, MA; DAVIDSON, J				MACKIE, MA; DAVIDSON, J			PRESCRIBING OF QUININE AND CRAMP INDUCING DRUGS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							MUSCLE		GLASGOW ROYAL INFIRM,DEPT CLIN PHARMACOL,GLASGOW G4 0SF,LANARK,SCOTLAND	University of Glasgow	MACKIE, MA (corresponding author), GLASGOW ROYAL INFIRM,DEPT MED PRESCRIBING,GLASGOW G4 0SF,LANARK,SCOTLAND.							BATEMAN DN, 1986, ADVERSE DRUG REACT, V4, P215; EATON JM, 1989, POSTGRAD MED, V86, P227; MANSONHING M, 1995, BMJ-BRIT MED J, V310, P13, DOI 10.1136/bmj.310.6971.13; MCGEE SR, 1990, ARCH INTERN MED, V150, P511, DOI 10.1001/archinte.150.3.511	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1541	1541		10.1136/bmj.311.7019.1541	http://dx.doi.org/10.1136/bmj.311.7019.1541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520397	Green Published			2022-12-28	WOS:A1995TK21400025
J	FENTON, B; GLOVER, DM				FENTON, B; GLOVER, DM			A CONSERVED MITOTIC KINASE ACTIVE AT LATE ANAPHASE TELOPHASE IN SYNCYTIAL DROSOPHILA EMBRYOS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; POLO	MUTATIONS in the Drosophila gene polo cause abnormal mitotic and meiotic divisions1,2. This gene encodes a 577-amino-acid protein that has an N-terminal putative kinase domain and a 300-residue C-terminal domain2. In budding yeast, a homologous kinase is encoded by CDC5 (ref. 3), a gene required for nuclear division late in the mitotic cycle4 and during meiosis5. Murine homologues have also been described6,7. Here we show that the polo gene product immunoprecipitated from extracts of single Drosophila embryos can phosphorylate casein in vitro, and that the kinase activity peaks cyclically at late anaphase/telophase. This contrasts with the cyclical activity of cyclin B-associated p34cdc2 kinase, which is maximal upon entry into mitosis during the rapid cycles of mitosis in the syncytium.	UNIV DUNDEE, INST MED SCI,DEPT ANAT & PHYSIOL, CANC RES CAMPAIGN,CELL CYCLE GENET GRP, DUNDEE DD1 4HN, SCOTLAND	University of Dundee				Glover, David/0000-0003-0956-0103				BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLAY F, IN PRESS P NATN ACAD; FOE VE, 1983, J CELL SCI, V61, P31; FRASCH M, 1986, J CELL SCI, V82, P155; GONZALEZ C, 1993, CELL CYCLE PRACTICAL; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; KITADA K, IN PRESS MOL CELL BI; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MALDONADOCODINA G, 1992, J CELL BIOL, V116, P967, DOI 10.1083/jcb.116.4.967; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; SCHILD D, 1980, GENETICS, V96, P859; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SUNKEL CE, 1988, J CELL SCI, V89, P25; WHITFIELD WGF, 1988, J CELL SCI, V89, P467; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	17	115	121	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1993	363	6430					637	640		10.1038/363637a0	http://dx.doi.org/10.1038/363637a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510757				2022-12-28	WOS:A1993LH13900059
J	GARDOSI, J; MONGELLI, M				GARDOSI, J; MONGELLI, M			RISK ASSESSMENT ADJUSTED FOR GESTATIONAL-AGE IN MATERNAL SERUM SCREENING FOR DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							LAST MENSTRUAL PERIOD; ULTRASOUND; PREGNANCY	Objective-To investigate the relation between errors in calculation of gestational age and assessment of risk of Down's syndrome and to analyse the implications for screening programmes. Design-Retrospective analysis of dating of gestational age by menstrual history v ultrasound scan. Computer program with maternal age and concentrations of alpha fetoprotein and free beta human chorionic gonadotrophin to calculate risk for a range of expected dates of delivery. Computer simulated prospective application of new screening programme. Setting-Teaching hospitals in Nottingham. Subjects-31561 women with singleton pregnancies with gestational age based on routine ultrasound scan. Computer simulation of 20000 women in three age ranges (up to 37; up to 40; all). Main outcome measures-Distribution of error between gestational age based on ultrasound scan v menstrual history. Proportion of women in the population who require precise dating of pregnancy; proportion of women who require amniocentesis. Results-With gestational age derived from ultrasound scan as reference the 95% confidence interval for gestational age by menstrual history was -27 to +9 days. A screening programme for Down's syndrome for women up to age 40 would yield a low risk (<1:250) for this range of days in 86.0% of cases. The 14.0% of women remaining would have one or more high risk values in their report and would thus require an ultrasound scan for precise dating of the pregnancy; 30% of these-that is, 3.7% of the screened population-would be identified as high risk and require consideration for amniocentesis. Conclusions-Screening programmes for Down's syndrome require the facility for precise dating of pregnancy to improve the accuracy of risk assessment. This can be achieved without introducing additional scans for early dating in the whole population but by selecting only those cases (about 14%) when an error in dates is likely to affect the risk of Down's syndrome.			GARDOSI, J (corresponding author), QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND.		Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; CUCKLE H, 1992, BRIT MED J, V305, P1504, DOI 10.1136/bmj.305.6867.1504; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; GEIRSSON RT, 1991, ULTRASOUND OBST GYN, V1, P212, DOI 10.1046/j.1469-0705.1991.01030212.x; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1992, ANN CLIN BIOCHEM, V29, P390, DOI 10.1177/000456329202900403; REYNOLDS TM, 1992, AM J OBSTET GYNECOL, V166, P872, DOI 10.1016/0002-9378(92)91353-C; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; von Neumann J., 1951, MONTE CARLO METHODS, V12, P36; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALDENSTROM U, 1990, OBSTET GYNECOL, V76, P336; WICHMANN BA, 1982, APPLIED STATISTICS, V31, P188; 1988, STATISTICAL PACKAGE	18	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1509	1511		10.1136/bmj.306.6891.1509	http://dx.doi.org/10.1136/bmj.306.6891.1509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518678	Bronze, Green Published			2022-12-28	WOS:A1993LF94000024
J	Eck, MJ; Pluskey, S; Trub, T; Harrison, SC; Shoelson, SE				Eck, MJ; Pluskey, S; Trub, T; Harrison, SC; Shoelson, SE			Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2	NATURE			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR RECEPTOR-BETA; TYROSINE PHOSPHORYLATION; PROTEIN MODELS; ASSOCIATION; ACTIVATION; SUBUNIT; SYP	THE domain organization of many signalling proteins facilitates a segregation of binding, catalytic and regulatory functions(1,2). The mammalian SH2 domain protein tyrosine phosphatases (PTPs) contain tandem SH2 domains and a single carboxy-terminal catalytic domain(3). SH-PTP1 (PTP1C, HCP) and SH-PTP2 (Syp, PTP2C, PTP1D) function downstream from tyrosine kinase-linked insulin, growth factor, cytokine and antigen receptors(4-12). As well as directing subcellular localization by binding to receptors and their substrates, the two SH2 domains of these PTPs function together to regulate catalysis(7,13,14). Here we report the structure of the tandem SH2 domains of SH-PTP2 in complex with monophosphopeptides. A fixed relative orientation of the two domains, stabilized by a disulphide bond and a small hydrophobic patch within the interface, separates the peptide binding sites by similar to 40 Angstrom. The defined orientation of the SH2 domains in the structure, and data showing that peptide orientation and spacing between binding sites is critical for enzymatic activation, suggest that spatial constraints are important in this multidomain protein-protein interaction.	HARVARD UNIV,CHILDRENS HOSP,MOLEC MED LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRUNGER AT, 1992, XPLOR VERSION 2 1 SY; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NAVAZA J, 1992, MOL REPLACEMENT, P87; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	30	164	168	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					277	280		10.1038/379277a0	http://dx.doi.org/10.1038/379277a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538796				2022-12-28	WOS:A1996TQ16900052
J	FitzGerald, MG; MacDonald, DJ; Krainer, M; Hoover, I; ONeil, E; Unsal, H; SilvaArrieto, S; Finkelstein, DM; BeerRomero, P; Englert, C; Sgroi, DC; Smith, BL; Younger, JW; Garber, JE; Duda, RB; Mayzel, KA; Isselbacher, KJ; Friend, SH; Haber, DA				FitzGerald, MG; MacDonald, DJ; Krainer, M; Hoover, I; ONeil, E; Unsal, H; SilvaArrieto, S; Finkelstein, DM; BeerRomero, P; Englert, C; Sgroi, DC; Smith, BL; Younger, JW; Garber, JE; Duda, RB; Mayzel, KA; Isselbacher, KJ; Friend, SH; Haber, DA			Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL PROGRESS; FAMILIAL BREAST; LINKAGE; HISTORY; RISK	Background. Mutations in a germ-line allele of the BRCA1 gene contribute to the familial breast cancer syndrome. However, the prevalence of these mutations is unknown in women with breast cancer who do not have the features of this familial syndrome. We sought BRCA1 mutations in women who were given a diagnosis of breast cancer at an early age, because early onset is characteristic of a genetic predisposition to cancer. Methods. Clinical information and peripheral-blood mononuclear cells were obtained from 418 women from the Boston metropolitan area in whom breast cancer was diagnosed at or before the age of 40. A comprehensive BRCA1 mutational analysis, involving automated nucleotide sequencing and a protein-truncation assay, was undertaken in 30 of these women, who had breast cancer before the age of 30. In addition, the BRCA1 mutation 185delAG, which is prevalent in the Ashkenazi Jewish population, was sought with an allele-specific polymerase-chain-reaction assay in 39 Jewish women among the 418 women who had breast cancer at or before the age of 40. Results. Among 30 women with breast cancer before the age of 30, 4 (13 percent) had definite, chain-terminating mutations and 1 had a missense mutation. Two of the four Jewish women in this cohort had the 185delAG mutation, Among the 39 Jewish women with breast cancer at or before the age of 40, 8 (21 percent) carried the 185delAG mutation (95 percent confidence interval, 9 to 36 percent). Conclusions. Germ-line BRCA1 mutations can be present in young women with breast cancer who do not belong to families with multiple affected members. The specific BRCA1 mutation known as 185delAG is strongly associated with the onset of breast cancer in Jewish women before the age of 40.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED & SURG ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; FAULKNER HOSP,BOSTON,MA 02130; CTR CANC RISK ANAL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center			Sgroi, Dennis/AAV-2487-2021	Krainer, Michael/0000-0002-7011-4957; Englert, Christoph/0000-0002-5931-3189				CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P1548; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fleiss JL, 1981, STAT METHODS RATES P; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOLDGAR DE, 1995, NAT GENET, V11, P113, DOI 10.1038/ng1095-113; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RIES LAG, 1994, NIH942789 PUBL; ROWELL S, 1994, AM J HUM GENET, V55, P861; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119	27	331	339	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					143	149		10.1056/NEJM199601183340302	http://dx.doi.org/10.1056/NEJM199601183340302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531968				2022-12-28	WOS:A1996TQ01700002
J	Mayhew, M; Hartl, FU				Mayhew, M; Hartl, FU			Lord of the rings: GroES structure	SCIENCE			English	Editorial Material							PROTEINS		MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Mayhew, M (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,1275 YORK AVE,NEW YORK,NY 10021, USA.		Hartl, F. Ulrich/Y-8206-2019					BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGEL A, 1995, SCIENCE, V269, P836; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	16	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					161	162		10.1126/science.271.5246.161	http://dx.doi.org/10.1126/science.271.5246.161			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539614				2022-12-28	WOS:A1996TP36400028
J	Sullivan, DJ; Gluzman, IY; Goldberg, DE				Sullivan, DJ; Gluzman, IY; Goldberg, DE			Plasmodium hemozoin formation mediated by histidine-rich proteins	SCIENCE			English	Article							FALCIPARUM INFECTED ERYTHROCYTES; MALARIA PARASITES; FERRIPROTOPORPHYRIN-IX; HEME POLYMERASE; GLYCOPROTEIN; CHLOROQUINE; IDENTIFICATION; SEQUENCE; PIGMENT; CDNA	The digestive vacuole of Plasmodium falciparum is the site of hemoglobin degradation, heme polymerization into crystalline hemozoin, and antimalarial drug accumulation. Antibodies identified histidine-rich protein II (HRP II) in purified digestive vacuoles. Recombinant or native HRP II promoted the formation of hemozoin, and chloroquine inhibited the reaction. The related HRP III also polymerized heme, and an additional HRP was identified in vacuoles. It is proposed that after secretion by the parasite into the host erythrocyte cytosol, HRPs are brought into the acidic digestive vacuole along with hemoglobin. After hemoglobin proteolysis, HRPs bind the liberated heme and mediate hemozoin formation.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NIAID NIH HHS [AI-31615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BURCH MK, 1985, BIOCHEMISTRY-US, V24, P5919, DOI 10.1021/bi00342a034; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; Goldberg Daniel E., 1993, Seminars in Cell Biology, V4, P355, DOI 10.1006/scel.1993.1042; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; KATAGIRI M, 1987, BIOCHEM BIOPH RES CO, V149, P1070, DOI 10.1016/0006-291X(87)90517-1; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENSTRA R, 1987, BIOCHEM BIOPH RES CO, V146, P368, DOI 10.1016/0006-291X(87)90734-0; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; PANTON LJ, 1989, MOL BIOCHEM PARASIT, V35, P149, DOI 10.1016/0166-6851(89)90117-5; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; ROCK EP, 1987, PARASITOLOGY, V95, P209, DOI 10.1017/S0031182000057681; Sambrook J, 1989, MOL CLONING LABORATO; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; STAHL HD, 1985, NUCLEIC ACIDS RES, V13, P7837, DOI 10.1093/nar/13.21.7837; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan D.J., UNPUB; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382	43	346	354	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					219	222		10.1126/science.271.5246.219	http://dx.doi.org/10.1126/science.271.5246.219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539625				2022-12-28	WOS:A1996TP36400047
J	BORJIGIN, J; WANG, MM; SNYDER, SH				BORJIGIN, J; WANG, MM; SNYDER, SH			DIURNAL-VARIATION IN MESSENGER-RNA ENCODING SEROTONIN N-ACETYLTRANSFERASE IN PINEAL-GLAND	NATURE			English	Article							MELATONIN; EXPRESSION; REPRESSOR; HAMSTER; CREM	FORMATION Of the pineal gland hormone melatonin increases markedly at night in response to light-dark environmental alterations(1-5). Melatonin is synthesized from serotonin by an initial N-acetylation followed by methylation of the 5-hydroxy moiety by hydroxyindole-O-methyltransferase(6,7). Serotonin N-acetyltransferase (NAT; EC2. 3.1.87), which catalyses the first reaction, is the rate-limiting enzyme in this process, and its activity increases dramatically with the onset of darkness. Because melatonin may play important biological roles in reproduction(1,2,8), ageing(1,2,9) and sleep(1,2,9), understanding the molecular factors that regulate NAT is of particular importance. To identify proteins that regulate light-dark variations in pineal function, we used a subtractive hybridization technique based on the polymerase chain reaction (PCR) to isolate rat pineal gland messages that are differentially expressed by day and night. Here we report the molecular cloning of NAT and dramatic diurnal variations in its transcription. Independently, Klein and associates have cloned NAT from sheep pineal glands(10).	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Borjigin, Jimo/GXA-3484-2022					AXELROD J, 1960, SCIENCE, V131, P1312, DOI 10.1126/science.131.3409.1312; Binkley S, 1988, PINEAL ENDOCRINE NON; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; COON SL, IN PRESS SCIENCE; CRAFT CM, 1984, NEUROENDOCRINOLOGY, V38, P193, DOI 10.1159/000123890; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; Hardie D. G., 1993, PROTEIN PHOSPHORYLAT; HOFFMAN R, 1966, SCIENCE, V148, P1609; KLEIN DC, 1970, SCIENCE, V168, P979, DOI 10.1126/science.168.3934.979; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; REITER RJ, 1991, TRENDS ENDOCRIN MET, V1, P13; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEINLECHNER S, 1984, P SOC EXP BIOL MED, V175, P93; TAKAHASHI JS, 1994, CURR BIOL, V4, P165, DOI 10.1016/S0960-9822(94)00040-0; TAMARKIN L, 1985, SCIENCE, V227, P714, DOI 10.1126/science.3881822; UNDERWOOD H, 1984, GEN COMP ENDOCR, V56, P70, DOI 10.1016/0016-6480(84)90063-7; VOISIN P, 1984, J BIOL CHEM, V259, P913; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WEISSBACH H, 1960, BIOCHIM BIOPHYS ACTA, V43, P352, DOI 10.1016/0006-3002(60)90453-4; WOLFE MS, 1995, BRAIN RES, V669, P100, DOI 10.1016/0006-8993(94)01267-L; 1993, MELATONIN PINEAL GLA	24	232	239	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					783	785		10.1038/378783a0	http://dx.doi.org/10.1038/378783a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524412				2022-12-28	WOS:A1995TL41900027
J	DUCKETT, DR; MURCHIE, AIH; LILLEY, DMJ				DUCKETT, DR; MURCHIE, AIH; LILLEY, DMJ			THE GLOBAL FOLDING OF 4-WAY HELICAL JUNCTIONS IN RNA, INCLUDING THAT IN U1 SNRNA	CELL			English	Article							4-WAY DNA JUNCTION; PHENYLALANINE TRANSFER-RNA; CONFORMATION; RESOLUTION; MODEL	Helical junctions are important elements in the architecture of folded RNA molecules. The global geometry of fully base-paired four-way junctions between RNA helices has been analyzed by comparative gel electrophoresis. Junctions appear to fold by pairwise coaxial helical stacking in one of two possible stereochemically equivalent isomers based upon alternative selections of stacking partners. In the presence of 1 mM Mg2+, the two continuous helical axes are approximately at right angles to each other for all junctions studied, but the RNA junctions exhibit significant sequence-dependent differences in their structures as a function of ionic conditions. The four-way junction found in the U1 snRNA folded by coaxial helical stacking. It retained the 90 degrees crossed stacked structure under all ionic conditions tested, despite the presence of a G . A mismatch at the point of strand exchange.	UNIV DUNDEE, DEPT BIOCHEM, NUCLE ACI STRUCT RES GRP, CANC RES CAMPAIGN, DUNDEE DD1 4HN, SCOTLAND	University of Dundee								AMIRI KMA, 1994, BIOCHEMISTRY-US, V33, P13172, DOI 10.1021/bi00249a003; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BEEKWILDER MJ, 1995, J MOL BIOL, V247, P903, DOI 10.1006/jmbi.1995.0189; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; CLEGG RM, 1994, BIOPHYS J, V66, P99, DOI 10.1016/S0006-3495(94)80765-9; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; DUCKETT DR, 1991, J MOL BIOL, V221, P147, DOI 10.1016/0022-2836(91)80211-C; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUCKETT DR, 1990, EMBO J, V9, P1659, DOI 10.1002/j.1460-2075.1990.tb08286.x; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; GESTELAND RF, 1993, RNA WORLD; GOUGH GW, 1985, NATURE, V313, P154, DOI 10.1038/313154a0; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; KISS T, 1988, NUCLEIC ACIDS RES, V16, P2734, DOI 10.1093/nar/16.6.2734; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LEONTIS NB, 1993, J BIOMOL STRUCT DYN, V11, P215, DOI 10.1080/07391102.1993.10508722; LILLEY DMJ, 1993, Q REV BIOPHYS, V26, P131, DOI 10.1017/S0033583500004054; LILLEY DMJ, 1994, EUR J BIOCHEM, V230, P1; LIPANOV A, 1993, BIOCHEMISTRY-US, V32, P1373, DOI 10.1021/bi00056a024; Maxam A M, 1980, Methods Enzymol, V65, P499; MOLLEGAARD NE, 1994, EMBO J, V13, P1508; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; POHLER JRG, 1994, J MOL BIOL, V238, P62, DOI 10.1006/jmbi.1994.1268; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; ROSEN MA, 1993, BIOCHEMISTRY-US, V32, P6576, DOI 10.1021/bi00077a011; SEEMAN NC, 1994, ANNU REV BIOPH BIOM, V23, P53, DOI 10.1146/annurev.bb.23.060194.000413; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WELCH JB, 1993, NUCLEIC ACIDS RES, V21, P4548, DOI 10.1093/nar/21.19.4548; WELCH JB, 1995, J MOL BIOL, V251, P507, DOI 10.1006/jmbi.1995.0452	41	71	71	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1027	1036		10.1016/0092-8674(95)90218-X	http://dx.doi.org/10.1016/0092-8674(95)90218-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521503	Bronze			2022-12-28	WOS:A1995TK74500021
J	LUND, VJ				LUND, VJ			FORTNIGHTLY REVIEW - DIAGNOSIS AND TREATMENT OF NASAL POLYPS	BRITISH MEDICAL JOURNAL			English	Article							ENDOSCOPIC SURGERY; DOUBLE-BLIND; SINUSES; PLACEBO; CT				LUND, VJ (corresponding author), UCL, SCH MED, INST LARYNGOL & OTOL, LONDON WC1X 8DA, ENGLAND.							CHALTON R, 1985, BRIT MED J, V291, P788, DOI 10.1136/bmj.291.6498.788; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P783, DOI 10.1017/S0022215100147462; LARSEN PL, 1964, RHINOLOGY, V32, P62; LILDHOLDT T, 1988, ACTA OTO-LARYNGOL, V105, P140, DOI 10.3109/00016488809119457; LLOYD GAS, 1991, J LARYNGOL OTOL, V105, P181, DOI 10.1017/S0022215100115300; LUND V J, 1987, Rhinology (Utrecht), V25, P83; LUND VJ, 1983, J LARYNGOL OTOL, V97, P503, DOI 10.1017/S0022215100094469; LUND VJ, 1992, OTOLARYNG CLIN N AM, V25, P803; LURIE H, 1959, ANN OTO RHINOL LARYN, V68, P478; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; NORLANDER T, 1993, OTOLARYNG HEAD NECK, V109, P522, DOI 10.1177/019459989310900322; NORLANDER T, IN PRES LARYNGOSCOPE; RUHNO J, 1990, J ALLERGY CLIN IMMUN, V86, P946, DOI 10.1016/S0091-6749(05)80158-7; SCHWACHMAN H, 1962, PEDIATRICS, V30, P389; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; STAMMBERGER H, 1991, FUNCTIONAL ENDOSCOPI, P217; Tos M, 1989, Rhinol Suppl, V8, P45; Widal MF, 1922, PRESSE MED, V30, P189; WIGAND ME, 1990, ENDOSCOPIC SURGERY P; Wright J, 1893, HIST LARYNGOLOGY RHI, P57; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	22	49	53	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1411	1414		10.1136/bmj.311.7017.1411	http://dx.doi.org/10.1136/bmj.311.7017.1411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520278	Green Published			2022-12-28	WOS:A1995TG90200025
J	CROWLEY, KS; REINHART, GD; JOHNSON, AE				CROWLEY, KS; REINHART, GD; JOHNSON, AE			THE SIGNAL SEQUENCE MOVES THROUGH A RIBOSOMAL TUNNEL INTO A NONCYTOPLASMIC AQUEOUS ENVIRONMENT AT THE ER MEMBRANE EARLY IN TRANSLOCATION	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SECRETORY PROTEIN TRANSLOCATION; RECOGNITION PARTICLE RECEPTOR; LIVER CELL FRACTIONS; ELONGATION-FACTOR-TU; TRANSFER-RNA; FLUORESCENCE LIFETIME; NASCENT POLYPEPTIDE; MICROSOMAL MEMBRANE; ESCHERICHIA-COLI	The signal sequence is in an aqueous milieu at an early stage in the translocation of a nascent secretory protein across the endoplasmic reticulum membrane. This was determined using fluorescent probes incorporated into the signal sequence of fully assembled ribosome-nascent chain-membrane complexes: the fluorescence lifetimes revealed that the probes were in an aqueous environment rather than buried in the nonpolar core of the membrane. Since these membrane-bound probes were not susceptible to collisional quenching by iodide ions, the space containing the signal sequence is sealed off from the cytoplasm by a tight ribosome-membrane junction. The nascent chain inside the ribosome is also not exposed to the cytoplasm and apparently passes through an aqueous tunnel in the ribosome.			CROWLEY, KS (corresponding author), UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019, USA.		Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [R01 GM 33216, R01 GM 26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, R01GM033216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JAMESON DM, 1984, APPL SPECTROSC REV, V20, P55, DOI 10.1080/05704928408081716; JOHNSON AE, 1980, NUCLEIC ACIDS RES, V8, P4185, DOI 10.1093/nar/8.18.4185; JOHNSON AE, 1978, P NATL ACAD SCI USA, V75, P3075, DOI 10.1073/pnas.75.7.3075; JOHNSON AE, 1980, J MOL BIOL, V138, P273, DOI 10.1016/0022-2836(80)90287-9; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MCKNIGHT CJ, 1991, BIOCHEMISTRY-US, V30, P6241, DOI 10.1021/bi00239a023; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P2368, DOI 10.1021/bi00123a023; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Reinhart G D, 1991, J Fluoresc, V1, P153, DOI 10.1007/BF00865362; ROBINSON A, 1987, BIOCHEM J, V242, P767, DOI 10.1042/bj2420767; RYABOVA LA, 1988, FEBS LETT, V226, P255, DOI 10.1016/0014-5793(88)81434-0; SABATINI DD, 1970, J CELL BIOL, V45, P146, DOI 10.1083/jcb.45.1.146; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHORE SK, 1991, THESIS U OKLAHOMA NO; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPENCER RD, 1970, J CHEM PHYS, V52, P1654, DOI 10.1063/1.1673201; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WAGENKNECHT T, 1989, BIOPHYS J, V55, P455, DOI 10.1016/S0006-3495(89)82839-5; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOLF DE, 1992, BIOCHEMISTRY-US, V31, P2865, DOI 10.1021/bi00126a004; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	70	239	240	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1101	1115		10.1016/0092-8674(93)90640-C	http://dx.doi.org/10.1016/0092-8674(93)90640-C			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513496				2022-12-28	WOS:A1993LH54800007
J	KINGMAN, S				KINGMAN, S			THE NEW NHS - THE 2ND YEAR - THE FREEMAN-HOSPITAL - DISILLUSIONMENT SETS IN	BRITISH MEDICAL JOURNAL			English	Article																		KINGMAN S, 1992, BRIT MED J, V304, P907, DOI 10.1136/bmj.304.6831.907	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1464	1467		10.1136/bmj.306.6890.1464	http://dx.doi.org/10.1136/bmj.306.6890.1464			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518647	Green Published			2022-12-28	WOS:A1993LE93500024
J	Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H				Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H			Attitudes of Michigan physicians and the public toward legalizing physician-assisted suicide and voluntary euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIE	Background. There has been a continuing public debate about assisted suicide and the proper role, if any, of physicians in this practice. Legislative bans and various forms of legalization have been proposed. Methods. We mailed questionnaires to three stratified random samples of Michigan physicians in specialties likely to involve the care of terminally ill patients: 500 in the spring of 1994, 500 in the summer of 1994, and 600 in the spring of 1995. Similar questionnaires were mailed to stratified random samples of Michigan adults: 449 in the spring of 1994 and 899 in the summer of 1994. Several different questionnaire forms were used, all of which included questions about whether physician-assisted suicide should be banned in Michigan or legalized under certain conditions. Results. Usable questionnaires were returned by 1119 of 1518 physicians eligible for the study (74 percent), and 998 of 1307 eligible adults in the sample of the general public (76 percent). Asked to choose between legalization of physician-assisted suicide and an explicit ban, 56 percent of physicians and 66 percent of the public supported legalization, 37 percent of physicians and 26 percent of the public preferred a ban, and 8 percent of each group were uncertain, When the physicians were given a wider range of choices, 40 percent preferred legalization, 37 percent preferred ''no law'' (i.e., no government regulation), 17 percent favored prohibition, and 5 percent were uncertain. If physician-assisted suicide were legal, 35 percent of physicians said they might participate if requested - 22 percent would participate in either assisted suicide or voluntary euthanasia, and 13 percent would participate only in assisted suicide. Support for physician-assisted suicide was lowest among the strongly religious. Conclusions. Most Michigan physicians prefer either the legalization of physician-assisted suicide or no law at all; fewer than one fifth prefer a complete ban on the practice, Given a choice between legalization and a ban, two thirds of the Michigan public prefer legalization and one quarter prefer a ban. (C) 1996, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT FAMILY PRACTICE, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; MICHIGAN STATE UNIV, CTR ETH & HUMANITIES LIFE SCI, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT PHILOSOPHY, E LANSING, MI 48824 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University; Michigan State University	Bachman, JG (corresponding author), UNIV MICHIGAN, INST SOCIAL RES, SURVEY RES CTR, ANN ARBOR, MI 48106 USA.		Doukas, David/ABB-9276-2021; Brody, Howard/GQA-6310-2022					ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; [Anonymous], 1978, MAIL TELEPHONE SURVE; BACHMAN JG, 1994, NEW ENGL J MED, V331, P812, DOI 10.1056/NEJM199409223311215; BATTIN MP, 1995, ACAD MED, V70, P583; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; FINLAY B, 1985, SOCIOL SOC RES, V69, P548; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; MCCARRICK P M, 1992, Kennedy Institute of Ethics Journal, V2, P79; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; Schuman H., 1981, QUESTIONS ANSWERS AT; SCHWARZ N, 1992, CONTEXT AFFECTS SOCI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; VOGT WP, 1993, DICT STATISTICS METH; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOOD FW, 1990, AM PROFILE OPINIONS; 1994, DEATH IS SOUGHT ASSI; 1991, J AM GERIATR SOC, V39, P826; 1994, FINAL REPORT MICHIGA	29	201	201	4	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					303	309		10.1056/NEJM199602013340506	http://dx.doi.org/10.1056/NEJM199602013340506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532027				2022-12-28	WOS:A1996TV69500006
J	Goodman, JL; Nelson, C; Vitale, B; Madigan, JE; Dumler, JS; Kurtti, TJ; Munderloh, UG				Goodman, JL; Nelson, C; Vitale, B; Madigan, JE; Dumler, JS; Kurtti, TJ; Munderloh, UG			Direct cultivation of the causative agent of human granulocytic ehrlichiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Human granulocytic ehrlichiosis is a potentially fatal tick-borne infection that has recently been described, This acute febrile illness is characterized by myalgias, headache, thrombocytopenia, and elevated serum aminotransferase levels, The disease is difficult to diagnose because the symptoms are nonspecific, intraleukocytic inclusions (morulae) may not be seen, and the serologic results are often initially negative, Little is known about the causative agent because it has never been cultivated. Methods. We studied three patients with symptoms and laboratory findings suggestive of human granulocytic ehrlichiosis, including unexplained fever after probable exposure to ticks, granulocytopenia, and thrombocytopenia. Peripheral blood was examined for ehrlichia microscopically and with use of the polymerase chain reaction (PCR), Blood was inoculated into cultures of HL60 cells (a line of human promyelocytic leukemia cells), and the cultures were monitored for infection by Giemsa staining and PCR. Results. Blood from the three patients, only one of whom had inclusions suggestive of ehrlichia in neutrophils, was positive for human granulocytic ehrlichiosis on PCR, Blood from all three patients was inoculated into HL60 cell cultures and caused infection, with intracellular organisms visualized as early as 5 days after inoculation and cell lysis occurring within 12 to 14 days, The identity of the cultured organisms was confirmed by immunofluorescence microscopy, PCR analysis, and DNA sequencing, DNA from the infected cells was sequenced in regions of the 16S ribosomal gene reported to differ between the agent of human granulocytic ehrlichiosis and closely related species, including Ehrlichia equi and E. phagocytophila, which cause infection in animals. The sequences from all three human isolates were identical and differed from the strain of E. equi studied in having guanine rather than adenine at nucleotide 84. Conclusions. We describe the cultivation of the agent of human granulocytic ehrlichiosis in cell culture, The ability to isolate this organism should lead to a better understanding of the biology, treatment, and epidemiology of this emerging infection. (C) 1996, Massachusetts Medical Society.	UNIV MINNESOTA,SCH MED,DIV INFECT DIS,DEPT MED,MINNEAPOLIS,MN 55455; GRANTSBURG CLIN,GRANTSBURG,WI; UNIV CALIF DAVIS,DEPT MED,SCH VET MED,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT EPIDEMIOL,SCH VET MED,DAVIS,CA 95616; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; UNIV MINNESOTA,DEPT ENTOMOL,COLL AGR,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Davis; University of California System; University of California Davis; University System of Maryland; University of Maryland Baltimore; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037772] Funding Source: NIH RePORTER; NIAID NIH HHS [9R01-AI37772-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BARLOUGH JE, 1995, J CLIN MICROBIOL, V33, P3333, DOI 10.1128/JCM.33.12.3333-3334.1995; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; Fukuda T., 1954, MED BIOL, V32, P200; GOODMAN JL, 1995, AM J MED, V99, P6, DOI 10.1016/S0002-9343(99)80097-7; JOHANSSON KE, 1995, RES VET SCI, V58, P109, DOI 10.1016/0034-5288(95)90061-6; MADIGAN JE, 1990, J AM VET MED ASSOC, V196, P1962; MADIGAN JE, 1995, J INFECT DIS, V172, P1141, DOI 10.1093/infdis/172.4.1141; MADIGAN JE, IN PRESS J CLIN MICR; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MUNDERLOH UG, 1994, J PARASITOL, V80, P533, DOI 10.2307/3283188; RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286, DOI 10.1128/CMR.4.3.286-308.1991; STANDAERT SM, 1995, NEW ENGL J MED, V333, P420, DOI 10.1056/NEJM199508173330704; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; 1995, MMWR-MORBID MORTAL W, V44, P593	20	383	400	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					209	215		10.1056/NEJM199601253340401	http://dx.doi.org/10.1056/NEJM199601253340401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8531996				2022-12-28	WOS:A1996TQ75500001
J	Marketos, SG; Diamandopoulos, AA; Bartsocas, CS; PoulakouRebelakou, E; Koutras, DA				Marketos, SG; Diamandopoulos, AA; Bartsocas, CS; PoulakouRebelakou, E; Koutras, DA			The Hippocratic Oath	LANCET			English	Article											Marketos, SG (corresponding author), UNIV ATHENS,SCH MED,INT HIPPOCRAT FDN,GR-10675 ATHENS,GREECE.			DIAMANDOPOULOS, ATHANASIOS/0000-0002-0921-7180				[Anonymous], 1823, LANCET, V1, P2; CAWADIAS P, 1883, ARCHAEOL J, P197; FREED DA, 1991, GUNDERSEN MED J, V1, P10; MARKETOS S, 1994, 4TH P INT C TRAD MED; Marketos S G, 1995, World Health Forum, V16, P77; MARKETOS SG, 1994, HIPPOCRATIC MED PHIL, P11; MEAD M, 1972, PSYCHIATRY ETHICS, P324; PAUSANIAS, CORIANTHIACA, V27, P3; ROBIN ED, 1994, BRIT MED J, V309, P96; ROBIN ED, 1995, LANCET, V345, P1422, DOI 10.1016/S0140-6736(95)92604-6; ROBIN ED, 1990, SAN FRANCISCO EXAMIN, pA28	11	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					101	102		10.1016/S0140-6736(96)90216-0	http://dx.doi.org/10.1016/S0140-6736(96)90216-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538300				2022-12-28	WOS:A1996TP28100015
J	Mattick, RP; Hall, W				Mattick, RP; Hall, W			Are detoxification programmes effective?	LANCET			English	Article							OPIATE WITHDRAWAL SYNDROME; ALCOHOL-WITHDRAWAL; HEROIN-ADDICTS; GENERAL-PRACTITIONERS; HOME DETOXIFICATION; CLINICAL-TRIAL; INPATIENT; METHADONE; BUPRENORPHINE; CLONIDINE		UNIV NEW S WALES,NATL DRUG & ALCOHOL RES CTR,SYDNEY,NSW 2052,AUSTRALIA	University of New South Wales Sydney			Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				ALLING FA, 1990, J SUBST ABUSE TREAT, V7, P173, DOI 10.1016/0740-5472(90)90019-M; ALTERMAN AI, 1988, J STUD ALCOHOL, V49, P160, DOI 10.15288/jsa.1988.49.160; Azatian Ashot, 1994, Journal of Addictive Diseases, V13, P35; BICKEL WK, 1988, CLIN PHARMACOL THER, V43, P72, DOI 10.1038/clpt.1988.13; CASTANEDA R, 1989, J CLIN PSYCHIAT, V50, P278; CHICK JD, 1994, BRIT J PSYCHIAT, V164, P853, DOI 10.1192/bjp.164.6.853a; COOPER DB, 1994, ALCOHOL HOME DETOXIC; DEVENYI P, 1986, PHYSICIANS HDB MED M; EDWARDS G, 1980, DRUG PROBLEMS BRITAI; Edwardss G., 1987, TREATMENT DRINKING P; FARRELL M, 1994, ADDICTION, V89, P1471, DOI 10.1111/j.1360-0443.1994.tb03745.x; FUDALA PJ, 1990, CLIN PHARMACOL THER, V47, P525, DOI 10.1038/clpt.1990.67; GERSTEIN DR, 1990, TREATING DRUG PROBLE, V1; GLUE P, 1990, BRIT J PSYCHIAT, V157, P491, DOI 10.1192/bjp.157.4.491; GOSSOP M, 1991, BRIT J PSYCHIAT, V159, P208, DOI 10.1192/bjp.159.2.208; GOSSOP M, 1988, DRUG ALCOHOL DEPEN, V21, P253, DOI 10.1016/0376-8716(88)90078-6; GOSSOP M, 1986, BRIT MED J, V293, P103, DOI 10.1136/bmj.293.6539.103; GOSSOP M, 1989, DRUG ALCOHOL DEPEN, V24, P143, DOI 10.1016/0376-8716(89)90077-X; GREEN L, 1988, BRIT J ADDICT, V83, P305; HAYSHIDA M, 1989, NEW ENGL J MED, V320, P358; HERSHON HI, 1977, J STUD ALCOHOL, V38, P953, DOI 10.15288/jsa.1977.38.953; JAFFE JH, 1992, GOODMAN GILMANS PHAR, P522; JANIRI L, 1994, DRUG ALCOHOL DEPEN, V36, P139, DOI 10.1016/0376-8716(94)90096-5; KLEBER HB, 1981, SUBSTANCE ABUSE CLIN; KOSTEN MA, 1985, DIAGNOSIS TREATMENT, P21; KOSTEN TR, 1992, BUPRENORPHINE ALTERN, P101; Lipton D, 1983, ADV ALCOHOL SUBSTANC, V2, P31; LISHMAN WA, 1987, ORGANIC PSYCHIATRY; MENDELSON JH, 1985, DIAGNOSIS TREATMENT, P1; MILBY JB, 1988, J NERV MENT DIS, V176, P409, DOI 10.1097/00005053-198807000-00003; MOSKOWITZ G, 1983, ALCOHOL CLIN EXP RES, V7, P42, DOI 10.1111/j.1530-0277.1983.tb05409.x; PEDERSEN C, 1986, AUST DRUG ALCOHOL RE, V5, P133; Poshyachinda Vichai, 1980, DRUG PROBLEMS SOCIOC, P121; ROSENBLATT SM, 1972, Q J STUD ALCOHOL, V33, P1060; SAN L, 1990, BRIT J ADDICT, V85, P141; SAN L, 1989, BRIT J ADDICT, V84, P81; SIMPSON DD, 1982, ARCH GEN PSYCHIAT, V39, P1318; STEWART T, 1994, HEROIN USERS; STOCKWELL T, 1990, BRIT J ADDICT, V85, P61; STOCKWELL T, 1986, BRIT MED J, V292, P733, DOI 10.1136/bmj.292.6522.733; STOCKWELL T, 1991, ALCOHOL ALCOHOLISM, V26, P645, DOI 10.1093/oxfordjournals.alcalc.a045169; TURNER RC, 1989, J GEN INTERN MED, V4, P432, DOI 10.1007/BF02599697; WARD J, 1992, KEY ISSUES METHADONE; WEST R, 1994, ADDICTION, V89, P1483, DOI 10.1111/j.1360-0443.1994.tb03747.x; 1990, BROADENING BASE TREA	45	148	149	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					97	100		10.1016/S0140-6736(96)90215-9	http://dx.doi.org/10.1016/S0140-6736(96)90215-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP281	8538351				2022-12-28	WOS:A1996TP28100014
J	Tobert, JA				Tobert, JA			Statin therapy and CHD	LANCET			English	Letter											Tobert, JA (corresponding author), MERCK LABS, DEPT CLIN RES, RAHWAY, NJ 07065 USA.		Tobert, Jonathan/AAD-2155-2020; Tobert, Jonathan/J-4294-2019	Tobert, Jonathan/0000-0001-7105-299X; 				GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; JACKSON R, 1995, LANCET, V346, P1440, DOI 10.1016/S0140-6736(95)92466-3; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	1996	347	8994					128	128		10.1016/S0140-6736(96)90258-5	http://dx.doi.org/10.1016/S0140-6736(96)90258-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538331				2022-12-28	WOS:A1996TP28100063
J	Zinkernagel, RM				Zinkernagel, RM			Immunology taught by viruses	SCIENCE			English	Review							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL MEMORY; VESICULAR STOMATITIS-VIRUS; IMMUNE-RESPONSE; TRANSGENIC MICE; MOLECULAR MECHANISMS; IMMUNOGENIC PEPTIDES; INFLUENZA-VIRUSES; VIRAL-ANTIGENS; HEPATITIS-B	The survival of viruses depends on the survival of susceptible hosts. The vertebrate immune system and viruses have therefore coevolved complementary facets. Evidence from various balanced virus-host relationships illustrates that immunological specificity and memory may best be defined biologically and that the mature immune system does not discriminate between ''self'' and ''nonself.'' Rather, B cells distinguish antigen patterns, whereas T cell responses depend on localization, transport, and kinetics of antigen within lymphatic organs.			Zinkernagel, RM (corresponding author), UNIV ZURICH, INST EXPTL IMMUNOL, SCHMELZBERGSTR 12, CH-8091 ZURICH, SWITZERLAND.							AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; ANDO K, 1994, J IMMUNOL, V152, P3245; [Anonymous], [No title captured]; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BACHMANN M, UNPUB; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bachmann MF, 1995, EUR J IMMUNOL, V25, P3445, DOI 10.1002/eji.1830251236; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BENACERRAF B, 1978, J IMMUNOL, V120, P1809; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BRAMBELL RWR, 1970, TRANSMISSION IMMUNIT; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BUMET FM, 1949, PRODUCTION ANTIBODIE; BURNS WH, 1975, NATURE, V256, P654, DOI 10.1038/256654a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CELADA F, 1971, PROG ALLERGY, V15, P223; CHARAN S, 1987, J VIROL, V61, P2509, DOI 10.1128/JVI.61.8.2509-2514.1987; CHARAN S, 1986, J IMMUNOL, V136, P3057; CHEN C, 1992, J EXP MED, V176, P855, DOI 10.1084/jem.176.3.855; CLAFLIN JL, 1988, J IMMUNOL, V141, P4012; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DIETZSCHOLD B, 1991, CRIT REV IMMUNOL, V10, P427; DINTZIS RZ, 1985, J IMMUNOL, V135, P423; DINTZIS RZ, 1983, J IMMUNOL, V131, P2196; DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55; DOHERTY PC, 1994, CURR OPIN IMMUNOL, V6, P545, DOI 10.1016/0952-7915(94)90139-2; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; DULBECCO R, 1956, VIROLOGY, V2, P162, DOI 10.1016/0042-6822(56)90017-4; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FELDMANN M, 1971, J EXP MED, V134, P103, DOI 10.1084/jem.134.1.103; FELDMANN M, 1972, IMMUNOL REV, V13, P3; FREUND J, 1947, J IMMUNOL, V57, P179; GERSHON RK, 1975, TRANSPLANT REV-DENMA, V26, P170; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; GRESSER I, 1976, J EXP MED, V144, P1316, DOI 10.1084/jem.144.5.1316; HOTCHIN J, 1971, MONOGR VIROL, V3, P1; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1995, SPRINGER SEM IMUNOPA, V17, P216; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KIRBERG J, 1995, IMMUNITY, V2, P37; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; KLINMAN NR, 1988, ADV IMMUNOL, P1; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; LAFFERTY KJ, 1977, IMMUNOL REV, V35, P231, DOI 10.1111/j.1600-065X.1977.tb00241.x; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LAWRENCE HS, 1959, PHYSIOL REV, V39, P811, DOI 10.1152/physrev.1959.39.4.811; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEVINE BERNARD B., 1963, JOUR EXPTL MED, V118, P953, DOI 10.1084/jem.118.6.953; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MARKER O, 1973, J EXP MED, V137, P1511, DOI 10.1084/jem.137.6.1511; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCDEVITT HO, 1965, J EXP MED, V122, P517, DOI 10.1084/jem.122.3.517; MCINTOSH K, 1990, VIROLOGY, P411; MILLER JF, 1961, LANCET, V2, P748; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; Mims C.A., 1974, BIOL ANIMAL VIRUSES; MIMS CA, 1982, PATHOGENESIS INFECTI; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOLLER G, 1975, TRANSPLANT REV, V23, P126; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; MORELL V, 1995, SCIENCE, V269, P773, DOI 10.1126/science.7638587; MOSKOPHIDIS D, 1994, J IMMUNOL, V152, P4976; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MOSKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937, DOI 10.1002/eji.1830170707; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NEWMAN MA, 1992, J IMMUNOL, V149, P3260; NOSSAI GJV, 1971, ANTIGENS LYMPHOID CE; NOSSAL GJ, 1971, ANTIGENS LYMPHOID CE; NOSSAL GJV, 1992, ADV IMMUNOL, V52, P283, DOI 10.1016/S0065-2776(08)60878-0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OHNO S, 1980, 4TH INT C IMM IMM 80, P577; OLDSTONE MB, 1967, SCIENCE, V158, P1193, DOI 10.1126/science.158.3805.1193; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PALESE P, 1982, SCIENCE, V215, P1468, DOI 10.1126/science.7038875; Paul W., 1993, FUNDAMENTAL IMMUNOLO, P1211; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PORTER P, 1972, IMMUNOLOGY, V23, P225; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; RAJEWSKY K, 1989, PROGRESS IN IMMUNOLOGY, VOL 7, P397; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SELIN LK, 1994, CURR OPIN IMMUNOL, V6, P553, DOI 10.1016/0952-7915(94)90140-6; SIlverstein AM., 1989, HIST IMMUNOLOGY; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; SPEISER DE, 1992, J IMMUNOL, V149, P972; SPRENT J, 1995, J IMMUNOL, V154, P1198; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; STGROTH SFD, 1967, COLD SPRING HARB SYM, V32, P525; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; Theofilopoulos A N, 1979, Adv Immunol, V28, P89; Tindle R W, 1994, Curr Top Microbiol Immunol, V186, P217; TISHON A, 1988, J IMMUNOL, V140, P1280; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; Traub E, 1936, J EXP MED, V63, P847, DOI 10.1084/jem.63.6.847; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; WAGNER RR, 1987, RHABDOVIRUSES; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; WALSH CM, 1994, NATURE, V91, P10854; WATERS JA, 1992, J CLIN INVEST, V90, P2543, DOI 10.1172/JCI116148; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WEBSTER RG, 1968, IMMUNOLOGY, V14, P39; WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; WHEELOCK EF, 1965, SCIENCE, V149, P310, DOI 10.1126/science.149.3681.310; WICKER LS, 1992, SCIENCE, V256, P1828, DOI 10.1126/science.1319611; ZINKERNAGEL RM, 1990, CURR TOP MICROBIOL, V159, P65; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x; ZINKERNAGEL RM, 1985, BRIT MED BULL, V41, P92, DOI 10.1093/oxfordjournals.bmb.a072033; ZINKERNAGEL RM, IN PRESS ANN REV IMM; [No title captured]	147	540	551	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					173	178		10.1126/science.271.5246.173	http://dx.doi.org/10.1126/science.271.5246.173			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539616				2022-12-28	WOS:A1996TP36400032
J	Matsumoto, M; Nakagawa, T; Inoue, T; Nagata, E; Tanaka, K; Takano, H; Minowa, O; Kuno, J; Sakakibara, S; Yamada, M; Yoneshima, H; Miyawaki, A; Fukuuchi, Y; Furuichi, T; Okano, H; Mikoshiba, K; Noda, T				Matsumoto, M; Nakagawa, T; Inoue, T; Nagata, E; Tanaka, K; Takano, H; Minowa, O; Kuno, J; Sakakibara, S; Yamada, M; Yoneshima, H; Miyawaki, A; Fukuuchi, Y; Furuichi, T; Okano, H; Mikoshiba, K; Noda, T			Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; MOUSE CEREBELLUM; P400 PROTEIN; PURIFICATION; EXPRESSION; CURRENTS; INVITRO; SLICES	THE inositol 1,4,5-trisphosphate (InsP(3)) receptor acts as an InsP(3)-gated Ca2+ release channel in a variety of cell types(1,2). Type 1 InsP(3) receptor (IP(3)R1) is the major neuronal member of the IP(3)R family in the central nervous system(3,4), predominantly enriched in cerebellar Purkinje cells but also concentrated in neurons in the hippocampal CA1 region, caudate-putamen, and cerebral cortex(5,6). Here we report that most IP(3)R1-deficient mice generated by gene targeting die in utero, and born animals have severe ataxia and tonic or tonic-clonic seizures and die by the weaning period. An electroencephalogram showed that they suffer from epilepsy, indicating that IP(3)R1 is essential for proper brain function. However, observation by light microscope of the haematoxylin-eosin staining of the brain and peripheral tissues of IP(3)R1-deficient mice showed no abnormality, and the unique electrophysiological properties of the cerebellar Purkinje cells of IP(3)R1-deficient mice were not severely impaired.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; INST CANC RES,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN; KEIO UNIV,SCH MED,DEPT NEUROL,SHINJUKU KU,TOKYO 160,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; EXPLORATORY RES ADV TECHNOL,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo; Keio University; RIKEN			Miyawaki, Atsushi/K-3569-2014; Furuichi, Teiichi/B-5086-2014; Okano, Hideyuki/I-7584-2019; Minowa, Osamu/AAM-1238-2020; Inoue, Takafumi/AAM-9533-2020; Noda, Tetsuo/B-1667-2016; Yamada, Maki/U-5251-2019; Mikoshiba, Katsuhiko/N-7943-2015; Yamada, Maki/A-1573-2015	Miyawaki, Atsushi/0000-0002-2329-3235; Furuichi, Teiichi/0000-0002-9676-1888; Inoue, Takafumi/0000-0002-2728-0060; Yamada, Maki/0000-0002-1956-6069; Nakagawa, Toshiyuki/0000-0001-8415-4119; Sakakibara, Shin-ichi/0000-0001-8983-2249				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CREPEL F, 1986, J PHYSIOL-LONDON, V372, P1; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; Lyon M., 1989, GENETIC VARIANTS STR; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAGATA E, 1994, NEUROSCIENCE, V61, P983, DOI 10.1016/0306-4522(94)90418-9; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKANISHI S, 1991, J NEUROSCI, V11, P2075; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAMAMOTOHINO M, 1995, NEUROREPORT, V6, P273, DOI 10.1097/00001756-199501000-00012	24	341	348	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					168	171		10.1038/379168a0	http://dx.doi.org/10.1038/379168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538767				2022-12-28	WOS:A1996TP36000059
J	BakkerArkema, RG; Davidson, MH; Goldstein, RJ; Davignon, J; Isaacsohn, JL; Weiss, SR; Keilson, LM; Brown, WV; Miller, VT; Shurzinske, LJ; Black, DM				BakkerArkema, RG; Davidson, MH; Goldstein, RJ; Davignon, J; Isaacsohn, JL; Weiss, SR; Keilson, LM; Brown, WV; Miller, VT; Shurzinske, LJ; Black, DM			Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TRIGLYCERIDE; CHOLESTEROL	Objective.-To assess the lipid-lowering effect of atorvastatin (a new 3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitor) on levels of serum triglycerides and other lipoprotein fractions in patients with primary hypertriglyceridemia, determine if atorvastatin causes a redistribution of triglycerides in various lipoprotein fractions, and assess its safety by reporting adverse events and clinical laboratory measurements. Design.-Randomized double-blind, placebo-controlled, parallel-group, multicenter trial. Setting.-Community- and university-based research centers. Patients.-A total of 56 patients (aged 26 to 74 years) with a mean baseline triglyceride level of 6.80 mmol/L (603.3 mg/dL) and a mean baseline low-density lipoprotein cholesterol (LDL-C) level of 3.07 mmol/L (118.7 mg/dL). Interventions.-Cholesterol-lowering diet (National Institutes of Health National Cholesterol Education Program Step I Diet) and either 5 mg, 20 mg, or 80 mg of atorvastatin, or placebo. Main Outcome Measures.-Percent change from baseline in total triglycerides for three dose levels of atorvastatin compared with placebo. Results.-Mean reductions in total triglycerides between 5 mg, 20 mg, and 80 mg of atorvastatin and placebo after 4 weeks of treatment were -26.5%, -32.4%, -45.8%, and -8.9%, respectively. Mean reductions in LDL-C were -16.7%, -33.2%, -41.4%, and -1.4%, respectively, and very low-density lipoprotein cholesterol (VLDL-C) were -34.3%, -45.9%, -57.7%, and -5.5%, respectively. Similar mean changes in total apolipoprotein B (apo B) (-16.9%, -32.8%, -41.7%, and +1.0%), apo B in LDL (-14.8%, -29.8%, -42.0%, and -3.1%), and apo B in VLDL (-23.8%, -35.8%, -34.4%, and +11.7%) were observed. In addition, comparable mean changes in LDL triglycerides (-22.5%, -30.7%, -39.9%, and +3.9%) and VLDL triglycerides (-28.1%, -34.0%, -47.3%, and -10.8%) were seen. Conclusions.-In atorvastatin treatment groups, total serum triglyceride levels decreased in a dose-dependent manner; reductions in the 20-mg and 80-mg groups were statistically significant (P<.05) compared with placebo. Atorvastatin did not cause a redistribution of triglycerides but consistently lowered triglycerides in all lipoprotein fractions. Atorvastatin was well tolerated.	CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA; CHICAGO CTR CLIN RES 3,CHICAGO,IL; CHRIST HOSP,CARDIOVASC RES CTR,CINCINNATI,OH 45219; SAN DIEGO ENDOCRINE & MED CLIN INC,SAN DIEGO,CA; CTR LIPIDS,PORTLAND,ME; EMORY UNIV,SCH MED,DIV ARTEIOROSCLOROSIS & LIPED METAB,ATLANTA,GA; GEORGE WASHINGTON UNIV,MED CTR,LIPID RES CLIN,WASHINGTON,DC 20037	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Christ Hospital - Ohio; Emory University; George Washington University	BakkerArkema, RG (corresponding author), PARKE DAVIS PHARMACEUT RES,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.		Brown, William/GXN-2777-2022					[Anonymous], 1992, NUTR METAB CARDIOVAS, V2, P113; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; EAST C, 1988, ANN INTERN MED, V109, P25, DOI 10.7326/0003-4819-109-1-25; FESKANICH D, 1988, J AM DIET ASSOC, V88, P1263; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GOH EH, 1977, J BIOL CHEM, V252, P2822; GRUNDY SM, 1992, ARCH INTERN MED, V152, P28, DOI 10.1001/archinte.152.1.28; GRUNDY SM, 1991, DRUG TREATMENT HYPER, P139; HAINLINE A, 1982, LIPID LIPOPROTEIN AN, P5; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KASIM SE, 1992, J LIPID RES, V33, P1; KRAUSE BR, 1993, FASEB J, V7, pA567; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MARAIS AD, 1994, ATHEROSCLEROSIS, V109, P316; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; NAWROCKI JW, 1995, ARTERIOSCL THROM VAS, V15, P678, DOI 10.1161/01.ATV.15.5.678; PARRA HJ, 1990, CLIN CHEM, V36, P1421; REMMELL PS, 1980, J AM DIET ASSOC, V76, P351; SCHONFELD G, 1977, J LIPID RES, V18, P645; WARNICK GR, 1982, CLIN CHEM, V28, P1379; 1992, NIH CONSENSUS STATE, V10, P1; 1993, JAMA-J AM MED ASSOC, V269, P3015	24	332	344	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					128	133		10.1001/jama.275.2.128	http://dx.doi.org/10.1001/jama.275.2.128			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531308				2022-12-28	WOS:A1996TN28000029
J	Long, JA; Moan, EI; Medford, JI; Barton, MK				Long, JA; Moan, EI; Medford, JI; Barton, MK			A member of the KNOTTED class of homeodomain proteins encoded by the STM gene of Arabidopsis	NATURE			English	Article							MAIZE HOMEOBOX GENE; THALIANA; MUTATION; CELLS; SITE	THE KNOTTED class of plant genes encodes homeodomain proteins(1,2). These genes have been found in all plant species where they have been sought(3-5) and, where examined, show expression patterns that suggest they play an important role in shoot meristem function(5-7). Until now, all mutant phenotypes associated with these genes have been due to gain-of-function mutations(4,5,8,9), making it difficult to deduce their wild-type function. Here we present evidence that the Arabidopsis SHOOT-MERISTEMLESS (STM) gene, required for shoot apical meristem formation during embryogenesis, encodes a class I KNOTTED-like protein. We also describe the expression pattern of this gene in the wild-type plant. To our knowledge, STM is the first gene shown to mark a specific pattern element in the developing plant embryo both phenotypically and molecularly.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,MOLEC & CELLULAR BIOL PROGRAM,MADISON,WI 53706; PENN STATE UNIV,DEPT BIOL,COLLEGE PARK,PA 16802	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; BARTON MK, 1993, DEVELOPMENT, V119, P823; BECRAFT PW, 1994, GENETICS, V136, P295; Bowman J., 1994, ARABIDOPSIS ATLAS MO, P133; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; FREELING M, 1985, GENETICS, V111, P617; JACKSON D, 1994, DEVELOPMENT, V120, P405; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KUIPER MTR, 1988, J BIOL CHEM, V263, P2848; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANSFIELD SG, 1991, CAN J BOT, V69, P447, DOI 10.1139/b91-062; MCCONNELL JR, 1995, DEV GENET, V16, P358, DOI 10.1002/dvg.1020160409; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; MULLER KJ, 1995, NATURE, V374, P727, DOI 10.1038/374727a0; SINHA N, 1993, GENE DEV, V7, P878; SMITH LG, 1992, DEVELOPMENT, V116, P21; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	20	1165	1247	10	185	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					66	69		10.1038/379066a0	http://dx.doi.org/10.1038/379066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538741				2022-12-28	WOS:A1996TN21600055
J	Gough, A; Faint, J; Salmon, M; Bacon, P; Emery, P				Gough, A; Faint, J; Salmon, M; Bacon, P; Emery, P			HLA-DR4 and career prospects in rheumatology: Is there a link?	BRITISH MEDICAL JOURNAL			English	Article							ARTHRITIS	Objective-To determine whether HLA type is associated with career progress in rheumatology. Design-Comparison of HLA type after HLA analysis of samples of venous blood. Setting-Department of Rheumatology Research, University of Birmingham. Subjects-All (37) staff in the department. Results-All the senior academics and most staff with a PhD expressed HLA-DR4. The prevalence of expression in each of these groups was significantly greater than that found in the controls. None of the junior doctors or secretaries expressed DR4. Conclusion-The junior doctors in the department have poor career prospects as HLA-DR4 seems to be associated with academic achievement.	UNIV BIRMINGHAM,DEPT RHEUMATOL RES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham			emery, paul/B-3560-2013		Arthritis Research UK [18475] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		BIDWELL JL, 1986, MOL IMMUNOL, V23, P1111, DOI 10.1016/0161-5890(86)90009-X; EMERY P, 1992, BRIT MED J, V305, P1387, DOI 10.1136/bmj.305.6866.1387; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1665	1666		10.1136/bmj.311.7021.1665	http://dx.doi.org/10.1136/bmj.311.7021.1665			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541751	Green Published			2022-12-28	WOS:A1995TL94200010
J	SEEDS, NW; WILLIAMS, BL; BICKFORD, PC				SEEDS, NW; WILLIAMS, BL; BICKFORD, PC			TISSUE-PLASMINOGEN ACTIVATOR INDUCTION IN PURKINJE NEURONS AFTER CEREBELLAR MOTOR LEARNING	SCIENCE			English	Article							IMPAIRED ACQUISITION; NEURITE OUTGROWTH; SENSORY NEURONS; LOCOMOTOR TASKS; RATS; DEGRADATION; BINDING; MEMORY; CELLS	The cerebellar cortex is implicated in the learning of complex motor skills. This learning may require synaptic remodeling of Purkinje cell inputs. An extracellular serine protease, tissue plasminogen activator (tPA), is involved in remodeling various nonneural tissues and is associated with developing and regenerating neurons. in situ hybridization showed that expression of tPA messenger RNA was increased in the Purkinje neurons of rats within an hour of their being trained for a complex motor task. Antibody to tPA also showed the induction of tPA protein associated with cerebellar Purkinje cells. Thus, the induction of tPA during motor learning may play a role in activity-dependent synaptic plasticity.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR MED SCI TRAINING,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SEEDS, NW (corresponding author), UNIV COLORADO,HLTH SCI CTR,PROGRAM NEUROSCI,DENVER,CO 80262, USA.		Bickford, Paula C/J-5970-2012	Bickford, Paula C/0000-0001-9657-7725	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04418] Funding Source: Medline; NIGMS NIH HHS [T32-GM 08497] Funding Source: Medline; NINDS NIH HHS [NS-09818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ANDERSON B, 1992, BEHAV NEUROSCI, V106, P509; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BICKFORD P, 1992, NEUROBIOL AGING, V13, P475, DOI 10.1016/0197-4580(92)90075-9; BICKFORD P, 1993, BRAIN RES, V620, P133, DOI 10.1016/0006-8993(93)90279-V; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; GILBERT PFC, 1974, BRAIN RES, V70, P1, DOI 10.1016/0006-8993(74)90208-X; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P147; ITO M, 1977, CEREBELLUM NEURAL CO; KALDERON N, 1979, P NATL ACAD SCI USA, V76, P5992, DOI 10.1073/pnas.76.11.5992; Kleim J. A., 1994, Society for Neuroscience Abstracts, V20, P1435; KRYSTOSEK A, 1978, FED PROC, V37, P1702; KRYSTOSEK A, 1991, SCIENCE, V213, P1532; LALONDE R, 1990, BRAIN RES REV, V15, P325, DOI 10.1016/0165-0173(90)90006-A; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARS WM, 1993, AM J PATHOL, V143, P949; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; MOONEN G, 1983, NATURE, V298, P753; PITTMAN RN, 1985, DEV BIOL, V110, P91, DOI 10.1016/0012-1606(85)90067-3; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Seeds N W, 1990, Adv Exp Med Biol, V265, P169; SEEDS NW, UNPUB; SEEDS NW, 1992, NERVE GROWTH CONE, P219; SIMMONS, 1990, J HISTOTECHN, V12, P169; SOREQ H, 1983, DEV BRAIN RES, V11, P149, DOI 10.1016/0165-3806(83)90212-2; VERRALL S, 1989, J CELL BIOL, V109, P265, DOI 10.1083/jcb.109.1.265; VERRALL S, 1989, THESIS U COLORADO HL; WATSON M, 1984, BRAIN RES, V296, P129, DOI 10.1016/0006-8993(84)90518-3	36	255	261	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1992	1994		10.1126/science.270.5244.1992	http://dx.doi.org/10.1126/science.270.5244.1992			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533091				2022-12-28	WOS:A1995TL42000042
J	STEHNOBITTEL, L; PEREZTERZIC, C; CLAPHAM, DE				STEHNOBITTEL, L; PEREZTERZIC, C; CLAPHAM, DE			DIFFUSION ACROSS THE NUCLEAR-ENVELOPE INHIBITED BY DEPLETION OF THE NUCLEAR CA2+ STORE	SCIENCE			English	Article							PORE COMPLEX; MEMBRANE; PROTEINS	Intact, isolated nuclei and a nuclear membrane (ghost) preparation were used to study regulation of the movement of small molecules across the Xenopus laevis oocyte nuclear membrane. In contrast to models of the nuclear pore complex, which assume passive bidirectional diffusion of molecules less than 70 kilodaltons, diffusion of intermediate-sized molecules was regulated by the nuclear envelope calcium stores. After depletion of nuclear store calcium by inositol 1,4,5-trisphosphate or calcium chelators, fluorescent molecules conjugated to 10-kilodalton dextran were unable to enter the nucleus. Dye exclusion after calcium store depletion was not dependent on the nuclear matrix because it occurred in nuclear ghosts lacking nucleoplasm. Smaller molecules and ions (500-dalton Lucifer yellow and manganese) diffused freely into the core of the nuclear ghosts and intact nuclei even after calcium store depletion. Thus, depletion of the nuclear calcium store blocks diffusion of intermediate-sized molecules.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Stehno-Bittel, Lisa/0000-0002-8879-6124	PHS HHS [41303] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V113, P259; DAVIS L I, 1992, Current Opinion in Cell Biology, V4, P424, DOI 10.1016/0955-0674(92)90007-Y; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6868; PAINE PL, 1992, BIOTECHNIQUES, V13, P238; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; SCHLENSTEDT G, 1992, J CELL BIOL, V123, P785; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; Stewart M, 1992, Semin Cell Biol, V3, P267, DOI 10.1016/1043-4682(92)90028-T	24	171	173	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1835	1838		10.1126/science.270.5243.1835	http://dx.doi.org/10.1126/science.270.5243.1835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525380				2022-12-28	WOS:A1995TK47600050
J	WILKINSON, JQ; LANAHAN, MB; YEN, HC; GIOVANNONI, JJ; KLEE, HJ				WILKINSON, JQ; LANAHAN, MB; YEN, HC; GIOVANNONI, JJ; KLEE, HJ			AN ETHYLENE-INDUCIBLE COMPONENT OF SIGNAL-TRANSDUCTION ENCODED BY NEVER-RIPE	SCIENCE			English	Article							EXPRESSION; ARABIDOPSIS; FAMILY	The ripening-impaired tomato mutant Never-ripe (Nr) is insensitive to the plant hormone ethylene. The gene that cosegregates with the Nr locus encodes a protein with homology to the Arabidopsis ethylene receptor ETR1 but is lacking the response regulator domain found in ETR1 and related prokaryotic two-component signal transducers. A single amino acid change in the sensor domain confers ethylene insensitivity when expressed in transgenic tomato plants. Modulation of NR gene expression during fruit ripening controls response to the hormone ethylene.	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; MONSANTO CO,CHESTERFIELD,MO 63198; CIBA GEIGY CORP,RES TRIANGLE PK,NC 27709; TEXAS A&M UNIV,DEPT HORT SCI,COLLEGE STN,TX 77843	State University System of Florida; University of Florida; Monsanto; Texas A&M University System; Texas A&M University College Station			Klee, Harry/A-7912-2008					Abeles F, 1992, ETHYLENE PLANT BIOL; BRADFORD KJ, 1994, PLANT PHYSIOL, V105, P1029, DOI 10.1104/pp.105.4.1029; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chang C. Y., COMMUNICATION; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kader A. A., 1976, In 'Second Tomato Quality Workshop' [see FSTA (1977) 9 12J1812]., P57; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; LANAHAN MB, 1994, PLANT CELL, V6, P521, DOI 10.1105/tpc.6.4.521; LINCOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793, DOI 10.1073/pnas.84.9.2793; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RUSSELL DA, 1991, MOL GEN GENET, V229, P219, DOI 10.1007/BF00272159; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; WILKINSON JD, UNPUB; WILKINSON JQ, 1995, PLANT MOL BIOL, V27, P1097, DOI 10.1007/BF00020883; Yang S.F, 1987, PLANT SENESCENCE ITS, P156; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	22	498	536	7	92	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1807	1809		10.1126/science.270.5243.1807	http://dx.doi.org/10.1126/science.270.5243.1807			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525371				2022-12-28	WOS:A1995TK47600041
J	CHEN, CC; DAVID, AS; NUNNERLEY, H; MICHELL, M; DAWSON, JL; BERRY, H; DOBBS, J; FAHY, T				CHEN, CC; DAVID, AS; NUNNERLEY, H; MICHELL, M; DAWSON, JL; BERRY, H; DOBBS, J; FAHY, T			ADVERSE LIFE EVENTS AND BREAST-CANCER - CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOLOGICAL RESPONSE; PSYCHOSOCIAL STRESS; COPING STRATEGIES; DIAGNOSIS; WOMEN; RISK	Objective--To investigate the strength of association between past life events and the development of breast cancer. Design--Case-control study. A standardised life events interview and rating was administered before a definitive diagnosis. Setting--Breast Cancer Screening Assessment Unit and surgical outpatient clinics at King's College Hospital, London. Subjects--119 consecutive women aged 20-70 who were referred for biopsy of a suspicious breast lesion. Main outcome measures--Odds ratio of the risk of developing breast cancer after life events in the preceding five years after adjustment for confounders. Results--41 women were diagnosed as having malignant disease while the remainder had benign conditions. Severe Life events increased the risk of breast cancer. The crude odds ratio was 3.2 (95% confidence interval 1.35 to 7.6). After adjustment for age and the menopause and other potential confounders this rose to 11.6 (3.1 to 43.7). Multiple logistic regression analysis showed that all severe events and coping with the stress of adverse events by confronting them and focusing on the problems significantly predicted a diagnosis of breast cancer. Non-severe life events and long term difficulties had no significant association. Conclusion--These findings suggest an aetiological association between life stress and breast cancer.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PSYCHOL MED,LONDON SE5 8AZ,ENGLAND; UNIV LONDON KINGS COLL HOSP,BREST SCREENING ASSESSMENT TEAM,LONDON SE5 9RS,ENGLAND; MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	CHEN, CC (corresponding author), NATL CHENG KUNG UNIV,COLL MED,DEPT PSYCHIAT,138 SHEN HI RD,TAINAN 70428,TAIWAN.		David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X				BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; Brown G., 1978, SOCIAL ORIGINS DEPRE; Brown GW, 1989, LIFE EVENTS ILLNESS; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHEN C, IN PRESS J PSYCHOSOM; CHEN CC, 1984, THESIS U LONDON LOND, P75; COOPER CL, 1992, PSYCHOL MED, V22, P447, DOI 10.1017/S0033291700030397; COOPER CL, 1993, PSYCHOL MED, V23, P653, DOI 10.1017/S0033291700025435; Eysenck H. J., 1964, EYSENCK PERSONALITY; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; FORSEN A, 1991, PSYCHOTHER PSYCHOSOM, V55, P176, DOI 10.1159/000288427; GEYER S, 1991, J PSYCHOSOM RES, V35, P355, DOI 10.1016/0022-3999(91)90090-B; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; GOODKIN K, 1992, J PSYCHOSOM RES, V36, P635, DOI 10.1016/0022-3999(92)90053-5; GREER S, 1975, J PSYCHOSOM RES, V19, P147, DOI 10.1016/0022-3999(75)90062-8; GREER S, 1990, LANCET, V335, P49, DOI 10.1016/0140-6736(90)90173-3; JASMIN C, 1990, ANN ONCOL, V1, P22, DOI 10.1093/oxfordjournals.annonc.a057666; Lewis CE, 1994, PSYCHOIMMUNOLOGY CAN; MUSLIN HL, 1966, ANN NY ACAD SCI, V125, P802, DOI 10.1111/j.1749-6632.1966.tb45429.x; PETTINGALE KW, 1988, J PSYCHOSOM RES, V32, P255, DOI 10.1016/0022-3999(88)90066-9; RAMIREZ AJ, 1990, LANCET, V335, P1408, DOI 10.1016/0140-6736(90)91294-K; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; SCHONFIELD J, 1975, J PSYCHOSOM RES, V19, P229, DOI 10.1016/0022-3999(75)90018-5; Tobin D. L., 1984, USERS MANUAL COPING	25	125	129	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1527	1530		10.1136/bmj.311.7019.1527	http://dx.doi.org/10.1136/bmj.311.7019.1527			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK214	8520393	Green Published			2022-12-28	WOS:A1995TK21400020
J	WHITNEY, JA; GOMEZ, M; SHEFF, D; KREIS, TE; MELLMAN, I				WHITNEY, JA; GOMEZ, M; SHEFF, D; KREIS, TE; MELLMAN, I			CYTOPLASMIC COAT PROTEINS INVOLVED IN ENDOSOME FUNCTION	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-COP; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; BREFELDIN-A; MDCK CELLS; GUANINE-NUCLEOTIDE; TRANSPORT; LYSOSOMES	Endosomes are intermediates for a complex series of sorting and transport events that occur during receptor-mediated endocytosis. These involve the recognition of targeting determinants on the cytoplasmic domains of many membrane proteins as well as the formation of specific transport vesicles. Accordingly, endosome function is likely to be governed by the regulated assembly of cytoplasmic coat complexes. We have found that, in vitro, endosomes recruit a characteristic set of cytoplasmic proteins in a GTP gamma S-stimulated and brefeldin A-sensitive fashion. Among these are members of the COP-I and ARF families of coat proteins. In addition, endosomes were also found to assemble distinct, clathrin-like coats. Since microinjection of antibodies to beta-COP inhibits the entry of enveloped viruses via the endocytic pathway, it is apparent that the recruitment of COP-I or COP-I-related proteins plays an important role in the function of endosomes in intact cells.	UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	WHITNEY, JA (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Sheff, David/A-1269-2007; Mellman, Ira/ABG-5896-2020					AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; KILLISCH I, 1992, J CELL SCI, V103, P211; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KREIS TE, 1995, IN PRESS ANN REV DEV; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWA.J, 1991, CELL, V67, P601; LOWE M, 1995, IN PRESS J BIOL CHEM; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, P NATL ACAD SCI USA, V90, P11089, DOI 10.1073/pnas.90.23.11089; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHEFF D, 1995, IN PRESS J BIOL CHEM; SODEIK B, 1994, J VIROL, V68, P1103, DOI 10.1128/JVI.68.2.1103-1114.1994; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	41	264	267	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					703	713						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521487				2022-12-28	WOS:A1995TH94800007
J	QUINN, M; ALLEN, E				QUINN, M; ALLEN, E			CHANGES IN INCIDENCE OF AND MORTALITY FROM BREAST-CANCER IN ENGLAND AND WALES SINCE INTRODUCTION OF SCREENING	BRITISH MEDICAL JOURNAL			English	Article							TRIAL; MAMMOGRAPHY; HEALTH; PROGRAM; UPDATE; STAGE; WOMEN	Objective-To assess the impact of the NHS breast screening programme on the incidence of and mortality from breast cancer. Design-Comparison of age specific incidence and mortality before and after the introduction of screening in the late 1980s. Setting-England and Wales. Subjects-Women aged over 30 years. Results-In 1992 the age standardised incidence of breast cancer was 40% higher than in 1979. After the introduction of screening in 1988 recorded incidence rates rose steeply in the screened age group (50-64 year olds) but not in others. In 1992 the rates levelled off at about 25% higher than in 1987. Total mortality hom breast cancer has increased steadily since the 1950s; the rates increased earlier in the younger age groups. By the mid-1980s rates had begun to fall in the younger age groups; but total mortality was still among the highest in the world. Age standardised mortality in the 55-69 age group changed little during the first three years of screening but then fell steeply and in 1994 was 12% lower than in 1987. Conclusion-Since the introduction of screening there have been pronounced increases in recorded incidence in the screened age group. Cancer registries have an essential role in assessing screening programmes and cancer services. The steep decrease in mortality in 55-69 year olds which began three years after screening started is unlikely to be due to screening. The widespread adoption of treatment with tamoxifen during this period may be important. With the reduction in mortality already observed and the expected additional benefits from screening, the Health of the Nation target should be achieved.			QUINN, M (corresponding author), OFF POPULAT CENSUSES & SURVEYS,NATL CANC REGISTRAT BUR,ST CATHERINES HOUSE,LONDON WC2B 6JP,ENGLAND.		Allen, Liz/B-2625-2012; Allen, Liz/AAK-3137-2020	Allen, Liz/0000-0002-9298-3168; Allen, Liz/0000-0002-9298-3168				ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; ANDERSON TJ, 1991, BRIT J CANCER, V64, P108, DOI 10.1038/bjc.1991.251; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1995, POLICY FRAMEWORK COM; BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; BAUM M, 1991, BRIT J CANCER, V64, P205, DOI 10.1038/bjc.1991.276; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; BERAL V, IN PRESS 2ND P INT S; Berrino F, 1995, IARC SCI PUBLICATION, V132; BREWSTER D, 1994, ACCURACY 1990 CANCER; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; COLEMAN MP, 1993, IARC SCI PUBLICATION, V121; CRISP WJ, 1993, BRIT J SURG, V80, P863, DOI 10.1002/bjs.1800800718; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELLIOTT P, 1992, LANCET, V339, P854, DOI 10.1016/0140-6736(92)90290-J; ELLIOTT P, 1992, J EPIDEMIOL COMMUN H, V46, P345, DOI 10.1136/jech.46.4.345; EVANS DGR, 1994, BRIT MED J, V308, P183, DOI 10.1136/bmj.308.6922.183; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; KEARSLEY JH, 1986, BMJ-BRIT MED J, V293, P871, DOI 10.1136/bmj.293.6551.871; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; LAW J, 1995, 4TH P INT C BREAST C; MCCARTHY M, 1991, EUR J CANCER, V27, P579, DOI 10.1016/0277-5379(91)90222-Y; MCPHERSON K, 1994, BRIT MED J, V309, P1003, DOI 10.1136/bmj.309.6960.1003; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; MOODY C, 1994, J ROY SOC MED, V87, P259; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PATNICK J, 1993, NHS BREAST SCREENING; PATNICK J, 1994, NHS BREAST SCREENING; ROBERTSON FM, 1990, SURG GYNECOL OBSTET, V171, P55; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SEDDON D, 1994, ACCURACY POPULATION; Shapiro S, 1988, PERIODIC SCREENING B; SIKORA K, 1994, BRIT MED J, V308, P188, DOI 10.1136/bmj.308.6922.188; SILVA ID, 1995, BRIT J CANCER, V72, P485, DOI 10.1038/bjc.1995.360; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; VERBEEK ALM, 1984, LANCET, V1, P1222; WILSON JMG, 1968, WHO34 PUBL HLTH PAP; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224; 1995, UPDATES; 1985, MORTALITY STATIS DH2; 1994, CANCER S E ENGLAND 1; 1983, LANCET, V1, P257; 1995, OUTCOME OBJECTIVES; 1994, CANCER SURVIVAL 1981; 1994, KEY POPULATION VI VS; 1991, EVIDENCE EXPERIENCE; 1983, CANCER STATISTIC MB1; 1994, BREAST CANCER B STIM; 1995, CANCER REGISTRY REPO, V3; 1994, SERIES MBI, V22; 1993, MED RES SERVICES; 1993, BREAST, V2, P13; 1992, USERS VIEWS REPORT S; 1986, BREAST CANCER SCREEN; 1994, TRENDS CANCER SURVIV; 1992, LANCET, V339, P71; 1995, MORTALITY STATIS DH2; 1986, BRIT MED J, V293, P946; 1993, HLTH NATION KEY AREA	64	151	151	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1391	1395		10.1136/bmj.311.7017.1391	http://dx.doi.org/10.1136/bmj.311.7017.1391			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520272	Green Published			2022-12-28	WOS:A1995TG90200016
J	KORETZ, RL; ABBEY, H; COLEMAN, E; GITNICK, G				KORETZ, RL; ABBEY, H; COLEMAN, E; GITNICK, G			NON-A, NON-B POSTTRANSFUSION HEPATITIS - LOOKING BACK IN THE 2ND DECADE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; BLOOD TRANSFUSION; ALANINE AMINOTRANSFERASE; FATIGUE	RECOMBINANT INTERFERON-ALFA; CONTROLLED TRIAL; POSTTRANSFUSION HEPATITIS; DOUBLE-BLIND; DISEASE	Objective: To determine the long-term course of non-A, non-B post-transfusion hepatitis. Design: Follow-up in 1989 to 1992 of patients prospectively identified as having contracted non-A, non-B post-transfusion hepatitis between 1972 and 1980. Setting: A university hospital. Patients: Patients who were prospectively followed from receipt of blood products and in whom otherwise unexplained abnormalities in their serum alanine aminotransferase levels developed without serologic evidence of exposure to hepatitis A or B. Measurements: The presence or absence of clinical evidence of liver failure or symptoms of chronic hepatitis. Results: Of 90 patients identified in the 1970s, 80 were recontacted and evaluated between 1989 and 1992. Based on the current status of these 80 patients and on the last known status of the remaining patients, the following observations were made: 1) Although about 40% had some symptoms during the early phase of the disease, none subsequently experienced significant clinical problems related to hepatic inflammation; 2) eight patients (seven with chronic hepatitis) developed hepatic failure; and 3) life-table analysis showed that the probabilities of developing clinical evidence of cirrhosis after 16 years of disease in the entire cohort, in the subgroup who developed chronic hepatitis, in the patients who had hepatitis C, and in those with chronic hepatitis C were 18%, 21%, 17%, and 20%, respectively. Conclusions: For most of the study patients, non-A, non-B post-transfusion hepatitis was a biochemical and histologic disease that had not yet caused hepatic symptoms. If hepatic failure does occur, it is usually seen only after 10 or more years of disease. Before that time, many infected persons die due to other disease processes.	UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles								AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; BERMAN M, 1979, ANN INTERN MED, V91, P1, DOI 10.7326/0003-4819-91-1-1; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; FEINMAN SV, 1988, GASTROENTEROLOGY, V95, P464, DOI 10.1016/0016-5085(88)90505-7; GREENSTEIN AJ, 1975, NEW ENGL J MED, V293, P685, DOI 10.1056/NEJM197510022931403; KNODELL RG, 1975, GASTROENTEROLOGY, V69, P1278; KORETZ RL, 1976, GASTROENTEROLOGY, V71, P797; KORETZ RL, 1990, HEPATOLOGY, V12, P880; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KORETZ RL, 1980, GASTROENTEROLOGY, V79, P893; PARFREY PS, 1985, KIDNEY INT, V28, P959, DOI 10.1038/ki.1985.224; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; [No title captured]; 1988, LANCET, V2, P1465	17	220	221	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					110	115		10.7326/0003-4819-119-2-199307150-00003	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512159				2022-12-28	WOS:A1993LU90200003
J	MARINGHINI, A; CIAMBRA, M; BACCELLIERE, P; RAIMONDO, M; ORLANDO, A; TINE, F; GRASSO, R; RANDAZZO, MA; BARRESI, L; GULLO, D; MUSICO, M; PAGLIARO, L				MARINGHINI, A; CIAMBRA, M; BACCELLIERE, P; RAIMONDO, M; ORLANDO, A; TINE, F; GRASSO, R; RANDAZZO, MA; BARRESI, L; GULLO, D; MUSICO, M; PAGLIARO, L			BILIARY SLUDGE AND GALLSTONES IN PREGNANCY - INCIDENCE, RISK-FACTORS, AND NATURAL-HISTORY	ANNALS OF INTERNAL MEDICINE			English	Article						CHOLELITHIASIS; PREGNANCY; BILIARY TRACT DISEASES; GALLBLADDER DISEASES; ULTRASONOGRAPHY	NATIONAL COOPERATIVE GALLSTONE; GALLBLADDER-DISEASE; ACUTE-PANCREATITIS; CHOLELITHIASIS; PREVALENCE; TIME; NUCLEATION; ESTROGEN; ORIGIN; ECHOES	Objective: To evaluate the incidence and symptoms of and risk factors for biliary sludge and gallstones during pregnancy and to assess the natural history of these conditions in the first year after delivery. Design: Cohort study. Patients: A total of 272 pregnant women recruited in the first trimester. Measurements: Biliary sludge and gallstones were diagnosed using ultrasonography, both during pregnancy and after delivery. Predictors of the presence or disappearance of sludge and stones were examined. Main Results: Overall, from the first trimester of pregnancy until the immediate postpartum period, 67 women were newly diagnosed with biliary sludge, and 6 women were newly diagnosed with gallstones. The respective incidence rates were 31% (95% CI, 25% to 37%) and 2% (95% CI, 0.2% to 4%). During pregnancy, 28% of women experienced biliary pain, which was associated only with presence of stones. After delivery, 92 women had sludge and 23 had stones. Sludge disappeared in 61 % of these women (CI, 50% to 73%) after a mean follow-up of 5 months, and stones disappeared in 28% of women (CI, 10% to 46%) after 9.7 months of follow-up. Conclusions: Biliary sludge occurred frequently during pregnancy but was generally asymptomatic and often disappeared spontaneously after delivery. Gallstones were much less frequent and were more likely to be associated with biliary pain.	UNIV PALERMO, I-90134 PALERMO, ITALY	University of Palermo			Barresi, Luca/B-4622-2013; Maringhini, Alberto/GRX-4152-2022	Barresi, Luca/0000-0002-3788-145X; Raimondo, Massimo/0000-0002-3750-1541; Maringhini, Alberto/0000-0002-0995-7701				AMARAL JF, 1985, AM J SURG, V149, P551, DOI 10.1016/S0002-9610(85)80055-6; ANGELICO M, 1988, HEPATOLOGY, V8, P907; BARBARA L, 1988, HEPATOLOGY, V8, P1256; BARBARA L, 1987, HEPATOLOGY, V7, P913, DOI 10.1002/hep.1840070520; BARBARA L, 1988, Journal of Hepatology, V7, pS6; BARTOLI E, 1984, GASTROINTEST RADIOL, V9, P35, DOI 10.1007/BF01887798; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; Bockus HL, 1935, PA MED J, V39, P482; BRAVERMAN DZ, 1988, J CLIN GASTROENTEROL, V10, P642, DOI 10.1097/00004836-198812000-00014; CAPOCACCIA L, 1984, AM J EPIDEMIOL, V119, P796; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; Chandrcharoensin-Wilde C, 1988, Birth Defects Orig Artic Ser, V23, P263; COLTON T, 1976, STATISTICS MED; CONRAD MR, 1979, AM J ROENTGENOL, V132, P967, DOI 10.2214/ajr.132.6.967; COOPERBERG PL, 1980, NEW ENGL J MED, V302, P1277, DOI 10.1056/NEJM198006053022303; DWORKEN HJ, 1960, GASTROENTEROLOGY, V38, P76; EVERSON GT, 1982, GASTROENTEROLOGY, V82, P711; FILLY RA, 1980, J CLIN ULTRASOUND, V8, P193, DOI 10.1002/jcu.1870080302; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; GLANCY JJ, 1980, J CLIN ULTRASOUND, V8, P27, DOI 10.1002/jcu.1870080107; GLENN F, 1968, SURG GYNECOL OBSTETR, V127, P1067; GOLDSTEIN A, 1981, J CLIN ULTRASOUND, V9, P365, DOI 10.1002/jcu.1870090704; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HOLAN KR, 1979, GASTROENTEROLOGY, V77, P611; HOPPESEYLER G, 1905, NORTHNAGELS ENCY PRA; JAFFE CC, 1979, RADIOLOGY, V131, P469, DOI 10.1148/131.2.469; JORGENSEN T, 1989, GUT, V30, P433; Kennedy R., 1880, LANCET, V2, P456; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEE SP, 1988, GASTROENTEROLOGY, V95, P1161, DOI 10.1016/0016-5085(88)90219-3; LYNN J, 1973, ANN SURG, V178, P514, DOI 10.1097/00000658-197310000-00014; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARAM ES, 1990, ARCH INTERN MED, V150, P1833, DOI 10.1001/archinte.150.9.1833; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARINGHINI A, 1988, GASTROENTEROLOGY, V95, P1160, DOI 10.1016/0016-5085(88)90218-1; Mauer KR, 1989, GASTROENTEROLOGY, V96, P487; PASSMORE R, 1986, HUMAN NUTRITION DIET, P516; ROBERTSON HE, 1944, INT ABSTR SURG, V78, P193; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SAMPLINER RE, 1970, NEW ENGL J MED, V283, P1358, DOI 10.1056/NEJM197012172832502; SCHOENFIELD LJ, 1981, ANN INTERN MED, V95, P257, DOI 10.7326/0003-4819-95-3-257; SCRAGG RKR, 1984, BRIT MED J, V288, P1795, DOI 10.1136/bmj.288.6433.1795; SEDAGHAT A, 1980, NEW ENGL J MED, V302, P1274, DOI 10.1056/NEJM198006053022302; SHERMAN BM, 1975, J CLIN INVEST, V55, P699, DOI 10.1172/JCI107979; SIMEONE JF, 1980, RADIOLOGY, V137, P181, DOI 10.1148/radiology.137.1.7422843; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SMALL DM, 1980, NEW ENGL J MED, V302, P1305, DOI 10.1056/NEJM198006053022309; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; THISTLE JL, 1984, ANN INTERN MED, V101, P171, DOI 10.7326/0003-4819-101-2-171; VANDERLINDEN W, 1961, ACTA CHIR SCAND    S, V269, P1; WYSOWSKI DK, 1986, AM J EPIDEMIOL, V123, P532, DOI 10.1093/oxfordjournals.aje.a114268	53	133	139	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					116	120		10.7326/0003-4819-119-2-199307150-00004	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512160				2022-12-28	WOS:A1993LU90200004
J	SKELTON, WP				SKELTON, WP			THE OTHER SIDE OF TOMORROW	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									UNIV S FLORIDA, COLL MED, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida									0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					161	162		10.7326/0003-4819-119-2-199307150-00011	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512165				2022-12-28	WOS:A1993LU90200011
J	NARANJO, D; BREHM, P				NARANJO, D; BREHM, P			MODAL SHIFTS IN ACETYLCHOLINE-RECEPTOR CHANNEL GATING CONFER SUBUNIT-DEPENDENT DESENSITIZATION	SCIENCE			English	Article							RAT SKELETAL-MUSCLE; ACTIVATED CHANNELS; LARGE-CONDUCTANCE; XENOPUS MYOCYTES; MEMBRANE PATCHES; MODES; GLUTAMATE; KINETICS; OOCYTES; AGONIST	During the transition from embryonic to adult skeletal muscle, a decreased mean channel open time and accelerated desensitization of nicotinic acetylcholine (ACh) receptors result from the substitution of an E subunit for gamma. A single ACh receptor channel of the embryonic type, expressed in Xenopus oocytes, interconverts between gating modes of short and long open time, whereas the adult receptor channel resides almost exclusively in the gating mode with short open time. Differences in the fraction of time spent in either gating mode account for the subunit dependence of both receptor open time and desensitization. Therefore, developmental changes in the kinetics of muscle ACh receptors may be imparted through subunit-dependent stabilization of intrinsic gating modes.			NARANJO, D (corresponding author), SUNY,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.			Naranjo, David/0000-0003-3482-5126	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018205, R37NS018205] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18205] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVAREZ O, 1992, METHODS ENZYMOL, V207, P816; AUERBACH A, 1986, J PHYSIOL-LONDON, V378, P119, DOI 10.1113/jphysiol.1986.sp016211; AUERBACH A, 1987, J PHYSIOL-LONDON, V393, P437, DOI 10.1113/jphysiol.1987.sp016832; BLATZ AL, 1986, J PHYSIOL-LONDON, V378, P141, DOI 10.1113/jphysiol.1986.sp016212; BRETT RS, 1986, BIOPHYS J, V50, P987, DOI 10.1016/S0006-3495(86)83539-1; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; COVARRUBIAS M, 1990, PFLUG ARCH EUR J PHY, V416, P385, DOI 10.1007/BF00370744; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DILGER JP, 1991, ANN NY ACAD SCI, V625, P616, DOI 10.1111/j.1749-6632.1991.tb33896.x; DILGER JP, 1992, PFLUG ARCH EUR J PHY, V420, P479, DOI 10.1007/BF00374622; FELTZ A, 1982, J PHYSIOL-LONDON, V322, P257, DOI 10.1113/jphysiol.1982.sp014036; FRANKE C, 1991, PFLUG ARCH EUR J PHY, V417, P509, DOI 10.1007/BF00370947; FRANKE C, 1993, BIOPHYS J, V64, P339, DOI 10.1016/S0006-3495(93)81374-2; GIBB AJ, 1990, P ROY SOC B-BIOL SCI, V242, P108, DOI 10.1098/rspb.1990.0112; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; KULLBERG R, 1990, P NATL ACAD SCI USA, V87, P2067, DOI 10.1073/pnas.87.6.2067; LINGLE CJ, 1992, J MEMBRANE BIOL, V126, P195; MACONOCHIE DJ, 1989, PFLUG ARCH EUR J PHY, V414, P589, DOI 10.1007/BF00580996; MCMANUS OB, 1988, J PHYSIOL-LONDON, V402, P79, DOI 10.1113/jphysiol.1988.sp017195; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; OWENS JL, 1989, J NEUROSCI, V9, P1018; PATLAK JB, 1989, J GEN PHYSIOL, V94, P279, DOI 10.1085/jgp.94.2.279; PATLAK JB, 1979, NATURE, V278, P643, DOI 10.1038/278643a0; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SHEPHERD D, UNPUB; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SINE SM, 1987, J PHYSIOL-LONDON, V385, P325, DOI 10.1113/jphysiol.1987.sp016496; SUMIKAWA K, 1989, P NATL ACAD SCI USA, V86, P367, DOI 10.1073/pnas.86.1.367; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	34	56	56	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1811	1814		10.1126/science.8511590	http://dx.doi.org/10.1126/science.8511590			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511590				2022-12-28	WOS:A1993LH20500052
J	CALVERLEY, PMA; SHAPIRO, CM				CALVERLEY, PMA; SHAPIRO, CM			MEDICAL PROBLEMS DURING SLEEP	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	CALVERLEY, PMA (corresponding author), AINTREE HOSP,LIVERPOOL,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1403	1405		10.1136/bmj.306.6889.1403	http://dx.doi.org/10.1136/bmj.306.6889.1403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518611	Bronze, Green Published			2022-12-28	WOS:A1993LD82900028
J	Emanuel, EJ; Emanuel, LL				Emanuel, EJ; Emanuel, LL			What is accountability in health care?	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGED COMPETITION; PROMOTE QUALITY; CONFLICTS; INSURANCE; MEDICINE; ECONOMY; 1990S; PLAN	Accountability has become a major issue in health care. Accountability entails the procedures and processes by which one party justifies and takes responsibility for its activities. The concept of accountability contains three essential components: 1) the loci of accountability-health care consists of at least 11 different parties that can be held accountable or hold others accountable; 2) the domains of accountability-in health care, parties can be held accountable for as many as six activities: professional competence, legal and ethical conduct, financial performance, adequacy of access, public health promotion, and community benefit; and 3) the procedures of accountability, including formal and informal procedures for evaluating compliance with domains and for disseminating the evaluation and responses by the accountable parties. Different models of accountability stress different domains, evaluative criteria, loci, and procedures. We characterize and compare three dominant models of accountability: 1) the professional model, in which the individual physician and patient participate in shared decision making and physicians are held accountable to professional colleagues and to patients; 2) the economic model, in which the market is brought to bear in health care and accountability is mediated through consumer choice of providers; and 3) the political model, in which physicians and patients interact as citizen-members within a community and in which physicians are accountable to a governing board elected from the members of the community, such as the board of a managed care plan. We argue that no single model of accountability is appropriate to health care. Instead, we advocate a stratified model of accountability in which the professional model guides the physician-patient relationship, the political model operates within managed care plans and other integrated health delivery networks, and the economic and political models operate in the relations between managed care plans and other groups such as employers, government, and professional associations.	HARVARD UNIV, SCH MED, DEPT MED ETH, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								ADAMS JL, 1958, 21ST BIENNIAL M AM A; ANDERSON ELIZABETH, 1993, VALUE ETHICS EC, P1; [Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; ARROW KJ, 1963, AM ECON REV, V53, P941; BEGLEY CE, 1987, TEX MED, V83, P64; BREO DL, 1993, JAMA-J AM MED ASSOC, V270, P1978, DOI 10.1001/jama.270.16.1978; BROCK DW, 1994, JAMA-J AM MED ASSOC, V271, P1189, DOI 10.1001/jama.271.15.1189; CHARLES C, 1993, J HEALTH POLIT POLIC, V18, P881, DOI 10.1215/03616878-18-4-881; CHECKOWAY B, 1981, CITIZENS HLTH CARE P, P3; Clinton B., 1993, PRESIDENTS HLTH SECU; DANIELS N, 1985, JUST HLTH CARE; Davis K, 1978, HLTH WAR POVERTY 10; Day P, 1987, ACCOUNTABILITIES, P4; DOUGHERTY C, 1988, AM HLTH CARE REALITI; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; EMANUEL EJ, 1991, ENDS HUMAN LIFE MED, P155; Emanuel LL, 1996, ANN INTERN MED, V124, P240, DOI 10.7326/0003-4819-124-2-199601150-00008; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1988, HEALTH AFFAIR, V7, P25, DOI 10.1377/hlthaff.7.3.25; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; EPSTEIN AM, 1993, NEW ENGL J MED, V329, P1672, DOI 10.1056/NEJM199311253292229; FEIN R, 1982, NEW ENGL J MED, V306, P863, DOI 10.1056/NEJM198204083061409; FOX DM, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.2.7; Freidson E., 1970, PROFESSION MED STUDY; GEIGER HJ, 1972, MED CHANGING SOC; GINZBERG E, 1984, NEW ENGL J MED, V310, P1162, DOI 10.1056/NEJM198405033101806; Gray Bradford H., 1991, PROFIT MOTIVE PATIEN, P71; Hurst J W, 1991, Health Care Financ Rev, V12, P73; IGLEHART JK, 1993, NEW ENGL J MED, V328, P1208, DOI 10.1056/NEJM199304223281627; KAUFMAN NJ, 1994, JAMA-J AM MED ASSOC, V271, P629, DOI 10.1001/jama.271.8.629; LAINE C, IN PRESS JAMA; LIGHT DW, 1985, MILBANK Q, V63, P615, DOI 10.2307/3349852; LUNDBERG GD, 1987, JAMA-J AM MED ASSOC, V258, P3157, DOI 10.1001/jama.258.21.3157; MENZEL PT, 1990, STRONG MED ETHICAL R; METSCH JM, 1976, MED CARE, V14, P283, DOI 10.1097/00005650-197604000-00001; Morone JA, 1990, DEMOCRATIC WISH POPU; NUTTING PA, 1984, COMMUNITY ORIENTED P; Parsons T, 1951, SOCIAL SYSTEM, P428; Rawls J, 1993, POLITICAL LIBERALISM; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; Rodwin M. A., 1993, MED MONEY MORALS PHY; Rosenberg Charles E., 1987, CARE STRANGERS RISE; ROTHSTEIN W, 1972, AM PHYSICIANS 19TH C; SCHORR LB, 1968, MILBANK FUND Q, V46, P289, DOI 10.2307/3349329; Seay J D, 1989, Front Health Serv Manage, V5, P3; STARR P, 1993, NEW ENGL J MED, V329, P1666, DOI 10.1056/NEJM199311253292228; Starr P, 1982, SOCIAL TRANSFORMATIO, V23, P26; Stone D., 1980, LIMITS PROFESSIONAL; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; THUROW LC, 1985, NEW ENGL J MED, V313, P611, DOI 10.1056/NEJM198509053131005; Weber M., 1947, THEORY SOCIAL EC ORG; Williams R., 1976, KEYWORDS; 1993, JAMA-J AM MED ASSOC, V269, P2533; 1993, MMWR-MORBID MORTAL W, V42, P854; 1990, GUIDELINES DEALING F	59	169	171	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					229	239		10.7326/0003-4819-124-2-199601150-00007	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ016	8533999				2022-12-28	WOS:A1996TQ01600007
J	Spinozzi, F; Agea, E; Bistoni, O; Forenza, N; Monaco, A; Bassotti, G; Nicoletti, I; Riccardi, C; Grignani, F; Bertotto, A				Spinozzi, F; Agea, E; Bistoni, O; Forenza, N; Monaco, A; Bassotti, G; Nicoletti, I; Riccardi, C; Grignani, F; Bertotto, A			Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN IGE SYNTHESIS; INTERLEUKIN-4; LYMPHOCYTES; RECEPTOR; APOPTOSIS; COMPLEX	Objective: To test the hypothesis that allergen-specific, steroid-sensitive gamma delta T lymphocytes are increased in bronchoalveolar lavage fluid of patients with asthma. Design: Case series. Setting: The outpatient allergy services at the University of Perugia, Perugia, Italy. Patients: 12 untreated atopic patients (6 children and 6 adults) with mildly symptomatic chronic asthma were studied. Bronchoalveolar ravage fluid from 10 healthy nonsmoking volunteers and age-matched children with cystic fibrosis (n = 5) or anatomic malformation of the airways (n = 4) served as control samples. Intervention: Three patients received treatment with deflazacort, 60 mg twice daily, for 1 week. Measurements: CD3(+), CD4(+), and CD8(+) T cells from patients and controls were examined by two-color flow cytometry for coexpression of V delta 1 and V delta 2 isoforms of the gamma delta T-cell receptor. In vitro pulmonary gamma delta T-cell proliferation in response to a specific allergen, the apoptotic death of these cells after incubation with 10(-7) M dexamethasone, and bronchoalveolar lavage fluid T-lymphocyte composition before and after 1 week of deflazacort therapy were evaluated in 3 Dermatophagoides pteronyssinus-sensitive patients. Results: The proportion of gamma delta T lymphocytes, primarily CD4(+) or CD4(-) CD8(-) cells, was higher in asthmatic patients than in controls (P < 0.05 by one-way analysis of variance). Most lung gamma delta CD4(+) lymphocytes expressed the gamma delta T-cell receptor V delta 1 chain. These cells proliferated in response to allergen stimulation, underwent steroid-induced apoptosis in vitro, and disappeared after systemic steroid treatment. Conclusions: Allergen-specific, steroid-sensitive gamma delta T cells may be one of the cellular components involved in the airway inflammation that characterizes allergic bronchial asthma.					bistoni, onelia/G-8234-2011; Riccardi, Carlo/N-4610-2014	Riccardi, Carlo/0000-0001-9257-3997				BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DELPRETE G, 1992, ALLERGY, V47, P450; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FAJAC I, 1992, CLIN EXP IMMUNOL, V87, P127; GASCAN H, 1992, EUR J IMMUNOL, V22, P1133, DOI 10.1002/eji.1830220505; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MIGLIORATI G, 1993, BLOOD, V81, P1352; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OKUDA M, 1992, ALLERGY, V47, P255, DOI 10.1111/j.1398-9995.1992.tb00659.x; PAWANKAR R, 1995, J ALLERGY CLIN IMMUN, V95, P190; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPINOZZI F, 1992, ARCH INTERN MED, V152, P99, DOI 10.1001/archinte.152.1.99; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053	23	67	69	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					223	227		10.7326/0003-4819-124-2-199601150-00005	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533997				2022-12-28	WOS:A1996TQ01600005
J	Panter, KR; Hannah, ME				Panter, KR; Hannah, ME			Umbilical cord prolapse: So far so good?	LANCET			English	Editorial Material											Panter, KR (corresponding author), UNIV TORONTO,WOMENS COLL HOSP,DEPT OBSTET & GYNAECOL,TORONTO,ON,CANADA.							FENTON AN, 1951, AM J OBSTET GYNECOL, V62, P52, DOI 10.1016/0002-9378(51)91090-3; FERRARA TB, 1989, AM J OBSTET GYNECOL, V161, P1114; Goldthorp W O, 1967, Br J Clin Pract, V21, P21; KOONINGS PP, 1990, J REPROD MED, V35, P690; Kurzrock J, 1932, AM J OBSTET GYNECOL, V23, P403, DOI 10.1016/S0002-9378(32)90832-1; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; MACFARLANE AJ, 1990, 3 4 MORE STUDY TRIPL, P218; MESLEH T, 1993, J OBSTET GYNECOL, V13, P24; MURPHY DJ, 1995, BRIT J OBSTET GYNAEC, V102, P826, DOI 10.1111/j.1471-0528.1995.tb10850.x; YLAOUTINEN A, 1985, ACTA OBSTET GYN SCAN, V64, P567	10	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					74	74		10.1016/S0140-6736(96)90207-X	http://dx.doi.org/10.1016/S0140-6736(96)90207-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538343				2022-12-28	WOS:A1996TP28100006
J	Turton, MD; OShea, D; Gunn, I; Beak, SA; Edwards, CMB; Meeran, K; Choi, SJ; Taylor, GM; Heath, MM; Lambert, PD; Wilding, JPH; Smith, DM; Ghatei, MA; Herbert, J; Bloom, SR				Turton, MD; OShea, D; Gunn, I; Beak, SA; Edwards, CMB; Meeran, K; Choi, SJ; Taylor, GM; Heath, MM; Lambert, PD; Wilding, JPH; Smith, DM; Ghatei, MA; Herbert, J; Bloom, SR			A role for glucagon-like peptide-1 in the central regulation of feeding	NATURE			English	Article							NEUROPEPTIDE-Y CONTENT; C-FOS; RATS; EXPRESSION; INSULIN; HYPOTHALAMUS; BEHAVIOR; SATIETY; BRAIN; CELLS	THE sequence of glucagon-like peptide-(1) (7-36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role(1). We have shown that GLP-1 and its specific receptors are present in the hypothalamus(2,3). No physiological role for central GLP-1 has been established. We report here that intracerebroventricular (ICV) GLP-1 powerfully inhibits feeding in fasted rats, ICV injection of the specific GLP-1-receptor antagonist, exendin (9-39)(4), blocked the inhibitory effect of GLP-1 on food intake. Exendin (9-39) alone had no influence on fast-induced feeding but more than doubled food intake in satiated rats, and augmented the feeding response to the appetite stimulant, neuropeptide Y. Induction of c-fos is a marker of neuronal activation(5). Following ICV GLP-1 injection, c-fos appeared exclusively in the paraventricular nucleus of the hypothalamus and central nucleus of the amygdala, and this was inhibited by prior administration of exendin (9-39). Both of these regions of the brain are of primary importance in the regulation of feeding(6). These findings suggest that central GLP-1 is a new physiological mediator of satiety.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,ENDOCRINE UNIT,LONDON W12 0NN,ENGLAND; UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	Imperial College London; University of Cambridge			Wilding, John PH/A-7106-2008; Wilding, John/ABB-6443-2020	Wilding, John PH/0000-0003-2839-8404; Wilding, John/0000-0003-2839-8404; Smith, David/0000-0001-6831-280X; O'Shea, Donal/0000-0002-1408-5274				ANTIN J, 1975, J COMP PHYSIOL PSYCH, V89, P784, DOI 10.1037/h0077040; ARNOLD FJL, 1992, NEUROSCIENCE, V51, P377, DOI 10.1016/0306-4522(92)90322-S; BILLINGTON CJ, 1983, AM J PHYSIOL, V245, pR920, DOI 10.1152/ajpregu.1983.245.6.R920; BLUNDELL JE, 1985, BRAIN RES BULL, V15, P371, DOI 10.1016/0361-9230(85)90004-8; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOW HL, 1984, EUR J PHARMACOL, V102, P297, DOI 10.1016/0014-2999(84)90261-9; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; GOKE R, 1993, J BIOL CHEM, V268, P19650; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KANSE SM, 1988, FEBS LETT, V241, P209, DOI 10.1016/0014-5793(88)81063-9; KREYMANN B, 1989, BRAIN RES, V502, P325, DOI 10.1016/0006-8993(89)90628-8; KULKARNI RN, 1995, REGUL PEPTIDES, V57, P201; LAMBERT PD, 1993, ENDOCRINOLOGY, V133, P29, DOI 10.1210/en.133.1.29; LAMBERT PD, 1995, BRAIN RES, V670, P59, DOI 10.1016/0006-8993(94)01224-6; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAI A, 1993, AM J PHYSIOL, V265, pG118, DOI 10.1152/ajpgi.1993.265.1.G118; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SUZUKI S, 1989, ENDOCRINOLOGY, V125, P3109, DOI 10.1210/endo-125-6-3109; VEALE PR, 1994, EUR J PHARMACOL, V262, P133, DOI 10.1016/0014-2999(94)90036-1; WANG ZL, 1995, J CLIN INVEST, V95, P417, DOI 10.1172/JCI117671; WILDING JPH, 1993, NEUROENDOCRINOLOGY, V57, P581, DOI 10.1159/000126410; WILDING JPH, 1992, J ENDOCRINOL, V132, P299, DOI 10.1677/joe.0.1320299	24	1478	1585	1	126	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					69	72		10.1038/379069a0	http://dx.doi.org/10.1038/379069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538742				2022-12-28	WOS:A1996TN21600056
J	LUCAS, WJ; BOUCHEPILLON, S; JACKSON, DP; NGUYEN, L; BAKER, L; DING, B; HAKE, S				LUCAS, WJ; BOUCHEPILLON, S; JACKSON, DP; NGUYEN, L; BAKER, L; DING, B; HAKE, S			SELECTIVE TRAFFICKING OF KNOTTED1 HOMEODOMAIN PROTEIN AND ITS MESSENGER-RNA THROUGH PLASMODESMATA	SCIENCE			English	Article							MAIZE HOMEOBOX GENE; MOSAIC-VIRUS; CELLS; FATES	Plasmodesmata are intercellular organelles in plants that establish cytoplasmic continuity between neighboring cells. Microinjection studies showed that plasmodesmata facilitate the cell-to-cell transport of a plant-encoded transcription factor, KNOTTED1 (KN1). KN1 can also mediate the selective plasmodesmal trafficking of kn1 sense RNA. The emerging picture of plant development suggests that cell fate is determined at least in part by supracellular controls responding to cellular position as well as lineage. One of the mechanisms that enables the necessary intercellular communication appears to involve transfer of informational molecules (proteins and RNA) through plasmodesmata.	UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616; UNIV CALIF BERKELEY,USDA,CTR PLANT GENE EXPRESS,ALBANY,CA 94710	University of California System; University of California Davis; United States Department of Agriculture (USDA); University of California System; University of California Berkeley								BECRAFT PW, 1994, GENETICS, V136, P295; CARPENTER R, 1995, DEVELOPMENT, V121, P19; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; HAKE S, 1986, NATURE, V320, P621, DOI 10.1038/320621a0; HANTKE SS, 1995, DEVELOPMENT, V121, P27; HUALA E, 1993, PLANT CELL, V5, P1157, DOI 10.1105/tpc.5.10.1157; JACKSON D, 1994, DEVELOPMENT, V120, P405; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Lucas William J., 1993, Trends in Cell Biology, V3, P308, DOI 10.1016/0962-8924(93)90013-Q; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; LUCAS WJ, 1995, CURR OPIN CELL BIOL, V7, P673, DOI 10.1016/0955-0674(95)80109-X; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; PALUKAITIS P, 1984, VIROLOGY, V132, P426, DOI 10.1016/0042-6822(84)90047-3; ROBARDS AW, 1990, ANNU REV PLANT PHYS, V41, P369, DOI 10.1146/annurev.pp.41.060190.002101; SINHA N, 1990, DEV BIOL, V141, P203, DOI 10.1016/0012-1606(90)90115-Y; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, DEVELOPMENT, V116, P21; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; SYMKOWIAK EJ, 1992, PLANT CELL, V4, P1089; VOLLBRECHT E, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P111; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377	26	579	612	5	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1980	1983		10.1126/science.270.5244.1980	http://dx.doi.org/10.1126/science.270.5244.1980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533088				2022-12-28	WOS:A1995TL42000038
J	GIBBARD, S; LEVY, EH; LUNINE, JI				GIBBARD, S; LEVY, EH; LUNINE, JI			GENERATION OF LIGHTNING IN JUPITER WATER CLOUD	NATURE			English	Article							MOIST CONVECTION; ICE; VOYAGER-1	LIGHTING is a familiar feature of storms on the Earth, and has also been seen on Jupiter(1-3) and inferred indirectly to occur on Venus and Neptune(4,5). On Jupiter, lightning mag. be important as a source of energy to drive chemical reactions in the atmosphere, perhaps determining the abundances of molecules such as CO, HCN and C2H2 (ref. 6). Lightning may be generated in Jupiter's water clouds by a mechanism similar to that which operates in terrestrial thunderstorms(7-9). Here we investigate the development of lightning by modelling the thunderstorm separation of electrical charge on precipitating ice particles at varying depths in Jupiter's atmosphere, We find that lightning can indeed be generated in the jovian water clouds, and that-in agreement with estimates from the analysis of Voyager images(10)-it is most likely to occur at the 3- or 4-bar pressure level, Our model also predicts that a condensed-water abundance in the range of at least 1-2 g m(-3) is required for lightning to occur in jovian thunderstorms-a prediction that may be tested when the Galileo probe arrives at Jupiter on 7 December 1995.			GIBBARD, S (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.							BORTUCKI WJ, 1986, J GEOPHYS RES, V91, P9893; BORUCKI WJ, 1992, ICARUS, V96, P1, DOI 10.1016/0019-1035(92)90002-O; CARANTI JM, 1985, J GEOPHYS RES-ATMOS, V90, P6041, DOI 10.1029/JD090iD04p06041; COOK AF, 1979, NATURE, V280, P794, DOI 10.1038/280794a0; GROSS GW, 1982, J GEOPHYS RES-OCEANS, V87, P7170, DOI 10.1029/JC087iC09p07170; ILLINGWORTH AJ, 1988, J GEOPHYS RES, V90, P6026; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; KEITH WD, 1989, J GEOPHYS RES-ATMOS, V94, P13103, DOI 10.1029/JD094iD11p13103; LEVIN Z, 1983, ICARUS, V56, P80, DOI 10.1016/0019-1035(83)90129-X; LUNINE JL, 1987, ICARUS, V60, P566; NORVILLE K, 1991, J GEOPHYS RES-ATMOS, V96, P7463, DOI 10.1029/90JD02577; PODOLAK M, 1988, ICARUS, V75, P566, DOI 10.1016/0019-1035(88)90165-0; RINNERT K, 1985, J GEOPHYS RES-ATMOS, V90, P6225, DOI 10.1029/JD090iD04p06225; RUSSELL CT, 1993, ANNU REV EARTH PL SC, V21, P43, DOI 10.1146/annurev.ea.21.050193.000355; SCARF FL, 1979, SCIENCE, V204, P991, DOI 10.1126/science.204.4396.991; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; STOKER CR, 1986, ICARUS, V67, P106, DOI 10.1016/0019-1035(86)90179-X; TAKAHASHI T, 1975, J ATMOS SCI, V32, P123, DOI 10.1175/1520-0469(1975)032<0123:ECLCIW>2.0.CO;2; UMAN MA, 1987, LIGHTNING DISCHARGE; WEAST R, 1967, CRC HDB CHEM PHYSICS; YAIR H, 1995, ICARUS, V115, P421; YAIR H, 1995, ICARUS, V114, P278; YANAI M, 1973, J ATMOS SCI, V30, P611, DOI 10.1175/1520-0469(1973)030<0611:DOBPOT>2.0.CO;2	23	27	27	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					592	595		10.1038/378592a0	http://dx.doi.org/10.1038/378592a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524392				2022-12-28	WOS:A1995TJ22100068
J	BUCKINGHAM, RA; BUCKINGHAM, RO				BUCKINGHAM, RA; BUCKINGHAM, RO			ROBOTS IN OPERATING-THEATERS	BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION; WORKSTATION	Robots designed for surgery have three main advantages over humans. They have greater three dimensional spatial accuracy, are more reliable, and can achieve much greater precision. Although few surgical robots are yet in clinical trials one or two have advanced to the stage of seeking approval from the UK's Medical Devices Agency and the US Federal Drug Administration. Safety is a key concern. A robotic device can be designed in an intrinsically safe way by restricting its range of movement to an area where it can do no damage. Furthermore, safety can be increased by making it passive, guided at all times by a surgeon. Nevertheless, some of the most promising developments may come from robots that are active (monitored rather than controlled by the surgeon) and not limited to intrinsically safe motion.	SOUTHMEAD GEN HOSP,BRISTOL BS10 5NB,AVON,ENGLAND; UNIV BRISTOL,FAC ENGN,ADV MFG & AUTOMAT RES CTR,BRISTOL BS8 1TR,AVON,ENGLAND	Southmead Hospital; University of Bristol								BACH JR, 1990, AM J PHYS MED REHAB, V69, P55, DOI 10.1097/00002060-199004000-00002; Benabid A L, 1992, Acta Neurochir Suppl (Wien), V54, P93; BRETT PN, 1995, J IEEE EMBS, V14, P264; DAVIES BL, 1993, ROBOTICA, V11, P561, DOI 10.1017/S026357470001941X; DRAKE JM, 1991, NEUROSURGERY, V29, P27, DOI 10.1227/00006123-199107000-00005; GLAUSER D, 1990, STEREOT FUNCT NEUROS, V54-5, P468, DOI 10.1159/000100256; GLAUSER D, 1993, ROBOTICA, V11, P567, DOI 10.1017/S0263574700019421; GREEN PS, 1995, J IEEE EMBS, V14, P324; GYBELS J, 1990, STEREOT FUNCT NEUROS, V54-5, P493, DOI 10.1159/000100261; HAMMEL JM, 1992, ARCH PHYS MED REHAB, V73, P683; HILLMAN M, 1992, J BIOMED ENG, V14, P187, DOI 10.1016/0141-5425(92)90050-U; HILLMAN MR, 1991, J BIOMED ENG, V13, P239, DOI 10.1016/0141-5425(91)90134-S; KALL B, 1992, OCT INF C IEE EMBS P; KIENZLE TC, 1995, J IEEE EMBS, V14, P301; MATSEN FA, 1993, CLIN ORTHOP RELAT R, V296, P178; Mckerrow P., 1991, INTRO ROBOTICS; MITTELSTADT B, 1993, ROBOTICA, V11, P553, DOI 10.1017/S0263574700019408; REGALBUTO MA, 1992, J REHABIL RES DEV, V29, P19, DOI 10.1682/JRRD.1992.01.0019; SACKIER JM, 1994, SURG ENDOSC-ULTRAS, V8, P63, DOI 10.1007/BF02909496; TUMONEY AG, 1991, J ENDOUROL, V5, P165; UPTON C, 1993, RAID WORKSTATION TOD; VANVLIET P, 1991, PHYS THER, V71, P39, DOI 10.1093/ptj/71.1.39	22	68	73	2	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1479	1482		10.1136/bmj.311.7018.1479	http://dx.doi.org/10.1136/bmj.311.7018.1479			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520340	Green Published			2022-12-28	WOS:A1995TJ04400030
J	TRICHOPOULOU, A; KOURISBLAZOS, A; WAHLQVIST, ML; GNARDELLIS, C; LAGIOU, P; POLYCHRONOPOULOS, E; VASSILAKOU, T; LIPWORTH, L; TRICHOPOULOS, D				TRICHOPOULOU, A; KOURISBLAZOS, A; WAHLQVIST, ML; GNARDELLIS, C; LAGIOU, P; POLYCHRONOPOULOS, E; VASSILAKOU, T; LIPWORTH, L; TRICHOPOULOS, D			DIET AND OVERALL SURVIVAL IN ELDERLY PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; COLORECTAL-CANCER; MORTALITY	Objective-To assess the influence of a specific dietary pattern on overall survival. Design-Cohort study. Setting-Three rural Greek villages, the data from which were collected as part of an international cross cultural study of food habits in later life. Subjects-182 elderly residents of the three villages. Main outcome measure-Overall mortality. Results-Diet was assessed with a validated extensive semiquantitative questionnaire on food intake. A one unit increase in diet score, devised a priori on the basis of eight component characteristics of the traditional common diet in the Mediterranean region, was associated with a significant 17% reduction in overall mortality (95% confidence interval 1% to 31%). Conclusion-A diet meeting currently understood health criteria does predict survival among people.	NATL SCH PUBL HLTH, NATL CTR NUTR, GR-11521 ATHENS, GREECE; MONASH MED CTR, DEPT MED, CLAYTON, VIC 3168, AUSTRALIA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, HARVARD CTR CANC PREVENT, BOSTON, MA 02115 USA	National & Kapodistrian University of Athens; Monash University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			TRICHOPOULOU, ANTONIA/ABF-8727-2021; Vassilakou, Tonia/R-6967-2017; Wahlqvist, Mark Lawrence/E-8800-2010	TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Vassilakou, Tonia/0000-0002-9993-1897; GNARDELLIS, CHARALAMPOS/0000-0001-8862-7868; Polychronopoulos, Evangelos/0000-0001-7061-4081				BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; DALES LG, 1978, INT J EPIDEMIOL, V7, P373, DOI 10.1093/ije/7.4.373; DALES LG, 1979, AM J EPIDEMIOL, V109, P132, DOI 10.1093/oxfordjournals.aje.a112668; GNARDELLIS C, 1995, EPIDEMIOLOGY, V6, P74, DOI 10.1097/00001648-199501000-00015; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; Helsing E., 1989, EUR J CLIN NUTR, V43, P1; HJERMANN I, 1981, LANCET, V2, P1303; KATSOUYANNI K, 1991, AM J EPIDEMIOL, V133, P24, DOI 10.1093/oxfordjournals.aje.a115798; KATSOUYANNI K, 1991, DIETARY VARIABILITY, P1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KROMHOUT D, 1982, LANCET, V2, P518; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; MENOTTI A, 1989, ANN MED, V21, P175, DOI 10.3109/07853898909149929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; TRICHOPOULOS D, 1990, RECENT PROGR RES NUT; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; Trichopoulou A, 1994, J Cardiovasc Risk, V1, P9, DOI 10.1097/00043798-199406000-00003; TRICHOPOULOU A, 1993, EUR J CLIN NUTR, V47, pS76; TRICHOPOULOU A, 1993, EUR J CLIN NUTR, V47, P549; TRICHOPOULOU A, 1992, COMPOSITION GREEK FO; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT W, 1991, NEW ENGL J MED, V324, P121, DOI 10.1056/NEJM199101103240209; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; [No title captured]; [No title captured]	29	909	922	5	73	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	1995	311	7018					1457	1460		10.1136/bmj.311.7018.1457	http://dx.doi.org/10.1136/bmj.311.7018.1457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520331	Green Published			2022-12-28	WOS:A1995TJ04400019
J	LIP, GYH; BEEVERS, DG; SINGH, SP; WATSON, RDS				LIP, GYH; BEEVERS, DG; SINGH, SP; WATSON, RDS			ABC OF ATRIAL-FIBRILLATION - ETIOLOGY, PATHOPHYSIOLOGY, AND CLINICAL-FEATURES	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND; WALSGRAVE GEN HOSP,DEPT CARDIOL,COVENTRY,W MIDLANDS,ENGLAND	University of Birmingham	LIP, GYH (corresponding author), UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							MURGATROYD FD, 1993, LANCET, V341, P1317	1	35	37	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1425	1428		10.1136/bmj.311.7017.1425	http://dx.doi.org/10.1136/bmj.311.7017.1425			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520281	Green Published			2022-12-28	WOS:A1995TG90200037
J	BOURNE, Y; TAYLOR, P; MARCHOT, P				BOURNE, Y; TAYLOR, P; MARCHOT, P			ACETYLCHOLINESTERASE INHIBITION BY FASCICULIN - CRYSTAL-STRUCTURE OF THE COMPLEX	CELL			English	Article							MAMBA DENDROASPIS-ANGUSTICEPS; LIGAND-BINDING; SNAKE-VENOM; PROTEIN; TOXINS; RECEPTOR; RESIDUES; SITE; BUTYRYLCHOLINESTERASE; POLYLEPIS	The crystal structure of the snake toxin fasciculin, bound to mouse acetylcholinesterase (mAChE), at 3.2 Angstrom resolution reveals a synergistic three-point anchorage consistent with the picomolar dissociation constant of the complex. Loop II of fasciculin contains a cluster of hydrophobic residues that interact with the peripheral anionic site of the enzyme and sterically occlude substrate access to the catalytic site. Loop I fits in a crevice near the lip of the gorge to maximize the surface area of contact of loop II at the gorge entry. The fasciculin core surrounds a protruding loop on the enzyme surface and stabilizes the whole assembly. Upon binding of fasciculin, subtle structural rearrangements of AChE occur that could explain the observed residual catalytic activity of the fasciculin-enzyme complex.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BOURNE, Y (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.		Bourne, Yves/AAC-4635-2022; MARCHOT, Pascale/AAC-4752-2022	Bourne, Yves/0000-0003-3850-0548; MARCHOT, Pascale/0000-0003-0630-0541	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEM A, 1988, BIOCHIM BIOPHYS ACTA, V968, P340, DOI 10.1016/0167-4889(88)90025-0; AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BARAK D, 1994, J BIOL CHEM, V269, P6296; BERTRAND D, 1995, NEUROSCIENCES, V7, P75; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BROWN LR, 1992, J MOL BIOL, V227, P1118, DOI 10.1016/0022-2836(92)90525-O; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Cervenansky C., 1991, P303; CERVENANSKY C, 1995, EUR J BIOCHEM, V229, P270, DOI 10.1111/j.1432-1033.1995.0270l.x; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; CYGLER M, 1993, PROTEIN SCI, V2, P366; DURAN R, 1994, BBA-GEN SUBJECTS, V1201, P381, DOI 10.1016/0304-4165(94)90066-3; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; Endo T., 1991, P165; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HENDERSON R, 1990, PHILOS T ROY SOC B, V326, P379, DOI 10.1098/rstb.1990.0019; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LEDU MH, 1995, IN PRESS ACTA CRYSTA; LIN WW, 1987, ASIA PAC J PHARMACOL, V2, P79; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SEGALAS I, 1995, BIOCHEMISTRY-US, V34, P1248, DOI 10.1021/bi00004a019; SHAFFERMAN A, 1994, EMBO J, V13, P3448, DOI 10.1002/j.1460-2075.1994.tb06650.x; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; STRYDOM DJ, 1972, J BIOL CHEM, V247, P4029; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VANDENBORN HKL, 1995, PROTEIN SCI, V4, P703	52	320	324	2	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					503	512		10.1016/0092-8674(95)90128-0	http://dx.doi.org/10.1016/0092-8674(95)90128-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521480	Green Submitted, Bronze			2022-12-28	WOS:A1995TC97700020
J	KIM, B; LITTLE, JW				KIM, B; LITTLE, JW			LEXA AND LAMBDA-CI-REPRESSORS AS ENZYMES - SPECIFIC CLEAVAGE IN AN INTERMOLECULAR REACTION	CELL			English	Article							RECA-MEDIATED CLEAVAGE; T7 EXPRESSION SYSTEM; GROUP-I INTRON; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; DEPENDENT CLEAVAGE; CBP2 PROTEIN; MUTAGENESIS; PHOSPHORYLATION; AUTODIGESTION	During the SOS response, LexA repressor is inactivated. by specific cleavage. Although cleavage requires RecA protein in vivo, RecA acts indirectly as a coprotease by stimulating an inherent self-cleavage activity of LexA. In lambda lysogens, cleavage of lambda CI repressor in a similar but far slower reaction results in prophage induction. We describe an intermolecular cleavage reaction in which the C-terminal fragment of LexA acted as an enzyme to cleave other molecules of LexA. The C-terminal fragment of lambda repressor cleaved the LexA substrates about as efficiently as did the LexA enzyme, suggesting that the slow rate of CI self-cleavage results from a weak interaction between its cleavage site and the active site.	UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, TUCSON, AZ 85721 USA	University of Arizona	KIM, B (corresponding author), UNIV ARIZONA, DEPT BIOCHEM, TUCSON, AZ 85721 USA.							AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Blair WS, 1991, CURR OPIN CELL BIOL, V3, P1039, DOI 10.1016/0955-0674(91)90126-J; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CECH TR, 1992, J BIOL CHEM, V267, P17479; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; EGUCHI Y, 1988, J MOL BIOL, V202, P565, DOI 10.1016/0022-2836(88)90286-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HORII T, 1981, CELL, V27, P515, DOI 10.1016/0092-8674(81)90393-7; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Johnson A D, 1980, Methods Enzymol, V65, P839; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KIM B, 1993, THESIS U ARIZONA TUC; LEY H, 1984, BRL FOCUS, V6, P5; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; ROBERTS JW, 1983, LAMBDA, V2, P123; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; SAUER RT, 1982, J BIOL CHEM, V257, P4458; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SLILATY SN, 1991, PROTEIN ENG, V4, P919, DOI 10.1093/protein/4.8.919; SMITH MH, 1991, P NATL ACAD SCI USA, V88, P7356, DOI 10.1073/pnas.88.16.7356; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	42	73	74	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1165	1173		10.1016/0092-8674(93)90645-7	http://dx.doi.org/10.1016/0092-8674(93)90645-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513500				2022-12-28	WOS:A1993LH54800012
J	VANVACTOR, D; SINK, H; FAMBROUGH, D; TSOO, R; GOODMAN, CS				VANVACTOR, D; SINK, H; FAMBROUGH, D; TSOO, R; GOODMAN, CS			GENES THAT CONTROL NEUROMUSCULAR SPECIFICITY IN DROSOPHILA	CELL			English	Article							SELECT APPROPRIATE PATHWAYS; PATTERNED NEURITE OUTGROWTH; JAPANESE MEDAKA FISH; GROWTH CONES; CHICK-EMBRYO; PRIMARY MOTONEURONS; LUMBOSACRAL LEVEL; PROXIMAL TISSUES; SENSORY NEURONS; NERVOUS-SYSTEM	In each abdominal hemisegment of the Drosophila embryo, an array of 30 muscle fibers is innervated by about 34 motoneurons in a highly stereotyped and cell-specific fashion. To begin to elucidate the molecular basis of neural specificity in this system, we conducted a genetic screen for mutations affecting neuromuscular connectivity. We focus on 5 genes required for specific aspects of pathway (beaten path, stranded, and short stop) and target (walkabout and clueless) recognition. The different classes of mutant phenotypes suggest that neural specificity is controlled by a hierarchy of molecular mechanisms: motoneurons are guided toward the correct region of mesoderm, in many cases navigating a series of choice points along the way; they then display an affinity for a particular domain of neighboring muscles; and finally, they recognize their specific muscle target from within this domain.			VANVACTOR, D (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Van Vactor, Jr., David L./0000-0001-8156-9482				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1990, DEVELOPMENT, V110, P791; BENTLEY D, 1992, NERVE GROWTH CONE, P265; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; BROADIE KS, 1993, J NEUROSCI, V13, P167; BROADIE KS, 1993, J NEUROSCI, V13, P144; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASH S, 1992, J NEUROSCI, V12, P2051; CHANG S, 1992, DEVELOPMENT, V114, P815; CHIBA A, 1993, J NEUROSCI, V13, P714; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; DAVIES JA, 1990, NEURON, V2, P11; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GATCHALIAN CL, 1992, NEURON, V9, P105, DOI 10.1016/0896-6273(92)90225-3; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KESHISHIAN H, 1993, IN PRESS J NEUROBIOL; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1993, IN PRESS COLD SPRING, V57; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKAMOTO H, 1991, DEV BIOL, V146, P62, DOI 10.1016/0012-1606(91)90446-A; OKAMOTO H, 1991, DEV BIOL, V146, P49, DOI 10.1016/0012-1606(91)90445-9; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PIKE SH, 1990, J NEUROSCI, V10, P44; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TEAR G, 1993, IN PRESS PERSPECT DE; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; TOSNEY KW, 1988, DEV BIOL, V127, P266, DOI 10.1016/0012-1606(88)90314-4; WESTERFIELD M, 1990, NEURON, V4, P867, DOI 10.1016/0896-6273(90)90139-7; WESTERFIELD M, 1988, TRENDS NEUROSCI, V11, P18, DOI 10.1016/0166-2236(88)90044-6; WHITELAW V, 1983, J NEUROSCI, V3, P1226; WIESCHAUS E, 1984, W ROUX ARCH DEV BIOL, V193, P283	63	376	376	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1137	1153		10.1016/0092-8674(93)90643-5	http://dx.doi.org/10.1016/0092-8674(93)90643-5			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513498				2022-12-28	WOS:A1993LH54800010
J	MANGTANI, P; SEED, P				MANGTANI, P; SEED, P			CIMETIDINE AND WEIGHT-LOSS	BRITISH MEDICAL JOURNAL			English	Letter											MANGTANI, P (corresponding author), LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1 7HT,ENGLAND.		Seed, Paul T/C-4435-2008	Seed, Paul T/0000-0001-7904-7933				GARROW J, 1993, BRIT MED J, V306, P1084, DOI 10.1136/bmj.306.6885.1084; POCOCK SJ, 1990, CLIN TRIALS PRACTICA, P216; RASMUSSEN MH, 1993, BRIT MED J, V306, P1093, DOI 10.1136/bmj.306.6885.1093; STOABIRKETVEDT G, 1993, BRIT MED J, V306, P1091, DOI 10.1136/bmj.306.6885.1091	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1542	1543		10.1136/bmj.306.6891.1542-c	http://dx.doi.org/10.1136/bmj.306.6891.1542-c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518701	Green Published			2022-12-28	WOS:A1993LF94000066
J	Kashina, AS; Baskin, RJ; Cole, DG; Wedaman, KP; Saxton, WM; Scholey, JM				Kashina, AS; Baskin, RJ; Cole, DG; Wedaman, KP; Saxton, WM; Scholey, JM			A bipolar kinesin	NATURE			English	Article							ELECTRON-MICROSCOPY; MITOTIC SPINDLE; FISSION YEAST; IN-VITRO; PROTEIN; MOTOR; MICROTUBULES; GENE; ORGANIZATION; ANTIBODY	CHROMOSOME Segregation during mitosis depends on the action of the mitotic spindle, a self-organizing, bipolar protein machine which uses microtubules (MTs) and their associated motors(1,2). Members of the BimC subfamily of kinesin-related MT-motor proteins are believed to be essential for the formation and functioning of a normal bipolar spindle(3-14). Here we report that KRP(130), a homotetrameric BimC-related kinesin purified from Drosophila melanogaster embryos(13), has an ultrastructure. It consists of four kinesin-related polypeptides assembled into a bipolar aggregate with motor domains at opposite ends, analogous to a miniature myosin filament(15). Such a bipolar 'minifilament' could crosslink spindle MTs and slide them relative to one another. We do not know of any other MT motors that have a bipolar structure.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	Kashina, AS (corresponding author), UNIV CALIF DAVIS,SECT MOLEC & CELLULAR BIOL,DAVIS,CA 95616, USA.				NIGMS NIH HHS [R01 GM046295-09, R01 GM046295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1987, J CELL SCI, V87, P105; ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; COLE DG, 1994, J BIOL CHEM, V269, P22913; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOGAN CJ, 1993, P NATL ACAD SCI USA, V90, P6611, DOI 10.1073/pnas.90.14.6611; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; KOONCE MP, 1987, NATURE, V328, P737, DOI 10.1038/328737a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; MITCHISON TJ, 1992, PHILOS T ROY SOC B, V336, P99, DOI 10.1098/rstb.1992.0049; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SANDERS WS, 1992, CELL, V70, P451; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; TSUPRUN VL, 1991, DOKL AKAD NAUK SSSR+, V320, P1270; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VEMOS I, 1995, TRENDS CELL BIOL, V5, P297; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	28	291	302	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					270	272		10.1038/379270a0	http://dx.doi.org/10.1038/379270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538794	Green Accepted			2022-12-28	WOS:A1996TQ16900050
J	Barr, S				Barr, S			The 1990 Florida dental investigation: Is the case really closed?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TRANSMISSION	In 1994, a magazine article, a newspaper article, and a segment of the television newsmagazine 60 Minutes presented information that cast doubt on the Centers for Disease Control and Prevention's conclusion that a dentist in Florida had infected six of his patients with the human immunodeficiency virus (HIV). These reports were based on previously unavailable documentary evidence, which suggested that the infected patients had unreported or undetected risk factors for HIV infection and that the molecular analyses used to determine that the dentist and his patients had the same strains of HIV had potentially serious flaws. A recent article in this journal sought to dismiss the relevance of this information in the eyes of the scientific community. That report, however, failed to respond directly to many key pieces of evidence, and it offered no rebuttal beyond personal invective and a reassertion of previously published material. Although scientists and clinicians should not rely solely on media reports when drawing conclusions about this complex and controversial case, they deserve a chance to consider and reflect on this material in a meaningful way.										BARR S, 1994, LEARS MAGAZINE   APR, P68; BARR S, 1994, NY TIMES        0416; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; CRANDALL KA, 1995, J VIROL, V69, P2351, DOI 10.1128/JVI.69.4.2351-2356.1995; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; HOLMES EC, 1993, NATURE, V364, P766, DOI 10.1038/364766b0; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; SMITH TF, 1992, SCIENCE, V256, P1155, DOI 10.1126/science.256.5060.1155	11	8	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					250	254		10.7326/0003-4819-124-2-199601150-00009	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534001				2022-12-28	WOS:A1996TQ01600009
J	Whitcup, SM				Whitcup, SM			Grand rounds at the Clinical Center of the National Institutes of Health - Ocular manifestations of AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CYTOMEGALO-VIRUS RETINITIS; RETINAL VASCULOPATHY; GANCICLOVIR; FOSCARNET; INFECTION; THERAPY; PATIENT				Whitcup, SM (corresponding author), NEI,CLIN BRANCH,10 CTR DR,BLDG 10,ROOM 10N 202,BETHESDA,MD 20892, USA.							AZAD RF, 1993, ANTIMICROB AGENTS CH, V37, P1945, DOI 10.1128/AAC.37.9.1945; DIAZLLOPIS M, 1992, AM J OPHTHALMOL, V114, P742, DOI 10.1016/S0002-9394(14)74054-1; FABER DW, 1992, INVEST OPHTH VIS SCI, V33, P2345; HENRY K, 1987, AM J OPHTHALMOL, V103, P17, DOI 10.1016/S0002-9394(14)74163-7; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JACOBS DS, 1994, AM J OPHTHALMOL, V118, P716, DOI 10.1016/S0002-9394(14)72550-4; JACOBSON MA, 1991, J INFECT DIS, V163, P1348, DOI 10.1093/infdis/163.6.1348; KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; NELSON MR, 1991, LANCET, V338, P250, DOI 10.1016/0140-6736(91)90385-3; NGUYEN BYT, 1993, J INFECT DIS, V168, P810, DOI 10.1093/infdis/168.4.810; PALESTINE AG, 1995, INVEST OPHTH VIS SCI, V36, pS181; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; PEPOSE JS, 1989, CURR TOP AIDS, V2, P191; POLIS MA, 1995, ANTIMICROB AGENTS CH, V39, P882, DOI 10.1128/AAC.39.4.882; POLLARD RB, 1992, ANTIVIRAL RES S1, V16, P111; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; SARAN BR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1159, DOI 10.1001/archopht.1994.01090210043015; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; SPECTOR SA, 1995, J INFECT DIS, V171, P1431, DOI 10.1093/infdis/171.6.1431; WHITCUP SM, 1992, AM J OPHTHALMOL, V113, P1; 1996, ARCH OPHTHALMOL-CHIC, V114, P23; 1992, NEW ENGL J MED, V326, P213; 1995, ARCH INTERN MED, V155, P65	26	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					142	144		10.1001/jama.275.2.142	http://dx.doi.org/10.1001/jama.275.2.142			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531310				2022-12-28	WOS:A1996TN28000031
J	Writer, JV; DeFraites, RF; Brundage, JF				Writer, JV; DeFraites, RF; Brundage, JF			Comparative mortality among US military personnel in the Persian Gulf region and worldwide during Operations Desert Shield and Desert Storm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH	Objective.-To determine cause-specific mortality rates among US troops stationed in the Persian Gulf region and compare them with those of US troops serving elsewhere during Operations Desert Shield and Desert Storm. Design.-Retrospective cohort. Population.-US men and women on active duty from August 1, 1990, through July 31, 1991. Main Outcome Measures.-Deaths occurring among all active-duty US military persons during the 1-year study period. Age-adjusted mortality rates among US troops stationed in the Persian Gulf region were compared with rates projected from mortality rates among troops on active duty elsewhere. Results.-A total of 1769 active-duty persons died during the study period, 372 in the Persian Gulf region and 1397 elsewhere. Of the 372 deaths in the Persian Gulf region, 147 (39.5%) occurred as a direct result of combat during the war, 194 (52.2%) resulted from injuries not incurred in battle, and 30 (8%) resulted from illness. Twenty-three of the deaths due to illness were considered unexpected or cardiovascular deaths. Based on age-adjusted mortality rates observed among US troops on active duty outside the Persian Gulf region, 165 deaths from unintentional injury and 32 deaths from illness (20 of which were unexpected or cardiovascular) would have been anticipated among Persian Gulf troops. Conclusion.-Except for deaths from unintentional injury, US troops in the Persian Gulf region did not experience significantly higher mortality rates than US troops serving elsewhere. There were no clusters of unexplained deaths. The number and circumstances of nonbattle deaths among Persian Gulf troops were typical for the US military population.	USA,CTR HLTH PROMOT & PREVENT MED,EPIDEMIOL & DIS SURVEILLANCE DIRECTORATE,ABERDEEN PROVING GROUND,MD		Writer, JV (corresponding author), WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307, USA.		Brundage, John/Q-9244-2019					BEARY JF, 1984, MIL MED, V149, P316; BEEBE GW, 1952, BATTLE CASUALTIES IN, P16; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P1559, DOI 10.1001/jama.271.20.1559; HELMKAMP JC, 1994, J OCCUP ENVIRON MED, V36, P609; HELMKAMP JC, 1988, MIL MED, V153, P621; KAHN HA, 1989, STATISTICAL METHODS, P100; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P53; REISTER RA, 1973, BATTLE CASUALTIES ME, P1; RICH BSE, 1994, MED CLIN N AM, V78, P267, DOI 10.1016/S0025-7125(16)30159-6; ROTHBERG JM, 1990, JAMA-J AM MED ASSOC, V264, P2241, DOI 10.1001/jama.264.17.2241; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P86; STONG GC, 1993, MIL MED, V158, P108, DOI 10.1093/milmed/158.2.108; VANCAMP SP, 1992, CLIN SPORT MED, V11, P273; 1992, CONDUCT PERSIAN GULF; 1995, ARCH INTERN MED, V155, P262; 1994, JAMA-J AM MED ASSOC, V272, P391	16	65	66	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					118	121		10.1001/jama.275.2.118	http://dx.doi.org/10.1001/jama.275.2.118			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531306				2022-12-28	WOS:A1996TN28000027
J	Heafield, MTE; Gammage, MD; Nightingale, S; Williams, AC				Heafield, MTE; Gammage, MD; Nightingale, S; Williams, AC			Idiopathic dysautonomia treated with intravenous gammaglobulin	LANCET			English	Article							ACUTE PANDYSAUTONOMIA; AUTONOMIC NEUROPATHY; RECOVERY; FAILURE	Background A previously healthy 23-year-old man presented with a short history of abdominal pain and diarrhoea followed by blurred vision, severe postural hypotension, reduced sweating and unremitting fever. Methods Examination revealed fixed dilated pupils, impaired sweating and postural hypotension. Clinical and neurophysiological examination showed no motor or sensory deficit. A diagnosis of idiopathic autonomic neuropathy was made. He became gravely ill with profound life-threatening hypotension and a prolonged ileus. Findings Within 36 h of receiving intravenous gammaglobulin (IVGG) his pupillary areflexia and severe hypotension resolved. 2 weeks later the autonomic failure recurred but again responded to treatment with IVGG. IVGG is a recognised treatment for Guillain-Barre syndrome. Interpretation This case report demonstrates that IVGG is also effective in the rare pure dysautonomic variant.	UNIV HOSP BIRMINGHAM TRUST, DEPT CARDIOVASC MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND		Heafield, MTE (corresponding author), UNIV BIRMINGHAM, UNIV HOSP BIRMINGHAM TRUST, DEPT CLIN NEUROL, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND.							APPENZELLER O, 1973, ARCH NEUROL-CHICAGO, V29, P334, DOI 10.1001/archneur.1973.00490290074010; FAGIUS J, 1983, J NEUROL NEUROSUR PS, V46, P725, DOI 10.1136/jnnp.46.8.725; HOPKINS A, 1974, LANCET, V1, P769; LOW PA, 1993, MAYO CLIN PROC, V68, P748, DOI 10.1016/S0025-6196(12)60631-4; MANN S, 1983, CIRCULATION, V68, P477, DOI 10.1161/01.CIR.68.3.477; SCHRODER JM, 1987, POLNEURITIDEN POLYNE, P23; SUAREZ GA, 1994, NEUROLOGY, V44, P1675, DOI 10.1212/WNL.44.9.1675; THOMASHEFSKY AJ, 1972, NEUROLOGY, V22, P251, DOI 10.1212/WNL.22.3.251; YOUNG R R, 1969, Transactions of the American Neurological Association, V94, P355; YOUNG RR, 1975, BRAIN, V98, P613, DOI 10.1093/brain/98.4.613	10	54	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					28	29		10.1016/S0140-6736(96)91559-7	http://dx.doi.org/10.1016/S0140-6736(96)91559-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531546				2022-12-28	WOS:A1996TN76200014
J	Hannigan, GE; LeungHagesteijn, C; FitzGibbon, L; Coppolino, MG; Radeva, G; Filmus, J; Bell, JC; Dedhar, S				Hannigan, GE; LeungHagesteijn, C; FitzGibbon, L; Coppolino, MG; Radeva, G; Filmus, J; Bell, JC; Dedhar, S			Regulation of cell adhesion and anchorage-dependent growth by a new beta(1)-integrin-linked protein kinase	NATURE			English	Article							EXPRESSION; DIFFERENTIATION; INTEGRINS; SEQUENCE	THE interaction of cells with the extracellular matrix regulates cell shape, motility, growth, survival, differentiation and gene expression, through integrin-mediated signal transduction(1-3). We used a two-hybrid screen to isolate genes encoding proteins that interact with the beta(1)-integrin cytoplasmic domain. The most frequently isolated complementary DNA encoded a new, 59K serine/threonine protein kinase, containing four ankyrin-like repeats. We report here that this integrin-linked kinase (ILK) phosphorylated a beta(1)-integrin cytoplasmic domain peptide in vitro and coimmunoprecipitated with beta(1) in lysates of mammalian cells. Endogenous ILK kinase activity was reduced in response to fibronectin. Overexpression of p59(ILK) disrupted epithelial cell architecture and inhibited adhesion to integrin substrates, while inducing anchorage-independent growth. We propose that ILK is a receptor-proximal protein kinase regulating integrin-mediated signal transduction.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CANC BIOL RES PROGRAM, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1N 6N5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa			Hannigan, Greg/A-5092-2009	Dedhar, Shoukat/0000-0003-4355-1657				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEDHAR S, 1993, CLIN EXP METASTAS, V11, P391, DOI 10.1007/BF00132982; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILMUS J, 1994, ONCOGENE, V9, P3627; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	29	932	1015	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	1996	379	6560					91	96		10.1038/379091a0	http://dx.doi.org/10.1038/379091a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538749				2022-12-28	WOS:A1996TN21600063
J	Doyle, G				Doyle, G			A new breed of parasuicide patient	BRITISH MEDICAL JOURNAL			English	Note											Doyle, G (corresponding author), ST LUKES HOSP,DEPT YOUNG PEOPLES,MIDDLESBROUGH TS4 3AF,CLEVELAND,ENGLAND.							1994, INT STATISTICAL CLAS	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1696	1696		10.1136/bmj.311.7021.1696	http://dx.doi.org/10.1136/bmj.311.7021.1696			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541763	Green Published			2022-12-28	WOS:A1995TL94200024
J	THEOLOGIS, A				THEOLOGIS, A			UPDATE - ETHYLENE SENSORS - HOW PERCEPTIVE	SCIENCE			English	Editorial Material							ARABIDOPSIS				THEOLOGIS, A (corresponding author), PLANT GENE EXPRESS CTR,800 BUCHANAN ST,ALBANY,CA 94710, USA.							Abeles F, 1992, ETHYLENE PLANT BIOL; BLEECKER A, COMMUNICATION; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHANG C, IN PRESS TRENDS BIOC; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; ZHOU D, IN PRESS PLANT MOL B	10	5	5	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1774	1774		10.1126/science.270.5243.1774	http://dx.doi.org/10.1126/science.270.5243.1774			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525365				2022-12-28	WOS:A1995TK47600032
J	ZHENG, YX; WONG, ML; ALBERTS, B; MITCHISON, T				ZHENG, YX; WONG, ML; ALBERTS, B; MITCHISON, T			NUCLEATION OF MICROTUBULE ASSEMBLY BY A GAMMA-TUBULIN-CONTAINING RING COMPLEX	NATURE			English	Article							ASPERGILLUS-NIDULANS; ORGANIZING CENTERS; CENTROSOME; MITOSIS; PROTEIN; CHROMOSOMES; COMPONENT; INVITRO; BINDING	The highly conserved protein gamma-tubulin is required for microtubule nucleation in vivo. When viewed in the electron microscope, a highly purified gamma-tubulin complex from Xenopus consisting of at least seven different proteins is seen to have an open ring structure. This complex acts as an active microtubule-nucleating unit which can cap the minus ends of microtubules in vitro.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	ZHENG, YX (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BRYAN J, 1971, P NATL ACAD SCI USA, V68, P1762, DOI 10.1073/pnas.68.8.1762; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS P, 1980, J CELL BIOL, V84, P668, DOI 10.1083/jcb.84.3.668; HORIO T, 1991, J CELL SCI, V99, P693; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; MALDELKOW E, 1995, TRENDS CELL BIOL, V5, P262; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; VASSILEV A, 1995, J CELL SCI, V108, P1083; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; WILSON EB, 1925, CELL DEV HEREDITY, P1232; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	36	693	703	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	1995	378	6557					578	583		10.1038/378578a0	http://dx.doi.org/10.1038/378578a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524390				2022-12-28	WOS:A1995TJ22100066
J	ZHOU, MM; RAVICHANDRAN, KS; OLEJNICZAK, ET; PETROS, AM; MEADOWS, RP; SATTLER, M; HARLAN, JE; WADE, WS; BURAKOFF, SJ; FESIK, SW				ZHOU, MM; RAVICHANDRAN, KS; OLEJNICZAK, ET; PETROS, AM; MEADOWS, RP; SATTLER, M; HARLAN, JE; WADE, WS; BURAKOFF, SJ; FESIK, SW			STRUCTURE AND LIGAND RECOGNITION OF THE PHOSPHOTYROSINE BINDING DOMAIN OF SHC	NATURE			English	Article							HIGH-AFFINITY; SIGNAL-TRANSDUCTION; PHOSPHOLIPID-VESICLES; DISTANCE GEOMETRY; PROTEINS; RECEPTOR; ASSOCIATION; ACTIVATION; PEPTIDE	The nuclear magnetic resonance structure of the phosphotyrosine binding (PTB) domain of Shc complexed to a phosphopeptide reveals an alternative means of recognizing tryosine-phosphorylated proteins. Unlike in SH2 domains, the phosphopeptide forms an antiparallel beta-strand with a beta-sheet of the protein, interacts with a hydrophobic pocket through the (pY-5) residue, and adopts a beta-turn. The PTB domain is structurally similar to pleckstrin homology domains (a alpha-sandwich capped by an alpha-helix) and binds to acidic phospholipids, suggesting a possible role in membrane localization.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Abbott Laboratories; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Sattler, Michael/C-1169-2010; Sattler, Michael/A-2407-2012	Sattler, Michael/0000-0002-1594-0527				BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; DIKIC I, 1985, J BIOL CHEM, V270, P15125; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FLOWER DR, 1993, FEBS LETT, V333, P99, DOI 10.1016/0014-5793(93)80382-5; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1993, J BIOL CHEM, V269, P1599; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TORTORELLA D, 1994, ANAL BIOCHEM, V217, P176, DOI 10.1006/abio.1994.1106; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	50	321	339	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					584	592		10.1038/378584a0	http://dx.doi.org/10.1038/378584a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524391				2022-12-28	WOS:A1995TJ22100067
J	HAN, TS; VANLEER, EM; SEIDELL, JC; LEAN, MEJ				HAN, TS; VANLEER, EM; SEIDELL, JC; LEAN, MEJ			WAIST CIRCUMFERENCE ACTION LEVELS IN THE IDENTIFICATION OF CARDIOVASCULAR RISK-FACTORS - PREVALENCE STUDY IN A RANDOM SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							CHOLESTEROL DETERMINATION; FAT DISTRIBUTION; WEIGHT-LOSS; MEN; OBESITY; DISEASE; DIET	Objective-To determine the frequency of cardiovascular risk factors in people categorised by previously defined ''action levels'' of waist circumference. Design-Prevalence study in a random population sample. Setting-Netherlands. Subjects- 2183 men and 2698 women aged 20-59 years selected at random from the civil registry of Amsterdam and Maastricht. Main outcome measures-Waist circumference. waist to hip ratio, body mass index (weight (kg)/height (m(2))), total plasma cholesterol concentration, high density lipoprotein cholesterol concentration, blood pressure, age, and lifestyle. Results-A waist circumference exceeding 94 cm in men and 80 cm in women correctly identified subjects with body mass index of greater than or equal to 25 and waist to hip ratios greater than or equal to 0.95 in men and greater than or equal to 0 80 in women with a sensitivity and specificity of greater than or equal to 96%. Men and women with at least one cardiovascular risk factor (total cholesterol greater than or equal to 6 5 mmol/l, high density lipoprotein cholesterol greater than or equal to 0.9 mmol/l, systolic blood pressure greater than or equal to 160 mm Hg, diastolic blood pressure greater than or equal to 95 mm Hg) were identified with sensitivities of 57% and 67% and specificities of 72% and 62% respectively. Compared with those with waist measurements below action levels, age and lifestyle adjusted odds ratios for having at least one risk factor were 2.2 (95% confidence interval 1.8 to 2.8) in men with a waist measurement of 94-102 cm and 1.6 (1.3 to 2.1) in women with a waist measurement of 80-88 cm, In men and women with larger waist measurements these age- and lifestyle adjusted odds ratios were 4.6 (3.5 to 6.0) and 2.6 (2.0 to 3.2) respectively, Conclusions-Larger waist circumference identifies people at increased cardiovascular risks.	UNIV GLASGOW,ROYAL INFIRM,DEPT HUMAN NUTR,GLASGOW G31 2ER,LANARK,SCOTLAND; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,BILTHOVEN,NETHERLANDS	Royal Infirmary of Edinburgh; University of Glasgow; Netherlands National Institute for Public Health & the Environment			seidell, jacob/AAF-5362-2019; seidell, jacob c/N-7427-2013	seidell, jacob/0000-0002-9262-9062; Han, Thang/0000-0003-2570-0938				CHAN JM, 1994, DIABETES CARE, V9, P961; DENTONKELAAR I, 1995, BREAST CANCER RES TR, V34, P55, DOI 10.1007/BF00666491; EDWARDS KL, 1994, ARTERIOSCLER THROMB, V14, P1940, DOI 10.1161/01.ATV.14.12.1940; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; ROSS R, 1992, J APPL PHYSIOL, V72, P787, DOI 10.1152/jappl.1992.72.2.787; ROSS R, 1993, AM J CLIN NUTR, V67, P470; SEIDELL JC, 1988, EUR J CLIN NUTR, V42, P805; SEIDELL JC, 1992, INT J OBESITY, V16, P17; SEIDELL JC, 1995, PROGR OBESITY RES, P303; SONNICHSEN AC, 1992, METABOLISM, V41, P1035, DOI 10.1016/0026-0495(92)90134-V; STURMANS F, 1984, EPIDEMIOLOGY THEORIE; SWINSCOW TDV, 1983, STATISTICS SQUARE ON; VERSCHUREN WMM, 1993, NETH J CARDIOL, V6, P205; Welsch R, 1980, REGRESSION DIAGNOSTI; WING RR, 1995, INT J OBESITY, V19, P67; WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086; 1989, EURICPNUT125 WHO NUT; 1988, WORLD HLTH STAT Q, V41, P115; [No title captured]	26	603	659	0	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1401	1405		10.1136/bmj.311.7017.1401	http://dx.doi.org/10.1136/bmj.311.7017.1401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520275	Green Published			2022-12-28	WOS:A1995TG90200021
J	LANGENBACH, R; MORHAM, SG; TIANO, HF; LOFTIN, CD; GHANAYEM, BI; CHULADA, PC; MAHLER, JF; LEE, CA; GOULDING, EH; KLUCKMAN, KD; KIM, HS; SMITHIES, O				LANGENBACH, R; MORHAM, SG; TIANO, HF; LOFTIN, CD; GHANAYEM, BI; CHULADA, PC; MAHLER, JF; LEE, CA; GOULDING, EH; KLUCKMAN, KD; KIM, HS; SMITHIES, O			PROSTAGLANDIN-SYNTHASE-1 GENE DISRUPTION IN MICE REDUCES ARACHIDONIC ACID-INDUCED INFLAMMATION AND INDOMETHACIN-INDUCED GASTRIC-ULCERATION	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IMMEDIATE-EARLY GENE; ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; G/H SYNTHASE; COMPLEMENTARY-DNA; CDNA CLONING; COLON CANCER; ASPIRIN USE; CYCLOOXYGENASE	Cyclooxygenases 1 and 2 (COX-1 and COX-2) are key enzymes in prostaglandin biosynthesis and the target enzymes for the widely used nonsteroidal anti-inflammatory drugs. To study the physiological roles of the individual isoforms, we have disrupted the mouse Ptgs1 gene encoding COX-1. Homozygous Ptgs1 mutant mice survive well, have no gastric pathology, and show less indomethacin-induced gastric ulceration than wild-type mice, even though their gastric prostaglandin E(2) levels are about 1% of wild type. The homozygous mutant mice have reduced platelet aggregation and a decreased inflammatory response to arachidonic acid, but not to tetradecanoyl phorbol acetate. Ptgs1 homozygous mutant females mated to homozygous mutant males produce few live offspring. COX-1-deficient mice provide a useful model to distinguish the physiological roles of COX-1 and COX-2.	NIEHS, BIOCHEM RISK ANAL LAB, RES TRIANGLE PK, NC 27709 USA; NIEHS, EXPTL PATHOL LAB, RES TRIANGLE PK, NC 27709 USA; NIEHS, REPROD & DEV TOXICOL LAB, RES TRIANGLE PK, NC 27709 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	LANGENBACH, R (corresponding author), NIEHS, EXPTL CARCINOGENESIS & MUTAGENESIS LAB, RES TRIANGLE PK, NC 27709 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49227] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK WS, 1990, ARCH TOXICOL, V64, P210, DOI 10.1007/BF02010727; BLACK H E, 1986, Toxicologic Pathology, V14, P83; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, METHOD ENZYMOL, V187, P469; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ETTARH RR, 1993, SCAND J GASTROENTERO, V28, P795, DOI 10.3109/00365529309104012; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; Ghanayem BI, 1987, GASTROENTEROLOGY, V92, P106, DOI 10.1016/0016-5085(87)90845-6; HEATH CW, 1994, CANCER-AM CANCER SOC, V74, P2885, DOI 10.1002/1097-0142(19941115)74:10<2885::AID-CNCR2820741023>3.0.CO;2-P; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; KARGMAN SL, 1995, CANCER RES, V55, P2556; KELLY RW, 1994, ENDOCR REV, V15, P684, DOI 10.1210/er.15.5.684; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEVI S, 1994, BRIT J RHEUMATOL, V33, P605; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARNETT LJ, 1992, CANCER RES, V52, P5575; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MORHAM SG, 1995, CELL, V83; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P181, DOI 10.1016/0021-9150(87)90245-0; PRICE AH, 1990, DRUGS, V40, P1, DOI 10.2165/00003495-199000405-00003; RAINSFORD KD, 1993, AGENT ACTION SUPPL, V44, P59; RAINSFORD KD, 1987, J PHARM PHARMACOL, V39, P669; RAO CV, 1995, CANCER RES, V55, P1464; ROBERT A, 1975, GASTROENTEROLOGY, V69, P1045; ROBERT A, 1979, GASTROENTEROLOGY, V77, P761, DOI 10.1016/0016-5085(79)90235-x; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SAMET JM, 1995, J BIOL CHEM, V270, P8044, DOI 10.1074/jbc.270.14.8044; SEIBERT K, 1994, RECEPTOR, V4, P17; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Simon Lee S., 1994, Current Opinion in Rheumatology, V6, P238, DOI 10.1097/00002281-199405000-00002; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; SMITH WL, 1990, STROKE, V21, P24; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; THORBURN GD, 1992, EARLY HUM DEV, V29, P63, DOI 10.1016/0378-3782(92)90059-P; THORBURN GD, 1991, REPROD FERT DEVELOP, V3, P277, DOI 10.1071/RD9910277; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; Vane J R, 1992, J Physiol Pharmacol, V43, P195; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WATANABE S, 1994, J LIPID MEDIAT CELL, V10, P283; WEN PZ, 1993, GENOMICS, V15, P458, DOI 10.1006/geno.1993.1091; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOKOYAMA M, 1985, AM J PATHOL, V119, P367; ZAHRADNIK HP, 1992, EICOSANOIDS, V5, pS56	82	949	977	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					483	492		10.1016/0092-8674(95)90126-4	http://dx.doi.org/10.1016/0092-8674(95)90126-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521478	Green Submitted, Bronze			2022-12-28	WOS:A1995TC97700018
J	ROBERTS, SGE; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR				ROBERTS, SGE; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR			INTERACTION BETWEEN AN ACIDIC ACTIVATOR AND TRANSCRIPTION FACTOR-TFIIB IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION	NATURE			English	Article							BINDING; MECHANISM; MEDIATOR; INVITRO; DOMAIN; VP16	HOW eukaryotic promoter-specific activator proteins (activators) stimulate transcription is a central question. We have previously shown that an acidic activator can directly interact with the general transcription factor TFIIB and increase its stable assembly into a preinitiation complex1,2. We have proposed that this increase in TFIIB assembly is at least part of the mechanism by which an acidic activator functions1,2. A prediction of this hypothesis is that a TFIIB mutant unable to interact with an acidic activator could not support activated transcription, and here we present experiments that verify this prediction. In conjunction with previous studies, our results argue that interaction between an acidic activator and TFIIB is necessary for transcriptional activation.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	ROBERTS, SGE (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365; Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x	18	209	212	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					741	744		10.1038/363741a0	http://dx.doi.org/10.1038/363741a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515819				2022-12-28	WOS:A1993LJ33900062
J	PIAZZA, A				PIAZZA, A			WHO ARE THE EUROPEANS	SCIENCE			English	Article									UNIV TURIN,CNR,CTR IMMUNOGENET & ISTOCOMPATIBIL,I-10124 TURIN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Turin	PIAZZA, A (corresponding author), UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,I-10124 TURIN,ITALY.			Piazza, Alberto/0000-0002-2355-4183				Ammerman A.J., 1973, EXPLANATION CULTURE, P343; BARBUJANI G, 1990, P NATL ACAD SCI USA, V87, P1816, DOI 10.1073/pnas.87.5.1816; CAVALLISFORZA LL, 1993, EUR J HUM GENET, V1, P3; CAVALLISFORZA LL, 1991, GENOMICS, V11, P490, DOI 10.1016/0888-7543(91)90169-F; CAVALLISFORZA LL, IN PRESS HIST GEOGRA; Gimbutas MA., 1991, CIVILIZATION GODDESS; GUGLIELMINO CR, 1990, AM J PHYS ANTHROPOL, V83, P57, DOI 10.1002/ajpa.1330830107; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; PIAZZA A, 1988, MUNIBE ANTROPOLOGIA, V6, P168; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; Ruhlen M., 1987, GUIDE WORLDS LANGUAG; Soffer O., 1990, WORLD 18000 BP; SOKAL RR, 1992, P NATL ACAD SCI USA, V89, P7669, DOI 10.1073/pnas.89.16.7669; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; SOKAL RR, 1992, NATURE, V355, P214, DOI 10.1038/355214b0; SPOOR CF, 1986, J HUM EVOL, V15, P399, DOI 10.1016/S0047-2484(86)80019-7; Trombetti A., 1925, ORIGINI LINGUA BASCA; WRIGHT S, 1951, ANN EUGENIC, V15, P323	18	43	44	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1767	1769		10.1126/science.8511584	http://dx.doi.org/10.1126/science.8511584			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511584				2022-12-28	WOS:A1993LH20500037
J	Carlos, L; daSilva, C; Muller, L; daSilva, C				Carlos, L; daSilva, C; Muller, L; daSilva, C			Multidrug-resistant tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											Carlos, L (corresponding author), UNIV FED RIO GRANDE SUL,BR-90049 PORTO ALEGRE,RS,BRAZIL.							DASILVA LCC, 1995, AM J RESP CRIT CARE, V151, pA554; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802	2	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					267	268						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532009				2022-12-28	WOS:A1996TQ75500014
J	Bateman, AC				Bateman, AC			Pathogenesis of sudden ischaemic cardiac death	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; THROMBOSIS				Bateman, AC (corresponding author), QUEEN ALEXANDRA HOSP, DEPT HISTOPATHOL, PORTSMOUTH, HANTS, ENGLAND.							ALFONSO F, 1995, J AM COLL CARDIOL, V26, P135, DOI 10.1016/0735-1097(95)00186-4; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DIMAIO VJM, 1993, AM J FOREN MED PATH, V14, P273, DOI 10.1097/00000433-199312000-00001; DISCIASCIO G, 1994, AM HEART J, V128, P419, DOI 10.1016/0002-8703(94)90612-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; HENNEKENS CH, 1995, J AM COLL CARDIOL, V25, pS18; LEACH IH, 1995, EUR HEART J, V16, P1181, DOI 10.1093/oxfordjournals.eurheartj.a061073; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6	11	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	1996	347	8994					70	71		10.1016/S0140-6736(96)90204-4	http://dx.doi.org/10.1016/S0140-6736(96)90204-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538340				2022-12-28	WOS:A1996TP28100003
J	Levy, A				Levy, A			Why flush?	LANCET			English	Editorial Material											Levy, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							GELLER J, 1991, J AM GERIATR SOC, V39, P1208, DOI 10.1111/j.1532-5415.1991.tb03576.x; GINSBURG J, 1983, BRIT MED J, V387, P262; HARDIMAN PJ, 1995, J N AM MENOPAUSE SOC, V2, P159; Huggins C, 1941, CANCER RES, V1, P293; KARLING P, 1994, J UROLOGY, V152, P1170, DOI 10.1016/S0022-5347(17)32530-2; LABRIE F, 1995, J CLIN ENDOCR METAB, V80, P2002, DOI 10.1210/jc.80.7.2002; LOPRINZI CL, 1994, J UROLOGY, V151, P634, DOI 10.1016/S0022-5347(17)35034-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; SMITH JA, 1994, J UROLOGY, V152, P132, DOI 10.1016/S0022-5347(17)32835-5	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					73	74		10.1016/S0140-6736(96)90206-8	http://dx.doi.org/10.1016/S0140-6736(96)90206-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538342				2022-12-28	WOS:A1996TP28100005
J	Kuwayama, H; Ecke, M; Gerisch, G; VanHaastert, PJM				Kuwayama, H; Ecke, M; Gerisch, G; VanHaastert, PJM			Protection against osmotic stress by cGMP-mediated myosin phosphorylation	SCIENCE			English	Article							HEAVY-CHAIN PHOSPHORYLATION; DICTYOSTELIUM-DISCOIDEUM; SIGNAL-TRANSDUCTION; ATPASE ACTIVITY; CYCLIC-AMP; MUTANTS; LACKING; GENE; REPLACEMENT; DISRUPTION	Conventional myosin functions universally as a generator of motive force in eukaryotic cells. Analysis of mutants of the microorganism Dictyostelium discoideum revealed that myosin also provides resistance against high external osmolarities. An osmo-induced increase of intracellular guanosine 3',5'-monophosphate was shown to mediate phosphorylation of three threonine residues on the myosin tail, which caused a relocalization of myosin required to resist osmotic stress. This redistribution of myosin allowed cells to adopt a spherical shape and may provide physical strength to withstand extensive cell shrinkage in high osmolarities.	UNIV GRONINGEN, DEPT BIOCHEM, 9747 AG GRONINGEN, NETHERLANDS; MAX PLANCK INST BIOCHEM, D-82143 MARTINSRIED, GERMANY	University of Groningen; Max Planck Society								CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GERISCH G, 1993, SYM SOC EXP BIOL, V47, P297; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; JUNGBLUTH A, 1994, J CELL SCI, V107, P117; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; KUWAYAMA H, UNPUB; LIU G, 1993, J CELL SCI, V106, P591; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MATO JM, 1977, P NATL ACAD SCI USA, V74, P2348, DOI 10.1073/pnas.74.6.2348; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; OYAMA M, UNPUB; PAGH K, 1986, J CELL BIOL, V103, P1527, DOI 10.1083/jcb.103.4.1527; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; SCHUSTER SC, UNPUB; SPUDICH JA, 1989, CELL REGUL, V1, P1; STREET HE, 1984, PHYSL FLOWERING PLAN; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P347, DOI 10.1083/jcb.96.2.347; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	33	101	101	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					207	209		10.1126/science.271.5246.207	http://dx.doi.org/10.1126/science.271.5246.207			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539621	Green Submitted			2022-12-28	WOS:A1996TP36400043
J	Cocker, JH; Piatti, S; Santocanale, C; Nasmyth, K; Diffley, JFX				Cocker, JH; Piatti, S; Santocanale, C; Nasmyth, K; Diffley, JFX			An essential role for the Cdc6 protein in forming the pre-replicative complexes of budding yeast	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; DIVISION; CYCLE	ORIGINS Of DNA replication in Saccharomyces cerevisiae are bound by two protein complexes during the cell cycle(1,2). Post-replicative complexes closely resemble those generated in vitro by purified origin recognition complex (ORC)(1,3-5), which is essential for DNA replication in vivo(6-11). Pre-replicative complexes (pre-RCs) are characterized by an extended region of nuclease protection overlapping the ORC footprint(1). We show here that the Cdc6 protein (Cdc6p), which is necessary for origin firing in vivo(12-16), is essential for the establishment and maintenance of pre-RCs, suggesting that it is a component of these complexes. Without Cdc6p, G1 origins closely resemble post-replicative origins, providing evidence that ORC is also a component of pre-RCs, These results suggest that pre-RCs play an essential role in initiating DNA replication and support a two-step mechanism for the assembly of functional initiation complexes.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Piatti, Simonetta/0000-0003-1958-8919; Nasmyth, Kim/0000-0001-7030-4403; Diffley, John/0000-0001-5184-7680; Santocanale, Corrado/0000-0003-1337-5656				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHEREST H, 1985, GENE, V34, P269; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351; [No title captured]	26	294	299	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					180	182		10.1038/379180a0	http://dx.doi.org/10.1038/379180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538771				2022-12-28	WOS:A1996TP36000063
J	Rothman, KJ				Rothman, KJ			Lessons from John Graunt	LANCET			English	Article									BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA	Boston University; Boston University				Rothman, Kenneth/0000-0003-2398-1705				COLE P, 1993, EPIDEMIOLOGY, V4, P96, DOI 10.1097/00001648-199303000-00004; GOODMAN SN, 1993, ANN INTERN MED, V118, P78, DOI 10.7326/0003-4819-118-1-199301010-00023; Graunt J, 1975, NATURAL POLITICAL OB; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; MESSORI A, 1933, ANN INTERN MED, V118, P77; POOLE C, 1987, AM J PUBLIC HEALTH, V77, P195, DOI 10.2105/AJPH.77.2.195; ROTHMAN KJ, 1993, EPIDEMIOLOGY, V4, P555, DOI 10.1097/00001648-199311000-00013; Sullivan K M, 1990, Epidemiology, V1, P39, DOI 10.1097/00001648-199001000-00009	8	31	36	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					37	39		10.1016/S0140-6736(96)91562-7	http://dx.doi.org/10.1016/S0140-6736(96)91562-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531550				2022-12-28	WOS:A1996TN76200017
J	Macready, WG; Siapas, AG; Kauffman, SA				Macready, WG; Siapas, AG; Kauffman, SA			Criticality and parallelism in combinatorial optimization	SCIENCE			English	Article							SYSTEMS; MODEL	Local search methods constitute one of the most successful approaches to solving large-scale combinatorial optimization problems. As these methods are increasingly parallelized, optimization performance initially im proves but then abruptly degrades to no better than that of random search beyond a certain point. The existence of this transition is demonstrated for a family of generalized spin-glass models and the traveling salesman problem. Finite-size scaling is used to characterize size-dependent effects near the transition, and analytical insight is obtained through a mean-field approximation.	MIT, DEPT ELECT ENGN & COMP SCI, CAMBRIDGE, MA 02139 USA; SANTA FE INST, SANTA FE, NM 87501 USA	Massachusetts Institute of Technology (MIT); The Santa Fe Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azencott R., 1992, SIMULATED ANNEALING; Binnet J. J, 1992, THEORY CRITICAL PHEN; Cheeseman PC., 1991, IJCAI, V91, P331; Creswick RJ, 1992, INTRO RENORMALIZATIO; CVIJOVIC D, 1995, SCIENCE, V267, P664, DOI 10.1126/science.267.5198.664; DERRIDA B, 1981, PHYS REV B, V24, P2613, DOI 10.1103/PhysRevB.24.2613; Fischer KH., 1991, SPIN GLASSES, DOI [10.1017/CBO9780511628771, DOI 10.1017/CBO9780511628771]; FORREST S, 1993, SCIENCE, V261, P872, DOI 10.1126/science.8346439; Glover F., 1989, ORSA Journal on Computing, V1, P190, DOI [10.1287/ijoc.2.1.4, 10.1287/ijoc.1.3.190]; HOGG T, 1991, IEEE T SYST MAN CYB, V21, P1325, DOI 10.1109/21.135679; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; LIN S, 1973, OPER RES, V21, P498, DOI 10.1287/opre.21.2.498; MACKEN CA, 1989, P NATL ACAD SCI USA, V86, P6191, DOI 10.1073/pnas.86.16.6191; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Reinelt G., 1994, TRAVELING SALESMAN C; SIAPAS AG, UNPUB; WEINBERGER ED, 1991, PHYS REV A, V44, P6399, DOI 10.1103/PhysRevA.44.6399	18	34	51	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					56	59		10.1126/science.271.5245.56	http://dx.doi.org/10.1126/science.271.5245.56			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539600				2022-12-28	WOS:A1996TP02200040
J	WIRSCHING, P; ASHLEY, JA; LO, CHL; JANDA, KD; LERNER, RA				WIRSCHING, P; ASHLEY, JA; LO, CHL; JANDA, KD; LERNER, RA			REACTIVE IMMUNIZATION	SCIENCE			English	Article							SERINE PROTEASES; CATALYZED HYDROLYSIS; ANTIBODY; ESTERS; CHYMOTRYPSIN; PHOSPHONATE; INHIBITION; ACETYLCHOLINESTERASE; PARAMETERS; MECHANISM	For almost 200 years inert antigens have been used for initiating the process of immunization. A procedure is now described in which the antigen used is so highly reactive that a chemical reaction occurs in the antibody combining site during immunization. An organophosphorus diester hapten was used to illustrate this concept coined ''reactive immunization.'' The organophosphonate recruited chemical potential from the immune response that resembled the way these compounds recruit the catalytic power of the serine hydrolases. During this recruitment, a large proportion of the isolated antibodies catalyzed the formation and cleavage of phosphonylated intermediates and subsequent ester hydrolysis. Reactive immunization can augment traditional immunization and enhance the scope of catalytic antibody chemistry. Among the compounds anticipated to be effective are those that contain appropriate reactive functionalities or those that are latently reactive, as in the mechanism-based inhibitors of enzymes.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008590] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA27489-16] Funding Source: Medline; NIDA NIH HHS [DA08590] Funding Source: Medline; NIGMS NIH HHS [GM48351] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHANI Y, 1981, 26TH P OH C ZICHR YA; BARTLETT PA, 1986, BIOORG CHEM, V14, P356, DOI 10.1016/0045-2068(86)90002-7; BECKER EL, 1967, BIOCHIM BIOPHYS ACTA, V147, P289, DOI 10.1016/0005-2795(67)90407-2; BENDER ML, 1962, J AM CHEM SOC, V84, P2577, DOI 10.1021/ja00872a023; Benkovic S. J., 1978, TRANSITION STATES BI; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BORDWELL FG, 1957, J AM CHEM SOC, V79, P717, DOI 10.1021/ja01560a059; BORDWELL FG, 1952, J AM CHEM SOC, V74, P1058, DOI 10.1021/ja01124a057; BRUICE TC, 1957, J AM CHEM SOC, V79, P1663, DOI 10.1021/ja01564a036; BRUICE TC, 1960, J AM CHEM SOC, V82, P3067, DOI 10.1021/ja01497a023; BRUICE TC, 1964, J AM CHEM SOC, V86, P418, DOI 10.1021/ja01057a026; Cleland W W, 1979, Methods Enzymol, V63, P103; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; EXNE O, 1972, ADV LINEAR FREE ENER; Exner O., 1988, CORRELATION ANAL CHE; FUKUTO TR, 1956, J AGR FOOD CHEM, V4, P930, DOI 10.1021/jf60069a001; GIBBS RA, 1992, J AM CHEM SOC, V114, P3528, DOI 10.1021/ja00035a057; GREEN BS, 1981, STUDIES ORGANIC CHEM, V10, P1; Guo Jincan, 1994, Journal of the American Chemical Society, V116, P6062, DOI 10.1021/ja00093a002; HARRIS LW, 1966, SCIENCE, V154, P404, DOI 10.1126/science.154.3747.404; HART GJ, 1973, BIOCHEMISTRY-US, V12, P2940, DOI 10.1021/bi00739a026; HOVANEC JW, 1972, BIOCHEMISTRY-US, V11, P1051, DOI 10.1021/bi00756a016; Johnson C. D, 1973, HAMMETT EQUATION; KEIJER JH, 1974, BIOCHIM BIOPHYS ACTA, V334, P146, DOI 10.1016/0005-2744(74)90158-2; KIRSCH JF, 1968, J ORG CHEM, V33, P127, DOI 10.1021/jo01265a023; KIRSCH JF, 1972, ADV LINEAR FREE ENER; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kovach I M, 1988, J Enzyme Inhib, V2, P199, DOI 10.3109/14756368809040726; KOVACH IM, 1993, J AM CHEM SOC, V115, P5138, DOI 10.1021/ja00065a027; KOVACH IM, 1991, J MOL STRUC-THEOCHEM, V79, P335, DOI 10.1016/0166-1280(91)85072-F; KOVACH IM, 1986, J AM CHEM SOC, V108, P5490, DOI 10.1021/ja00278a020; KOVACH IM, 1991, THEOCHEM-J MOL STRUC, V72, P99, DOI 10.1016/0166-1280(91)80008-V; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OLEKSYSZYN J, 1991, BIOCHEMISTRY-US, V30, P485, DOI 10.1021/bi00216a026; OOMS AJJ, 1966, BIOCHEM PHARMACOL, V15, P1361, DOI 10.1016/0006-2952(66)90047-5; RELIMPIO AM, 1978, GEN PHARMACOL, V9, P49, DOI 10.1016/0306-3623(78)90058-7; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; SCHERER H, 1972, CHEM BER-RECL, V105, P3357, DOI 10.1002/cber.19721051024; Seiler N, 1978, ENZYME ACTIVATED IRR; SILVERMAN RB, 1988, MECHANISM BASED ENZY, V1; SILVERMAN RB, 1988, MECHANISM BASED ENZY, V2; STEWARD MW, 1986, HDB EXPT IMMUNOLOGY, V1, pCH25; THATCHER GRJ, 1989, ADV PHYS ORG CHEM, V25, P99; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; WALEY SG, 1985, BIOCHEM J, V227, P843, DOI 10.1042/bj2270843; WALSH C, 1982, TETRAHEDRON, V38, P871, DOI 10.1016/0040-4020(82)85068-0; WILLIAMS A, 1970, BIOCHEMISTRY-US, V9, P3383, DOI 10.1021/bi00819a014; WILLIAMS RE, 1971, CAN J BIOCHEM CELL B, V49, P210, DOI 10.1139/o71-031; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120	50	109	116	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1775	1782		10.1126/science.270.5243.1775	http://dx.doi.org/10.1126/science.270.5243.1775			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	TK476	8525366				2022-12-28	WOS:A1995TK47600033
J	JOBANPUTRA, P; DAVIDON, F; GRAHAM, S; ONEILL, H; SIMMONDS, P; YAP, PL				JOBANPUTRA, P; DAVIDON, F; GRAHAM, S; ONEILL, H; SIMMONDS, P; YAP, PL			HIGH-FREQUENCY OF PARVOVIRUS B19 IN PATIENTS TESTED FOR RHEUMATOID-FACTOR	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL VICTORIA HOSP,REG VIRUS LAB,BELFAST BT12 6BN,ANTRIM,NORTH IRELAND; UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	JOBANPUTRA, P (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,RHEUMAT DIS UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Jobanputra, Paresh/R-2311-2019	Jobanputra, Paresh/0000-0002-2712-667X; Simmonds, Peter/0000-0002-7964-4700				ADLER SP, 1993, J INFECT DIS, V168, P361, DOI 10.1093/infdis/168.2.361; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; ONEILL HJ, 1995, CLIN DIAGN VIROL, V3, P181, DOI 10.1016/0928-0197(94)00036-T; WHITE DG, 1985, LANCET, V1, P419; 1990, BRIT MED J, V300, P166	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1542	1542		10.1136/bmj.311.7019.1542	http://dx.doi.org/10.1136/bmj.311.7019.1542			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520398	Green Published, Green Submitted			2022-12-28	WOS:A1995TK21400026
J	DISS, TC; PENG, HZ; WOTHERSPOON, AC; PAN, LX; SPEIGHT, PM; ISAACSON, PG				DISS, TC; PENG, HZ; WOTHERSPOON, AC; PAN, LX; SPEIGHT, PM; ISAACSON, PG			A SINGLE NEOPLASTIC CLONE IN SEQUENTIAL BIOPSY SPECIMENS FROM A PATIENT WITH PRIMARY GASTRIC-MUCOSA-ASSOCIATED LYMPHOID-TISSUE LYMPHOMA AND SJOGRENS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							B-CELL LYMPHOMA; SOMATIC HYPERMUTATION; GENE; LEUKEMIA; REARRANGEMENT; POLYMERASE		UNIV LONDON UNIV COLL, SCH MED, DEPT HISTOPATHOL, LONDON WC1E 6JJ, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1X 8LD, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKKUS MHC, 1992, BLOOD, V80, P2326; BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; BIENENSTOCK J, 1980, IMMUNOLOGY, V41, P249; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FALZON M, 1991, AM J SURG PATHOL, V15, P59, DOI 10.1097/00000478-199101000-00007; FISHLEDER A, 1987, NEW ENGL J MED, V316, P1118, DOI 10.1056/NEJM198704303161803; HEIRMAN C, 1990, LEUKEMIA, V4, P856; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; ISAACSON P, 1984, CANCER, V53, P2515, DOI 10.1002/1097-0142(19840601)53:11<2515::AID-CNCR2820531125>3.0.CO;2-C; ISAACSON PG, 1991, AM J SURG PATHOL, V15, P819, DOI 10.1097/00000478-199109000-00001; ISAACSON PG, 1990, HISTOPATHOLOGY, V16, P617, DOI 10.1111/j.1365-2559.1990.tb01173.x; LEVY R, 1987, IMMUNOL REV, V96, P43, DOI 10.1111/j.1600-065X.1987.tb00508.x; MEEKER TC, 1988, J IMMUNOL, V141, P3994; NORTON AJ, 1987, AM J PATHOL, V128, P225; PALUMBO A, 1992, BRIT J HAEMATOL, V82, P676, DOI 10.1111/j.1365-2141.1992.tb06943.x; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; WAN JH, 1990, J CLIN PATHOL, V43, P888, DOI 10.1136/jcp.43.11.888; WOTHERSPOON AC, 1992, HISTOPATHOLOGY, V20, P29, DOI 10.1111/j.1365-2559.1992.tb00912.x; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	22	74	76	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					172	175		10.1056/NEJM199307153290305	http://dx.doi.org/10.1056/NEJM199307153290305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL460	8515789				2022-12-28	WOS:A1993LL46000005
J	IQBAL, TH; WOOD, GM; LEWIS, KO; LEEK, JP; COOPER, BT				IQBAL, TH; WOOD, GM; LEWIS, KO; LEEK, JP; COOPER, BT			PREVALENCE OF PRIMARY LACTASE DEFICIENCY IN ADULT RESIDENTS OF WEST BIRMINGHAM	BMJ-BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP, GASTROENTEROL UNIT, BIRMINGHAM B17 7QH, ENGLAND; DUDLEY RD GEN HOSP, DEPT CLIN CHEM, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND; GEORGE ELLIOT HOSP, NUNEATON CV10 7BL, ENGLAND; ST JAMES UNIV HOSP, DEPT MED, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	Saint James's University Hospital				iqbal, tariq/0000-0002-6681-9882				BOND JH, 1972, J CLIN INVEST, V51, P1219, DOI 10.1172/JCI106916; Cooper B T, 1986, Dig Dis, V4, P72, DOI 10.1159/000171139; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; FERGUSON A, 1984, GUT, V25, P163, DOI 10.1136/gut.25.2.163; [No title captured]	5	4	4	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	1993	306	6888					1303	1303		10.1136/bmj.306.6888.1303	http://dx.doi.org/10.1136/bmj.306.6888.1303			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518570	Bronze, Green Published			2022-12-28	WOS:A1993LC72200020
J	Dougherty, DA				Dougherty, DA			Cation-pi interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; AMINO-AROMATIC INTERACTIONS; PROTEIN-COUPLED RECEPTORS; IONIC HYDROGEN-BONDS; BINDING-SITE; MOLECULAR RECOGNITION; POTASSIUM CHANNELS; QUADRUPOLE-MOMENT; SODIUM-CHANNELS; BIOMIMETIC CATALYSIS	Cations bind to the ir face of an aromatic structure through a surprisingly strong, noncovalent force termed the cation-pi interaction. The magnitude and generality of the effect have been established by gas-phase measurements and by studies of model receptors in aqueous media. To first order, the interaction can be considered an electrostatic attraction between a positive charge and the quadrupole moment of the aromatic. A great deal of direct and circumstantial evidence indicates that cation-pi interactions are important in a variety of proteins that bind cationic ligands or substrates. In this context, the amino acids phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp) can be viewed as polar, yet hydrophobic, residues.			Dougherty, DA (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043936] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43936] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SN, 1991, DRUG DEVELOP RES, V24, P297, DOI 10.1002/ddr.430240402; ARAKI K, 1993, CHEM LETT, P205, DOI 10.1246/cl.1993.205; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BOGUSZ S, 1992, PROTEIN ENG, V5, P285, DOI 10.1093/protein/5.4.285; BROCCHIERI L, 1994, P NATL ACAD SCI USA, V91, P9297, DOI 10.1073/pnas.91.20.9297; BUNTEL CJ, 1994, ISOPENTENOIDS OTHER, P44; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COHEN JB, 1991, J BIOL CHEM, V266, P23354; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; COZZI F, 1992, J AM CHEM SOC, V114, P5729, DOI 10.1021/ja00040a036; CRAVEN IE, 1989, J PHYS CHEM-US, V93, P627, DOI 10.1021/j100339a026; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DEAKYNE CA, 1985, J AM CHEM SOC, V107, P474; DENNIS GR, 1991, J PHYS CHEM-US, V95, P656, DOI 10.1021/j100155a029; DHAENENS M, 1991, NEW J CHEM, V15, P873; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DOUGHERTY DA, IN PRESS COMPREHENSI, V2; DUFFY EM, 1993, J AM CHEM SOC, V115, P9271, DOI 10.1021/ja00073a050; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; FRAENKEL Y, 1991, FEBS LETT, V291, P225, DOI 10.1016/0014-5793(91)81290-O; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GAREL L, 1993, J AM CHEM SOC, V115, P11652, DOI 10.1021/ja00077a096; GATZI JL, 1991, ANNU REV PHARMACOL, V31, P37; GENTLE IR, 1989, J PHYS CHEM-US, V93, P7740, DOI 10.1021/j100359a041; GROSS J, 1995, ANGEW CHEM INT EDIT, V34, P481, DOI 10.1002/anie.199504811; GUO BC, 1990, CHEM PHYS LETT, V168, P155, DOI 10.1016/0009-2614(90)85122-S; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JANDA KC, 1975, J CHEM PHYS, V63, P1419, DOI 10.1063/1.431502; JOHNSON WS, 1987, J AM CHEM SOC, V109, P5882; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KARLIN S, 1994, J MOL BIOL, V239, P227, DOI 10.1006/jmbi.1994.1365; KAUFMANN C, 1993, P NATL ACAD SCI USA, V90, P6284; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KEARNEY PC, 1993, J AM CHEM SOC, V115, P9907, DOI 10.1021/ja00075a006; KIM KS, 1994, J AM CHEM SOC, V116, P7399, DOI 10.1021/ja00095a050; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; KUMPF RA, UNPUB; LEDERER E, 1969, Q REV CHEM SOC, V23, P453, DOI 10.1039/qr9692300453; LEE JY, 1995, CHEM PHYS LETT, V232, P67, DOI 10.1016/0009-2614(94)01330-X; LENTZ TL, 1995, BIOCHEMISTRY-US, V34, P1316, DOI 10.1021/bi00004a026; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LU Z, 1994, BIOPHYS J, V6, P1061; LUHMER M, 1994, B SOC CHIM FR, V131, P603; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Maw G. A., 1981, CHEM SULPHONIUM GROU; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; MECOZZI S, UNPUB; MEOTNER M, 1985, J AM CHEM SOC, V107, P469, DOI 10.1021/ja00288a033; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MITCHELL JBO, 1993, NATURE, V366, P413, DOI 10.1038/366413a0; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MOEREELS H, 1993, RECEPTOR CHANNEL, V1, P89; NANDI CL, 1993, PROTEIN ENG, V6, P247, DOI 10.1093/protein/6.3.247; NARAYSZABO G, 1995, CHEM REV, V95, P829, DOI 10.1021/cr00036a002; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; ORTIZ AR, 1992, BIOCHEMISTRY-US, V31, P2887, DOI 10.1021/bi00126a007; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; PERUTZ MF, 1993, PHILOS T R SOC A, V345, P105, DOI 10.1098/rsta.1993.0122; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; PRICE SL, 1987, J CHEM PHYS, V86, P2859, DOI 10.1063/1.452037; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; RODHAM DA, 1993, NATURE, V362, P735, DOI 10.1038/362735a0; ROESSNER CA, 1993, GENE, V127, P149, DOI 10.1016/0378-1119(93)90631-C; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHNEIDER HJ, 1991, ANGEW CHEM INT EDIT, V30, P1417, DOI 10.1002/anie.199114171; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHEPODD TJ, 1986, J AM CHEM SOC, V108, P6085, DOI 10.1021/ja00279a093; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; STAUFFER DA, 1990, ANGEW CHEM INT EDIT, V29, P915, DOI 10.1002/anie.199009151; SUNNER J, 1981, J PHYS CHEM-US, V85, P1814, DOI 10.1021/j150613a011; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Sussman JL, 1992, CURR OPIN STRUC BIOL, V2, P721; SUZUKI S, 1992, SCIENCE, V257, P942, DOI 10.1126/science.257.5072.942; TAFT RW, 1990, PURE APPL CHEM, V62, P17, DOI 10.1351/pac199062010017; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WAKSMAN G, 1994, CELL MOL BIOL, V40, P611; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WALSH C, 1979, ENZYMATIC REACTION M, P851; WESS J, 1992, J BIOL CHEM, V267, P19313; WIBLE BA, 1994, DRUG DEVELOP RES, V33, P225, DOI 10.1002/ddr.430330306; WILLIAMS JH, 1993, ACCOUNTS CHEM RES, V26, P593, DOI 10.1021/ar00035a005; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; 1988, ADV PROTEIN CHEM, V39	100	2441	2465	14	536	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					163	168		10.1126/science.271.5246.163	http://dx.doi.org/10.1126/science.271.5246.163			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539615				2022-12-28	WOS:A1996TP36400030
J	Mannuzzu, LM; Moronne, MM; Isacoff, EY				Mannuzzu, LM; Moronne, MM; Isacoff, EY			Direct physical measure of conformational rearrangement underlying potassium channel gating	SCIENCE			English	Article							SHAKER K+ CHANNELS; SODIUM-CHANNEL; S4 REGION; INACTIVATION; DROSOPHILA; CURRENTS; CHARGE; GENE	In response to membrane depolarization, voltage-gated ion channels undergo a structural rearrangement that moves charges or dipoles in the membrane electric field and opens the channel-conducting pathway. By combination of site-specific fluorescent labeling of the Shaker potassium channel protein with voltage clamping, this gating conformational change was measured in real time. During channel activation, a stretch of at least seven amino acids of the putative transmembrane segment S4 moved from a buried position into the extracellular environment. This movement correlated with the displacement of the gating charge, providing physical evidence in support of the hypothesis that S4 is the voltage sensor of voltage-gated ion channels.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory			isacoff, ehud/AAP-1459-2020	Isacoff, Ehud Y./0000-0003-4775-9359				Aggarwal Sanjay K., 1995, Biophysical Journal, V68, pA138; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; MCCORMACK K, 1994, NEURON, V12, P301, DOI 10.1016/0896-6273(94)90273-9; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SIGG D, 1994, SCIENCE, V264, P578, DOI 10.1126/science.8160016; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	30	500	515	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					213	216		10.1126/science.271.5246.213	http://dx.doi.org/10.1126/science.271.5246.213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539623				2022-12-28	WOS:A1996TP36400045
J	Tan, BB; Weald, D; Strickland, I; Friedmann, PS				Tan, BB; Weald, D; Strickland, I; Friedmann, PS			Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis	LANCET			English	Article							DUST MITE; INHALANT ALLERGENS; ASTHMATIC-CHILDREN; ALLERSEARCH DMS; REDUCTION; ACARICIDE; EXPOSURE; ANTIGEN; HOMES	Background The role of housedust-mite (HDM) allergen (Der p1) in the pathogenesis of atopic dermatitis is controversial. We tested the hypothesis that atopic dermatitis improves if amounts of HDM allergen in the home are reduced. Methods Active treatment comprised Goretex bedcovers (placebo, cotton covers), benzyltannate spray (placebo, water), and a high-filtration vacuum cleaner (placebo, a conventional domestic vacuum cleaner). Dust was sampled monthly from the mattress covers and bedroom and living-room carpets. 48 patients (24 adults [mean age 30] and 24 children [mean age 10]) completed the B-month study. 28 were in the active treatment group and 20 in the placebo group. Findings The weight of dust collected from Goretex-covered mattresses had fallen by 98% at 1 month (from 386 to 9 mg/m(2)) with no change thereafter. Placebo covers caused a smaller reduction in dust load (361 to 269 mg/m(2)); the difference between active and placebo covers at 6 months was highly significant (p=0.002). Both active and placebo treatments caused significant reductions in Der pi concentrations in bedroom and living-room carpets and the differences between the treatments were not significant. The severity of eczema decreased in both groups, but the active group showed significantly greater improvements in severity score (difference between mean final scores 4.3 units, p=0.006) and area affected (difference between mean final areas 10%, p=0.006) in analysis of covariance with initial mattress dust weights and bedroom carpet load as covariates. Reported analysis with final for the covariates showed that most of the treatment effect was due to the reduction in mattress dust and carpet Der pi. Interpretation The activity of atopic dermatitis can be greatly reduced by effective HDM avoidance. Methods to identify individuals who will benefit most from such measures are needed.	UNIV LIVERPOOL,DEPT DERMATOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool								[Anonymous], CLIN EXPT ALLERGY; AUGUST PJ, 1984, BRIT J DERMATOL, V111, P10; BRUYNZEELKOOMEN CAFM, 1988, BRIT J DERMATOL, V118, P229, DOI 10.1111/j.1365-2133.1988.tb01779.x; CLARK RA, 1989, CLIN IMMUNOPATHOL, V53, P132; COLLOFF MJ, 1992, BRIT J DERMATOL, V127, P322, DOI 10.1111/j.1365-2133.1992.tb00449.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; DENMAN AM, 1990, LANCET, V335, P1038, DOI 10.1016/0140-6736(90)91103-H; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; GREEN WF, 1984, LANCET, V2, P160; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; KALRA S, 1993, THORAX, V48, P10, DOI 10.1136/thx.48.1.10; KALRA S, 1990, LANCET, V336, P449, DOI 10.1016/0140-6736(90)92004-2; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; MITCHELL EB, 1982, LANCET, V1, P127; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; ROBERTS DLL, 1984, BRIT J DERMATOL, V110, P735, DOI 10.1111/j.1365-2133.1984.tb04714.x; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; WALSHAW MJ, 1986, Q J MED, V58, P199; WARNER JA, 1993, CLIN EXP ALLERGY, V23, P279, DOI 10.1111/j.1365-2222.1993.tb00323.x	25	308	312	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					15	18		10.1016/S0140-6736(96)91556-1	http://dx.doi.org/10.1016/S0140-6736(96)91556-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531541				2022-12-28	WOS:A1996TN76200011
J	Edmondstone, WM				Edmondstone, WM			Cardiac chest pain: Does body language help the diagnosis?	BRITISH MEDICAL JOURNAL			English	Article											Edmondstone, WM (corresponding author), ROYAL NAVAL HOSP,GOSPORT PO12 2AA,HANTS,ENGLAND.							BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1	1	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1660	1661		10.1136/bmj.311.7021.1660	http://dx.doi.org/10.1136/bmj.311.7021.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541748	Green Published			2022-12-28	WOS:A1995TL94200007
J	CUKIERMAN, E; HUBER, I; ROTMAN, M; CASSEL, D				CUKIERMAN, E; HUBER, I; ROTMAN, M; CASSEL, D			THE ARF1 GTPASE-ACTIVATING PROTEIN - ZINC-FINGER MOTIF AND GOLGI-COMPLEX LOCALIZATION	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; BINDING-PROTEIN; GUANINE-NUCLEOTIDE; PHOSPHOLIPASE-D; BREFELDIN-A; MEMBRANES; COATOMER; EXCHANGE; COP	Hydrolysis of guanosine triphosphate (GTP) by the small guanosine triphosphatase (GTPase) adenosine diphosphate ribosylation factor-1 (ARF1) depends on a GTPase-activating protein (GAP). A complementary DNA encoding the ARF1 GAP was cloned from rat liver and predicts a protein with a zinc finger motif near the amino terminus. The GAP function required an intact zinc finger and additional amino-terminal residues. The ARF1 GAP was localized to the Golgi complex and was redistributed into a cytosolic pattern when cells were treated with brefeldin A, a drug that prevents ARF1-dependent association of coat proteins with the Golgi. Thus, the GAP is likely to be recruited to the Golgi by an ARF1-dependent mechanism.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			cukierman, edna/AAU-8932-2020; Cukierman, Edna/A-3951-2013	cukierman, edna/0000-0002-1452-9576; 				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, UNPUB; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IRELAND LS, 1995, EMBO J, V13, P3812; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARTICK S, 1991, NUCLEIC ACIDS RES, V19, P4008; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POON P, UNPUB; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561	22	264	268	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1999	2002		10.1126/science.270.5244.1999	http://dx.doi.org/10.1126/science.270.5244.1999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533093				2022-12-28	WOS:A1995TL42000044
J	COHEN, JE				COHEN, JE			UNEXPECTED DOMINANCE OF HIGH-FREQUENCIES IN CHAOTIC NONLINEAR POPULATION-MODELS	NATURE			English	Article							SYSTEMS	BECAUSE water has a higher heat capacity than air, large bodies of water fluctuate in temperature more slow ly than does the atmosphere(1). Marine temperature time series are 'redder' than atmospheric temperature time series by analog to light: in red light, low-frequency variability has greater amplitude than high-frequency variability, whereas in white light all frequencies have the same amplitude(2). Differences in the relative importance of high- and low-frequency variability in different habitats affect the population dynamics of individual species and the structure of ecological communities(3-9). Population dynamics of individual species are thought to be dominated hy low-frequency fluctuations, that is, to display reddened fluctuations(10). Here I report, however, that in eight nonlinear, iterative, deterministic, autonomous, discrete-time population models, some of which have been used to model real biological populations, the power spectral densities of chaotic trajectories are neither white nor reddened but are notably blue, with increasing power at higher frequencies.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL,NERC,CTR POPULAT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	COHEN, JE (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							ARINO A, 1995, EVOL ECOL, V9, P429, DOI 10.1007/BF01237765; AUSTIN AL, 1971, TECHNOL FORECAST SOC, V3, P23, DOI 10.1016/S0040-1625(71)80002-1; CASWELL H, 1995, J THEOR BIOL, V176, P301, DOI 10.1006/jtbi.1995.0200; COHEN JE, 1995, SCIENCE, V269, P341, DOI 10.1126/science.7618100; FARMER D, 1980, ANN NY ACAD SCI, V357, P453; GURNEY WSC, 1983, J ANIM ECOL, V52, P479, DOI 10.2307/4567; HALLEY JM, IN PRESS TRNEDS ECOL; HASSELL MP, 1976, J ANIM ECOL, V45, P471, DOI 10.2307/3886; HASSELL MP, 1974, J ANIM ECOL, V44, P283; HASTINGS A, 1993, ANNU REV ECOL SYST, V24, P1, DOI 10.1146/annurev.es.24.110193.000245; Jenkins G., 1968, SPECTRAL ANAL ITS AP; LEVIN SA, 1980, J MATH BIOL, V9, P245, DOI 10.1007/BF00276028; LEWONTIN RC, 1969, P NATL ACAD SCI USA, V62, P1056, DOI 10.1073/pnas.62.4.1056; LI TY, 1982, PHYS LETT A, V87, P271, DOI 10.1016/0375-9601(82)90692-2; Markus M., 1987, NATO ASI (Advanced Science Institutes) Series Series A Life Sciences, V138, P267; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; MONIN AS, 1977, VARIABILITY OCEANS; MORAN PAP, 1950, BIOMETRICS, V6, P250, DOI 10.2307/3001822; MURATORI S, 1992, SIAM J APPL MATH, V52, P1688, DOI 10.1137/0152097; PENNYCUICK CJ, 1968, J THEOR BIOL, V18, P316, DOI 10.1016/0022-5193(68)90081-7; PIMM SL, 1988, NATURE, V334, P613, DOI 10.1038/334613a0; RICKER W. E., 1954, JOUR FISH RES BD CANADA, V11, P559; RUXTON GD, 1994, J ANIM ECOL, V63, P1002, DOI 10.2307/5276; Schaffer W.M., 1987, NATO ASI (Advanced Science Institutes) Series Series A Life Sciences, V138, P233; Smith J. Maynard, 1974, MODELS ECOLOGY; STEELE JH, 1985, NATURE, V313, P355, DOI 10.1038/313355a0; STEELE JH, 1984, SCIENCE, V224, P985, DOI 10.1126/science.224.4652.985; STEELE JH, 1991, J THEOR BIOL, V153, P425, DOI 10.1016/S0022-5193(05)80579-X; STEELE JH, 1994, SCIENCE, V343, P5; Varley G.C., 1973, INSECT POPULATION EC	30	89	91	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					610	612		10.1038/378610a0	http://dx.doi.org/10.1038/378610a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524393				2022-12-28	WOS:A1995TJ22100075
J	PEACOCK, S; MURRAY, V; TURTON, C				PEACOCK, S; MURRAY, V; TURTON, C			RESPIRATORY-DISTRESS AND ROYAL JELLY	BRITISH MEDICAL JOURNAL			English	Letter											PEACOCK, S (corresponding author), ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND.							BULLOCK RJ, 1994, MED J AUSTRALIA, V160, P44, DOI 10.5694/j.1326-5377.1994.tb138207.x; THIEN FCK, 1993, MED J AUSTRALIA, V159, P639, DOI 10.5694/j.1326-5377.1993.tb138070.x	2	15	16	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1472	1472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520337				2022-12-28	WOS:A1995TJ04400026
J	FORMAN, BM; TONTONOZ, P; CHEN, J; BRUN, RP; SPIEGELMAN, BM; EVANS, RM				FORMAN, BM; TONTONOZ, P; CHEN, J; BRUN, RP; SPIEGELMAN, BM; EVANS, RM			15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2) IS A LIGAND FOR THE ADIPOCYTE DETERMINATION FACTOR PPAR-GAMMA	CELL			English	Article							NECROSIS-FACTOR-ALPHA; HORMONE RECEPTOR SUPERFAMILY; 9-CIS RETINOIC ACID; ANTIDIABETIC AGENTS; ACTIVATED RECEPTOR; INSULIN RESISTANCE; GROWTH-INHIBITION; FATTY-ACIDS; X RECEPTOR; CELLS	Regulation of adipose cell mass is a critical homeostatic process in higher vertebrates. The conversion of fibroblasts into cells of the adipose lineage is induced by expression of the orphan nuclear receptor PPAR gamma. This suggests that an endogenous PPAR gamma ligand mar be an important regulator of adipogenesis. By assaying arachidonate metabolites for their capacity to activate PPAR response elements, we have identified 15-deoxy-Delta(12,14)-prostaglandin J(2) as both a PPAR gamma ligand and an inducer of adipogenesis. Similarly, the thiazolidinedione class of antidiabetic drugs also bind to PPAR gamma and act as potent regulators of adipocyte development. Thus, adipogenic prostanoids and antidiabetic thiazolidinediones initiate key transcriptional events through a common nuclear receptor signaling pathway. These findings suggest a pivotal role for PPAR gamma and its endogenous ligand in adipocyte development and glucose homeostasis and as a target for intervention in metabolic disorders.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031405, R37DK031405, F32DK009090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-31405, DK09090] Funding Source: Medline; NIGMS NIH HHS [T32 GM07753, T32 GM007753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CANTELLO BCC, 1994, J MED CHEM, V37, P3977, DOI 10.1021/jm00049a017; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FOXWORTHY PS, 1988, BIOCHEM J, V252, P409, DOI 10.1042/bj2520409; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRUNDY SM, 1990, DM-DIS MON, V36, P641; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARRIS PKW, 1994, MOL PHARMACOL, V45, P439; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOFMANN CA, 1992, DIABETES CARE, V15, P1075, DOI 10.2337/diacare.15.8.1075; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P659; MAHMUD I, 1984, PROSTA LEUKOTR MED, V16, P131, DOI 10.1016/0262-1746(84)90066-0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARSHALL WS, 1987, J MED CHEM, V30, P682, DOI 10.1021/jm00387a018; MCCALL JL, 1992, BRIT J SURG, V79, P1361, DOI 10.1002/bjs.1800791240; MCKINNEY B, 1967, STAIN TECHNOL, V42, P245, DOI 10.3109/10520296709115018; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1995, ADV PROSTAG THROMB L, V23, P17; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OHSUMI J, 1994, ENDOCRINOLOGY, V135, P2279, DOI 10.1210/en.135.5.2279; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SOHDA T, 1990, ARZNEIMITTEL-FORSCH, V40-1, P37; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	66	2639	2714	2	86	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					803	812		10.1016/0092-8674(95)90193-0	http://dx.doi.org/10.1016/0092-8674(95)90193-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521497	Bronze			2022-12-28	WOS:A1995TH94800017
J	MORHAM, SG; LANGENBACH, R; LOFTIN, CD; TIANO, HF; VOULOUMANOS, N; JENNETTE, JC; MAHLER, JF; KLUCKMAN, KD; LEDFORD, A; LEE, CA; SMITHIES, O				MORHAM, SG; LANGENBACH, R; LOFTIN, CD; TIANO, HF; VOULOUMANOS, N; JENNETTE, JC; MAHLER, JF; KLUCKMAN, KD; LEDFORD, A; LEE, CA; SMITHIES, O			PROSTAGLANDIN-SYNTHASE-2 GENE DISRUPTION CAUSES SEVERE RENAL PATHOLOGY IN THE MOUSE	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; ENDOPEROXIDE SYNTHASE; G/H SYNTHASE; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; MESSENGER-RNA; CDNA CLONING; EXPRESSION; INHIBITION	The prostaglandin endoperoxide H synthase isoform 2, cyclooxygenase 2 (COX-2), is induced at high levels in migratory and other responding cells by proinflammatory stimuli. COX-2 is generally considered to be a mediator of inflammation. Its isoform, COX-1, is constitutively expressed in most tissues and is thought to mediate ''housekeeping'' functions. These two enzymes are therapeutic targets of the widely used nonsteroidal anti-inflammatory drugs (NSAIDs). To investigate further the different physiologic roles of these isoforms, we have used homologous recombination to disrupt the mouse gene encoding COX-2 (PtgsS). Mice lacking COX-2 have normal inflammatory responses to treatments with tetradecanoyl phorbol acetate or with arachidonic acid. However, the; develop severe nephropathy and are susceptible to peritonitis.	NIEHS,EXPTL CARCINOGENESIS & MUTAGENESIS LAB,RES TRIANGLE PK,NC 27709; NIEHS,EXPTL PATHOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	MORHAM, SG (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.			Jennette, John Charles/0000-0002-8081-6565	NHLBI NIH HHS [HL49227] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CELSI G, 1986, PEDIATR RES, V20, P347, DOI 10.1203/00006450-198604000-00018; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CROMLISH WA, 1994, ARCH BIOCHEM BIOPHYS, V314, P193, DOI 10.1006/abbi.1994.1429; DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; GILBERT T, 1991, PEDIATR RES, V30, P450, DOI 10.1203/00006450-199111000-00011; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HOOPER M, 1987, NATURE, V336, P348; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; KESTER M, 1994, J BIOL CHEM, V269, P22574; KIM HS, 1988, NUCLEIC ACIDS RES, V162, P8887; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LANGENBACH R, 1995, CELL, V83; LEE SH, 1992, J BIOL CHEM, V267, P25934; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MCGRAW M, 1984, INT J PED NEPHROL, V5, P67; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Meade T. W., 1992, P321; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROME LH, 1976, PROSTAGLANDINS, V11, P23, DOI 10.1016/0090-6980(76)90169-6; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P6168; SIMMONS DL, 1992, PROSTAGLANDINS LEUKO, P67; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; THUN MJ, 1993, CANCER RES, V53, P1322; THUN MJ, 1991, NEW ENGL J MED, V25, P1593; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568	60	948	963	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					473	482		10.1016/0092-8674(95)90125-6	http://dx.doi.org/10.1016/0092-8674(95)90125-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521477	Bronze			2022-12-28	WOS:A1995TC97700017
J	Behar, E; Chao, NJ; Hiraki, DD; Krishnaswamy, S; Brown, BW; Zehnder, JL; Grumet, FC				Behar, E; Chao, NJ; Hiraki, DD; Krishnaswamy, S; Brown, BW; Zehnder, JL; Grumet, FC			Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; CARDIAC TRANSPLANTATION; LYMPHOCYTES-T; REJECTION; CLONING; MARROW; GENE	Background. Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e,, other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is a minor alloantigen. Methods. We directly sequenced samples of complementary DNA (cDNA) encoding CD31 molecules from 21 unrelated normal subjects. Sequence-specific primers were then designed to amplify alleles by the polymerase chain reaction, thereby permitting CD31 typing of genomic DNA from additional normal subjects. To assess the relevance of CD31 matching to bone marrow transplantation, we performed CD31 typing of 46 recipients of bone marrow (32 without GVHD and 14 with severe [grade III or IV] acute GVHD) and their HLA-identical sibling donors. The immunoreactivity of CD31 phenotypes with anti-CD31 monoclonal antibodies was compared by flow cytometry. Results. Direct sequencing of cDNA for CD31 from the 21 normal subjects identified a single polymorphism, (C) under bar TG-->(G) under bar TG (Leu-->Val), at codon 125; we designated the resulting alleles CD31.L and CD31.V, respectively. The CD31 genotypes of these and 142 other unrelated subjects were of the expected frequencies. Among the transplant recipients, 71 percent of those with acute GVHD had CD31 genotypes that were not identical to the donor's genotype, as compared with 22 percent of the recipients without GVHD (P = 0.004). The binding of anti-CD31 monoclonal antibodies as measured by fluorescence-activated cell sorting correlated with the CD31 types of homozygous cell lines. Conclusions. The adhesion molecule CD31 is polymorphic. When donor and recipient genotypes are not identical, the risk of GVHD increases. Prospective CD31 typing may reduce the risk of acute GVHD. (C) 1996, Massachusetts Medical Society.	STANFORD UNIV,CTR BLOOD,DEPT PATHOL,PALO ALTO,CA 94304; STANFORD UNIV,DEPT HLTH RES & POLICY,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,PALO ALTO,CA 94304	Stanford University; Stanford University; Stanford University					NHLBI NIH HHS [HL33811] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armitage P., 1994, STAT METHODS MED RES, V3; BEHAR E, 1994, TISSUE ANTIGENS, V44, P332, DOI 10.1111/j.1399-0039.1994.tb02406.x; BRASILE L, 1985, TRANSPLANTATION, V40, P672, DOI 10.1097/00007890-198512000-00020; CERILLI J, 1987, TRANSPL P, V19, P4468; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; DAVENPORT C, 1995, J IMMUNOL, V154, P2568; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; Fleiss JL, 1981, STAT METHODS RATES P; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GUMINA RJ, 1993, THROMB HAEMOSTASIS, V69, P923; HANSEN JA, 1994, CLIN TRANSPLANTS 199, P193; HARTL DL, 1987, PRIMER PROPULATION G, P23; KALIL J, 1989, TRANSPLANT P, V21, P711; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KITAJIMA T, 1994, IMMUNOL LETT, V40, P207, DOI 10.1016/0165-2478(93)00017-8; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; MARIJT WAF, 1993, BLOOD, V82, P3778; METZELAAR MJ, 1991, THROMB HAEMOSTASIS, V66, P700; MILSTEIN CP, 1974, NATURE, V248, P160, DOI 10.1038/248160a0; MORAES JR, 1989, TRANSPLANTATION, V48, P951, DOI 10.1097/00007890-198912000-00010; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; PIERSON GR, 1987, UCLA S MOL CELLULAR, V53, P307; SEKIMATA M, 1992, INT IMMUNOL, V4, P301, DOI 10.1093/intimm/4.2.301; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; STASTNY P, 1981, TRANSPLANTATION CLIN, P132; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; VANDERHARST D, 1994, BLOOD, V83, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VINCI G, 1994, TRANSPLANTATION, V58, P361, DOI 10.1097/00007890-199408000-00019; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; ZEHNDER JL, 1995, BLOOD, V85, P1282, DOI 10.1182/blood.V85.5.1282.bloodjournal8551282; 1991, LANCET, V337, P649	39	121	128	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					286	291		10.1056/NEJM199602013340502	http://dx.doi.org/10.1056/NEJM199602013340502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532023				2022-12-28	WOS:A1996TV69500002
J	Diaz, JJ; Dodon, MD; SchaererUthurralt, N; Simonin, D; Kindbeiter, K; Gazzolo, L; Madjar, JJ				Diaz, JJ; Dodon, MD; SchaererUthurralt, N; Simonin, D; Kindbeiter, K; Gazzolo, L; Madjar, JJ			Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein	NATURE			English	Article							REX-RESPONSE ELEMENT; RNA-BINDING PROTEIN; VIRAL MESSENGER-RNA; HTLV-I REX; GENE-EXPRESSION; INFECTED-CELLS; TYPE-1; SEQUENCE; PRODUCT; DNA	HERPES simplex virus type 1 (HSV-1) Us11 protein, a true late gene product packaged within the virion, is delivered into cells after infection, exhibits a nucleocytoplasmic localization at early times, and later accumulates in the nucleoli(1-5). This RNA-binding basic phosphoprotein, capable of oligomerization, is supposed to be involved in post-transcriptional regulation of gene expression after HSV-1 infection(6,7). Expression of human T-cell leukaemia/lymphoma virus type-I (HTLV-I) and of human immunodeficiency virus type 1 (HIV-1) is post-transcriptionally regulated by Rex and Rev, respectively(8). These proteins are required for the cytoplasmic expression of unspliced gag-pol and singly spliced env transcripts(9,10). Here we show that HSV-1 Us11 protein is able to bind Rex- and Rev-responsive elements and to transactivate envelope retroviral glycoprotein expression.			Diaz, JJ (corresponding author), UNIV LYON 1,CNRS UMR30,FAC MED,RUE GUILLAUME PARADIN,F-69372 LYON 08,FRANCE.		Duc-Dodon, Madeleine/I-6580-2016; DIAZ, Jean-Jacques/AAT-3846-2021; DIAZ, Jean-Jacques/H-3018-2014	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319				BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BOGERD HP, 1992, J VIROL, V66, P7572, DOI 10.1128/JVI.66.12.7572-7575.1992; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIAZ JJ, 1993, J GEN VIROL, V74, P397, DOI 10.1099/0022-1317-74-3-397; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; INOUE J, 1991, ONCOGENE, V6, P1753; JOHNSON PA, 1986, J GEN VIROL, V67, P871, DOI 10.1099/0022-1317-67-5-871; MACLEAN CA, 1987, J GEN VIROL, V68, P1921, DOI 10.1099/0022-1317-68-7-1921; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MASSE T, 1990, MOL GEN GENET, V220, P377, DOI 10.1007/BF00391742; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PALKER TJ, 1992, J VIROL, V66, P5879, DOI 10.1128/JVI.66.10.5879-5889.1992; PUVIONDUTILLEUL F, 1987, EUR J CELL BIOL, V43, P487; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; RIXON FJ, 1984, NUCLEIC ACIDS RES, V12, P2473, DOI 10.1093/nar/12.5.2473; ROLLER RJ, 1990, J VIROL, V64, P3463, DOI 10.1128/JVI.64.7.3463-3470.1990; ROLLER RJ, 1992, J VIROL, V66, P3624, DOI 10.1128/JVI.66.6.3624-3632.1992; ROLLER RJ, 1991, J VIROL, V65, P5873, DOI 10.1128/JVI.65.11.5873-5879.1991; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TANAKA Y, 1991, J IMMUNOL, V147, P354	30	78	79	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					273	277		10.1038/379273a0	http://dx.doi.org/10.1038/379273a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538795				2022-12-28	WOS:A1996TQ16900051
J	Shea, S; Nickerson, KG; Tenenbaum, J; Morris, TQ; Rabinowitz, D; ODonnell, K; Perez, E; Weisfeldt, ML				Shea, S; Nickerson, KG; Tenenbaum, J; Morris, TQ; Rabinowitz, D; ODonnell, K; Perez, E; Weisfeldt, ML			Compensation to a department of medicine and its faculty members for the teaching of medical students and house staff	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Changes in the organization and financing of health care threaten to alter the prevailing system of financing the teaching of medical students and residents, Little information is available from private medical schools and teaching hospitals about the extent of teaching by faculty members or the mechanisms and levels of reimbursement for teaching. Methods. We surveyed faculty members in the Department of Medicine at Columbia-Presbyterian Medical Center to ascertain the extent of their teaching activities, A standard number of hours was assigned to each activity, and the total number of teaching hours was calculated for each faculty member, Teaching of fellows and in continuing medical education programs was excluded. We also determined how much money the Department of Medicine received in payment for faculty members' teaching activities, and the sources of this compensation. Results. In the 1992-1993 academic year, the 188 full-time faculty members spent a total of 46,086 hours teaching (mean [+/-SD], 245+/-178 hours per faculty member); 10,780 hours (23.4 percent) were spent teaching medical students, and 35,306 hours (76.6 percent) teaching house staff, Eighty percent of faculty members taught for 137 or more hours each. In a multivariate analysis including faculty rank, subspecialty division, years since graduation from medical school, sex, and tenure or clinical track, we found that senior faculty members (P=0.02), members of certain subspecialty divisions (P<0.001), and women (P=0.05) contributed more than the average number of teaching hours, An additional 56 non-full-time faculty members contributed a total of 5684 hours, The net reimbursement to the department for teaching totaled $965,808, or about $16 per hour of teaching by full-time faculty members, after the cost of fringe benefits was excluded. Conclusions. Faculty members of the department of medicine at a major medical center contribute a large number of hours teaching medical students and house staff. This effort is poorly compensated, Cost-containment efforts have the potential to jeopardize fragile social contracts at academic health centers whereby the faculty participates in teaching by contributing unreimbursed or underreimbursed time.	COLUMBIA UNIV,DEPT STAT,NEW YORK,NY 10032	Columbia University	Shea, S (corresponding author), COLUMBIA UNIV,DEPT MED,DIV GEN MED,PH 9 E,622 W 168TH ST,NEW YORK,NY 10032, USA.							GINZBERG E, 1993, EC MED ED; GOLDBERG J, 1994, MED EC           SEP, P122; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; LICHTENSTEIN LM, 1993, SCIENCE, V261, P113; MANDEL HG, 1994, SCIENCE, V266, P1789, DOI 10.1126/science.7997868; MANDEL HG, 1995, SCIENCE, V269, P13, DOI 10.1126/science.7604271; 1993, ACADEMIC MED HLTH CA; 1993, JAMA-J AM MED ASSOC, V270, P1100	8	101	101	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					162	167		10.1056/NEJM199601183340307	http://dx.doi.org/10.1056/NEJM199601183340307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531973				2022-12-28	WOS:A1996TQ01700007
J	Appelman, YEA; Piek, JJ; Strikwerda, S; Tijssen, JGP; deFeyter, PJ; David, GK; Serruys, PW; Margolis, JR; Koelemay, MJ; vanSwijndregt, EWJM; Koolen, JJ				Appelman, YEA; Piek, JJ; Strikwerda, S; Tijssen, JGP; deFeyter, PJ; David, GK; Serruys, PW; Margolis, JR; Koelemay, MJ; vanSwijndregt, EWJM; Koolen, JJ			Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RESTENOSIS; ABLATION; ULTRAVIOLET; PREVENTION; RATES	Background Excimer laser coronary angioplasty is reported to give excellent procedural results for treatment of complex coronary lesions, but this method has not been compared with balloon angioplasty in a randomised trial. Methods Patients (n=308) with stable angina and coronary lesions longer than 10 mm on visual assessment were included. 151 patients (158 lesions) were assigned randomly to laser angioplasty and 157 (167 lesions) to balloon angioplasty. The primary clinical endpoints were death, myocardial infarction, coronary bypass surgery, or repeat coronary angioplasty of the randomised segment during 6 months of follow-up. The primary angiographic end-point was the minimal lumen diameter at follow-up in relation to the baseline value (net gain), as determined by quantitative coronary angiography. Findings Laser angioplasty was followed by balloon angioplasty in 98% of procedures. The angiographic success rate was 80% in patients treated with laser angioplasty compared with 79% in patients treated with balloon angioplasty. There were no deaths. Myocardial infarction, coronary bypass surgery, and repeat angioplasty occurred in 4.6%, 10.6%, and 21.2%, respectively, of the patients in the laser angioplasty group compared with 5.7%, 10.8%, and 18.5% of the balloon angioplasty group. Net mean (SD) gain in minimal lumen diameter was 0.40 (0.69) mm in patients treated with laser angioplasty and 0.48 (0.66) mm in those treated with balloon angioplasty (p=0.34). The restenosis rate (>50% diameter stenosis) was 51.6% in the laser angioplasty group versus 41.3% in the balloon angioplasty group (p=0.13). Interpretation Excimer laser angioplasty followed by balloon angioplasty provides no benefit additional to balloon angioplasty alone with respect to the initial and long-term clinical and angiographic outcome in the treatment of obstructive coronary artery disease.	UNIV AMSTERDAM,ACAD MED CTR,DEPT CARDIOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1105 AZ AMSTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,THORAXCTR,3000 DR ROTTERDAM,NETHERLANDS; MIAMI HEART INST,MIAMI,FL; CATHARINA HOSP,EINDHOVEN,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Catharina Hospital								APPELMAN YEA, IN PRESS LASER SURG; BAUMBACH A, 1994, LASER SURG MED, V14, P3, DOI 10.1002/lsm.1900140104; BAUMBACH A, 1994, EUR HEART J, V15, P89, DOI 10.1093/oxfordjournals.eurheartj.a060385; BITTL JA, 1992, CIRCULATION, V86, P71, DOI 10.1161/01.CIR.86.1.71; BITTL JA, 1994, J AM COLL CARDIOL, V23, P1314, DOI 10.1016/0735-1097(94)90372-7; BITTL JA, 1992, AM J CARDIOL, V70, P1533, DOI 10.1016/0002-9149(92)90453-6; CAMBEAU L, 1976, CIRCULATION, V54, P522; DIMARIO C, 1995, AM J CARDIOL, V75, P772, DOI 10.1016/S0002-9149(99)80409-3; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; GRUNDFEST WS, 1985, AM J SURG, V150, P220, DOI 10.1016/0002-9610(85)90124-2; GRUNDFEST WS, 1985, J AM COLL CARDIOL, V5, P929, DOI 10.1016/S0735-1097(85)80435-6; HAASE KK, 1994, LASER MED SCI, V9, P7, DOI 10.1007/BF02594180; ISNER JM, 1985, J AM COLL CARDIOL, V6, P1102, DOI 10.1016/S0735-1097(85)80316-8; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; KUGELMASS AD, 1994, AM J CARDIOL, V74, P748, DOI 10.1016/0002-9149(94)90427-8; LITVACK F, 1994, J AM COLL CARDIOL, V23, P323, DOI 10.1016/0735-1097(94)90414-6; MARGOLIS JR, 1992, AM J CARDIOL, V69, pF3, DOI 10.1016/0002-9149(92)91176-5; MINTZ GS, 1994, AM J CARDIOL, V74, P1278, DOI 10.1016/0002-9149(94)90566-5; SARTORI M, 1987, LASER SURG MED, V7, P300, DOI 10.1002/lsm.1900070404; Serruys P.W., 1994, QUANTITATIVE CORONAR; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1993, CIRCULATION, V88, P1588, DOI 10.1161/01.CIR.88.4.1588; STONE GW, 1990, J AM COLL CARDIOL, V15, P849, DOI 10.1016/0735-1097(90)90285-W; STRIKWERDA S, 1993, AM HEART J, V125, P838, DOI 10.1016/0002-8703(93)90179-D; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; VANLEEUWEN TG, 1992, J AM COLL CARDIOL, V19, P1610, DOI 10.1016/0735-1097(92)90627-Y; VANLEEUWEN TG, 1993, CIRCULATION, V3, P231; 1993, LANCET, V341, P573; 1988, CIRCULATION, V78, P486; 1985, NEW ENGL J MED, V312, P932	31	75	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					79	84		10.1016/S0140-6736(96)90209-3	http://dx.doi.org/10.1016/S0140-6736(96)90209-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538345	Green Submitted			2022-12-28	WOS:A1996TP28100008
J	Rhodes, JM				Rhodes, JM			Unifying hypothesis for inflammatory bowel disease and associated colon cancer: Sticking the pieces together with sugar	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CIGARETTE-SMOKING; GLYCOPROTEINS; PATHOGENESIS; ALLELE; MUCUS				Rhodes, JM (corresponding author), UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Rhodes, Jonathan M/C-2496-2009					AMENT ME, 1973, NEW ENGL J MED, V288, P382, DOI 10.1056/NEJM197302222880802; BENYON RC, 1992, INFLAMMATORY BOWEL D, P189; BOLAND CR, 1987, GASTROENTEROLOGY, V92, P625, DOI 10.1016/0016-5085(87)90010-2; BREUER R, 1993, EXP LUNG RES, V19, P273, DOI 10.3109/01902149309031724; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; CAMPBELL BJ, 1995, J CLIN INVEST, V95, P571, DOI 10.1172/JCI117700; CORFIELD AP, 1988, CLIN SCI, V74, P71, DOI 10.1042/cs0740071; DWARAKANATH AD, 1994, GUT, V35, P1141, DOI 10.1136/gut.35.8.1141; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; FIDLER HM, 1994, GUT, V35, P506, DOI 10.1136/gut.35.4.506; FILIPE MI, 1970, GUT, V11, P229, DOI 10.1136/gut.11.3.229; GILLEN CD, 1994, GUT, V35, P651, DOI 10.1136/gut.35.5.651; GONZALEZ A, 1965, GASTROENTEROLOGY, V48, P383; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HARRIES AD, 1982, BRIT MED J, V284, P706, DOI 10.1136/bmj.284.6317.706; HODGSON HFJ, 1990, INFLAMM BOWEL DIS, P121; HOSKINS LC, 1981, J CLIN INVEST, V67, P163, DOI 10.1172/JCI110009; JASS JR, 1983, LANCET, V1, P28; LEVENSTEIN S, 1994, AM J GASTROENTEROL, V89, P1219; MACFARLANE GD, 1992, J PERIODONTOL, V63, P908, DOI 10.1902/jop.1992.63.11.908; MACQUEEN G, 1989, SCIENCE, V243, P83, DOI 10.1126/science.2911721; OMORAIN C, 1984, BRIT MED J, V288, P1859, DOI 10.1136/bmj.288.6434.1859; PIRZER U, 1991, LANCET, V338, P1238, DOI 10.1016/0140-6736(91)92104-A; PROBERT CSJ, 1995, GUT, V36, P696, DOI 10.1136/gut.36.5.696; PULLAN RD, 1994, GUT, V35, P353, DOI 10.1136/gut.35.3.353; RAOUF A, 1991, GUT, V32, P1139, DOI 10.1136/gut.32.10.1139; RHODES JM, 1986, J CLIN PATHOL, V39, P1331, DOI 10.1136/jcp.39.12.1331; RHODES JM, 1985, GUT, V26, P1312, DOI 10.1136/gut.26.12.1312; RHODES JM, 1994, RECENT ADV GASTROENT, V10, P57; RHODES JM, 1983, GASTROENTEROLOGY, V82, P1327; ROE TF, 1992, NEW ENGL J MED, V326, P1666, DOI 10.1056/NEJM199206183262504; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A; RYDER SD, 1994, GASTROENTEROLOGY, V106, P117, DOI 10.1016/S0016-5085(94)94775-9; SADEK SK, 1994, CLIN SCI, V86, P33; SATSANGI J, 1994, GUT, V35, P696, DOI 10.1136/gut.35.5.696; SEGAL AW, 1976, LANCET, V2, P219; SELBY C, 1992, EXP LUNG RES, V18, P813, DOI 10.3109/01902149209031709; STONEROOK MJ, 1994, J MED PRIMATOL, V23, P16, DOI 10.1111/j.1600-0684.1994.tb00090.x; TAYLORROBINSON S, 1989, LANCET, V2, P113; THURNHER M, 1993, J CLIN INVEST, V91, P2103, DOI 10.1172/JCI116434; TOBIN MV, 1987, GASTROENTEROLOGY, V93, P316, DOI 10.1016/0016-5085(87)91021-3; TSAI HH, 1992, CLIN SCI, V82, P447, DOI 10.1042/cs0820447; TSAI HH, 1995, GUT, V36, P570, DOI 10.1136/gut.36.4.570; TYSK C, 1991, GASTROENTEROLOGY, V100, P419, DOI 10.1016/0016-5085(91)90211-3; UGOZZOLI L, 1992, GENOMICS, V12, P670, DOI 10.1016/0888-7543(92)90292-Z; VANDYKE TE, 1986, INFECT IMMUN, V53, P671, DOI 10.1128/IAI.53.3.671-677.1986; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WANDALL JH, 1982, GUT, V23, P173, DOI 10.1136/gut.23.3.173	49	95	96	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					40	44		10.1016/S0140-6736(96)91563-9	http://dx.doi.org/10.1016/S0140-6736(96)91563-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531552	Bronze			2022-12-28	WOS:A1996TN76200018
J	Scally, G				Scally, G			Citizen health	LANCET			English	Editorial Material											Scally, G (corresponding author), S & W REG HLTH AUTHOR,BRISTOL,AVON,ENGLAND.							Ashton J, 1992, HLTH CITIES; Chave S P, 1984, Community Med, V6, P61; MEEHAN E, 1995, 4 JOINT ESRC RSA SEM; Stewart J., 1994, CITIZENS JURIES; 1995, CITY HLTH PROFILES R	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					3	4		10.1016/S0140-6736(96)91549-4	http://dx.doi.org/10.1016/S0140-6736(96)91549-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531547				2022-12-28	WOS:A1996TN76200004
J	Chapman, S				Chapman, S			Great expectorations! The decline of public spitting: Lessons for passive smoking?	BRITISH MEDICAL JOURNAL			English	Article											Chapman, S (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH & COMMUNITY MED, SYDNEY, NSW 2006, AUSTRALIA.							Bryder Lynn, 1988, MAGIC MOUNTAIN SOCIA; COLLEY JRT, 1974, LANCET, V2, P1031; Elias Norbert, 1982, HIST MANNERS, V1; LINENTHAL H, 1908, MASSSACHUSETTS COMMI, P28; NEWTON RJ, 1910, NASPT T, V6, P109; ROGERS OH, 1907, NASPT T, V3, P92; SMITH FB, 1988, RETREAT TUBERCULOSIS, P80; Sullivan Mark, 1926, OUR TIMES US 1900 19, V4, P281; TELLER ME, 1988, TUBERCULOSIS MOVEMEN, P22; TUCK GAP, 1935, BRIT MED J, V2, P364; 1916, TUBERCULOSIS DIRECTO, P303; 1909, NEW YORK STATE DEP H, P294; 1886, BRIT MED J, V1, P564	13	8	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1685	1686		10.1136/bmj.311.7021.1685	http://dx.doi.org/10.1136/bmj.311.7021.1685			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541757	Green Published			2022-12-28	WOS:A1995TL94200017
J	Fowler, D				Fowler, D			A case for non-intervention	BRITISH MEDICAL JOURNAL			English	Article											Fowler, D (corresponding author), UNIV WARWICK,INST MATH,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1691	1693		10.1136/bmj.311.7021.1691	http://dx.doi.org/10.1136/bmj.311.7021.1691			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541761	Green Published			2022-12-28	WOS:A1995TL94200021
J	Woyka, J				Woyka, J			Hospice at home	BRITISH MEDICAL JOURNAL			English	Article											Woyka, J (corresponding author), HARROW HLTH CARE CTR,HARROW HA1 4LF,MIDDX,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1687	1688		10.1136/bmj.311.7021.1687	http://dx.doi.org/10.1136/bmj.311.7021.1687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541758	Green Published			2022-12-28	WOS:A1995TL94200018
J	AYALA, FJ				AYALA, FJ			THE MYTH OF EVE - MOLECULAR-BIOLOGY AND HUMAN ORIGINS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; II NUCLEOTIDE-SEQUENCES; HUMAN MITOCHONDRIAL-DNA; HUMAN-EVOLUTION; ALLELIC GENEALOGY; MHC POLYMORPHISM; SEVERE MALARIA; ANTIGEN; LOCI; SUBSTITUTION	It has been proposed that modern humans descended from a single woman, the ''mitochondrial Eve'' who lived in Africa 100,000 to 200,000 years ago. The human immune system DRB1 genes are extremely polymorphic, with gene lineages that coalesce into an ancestor who lived around 60 million years ago, a time before the divergence of the apes from the Old World monkeys. The theory of gene coalescence suggests that, throughout the last 60 million years, human ancestral populations had an effective size of 100,000 individuals or greater. Molecular evolution data favor the African origin of modern humans, but the weight of the evidence is against a population bottleneck before their emergence. The mitochondrial Eve hypothesis emanates from a confusion between gene genealogies and individual genealogies.			AYALA, FJ (corresponding author), UNIV CALIF IRVINE, IRVINE, CA 92717 USA.							ARDEN B, 1982, P NATL ACAD SCI-BIOL, V79, P2342, DOI 10.1073/pnas.79.7.2342; AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; AYALA FJ, IN PRESS MOL PHYLOGE; BERGSTROM T, 1995, IMMUNOL REV, V143, P13, DOI 10.1111/j.1600-065X.1995.tb00668.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BONTROP RE, 1994, IMMUNOGENETICS, V39, P81; BONTROP RE, 1995, IMMUNOL REV, V143, P33, DOI 10.1111/j.1600-065X.1995.tb00669.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CARBONELL E, 1995, SCIENCE, V269, P826, DOI 10.1126/science.7638598; Clark G. A., 1992, MIDDLE PALEOLITHIC A, P183; CLARK GA, 1989, AM ANTHROPOL, V91, P962, DOI 10.1525/aa.1989.91.4.02a00090; CLARK GA, 1994, RECHERCHE, V25, P316; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; FAN WM, 1989, HUM IMMUNOL, V26, P107, DOI 10.1016/0198-8859(89)90096-7; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; GIBBONS A, 1995, SCIENCE, V267, P1272, DOI 10.1126/science.7871421; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GRIFFITHS RC, 1980, THEOR POPUL BIOL, V17, P37, DOI 10.1016/0040-5809(80)90013-1; GYLLENSTEN UB, 1989, P NATL ACAD SCI USA, V86, P9986, DOI 10.1073/pnas.86.24.9986; GYLLENSTEN UB, 1990, P NATL ACAD SCI USA, V87, P1835, DOI 10.1073/pnas.87.5.1835; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HEDRICK PW, 1994, AM NAT, V143, P945, DOI 10.1086/285643; HILL AVS, 1992, NATURE, V355, P403, DOI 10.1038/355403a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1992, NATURE, V355, P402, DOI 10.1038/355402b0; JONES S, 1992, CAMBRIDGE ENCY HUMAN, P246; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; Kimura M., 1983, NEUTRAL THEORY MOL E; Kingman J, 1982, J APPL PROB A, V19, P27, DOI DOI 10.2307/3213548; Kingman JFC., 1982, STOCH PROC APPL, V13, P235, DOI [DOI 10.1016/0304-4149(82)90011-4, 10.1016/0304-4149(82)90011-4]; KLEIN J, 1994, PHILOS T R SOC B, V346, P351, DOI 10.1098/rstb.1994.0152; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; KLEIN J, 1986, NATURAL HIST MAJOR H; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; Li Wen-Hsiung, 1993, P253; Lowenstein J.M., 1986, Pacific Discovery, V39, P38; MARSH SGE, 1993, IMMUNOGENETICS, V37, P79; MARSH SGE, 1991, IMMUNOGENETICS, V33, P321, DOI 10.1007/BF00216691; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; MCDEVITT H, 1995, IMMUNOL REV, V143, P113, DOI 10.1111/j.1600-065X.1995.tb00672.x; Menozzi Cavalli-Sforza P, 1994, HIST GEOGRAPHY HUMAN; MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415; NEI M, 1987, MOL EVOLUTIONARY GEN, P395; OHUIGIN C, 1993, IMMUNOGENETICS, V38, P165; PARES JM, 1995, SCIENCE, V269, P830, DOI 10.1126/science.7638599; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; ROGERS AR, 1995, HUM BIOL, V67, P1; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SATTA Y, 1993, P NATL ACAD SCI USA, V90, P7480, DOI 10.1073/pnas.90.16.7480; SATTA Y, 1991, MOL EVOLUTION MAJOR, P51; SCHWAIGER FW, 1995, IMMUNOL REV, V143, P199, DOI 10.1111/j.1600-065X.1995.tb00676.x; SNEATH P H, 1973, P573; Spuhler James N., 1993, P262; STONEKING M, 1990, GENETICS, V124, P717; STRINGER CB, 1992, PHILOS T ROY SOC B, V337, P217, DOI 10.1098/rstb.1992.0099; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; STRINGER CB, 1990, SCI AM, V263, P98, DOI 10.1038/scientificamerican1290-98; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; Swofford David L., 1990, P411; TAJIMA F, 1983, GENETICS, V105, P437; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P2419, DOI 10.1073/pnas.87.7.2419; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1985, GENETICS, V110, P325; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; THORNE AG, 1992, SCI AM, V266, P76, DOI 10.1038/scientificamerican0492-76; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WADDLE DM, 1994, NATURE, V368, P452, DOI 10.1038/368452a0; WADDLE DM, 1992, CONTINUITY REPLACEME, P83; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITFIELD LS, 1995, NATURE, V378, P379, DOI 10.1038/378379a0; WILLS C, 1995, EVOLUTION, V49, P593, DOI 10.1111/j.1558-5646.1995.tb02296.x; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOLPOFF MH, 1988, SCIENCE, V241, P772, DOI 10.1126/science.3136545; 1992, B WORLD HEALTH ORGAN, V70, P801	88	144	150	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	1995	270	5244					1930	1936		10.1126/science.270.5244.1930	http://dx.doi.org/10.1126/science.270.5244.1930			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533083				2022-12-28	WOS:A1995TL42000025
J	COHEN, B				COHEN, B			FORTNIGHTLY REVIEW - PARVOVIRUS B19 - AN EXPANDING SPECTRUM OF DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM PARVOVIRUS; INFECTION; ANEMIA; B19-PARVOVIRUS; ARTHROPATHY; CONCENTRATE; CHILDREN; CRISIS; VIRUS				COHEN, B (corresponding author), CENT PUBL HLTH LAB, DIV VIRUS REFERENCE, PUBL HLTH LAB SERV, 61 COLINDALE AVE, LONDON NW9 5HT, ENGLAND.							ANDERSON MJ, 1983, LANCET, V1, P1378; BANSAL GP, 1993, J INFECT DIS, V167, P1034, DOI 10.1093/infdis/167.5.1034; BROWN KE, 1994, NEW ENGL J MED, V330, P1192, DOI 10.1056/NEJM199404283301704; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; COHEN BJ, 1988, J MED MICROBIOL, V25, P151, DOI 10.1099/00222615-25-2-151; COSSART YE, 1975, LANCET, V1, P72; COUROUCE AM, 1984, LANCET, V1, P160; DENNING DW, 1987, J NEUROL NEUROSUR PS, V50, P641, DOI 10.1136/jnnp.50.5.641; EVANS JPM, 1984, BRIT MED J, V288, P681, DOI 10.1136/bmj.288.6418.681; FADEN H, 1990, J INFECT DIS, V161, P354, DOI 10.1093/infdis/161.2.354; FAIRLEY CK, 1995, LANCET, V346, P1335, DOI 10.1016/S0140-6736(95)92346-2; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; FRICKHOFEN N, 1986, NEW ENGL J MED, V314, P646; HALL SM, 1990, BMJ-BRIT MED J, V300, P1166; JOBANPUTRA P, 1995, BRIT MED J, V311, P1542, DOI 10.1136/bmj.311.7019.1542; KELLEHER JF, 1983, J PEDIATR-US, V102, P720, DOI 10.1016/S0022-3476(83)80243-1; KINSELY AS, 1988, PEDIATR PATHOL, V8, P665; KURTZMAN GJ, 1988, LANCET, V2, P1159; KURTZMAN GJ, 1987, NEW ENGL J MED, V317, P287, DOI 10.1056/NEJM198707303170506; LEFRERE JJ, 1986, J CLIN PATHOL, V39, P1277, DOI 10.1136/jcp.39.11.1277; LOONG TCL, 1986, POSTGRAD MED J, V62, P493, DOI 10.1136/pgmj.62.728.493; LYON DJ, 1989, LANCET, V1, P1085; MAIM C, 1993, LANCET, V341, P1408; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORFINI M, 1992, AM J HEMATOL, V39, P149, DOI 10.1002/ajh.2830390217; MORTIMER PP, 1983, LANCET, V2, P482; MORTIMER PP, 1991, REV MED VIROL, V1, P73; NAIDES SJ, 1991, CLIN RES, V39, pA733; NIGRO G, 1994, LANCET, V343, P1260, DOI 10.1016/S0140-6736(94)92154-7; NIKKARI S, 1995, ANN RHEUM DIS, V54, P597, DOI 10.1136/ard.54.7.597; OKUMURA A, 1993, ARCH DIS CHILD, V68, P784, DOI 10.1136/adc.68.6.784; OSULLIVAN MG, 1994, J CLIN INVEST, V93, P1571, DOI 10.1172/JCI117136; PATTISON JR, 1981, LANCET, V1, P664; PAVER WK, 1976, J CLIN MICROBIOL, V4, P67; PORTER HJ, 1988, LANCET, V1, P535; RAMAGE JK, 1994, LANCET, V343, P667, DOI 10.1016/S0140-6736(94)92659-X; SAAL JG, 1992, RHEUMATOL INT, V12, P147, DOI 10.1007/BF00274934; SHNEERSON JM, 1980, BRIT MED J, V280, P1580, DOI 10.1136/bmj.280.6231.1580; WATANABE T, 1994, ARCH DIS CHILD, V70, P71, DOI 10.1136/adc.70.1.71-a; WEILAND HT, 1989, BRIT J HAEMATOL, V71, P300, DOI 10.1111/j.1365-2141.1989.tb04276.x; WHITE DG, 1985, LANCET, V1, P419; WIERENGA KJJ, 1995, LANCET, V346, P475, DOI 10.1016/S0140-6736(95)91324-6; YEE TT, 1995, LANCET, V345, P794; YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1; YOTO Y, 1995, 6TH P PARV WORKSH MO, P60; ZANELLA A, 1995, TRANSFUSION, V35, P769, DOI 10.1046/j.1537-2995.1995.35996029163.x	46	66	68	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	1995	311	7019					1549	1552		10.1136/bmj.311.7019.1549	http://dx.doi.org/10.1136/bmj.311.7019.1549			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520401	Green Published			2022-12-28	WOS:A1995TK21400029
J	TANG, JL; MORRIS, JK; WALD, NJ; HOLE, D; SHIPLEY, M; TUNSTALLPEDOE, H				TANG, JL; MORRIS, JK; WALD, NJ; HOLE, D; SHIPLEY, M; TUNSTALLPEDOE, H			MORTALITY IN RELATION TO TAR YIELD OF CIGARETTES - A PROSPECTIVE-STUDY OF 4 COHORTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER RISK; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; SMOKERS; HEALTH	Objective--To investigate relation between tar yield of manufactured cigarettes and mortality from smoking related diseases. Design--Prospective epidemiological study of four cohorts of men studied between 1967 and 1982. Setting--Combined data from British United Provident Association (BUPA) study (London), Whitehall study (London), Paisley-Renfrew study (Scotland), and United Kingdom heart disease prevention project (England and Wales). Subjects--Of the 56 255 men aged over 35 who were included in the studies, 2742 deaths occurred among 12 400 smokers. Average follow up was 13 years. Main outcome measures--Relative mortality from smoking related diseases according to tar yields of cigarettes smoked. Results--Age adjusted mortality from smoking related diseases in smokers of filter cigarettes was 9% lower (95% confidence interval 1% to 17%) than in smokers of plain cigarettes (P=0.017). Mortality from smoking related diseases consistently decreased with decreasing tar yield. Relative mortality in cigarette smokers for a 15 mg decrease in tar yield per cigarette was 0.75 (0.52 to 1.09) for lung cancer, 0.77 (0.61 to 0.97) for coronary heart disease, 0.86 (0.50 to 1.50) for stroke, 0.78 (0.40 to 1.48) for chronic obstructive lung disease, 0.78 (0.65 to 0.93) for these smoking related diseases combined, and 0.77 (0.65 to 0.90) for all smoking related diseases. Conclusion--About a quarter of deaths from lung cancer, coronary heart disease, and possibly other smoking related diseases would have been avoided by lowering tar yield from 30 mg per cigarette to 15 mg. Reducing cigarette tar yields in Britain has had a modest effect in reducing smoking related mortality.	ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6QB, ENGLAND; RUCHILL HOSP, GREATER GLASGOW HLTH BOARD, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of London; Queen Mary University London; University of Glasgow; University of Dundee			Tang, Jin-Ling/AAJ-4090-2021; Wald, Nicholas/AAY-8924-2021; Tang, JL/G-1759-2013; Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				[Anonymous], 1986, IARC MONOGRAPHS EVAL, V38; CASTELLI WP, 1981, LANCET, V2, P109, DOI 10.1016/S0140-6736(81)90297-X; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HIGENBOTTAM T, 1982, J EPIDEMIOL COMMUN H, V36, P113, DOI 10.1136/jech.36.2.113; KAUFMAN DW, 1989, AM J EPIDEMIOL, V129, P703, DOI 10.1093/oxfordjournals.aje.a115185; KOZLOWSKI LT, 1989, AM J PUBLIC HEALTH, V79, P198, DOI 10.2105/AJPH.79.2.198; LUBIN JH, 1984, INT J CANCER, V33, P569, DOI 10.1002/ijc.2910330504; NEGRI E, 1993, BRIT MED J, V306, P1567, DOI 10.1136/bmj.306.6892.1567; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; PEACH H, 1986, THORAX, V41, P203, DOI 10.1136/thx.41.3.203; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; PETITTI DB, 1985, PREV MED, V14, P217, DOI 10.1016/0091-7435(85)90037-4; REID DD, 1974, LANCET, V1, P469; ROSE G, 1980, BRIT MED J, V1, P745; STELLMAN SD, 1989, PREV MED, V18, P518, DOI 10.1016/0091-7435(89)90010-8; STELLMAN SD, 1986, IARC SCI PUBL, V74, P237; Tang J, 1992, J SMOKING RELATED DI, V3, P203; VUTUC C, 1983, J NATL CANCER I, V71, P435; WALD N, 1980, LANCET, V2, P813; WALD N, 1991, UK SMOKING STATISTIC; Wald N, 1989, NICOTINE SMOKING LOW; WALD NJ, 1985, LANCET, V2, P1111; WALD NJ, 1976, BRIT MED J, V1, P434, DOI 10.1136/bmj.1.6007.434-a; WYNDER EL, 1979, NEW ENGL J MED, V300, P894, DOI 10.1056/NEJM197904193001605	27	52	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	1995	311	7019					1530	1533		10.1136/bmj.311.7019.1530	http://dx.doi.org/10.1136/bmj.311.7019.1530			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520394	Green Published			2022-12-28	WOS:A1995TK21400021
J	HIRSCH, JA; ALONSO, JM; REID, RC				HIRSCH, JA; ALONSO, JM; REID, RC			VISUALLY EVOKED CALCIUM ACTION-POTENTIALS IN CAT STRIATE CORTEX	NATURE			English	Article							PYRAMIDAL CELLS; DENDRITES; NEURONS; INVITRO; INVIVO	EARLY intracellular studies of cerebral cortical neurons indicated that synaptic input evokes dendritic action potentials that convey information towards the soma(1). Subsequent work in vitro established that neocortical neurons produce dendritic Ca2+ action potentials(2-5). To determine whether natural stimuli elicit Ca2+ spikes, we combined the techniques of whole-cell recording(6,7), pharmacology(8) and quantitative receptive field mapping(9). Our findings show that visual stimulation routinely evoked Ca2+ spikes in distinct functional(10) and anatomical(11) classes of cells in different layers of the cat striate cortex(12). Hence regenerative Ca2+ potentials appear to play a role in both the initial and later stages of cortical sensory processing.			HIRSCH, JA (corresponding author), ROCKEFELLER UNIV,NEUROBIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Hirsch, Judith/E-9006-2013					AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; AMITAI Y, 1993, CEREB CORTEX, V3, P26, DOI 10.1093/cercor/3.1.26; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; BORST A, 1992, P NATL ACAD SCI USA, V89, P4139, DOI 10.1073/pnas.89.9.4139; DENO RL, 1944, CEREB CORTEX, P291; FERSTER D, 1992, J NEUROSCI, V14, P1262; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRSCH JA, 1995, J PHYSIOL-LONDON, V483, P183, DOI 10.1113/jphysiol.1995.sp020577; Hirsch Judith A., 1994, Society for Neuroscience Abstracts, V20, P1476; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; LLINAS R, 1971, J NEUROPHYSIOL, V34, P532, DOI 10.1152/jn.1971.34.4.532; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; POCKBERGER H, 1991, BRAIN RES, V539, P181, DOI 10.1016/0006-8993(91)91619-C; PURPURA D, 1963, J NEUROPHYSIOL, V27, P117; REGEHR W, 1993, NEURON, V11, P145, DOI 10.1016/0896-6273(93)90278-Y; REGEHR WG, 1992, J NEUROSCI, V12, P4202; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; REUVENI I, 1993, J NEUROSCI, V13, P4609; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; STAFSTROM CE, 1985, J NEUROPHYSIOL, V53, P153, DOI 10.1152/jn.1985.53.1.153; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	30	59	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					612	616		10.1038/378612a0	http://dx.doi.org/10.1038/378612a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524394				2022-12-28	WOS:A1995TJ22100076
J	RAMEH, LE; CHEN, CS; CANTLEY, LC				RAMEH, LE; CHEN, CS; CANTLEY, LC			PHOSPHATIDYLINOSITOL (3,4,5)P-3 INTERACTS WITH SH2 DOMAINS AND MODULATES PI-3-KINASE ASSOCIATION WITH TYROSINE-PHOSPHORYLATED PROTEINS	CELL			English	Article							GROWTH-FACTOR STIMULATION; KINASE-ACTIVITY; INSULIN STIMULATION; SIGNAL TRANSDUCTION; CATALYTIC SUBUNIT; INTACT-CELLS; RAT-LIVER; RECEPTOR; POLYPHOSPHOINOSITIDES; TRANSFORMATION	Src homology 2 (SH2) domains on the regulatory subunit of phosphoinositide 3-kinase (PI 3-kinase) mediate its binding to specific tyrosine-phosphorylated proteins in stimulated cells. Using a pharmacological and genetic approach, we show that the amount of PI 3-kinase associated with tyrosine-phosphorylated proteins inversely correlates with the amount of PI 3-kinase lipid products present in the cell. An explanation for this observation is provided by our finding that phosphatidylinositol (3,4,5)trisphosphate (PtdIns [3,4,5]P-3) binds directly and selectively to the SH2 domains of the 85 kDa subunit of PI 3-kinase and thereby blocks binding to tyrosine-phosphorylated proteins. The SH2 domain of pp60(c-src) also specifically bound PtdIns (3,4,5)P-3, and the binding was competed by a phosphopeptide specific for the Src SH2 domain. These results indicate that production of PtdIns (3,4,5)P-3 at the membrane disrupts the binding of PI 3-kinase to phosphoproteins. This lipid may also recruit other SH2-containing proteins to the membrane to initiate downstream signaling.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; UNIV KENTUCKY, COLL PHARM, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40536 USA	Harvard University; Beth Israel Deaconess Medical Center; University of Kentucky	RAMEH, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890, R01GM036624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41890, R01 GM041890, GM36624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTLEY LC, 1991, CELL, V65; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; END P, 1993, J BIOL CHEM, V268, P10066; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1991, ONCOGENE, V6, P407; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sambrook J, 1989, MOL CLONING LABORATO; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	284	318	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					821	830		10.1016/0092-8674(95)90195-7	http://dx.doi.org/10.1016/0092-8674(95)90195-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521499	Bronze			2022-12-28	WOS:A1995TH94800019
J	HISATAKE, K; ROEDER, RG; HORIKOSHI, M				HISATAKE, K; ROEDER, RG; HORIKOSHI, M			FUNCTIONAL DISSECTION OF TFIIB DOMAINS REQUIRED FOR TFIIB-TFIID-PROMOTER COMPLEX-FORMATION AND BASAL TRANSCRIPTION ACTIVITY	NATURE			English	Article							RNA POLYMERASE-II; PREINITIATION COMPLEX; TATA FACTOR; FACTOR ATF; INITIATION; MUTATIONS; SUBUNIT	THE protein TFIIB is a general transcription initiation factor1 that interacts with a promoter complex (D.DNA) containing the TATA-binding subunit (TFIIDtau, or TBP) of TFIID to facilitate subsequent interaction with RNA polymerase II (ref. 2) through the associated TFIIF (ref. 3). The potential bridging function2,4 of TFIIB raises the possibility of two structural domains and emphasizes the importance of TFIIB structure-function studies for a further understanding of preinitiation complex assembly and function1. Here we show that human TFIIB (refs 5,6) is comprised of functionally distinct N- and C-terminal domains. The C-terminal domain, containing the direct repeats and associated bask regions, is necessary and sufficient for interaction with the D.DNA complex. By contrast, the N-terminal domain that is dispensable for formation of the TFIIDtau-TFIIB-promoter (D.B.DNA) complex is required for subsequent events leading to basal transcription initiation. On the basis of these results, we discuss structural and functional similarities between TFIIB and TFIIDtau, which have similar structural organization and motifs5.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Rockefeller University; University of Tokyo				Hisatake, Koji/0000-0002-5795-3115				ALLFREDO L, 1992, CELL, V71, P211; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P6639, DOI 10.1093/nar/19.23.6639; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WERNER M, 1992, MOL CELL BIOL, V12, P1087, DOI 10.1128/MCB.12.3.1087; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754	27	72	72	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					744	747		10.1038/363744a0	http://dx.doi.org/10.1038/363744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515820				2022-12-28	WOS:A1993LJ33900063
J	MURAKAMI, M; HIBI, M; NAKAGAWA, N; NAKAGAWA, T; YASUKAWA, K; YAMANISHI, K; TAGA, T; KISHIMOTO, T				MURAKAMI, M; HIBI, M; NAKAGAWA, N; NAKAGAWA, T; YASUKAWA, K; YAMANISHI, K; TAGA, T; KISHIMOTO, T			IL-6-INDUCED HOMODIMERIZATION OF GP-130 AND ASSOCIATED ACTIVATION OF A TYROSINE KINASE	SCIENCE			English	Article							SIGNAL TRANSDUCER; VACCINIA VIRUS; STIMULATING FACTOR; FACTOR RECEPTOR; INTERLEUKIN-6; GP130; CELLS; GLYCOPROTEIN; EXPRESSION; CYTOKINES	The biological functions of interleukin-6 (IL-6) are mediated through a signal-transducing component of the IL-6 receptor, gp130, which is associated with the ligand-occupied IL-6 receptor (IL-6R) protein. Binding of IL-6 to IL-6R induced disulfide-linked homodimerization of gp130. Tyrosine kinase activity was associated with dimerized but not monomeric gp130 protein. Substitution of serine for proline residues 656 and 658 in the cytoplasmic motif abolished tyrosine kinase activation and cellular responses but not homodimerization of gp130. The IL-6-induced gp130 homodimer appears to be similar in function to the heterodimer formed between the leukemia inhibitory factor (LIF) receptor (LIFR) and gp130 in response to the LIF or ciliary neurotrophic factor (CNTF). Thus, a general first step in IL-6-related cytokine signaling may be the dimerization of signal-transducing molecules and activation of associated tyrosine kinases.	TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,OSAKA 553,JAPAN	Tosoh Corporation; Osaka University; Osaka University	MURAKAMI, M (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUBER R, 1980, KLIN WOCHENSCHR, V58, P1217, DOI 10.1007/BF01478928; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MICHAELSEN TE, 1977, J BIOL CHEM, V252, P883; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, UNPUB; SUGIMOTO M, 1985, MICROBIOL IMMUNOL, V29, P421, DOI 10.1111/j.1348-0421.1985.tb00843.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Westermark B, 1989, Prog Growth Factor Res, V1, P253, DOI 10.1016/0955-2235(89)90014-8; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YASUDA A, 1990, J VIROL, V64, P2788, DOI 10.1128/JVI.64.6.2788-2795.1990; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261	34	667	683	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1808	1810		10.1126/science.8511589	http://dx.doi.org/10.1126/science.8511589			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511589				2022-12-28	WOS:A1993LH20500051
J	GIBSON, P; HENRY, D; FRANCIS, L; CRUICKSHANK, D; DUPEN, F; HIGGINBOTHAM, N; HENRY, R; SUTHERLAND, D				GIBSON, P; HENRY, D; FRANCIS, L; CRUICKSHANK, D; DUPEN, F; HIGGINBOTHAM, N; HENRY, R; SUTHERLAND, D			ASSOCIATION BETWEEN AVAILABILITY OF NONPRESCRIPTION BETA(2) AGONIST INHALERS AND UNDERTREATMENT OF ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							METAPROTERENOL; DRUGS	Objective-To determine whether the availability of beta2 agonist inhalers without prescription leads to undertreatment of asthma. Design-Cross sectional study of adequacy of treatment in asthmatic subjects who purchased beta2 agonist inhalers and subjects who obtained inhalers by prescription. Setting-Community pharmacies in New South Wales, Australia. Subjects-403 eligible consecutive asthmatic subjects aged 13 to 55 purchasing salbutamol metered dose inhalers over the counter or by prescription; 197 attended for follow up and spirometry and 139 returned 14 day symptom, peak flow, and medication diaries. Main outcome measures-Severity of asthma assessed on frequency of day time and night time wheezing, frequency of inhaler use, and peak expiratory flow rates. Adequacy of treatment according to published guidelines. Results-Of the 139 patients who completed the diary 83, (60%) purchased their inhalers without prescription and 83 were undertreated. The characteristics of patients in the prescription and purchasing groups were similar. Multiple logistic regression analysis identified use of non-prescribed salbutamol as being associated with a 2.9-fold increase in the odds of undertreatment (95% confidence interval 1.3 to 6.8). Smoking increased the odds of undertreatment (3.3, 1.2 to 9.5) and use of a peak flow meter reduced the odds (0.11, 0.04 to 0.34). Adjustment for frequency of consultation made use of non-prescription, salbutamol insignificant (1.4, 0.55 to 3.8). Attitudes to services provided by doctors and pharmacists were favourable and not associated with undertreatment. Conclusion-Over the counter purchase of salbutamol is associated with infrequent consultation with doctors and undertreatment of asthma.	JOHN HUNTER HOSP,CLIN IMMUNOL UNIT,NEW LAMBTON HTS,NSW 2305,AUSTRALIA; UNIV NEWCASTLE,MATER MISERICORDIAE HOSP,FAC MED,DISCIPLINE CLIN PHARMACOL,WARATAH,NSW 2298,AUSTRALIA; UNIV NEWCASTLE,ROYAL NEWCASTLE HOSP,CTR EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2300,AUSTRALIA	John Hunter Hospital; University of Newcastle; University of Newcastle			Henry, David/AAU-4650-2020; gibson, peter/G-6194-2014; Henry, David/L-3895-2017	Henry, David/0000-0001-7169-7704; gibson, peter/0000-0001-5865-489X; Henry, David/0000-0003-2934-2242				[Anonymous], 1990, BMJ, V301, P651; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; CRANZ H, 1990, DRUG SAFETY, V5, P120, DOI 10.2165/00002018-199000051-00019; FENNERTY AG, 1987, EUR J RESPIR DIS, V71, P395; FITZCLARENCE CAB, 1990, J PAEDIATR CHILD H, V26, P200, DOI 10.1111/j.1440-1754.1990.tb02429.x; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HENDELES L, 1984, NEW ENGL J MED, V310, P207, DOI 10.1056/NEJM198401193100326; HENRY DA, 1989, MED J AUSTRALIA, V150, P445; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JENKINS MA, 1990, MED J AUSTRALIA, V153, P323, DOI 10.5694/j.1326-5377.1990.tb136939.x; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KNIGHT A, 1985, MED J AUSTRALIA, V142, P194, DOI 10.5694/j.1326-5377.1985.tb133098.x; MADHAVAN S, 1989, AM J HOSP PHARM, V46, P2486, DOI 10.1093/ajhp/46.12.2486; MCLEOD DC, 1989, DICP ANN PHARMAC, V23, P606, DOI 10.1177/1060028089023007-820; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; RUFFIN RE, 1991, CHEST, V99, P77, DOI 10.1378/chest.99.1.77; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; WOOLCOCK A, 1989, MED J AUSTRALIA, V151, P650, DOI 10.5694/j.1326-5377.1989.tb139640.x; 1991, SCRIP, V1609, P4	21	43	43	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1514	1518		10.1136/bmj.306.6891.1514	http://dx.doi.org/10.1136/bmj.306.6891.1514			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518681	Green Published, Bronze			2022-12-28	WOS:A1993LF94000028
J	WARD, M				WARD, M			THE 1ST ASCENT OF MOUNT EVEREST	BRITISH MEDICAL JOURNAL			English	Article							EXTREME		SOC APOTHECARIES,LONDON EC4V 6EJ,ENGLAND									BOURDILLON TD, 1953, SLPINE J, V59, P247; Conway W. M., 1894, CLIMBING EXPLORATION; Dent C., 1893, GEOGR J, V1, P46; FINCH GL, 1921, GEOGR J, V57, P279; Glaisher James, 1871, TRAVELS AIR; HOUSTON CS, 1947, AM J PHYSIOL, V149, P565, DOI 10.1152/ajplegacy.1947.149.3.565; LLOYD P, 1980, ALPINE J, V85, P3; MATHEWS B, 1932, J PHYSL, V77, P28; Norton EF, 1925, FIGHT EVEREST 1924; OELZ O, 1990, J WILDERNESS MED, V1, P141, DOI 10.1580/0953-9859-1.3.141; PUGH L G, 1962, Br Med J, V2, P621; PUGH LGC, 1952, 1952 MED RES COUNC R; Unna P.J.H., 1922, ALPINE J, V34, P235; Ward M., 1989, HIGH ALTITUDE MED PH; WARD MP, 1992, GEOGR J, V158, P47, DOI 10.2307/3060016; WARD MP, 1954, P R SOC LOND, V143, pB40; WARD MP, 1990, ALPINE J, V95, P188; WAUGH AS, 1855, P ROYAL GEOGRAPHICAL, V1, P345; WEST JB, 1983, J APPL PHYSIOL, V54, P1188, DOI 10.1152/jappl.1983.54.5.1188; WEST JB, 1989, ALPINE J, V94, P207	20	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1455	1458		10.1136/bmj.306.6890.1455	http://dx.doi.org/10.1136/bmj.306.6890.1455			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518644	Green Published, Bronze			2022-12-28	WOS:A1993LE93500021
J	Barst, RJ; Rubin, LJ; Long, WA; McGoon, MD; Rich, S; Badesch, DB; Groves, BM; Tapson, VF; Bourge, RC; Brundage, BH; Koerner, SK; Langleben, D; Keller, CA; Murali, S; Uretsky, BF; Clayton, LM; Jobsis, MM; Blackburn, SD; Shortino, D; Crow, JW				Barst, RJ; Rubin, LJ; Long, WA; McGoon, MD; Rich, S; Badesch, DB; Groves, BM; Tapson, VF; Bourge, RC; Brundage, BH; Koerner, SK; Langleben, D; Keller, CA; Murali, S; Uretsky, BF; Clayton, LM; Jobsis, MM; Blackburn, SD; Shortino, D; Crow, JW			A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-LUNG TRANSPLANTATION; FAILURE; COMPLICATIONS; SURVIVAL; REGISTRY; TRIAL; PGI2	Background. Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival. Methods. We conducted a 12-week prospective, randomized, multicenter open trial comparing the effects of the continuous intravenous infusion of epoprostenol (formerly called prostacyclin) plus conventional therapy with those of conventional therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Association functional class III or IV). Results. Exercise capacity was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362 m at 12 weeks vs. 315 m at base line), but it decreased in the 40 patients treated with conventional therapy alone (204 m at 12 weeks vs. 270 m at base line; P < 0.002 for the comparison of the treatment groups). Indexes of the quality of life were improved only in the epoprostenol group (P < 0.01). Hemodynamics improved at 12 weeks in the epoprostenoltreated patients. The changes in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 percent and +3 percent, respectively (difference in mean change, -6.7 mm Hg; 95 percent confidence interval, -10.7 to -2.6 mm Hg; P < 0.002), and the mean changes in pulmonary vascular resistance for the epoprostenol and control groups were -21 percent and +9 percent, respectively (difference in mean change, -4.9 mm Hg per liter per minute; 95 percent confidence interval, -7.6 to -2.3 mm Hg per liter per minute; P < 0.001). Eight patients died during the study, all of whom had been randomly assigned to conventional therapy (P = 0.003). Serious complications included four episodes of catheter-related sepsis and one thrombotic event. Conclusions. As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension. (C) 1996, Massachusetts Medical Society.	UNIV MARYLAND, DEPT MED, BALTIMORE, MD 21201 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC USA; MAYO MED CTR, DEPT MED, ROCHESTER, MN USA; UNIV ILLINOIS, DEPT MED, CHICAGO, IL USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT MED, TORRANCE, CA 90509 USA; CEDARS SINAI MED CTR, DEPT MED, LOS ANGELES, CA 90048 USA; MCGILL UNIV, SIR MORTIMER B DAVIS JEWISH GEN HOSP, DEPT MED, MONTREAL, PQ, CANADA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV PITTSBURGH, PRESBYTERIAN UNIV HOSP, DEPT MED, PITTSBURGH, PA USA; BURROUGHS WELLCOME CO, DIV MED, RES TRIANGLE PK, NC 27709 USA	University System of Maryland; University of Maryland Baltimore; University of North Carolina; University of North Carolina Chapel Hill; Mayo Clinic; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Duke University; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Cedars Sinai Medical Center; McGill University; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Burroughs Wellcome Fund	Barst, RJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PEDIAT, DIV PEDIAT CARDIOL, BH 262N, 3959 BROADWAY, NEW YORK, NY 10032 USA.		Langleben, David/AAJ-9152-2020					BALINT GA, 1983, ACTA PHYSIOL HUNG, V61, P115; BANDO K, 1994, J THORAC CARDIOV SUR, V108, P1056, DOI 10.1016/S0022-5223(94)70148-2; BARST RJ, 1986, CHEST, V89, P497, DOI 10.1378/chest.89.4.497; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; BORDA LS, 1979, EXPERIENTIA, V35, P529, DOI 10.1007/BF01922751; CHAPELIER A, 1993, J THORAC CARDIOV SUR, V106, P299; Cox D. R., 1984, ANAL SURVIVAL DATA; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DATA JL, 1981, CIRCULATION, V64, P4, DOI 10.1161/01.CIR.64.1.4; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; FEINSTEIN AR, 1989, AM J CARDIOL, V64, P50, DOI 10.1016/0002-9149(89)90652-8; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GLANVILLE AR, 1987, CHEST, V91, P675, DOI 10.1378/chest.91.5.675; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; HERFINDAL ET, 1992, CLIN PHARMACY, V11, P543; HUNT SM, 1986, NOTTINGHAM HLTH PROF; HYMAN AL, 1979, CIRC RES, V45, P404, DOI 10.1161/01.RES.45.3.404; KONTUREK SJ, 1981, GUT, V22, P927, DOI 10.1136/gut.22.11.927; LEFER AM, 1978, SCIENCE, V200, P52, DOI 10.1126/science.345441; PASQUE MK, 1991, CIRCULATION, V84, P2275, DOI 10.1161/01.CIR.84.6.2275; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; QUADE D, 1967, J AM STAT ASSOC, V62, P1187, DOI 10.2307/2283769; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUBIN LJ, 1982, CIRCULATION, V66, P334, DOI 10.1161/01.CIR.66.2.334; STARLING MB, 1979, PROSTAG LEUKOTR ESS, V3, P105, DOI 10.1016/0161-4630(79)90078-8; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269	35	1948	2019	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					296	301		10.1056/NEJM199602013340504	http://dx.doi.org/10.1056/NEJM199602013340504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532025	Bronze			2022-12-28	WOS:A1996TV69500004
J	McIver, B; Rae, P; Beckett, G; Wilkinson, E; Gold, A; Toft, A				McIver, B; Rae, P; Beckett, G; Wilkinson, E; Gold, A; Toft, A			Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; THERAPY; REMISSION; DURATION; IODINE	Background. Antithyroid drugs are effective in patients with hyperthyroidism due to Graves' disease, but the rate of recurrence after treatment is high. In a recent Japanese study, adjunctive treatment with thyroxine (T-4) was associated with a recurrence rate 20 times lower than that among patients who received only an antithyroid drug. If these results are confirmed, combined therapy with an antithyroid drug and T-4 might become the treatment of choice for all patients with Graves' hyperthyroidism. Methods. We treated 111 patients (89 women and 22 men) who had Graves' hyperthyroidism. All patients initially received 40 mg of carbimazole daily for one month. Then one group received carbimazole alone for 17 months (52 patients), and the other group received carbimazole plus T-4 for 17 months and T-4 alone for 18 months (59 patients). In the carbimazole group, the dose was adjusted after one month to maintain a normal serum thyrotropin concentration. in the carbimazole-T-4 group, the dose of carbimazole was not changed, but 100 mu g of T-4 per day was added to the regimen and the dose was adjusted to maintain an undetectable serum thyrotropin concentration (<0.04 mu U per milliliter). Results. At the time of our analysis, 53 of the 111 patients had completed at least 3 months of follow-up (median, 12 months) after carbimazole was withdrawn. Hyperthyroidism recurred in eight patients in each group after a mean (+/-SD) of 6+/-4 months in the carbimazole group and 7+/-4 months in the carbimazole-T-4 group. There was no difference between the recurrence rates in the two groups, despite the fact that serum thyrotropin concentrations were undetectable in 73 percent of patients in the carbimazole-T-4 group on at least 75 percent of their visits. Conclusions. The administration of T-4 to patients with Graves' disease during carbimazole treatment and after its withdrawal neither delays nor prevents the recurrence of hyperthyroidism. (C) 1996, Massachusetts Medical Society.	ROYAL INFIRM, NHS TRUST, ENDOCRINE CLIN, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, ROYAL INFIRM, DEPT CLIN BIOCHEM, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh								ALEXANDE.WD, 1965, LANCET, V2, P866; ALLANNIC H, 1990, J CLIN ENDOCR METAB, V70, P675, DOI 10.1210/jcem-70-3-675; FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; Ishizuki Y, 1992, Nihon Naibunpi Gakkai Zasshi, V68, P550; LEE SM, 1994, BRIT J NUTR, V72, P435, DOI 10.1079/BJN19940045; REINWEIN D, 1993, J CLIN ENDOCR METAB, V76, P1516; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SOLOMON BL, 1987, ANN INTERN MED, V107, P510, DOI 10.7326/0003-4819-107-4-510; SPENCER CA, 1995, CLIN CHEM, V41, P367; SUGRUE D, 1980, Q J MED, V49, P51; TAMAI H, 1980, ANN INTERN MED, V92, P488, DOI 10.7326/0003-4819-92-4-488; TAMAI H, 1995, J CLIN ENDOCR METAB, V80, P1481, DOI 10.1210/jc.80.5.1481; TOFT AD, 1994, NEW ENGL J MED, V331, P174; VOLPE R, 1991, WERNER INGBARS THYRO, P648; WARTOFSKY L, 1973, JAMA-J AM MED ASSOC, V226, P1083, DOI 10.1001/jama.226.9.1083; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x	18	115	117	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					220	224		10.1056/NEJM199601253340403	http://dx.doi.org/10.1056/NEJM199601253340403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8531998				2022-12-28	WOS:A1996TQ75500003
J	Ferguson, JH				Ferguson, JH			On-line medicine @nih.gov	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Ferguson, JH (corresponding author), NIH,OFF MED APPLICAT RES,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					94	94						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531318				2022-12-28	WOS:A1996TN28000004
J	Burling, FT; Weis, WI; Flaherty, KM; Brunger, AT				Burling, FT; Weis, WI; Flaherty, KM; Brunger, AT			Direct observation of protein solvation and discrete disorder with experimental crystallographic phases	SCIENCE			English	Article							MANNOSE-BINDING PROTEIN; MOLECULAR-DYNAMICS SIMULATION; ANOMALOUS SCATTERING FACTORS; ATOMIC FLUCTUATIONS; CRYSTAL-STRUCTURES; WATER-STRUCTURE; REFINEMENT; ANHARMONICITY; ANISOTROPY; DOMAIN	A complete and accurate set of experimental crystallographic phases to a resolution of 1.8 angstroms was obtained for a 230-residue dimeric fragment of rat mannose-binding protein A with the use of multiwavelength anomalous dispersion (MAD) phasing. An accurate image of the crystal structure could thus be obtained without resort to phases calculated from a model. Partially reduced disulfide bonds, local disorder, and differences in the mobility of chemically equivalent molecules are apparent in the experimental electron density map. A solvation layer is visible that includes well-ordered sites of hydration around polar and charged protein atoms, as well as diffuse, partially disordered solvent shells around exposed hydrophobic groups. Because the experimental phases and the resulting electron density map are free from the influence of a model, they provide a stringent test of theoretical models of macromolecular solvation, motion, and conformational heterogeneity.	STANFORD UNIV,DEPT BIOL STRUCT,STANFORD,CA 94305; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Stanford University; Howard Hughes Medical Institute; Yale University; Yale University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Brunger, Axel/0000-0001-5121-2036	NIGMS NIH HHS [GM50565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BADGER J, 1991, P NATL ACAD SCI USA, V88, P622, DOI 10.1073/pnas.88.2.622; BADGER J, 1995, NAT STRUCT BIOL, V2, P77, DOI 10.1038/nsb0195-77; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, UNPUB; BURLING FT, 1994, ISRAEL J CHEM, V34, P165; CLORE GM, 1994, STRUCTURE, V2, P89, DOI 10.1016/S0969-2126(00)00011-3; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Drenth J, 1994, PRINCIPLES PROTEIN X; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENDRICKSON WA, UNPUB; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; ICHIYE T, 1987, PROTEINS, V2, P236, DOI 10.1002/prot.340020308; ICHIYE T, 1988, BIOCHEMISTRY-US, V27, P3487, DOI 10.1021/bi00409a054; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLE J, 1980, INT J QUANTUM CHEM, V7, P356; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KOMEIJI Y, 1993, PROTEINS, V16, P268, DOI 10.1002/prot.340160305; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LEVITT M, 1988, P NATL ACAD SCI USA, V85, P7557, DOI 10.1073/pnas.85.20.7557; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LOUNNAS V, 1994, BIOPHYS J, V66, P601, DOI 10.1016/S0006-3495(94)80835-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NALL BT, 1991, CONFORMATIONS FORCES; OTWINOWSKI Z, 1993, JAN P CCP4 STUD WEEK; OTWINOWSKI Z, 1991, JAN P CCP4 STUD WEEK; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REES DC, 1983, ACTA CRYSTALLOGR A, V39, P94, DOI 10.1107/S0108767383000173; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; STEINBACH PJ, 1993, P NATL ACAD SCI USA, V90, P9135, DOI 10.1073/pnas.90.19.9135; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P6, DOI 10.1107/S0108767387099987; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WEIS WI, UNPUB; Westhof E., 1993, WATER BIOL MACROMOLE; 1994, CCP4 SUITE PROGRAMS	55	221	223	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					72	77		10.1126/science.271.5245.72	http://dx.doi.org/10.1126/science.271.5245.72			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539602				2022-12-28	WOS:A1996TP02200046
J	Sackmann, E				Sackmann, E			Supported membranes: Scientific and practical applications	SCIENCE			English	Article							LIPID BILAYERS; IMMUNE-SYSTEM; RECOGNITION; MONOLAYERS; SURFACES; LAYERS; CELL; TRANSITIONS; INTERFACE; RESONANCE	Scientific and practical applications of supported lipid-protein bilayers are described. Membranes can be covalently coupled to or separated from solids by ultrathin layers of water or soft polymer cushions, The latter systems maintain the structural and dynamic properties of free bilayers, forming a class of models of biomembranes that allow the application of a manifold of surface-sensitive techniques, They form versatile models of low-dimensionality complex fluids, which can be used to study interfacial forces and wetting phenomena, and enable the design of phantom cells to explore the interplay of lock-and-key forces (such as receptor-ligand binding) and universal forces for cell adhesion, Practical applications are the design of (highly selective) receptor surfaces of biosensors on electrooptical devices or the biofunctionalization of inorganic solids.			Sackmann, E (corresponding author), TECH UNIV MUNICH,DEPT PHYS E22,BIOPHYS LAB,D-85747 GARCHING,GERMANY.		Zdilla, Michael J/B-4145-2011; Wunder, Stephanie L/B-5066-2012					ABSTREITER G, 1993, PHYS SCRIPTA, VT49A, P42, DOI 10.1088/0031-8949/1993/T49A/006; ALMEIDA PFF, 1995, HDB BIOL PHYSICS, V1; BAYERL T, 1992, CHOLESTEROL MEMBRANE; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; BEACKMARK T, IN PRESS LANGMUIR; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; BRINK G, 1994, BBA-BIOMEMBRANES, V1196, P227, DOI 10.1016/0005-2736(94)00218-5; BRUINSMA R, 1994, BIOPHYS J, V67, P746, DOI 10.1016/S0006-3495(94)80535-1; DEGENNES PG, 1982, MACROMOLECULES, V15, P492, DOI 10.1021/ma00230a055; DUWE HP, 1990, J PHYS-PARIS, V51, P945, DOI 10.1051/jphys:019900051010094500; EGGER M, 1990, BIOPHYS J, V57, P669, DOI 10.1016/S0006-3495(90)82586-8; EGGL P, 1990, MACROMOLECULES, V23, P3472, DOI 10.1021/ma00216a015; ELENDER G, 1994, J PHYS II, V4, P455, DOI 10.1051/jp2:1994107; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1988, J FLUID MECH, V194, P553, DOI 10.1017/S0022112088003106; FEDER TJ, 1995, PHYS REV E, V51, P3427, DOI 10.1103/PhysRevE.51.3427; Fischer A., 1984, Journal de Physique Lettres, V45, P785, DOI 10.1051/jphyslet:019840045016078500; FROMHERZ P, 1991, SCIENCE, V252, P1290, DOI 10.1126/science.1925540; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; HELM CA, 1987, EUROPHYS LETT, V4, P697, DOI 10.1209/0295-5075/4/6/010; ISRAELACHVILI JN, 1990, LANGMUIR, V6, P873, DOI 10.1021/la00094a028; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; KONIG S, 1992, J PHYS II, V2, P1589, DOI 10.1051/jp2:1992100; KOSHLAND DE, 1984, TRENDS BIOCHEM SCI, V9, P155, DOI 10.1016/0968-0004(84)90125-7; KOSSLINGER C, IN PRESS SENS ACTU B; KUHL TL, 1994, BIOPHYS J, V66, P1474; KUHN H, 1972, PHYSICAL METHODS 3B; KUHNER M, 1994, BIOPHYS J, V67, P217; LANG H, 1992, THIN SOLID FILMS, V210, P818, DOI 10.1016/0040-6090(92)90413-6; LEHN JM, 1985, SCIENCE, V227, P849, DOI 10.1126/science.227.4689.849; LIPOWSKY R, 1989, PHYS REV LETT, V62, P1572, DOI 10.1103/PhysRevLett.62.1572; LIPOWSKY R, 1986, PHYS REV LETT, V56, P2541, DOI 10.1103/PhysRevLett.56.2541; LOFAS S, 1991, SENSOR ACTUAT B-CHEM, V5, P79, DOI 10.1016/0925-4005(91)80224-8; MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MERKEL R, 1989, J PHYS-PARIS, V50, P1535, DOI 10.1051/jphys:0198900500120153500; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; MULLER W, 1993, SCIENCE, V262, P1706, DOI 10.1126/science.8259513; NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y; PARSEGIAN VA, 1979, P NATL ACAD SCI USA, V76, P2750, DOI 10.1073/pnas.76.6.2750; RADLER J, 1993, J PHYS II, V3, P727; RADLER J, IN PRESS LANGMUIR; RADLER JO, 1995, PHYS REV E, V51, P4526, DOI 10.1103/PhysRevE.51.4526; ROTHENHAUSLER B, 1988, NATURE, V332, P615, DOI 10.1038/332615a0; SACKMANN E, UNPUB; SCHMITT L, 1994, J AM CHEM SOC, V116, P8485, DOI 10.1021/ja00098a008; SEIFERT U, 1991, PHYS REV A, V42, P4768; SPINKE J, 1992, BIOPHYS J, V63, P167; STELZLE M, 1993, J PHYS CHEM-US, V97, P2974, DOI 10.1021/j100114a025; STELZLE M, 1992, BIOPHYS J, V63, P1346, DOI 10.1016/S0006-3495(92)81712-5; TOEZEREN A, 1992, J CELL BIOL, V116, P997; WATTS TH, 1987, ANNU REV IMMUNOL, V5, P461, DOI 10.1146/annurev.immunol.5.1.461; WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0; WEGNER G, 1992, THIN SOLID FILMS, V216, P105, DOI 10.1016/0040-6090(92)90878-F; WOLLENBERGER U, 1994, ANALYST, V119, P1245, DOI 10.1039/an9941901245; ZILKER A, 1992, PHYS REV A, V46, P7998, DOI 10.1103/PhysRevA.46.7998	58	1907	1959	7	523	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					43	48		10.1126/science.271.5245.43	http://dx.doi.org/10.1126/science.271.5245.43			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539599				2022-12-28	WOS:A1996TP02200036
J	Truman, JW				Truman, JW			Ecdysis control sheds another layer	SCIENCE			English	Editorial Material							AMINO-ACID SEQUENCE; ECLOSION HORMONE; MANDUCA-SEXTA; TOBACCO HORNWORM; RELEASE				Truman, JW (corresponding author), UNIV WASHINGTON, DEPT ZOOL, POB 351800, SEATTLE, WA 98195 USA.							HEWES RS, 1991, J COMP PHYSIOL A, V168, P697; KATAOKA H, 1987, BIOCHEM BIOPH RES CO, V146, P746, DOI 10.1016/0006-291X(87)90592-4; KONO T, 1987, AGR BIOL CHEM TOKYO, V51, P2307; MARTI T, 1987, FEBS LETT, V219, P415, DOI 10.1016/0014-5793(87)80263-6; Reynolds S.E., 1980, Advances in Insect Physiology, V15, P475, DOI 10.1016/S0065-2806(08)60144-7; TRUMAN JW, 1978, J EXP BIOL, V74, P151; TRUMAN JW, 1970, SCIENCE, V167, P1624, DOI 10.1126/science.167.3925.1624; TRUMAN JW, 1990, PROG BRAIN RES, V86, P25; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88	9	18	20	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					40	41		10.1126/science.271.5245.40	http://dx.doi.org/10.1126/science.271.5245.40			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539597				2022-12-28	WOS:A1996TP02200033
J	Dalen, JE; Dalton, WS				Dalen, JE; Dalton, WS			Does lowering cholesterol cause cancer?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARCINOGENIC POTENCY DATABASE; RODENT CARCINOGENS; SERUM-CHOLESTEROL; ANIMAL BIOASSAYS; RISK; MORTALITY; MEN				Dalen, JE (corresponding author), UNIV ARIZONA,COLL MED,OFF VICE PRESIDENT HLTH SCI,TUCSON,AZ 85724, USA.							AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; [Anonymous], 1984, LANCET, V2, P600; ARKY R, 1992, PHYSICIANS DESK REFE; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; GOLD LS, 1992, SCIENCE, V258, P261, DOI 10.1126/science.1411524; GOLD LS, 1986, ENVIRON HEALTH PERSP, V67, P161, DOI 10.2307/3430332; GOLD LS, 1984, ENVIRON HEALTH PERSP, V58, P9, DOI 10.2307/3429857; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; HUTTUNEN JK, 1994, J INTERN MED, V235, P31, DOI 10.1111/j.1365-2796.1994.tb01029.x; KRITCHEVSKY SB, 1992, ANNU REV NUTR, V12, P391, DOI 10.1146/annurev.nu.12.070192.002135; KULLER LH, 1980, PROG CARDIOVASC DIS, V23, P1, DOI 10.1016/0033-0620(80)90002-X; LAVE LB, 1988, NATURE, V336, P631, DOI 10.1038/336631a0; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MORDENTI J, 1986, J PHARM SCI, V75, P1028, DOI 10.1002/jps.2600751104; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PEARCE ML, 1971, LANCET, V1, P464; SANTIAGO JM, 1994, ARCH INTERN MED, V154, P1317, DOI 10.1001/archinte.154.12.1317; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; TOMATIS L, 1990, EXP PATHOL-JENA, V40, P251, DOI 10.1016/S0232-1513(11)80309-9; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1993, JAMA-J AM MED ASSOC, V269, P3015	26	42	42	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					67	69		10.1001/jama.275.1.67	http://dx.doi.org/10.1001/jama.275.1.67			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531290				2022-12-28	WOS:A1996TM23800025
J	Heathcote, JA				Heathcote, JA			Why do old men have big ears?	BRITISH MEDICAL JOURNAL			English	Article											Heathcote, JA (corresponding author), S VIEW LODGE,BROMLEY BR1 3DR,KENT,ENGLAND.								0	39	40	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1668	1668		10.1136/bmj.311.7021.1668	http://dx.doi.org/10.1136/bmj.311.7021.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541753	Green Published			2022-12-28	WOS:A1995TL94200012
J	Williams, TM; Kim; Williams, G				Williams, TM; Kim; Williams, G			Excessive impertinence or a missed diagnosis?	BRITISH MEDICAL JOURNAL			English	Note											Williams, TM (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MED,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							CAVALIERO G, 1986, B POTTERS J; Gilles de la Tourette G., 1885, ARCH NEUROL-CHICAGO, V9, P158; PEARCE JMS, 1994, J ROY SOC MED, V87, P396; Potter B., 1903, TALE SQUIRREL NUTKIN; POTTER B, 1905, TALE MRS TIGGY WINKL; ROBERTSON MM, 1988, BRIT J PSYCHIAT, V152, P383, DOI 10.1192/bjp.152.3.383; SACKS O, 1992, BRIT MED J, V305, P1515, DOI 10.1136/bmj.305.6868.1515; SIMKIN B, 1992, BRIT MED J, V305, P1563, DOI 10.1136/bmj.305.6868.1563; TAYLOR J, 1987, ARTIST WORLD	9	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1700	1701		10.1136/bmj.311.7021.1700	http://dx.doi.org/10.1136/bmj.311.7021.1700			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541765	Green Published			2022-12-28	WOS:A1995TL94200026
J	COLLINGE, J; PALMER, MS; SIDLE, KCL; HILL, AF; GOWLAND, I; MEADS, J; ASANTE, E; BRADLEY, R; DOEY, LJ; LANTOS, PL				COLLINGE, J; PALMER, MS; SIDLE, KCL; HILL, AF; GOWLAND, I; MEADS, J; ASANTE, E; BRADLEY, R; DOEY, LJ; LANTOS, PL			UNALTERED SUSCEPTIBILITY TO BSE IN TRANSGENIC MICE EXPRESSING HUMAN PRION PROTEIN	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB DISEASE; SCRAPIE; PRP; TRANSMISSION; GENE	PRION diseases are transmissible neurodegenerative conditions of humans and animals. Prions consist principally of a post-translationally modified form of prion protein (PrP), PrPSc, which is partly protease resistant(1). Transmission of prion diseases between species is limited by a 'species barrier'(2) determined in part by the degree of sequence homology between host PrP and inoculated PrPSc (ref.3) and by prion strain type(4). The epidemic of bovine spongiform encephalopathy (BSE) in the United Kingdom and other countries has led to concerns that transmission to humans may occur by dietary exposure. BSE appears to be caused by a single strain, distinct from those of natural or experimental scrapie(4), which is also seen in the nerv prion diseases of cats and ruminants that have presumably arisen from dietary BSE exposure(4). Here we show that transgenic mice expressing human PrP in addition to mouse PrP can generate human PrPSc and 'human' prions. These mice therefore provide a model to study experimentally the species barrier limiting BSE transmission to humans. Incubation periods to BSE in transgenic mice are not shortened by expression of human PrP, and only mouse PrPSc is produced in response to such challenge.	ST MARYS HOSP,DEPT NEUROL,LONDON W2 1NY,ENGLAND; MAFF,CENT VET LAB,WEYBRIDGE KT15 3NB,SURREY,ENGLAND; INST PSYCHIAT,DEPT NEUROPATHOL,LONDON SE5 8AF,ENGLAND	Imperial College London; University of London; King's College London	COLLINGE, J (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.		Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022; Hill, Andrew F/B-4527-2009	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Asante, Emmanuel A/0000-0003-3771-4843	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BARLOW RM, 1990, VET REC, V126, P111; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; FRASER H, 1988, VET REC, V123, P472, DOI 10.1136/vr.123.18.472; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1994, 1993 P CONS BSE SCI, P455; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTOS PL, 1992, NEUROSCI LETT, V147, P67, DOI 10.1016/0304-3940(92)90776-4; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; TAYLOR DM, 1994, ARCH VIROL, V139, P313, DOI 10.1007/BF01310794; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Wells GAH, 1991, BRAIN PATHOL, V1, P69, DOI 10.1111/j.1750-3639.1991.tb00642.x; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197	30	185	194	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					779	783		10.1038/378779a0	http://dx.doi.org/10.1038/378779a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524411				2022-12-28	WOS:A1995TL41900026
J	KASTNER, P; MARK, M; CHAMBON, P				KASTNER, P; MARK, M; CHAMBON, P			NONSTEROID NUCLEAR RECEPTORS - WHAT ARE GENETIC-STUDIES TELLING US ABOUT THEIR ROLE IN REAL-LIFE	CELL			English	Review							VITAMIN-D RECEPTOR; RETINOIC ACID; NEURAL CREST; DISRUPTION; MUTATIONS; RICKETS; GROWTH; GAMMA; MICE				KASTNER, P (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1, CTR NATL RECH SCI, INST GENET & BIOL MOLEC & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.							ANDERSEN B, 1995, NATURE, V374, P118, DOI 10.1038/374118a0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BROOKFIELD J, 1992, EVOL GENET, V2, P553; BURRIS TP, 1995, BIOCHEM BIOPH RES CO, V214, P576, DOI 10.1006/bbrc.1995.2324; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; CONLON RA, 1995, TRENDS GENET, V11, P314, DOI 10.1016/S0168-9525(00)89089-7; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; Darmon M., 1991, SEMINARS DEV BIOL, V2, P219; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; FORREST D, 1995, 2ND INT WORKSH THYRO, P11; FRASCH M, 1995, DEVELOPMENT, V121, P957; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KASTNER P, 1996, IN PRESS GENES DEV; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; LAMPRON C, 1995, DEVELOPMENT, V121, P539; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARK M, 1995, INT J DEV BIOL, V39, P111; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; ORO AE, 1992, DEVELOPMENT, V115, P449; PECORINO LT, 1994, DEVELOPMENT, V120, P325; QIU Y, 1995, IN PRESS J STEROID B; REFETOFF S, 1982, AM J PHYSIOL, V243, pE88, DOI 10.1152/ajpendo.1982.243.2.E88; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUTLEDGE JC, 1994, P NATL ACAD SCI USA, V91, P5436, DOI 10.1073/pnas.91.12.5436; SADOVSKY Y, 1995, IN PRESS P NATL ACAD; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SCHILTHUIS JG, 1993, EMBO J, V12, P3459, DOI 10.1002/j.1460-2075.1993.tb06020.x; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SMITH DP, 1994, ROUX ARCH DEV BIOL, V203, P254, DOI 10.1007/BF00360521; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SUCOV HM, 1995, IN PRESS DEVELOPMENT; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; WARKANY J, 1946, ARCH OPHTHALMOL-CHIC, V35, P150, DOI 10.1001/archopht.1946.00890200155008; WIESE RJ, 1993, MOL CELL ENDOCRINOL, V90, P197, DOI 10.1016/0303-7207(93)90152-A; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	71	914	937	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					859	869		10.1016/0092-8674(95)90202-3	http://dx.doi.org/10.1016/0092-8674(95)90202-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521510	Bronze			2022-12-28	WOS:A1995TK74500005
J	SONG, WY; WANG, GL; CHEN, LL; KIM, HS; PI, LY; HOLSTEN, T; GARDNER, J; WANG, B; ZHAI, WX; ZHU, LH; FAUQUET, C; RONALD, P				SONG, WY; WANG, GL; CHEN, LL; KIM, HS; PI, LY; HOLSTEN, T; GARDNER, J; WANG, B; ZHAI, WX; ZHU, LH; FAUQUET, C; RONALD, P			A RECEPTOR KINASE-LIKE PROTEIN ENCODED BY THE RICE DISEASE RESISTANCE GENE, XA21	SCIENCE			English	Article							BACTERIAL-BLIGHT; CLONING; INHERITANCE; LOCUS	The rice Xa21 gene, which confers resistance to Xanthomonas oryzae pv. oryzae race 6, was isolated by positional cloning. Fifty transgenic rice plants carrying the cloned Xa21 gene display high levels of resistance to the pathogen. The sequence of the predicted protein, which carries both a leucine-rich repeat motif and a serine-threonine kinase-like domain, suggests a role in cell surface recognition of a pathogen ligand and subsequent activation of an intracellular defense response. Characterization of Xa21 should facilitate understanding of plant disease resistance and lead to engineered resistance in rice.	SCRIPPS RES INST, INST FRANCAIS RECH SCI & TECH DEV COOPERAT, LA JOLLA, CA 92037 USA; UNIV CALIF DAVIS, CTR ENGN PLANTS RESISTANCE AGAINST PATHOGENS, DAVIS, CA 95616 USA; ACAD SINICA, INST GENET, BEIJING 100101, PEOPLES R CHINA	Scripps Research Institute; University of California System; University of California Davis; Chinese Academy of Sciences	SONG, WY (corresponding author), UNIV CALIF DAVIS, DEPT PLANT PATHOL, DAVIS, CA 95616 USA.		Ronald, Pamela/AAK-7664-2020					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYANOSAITO Y, 1993, 15TH INT BOT C YOK; JIANG JM, 1995, P NATL ACAD SCI USA, V92, P4487, DOI 10.1073/pnas.92.10.4487; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KAUFFMAN HE, 1973, PLANT DIS REP, V57, P537; Khush G. S., 1989, BACTERIAL BLIGHT RIC, P207; MACKILL DJ, 1992, PHYTOPATHOLOGY, V82, P746, DOI 10.1094/Phyto-82-746; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; RONALD PC, 1992, MOL GEN GENET, V236, P113, DOI 10.1007/BF00279649; STASKAWICZ B, COMMUNICATION; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STEINMAYR M, 1994, PLANT J, V5, P459, DOI 10.1046/j.1365-313X.1994.5040459.x; TOUBART P, 1992, PLANT J, V2, P367; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WALKER JC, 1994, PLANT MOL BIOL, V26, P363; WANG GL, 1995, PLANT J, V7, P525, DOI 10.1046/j.1365-313X.1995.7030525.x; WANG GL, 1994, GENETICS, V136, P1421; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; YOSHIMURA A, 1983, PHYTOPATHOLOGY, V73, P1409, DOI 10.1094/Phyto-73-1409; ZHANG S, IN PRESS PLANT CELL	25	1640	2031	8	247	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1804	1806		10.1126/science.270.5243.1804	http://dx.doi.org/10.1126/science.270.5243.1804			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525370	Green Submitted			2022-12-28	WOS:A1995TK47600040
J	LIP, GYH; SINGH, SP; WATSON, RDS				LIP, GYH; SINGH, SP; WATSON, RDS			ABC OF ATRIAL-FIBRILLATION - INVESTIGATION AND NONDRUG MANAGEMENT OF ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham								BRUGADA P, 1993, LANCET, V341, P1254, DOI 10.1016/0140-6736(93)91155-F; MCCOMB J, 1994, BRIT HEART J, V71, P501; WAGSHAL AB, 1995, ARCH INTERN MED, V155, P137, DOI 10.1001/archinte.155.2.137	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1562	1565		10.1136/bmj.311.7019.1562	http://dx.doi.org/10.1136/bmj.311.7019.1562			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520405	Green Published			2022-12-28	WOS:A1995TK21400035
J	KAY, SA; MILLAR, AJ				KAY, SA; MILLAR, AJ			NEW MODELS IN VOGUE FOR CIRCADIAN CLOCKS	CELL			English	Review											KAY, SA (corresponding author), UNIV VIRGINIA,DEPT BIOL,NATL SCI FDN CTR BIOL TIMING,GILMER HALL,CHARLOTTESVILLE,VA 22903, USA.		Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; CROSTHWAITE SK, 1995, CELL, V81, P1001; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; GEKAKIS N, 1995, IN PRESS SCIENCE; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, IN PRESS SCIENCE; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEHGAL A, 1995, IN PRESS SCIENCE; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x	20	44	44	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					361	364		10.1016/0092-8674(95)90113-2	http://dx.doi.org/10.1016/0092-8674(95)90113-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521465	Bronze			2022-12-28	WOS:A1995TC97700005
J	WU, L; RUSSELL, P				WU, L; RUSSELL, P			NIM1 KINASE PROMOTES MITOSIS BY INACTIVATING WEE1 TYROSINE KINASE	NATURE			English	Article							FISSION YEAST; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; ACTIVATES P34CDC2; MITOTIC INDUCER; CDC25 PROTEIN; PHOSPHORYLATION; PHOSPHATASE; CELLS; GENE	IN most species, including the fission yeast Schizosaccharomyces pombe, the Cdc2/cyclin B mitosis-inducing kinase is maintained in an inhibited state during interphase as a result of phosphorylation of a tyrosine residue in the ATP-binding region of Cdc2 (refs 1-3). This site is phosphorylated by Wee1 kinase4-9 and dephosphorylated by Cdc25 phosphatase10-15. In fission yeast an additional element of the G2/M control Nim1/Cdr1 kinase, has been identified which functions as a potent mitotic inducer16,17. These studies suggested that Nim1 acts by inhibiting Wee1, perhaps by direct phosphorylation. Consistent with this model, we report here that Wee1 is hyperphosphorylated in cells that overproduce Nim1. Likewise, Weel phosphorylation is reduced in nim1- cells. Highly purified Nim1 kinase phosphorylates Wee1 in vitro, resulting in strong inhibition of Weel kinase. These observations show that Nim1 promotes the onset of mitosis by inhibiting Wee1.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	26	137	138	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1993	363	6431					738	741		10.1038/363738a0	http://dx.doi.org/10.1038/363738a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515818				2022-12-28	WOS:A1993LJ33900061
J	COX, JS; SHAMU, CE; WALTER, P				COX, JS; SHAMU, CE; WALTER, P			TRANSCRIPTIONAL INDUCTION OF GENES ENCODING ENDOPLASMIC-RETICULUM RESIDENT PROTEINS REQUIRES A TRANSMEMBRANE PROTEIN-KINASE	CELL			English	Article							GLUCOSE-REGULATED PROTEINS; CHAIN BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; HEMAGGLUTININ-NEURAMINIDASE; DISULFIDE ISOMERASE; ESCHERICHIA-COLI; SHUTTLE VECTORS; S-CEREVISIAE; YEAST	The transcription of genes encoding soluble proteins that reside in the endoplasmic reticulum (ER) is induced when unfolded proteins accumulate in the ER. Thus, an intracellular signal transduction pathway must exist that mediates communication between the ER lumen and the nucleus. We have identified a gene in S. cerevisiae, IRE1, that is required for this pathway: ire1- mutants cannot activate transcription of KAR2 and PDI1, which encode the ER resident proteins BiP and protein disulfide isomerase. Moreover, IRE1 is essential for cell viability under stress conditions that cause unfolded proteins to accumulate in the ER. IRE1 encodes a transmembrane serine/threonine kinase that we propose transmits the unfolded protein signal across the ER or inner nuclear membrane. IRE1 is also required for inositol prototrophy, suggesting that the induction of ER resident proteins is coupled to the biogenesis of new ER membrane.			COX, JS (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CULBERTSON MR, 1975, GENETICS, V80, P23; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Favaloro J, 1980, Methods Enzymol, V65, P718; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1	57	910	951	2	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1197	1206		10.1016/0092-8674(93)90648-A	http://dx.doi.org/10.1016/0092-8674(93)90648-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513503				2022-12-28	WOS:A1993LH54800015
J	MCMICHAEL, A				MCMICHAEL, A			NATURAL-SELECTION AT WORK ON THE SURFACE OF VIRUS-INFECTED CELLS	SCIENCE			English	Article							CLASS-II REGION; CYTOTOXIC T-CELLS; MHC; PEPTIDES; ANTIGENS; MOLECULES; TRANSPORTERS; SPECIFICITY; RECOGNITION; HLA-B27				MCMICHAEL, A (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN MG, 1991, NATURE, V353, P365; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; LJUNGGREN HG, 1990, NATURE, V346, P4476; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	30	14	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1771	1772		10.1126/science.8511585	http://dx.doi.org/10.1126/science.8511585			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511585				2022-12-28	WOS:A1993LH20500039
J	REICHARD, P				REICHARD, P			FROM RNA TO DNA, WHY SO MANY RIBONUCLEOTIDE REDUCTASES	SCIENCE			English	Article							ESCHERICHIA-COLI; TRIPHOSPHATE REDUCTASE; MECHANISM; COFACTOR; PROTEIN; ENZYME; WORLD	It is generally accepted that DNA appeared after RNA during the chemical evolution of life. To synthesize DNA, deoxyribonucleotides are required as building blocks. At present, these are formed from the corresponding ribonucleotides through the enzymatic action of ribonucleotide reductases. Three classes of enzymes are present in various organisms. There is little sequence similarity among the three classes of reductases. However, enzymic mechanisms and the allosteric behavior of the enzymes from various organisms are strongly conserved, suggesting that the enzymes might have evolved from a common ancestor, with the class III anaerobic Escherichia coli reductase as its closest relative.			REICHARD, P (corresponding author), KAROLINSKA INST, DEPT BIOCHEM 1, S-10401 STOCKHOLM 60, SWEDEN.							ABELES RH, 1967, J BIOL CHEM, V242, P3589; ABERG A, 1989, J BIOL CHEM, V264, P12249; ASHLEY GW, 1985, PHARMACOL THERAPEUT, V30, P301, DOI 10.1016/0163-7258(85)90054-3; BARLOW T, 1983, P NATL ACAD SCI-BIOL, V80, P1492, DOI 10.1073/pnas.80.6.1492; BECK WS, 1967, J BIOL CHEM, V242, P3148; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BLAKLEY RL, 1964, BIOCHEM BIOPH RES CO, V16, P391, DOI 10.1016/0006-291X(64)90363-8; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; COWLES JR, 1968, ARCH BIOCHEM BIOPHYS, V127, P770, DOI 10.1016/0003-9861(68)90288-9; DURHAM LJ, 1967, EUR J BIOCHEM, V1, P92, DOI 10.1111/j.1432-1033.1967.tb00048.x; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ELIASSON R, UNPUB; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HAMMARSTEN E, 1950, J BIOL CHEM, V183, P105; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; ISAACS SY, 1992, BIOCHEM BIOPH RES CO, V84, P1101; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; PETROVICH RM, 1991, J BIOL CHEM, V266, P7656; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; REICHARD P, 1987, BIOCHEMISTRY-US, V26, P3245, DOI 10.1021/bi00386a001; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1951, J BIOL CHEM, V188, P839; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE J, COMMUNICATION; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1974, J BIOL CHEM, V249, P4858; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	50	506	522	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1993	260	5115					1773	1777		10.1126/science.8511586	http://dx.doi.org/10.1126/science.8511586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511586				2022-12-28	WOS:A1993LH20500040
J	LONDON, NJM; WILLIAMS, B; STEIN, A				LONDON, NJM; WILLIAMS, B; STEIN, A			LESSON OF THE WEEK - SYSTEMIC THROMBOLYSIS CAUSING HEMORRHAGE AROUND A PROSTHETIC ABDOMINAL AORTIC GRAFT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STREPTOKINASE; MANAGEMENT		LEICESTER GEN HOSP, LEICESTER LE5 4PW, ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital				Williams, Bryan/0000-0002-8094-1841				[Anonymous], 1988, LANCET, V2, P349; ELLIS SG, 1990, CIRCULATION, V81, P43; GRINES CL, 1991, CIRCULATION, V84, P540, DOI 10.1161/01.CIR.84.2.540; HAMILTON G, 1992, EMERGENCY VASCULAR S, P37; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; JOHNSTON KW, 1988, J VASC SURG, V7, P69, DOI 10.1067/mva.1988.avs0070069; RABE FE, 1982, AM J ROENTGENOL, V138, P917, DOI 10.2214/ajr.138.5.917; SMITH SRG, 1987, BRIT J HOSP MED, V38, P358; TAYLOR GJ, 1992, THROMBOLYTIC THERAPY	9	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1993	306	6891					1530	1531		10.1136/bmj.306.6891.1530	http://dx.doi.org/10.1136/bmj.306.6891.1530			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518685	Bronze, Green Published			2022-12-28	WOS:A1993LF94000033
J	Emanuel, LL				Emanuel, LL			A professional response to demands for accountability: Practical recommendations regarding ethical aspects of patient care	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY IMPROVEMENT TOOL; MALPRACTICE CLAIMS DATA; MEDICAL-CARE; HEALTH-CARE; HOSPITAL-CARE; OF-INTEREST; RISK; APPROPRIATENESS; ORGANIZATIONS; DECISIONS	Forceful new demands for accountability in medicine are arising from many interested parties. To maintain professional standards, physicians need to establish which demands are desirable and which are not. We adopt a model of stratified accountability that includes three major components: the accountable parties, the subject matter, and the processes for accountability. To begin describing the model, we focus on physicians and health care institutions. We focus on the ethical dimensions of medical practice, both because the difficulty of measuring such behaviors makes this a test case for accountability and because of the importance of ethical standards in maintaining patient trust. We first identify eight widely endorsed content areas for accountability in ethical conduct: medical decision making, confidentiality, fiduciary obligations (including conflicts of interest), responsibilities arising from patient vulnerability, personal standards, equity among patients, cultural representation, and procedures for resolving dilemmas. We then identify the currently most valid and reliable methods for assessing conduct: surveys among all involved parties, testing methods used for accreditation, limited audits, publication of policy, and careful use of report cards. A prototypical survey and report card are illustrated. However, we also note the need for improved accountability assessment methods. We next identify mechanisms for taking responsibility: sharing information, exchanging perspectives, making adjustments, and enforcing standards when necessary. Finally, because this report only begins to describe a small part of the accountability model, we urge explicit identification and development of professional standards for accountability in the many other areas of medicine.			Emanuel, LL (corresponding author), HARVARD UNIV, SCH MED, DIV MED ETH, 641 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ALPERT HR, 1996, J GEN INTERN MED, V10, P59; APPLEBAUM P, 1987, INFORMED CONSENT LEG; Berglund S, 1991, J Ark Med Soc, V87, P482; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BETZ M, 1983, SOC PROBL, V31, P84, DOI 10.1525/sp.1983.31.1.03a00060; BOSK CL, 1979, FORGIVE REMEMBER; Brock D W, 1991, Kennedy Inst Ethics J, V1, P28; BROOK RH, 1994, ANN INTERN MED, V120, P84, DOI 10.7326/0003-4819-120-1-199401010-00015; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; Clinton B., 1993, PRESIDENTS HLTH SECU; Daniels N, 1984, JUST HLTH CARE; DAY P, 1987, ACCOUNTABILITIES; DEMOS MP, 1991, ARCH INTERN MED, V151, P1708, DOI 10.1001/archinte.151.9.1708; Edelstein L, 1943, HIPPOCRATIC OATH TEX; Emanuel EJ, 1996, ANN INTERN MED, V124, P229, DOI 10.7326/0003-4819-124-2-199601150-00007; Emanuel Ezekial, 1991, ENDS HUMAN LIFE MED; EMANUEL LL, 1993, HASTINGS CENT REP, V23, P6, DOI 10.2307/3562059; FLETCHER JC, 1994, ANN INTERN MED, V120, P335, DOI 10.7326/0003-4819-120-4-199402150-00012; GELLHORN A, 1991, JAMA-J AM MED ASSOC, V265, P752, DOI 10.1001/jama.265.6.752; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; Gray Bradford H., 1991, PROFIT MOTIVE PATIEN, P71; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GUTHEIL TG, 1993, AM J PSYCHIAT, V150, P188; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HALL MA, 1992, U PENN LAW REV, V140, P1637, DOI 10.2307/3312428; HELMS LB, 1993, ACAD MED, V68, P7, DOI 10.1097/00001888-199301000-00002; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; JOHNSON SH, 1993, JAMA-J AM MED ASSOC, V270, P1596, DOI 10.1001/jama.270.13.1596; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KRAVITZ RL, 1991, JAMA-J AM MED ASSOC, V266, P2087, DOI 10.1001/jama.266.15.2087; KURTIN PS, 1992, MED CARE, V30, pMS136, DOI 10.1097/00005650-199205001-00012; LACOMBE MA, 1993, ANN INTERN MED, V119, P623, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00012; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LESTER GW, 1993, WESTERN J MED, V158, P268; LIND SE, 1990, NEW ENGL J MED, V323, P192, DOI 10.1056/NEJM199007193230310; MONAGLE JF, 1992, MED ETHICS POLICIES; Morreim E H, 1992, Law Med Health Care, V20, P40; Nelson E C, 1991, QRB Qual Rev Bull, V17, P278; Nelson E C, 1992, QRB Qual Rev Bull, V18, P284; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2366; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; Reiser S J, 1993, Health Manage Q, V15, P22; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; RODWIN MA, 1994, AM J LAW MED, V20, P147; ROLPH JE, 1991, JAMA-J AM MED ASSOC, V266, P2093, DOI 10.1001/jama.266.15.2093; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; Schneider K C, 1989, Tex Med, V85, P58; SIDDHARTHAN K, 1993, AM J PUBLIC HEALTH, V83, P410, DOI 10.2105/AJPH.83.3.410; Thompson Dennis F, 1992, Camb Q Healthc Ethics, V1, P203; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; VEATCH RM, 1991, PHYSICIAN PATIENT RE, P143; WARE JE, 1990, MED CARE, V28, pS39, DOI 10.1097/00005650-199009001-00009; WILLIG C, 1992, J COMMUNITY APPL SOC, V2, P217, DOI 10.1002/casp.2450020306; WOLF SM, 1994, AM J LAW MED, V20, P105; Wolf Susan M, 1991, MD Law Rev, V50, P798; Wolf Susan M, 1992, Law Med Health Care, V20, P278; WOLFE S, 1985, PUBLIC CITIZEN HLTH; Wolfe S M, 1981, Internist, V22, P8; Zusman J, 1990, QRB Qual Rev Bull, V16, P143; 1974, CAN MED ASSOC J, V110, P344; 1986, 1980 CODE ETHICS CUR; 1974, CAN MED ASSOC J, V110, P81; 1994, GENEAL GUIDELINES RE; 1992, ANN INTERN MED, V117, P947; 1974, CAN MED ASSOC J, V110, P231; 1973, CAN MED ASSOC J, V109, P1160; 1994, ACCREDITATION MANUAL; 1973, CAN MED ASSOC J, V109, P1237; 1992, GUIDE AWARENESS EVAL, P5; 1978, DHEW OS780012 PUBL; 1994, HARVARD MED SCH POLI; 1979, MED MALPRACT COST CO, V1, P254	82	33	34	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					240	249		10.7326/0003-4819-124-2-199601150-00008	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ016	8534000				2022-12-28	WOS:A1996TQ01600008
J	Gibson, G; Hogness, DS				Gibson, G; Hogness, DS			Effect of polymorphism in the Drosophila regulatory gene Ultrabithorax on homeotic stability	SCIENCE			English	Article							BITHORAX COMPLEX; LINKAGE DISEQUILIBRIUM; MELANOGASTER; EXPRESSION; REGION; SELECTION; PRODUCTS	Development is buffered against unpredictable environmental and genetic effects. Here, a molecular genetic analysis of one type of developmental homeostasis, the establishment of thoracic segmental identity under the control of the Ultrabithorax (Ubx) gene in Drosophila melanogaster, is presented. Flies were artificially selected for differential sensitivity to the induction of bithorax phenocopies by ether vapor, The experiments demonstrated that increased sensitivity to ether correlated with a loss of expression of UBX in the third thoracic imaginal discs and that a significant proportion of the genetic variation for transcriptional stability can be attributed to polymorphism in the Ubx gene.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	Gibson, G (corresponding author), UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109, USA.							AKAM ME, 1983, NATURE, V309, P635; AQUADRO CF, 1992, GENETICS, V132, P443; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BUSTURIA A, 1989, DEVELOPMENT, V107, P575; CAIZZI R, 1990, J MOL BIOL, V212, P17, DOI 10.1016/0022-2836(90)90301-2; CAPDEVILA MP, 1981, ROUX ARCH DEV BIOL, V190, P339, DOI 10.1007/BF00863271; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; FALCONER DS, 1981, INTRO QUANTITATIVE G, P272; GLOOR HANS. JU, 1947, REV SUISSE ZOOL, V54, P637; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; HOGNESS DS, 1985, COLD SPRING HARB SYM, V50, P181, DOI 10.1101/SQB.1985.050.01.024; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAI CG, 1994, SCIENCE, V266, P1697, DOI 10.1126/science.7992053; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MACKAY TFC, 1990, NATURE, V348, P64, DOI 10.1038/348064a0; MACPHERSON JN, 1990, GENETICS, V126, P121; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; ZAPATA C, 1992, EVOLUTION, V46, P1900, DOI [10.2307/2410039, 10.1111/j.1558-5646.1992.tb01177.x]; ZHIVOTOVSKY LA, 1992, THEOR POPUL BIOL, V42, P254, DOI 10.1016/0040-5809(92)90015-L	28	134	135	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					200	203		10.1126/science.271.5246.200	http://dx.doi.org/10.1126/science.271.5246.200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539619				2022-12-28	WOS:A1996TP36400041
J	MoyaSola, S; Kohler, M				MoyaSola, S; Kohler, M			A Dryopithecus skeleton and the origins of great-ape locomotion	NATURE			English	Article							PROCONSUL-NYANZAE; SIVAPITHECUS; PROPORTIONS; EVOLUTION; PAKISTAN; HOMINIDS; MIOCENE; KENYA; SIZE	THE evolution of skeletal adaptations to orthograde postures, characteristic of extant hominoids, is of great interest as it provides the key to understanding the origins of apes and humans. We report here the recent discovery of an extraordinary partial skeleton of Dryopithiecus laietanus from Can Llobateres (Spain). It provides evidence that orthograde postures and locomotion appeared at least 9.5 million years ago(1). Our results indicate that the body structure of this Miocene ape closely resembles that of extant hominoids(2,3) and differs from the pronograde pattern of Miocene proconsulids(4,5) in a set of important morphological characters. Dryopithecus also shows more traits reflecting structural adaptations for suspension than occurs in African apes. A similar positional behaviour is inferred for Simpithecus indicus, thus strengthening previous hypotheses linking both Miocene forms with Pongo(6-9).			MoyaSola, S (corresponding author), INST PALEONTOL MIQUEL CRUSAFONT,C IND 23,E-08201 SABADELL,SPAIN.			Kohler, Meike/0000-0002-6816-6651; Moya-Sola, Salvador/0000-0001-8506-1061; Kohler, Meike/0000-0001-9228-3164				AGUSTI J, IN PRESS J HUM EVOL; ANDREWS P, 1982, NATURE, V297, P541, DOI 10.1038/297541a0; ANDREWS P, 1976, GIBBON SIAMANG, P167; Begun David R., 1994, Yearbook of Physical Anthropology, V37, P11; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; ERIKSON GE, 1963, S ZOOL SOC LOND, V10, P136; HARRISON T, 1986, J HUM EVOL, V15, P541, DOI 10.1016/S0047-2484(86)80073-2; Hurzeler J., 1968, ANN PALEONT VERT, V54, P195; Jungers W.L., 1984, P146; Jungers W.L., 1985, P345; JUNGERS WL, 1987, J HUM EVOL, V16, P445, DOI 10.1016/0047-2484(87)90072-8; JUNGERS WL, 1984, YEARB PHYS ANTHROPOL, V27, P73; Jungers WL, 1990, BODY SIZE MAMMALIAN, P107; KELLEY J, 1986, COMP PRIMATE BIOL, P316; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; NAPIER JR, 1959, FORE LIMB SKELETON A, P1; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; PILBEAM D, 1971, NATURE, V229, P408; Preuschoft H., 1990, P109; ROSE MD, 1994, J HUM EVOL, V26, P387, DOI 10.1006/jhev.1994.1025; Ruff C., 1990, P119; RUFF CB, 1989, J HUM EVOL, V18, P515, DOI 10.1016/0047-2484(89)90016-X; SANDERS WJ, 1994, J HUM EVOL, V26, P203, DOI 10.1006/jhev.1994.1012; SOLA SM, 1993, NATURE, V365, P543, DOI 10.1038/365543a0; SOLA SM, 1995, J HUM EVOL, V28, P101; WARD CV, 1993, AM J PHYS ANTHROPOL, V90, P77, DOI 10.1002/ajpa.1330900106; WARD CV, 1993, AM J PHYS ANTHROPOL, V92, P291, DOI 10.1002/ajpa.1330920306; [No title captured]	29	144	144	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					156	159		10.1038/379156a0	http://dx.doi.org/10.1038/379156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP360	8538764				2022-12-28	WOS:A1996TP36000055
J	Stuart, LM; Rice, PS; Lloyd, G; Beale, RJ				Stuart, LM; Rice, PS; Lloyd, G; Beale, RJ			A soldier in respiratory distress	LANCET			English	Article									GUYS HOSP,GUYS & ST THOMAS NHS TRUST,INTENS CARE UNIT,LONDON SE1 9RT,ENGLAND; GUYS HOSP,GUYS & ST THOMAS NHS TRUST,DEPT VIROL,LONDON SE1 9RT,ENGLAND; PHLS,CTR APPL MICROBIOL & RES,VIRAL DIAG GRP,PORTON DOWN,WILTS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								Earle D, 1954, AM J MED, V16, P617; FISHERHOCH SP, 1995, LANCET, V346, P472, DOI 10.1016/S0140-6736(95)91323-8; GLIGIC A, 1992, J INFECT DIS, V166, P113, DOI 10.1093/infdis/166.1.113; Ler Z, 1991, Med Arh, V45, P55; 1995, CDR, V6, P193	5	18	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					30	30		10.1016/S0140-6736(96)91560-3	http://dx.doi.org/10.1016/S0140-6736(96)91560-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531548	Bronze			2022-12-28	WOS:A1996TN76200015
J	HUDSON, TJ; STEIN, LD; GERETY, SS; MA, JL; CASTLE, AB; SILVA, J; SLONIM, DK; BAPTISTA, R; KRUGLYAK, L; XU, SH; HU, XT; COLBERT, AME; ROSENBERG, C; REEVEDALY, MP; ROZEN, S; HUI, L; WU, XY; VESTERGAARD, C; WILSON, KM; BAE, JS; MAITRA, S; GANIATSAS, S; EVANS, CA; DEANGELIS, MM; INGALLS, KA; NAHF, RW; HORTON, LT; ANDERSON, MO; COLLYMORE, AJ; YE, WJ; KOUYOUMJIAN, V; ZEMSTEVA, IS; TAM, J; DEVINE, R; COURTNEY, DF; RENAUD, MT; NGUYEN, H; OCONNOR, TJ; FIZAMES, C; FAURE, S; GYAPAY, G; DIB, C; MORISSETTE, J; ORLIN, JB; BIRREN, BW; GOODMAN, N; WEISSENBACH, J; HAWKINS, TL; FOOTE, S; PAGE, DC; LANDER, ES				HUDSON, TJ; STEIN, LD; GERETY, SS; MA, JL; CASTLE, AB; SILVA, J; SLONIM, DK; BAPTISTA, R; KRUGLYAK, L; XU, SH; HU, XT; COLBERT, AME; ROSENBERG, C; REEVEDALY, MP; ROZEN, S; HUI, L; WU, XY; VESTERGAARD, C; WILSON, KM; BAE, JS; MAITRA, S; GANIATSAS, S; EVANS, CA; DEANGELIS, MM; INGALLS, KA; NAHF, RW; HORTON, LT; ANDERSON, MO; COLLYMORE, AJ; YE, WJ; KOUYOUMJIAN, V; ZEMSTEVA, IS; TAM, J; DEVINE, R; COURTNEY, DF; RENAUD, MT; NGUYEN, H; OCONNOR, TJ; FIZAMES, C; FAURE, S; GYAPAY, G; DIB, C; MORISSETTE, J; ORLIN, JB; BIRREN, BW; GOODMAN, N; WEISSENBACH, J; HAWKINS, TL; FOOTE, S; PAGE, DC; LANDER, ES			AN STS-BASED MAP OF THE HUMAN GENOME	SCIENCE			English	Article							PHYSICAL MAP; LINKAGE MAP; HUMAN DNA; CHROMOSOMES; CLONES; POLYMORPHISMS; YEAST; STRATEGY; PANEL-2; REGION	A physical map has been constructed of the human genome containing 15,086 sequence-tagged sites (STSs), with an average spacing of 199 kilobases. The project involved assembly of a radiation hybrid map of the human genome containing 6193 loci and incorporated a genetic linkage map of the human genome containing 5264 loci. This information was combined with the results of STS-content screening of 10,850 loci against a yeast artificial chromosome library to produce an integrated map, anchored by the radiation hybrid and genetic maps. The map provides radiation hybrid coverage of 99 percent and physical coverage of 94 percent of the human genome. The map also represents an early step in an international project to generate a transcript map of the human genome, with more than 3235 expressed sequences localized. The STSs in the map provide a scaffold for initiating large-scale sequencing of the human genome.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; GENETHON SA,CNRS,URA 1922,F-91000 EVRY,FRANCE; CHU LAVAL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); Laval University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	HUDSON, TJ (corresponding author), WHITEHEAD MIT CTR GENOME RES,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Foote, Simon J/F-2802-2013; DeAngelis, e/J-7863-2015; Rozen, Steven G./J-5939-2013	Slonim, Donna/0000-0003-3357-437X; Gerety, Sebastian/0000-0002-6126-5040; Foote, Simon/0000-0002-9142-2107; Orlin, James/0000-0002-7488-094X; Rozen, Steven G./0000-0002-4288-0056; Hudson, Thomas/0000-0002-1376-4849; Fizames, Cecile/0000-0002-0551-8250	NHGRI NIH HHS [HG00017, HG00098] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS MD, 1995, NATURE, V377, pS3; ALITALO T, 1995, GENOMICS, V25, P691, DOI 10.1016/0888-7543(95)80012-B; ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BELL CJ, 1995, HUM MOL GENET, V4, P59; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1995, NATURE, V377, pS175; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS JE, 1995, NATURE, V377, pS367; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DIB C, IN PRESS NATURE; DOGGETT NA, 1995, NATURE, V377, pS335; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GEMMILL RM, 1995, NATURE, V377, pS299; Gijlswijk R. P. M. van, 1992, Molecular and Cellular Probes, V6, P223, DOI 10.1016/0890-8508(92)90020-X; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GYAPAY G, IN PRESS HUM MOL GEN; GYAPAY G, 1994, NAT GENET, V7, P247; HALDI M, 1994, GENOMICS, V24, P478, DOI 10.1006/geno.1994.1656; HESLOPHARRISON JS, 1989, HUM GENET, V84, P27, DOI 10.1007/BF00210666; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAUTER K, 1995, NATURE, V377, pS321; KRUGTYAK L, 1987, P NATL ACAD SCI USA, V84, P2363; LANDER ES, 1992, GENOMICS, V14, P604; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; Ott J., 1991, ANAL HUMAN GENETIC L; QUACKENBUSH J, 1995, GENOMICS, V29, P512, DOI 10.1006/geno.1995.9974; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SELLERI L, 1992, GENOMICS, V14, P536, DOI 10.1016/S0888-7543(05)80263-0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	45	735	771	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1945	1954		10.1126/science.270.5244.1945	http://dx.doi.org/10.1126/science.270.5244.1945			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533086				2022-12-28	WOS:A1995TL42000029
J	ALDROVANDI, GM; FEUER, G; GAO, LY; JAMIESON, B; KRISTEVA, M; CHEN, ISY; ZACK, JA				ALDROVANDI, GM; FEUER, G; GAO, LY; JAMIESON, B; KRISTEVA, M; CHEN, ISY; ZACK, JA			THE SCID-HU MOUSE AS A MODEL FOR HIV-1 INFECTION	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LYMPHOCYTES	DURING normal fetal ontogeny, one of the first organs to harbour CD4-positive cells is the thymus1. This organ could therefore be one of the earliest targets infected by human immunodeficiency virus type 1 (HIV-1) in utero. HIV-1-infected cells and pathological abnormalities of the thymus have been seen in HIV-1-infected adults and children, and in some fetuses aborted from infected women2-5. Studies of HIV-1 pathogenesis have been hampered by lack of a suitable animal model system. Here we use the SCID-hu mouse6 as a model to investigate the effect of virus infection on human tissue. The mouse is homozygous for the severe combined immunodeficiency (SCID) defect7,8. The model is constructed by implanting human fetal fiver and thymus under the mouse kidney capsule. A conjoint human organ develops, which allows normal maturation of human thymocytes. After direct inoculation of HIV-1 into these implants, we observed severe depletion of human CD4-bearing cells within a few weeks of infection. This correlated with increasing virus load in the implants. Thus the SCID-hu mouse may be a useful in vivo system for the study of HIV-1-induced pathology.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT PEDIAT, DIV INFECT DIS, TORRANCE, CA 90509 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANN AJ, 1988, ONCOGENE, V3, P123; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HAYS EF, 1992, AIDS, V6, P265, DOI 10.1097/00002030-199203000-00002; JOSHI VV, 1986, ARCH PATHOL LAB MED, V110, P837; KANESHIMA H, 1991, P NATL ACAD SCI USA, V88, P4523, DOI 10.1073/pnas.88.10.4523; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; MANO H, 1991, AIDS RES HUM RETROV, V7, P83, DOI 10.1089/aid.1991.7.83; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	19	268	276	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					732	736		10.1038/363732a0	http://dx.doi.org/10.1038/363732a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515816				2022-12-28	WOS:A1993LJ33900059
J	LUYT, DK; BURTON, PR; SIMPSON, H				LUYT, DK; BURTON, PR; SIMPSON, H			EPIDEMIOLOGIC-STUDY OF WHEEZE, DOCTOR DIAGNOSED ASTHMA, AND COUGH IN PRESCHOOL-CHILDREN IN LEICESTERSHIRE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; NATURAL-HISTORY; RESPIRATORY SYMPTOMS; GENERAL-PRACTICE; PREVALENCE; HOSPITALIZATION; SCHOOLCHILDREN; TRENDS	Objective-To determine the cumulative prevalences of wheeze and doctor diagnosed asthma and the point prevalences of recurrent cough and wheeze in children aged 5 years and under. Design-Questionnaire survey of population based random sample of children registered on regional authority's child health index for immunisation; questionnaire completed by parents. Setting-Leicestershire. Subjects-1650 white children born in 1985-9 who were surveyed in 1990. Main outcome measures-Cumulative prevalences of wheeze and doctor diagnosed asthma and point prevalences of recurrent cough and wheeze by age and sex. Results-There were 1422 replies (86.2%; 726 for boys, 696 for girls). Overall, 11.0% (95% confidence interval 9.4% to 12.6%) of children had formally been diagnosed as having asthma, the cumulative prevalence in boys (12.7%) being somewhat higher than in girls (9.2%) (age adjusted odds ratio 1.47, p=0.03). As expected, the cumulative prevalence of asthma increased significantly with age (7.5% (13/173) in children under 1 year, 15.9% (61/383) in children of 4 years and over; p<0.001). The cumulative prevalence of wheeze overall was 15.6% (13.7% to 17.5%), being higher in boys (17.6%) than in girls (13.5%) (odds ratio 1.38, p=0.03). The overall prevalence of recurrent cough without colds was 21.8% (19.6% to 23.9%), with a non-significant excess in boys (23.1% v 20.4%). The overall prevalence of wheezing attacks during the previous 12 months was 13.0% (11.3% to 14.8%) with a non-significant excess in boys (14.5% v 11.5%). Conclusions-These findings are baseline results and emphasise the importance of studying the age group of interest rather than relying on the recall of parents of school age children.	UNIV LEICESTER, LEICESTER ROYAL INFIRM,DEPT CHILD HLTH, CLIN SCI BLDG,POB 65, LEICESTER LE2 7LX, W YORKSHIRE, ENGLAND; UNIV LEICESTER, LEICESTER ROYAL INFIRM, DEPT EPIDEMIOL & PUBL HLTH, LEICESTER LE2 7LX, W YORKSHIRE, ENGLAND	University of Leicester; University of Leicester			Burton, Paul R/H-7527-2016					ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABRAHAMSON JII, 1988, MAKING SENSE DATA; AITKIN M, 1989, STATISTICAL MODELLIN; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; ANDERSON HR, 1978, ARCH DIS CHILD, V53, P295, DOI 10.1136/adc.53.4.295; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; ARMITAGE P, 1987, METHODS MED RES; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1987, J EPIDEMIOL COMMUN H, V41, P185, DOI 10.1136/jech.41.3.185; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DAWSON B, 1969, LANCET, V1, P827; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GIBSON HB, 1969, MED J AUSTRALIA, P210; GREGG I, 1986, CLIN ALLERGY, V16, P17, DOI 10.1111/j.1365-2222.1986.tb01949.x; GREGG I, 1983, ASTHMA, P242; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HART JT, 1986, J ROY COLL GEN PRACT, V36, P78; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; JONES A, 1990, RESP MED, V84, P139, DOI 10.1016/S0954-6111(08)80017-0; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; LEVY M, 1984, BRIT MED J, V289, P1115, DOI 10.1136/bmj.289.6452.1115; MARKS BE, 1983, BRIT MED J, V287, P949, DOI 10.1136/bmj.287.6397.949; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; Miller R. G., 1981, SURVIVAL ANAL; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MORRISONSMITH J, 1976, BR J DIS CHEST, V70, P73; NINAN TK, 1991, THORAX, V46, pP322; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SAMET JM, 1987, CHEST, V91, pS74, DOI 10.1378/chest.91.6.74S; SIBBALD B, 1986, SEMIN RESPIR MED, V7, P307, DOI 10.1055/s-2007-1012626; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; STRACHAN DP, 1985, J ROY COLL GEN PRACT, V35, P182; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; 1982, CENSUS 1981 COUNTY R	40	117	121	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1993	306	6889					1386	1390		10.1136/bmj.306.6889.1386	http://dx.doi.org/10.1136/bmj.306.6889.1386			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518607	Bronze, Green Published			2022-12-28	WOS:A1993LD82900024
J	EISEN, J; MACFARLANE, J; SHAPIRO, CM				EISEN, J; MACFARLANE, J; SHAPIRO, CM			ABC OF SLEEP DISORDERS - PSYCHOTROPIC-DRUGS AND SLEEP	BRITISH MEDICAL JOURNAL			English	Article									TORONTO HOSP,SLEEP DISORDERS CLIN,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto	EISEN, J (corresponding author), UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA.								0	9	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1331	1334		10.1136/bmj.306.6888.1331	http://dx.doi.org/10.1136/bmj.306.6888.1331			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518577	Bronze, Green Published			2022-12-28	WOS:A1993LC72200031
J	RUSSELL, MAH; STAPLETON, JA; FEYERABEND, C; WISEMAN, SM; GUSTAVSSON, G; SAWE, U; CONNOR, P				RUSSELL, MAH; STAPLETON, JA; FEYERABEND, C; WISEMAN, SM; GUSTAVSSON, G; SAWE, U; CONNOR, P			TARGETING HEAVY SMOKERS IN GENERAL-PRACTICE - RANDOMIZED CONTROLLED TRIAL OF TRANSDERMAL NICOTINE PATCHES	BRITISH MEDICAL JOURNAL			English	Article							SMOKING CESSATION; INTERVENTION; THERAPY; GUM	Objectives-(a) To evaluate the efficacy of transdermal nicotine patches as an aid to stopping smoking when used as an adjunct to brief advice and support in a general practice setting; (b) to see whether an increase in nicotine patch dosage enhances the rate of initial cessation. Design-Randomised double blind placebo controlled parallel group study with one year of follow up. Setting-30 general practices in 15 English counties. Subjects-600 dependent heavy smokers (greater-than-or-equal-to 15 cigarettes daily) who were well motivated to give up. Interventions-Brief general practitioner advice, booklet, and 16 hours per day patch treatment for 18 weeks with brief support and follow up at one, three, six, 12, 26, and 52 weeks. Main outcome measures-Self reported complete abstinence for up to one year with biochemical validation at all follow up points. Results-Nicotine patches reduced the severity of craving and adverse mood changes in the first weeks of withdrawal and doubled the rate of initial cessation at week 3 (nicotine group 36% of patients (144/400), placebo group 16.5% of patients (33/200)) and of continuous abstinence throughout one year (nicotine group 9.3% (37), placebo group 5.0% (10)). A dose increase at week 1 among patients experiencing difficulty in quitting increased the proportion who achieved abstinence at week 3. There were no adverse systemic effects attributable to nicotine, but the incidence of moderate or severe local irritation or itching at the patch site was 16.4% (63 patients), compared with 3.8% (seven) with placebo. Conclusion-Transdermal nicotine patches used as an adjunct to brief advice and support in a general practice setting are an effective aid to long term cessation of smoking in highly dependent smokers.	WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND; KABI PHARMACIA THERAPEUT AB,HELSINGBORG,SWEDEN; LUNDBECK UK LTD,MILTON KEYNES MK7 8LF,ENGLAND	University of London; University College London	RUSSELL, MAH (corresponding author), INST PSYCHIAT,HLTH BEHAV UNIT,LONDON SE5 8AF,ENGLAND.		Stapleton, John A/I-6550-2012					ABELIN T, 1989, LANCET, V1, P7; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HUGHES JR, 1989, JAMA-J AM MED ASSOC, V261, P1300, DOI 10.1001/jama.261.9.1300; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; JACKSON PH, 1986, PREV MED, V15, P244, DOI 10.1016/0091-7435(86)90044-7; JARVIS MJ, 1989, INT REV PSYCHIATR, V1, P139; LAM W, 1987, LANCET, V2, P27; MULLIGAN SC, 1990, CLIN PHARMACOL THER, V47, P331, DOI 10.1038/clpt.1990.36; PALMER KJ, 1992, DRUGS, V44, P498, DOI 10.2165/00003495-199244030-00011; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; ROSE JE, 1990, CLIN PHARMACOL THER, V47, P323, DOI 10.1038/clpt.1990.35; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; WEST R, 1985, PSYCHOPHARMACOLOGY, V86, P334; [No title captured]; 1990, 19907F KAB PHARM RES; 1991, JAMA-J AM MED ASSOC, V266, P3133	19	138	139	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1308	1312		10.1136/bmj.306.6888.1308	http://dx.doi.org/10.1136/bmj.306.6888.1308			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518572	Green Published, Bronze			2022-12-28	WOS:A1993LC72200023
J	Askari, FK; McDonnell, WM				Askari, FK; McDonnell, WM			Molecular medicine - Antisense oligonucleotide therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									VET AFFAIRS MED CTR,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV GASTROENTEROL,ANN ARBOR,MI 48109	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan								CLARK RE, 1995, LEUKEMIA LYMPHOMA, V19, P189, DOI 10.3109/10428199509107888; LU XM, 1994, J NUCL MED, V35, P269; PALESTINE AG, 1994, 10TH INT C AIDS YOK; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; TOMITA N, 1995, HYPERTENSION, V26, P131, DOI 10.1161/01.HYP.26.1.131; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0	6	107	127	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					316	318		10.1056/NEJM199602013340508	http://dx.doi.org/10.1056/NEJM199602013340508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532029				2022-12-28	WOS:A1996TV69500008
J	Norris, MD; Bordow, SB; Marshall, GM; Haber, PS; Cohn, SL; Haber, M				Norris, MD; Bordow, SB; Marshall, GM; Haber, PS; Cohn, SL; Haber, M			Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; N-MYC ONCOGENE; POLYMERASE CHAIN-REACTION; NEURO-BLASTOMA; MDR1; AMPLIFICATION; TUMORS; CHILDHOOD; CANCER; CELLS	Background. Overexpression of the gene for the multidrug-resistance-associated protein (MRP) has been linked with resistance to chemotherapeutic agents (multidrug resistance) in vitro. The expression of MRP by neuroblastoma cells correlates with N-myc oncogene amplification, a well-established prognostic indicator in patients with neuroblastoma. Methods. To relate MRP gene expression to established prognostic markers and the clinical outcome of neuroblastoma, we analyzed MRP expression in specimens of primary tumors from 60 patients with neuroblastoma. Results. Levels of MRP gene expression were significantly higher in tumors with N-myc amplification than in tumors without such amplification (P<0.001). High levels of MRP expression were strongly associated with reductions in both survival and event-free survival (P<0.001) in the overall study population and in subgroups of patients without N-myc amplification and patients with localized disease. For the overall study population, the five-year cumulative survival rates in the groups with high and low levels of MRP expression were 57 percent (95 percent confidence interval, 37 to 78 percent) and 94 percent (95 percent confidence interval, 86 to 100 percent), respectively. In contrast, expression of the MDR1 multidrug-resistance gene was not predictive of survival or event-free survival. After adjustment by multivariate analysis for the effects of N-myc amplification and other prognostic indicators, high levels of MRP expression retained significant prognostic value for poor survival (relative hazard, 14.9; P=0.01) and poor event-free survival (relative hazard, 9.7; P=0.004), whereas N-myc amplification had no prognostic value. Conclusions. High levels of MRP gene expression in patients with neuroblastoma correlate strongly with poor outcome. The findings suggest that expression of this multidrug-resistance gene accounts for the association between N-myc amplification and reduced survival. (C) 1996, Massachusetts Medical Society.	UNIV NEW S WALES,CHILDRENS LEUKAEMIA & CANC RES CTR,SYDNEY,NSW,AUSTRALIA; PRINCE WALES CHILDRENS HOSP,DEPT GASTROENTEROL,SYDNEY,NSW,AUSTRALIA; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611; CHILDRENS MEM HOSP,CHICAGO,IL 60614	University of New South Wales Sydney; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650; Norris, Murray/0000-0002-0632-4589; Haber, Michelle/0000-0003-2036-8817				Benard J, 1994, Prog Clin Biol Res, V385, P111; BERNARD JL, 1987, J CLIN ONCOL, V5, P1952, DOI 10.1200/JCO.1987.5.12.1952; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BORDOW SB, 1994, CANCER RES, V54, P5036; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; BOWMAN LC, 1990, MED PEDIATR ONCOL, V18, P364; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Brodeur GM, 1993, PRINCIPLES PRACTICE, P739; CASTLEBERRY RP, 1991, J CLIN ONCOL, V9, P789, DOI 10.1200/JCO.1991.9.5.789; CASTLEBERRY RP, 1994, J CLIN ONCOL, V12, P1616, DOI 10.1200/JCO.1994.12.8.1616; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1995, EUR J CANCER, V31A, P541, DOI 10.1016/0959-8049(95)00030-M; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORRIAS MV, 1990, ANTICANCER RES, V10, P897; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FAVROT M, 1991, BRIT J CANCER, V64, P233, DOI 10.1038/bjc.1991.282; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V206, P119, DOI 10.1006/bbrc.1995.1017; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; GILBERT J, 1993, MOL CELL PROBE, V7, P227, DOI 10.1006/mcpr.1993.1033; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GRANT CE, 1994, CANCER RES, V54, P357; Haber M, 1994, Prog Clin Biol Res, V385, P245; HOLZMAYER TA, 1992, J NATL CANCER I, V84, P1486, DOI 10.1093/jnci/84.19.1486; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JOSHI VV, 1993, CANCER-AM CANCER SOC, V71, P3173, DOI 10.1002/1097-0142(19930515)71:10<3173::AID-CNCR2820711045>3.0.CO;2-P; KRUH GD, 1994, CANCER RES, V54, P1649; LEIER I, 1994, J BIOL CHEM, V269, P27807; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MARSHALL GM, 1995, ONCOGENE, V11, P485; MCCOWAGE GB, 1995, J CLIN ONCOL, V13, P2789, DOI 10.1200/JCO.1995.13.11.2789; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; NITSCHKE R, 1988, J CLIN ONCOL, V6, P1271, DOI 10.1200/JCO.1988.6.8.1271; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLOVAK ML, 1993, CANCER RES, V53, P3221; STROTHER D, 1995, J PEDIAT HEMATOL ONC, V17, P254, DOI 10.1097/00043426-199508000-00007; TELFORD DJ, 1992, J PAEDIATR CHILD H, V28, P58, DOI 10.1111/j.1440-1754.1992.tb02619.x; TEW KD, 1994, CANCER RES, V54, P4313; VERSANTVOORT CHM, 1994, BIOCHEM PHARMACOL, V48, P1129, DOI 10.1016/0006-2952(94)90149-X; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHU QC, 1994, CANCER RES, V54, P4488	51	271	281	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					231	238		10.1056/NEJM199601253340405	http://dx.doi.org/10.1056/NEJM199601253340405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532000				2022-12-28	WOS:A1996TQ75500005
J	Martyn, C				Martyn, C			Not quite as random as I pretended	LANCET			English	Editorial Material											Martyn, C (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	2	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					70	70		10.1016/S0140-6736(96)90203-2	http://dx.doi.org/10.1016/S0140-6736(96)90203-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538339				2022-12-28	WOS:A1996TP28100002
J	Volberding, PA				Volberding, PA			HIV quantification: Clinical applications	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION				Volberding, PA (corresponding author), SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110, USA.							BAGNARELLI P, 1991, J MED VIROL, V34, P89, DOI 10.1002/jmv.1890340204; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; ERON J, 1995, 2ND NAT C HUM RETR R; HAVLIR D, 1995, J INFECT DIS, V172, P1379, DOI 10.1093/infdis/172.5.1379; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; JURRIAANS S, 1995, AIDS RES HUM RETROV, V11, P473, DOI 10.1089/aid.1995.11.473; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; LOVEDAY C, 1995, LANCET, V345, P790, DOI 10.1016/S0140-6736(95)90668-1; MELLORS JW, 1995, ANN INTERN MED, V122, P537; OBRIEN W, 1995, 10TH P INT C AIDS IN; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PAXTON W, 1995, 2ND NAT C HUM RETR R; REVETS H, 1995, FEB P MOL APPR LAB D; VERHOFSTEDE C, 1994, AIDS, V8, P1421, DOI 10.1097/00002030-199410000-00008; YERLY S, 1995, AIDS, V9, P159, DOI 10.1097/00002030-199509020-00007	16	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					71	73		10.1016/S0140-6736(96)90205-6	http://dx.doi.org/10.1016/S0140-6736(96)90205-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538341				2022-12-28	WOS:A1996TP28100004
J	Tirrell, DA				Tirrell, DA			Putting a new spin on spider silk	SCIENCE			English	Editorial Material											Tirrell, DA (corresponding author), UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003, USA.							Byrom D., 1991, BIOMATERIALS; FOURNIER MJ, 1995, MOL BIOL BIOTECHNOLO, P714; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018	8	42	55	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					39	40		10.1126/science.271.5245.39	http://dx.doi.org/10.1126/science.271.5245.39			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539596				2022-12-28	WOS:A1996TP02200032
J	Lehmuskallio, E; Lindholm, H; Koskenvuo, K; Sarna, S; Friberg, O; Viljanen, A				Lehmuskallio, E; Lindholm, H; Koskenvuo, K; Sarna, S; Friberg, O; Viljanen, A			Frostbite of the face and ears: Epidemiological study of risk factors in Finnish conscripts	BRITISH MEDICAL JOURNAL			English	Article							MILITARY OPERATIONS; COLD	Objective-To determine the incidence of and the risk factors for local cold injuries of the face and ears in peacetime military service. Design-Prospective, controlled epidemiological study using a questionnaire. Setting-Finnish defence forces, 1976-89. Subjects-913 young male conscripts with local frostbite of the head that needed medical attention and 2478 uninjured control conscripts. Main outcome measures-Type of activity, clothing, and other risk factors at the time of cold injury. Odds ratios were used to calculate risk. Controls were handled as one group. Results-The mean annual incidence of frostbite was 1 . 8 per 1000 conscripts. Frostbite of the ear was most common (533 conscripts (58%)), followed by frostbite of the nose (197 (22%)) and of the cheeks and other regions of the face (183 (20%)). Most conscripts (803 (88%)) had mild or superficial frostbite. Risk factors included not wearing a hat with earflaps (odds ratio 18 . 5 for frostbite of the ear); not wearing a scarf(odds ratio 2 . 1 and 3 . 8 for frostbite of the ear and cheeks respectively); using protective ointments (odds ratio 3 . 3, 4 . 5, and 5 . 6 for frostbite of the cheeks, ear, and nose respectively); being extremely sensitive to cold and having hands and feet that sweat profusely (odds ratio 3 . 5 for frostbite of the nose); and being transported in the open or in open vehicles under windy conditions (odds ratio 2 . 2 for frostbite of the cheek). Conclusions-Wearing warm clothing, including a scarf and a hat with earflaps, helps to prevent frostbite. Each person's sensitivity to cold may also be important. The routine use of protective ointments should not be recommended.	FINNISH DEF FORCES,INST MIL MED,SF-00300 HELSINKI,FINLAND; FINNISH DEF STAFF,MED SECT,SF-00101 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00014 HELSINKI,FINLAND	University of Helsinki	Lehmuskallio, E (corresponding author), SANTAHAMINA MIL HLTH CTR,POB 6,SF-00861 HELSINKI,FINLAND.			Sarna, Seppo/0000-0003-3458-1627				DICK HJ, 1989, MED CORPS INT, V4, P41; FRITZ RL, 1989, CLIN SPORT MED, V8, P111; HAMLET MP, 1987, MIL MED, V152, P393; HANSON HE, 1969, MIL MED, V134, P1307; KOSKENVUO K, 1977, ANN MED MILITARIS FE, V52, P9; KOSKENVUO K, 1976, ANN MED MILITARIS FE, V51, P59; LEHMUSKALLIO E, 1993, 3RD P C EUR AC DERM, P10; LINDHOLM H, 1993, A19931 SCI COMM NAT; Siple Paul A., 1945, PROC AMER PHIL SOC, V89, P177; STEINMAN AM, 1987, MIL MED, V152, P389; TERVAHAUTA R, 1993, FIELD SURGERY MED, P461; VAUGHN PB, 1980, MIL MED, V145, P305; WILSON O, 1970, J APPL PHYSIOL, V29, P658, DOI 10.1152/jappl.1970.29.5.658	13	37	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1661	1663		10.1136/bmj.311.7021.1661	http://dx.doi.org/10.1136/bmj.311.7021.1661			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541749	Green Published			2022-12-28	WOS:A1995TL94200008
J	ZWIEBEL, LJ; SACCONE, G; ZACHAROPOULOU, A; BESANSKY, NJ; FAVIA, G; COLLINS, FH; LOUIS, C; KAFATOS, FC				ZWIEBEL, LJ; SACCONE, G; ZACHAROPOULOU, A; BESANSKY, NJ; FAVIA, G; COLLINS, FH; LOUIS, C; KAFATOS, FC			THE WHITE GENE OF CERATITIS-CAPITATA - A PHENOTYPIC MARKER FOR GERMLINE TRANSFORMATION	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; DNA; INTEGRATION; CLONING	Reliable germline transformation is required for molecular studies and ultimately for genetic control of economically important insects, such as the Mediterranean fruit fly (medfly) Ceratitis capitata. A prerequisite for the establishment and maintenance of transformant lines is selectable or phenotypically dominant markers. To this end, a complementary DNA clone derived from the medfly white gene was isolated, which showed substantial similarity to white genes in Drosophila melanogaster and other Diptera. It is correlated with a spontaneous mutation causing white eyes in the medfly and can be used to restore partial eye color in transgenic Drosophila carrying a null mutation in the endogenous white gene.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; FORTH,INST MOLEC BIOL & BIOTECHNOL,CRETE,GREECE; UNIV NAPLES FEDERICO II,DIPARTIMENTO GENET BIOL GEN & MOLEC,NAPLES,ITALY; UNIV PATRAS,DEPT BIOL,PATRAI,GREECE; CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,ATLANTA,GA 30341	European Molecular Biology Laboratory (EMBL); Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Naples Federico II; University of Patras; Centers for Disease Control & Prevention - USA			Louis, Christos/F-2527-2012; saccone, giuseppe/F-8627-2013	saccone, giuseppe/0000-0002-9835-3693; Favia, Guido/0000-0002-4420-8482; Zwiebel, Laurence/0000-0001-6686-7289				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Besansky NJ, 1995, INSECT MOL BIOL, V4, P217, DOI 10.1111/j.1365-2583.1995.tb00027.x; BEVERLY S, 1984, J MOL EVOL, V12, P1; BROGNA S, UNPUB; CHRISTENSON LD, 1960, ANNU REV ENTOMOL, V5, P171, DOI 10.1146/annurev.en.05.010160.001131; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; ELIZUR A, 1990, J MOL EVOL, V30, P347, DOI 10.1007/BF02101889; FIMIANI P, 1989, FRUIT FLIES THEIR A, V3, P39; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Malacrida A., 1986, ATTI ASSOC GENET IT, V31, P121; MCGRANE V, 1988, AM J TROP MED HYG, V39, P502, DOI 10.4269/ajtmh.1988.39.502; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; OBROCHTA DA, 1994, MOL GEN GENET, V244, P9, DOI 10.1007/BF00280181; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saul S.H., 1986, Agricultural Zoology Reviews, V1, P73; SAVAKIS C, COMMUNICATION; TEARLE RG, 1989, GENETICS, V122, P595; WALKER JE, 1992, EMBO J, V1, P945; ZACHAROPOULOU A, 1992, CHROMOSOMA, V101, P448, DOI 10.1007/BF00582839; ZACHAROPOULOU A, 1990, GENOME, V33, P184, DOI 10.1139/g90-030; ZACHAROPOULOU A, UNPUB; ZIEGLER I, 1965, Z NATURFORSCH PT B, VB 20, P318, DOI 10.1515/znb-1965-0410	31	78	82	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2005	2008		10.1126/science.270.5244.2005	http://dx.doi.org/10.1126/science.270.5244.2005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533095				2022-12-28	WOS:A1995TL42000046
J	FERGUSON, KM; LEMMON, MA; SCHLESSINGER, J; SIGLER, PB				FERGUSON, KM; LEMMON, MA; SCHLESSINGER, J; SIGLER, PB			STRUCTURE OF THE HIGH-AFFINITY COMPLEX OF INOSITOL TRISPHOSPHATE WITH A PHOSPHOLIPASE-C PLECKSTRIN HOMOLOGY DOMAIN	CELL			English	Article							BINDING; C-DELTA-1; PROTEINS; VESICLES	The X-ray crystal structure of the high affinity complex between the pleckstrin homology (PH) domain from rat phospholipase C-delta(1) (PLC-delta(1)) and inositol-(1,4,5)-trisphosphate (Ins(1,4,5)P-3) has been refined to 1.9 Angstrom resolution. The domain fold is similar to others of known structure. Ins(1,4,5)P-3 binds on the positively charged face of the electrostatically polarized domain, interacting predominantly with the beta 1/beta 2 and beta 3/beta 4 loops. The 4- and B-phosphate groups of Ins(1,4,5)P-3 interact much more extensively than the l-phosphate. Two amino acids in the PLC-delta(1) PH domain that contact lns(1,4,5)P-3 have counterparts in the Bruton's tyrosine kinase (Btk) PH domain, where mutational changes cause inherited agammaglobulinemia, suggesting a mechanism for loss of function in Btk mutants. Using electrostatics and varying levels of head-group specificity, PH domains may localize and orient signaling proteins, providing a general membrane targeting and regulatory function.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; New York University				Lemmon, Mark/0000-0002-3379-5319	NIGMS NIH HHS [GM15225, GM22324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015225, R01GM015225, R01GM022324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMMON MA, 1995, P NATL ACAD SCI USA, V62, P10472; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P55; OTWINOWSKI Z, 1991, ML PHARE; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SARASTE M, 1995, CURR OPIN STRUC BIOL, V8, P403; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHENG J, 1996, IN PRESS J MOL BIOL	42	517	522	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					1037	1046		10.1016/0092-8674(95)90219-8	http://dx.doi.org/10.1016/0092-8674(95)90219-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521504	hybrid			2022-12-28	WOS:A1995TK74500022
J	TSUKIYAMA, T; DANIEL, C; TAMKUN, J; WU, C				TSUKIYAMA, T; DANIEL, C; TAMKUN, J; WU, C			ISWI, A MEMBER OF THE SW12/SNF2 ATPASE FAMILY, ENCODES THE 140-KDA SUBUNIT OF THE NUCLEOSOME REMODELING FACTOR	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; DROSOPHILA; CHROMATIN; PROTEIN; ANTENNAPEDIA; EXPRESSION	The generation of an accessible heat shock promoter in chromatin in vitro requires the concerted action of the GAGA transcription factor and NURF, an ATP-dependent nucleosome remodeling factor. NURF is composed of four subunits and is biochemically distinct from the SW12/SNF2 multiprotein complex, a transcriptional activator that also appears to alter nucleosome structure. We have obtained protein microsequence and immunological evidence identifying the 140 kDa subunit of NURF as ISWI, previously of unknown function but highly related to SW12/SNF2 only in the ATPase domain. The ISWI protein is localized to the cell nucleus and is expressed throughout Drosophila development at levels as high as 100,000 molecules/cell. The convergence of biochemical and genetic studies on ISWI and SW12/SNF2 underscores these ATPases and their close relatives as key components of independent systems for chromatin remodeling.	NCI,BIOCHEM LAB,BETHESDA,MD 20892; UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Santa Cruz					NIGMS NIH HHS [R01 GM49883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KHAVARI PA, 1993, NATURE, V336, P170; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PATTATUCCI AM, 1991, GENETICS, V129, P443; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; REUTER R, 1990, DEVELOPMENT, V109, P289; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1	44	310	315	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					1021	1026		10.1016/0092-8674(95)90217-1	http://dx.doi.org/10.1016/0092-8674(95)90217-1			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521502	Bronze			2022-12-28	WOS:A1995TK74500020
J	FRANCESCHI, S; DALMASO, L; LAVECCHIA, C				FRANCESCHI, S; DALMASO, L; LAVECCHIA, C			TRENDS IN INCIDENCE OF AIDS-ASSOCIATED WITH TRANSFUSION OF BLOOD AND BLOOD PRODUCTS IN EUROPE AND THE UNITED-STATES, 1985-93	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PERIOD	Objective--To quantify patterns and trends in incidence of AIDS associated with transfusion of blood and its products in 14 European countries and the United States. Design--Data were derived ti om the World Health Organisation's European non-aggregate AIDS dataset and, for the United States, from the Centers for Disease Control AIDS public information dataset. Rates were standardised by using the world standard populations and adjusted for reporting delays in each country. Subjects--Cases of AIDS in patients with haemophilia and recipients of transfusions. Results--Overall, between 1985 and 1993 almost 6000 cases of AIDS associated with transfusions were registered in the 14 European countries considered and over 8000 in the United States between 1985 and 1992. Most European countries had annual age adjusted rates lower than 0.5 per million children aged 12 or less and between 1 and 2 per million adults. The United States had rates around 1 per million children and 5 per million adults in the most recent period. For children, the highest rates were generally reached in 1985-7, whereas in adults the highest rates were in the late 1980s. France had the highest overall incidence of AIDS related to transfusion in Europe (3.3 per million). Romania had a major epidemic in children (over 30 cases per million children in 1988-90). Incidence rates of AIDS associated with transfusion were still increasing in some southern European countries in the early 1990s. Conclusions--Apart from in France and Romania it is clear that rates of bloodborne AIDS in European countries are lower than those registered in the United States.	IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	FRANCESCHI, S (corresponding author), CTR RIFERIMENTO ONCOL,SERV EPIDEMIOL,12,I-33081 AVIANO,ITALY.		dal maso, luigino/J-3616-2018; franceschi, silvia/M-2452-2014	dal maso, luigino/0000-0001-6163-200X; franceschi, silvia/0000-0003-4181-8071; La Vecchia, Carlo/0000-0003-1441-897X				ANDERSON C, 1991, NATURE, V353, P197; Bader J M, 1992, Lancet, V340, P360, DOI 10.1016/0140-6736(92)91419-9; BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; DALMASO L, 1995, SOZ PRAVENTIV MED, V40, P239, DOI 10.1007/BF01354479; DOLL R, 1982, SCI PUBLICATION 42, V4, P58; FRANCESCHI S, 1994, AIDS, V8, P1173, DOI 10.1097/00002030-199408000-00022; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; MEDLEY GF, 1987, NATURE, V328, P719, DOI 10.1038/328719a0; NESS PM, 1994, ARCH PATHOL LAB MED, V118, P337; PATRASCU IV, 1993, AIDS RES HUM RETROV, V9, P99, DOI 10.1089/aid.1993.9.99; ROSENBERG PS, 1990, J ACQ IMMUN DEF SYND, V3, P49; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SELIK RM, 1994, AM J EPIDEMIOL, V140, P105, DOI 10.1093/oxfordjournals.aje.a117221; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; 1985, MMWR-MORBID MORTAL W, V34, P373; 1986, WKLY EPIDEMIOL RES, V61, P69; 1993, AIDS SURVEILLANCE EU; 1982, MMWR-MORBID MORTAL W, V31, P652; 1987, MMWR-MORBID MORTAL W, V36, pS3; 1988, WKLY EPIDEMIOL REC, V63, P1	21	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1534	1536		10.1136/bmj.311.7019.1534	http://dx.doi.org/10.1136/bmj.311.7019.1534			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520395	Green Published			2022-12-28	WOS:A1995TK21400022
J	STURDY, P; NAISH, J; PEREIRA, F; GRIFFITHS, C; DOLAN, S; TOON, P; CHAMBERS, M				STURDY, P; NAISH, J; PEREIRA, F; GRIFFITHS, C; DOLAN, S; TOON, P; CHAMBERS, M			CHARACTERISTICS OF GENERAL PRACTICES THAT PRESCRIBE APPROPRIATELY FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,MED COLL ST BARTHOLOMEWS & LONDON HOSP,LONDON E1 4NS,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP MED COLL,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND; ST MARYS HOSP,SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,LONDON W2 1PG,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; CAMPBELL M, 1995, BRIT MED J, V310, P1069, DOI 10.1136/bmj.310.6986.1069b; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1547	1548		10.1136/bmj.311.7019.1547	http://dx.doi.org/10.1136/bmj.311.7019.1547			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520400	Green Published			2022-12-28	WOS:A1995TK21400028
J	UNGEWICKELL, E; UNGEWICKELL, H; HOLSTEIN, SEH; LINDNER, R; PRASAD, K; BAROUCH, W; MARTIN, B; GREENE, LE; EISENBERG, E				UNGEWICKELL, E; UNGEWICKELL, H; HOLSTEIN, SEH; LINDNER, R; PRASAD, K; BAROUCH, W; MARTIN, B; GREENE, LE; EISENBERG, E			ROLE OF AUXILIN IN UNCOATING CLATHRIN-COATED VESICLES	NATURE			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; BOVINE BRAIN; ATPASE; BINDING; DISSOCIATION; HYDROLYSIS; HOMOLOGS; BASKETS; DOMAIN	CLATHRIN-coated vesicles transport selected integral membrane proteins from the cell surface and the a trans-Golgi network to the endosomal system(1,2). Before fusing with their target the vesicles must be stripped of their coats, This process is effected by the chaperone protein hsp70c together with a 100K cofactor(3) which we here identify as the coat protein auxilin. Auxilin binds with high affinity to assembled clathrin lattices and, in the presence of ATP, recruits hsp70c. Dissociation of the lattice does not depend as previously supposed on clathrin light chains or on the aminoterminal domain of the heavy chain4,5. The presence of a J-domain at its carboxy terminus now defines auxilin as a member of the DnaJ protein family. In conjunction with hsp70, DnaJ proteins catalyse protein folding, protein transport across membranes and the selective disruption of protein-protein interactions(6-8). We show that deletion of the J-domain of auxilin results in the loss of cofactor activity.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	UNGEWICKELL, E (corresponding author), WASHINGTON UNIV,SCH MED,CTR IMMUNOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Lindner, Robert/AAO-9538-2020	Lindner, Robert/0000-0002-6421-5778				AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CRY DM, 1994, TRENDS BIOCHEM SCI, V19, P176; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN JL, 1988, REV CELL BIOL, V1, P1; Hartl F U, 1991, Semin Immunol, V3, P5; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LINDNER R, 1992, J BIOL CHEM, V267, P16567; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; SCHMID SL, 1985, J BIOL CHEM, V26, P10057; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; WALL D, 1994, J BIOL CHEM, V269, P5446; WINKLER FK, 1983, EMBO J, V2, P1363	30	388	395	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					632	635		10.1038/378632a0	http://dx.doi.org/10.1038/378632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524399				2022-12-28	WOS:A1995TJ22100082
J	REISER, L; MODRUSAN, Z; MARGOSSIAN, L; SAMACH, A; OHAD, N; HAUGHN, GW; FISCHER, RL				REISER, L; MODRUSAN, Z; MARGOSSIAN, L; SAMACH, A; OHAD, N; HAUGHN, GW; FISCHER, RL			THE BELL1 GENE ENCODES A HOMEODOMAIN PROTEIN INVOLVED IN PATTERN-FORMATION IN THE ARABIDOPSIS OVULE PRIMORDIUM	CELL			English	Article							MAIZE HOMEOBOX GENE; FLOWER DEVELOPMENT; EMBRYO SAC; WILD-TYPE; EXPRESSION; KNOTTED-1; THALIANA; PLANTS; CELLS; FATES	Ovule development in Arabidopsis involves the formation of three morphologically defined proximal-distal pattern elements. Integuments arise from the central pattern element. Analysis of Bell1 (Bel1) mutant ovules indicated that BEL1 was required for integument development, Cloning of the BEL1 locus reveals that it encodes a homeodomain transcription factor. Prior to integument initiation, BEL1 RNA localizes to the central domain, providing molecular evidence for a central pattern element. Therefore, proximal-distal patterning of the ovule involves the regulated expression of the BEL1 gene that controls integument morphogenesis. A model for BEL1 function is evaluated with regard to new data showing the expression pattern of the floral homeotic gene AGAMOUS (AG) early in wild-type and Bel1 ovule development.	UNIV BRITISH COLUMBIA,DEPT BOT,VANCOUVER,BC V6T 1Z4,CANADA	University of British Columbia	REISER, L (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720, USA.			Ohad, Nir/0000-0002-7094-2939; Reiser, Leonore/0000-0003-0073-0858				[Anonymous], 1960, [No title captured], DOI DOI 10.1097/00010694-196008000-00031; BARTON MK, 1993, DEVELOPMENT, V119, P823; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COLUMBO L, 1995, IN PRESS PLANT CELL, V7; COMAI L, 1992, PLANT PHYSIOL, V98, P53, DOI 10.1104/pp.98.1.53; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRIIS EM, 1990, ADV BOT RES, V17, P99, DOI 10.1016/S0065-2296(08)60133-0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLDBERG RB, 1994, SCIENCE, V466, P605; HERR JM, 1995, AM J BOT, V82, P547, DOI 10.2307/2445703; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; JACKSON D, 1994, DEVELOPMENT, V120, P405; JORGENSEN RA, 1987, PLANT MOL BIOL, V8, P3, DOI 10.1007/BF00016429; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; KATAVIC V, 1994, MOL GEN GENET, V245, P363, DOI 10.1007/BF00290117; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; LUPPUNER V, 1994, J BIOL CHEM, V269, P7863; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MANSFIELD SG, 1991, CAN J BOT, V69, P447, DOI 10.1139/b91-062; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MODRUSAN Z, 1994, PLANT CELL, V6, P333, DOI 10.1105/tpc.6.3.333; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; RAY A, 1994, P NATL ACAD SCI USA, V91, P5761, DOI 10.1073/pnas.91.13.5761; REISER L, 1993, PLANT CELL, V5, P1291, DOI 10.1105/tpc.5.10.1291; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; ROBINSONBEERS K, 1992, PLANT CELL, V4, P1237, DOI 10.1105/tpc.4.10.1237; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SCHNEEBERGER RG, 1995, GENE DEV, V9, P2292, DOI 10.1101/gad.9.18.2292; SCHNEITZ K, 1995, PLANT J, V7, P731, DOI 10.1046/j.1365-313X.1995.07050731.x; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; Slack J, 1983, EGG EMBRYO; SMITH LG, 1992, DEVELOPMENT, V116, P21; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; Takhtadzhian A., 1991, EVOLUTIONARY TRENDS; VOLLBRECHT E, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P111; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	50	197	229	3	40	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					735	742		10.1016/0092-8674(95)90186-8	http://dx.doi.org/10.1016/0092-8674(95)90186-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521490	Bronze			2022-12-28	WOS:A1995TH94800010
J	STENMARK, H; VITALE, G; ULLRICH, O; ZERIAL, M				STENMARK, H; VITALE, G; ULLRICH, O; ZERIAL, M			RABAPTIN-5 IS A DIRECT EFFECTOR OF THE SMALL GTPASE RAB5 IN ENDOCYTIC MEMBRANE-FUSION	CELL			English	Article							BINDING PROTEIN; YEAST; TRANSPORT; DOMAIN; CELLS; EXPRESSION; ANTIBODIES; VESICLES; PATHWAY; INVITRO	We have identified a novel 100 kDa coiled-coil protein, rabaptin-5, that specifically interacts with the GTP form of the small GTPase Rab5, a potent regulator of endocytic transport. It is mainly cytosolic, but a fraction colocalizes with Rab5 to early endosomes. Expression of a GTPase-deficient Rab5 mutant enhances the binding of rabaptin-5 to enlarged endosomes. Over-expression of rabaptin-5 alone is sufficient to promote expansion of early endosomes. Rab5 recruits rabaptin-5 to purified early endosomes in a GTP-dependent manner, demonstrating functional similarities with other members of the Ras superfamily. Immunodepletion of rabaptin-5 from cytosol strongly inhibits Rab5-dependent early endosome fusion. Rabaptin-5 is thus a Rab effector required for membrane docking and fusion.	NORWEGIAN RADIUM HOSP,DEPT BIOCHEM,N-0310 OSLO,NORWAY	University of Oslo	STENMARK, H (corresponding author), EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY.		Stenmark, Harald/B-8868-2008					ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; DIAZ R, 1988, J BIOL CHEM, V263, P6093; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRUENBERG J, 1988, CELL FREE ANAL MEMBR, P317; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HORIUCHI H, 1995, J BIOL CHEM, V271, P11257; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI GP, 1994, J BIOL CHEM, V269, P14631; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MU FT, 1995, J BIOL CHEM, V270, P13505; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OIKKONEN VM, 1993, J CELL SCI, V106, P1249; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	58	399	413	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					423	432		10.1016/0092-8674(95)90120-5	http://dx.doi.org/10.1016/0092-8674(95)90120-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521472	Bronze			2022-12-28	WOS:A1995TC97700012
J	WARRELL, RP; DETHE, H; WANG, ZY; DEGOS, L				WARRELL, RP; DETHE, H; WANG, ZY; DEGOS, L			ACUTE PROMYELOCYTIC LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RETINOIC ACID RECEPTOR; DISSEMINATED INTRAVASCULAR COAGULATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; CELL-DIFFERENTIATION; REMISSION INDUCTION; MYELOID-LEUKEMIA; ALPHA GENE; RAR-ALPHA; ALPHA-2-PLASMIN INHIBITOR; HEPATOCELLULAR-CARCINOMA		SHANGHAI MED UNIV 2, SHANGHAI INST HEMATOL, SHANGHAI, PEOPLES R CHINA; UNIV PARIS, HOP ST LOUIS, INST UNIV HEMATOL, PARIS, FRANCE; CORNELL UNIV, MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR, DEPT MED,LEUKEMIA SERV, NEW YORK, NY 10021 USA	Shanghai Jiao Tong University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Cornell University; Memorial Sloan Kettering Cancer Center	WARRELL, RP (corresponding author), CORNELL UNIV, MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR, DEPT MED, DEV CHEMOTHERAPY SERV, NEW YORK, NY 10021 USA.				FDA HHS [FD-R-000764] Funding Source: Medline	FDA HHS		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; AVVISATI G, 1988, BRIT J HAEMATOL, V70, P43, DOI 10.1111/j.1365-2141.1988.tb02432.x; AVVISATI G, 1990, EUR J HAEMATOL, V44, P257; BASHFORD J, 1991, BRIT J HAEMATOL, V79, P331, DOI 10.1111/j.1365-2141.1991.tb04542.x; BAUER KA, 1984, BLOOD, V64, P791; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENNETT B, 1989, BRIT J HAEMATOL, V71, P511, DOI 10.1111/j.1365-2141.1989.tb06311.x; Berman E, 1991, BLOOD S, V78, p43A; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BIONDI A, 1992, BLOOD, V80, P492; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOLLAG W, 1991, BRIT J HAEMATOL, V79, P87, DOI 10.1111/j.1365-2141.1991.tb08129.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BORROW J, 1992, BRIT J HAEMATOL, V82, P529, DOI 10.1111/j.1365-2141.1992.tb06463.x; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAZZELL RK, 1983, EUR J CLIN PHARMACOL, V24, P695, DOI 10.1007/BF00542225; BREITMAN TR, 1990, CANCER RES, V50, P6268; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P5542, DOI 10.1073/pnas.88.13.5542; BROWER MS, 1982, J BIOL CHEM, V257, P9849; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; Castaigne S, 1990, BLOOD S, V76, p260a; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1991, LEUKEMIA, V5, P200; CHANG KS, 1992, BLOOD, V79, P554; CHEN SJ, 1992, ONCOGENE, V7, P1223; CHEN SJ, 1991, BLOOD, V78, P2696; CHEN SJ, 1992, BLOOD S, V80, pA255; CHEN Z, 1991, LEUKEMIA, V5, P288; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLOMBAT P, 1991, BRIT J HAEMATOL, V79, P382, DOI 10.1111/j.1365-2141.1991.tb08045.x; CORDONNIER C, 1985, CANCER-AM CANCER SOC, V55, P18, DOI 10.1002/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B; CORNIC M, 1992, CANCER RES, V52, P3329; CUNNINGHAM I, 1989, BLOOD, V73, P1116; DAENEN S, 1986, BLOOD, V67, P559; DANIEL MT, IN PRESS BLOOD; DEGOS L, 1990, LANCET, V336, P1440, DOI 10.1016/0140-6736(90)93135-C; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; EARDLEY A, 1992, BLOOD S, V80, pA109; ELLIOTT S, 1992, BLOOD, V79, P1916; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FENAUX P, 1992, BLOOD, V80, P2176; FENAUX P, 1993, P AN M AM SOC CLIN, V12, P300; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; FRANCIS PA, 1992, P AN M AM SOC CLIN, V11, P108; FRANCIS RB, 1987, J LAB CLIN MED, V110, P541; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FRICKEL F, 1984, RETINOIDS, V1, P8; GALLAGHER RE, 1987, LEUKEMIA RES, V11, P609, DOI 10.1016/0145-2126(87)90033-6; GANEM G, 1983, BLOOD S, V63, pA171; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; GOUAULTHEILMANN M, 1975, BRIT J HAEMATOL, V30, P151, DOI 10.1111/j.1365-2141.1975.tb00529.x; GRALNICK HR, 1975, BRIT J HAEMATOL, V29, P373, DOI 10.1111/j.1365-2141.1975.tb01834.x; HASSAN HT, 1990, CANCER CHEMOTH PHARM, V26, P26, DOI 10.1007/BF02940289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HILLESTAD LK, 1957, ACTA MED SCAND, V159, P189, DOI 10.1111/j.0954-6820.1957.tb00124.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG ME, 1987, CHINESE MED J-PEKING, V100, P949; HUGHES TP, 1991, BLOOD, V77, P874; JONES ME, 1978, AM J MED, V65, P673, DOI 10.1016/0002-9343(78)90856-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANTARJIAN HM, 1986, AM J MED, V80, P789, DOI 10.1016/0002-9343(86)90617-0; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P793, DOI 10.1200/JCO.1985.3.6.793; KANTARJIAN HM, 1987, CANCER-AM CANCER SOC, V59, P1258, DOI 10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G; KASTNER P, 1991, CR SOC BIOL, V185, P391; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIZAKI M, 1991, BLOOD, V77, P1238; KUBOTA T, 1991, THROMB HAEMOSTASIS, V65, P59; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEFEBVRE P, 1991, LEUKEMIA, V5, P1054; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIGHT SE, 1992, P AN M AM SOC CLIN, V11, P263; LOCOCO F, 1991, BLOOD, V77, P1657; LOCOCO F, 1992, EUR J HAEMATOL, V48, P173; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MARTY M, 1984, NOUV REV FR HEMATOL, V26, P371; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MAYER RJ, 1987, SEMIN ONCOL, V14, P25; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLER WH, 1992, P AN M AM SOC CLIN, V11, P259; MILLER WH, 1992, BLOOD S, V80, pA108; MUINDI, 1992, BLOOD, V80, P855; MUINDI J, 1992, BLOOD, V79, P299; MUINDI JF, 1993, CANCER RES, V53, P1226; MUINDI JRF, 1992, CANCER RES, V52, P2138; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSSON B, 1984, BRIT J HAEMATOL, V57, P365, DOI 10.1111/j.1365-2141.1984.tb02910.x; OHNO R, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P234; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PERLMAN K, 1990, BIOCHEMISTRY-US, V29, P190, DOI 10.1021/bi00453a026; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PHILLIPS WE, 1970, CAN MED ASSOC J, V102, P1085; PUI CH, 1991, BLOOD, V78, P1327, DOI 10.1182/blood.V78.5.1327.1327; ROBERTSON KA, 1992, BLOOD, V80, P1885; RODEGHIERO F, 1990, BLOOD, V75, P2112; ROUSSELOT P, 1992, BLOOD S, V80, pA255; ROWLEY JD, 1977, LANCET, V1, P549; RUNDE V, 1992, ANN HEMATOL, V64, P270, DOI 10.1007/BF01695469; SAITO M, 1989, THROMB RES, V53, P163, DOI 10.1016/0049-3848(89)90376-9; SAKATA Y, 1991, BLOOD, V77, P1949; SANZ MA, 1988, CANCER, V61, P7, DOI 10.1002/1097-0142(19880101)61:1<7::AID-CNCR2820610103>3.0.CO;2-6; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHWARTZ BS, 1986, ANN INTERN MED, V105, P873, DOI 10.7326/0003-4819-105-6-873; SCROBOHACI M, 1991, BLOOD S, V78, pA48; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STERRENBERG L, 1985, HAEMOSTASIS, V15, P126; STONE RM, 1990, J CLIN ONCOL, V8, P1913, DOI 10.1200/JCO.1990.8.11.1913; STONE RM, 1988, BLOOD, V71, P690; SUN GL, 1992, CHIN J HEMATOL, V13, P135; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TALLMAN MS, 1992, BLOOD, V79, P543; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THOMAS X, 1991, LEUKEMIA LYMPHOMA, V4, P249, DOI 10.3109/10428199109068073; TOBLER A, 1986, J CLIN INVEST, V78, P303, DOI 10.1172/JCI112565; TOHDA S, 1991, LEUKEMIA, V5, P951; TONG JH, 1992, ONCOGENE, V7, P311; VENTURA G J, 1989, Hematologic Pathology, V3, P23; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1992, BLOOD S, V80, pA360; WIJERMANS PW, 1989, BLOOD, V73, P800; WILSON EL, 1983, BLOOD, V61, P568; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	153	825	846	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					177	189		10.1056/NEJM199307153290307	http://dx.doi.org/10.1056/NEJM199307153290307			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL460	8515790				2022-12-28	WOS:A1993LL46000007
J	VERHEIJ, C; BAKKER, CE; DEGRAAFF, E; KEULEMANS, J; WILLEMSEN, R; VERKERK, AJMH; GALJAARD, H; REUSER, AJJ; HOOGEVEEN, AT; OOSTRA, BA				VERHEIJ, C; BAKKER, CE; DEGRAAFF, E; KEULEMANS, J; WILLEMSEN, R; VERKERK, AJMH; GALJAARD, H; REUSER, AJJ; HOOGEVEEN, AT; OOSTRA, BA			CHARACTERIZATION AND LOCALIZATION OF THE FMR-1 GENE-PRODUCT ASSOCIATED WITH FRAGILE-X SYNDROME	NATURE			English	Article							EXPRESSION; PURIFICATION; CELLS	THE fragile X syndrome is the most frequent form of inherited mental retardation after Down's syndrome, having an incidence of one in 1,250 males1,2. The fragile X syndrome results from amplification of the CGG repeat found in the FMR-1 gene3-6. This CGG repeat shows length variation in normal individuals and is increased significantly in both carriers and patients3-6; it is located 250 base pairs distal to a CpG island6 which is hypermethylated in fragile X patients4-7. The methylation probably results in downregulation of FMR-1 gene expression8. No information can be deduced about the function of the FMR-1 protein from its predicted sequence. Here we investigate the nature and function of the protein encoded by the FMR-1 gene using polyclonal antibodies raised against the predicted amino-acid sequences. Four different protein products, possibly resulting from alternative splicing, have been identified by immunoblotting in lymphoblastoid cell lines of healthy individuals. All these proteins were missing in cell lines from patients not expressing FMR-1 messenger RNA. The intracellular localization of the FMR-1 gene products was investigated by transient expression in COS-1 cells and found to be cytoplasmic. Localization was also predominantly cytoplasmic in the epithelium of the oesophagus, but in some cells was obviously nuclear.	ERASMUS UNIV ROTTERDAM,MGC DEPT CLIN GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			de Graaff, Esther/D-3287-2011	Verkerk, Annemieke JMH/0000-0002-7523-3656				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OBERLE I, 1991, SCIENCE, V252, P1179; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDONGEN JM, 1984, HISTOCHEM J, V16, P941, DOI 10.1007/BF01003850; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	17	292	299	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					722	724		10.1038/363722a0	http://dx.doi.org/10.1038/363722a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515814	Green Published			2022-12-28	WOS:A1993LJ33900056
J	MOORE, D; HOUSE, I; DIXON, A; WILLIAMS, G; VOLANS, G; HENRY, J; HUGHES, RAC; COCHRANE, GM; ATKINSON, PL; MILBURN, H				MOORE, D; HOUSE, I; DIXON, A; WILLIAMS, G; VOLANS, G; HENRY, J; HUGHES, RAC; COCHRANE, GM; ATKINSON, PL; MILBURN, H			GRAND ROUNDS - GUYS-HOSPITAL - THALLIUM POISONING	BRITISH MEDICAL JOURNAL			English	Discussion								Thallium is a heavy metal whose salts are used in some rodent poisons and in the manufacture of optical lenses, semiconductors, scintillation counters, low temperature thermometers and switching devices, green coloured fireworks, and imitation jewellery, and as chemical catalysts. In clinical practice thallium isotopes are used in cardiac scanning,1 2 but the use of thallium salts to treat scalp ringworm was abandoned earlier this century because of their toxicity. The sale of thallium in Britain is strictly licensed because of its toxicity and potential for use in murder, which is helped by the fact that thallous salts are colourless, tasteless, and odourless. The more water soluble salts (such as thallium sulphate, acetate, or carbonate) have higher toxicity, and although the toxic dose is variable most deaths occur after the ingestion of 10-15 mg/kg of soluble salt. Most cases of thallium toxicity occur after oral ingestion but severe toxicity has been reported after inhalation of contaminated dust from pyrite burners, in zinc and lead smelting, and in the manufacture of cadmium, after dermal absorption through protective rubber gloves,3 and after snorting what was thought to be cocaine.4 The elimination half time of thallium is between 1.7 and 30 days2 5 depending on the time since, and chronicity of, ingestion. The elimination time phases are apparent and because of the long terminal elimination half time thallium may act as a cumulative poison. We present two cases of thallium poisoning with intent to kill.			MOORE, D (corresponding author), GUYS HOSP,POISONS UNIT,LONDON SE1 9RT,ENGLAND.							BANK WJ, 1972, ARCH NEUROL-CHICAGO, V26, P456, DOI 10.1001/archneur.1972.00490110090009; BARCLAY RK, 1953, J PHARMACOL EXP THER, V107, P178; Baselt R.C., 1982, DISPOSITION TOXIC DR; CAVANAGH JB, 1991, NEUROPATH APPL NEURO, V17, P3, DOI 10.1111/j.1365-2990.1991.tb00687.x; DAVIS LE, 1981, ANN NEUROL, V10, P38, DOI 10.1002/ana.410100108; DEGROOT G, 1988, SCI TOTAL ENVIRON, V71, P411, DOI 10.1016/0048-9697(88)90213-6; DEGROOT G, 1985, ARCH TOXICOL, V57, P61, DOI 10.1007/BF00286577; DUMITRU D, 1990, MUSCLE NERVE, V13, P433, DOI 10.1002/mus.880130510; DVORAK P, 1971, N-S ARCH PHARMAKOL, V269, P48, DOI 10.1007/BF01422015; FORTH W, 1979, DTSCH ARZTEBLATT, V43, P2803; FRETWURST F, 1955, Arch Toxikol, V15, P327; GRANT WM, 1986, TOXICOLOGY EYE; GRISHAM CM, 1974, J BIOL CHEM, V249, P6738; HEYL T, 1989, BRIT J DERMATOL, V121, P787, DOI 10.1111/j.1365-2133.1989.tb08223.x; HOLLOGGINITAS C, 1980, J ANAL TOXICOL, V4, P68; HUGHES MN, 1978, CLIN BIOL INTERACT, V28, P85; INSLEY BM, 1986, AM J EMERG MED, V4, P545, DOI 10.1016/S0735-6757(86)80016-X; LIMOS LC, 1982, MUSCLE NERVE, V5, P698, DOI 10.1002/mus.880050906; Lynch GR, 1930, LANCET, V2, P1340; PAPP JP, 1969, ANN INTERN MED, V71, P119, DOI 10.7326/0003-4819-71-1-119; PRICK JJG, 1955, THALLIUM POISONING; RAUWS AG, 1974, N-S ARCH PHARMACOL, V284, P295, DOI 10.1007/BF00500348; REED D, 1963, JAMA-J AM MED ASSOC, V183, P516; SADDIQUE A, 1983, VET HUM TOXICOL, V25, P16; SCHAFER SG, 1983, BIOL TRACE ELEM RES, V5, P205, DOI 10.1007/BF02916624; STEVENS W, 1974, INT J CLIN PHARM TH, V10, P1; VANKESTEREN RG, 1980, INTENSIVMED, V17, P293; VILLANUEVA E, 1990, DRUG SAFETY, V5, P384, DOI 10.2165/00002018-199005050-00006; WAINWRIGHT AP, 1988, Q J MED, V69, P939; [No title captured]	30	66	83	2	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1527	1529		10.1136/bmj.306.6891.1527	http://dx.doi.org/10.1136/bmj.306.6891.1527			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518684	Green Published, Bronze			2022-12-28	WOS:A1993LF94000032
J	RAFNSSON, V; GUNNARSDOTTIR, H				RAFNSSON, V; GUNNARSDOTTIR, H			RISK OF FATAL ACCIDENTS OCCURRING OTHER THAN AT SEA AMONG ICELANDIC SEAMEN	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; FISHERMEN	Objective-To study mortality among seamen, particularly from fatal accidents that occurred other than at sea. Design-Cohort study. Setting-Iceland. Subjects-27 884 seamen, both fishermen and sailors from the merchant fleet, who had been members of a pension fund from 1958 to 1986. Main outcome measures-Cause of death (ICD seventh revision), standardised mortality ratio. Results-Most standardised mortality ratios were greater than 1, being 1.26 for an causes and 1.83 for all external causes. There was no healthy worker effect. The excess of deaths from all external causes included all subcategories of death from accidents, poisonings, and violence and not just accidents at sea (water transport accidents, ICD codes E850-E858). A significant trend was found for length of employment and mortality from all accidents at sea, drowning at sea, accidental poisoning, other accidents, and accidental drowning; correlation coefficients for all causes, all accidents, suicide, and injuries undetermined whether accidentally or purposely inflicted were 0.7-0.8. Compared with seamen who started work during 1968-77, those who started work in 1978 or later had higher mortality from all causes, road traffic accidents, poisoning, other accidents, homicide, and injuries unknown whether accidentally or purposely inflicted, but not from all accidents at sea and accidental drowning. Conclusion-Seamen seem to be a special group with a high risk of fatal accidents occurring not only at sea. The association between fatal accidents other than at sea and length of employment as seamen indicates that seamen are modified by their occupation towards hazardous behaviour or a risky lifestyle.			RAFNSSON, V (corresponding author), ADM OCCUPAT SAFETY & HLTH,DEPT OCCUPAT MED,BILDSHOEFDI 16,IS-112 REYKJAVIK,ICELAND.							AXELSON O, 1981, EPIDEMOLOGI FOR ARBE; CONE JE, 1991, J OCCUP ENVIRON MED, V33, P813, DOI 10.1097/00043764-199107000-00017; HABERMAN PW, 1983, INT J ADDICT, V18, P303, DOI 10.3109/10826088309039349; HAGMAR L, 1992, SCAND J WORK ENV HEA, V18, P217, DOI 10.5271/sjweh.1586; HASSELBACK P, 1990, BRIT J IND MED, V47, P498; HELGASON T, 1977, TIDSSKR NOR LAEGEFOR, V27, P1389; HERNBERG S, 1992, INTRO OCCUPATIONAL E; LUOVIKSDOTTIR D, 1992, LAEKNABLADID S21, V8; MacMahon B, 1970, EPIDEMIOLOGY PRINCIP; MOORE SRW, 1969, BRIT J IND MED, V26, P25; NEUTEL CI, 1990, BRIT J IND MED, V47, P528; NORTON RN, 1989, ALCOHOL ALCOHOLISM, V24, P565, DOI 10.1093/oxfordjournals.alcalc.a044960; Palsson G, 1991, COASTAL EC CULTURAL; RAFNSSON V, 1988, SCAND J WORK ENV HEA, V14, P197, DOI 10.5271/sjweh.1931; RAFNSSON V, 1992, BRIT J IND MED, V49, P694; RAFNSSON V, 1990, BRIT J IND MED, V47, P721; RAFNSSON V, 1991, SCAND J WORK ENV HEA, V17, P312, DOI 10.5271/sjweh.1697; RAPITI E, 1992, AM J IND MED, V21, P863, DOI 10.1002/ajim.4700210609; REILLY MSJ, 1985, BRIT J IND MED, V42, P806; RIX KJB, 1982, BRIT J IND MED, V39, P11; SCHILLING RS, 1966, P ROY SOC MED, V59, P405, DOI 10.1177/003591576605900504; Siegel S., 1956, NONPARAMETRIC STAT B; SKULASON H, 1987, LAEKNABLADID, V73, P315; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; SWAEN GMH, 1987, BRIT J IND MED, V44, P642; THORLINDSSON T, 1988, HUM ORGAN, V47, P199, DOI 10.17730/humo.47.3.1584t42x24702552; WATANABE KK, 1991, J OCCUP ENVIRON MED, V33, P780, DOI 10.1097/00043764-199107000-00010; WEIHE P, 1988, SOFARIS FISKERIMEDIC, P123; 1991, STATISTICAL ABSTRACT	29	22	22	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1379	1381		10.1136/bmj.306.6889.1379	http://dx.doi.org/10.1136/bmj.306.6889.1379			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518604	Bronze, Green Published			2022-12-28	WOS:A1993LD82900021
J	RUSSELL, R; GROVES, P; TAUB, N; ODOWD, J; REYNOLDS, F				RUSSELL, R; GROVES, P; TAUB, N; ODOWD, J; REYNOLDS, F			ASSESSING LONG-TERM BACKACHE AFTER CHILDBIRTH	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate the factors associated with long term backache after childbirth, to assess all women reporting new onset long term backache, and to investigate any relation with pain relief in labour. Design-Data collected from obstetric records and postal questionnaires or telephone interviews on morbidity after childbirth from all women delivering their first baby between March 1990 and February 1991, followed by analysis of data collected from outpatient consultations. Setting-St Thomas's Hospital, London. Subjects-Questionnaires were sent to 1615 women who had delivered their first baby in the defined period; 1015 either replied by post or were contacted by telephone. Results-299 women (29.5% of responders) reported backache lasting more than six months and of these 156 (15.4%) said they had had no back problems previously. Those women who had received epidural analgesia in labour were significantly more likely to report new onset backache (17.8%; 95% confidence interval 14.8% to 20.8%) than those who did not (11.7%; 8.6% to 14.8%). Younger women, unmarried women, and those reporting other antenatal symptoms were significantly more likely to report new long term backache. The 156 women reporting new backache were asked to attend an outpatient clinic and 36 (23%) did so. The majority had a postural backache which was not severe. Psychological factors were present in 14 women. Conclusions-Though new long term backache is reported more commonly after epidural analgesia in labour, it tends to be postural and not severe. There were no differences in the nature of the backache between those who had or had not received epidural analgesia in labour.	ST THOMAS HOSP,DEPT ORTHOPAED SURG,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	RUSSELL, R (corresponding author), ST THOMAS HOSP,DEPT ANAESTHET,LONDON SE1 7EH,ENGLAND.			Russell, Robin/0000-0001-7294-6629				DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P1013; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1992, BRIT MED J, V304, P1279, DOI 10.1136/bmj.304.6837.1279; MAIN CJ, 1983, J PSYCHOSOM RES, V27, P503, DOI 10.1016/0022-3999(83)90040-5; Ransford AO., 1976, SPINE, V1, P127, DOI DOI 10.1097/00007632-197606000-00007; WADDELL G, 1987, LUMBAR SPINE BACK PA, P419; WHITEHEAD CR, 1986, DEWHURSTS TXB OBSTET	7	70	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1299	1303		10.1136/bmj.306.6888.1299	http://dx.doi.org/10.1136/bmj.306.6888.1299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518569	Green Published, Bronze			2022-12-28	WOS:A1993LC72200019
J	Dodds, AW; Ren, XD; Willis, AC; Law, SKA				Dodds, AW; Ren, XD; Willis, AC; Law, SKA			The reaction mechanism of the internal thioester in the human complement component C4	NATURE			English	Article							STRUCTURAL BASIS; NUCLEOPHILIC MODIFICATION; 4TH COMPONENT; 3RD COMPONENT; BINDING; C-3; SEQUENCE; SITE; C3B; IDENTIFICATION	A KEY step in the elimination of pathogens from the body is the covalent binding of complement proteins C3 and C4 to their surfaces(1-5). Proteolytic activation of these proteins results in a conformational change(6,7), and an internal thioester(8-10) is exposed which reacts with amino or hydroxyl groups on the target surface to form amide or ester bonds, or is hydrolysed(11-15). We report here that the binding of the human C4A isotype involves a direct reaction between amino-nucleophiles and the thioester. A two-step mechanism is used by the C4B isotype. The histidine at position 1,106 (aspartic acid in C4A) first attacks the thioester to form an acyl-imidazole intermediate. The released thiol then acts as a base to catalyse the transfer of the acyl group to amino- and hydroxyl-nucleophiles, including water.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford			Law, Alex/A-2212-2011	Dodds, Alister William/0000-0003-3396-1257				BELT KT, 1984, CELL, V36, P907; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CAMPBELL RD, 1981, BIOCHEM J, V199, P359, DOI 10.1042/bj1990359; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; CHU CT, 1994, LAB INVEST, V71, P792; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DODDS AW, 1988, COMPLEMENT INFLAMMAT, V5, P89, DOI 10.1159/000463039; DODDS AW, 1986, IMMUNOGENETICS, V24, P279, DOI 10.1007/BF00395532; DODDS AW, 1990, BIOCHEM J, V265, P494; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; HOSTETTER MK, 1982, NATURE, V298, P72, DOI 10.1038/298072b0; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1982, BIOCHEMISTRY-US, V21, P1109, DOI 10.1021/bi00535a001; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1979, J IMMUNOL, V123, P1388; LAW SKA, 1984, EMBO J, V3, P1819, DOI 10.1002/j.1460-2075.1984.tb02052.x; LAW SKA, 1995, FOCUS SERIES; LEVINE RP, 1989, CURR TOP MICROBIOL I, V153, P73; NG YC, 1993, COMPLEMENT HLTH DISE, P199; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; REN XD, 1995, FEBS LETT, V368, P87, DOI 10.1016/0014-5793(95)00606-A; REN XD, 1993, IMMUNOGENETICS, V37, P120, DOI 10.1007/BF00216835; SCHWEIZER M, 1987, EUR J BIOCHEM, V164, P375, DOI 10.1111/j.1432-1033.1987.tb11068.x; SEPP A, 1993, PROTEIN SCI, V2, P706, DOI 10.1002/pro.5560020502; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; THOMAS ML, 1983, BIOCHEMISTRY-US, V22, P942, DOI 10.1021/bi00273a036; WEITZMAN JB, 1993, COMPLEMENT HLTH DISE, P269; YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x	30	149	155	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					177	179		10.1038/379177a0	http://dx.doi.org/10.1038/379177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538770				2022-12-28	WOS:A1996TP36000062
J	Penny, GD; Kay, GF; Sheardown, SA; Rastan, S; Brockdorff, N				Penny, GD; Kay, GF; Sheardown, SA; Rastan, S; Brockdorff, N			Requirement for Xist in X chromosome inactivation	NATURE			English	Article							STEM-CELLS; CONTROLLING ELEMENTS; MOUSE DEVELOPMENT; GENE; EXPRESSION; EMBRYOS; TRANSLOCATION; LOCATION; POSITION; CONTAINS	The Xist gene has been proposed as a candidate for the X inactivation centre the master regulatory switch locus that controls X chromosome inactivation. So far this hypothesis has been supported solely by indirect evidence. Here we describe gene targeting of Xist, and provide evidence for its absolute requirement in the process of X chromosome inactivation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,COMPARAT MED SECT,MRC,CLIN SCI CTR,LONDON W12 0NN,ENGLAND	Imperial College London			Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BALL TC, 1995, BLOOD, V85, P3086, DOI 10.1182/blood.V85.11.3086.bloodjournal85113086; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; CATTANACH BM, 1970, GENET RES, V15, P183, DOI 10.1017/S0016672300001518; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; CATTANACH BM, 1967, GENETICS, V57, P331; DUTRILLAUX B, 1974, ANN GENET-PARIS, V17, P207; GREEN MC, 1989, GENETIC VARIANTS STR, P282; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Nagy A., 1993, Gene targeting: a practical approach., P147; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; PAMIERI SL, 1994, DEV BIOL, V166, P259; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUSSELL LB, 1970, GENETICS, V64, P281; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P10469, DOI 10.1073/pnas.89.21.10469; TADA T, 1993, DEVELOPMENT, V119, P813; TAKAGI N, 1984, DEV BIOL, V103, P425, DOI 10.1016/0012-1606(84)90330-0; TAKAGI N, 1990, DEVELOPMENT, V109, P189; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; ZINN AR, 1991, GENOMICS, V11, P1097, DOI 10.1016/0888-7543(91)90037-F	46	976	1005	1	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					131	137		10.1038/379131a0	http://dx.doi.org/10.1038/379131a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538762				2022-12-28	WOS:A1996TP36000048
J	Sun, J; Perona, P				Sun, J; Perona, P			Early computation of shape and reflectance in the visual system	NATURE			English	Article							PERCEPTION	A COMPELLING sense of three-dimensional shape may be conveyed by the photograph of an object. Cues such as contour, shading, perspective and occlusion, to name a few, contribute to this percept. Psychophysical experiments suggest that certain aspects of three-dimensional shape are computed rapidly and in parallel by the visual system(1-7,15). Here we report that reflectance is also computed rapidly; moreover, it is the apparent reflectance, rather than brightness or perceptual three-dimensional shape, that is the primary basis for discrimination during the early stages of visual processing.	CALTECH 11681, PASADENA, CA 91125 USA	California Institute of Technology	Sun, J (corresponding author), CALTECH 11681, PASADENA, CA 91125 USA.							ADELSON EH, 1993, SCIENCE, V262, P2042, DOI 10.1126/science.8266102; BERGSTROM SS, 1977, SCAND J PSYCHOL, V18, P180, DOI 10.1111/j.1467-9450.1977.tb00275.x; BRAUN J, 1993, SPATIAL VISION, V7, P311, DOI 10.1163/156856893X00469; BRAUN J, 1990, PERCEPTION, V19, pA112; ENNS JT, 1991, PSYCHOL REV, V98, P335, DOI 10.1037/0033-295X.98.3.335; ENNS JT, 1990, SCIENCE, V247, P71; GILCHRIST AL, 1979, SCI AM, V240, P112, DOI 10.1038/scientificamerican0379-112; KLEFFNER DA, 1992, PERCEPT PSYCHOPHYS, V52, P18, DOI 10.3758/BF03206757; KNILL DC, 1991, NATURE, V351, P228, DOI 10.1038/351228a0; McNicol D., 1972, PRIMER SIGNAL DETECT; METELLI F, 1974, SCI AM, V230, P91, DOI 10.1038/scientificamerican0474-90; RAMACHANDRAN VS, 1988, NATURE, V331, P163, DOI 10.1038/331163a0; SUN JY, 1993, INVEST OPHTH VIS SCI, V34, P1083; SUN JY, IN PRESS VISION RES; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5	15	45	46	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					165	168		10.1038/379165a0	http://dx.doi.org/10.1038/379165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP360	8538766				2022-12-28	WOS:A1996TP36000058
J	KritzSilverstein, D; BarrettConnor, E				KritzSilverstein, D; BarrettConnor, E			Long-term postmenopausal hormone use, obesity, and fat distribution in older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BODY-FAT; REPLACEMENT THERAPY; ADIPOSE-TISSUE; RISK-FACTORS; MENOPAUSE; POPULATION; ASSOCIATION; GOTHENBURG; HISTORY	Objective.-To determine whether long-term postmenopausal hormone replacement is associated with measures of obesity and body composition in elderly women. Design.-A 15-year prospective and cross-sectional cohort study. Setting.-Rancho Bernardo, a geographically defined community in Southern California. Participants.-A total of 671 women aged 65 to 94 years, who were initially enrolled in the Rancho Bernardo Study between 1972 and 1974 and participated in a 1988 to 1991 follow-up clinic visit. These women had never used hormone replacement therapy (n=194), used hormones intermittently (n=331), or used hormones continuously (n=146) for the 15 years between baseline and follow-up. Main Outcome Measures.-Height and weight were obtained at both clinic visits; differences in body mass index (BMI) between baseline and follow-up were computed. At follow-up, waist and hip circumferences and bioelectric impedance were measured. Results.-Age-adjusted comparisons indicated intermittent and continuous hormone users had significantly lower mean BMIs at baseline than women who had never used hormone replacement therapy. After adjustment for potentially confounding covariates, there were no significant differences between estrogen users and nonusers in BMI at follow-up, change in weight or BMI between baseline and follow-up, or waist-hip ratio or fat mass at follow-up. Conclusion.-Hormone replacement therapy, whether used intermittently or continuously for 15 or more years, is not associated with the weight gain and central obesity that is commonly observed in postmenopausal women.	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,DIV EPIDEMIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					AHRQ HHS [HS06726] Funding Source: Medline; NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1980, AM J EPIDEMIOL, V111, P705, DOI 10.1093/oxfordjournals.aje.a112948; GOODMAN MT, 1990, AM J EPIDEMIOL, V131, P815, DOI 10.1093/oxfordjournals.aje.a115572; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HART DM, 1978, FRONT HORM RES, V5, P174; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HASSAGER C, 1989, METABOLISM, V38, P662, DOI 10.1016/0026-0495(89)90104-2; KAYE SA, 1990, INT J OBESITY, V14, P583; KULLER L, 1990, SERONO S; KULLER LH, 1994, EXP GERONTOL, V29, P495, DOI 10.1016/0531-5565(94)90030-2; KUSHNER RF, 1992, J AM COLL NUTR, V11, P199; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; LUNDGREN H, 1989, INT J OBESITY, V13, P413; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOTELOVITZ M, 1982, CURR THER RES CLIN E, V31, P746; NOTELOVITZ M, 1975, S AFR MED J, V49, P2251; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; TONKELAAR I, 1990, INT J OBESITY, V14, P753; Tonkelaar I D, 1989, Int J Obes, V13, P817; UTIAN WH, 1978, MATURITAS, V1, P3, DOI 10.1016/0378-5122(78)90003-8; WING RR, 1991, ARCH INTERN MED, V151, P97, DOI 10.1001/archinte.151.1.97; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250; 1995, JAMA-J AM MED ASSOC, V273, P199	26	86	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					46	49						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531286				2022-12-28	WOS:A1996TM23800021
J	Morrow, M; Daley, J				Morrow, M; Daley, J			A 47-year-old woman with ductal carcinoma in situ	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							CONTRALATERAL BREAST-CANCER; INTRADUCTAL CARCINOMA; RADIATION-THERAPY; FOLLOW-UP; INSITU; SURGERY; RISK; RADIOTHERAPY; PREVALENCE; BIOPSY		NORTHWESTERN UNIV,SCH MED,LYNN SAGE COMPREHENS BREAST PROGRAM,CHICAGO,IL	Northwestern University								ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; BROET P, 1995, J CLIN ONCOL, V13, P1578, DOI 10.1200/JCO.1995.13.7.1578; EBERLEIN TJ, 1993, ANN SURG, V218, P29, DOI 10.1097/00000658-199307000-00006; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FVERLY DR, 1994, SEMIN DIAGN PATHOL, V11, P193; GUIDI AJ, 1994, J NATL CANCER I, V86, P614, DOI 10.1093/jnci/86.8.614; HABEL LA, 1995, 48TH CANC S SOC SURG; Harris J, 1996, DIS BREAST, P487; HEALEY EA, 1993, J CLIN ONCOL, V11, P1545, DOI 10.1200/JCO.1993.11.8.1545; Hiramatsu H, 1995, Cancer J Sci Am, V1, P55; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P181; KESSLER LG, 1991, PREV MED, V201, P179; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LAGIOS MD, 1994, J CELL BIOCH S, V19, P186; MCCORMICK B, 1991, INT J RADIAT ONCOL, V21, P289, DOI 10.1016/0360-3016(91)90773-W; MORROW M, 1994, ARCH SURG-CHICAGO, V129, P1091; MORROW M, DISEASES BREAST, P355; MORROW M, 1996, DIS BREAST, P369; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; RECHT A, 1994, EUR J CANCER, V30A, P1895, DOI 10.1016/0959-8049(94)90611-4; ROSE MA, 1989, ARCH SURG-CHICAGO, V124, P153; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SILVERSTEIN MJ, 1990, CANCER, V66, P102, DOI 10.1002/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5; SOLIN LJ, 1991, CANCER-AM CANCER SOC, V68, P2337, DOI 10.1002/1097-0142(19911201)68:11<2337::AID-CNCR2820681102>3.0.CO;2-R; STORM HH, 1992, J NATL CANCER I, V84, P1245, DOI 10.1093/jnci/84.16.1245; SWAIN SM, 1992, CANCER INVEST, V10, P443, DOI 10.3109/07357909209024802; WEBBER BL, 1981, CANCER, V47, P2928, DOI 10.1002/1097-0142(19810615)47:12<2928::AID-CNCR2820471232>3.0.CO;2-5; WINCHESTER DP, 1995, ANN SURG ONCOL, V2, P296; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208	34	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					61	66						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531289				2022-12-28	WOS:A1996TM23800024
J	Newman, TB; Hulley, SB				Newman, TB; Hulley, SB			Carcinogenicity of lipid-lowering drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATIC PEROXISOME PROLIFERATORS; NATIONAL-TOXICOLOGY-PROGRAM; LOW BLOOD CHOLESTEROL; CANCER RISK; SERUM-CHOLESTEROL; UNITED-STATES; ACID CPIB; MORTALITY; GEMFIBROZIL; PREVENTION	Objective.-To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs. Data Sources.-Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts. Study Sample.-We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as ''hypolipidemics.'' For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans. Data Synthesis.-All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans. In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up. Conclusions.-Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOSTAT & EPIDEMIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Newman, TB (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT LAB MED, BOX 0626, SAN FRANCISCO, CA 94143 USA.							[Anonymous], 1992, Arch Intern Med, V152, P1399; ARKY R, 1994, PHYSICIANS DESK REFE; BENTLEY P, 1993, FOOD CHEM TOXICOL, V31, P857, DOI 10.1016/0278-6915(93)90225-N; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COHEN AJ, 1981, FOOD COSMET TOXICOL, V19, P585, DOI 10.1016/0015-6264(81)90509-5; CONTRERA JF, 1995, J AM COLL TOXICOL, V14, P1; CRIQUI MH, 1991, ANN INTERN MED, V115, P973, DOI 10.7326/0003-4819-115-12-973; DAVIES TS, 1995, J AM COLL TOXICOL, V14, P90, DOI 10.3109/10915819509008684; DELAIGLESIA FA, 1982, ATHEROSCLEROSIS, V43, P19, DOI 10.1016/0021-9150(82)90096-X; Freedman DA., 1988, STAT SCI, V3, P3, DOI DOI 10.1214/SS/1177012993; FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GOLD LS, 1992, SCIENCE, V258, P261, DOI 10.1126/science.1411524; GORI GB, 1992, REGUL TOXICOL PHARM, V16, P10, DOI 10.1016/0273-2300(92)90019-6; GRAHAM MJ, 1994, FUND APPL TOXICOL, V22, P58, DOI 10.1006/faat.1994.1008; GREGORY AR, 1992, REGUL TOXICOL PHARM, V15, P271, DOI 10.1016/0273-2300(92)90038-B; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HANEFELD M, 1980, ATHEROSCLEROSIS, V36, P159, DOI 10.1016/0021-9150(80)90225-7; HANEFELD M, 1983, ATHEROSCLEROSIS, V46, P239, DOI 10.1016/0021-9150(83)90115-6; HASEMAN JK, 1984, J TOXICOL ENV HEALTH, V14, P621, DOI 10.1080/15287398409530613; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HUFF JE, 1988, ANN NY ACAD SCI, V534, P1, DOI 10.1111/j.1749-6632.1988.tb30085.x; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; HUTTUNEN JK, 1994, J INTERN MED, V235, P31, DOI 10.1111/j.1365-2796.1994.tb01029.x; IRIBARREN C, 1995, JAMA-J AM MED ASSOC, V273, P1926, DOI 10.1001/jama.273.24.1926; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KRITCHEVSKY SB, 1992, ANNU REV NUTR, V12, P391, DOI 10.1146/annurev.nu.12.070192.002135; KRITCHEVSKY SB, 1992, AM J EPIDEMIOL, V135, P509, DOI 10.1093/oxfordjournals.aje.a116318; KRITCHEVSKY SB, 1991, CANCER RES, V51, P3198; LAVE LB, 1988, NATURE, V336, P631, DOI 10.1038/336631a0; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEWMAN TB, 1992, JAMA-J AM MED ASSOC, V267, P100, DOI 10.1001/jama.267.1.100; OGAWA T, 1992, CARCINOGENESIS, V13, P2047, DOI 10.1093/carcin/13.11.2047; PEARCE ML, 1971, LANCET, V1, P464; PEDERSEN TR, 1994, LANCET, V344, P1383; PURCHASE IFH, 1980, BRIT J CANCER, V41, P454, DOI 10.1038/bjc.1980.70; RALL DP, 1987, ANNU REV PUBL HEALTH, V8, P355, DOI 10.1146/annurev.publhealth.8.1.355; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SABADIE N, 1980, CANCER RES, V40, P119; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; TAYLOR M, 1994, FED REGISTER, V59, P9752; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; ZURICH D, 1992, PHYSICIANS DESK REFE; 1990, IARC MONOGRAPHS EVAL, P17; 1993, STAT B METROP INSUR, V74, P10	54	316	322	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					55	60		10.1001/jama.275.1.55	http://dx.doi.org/10.1001/jama.275.1.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531288				2022-12-28	WOS:A1996TM23800023
J	CARROLL, JM; ROMERO, MR; WATT, FM				CARROLL, JM; ROMERO, MR; WATT, FM			SUPRABASAL INTEGRIN EXPRESSION IN THE EPIDERMIS OF TRANSGENIC MICE RESULTS IN DEVELOPMENTAL DEFECTS AND A PHENOTYPE RESEMBLING PSORIASIS	CELL			English	Article							TGF-ALPHA; TERMINAL DIFFERENTIATION; GROWTH-FACTOR; SKIN; CELLS; MOUSE; DISEASE; OVEREXPRESSION; CARCINOGENESIS; HYPERPLASIA	Integrin expression is normally confined to the basal layer of the epidermis, but when epidermal homeostasis is perturbed, the receptors are also expressed by suprabasal, differentiating keratinocytes. We have used the involucrin promoter to express functional human integrin subunits alpha(2), alpha(5), and beta(1) in the suprabasal epidermal layers of transgenic mice. In mice expressing alpha(5) or beta(1) alone or alpha(2) beta(1) or alpha(5) beta(1) heterodimers, there were hair and whisker abnormalities and a failure of eyelid fusion. In addition, mice expressing beta(1) alone or in combination with an or as exhibited epidermal hyperproliferation, perturbed keratinocyte differentiation, and skin inflammation, all of which are features of a common human skin disease, psoriasis.	IMPERIAL CANC RES FUND,KERATINOCYTE LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DJIAN P, 1993, MOL BIOL EVOL, V10, P1136; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; FINDLATER GS, 1993, J ANAT, V183, P121; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOTTLIEB JL, 1995, NATURE MED, V1, P442; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HERTLE MD, 1995, J INVEST DERMATOL, V104, P260, DOI 10.1111/1523-1747.ep12612801; HEYDEN A, 1994, EPITHELIAL CELL BIOL, V3, P96; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HYNES RO, 1988, J CELL BIOL, V109, P409; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KRUEGER GG, 1994, J INVEST DERMATOL, V102, pS14, DOI 10.1111/1523-1747.ep12386079; KRUEGER GG, 1984, J AM ACAD DERMATOL, V11, P937, DOI 10.1016/S0190-9622(84)80018-3; KRUEGER JG, 1994, PSORIASIS, P18; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MENDRICK DL, 1993, LAB INVEST, V69, P690; MILLER DR, 1987, CANCER RES, V47, P1935; Morris RJ, 1994, KERATINOCYTE METHODS, P25; NASIR A, 1994, J CLIN INVEST, V94, P892, DOI 10.1172/JCI117411; PAUKKONEN K, 1995, ARCH DERMATOL RES, V287, P166; ROOP DR, 1984, J BIOL CHEM, V259, P8037; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SCHWARTZBERG PL, 1991, CELL, V85, P1165; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUNDBERG JP, 1993, IMMUNOL INVEST, V22, P389, DOI 10.3109/08820139309063417; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1994, KERATINOCYTE HDB, P153; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P9710, DOI 10.1073/pnas.91.21.9710; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P12780, DOI 10.1073/pnas.91.26.12780; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	50	265	280	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					957	968		10.1016/0092-8674(95)90211-2	http://dx.doi.org/10.1016/0092-8674(95)90211-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521519	Bronze			2022-12-28	WOS:A1995TK74500014
J	HUANG, YZ; BAKER, RT; FISCHERVIZE, JA				HUANG, YZ; BAKER, RT; FISCHERVIZE, JA			CONTROL OF CELL FATE BY A DEUBIQUITINATING ENZYME ENCODED BY THE FAT FACETS GENE	SCIENCE			English	Article							CARBOXYL-TERMINAL HYDROLASE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; DROSOPHILA; CLONING; EXPRESSION	Ubiquitin is a highly conserved polypeptide found in all eukaryotes. The major function of ubiquitin is to target proteins for complete or partial degradation by a multisubunit protein complex called the proteasome. Here, the Drosophila fat facets gene, which is required for the appropriate determination of particular cells in the fly eye, was shown to encode a ubiquitin-specific protease (Ubp), an enzyme that cleaves ubiquitin from ubiquitin-protein conjugates. The Fat facets protein (FAF) acts as a regulatory Ubp that prevents degradation of its substrate by the proteasome. Flies bearing fat facets gene mutations were used to show that a Ubp is cell type- and substrate-specific and a regulator of cell fate decisions in a multicellular organism.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,GENET GRP,CANBERRA,ACT 2601,AUSTRALIA	University of Texas System; University of Texas Austin; Australian National University; John Curtin School of Medical Research								BAKER RR, UNPUB; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FISCHERVIZE JA, UNPUB; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; OH CE, 1994, J NEUROSCI, V14, P3166; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAMBROOK G, 1989, MOL CLONING LABORATO; SAVILLE KJ, 1993, P NATL ACAD SCI USA, V90, P8842, DOI 10.1073/pnas.90.19.8842; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THUMMEL CS, 1988, GENE, V74, P543; Thummel CS, 1992, DROS INF SERV, V71, P150; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, pCH22; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	30	236	249	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1828	1831		10.1126/science.270.5243.1828	http://dx.doi.org/10.1126/science.270.5243.1828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525378				2022-12-28	WOS:A1995TK47600048
J	TREIER, M; BOHMANN, D; MLODZIK, M				TREIER, M; BOHMANN, D; MLODZIK, M			JUN COOPERATES WITH THE ETS DOMAIN PROTEIN POINTED TO INDUCE PHOTORECEPTOR R7 FATE IN THE DROSOPHILA EYE	CELL			English	Article							RECEPTOR TYROSINE KINASE; C-JUN; TRANSCRIPTION FACTORS; SEVENLESS; ACTIVATION; CELLS; GENE; RAS; PHOSPHORYLATION; FOS	R7 photoreceptor fate in the Drosophila eye is induced by the activation of the Sevenless receptor tyrosine kinase and the RAS/MAP kinase signal transduction pathway. We show that expression of a constitutively activated JUN isoform in ommatidial precursor cells is sufficient to induce R7 fate independent of upstream signals normally required for photoreceptor determination. We present evidence that JUN interacts with the ETS domain protein Pointed to promote R7 formation. This interaction is cooperative when both proteins are targeted to the same promoter and is antagonized by another ETS domain protein, YAN, a negative regulator of R7 development, furthermore, phyllopod, a putative transcriptional target of RAS pathway activation during R7 induction, behaves as a suppressor of activated JUN. Taken together, these data suggest that JUN and Pointed act on common target genes to promote neuronal differentiation in the Drosophila eye, and that phyllopod might be such a common target.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Treier, Mathias/AAD-6388-2021					BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEGEMANN G, 1995, DEVELOPMENT, V121, P225; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MLODZIK M, 1992, MECH DEVELOP, V37, P37, DOI 10.1016/0925-4773(92)90013-A; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH SE, 1992, CELL GROWTH DIFFER, V3, P523; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	39	104	104	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					753	760		10.1016/0092-8674(95)90188-4	http://dx.doi.org/10.1016/0092-8674(95)90188-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521492	Bronze			2022-12-28	WOS:A1995TH94800012
J	PALLEN, M				PALLEN, M			GUIDE TO THE INTERNET .1. INTRODUCING THE INTERNET	BRITISH MEDICAL JOURNAL			English	Article								The benefits to medical practitioners of using the Internet are growing rapidly as the Internet becomes easier to use and ever more biomedical resources become available on line. The Internet is the largest computer network in the world; it is also a virtual community, larger than many nation states, with its own rules of behaviour or ''netiquette.'' There are several types of Internet connection and various ways of acquiring a connection. Once connected, you can obtain, free of charge, programs that allow easy use of the Internet's resources and help on how to use these resources; you can access many of these resources through the hypertext references in the on line version of this series (go to http//www.bmj.com/bmj/ to reach the electronic version). You can then explore the various methods for accessing, manipulating, or disseminating data on the Internet, such as electronic mail, telnet, file transfer protocol, and the world wide web. Results from a search of the world wide web for information on the rare condition of Recklinghausen's neurofibromatosis illustrate the breadth of medical information available on the Internet.			PALLEN, M (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,DEPT MED MICROBIOL,LONDON EC1A 7BE,ENGLAND.		Pallen, Mark J./E-7619-2011	Pallen, Mark/0000-0003-1807-3657				FAUGHNAN JG, 1994, J FAM PRACTICE, V39, P365; FRISSE ME, 1994, ACAD MED, V69, P20, DOI 10.1097/00001888-199401000-00004; GALVIN JR, 1995, AM J ROENTGENOL, V164, P475, DOI 10.2214/ajr.164.2.7839992; HERZ JC, 1995, SURFING INTERNET; HUNTLEY AC, 1994, MED EDUC, V28, P508, DOI 10.1111/j.1365-2923.1994.tb02727.x; KRUPER JA, 1994, 1994 P ANN S COMP AP, P32; LAPORTE RE, 1995, BRIT MED J, V310, P1387, DOI 10.1136/bmj.310.6991.1387; MCENERY KW, 1995, AM J ROENTGENOL, V164, P469, DOI 10.2214/ajr.164.2.7839991; MCKINNEY WP, 1993, AM J MED SCI, V306, P141, DOI 10.1097/00000441-199309000-00002; Negroponte N, 1995, BEING DIGITAL; RHEINGOLD G, 1994, VIRTUAL COMMUNITY; Stoll C., 1995, SILICON SNAKE OIL	12	47	49	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1422	1424		10.1136/bmj.311.7017.1422	http://dx.doi.org/10.1136/bmj.311.7017.1422			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520280	Green Published			2022-12-28	WOS:A1995TG90200036
J	[Anonymous]				[Anonymous]			CREUTZFELDT-JAKOB-DISEASE AND BOVINE SPONGIFORM ENCEPHALOPATHY - ANY CONNECTION	BRITISH MEDICAL JOURNAL			English	Editorial Material							BSE											BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; DAVIES PTG, 1993, LANCET, V342, P680, DOI 10.1016/0140-6736(93)91787-M; SAWCER SJ, 1993, LANCET, V341, P642, DOI 10.1016/0140-6736(93)90414-C; SMITH PEM, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92734-4	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1415	1415		10.1136/bmj.311.7017.1415a	http://dx.doi.org/10.1136/bmj.311.7017.1415a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520279	Green Published			2022-12-28	WOS:A1995TG90200027
J	TAKIZAWA, PA; YUCEL, JK; VEIT, B; FAULKNER, DJ; DEERINCK, T; SOTO, G; ELLISMAN, M; MALHOTRA, V				TAKIZAWA, PA; YUCEL, JK; VEIT, B; FAULKNER, DJ; DEERINCK, T; SOTO, G; ELLISMAN, M; MALHOTRA, V			COMPLETE VESICULATION OF GOLGI MEMBRANES AND INHIBITION OF PROTEIN-TRANSPORT BY A NOVEL SEA SPONGE METABOLITE, ILIMAQUINONE	CELL			English	Article							FLUORESCENT CERAMIDE ANALOG; BREFELDIN-A; COATED VESICLES; HELA-CELLS; APPARATUS; STACK; MICROTUBULES; CISTERNAE; ELEMENTS; PATHWAY	We have identified a novel natural metabolite, ilimaquinone (IQ), from sea sponges that causes Golgi membranes to break down completely in vivo into small vesicular structures (called vesiculated Golgi membranes [VGMs]). Under these conditions, transport of newly synthesized proteins from endoplasmic reticulum (ER) to the cis-Golgi-derived VGMs is unaffected; however, further transport along the secretory pathway is blocked. Upon removal of the drug, VGMs reassemble rapidly into a Golgi complex, and protein transport is restored. By employing a cell-free system that reconstitutes vesicular transport between successive Golgi cisternae, we provide evidence that the inhibition of protein transport by IQ is specifically due to an inhibition of transport vesicle formation. In addition, like brefeldin A (BFA), IQ treatment prevents the association of beta-COP and ADP-ribosylation factor to the Golgi membranes; however, unlike BFA treatment, there is no retrograde transport of Golgi enzymes into ER.	UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,DEPT NEUROL,LA JOLLA,CA 92093	University of California System; University of California San Diego; Scripps Institution of Oceanography	TAKIZAWA, PA (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,DEPT BIOL,LA JOLLA,CA 92093, USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026739] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIGMS NIH HHS [R01-GM46224] Funding Source: Medline; NINDS NIH HHS [NS26739] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; LUIBRAND RT, 1979, TETRAHEDRON, V35, P609, DOI 10.1016/0040-4020(79)87004-0; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYOR KN, 1992, ANNU REV BIOCHEM, V61, P471; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Saraste J, 1988, Prog Clin Biol Res, V270, P129; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	38	184	187	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1079	1090		10.1016/0092-8674(93)90638-7	http://dx.doi.org/10.1016/0092-8674(93)90638-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513494				2022-12-28	WOS:A1993LH54800005
J	Chassin, MR; Hannan, EL; DeBuono, BA				Chassin, MR; Hannan, EL; DeBuono, BA			Benefits and hazards of reporting medical outcomes publicly	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEW-YORK-STATE; MORTALITY; SURGERY		MT SINAI SCH MED,NEW YORK,NY 10029; SUNY ALBANY,ALBANY,NY 12222; NEW YORK STATE DEPT HLTH,ALBANY,NY 12237	Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System								[Anonymous], 1992, CORONARY ARTERY BYPA; Ash A, 1994, RISK ADJUSTMENT MEAS, P313; BYER MJ, 1992, NY TIMES        0321, P23; COX DR, 1992, AM STAT, V46, P1, DOI 10.2307/2684400; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; GORDON T, 1979, J CHRON DIS, V32, P427, DOI 10.1016/0021-9681(79)90103-6; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HADORN DC, 1994, ASSESSING PERFORMANC; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; NOBLE HB, 1995, NY TIMES        0703, P1; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; ROSENTHAL E, 1995, NY TIMES        0504, pB5; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; ZINMAN D, 1990, NEWSDAY         1205, P4; ZINMAN D, 1990, NEWSDAY         1205, p3P3; 1993, CORONARY ARTERY BYPA; 1994, CORONARY ARTERY BYPA, V2; 1995, CORONARY ARTERY BYPA; 1995, NY TIMES        0907, pA26	27	296	296	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					394	398		10.1056/NEJM199602083340611	http://dx.doi.org/10.1056/NEJM199602083340611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538714				2022-12-28	WOS:A1996TT48700011
J	Langston, AA; Malone, KE; Thompson, JD; Daling, JR; Ostrander, EA				Langston, AA; Malone, KE; Thompson, JD; Daling, JR; Ostrander, EA			BRCA1 mutations in a population-based sample of young women with breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL BREAST; OVARIAN-CANCER; LINKAGE ANALYSIS	Background. Inherited mutations in the BRCA1 gene are associated with a high risk of breast and ovarian cancer in some families, However, little is known about the contribution of BRCA1 mutations to breast cancer in the general population, We analyzed DNA samples from women enrolled in a population-based study of early-onset breast cancer to assess the spectrum and frequency of germ-line BRCA1 mutations in young women with breast cancer. Methods. We studied 80 women in whom breast cancer was diagnosed before the age of 35, and who were not selected on the basis of family history. Genomic DNA was studied for BRCA1 mutations by analysis involving singlestrand conformation polymorphisms and with allele-specific assays, Alterations were defined by DNA sequencing. Results. Germ-line BRCA1 mutations were identified in 6 of the 80 women, Four additional rare sequence variants of unknown functional importance were also identified, Two of the mutations and three of the rare sequence variants were found among the 39 women who reported no family history of breast or ovarian cancer. None of the mutations and only one of the rare variants was identified in a reference population of 73 unrelated subjects. Conclusions. Alterations in BRCA1 were identified in approximately 10 percent of this cohort of young women with breast cancer, The risk of harboring a mutation was not limited to women with family histories of breast or ovarian cancer, These results represent a minimal estimate of the frequency of BRCA1 mutations in this population. Comprehensive methods of identifying BRCA1 mutations and understanding their importance will be needed before testing of women in the general population can be undertaken.	FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, SEATTLE, WA 98104 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Ostrander, Elaine/0000-0001-6075-9738	NCI NIH HHS [R01 CA63705, R01 CA41416, N01 CN 05230] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA041416, R01CA063705] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FRIEDMAN LS, 1995, THESIS U CALIFORNIA; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sambrook J, 1989, MOL CLONING LABORATO; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; 1995, CANCER FACTS FIGURES, P10	32	277	280	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					137	142		10.1056/NEJM199601183340301	http://dx.doi.org/10.1056/NEJM199601183340301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531967				2022-12-28	WOS:A1996TQ01700001
J	Boismenu, R; Rhein, M; Fischer, WH; Havran, WL				Boismenu, R; Rhein, M; Fischer, WH; Havran, WL			A role for CD81 in early T cell development	SCIENCE			English	Article							RECEPTOR-BETA-CHAIN; TAPA-1; TCR; RESTORATION; CD3-EPSILON; ANTIBODY; PROTEINS; IMMATURE; SURFACE; THYMUS	Early stages of T cell development are thought to include a series of coordinated interactions between thymocytes and other cells of the thymus. A monoclonal antibody specific for mouse CD81 was identified that blocked the appearance of alpha beta but nor gamma delta T cells in fetal organ cultures initiated with day 14.5 thymus lobes. In reaggregation cultures with CD81-transfected fibroblasts, CD4(-)CD8(-) thymocytes differentiated into CD4(+)CD8(+) T cells, Thus, interactions between immature thymocytes and stromal cells expressing CD81 are required and may be sufficient to induce early events associated with T cell development.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Salk Institute					NIAID NIH HHS [AI32751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032751, R29AI032751, R21AI032751] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1982, J IMMUNOL, V129, P2293; Alschul S F, 1990, J Mol Biol, V215, P403; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; BOISMENU R, UNPUB; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Jenkinson E J, 1990, Semin Immunol, V2, P51; JENKINSON EJ, 1994, CURR OPIN IMMUNOL, V6, P293, DOI 10.1016/0952-7915(94)90104-X; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISLELOW P, 1995, ADV IMMUNOL, V58, P87; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVY S, 1991, J BIOL CHEM, V266, P14597; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; STEEDMAN HF, 1957, NATURE, V179, P1345, DOI 10.1038/1791345a0; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	26	92	94	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					198	200		10.1126/science.271.5246.198	http://dx.doi.org/10.1126/science.271.5246.198			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539618				2022-12-28	WOS:A1996TP36400040
J	Barton, K; Muthusamy, N; Chanyangam, M; Fischer, C; Clendenin, C; Leiden, JM				Barton, K; Muthusamy, N; Chanyangam, M; Fischer, C; Clendenin, C; Leiden, JM			Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB	NATURE			English	Article							CYCLIC-AMP; T-CELLS; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; NUCLEAR FACTOR; BINDING; PHOSPHORYLATION; PROTEIN; GENE; FOS	THE basic/leucine zipper (bZip) transcription factor, CREB, binds to the CRE element (TGANNTCA)(1-5). The transcriptional activity of CREB requires phosphorylation of the protein on a serine residue at position 119 (ref. 6). CREs are present in a number of T-cell genes(7,8) but the precise role of CREB in T-cell differentiation and function was unknown. Here we show that resting thymocytes contain predominantly unphosphorylated (inactive) CREB, which is rapidly activated by phosphorylation on Ser 119 following thymocyte activation. T-cell development is normal in transgenic mice that express a dominant-negative form of CREB (CREB(A119), with alanine at position 119) under the control of the T-cell-specific CD2 promoter/enhancer. In contrast, thymocytes and T cells from these animals display a profound proliferative defect characterized by markedly decreased interleukin-2 production, G1 cell-cycle arrest and subsequent apoptotic death in response to a number of different activation signals. This proliferative defect is associated with the markedly reduced induction of c-jun, c-fos, Fra-2 and FosB following activation of the CREB(A119), transgenic thymocytes. We propose that T-cell activation leads to the phosphorylation and activation of CREB, which in turn is required for normal induction of the transcription factor AP1 and subsequent interleukin-2 production and cell-cycle progression.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago			Muthusamy, Natarajan/A-6915-2009					BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CALAME K, 1988, ADV IMMUNOL, V43, P235; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; OTIR R, 1991, GENE EXPRESSION, V1, P55; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; VALLEJO MJ, 1994, NEUROENDOCRINOLOGY, V6, P587; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578	29	209	213	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	1996	379	6560					81	85		10.1038/379081a0	http://dx.doi.org/10.1038/379081a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538746				2022-12-28	WOS:A1996TN21600060
J	Takeuchi, Y; Porter, CD; Strahan, KM; Preece, AF; Gustafsson, K; Cosset, FL; Weiss, RA; Collins, MKL				Takeuchi, Y; Porter, CD; Strahan, KM; Preece, AF; Gustafsson, K; Cosset, FL; Weiss, RA; Collins, MKL			Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase	NATURE			English	Article							COMPLEMENT PATHWAY ACTIVATION; RNA TUMOR-VIRUSES; HUMAN-ANTIBODIES; LYSIS; INACTIVATION; ONCORNAVIRUSES; GLYCOPROTEINS; SPECIFICITY; RECEPTOR; ANTIGEN	MAMMALIAN C-type retroviruses are inactivated by human serum(1,2), following triggering of the classical complement cascade(3). This may have inhibited transmission to humans of C-type oncoviruses from other mammals(1). Indeed, the retroviruses human immunodeficiency virus and human T-cell leukaemia virus are resistant of human C1q, the first component of the classical pathway, by retroviral envelope proteins has been described(6). However, retroviruses produced from human cells are resistant to inactivation by human complement(7,8) and human serum is known to contain antibodies directed against carbohydrates on retroviral envelopes(9-11). Gal(alpha 1-3)Gal terminal carbohydrates are expressed by most mammals but are absent in humans, which lack a functional (alpha 1-3)galactosyltransferase gene (12,13). Here, we demonstrate that anti-Gal(alpha 1-3)Gal antibodies in human serum inactivate retroviruses produced from animal cells. Expression of porcine (alpha 1-3)galactosyltransferase(14,16) in human cells renders the cells and the retroviruses they produce sensitive to human serum.	UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Takeuchi, Y (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Cosset, François-Loïc/M-5862-2019	Cosset, François-Loïc/0000-0001-8842-3726				ALMEIDA IC, 1993, J CLIN LAB ANAL, V7, P307, DOI 10.1002/jcla.1860070603; BANAPOUR B, 1986, VIROLOGY, V152, P268, DOI 10.1016/0042-6822(86)90392-2; BARBACID M, 1979, P NATL ACAD SCI USA, V77, P1617; BARTHOLOMEW RM, 1978, J EXP MED, V147, P844, DOI 10.1084/jem.147.3.844; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; COOPER NR, 1976, J EXP MED, V144, P970, DOI 10.1084/jem.144.4.970; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; COSSET FL, IN PRESS J VIROL; FABRE JW, 1995, NAT MED, V1, P403, DOI 10.1038/nm0595-403; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GUSTAFSSON K, 1994, IMMUNOL REV, V141, P59, DOI 10.1111/j.1600-065X.1994.tb00872.x; HAMADEH RM, 1992, J CLIN INVEST, V89, P1223, DOI 10.1172/JCI115706; HIRSCH RL, 1981, J IMMUNOL, V127, P1740; HOSHINO H, 1984, NATURE, V310, P324, DOI 10.1038/310324a0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LOWER J, 1981, VIROLOGY, V109, P409, DOI 10.1016/0042-6822(81)90511-0; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MCKENZIE IF, 1968, LANCET, V2, P386; ORLOL R, 1993, TRANSPLANTATION, V56, P1433; REPIK PM, 1994, J GEN VIROL, V75, P1177, DOI 10.1099/0022-1317-75-5-1177; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SNYDER HW, 1980, P NATL ACAD SCI-BIOL, V77, P1622, DOI 10.1073/pnas.77.3.1622; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; WELSH RM, 1976, VIROLOGY, V74, P432, DOI 10.1016/0042-6822(76)90349-4; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; WELSH RM, 1977, J IMMUNOL, V118, P348	30	237	244	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					85	88		10.1038/379085a0	http://dx.doi.org/10.1038/379085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538747				2022-12-28	WOS:A1996TN21600061
J	KORNFELD, K; HOM, DB; HORVITZ, HR				KORNFELD, K; HOM, DB; HORVITZ, HR			THE KSR-1 GENE ENCODES A NOVEL PROTEIN-KINASE INVOLVED IN RAS-MEDIATED SIGNALING IN C-ELEGANS	CELL			English	Article							VULVAL CELL LINEAGES; CAENORHABDITIS-ELEGANS; MAP KINASE; LET-60; NEMATODE; PATHWAY; FATES; INDUCTION; ONCOGENE; DOMAINS	By screening for mutations that suppress the vulval defects caused by a constitutively active let gb ras gene, we identified six loss-of-function alleles of ksr-1, a novel C. elegans gene. Our genetic analysis showed ksr-1 positively mediates Ras signaling and functions downstream of or in parallel to let-60. In the absence of ksr-1 function, normal Ras signaling is impaired only slightly, suggesting ksr-1 may act to modulate, or in a branch that diverges from, the main signaling pathway. The predicted KSR-1 protein has a protein kinase domain and is most similar to a recently identified Drosophila protein involved in Ras signaling. We propose that the function of ksr-1 is evolutionarily conserved.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								Ausubel FM., 2006, ENZYMATIC MANIPULATI; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNER S, 1974, GENETICS, V77, P71; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARK SG, 1992, COLD SPRING HARB SYM, V57, P363, DOI 10.1101/SQB.1992.057.01.041; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FERGUSON EL, 1985, THESIS MIT CAMBRIDGE; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wood WB, 1988, NEMATODE CAENORHABDI; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742	52	234	250	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					903	913		10.1016/0092-8674(95)90206-6	http://dx.doi.org/10.1016/0092-8674(95)90206-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521514	Bronze			2022-12-28	WOS:A1995TK74500009
J	SNYDER, PM; PRICE, MP; MCDONALD, FJ; ADAMS, CM; VOLK, KA; ZEIHER, BG; STOKES, JB; WELSH, MJ				SNYDER, PM; PRICE, MP; MCDONALD, FJ; ADAMS, CM; VOLK, KA; ZEIHER, BG; STOKES, JB; WELSH, MJ			MECHANISM BY WHICH LIDDLES SYNDROME MUTATIONS INCREASE ACTIVITY OF A HUMAN EPITHELIAL NA+ CHANNEL	CELL			English	Article							INTERNALIZATION SIGNAL; CAENORHABDITIS-ELEGANS; PROTEIN	Liddle's syndrome is an inherited form of hypertension caused by mutations that truncate the C-terminus of human epithelial Na+ channel (hENaC) subunits, Expression of truncated beta and gamma hENaC subunits increased Na+ current, However, truncation did not alter single-channel conductance or open state probability, suggesting there were more channels in the plasma membrane. Moreover, truncation of the C-terminus of the beta subunit increased apical cell-surface expression of hENaC in a renal epithelium, We identified a conserved motif in the C-terminus of all three subunits that, when mutated, reproduced the effect of Liddle's truncations. Further, both truncation of the C-terminus and mutation of the conserved C-terminal motif increased surface expression of chimeric proteins containing the C-terminus of beta hENaC, Thus, by deleting a conserved motif, Liddle's mutations increase the number of Na+ channels in the apical membrane, which increases renal Na+ absorption and creates a predisposition to hypertension.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa	SNYDER, PM (corresponding author), UNIV IOWA, HOWARD HUGHES MED INST, COLL MED, IOWA CITY, IA 52242 USA.			Adams, Christopher/0000-0002-5795-7212; Welsh, Michael/0000-0002-1646-6206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025231] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07344] Funding Source: Medline; NIDDK NIH HHS [DK-25231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BOLEROVELEZ M, 1994, NEW ENGL J MED, V330, P178; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GORDON RD, 1995, NAT GENET, V11, P6, DOI 10.1038/ng0995-6; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; MCDONALD FJ, 1995, BIOCHEM J, V312, P491, DOI 10.1042/bj3120491; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; VOLK KA, 1995, IN PRESS J CLIN INVE; WILDE A, 1994, J BIOL CHEM, V269, P7131; YOKOYAMA WM, 1992, CURRENT PROTOCOLS IM	36	365	370	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					969	978		10.1016/0092-8674(95)90212-0	http://dx.doi.org/10.1016/0092-8674(95)90212-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521520	Bronze			2022-12-28	WOS:A1995TK74500015
J	PALLEN, M				PALLEN, M			GUIDE TO THE INTERNET - THE WORLD-WIDE-WEB	BRITISH MEDICAL JOURNAL			English	Article								The world wide web provides a uniform, user friendly interface to the Internet. Web pages can contain text and pictures and are interconnected by hypertext links. The addresses of web pages are recorded as uniform resource locators (URLs), transmitted by hypertext transfer protocol (HTTP), and written in hypertext markup language (HTML). Programs that allow you to use the web are available for most operating systems. Powerful on line search engines make it relatively easy to find information on the web. Browsing through the web-''net surfing''--is both easy and enjoyable. Contributing to the web is not difficult, and the web opens up new possibilities for electronic publishing and electronic journals.			PALLEN, M (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED MICROBIOL,LONDON EC1A 7BE,ENGLAND.		Pallen, Mark J./E-7619-2011	Pallen, Mark/0000-0003-1807-3657				BUSH V, E COMMUNICATION; GRAHAM AIS, 1995, HTML SOURCEBOOK; HARNAD S, 1995, ELECTRONIC PUBLISHIN; MORRIS M, 1995, HTML AUTHORING FUN P	4	73	73	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1552	1556		10.1136/bmj.311.7019.1552	http://dx.doi.org/10.1136/bmj.311.7019.1552			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520402	Green Published			2022-12-28	WOS:A1995TK21400030
J	BROWN, EM; VASSILEV, PM; HEBERT, SC				BROWN, EM; VASSILEV, PM; HEBERT, SC			CALCIUM-IONS AS EXTRACELLULAR MESSENGERS	CELL			English	Review									BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BROWN, EM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,75 FRANCIS ST,BOSTON,MA 02115, USA.							BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHEBABO SR, 1995, J PHYSL, V487, P686; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; ECKENHOFF RG, 1989, J CLIN INVEST, V84, P1295, DOI 10.1172/JCI114297; HEATH H, 1993, AM J HUM GENET, V53, P193; HEINEMANN U, 1977, EXP BRAIN RES, V27, P237; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; LUNDGREN S, 1994, EXP CELL RES, V212, P344, DOI 10.1006/excr.1994.1153; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NICHOLSON C, 1977, P NATL ACAD SCI USA, V74, P1287, DOI 10.1073/pnas.74.3.1287; REITZ RE, 1977, OBSTET GYNECOL, V50, P701; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SMITH JB, 1989, J BIOL CHEM, V264, P831; STABEL J, 1990, NEUROSCI LETT, V110, P60, DOI 10.1016/0304-3940(90)90787-A; STEWART AF, 1987, ENDOCRINOL METAB, P1317	20	149	155	1	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					679	682		10.1016/0092-8674(95)90180-9	http://dx.doi.org/10.1016/0092-8674(95)90180-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521484	Bronze			2022-12-28	WOS:A1995TH94800004
J	KOTLER, DP; ORENSTEIN, JM				KOTLER, DP; ORENSTEIN, JM			CHRONIC DIARRHEA AND MALABSORPTION ASSOCIATED WITH ENTEROPATHOGENIC BACTERIAL-INFECTION IN A PATIENT WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; INTESTINAL INFECTIONS; ESCHERICHIA-COLI; INFANTS		GEORGE WASHINGTON UNIV, SCH MED, WASHINGTON, DC 20052 USA	George Washington University	KOTLER, DP (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, ST LUKES ROOSEVELT HOSP CTR, GASTROINTESTINAL IMMUNOL SECT, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021414] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21414] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNOLLY GM, 1989, GUT, V30, P195, DOI 10.1136/gut.30.2.195; DOUGAN G, 1989, J GEN MICROBIOL, V135, P1397; KOTLER DP, 1987, DIGEST DIS SCI, V32, P129, DOI 10.1007/BF01297100; KOTLER DP, 1988, ADV INTERNAL MED, V34, P43; RENE E, 1989, DIGEST DIS SCI, V34, P773, DOI 10.1007/BF01540353; ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441; ROTHBAUM RJ, 1983, ULTRASTRUCT PATHOL, V4, P291, DOI 10.3109/01913128309140582; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15	9	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					127	128		10.7326/0003-4819-119-2-199307150-00006	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512161				2022-12-28	WOS:A1993LU90200006
J	RIVO, ML				RIVO, ML			INTERNAL-MEDICINE AND THE JOURNEY TO MEDICAL GENERALISM	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE REFORM; RESIDENCY PROGRAMS; PHYSICIANS; CURRICULUM; EDUCATION; ELECTION; SYSTEM; CHOICE	The overspecialized U.S. physician workforce and mix of graduating residents undermine strategies to provide quality and affordable health care to all Americans. Several respected advisory bodies have recently proposed fundamental changes in federal policy to better match physician supply and specialty mix with health care needs. They recommend that Congress limit the total number of filled first-year resident positions to 110% of the number of U.S. medical school graduates, a 20% reduction from current levels. They have proposed that positions and funding be allocated to medical schools, teaching hospitals, residency programs, or consortia of such entities to ensure that at least 50% of each graduating residency class enters generalist practice. An all-payer, graduate medical education pool and financing system have been suggested as ways to uncouple the physician workforce from hospital service needs and to eliminate disincentives toward ambulatory and primary care training. Increases in generalist production must be accompanied by decreases in nonprimary care specialty and subspecialty positions. In addition, generalist physicians must be better prepared in managed care competencies. Given today's subspecialist surplus, managed care organizations are considering how to retrain subspecialists as generalists. The Federated Council of Internal Medicine's goal that 50% of its graduates become general internists is an important step because internists compose one sixth of all physicians and one third of all first-year residents. This article identifies the challenges that lay ahead on the road to medical generalism and what it may take to get there.			RIVO, ML (corresponding author), US HLTH RESOURCES & SERV ADM, BUR HLTH PROFESS,DIV MED,5600 FISHERS LANE, PARKLAWN BLDG, ROOM 4C-25, ROCKVILLE, MD 20857 USA.							ALTMAN SH, 1992, P NATIONAL PRIMARY C, V5, P66; BLANK LL, 1992, ANN INTERN MED, V117, P778; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V268, P3371, DOI 10.1001/jama.268.23.3371; BUDETTI PP, 1993, JAMA-J AM MED ASSOC, V269, P498, DOI 10.1001/jama.269.4.498; BURKE W, 1992, ANN INTERN MED, V116, P1065, DOI 10.7326/0003-4819-116-12-1065; CHERKIN DC, 1986, MED CARE, V24, P1136, DOI 10.1097/00005650-198612000-00006; CLINTON B, 1992, NEW ENGL J MED, V327, P804, DOI 10.1056/NEJM199209103271112; CORRIGAN JM, 1992, J FAM PRACTICE, V35, P543; DODGSON CL, 1963, ALICE IN WONDERLAND; EARLEY LE, 1992, ANN INTERN MED, V116, P1080, DOI 10.7326/0003-4819-116-12-1080; ENTHOVEN AC, 1993, HLTH AFFAIRS S, V12, P26; FEDERMAN DD, 1992, ANN INTERN MED, V116, P1061, DOI 10.7326/0003-4819-116-12-1061; FELTOVICH J, 1989, ACAD MED, V64, P36, DOI 10.1097/00001888-198901000-00015; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GINZBERG E, 1992, NEW ENGL J MED, V327, P1310, DOI 10.1056/NEJM199210293271812; GLASSOCK RJ, 1991, ANN INTERN MED, V114, P59, DOI 10.7326/0003-4819-114-1-59; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; JONAS HS, 1992, JAMA-J AM MED ASSOC, V268, P1083, DOI 10.1001/jama.268.9.1083; KLETKE PR, 1987, ANN INTERN MED, V107, P93, DOI 10.7326/0003-4819-107-1-93; LIPKIN M, 1990, ANN INTERN MED, V112, P371, DOI 10.7326/0003-4819-112-5-371; LUNDBERG GD, 1992, JAMA-J AM MED ASSOC, V268, P2082; MACY J, 1992, SEP C GRAD MED ED NE; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; MULLAN F, 1992, MILBANK Q, V70, P381, DOI 10.2307/3350065; MURRAY JL, 1992, ACAD MED, V67, P8, DOI 10.1097/00001888-199201000-00002; NOBLE J, 1992, ANN INTERN MED, V116, P482, DOI 10.7326/0003-4819-116-6-482; NOLAN JP, 1992, ANN INTERN MED, V116, P1042, DOI 10.7326/0003-4819-116-12-1042; NUCKOLLS JG, 1992, ANN INTERN MED, V116, P1051, DOI 10.7326/0003-4819-116-12-1051; PETERSDORF RG, 1992, AM J DIS CHILD, V146, P1338, DOI 10.1001/archpedi.1992.02160230096027; PETERSDORF RG, 1993, ACAD MED, V68, P113, DOI 10.1097/00001888-199302000-00001; RELMAN AS, 1992, KEY REPORTER, V58, P1; SCHROEDER SA, 1993, ACAD MED, V68, P118, DOI 10.1097/00001888-199302000-00002; SCHROEDER SA, 1992, ANN INTERN MED, V116, P583, DOI 10.7326/0003-4819-116-7-583; SCHROEDER SA, 1992, HLTH AFF MILLWOO SPR, P235; SWANSON AG, 1991, ACAD MED, V66, P632, DOI 10.1097/00001888-199110000-00027; THOMPSON JS, 1992, ANN INTERN MED, V116, P1084, DOI 10.7326/0003-4819-116-12-1084; WARTMAN SA, 1992, ANN INTERN MED, V116, P1071, DOI 10.7326/0003-4819-116-12-1071; WEINER JP, 1992, EFFECTS FUTURE HLTH; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNBERG J, IN PRESS HLTH AFF MI; 1991, HLTH AM PRACTITIONER; 1992, IMPROVING ACCESS HLT; 1993, PRIMARY CARE WORKFOR; 1991, HLTH PERSONNEL US 8T, P13; 1992, DIRECTORY PRIMARY CA; 1993 ANN REPORT C; 1989, JAMA-J AM MED ASSOC, V262, P2119; 1993, DIRECTORY GRADUATE M; 1992, NATIONAL STUDY INTER; 1992, HMO IND PROFILE, P61; 1993, RECRUITMENT EXPERIEN; 1992, 1992 ASS AM MED COLL	54	47	47	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					146	152		10.7326/0003-4819-119-2-199307150-00009	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512163				2022-12-28	WOS:A1993LU90200009
J	BOYLE, L; ONEILL, SL; ROBERTSON, HM; KARR, TL				BOYLE, L; ONEILL, SL; ROBERTSON, HM; KARR, TL			INTERSPECIFIC AND INTRASPECIFIC HORIZONTAL TRANSFER OF WOLBACHIA IN DROSOPHILA	SCIENCE			English	Article							CYTOPLASMIC INCOMPATIBILITY; POPULATIONS; SIMULANS	Cytoplasmic incompatibility (CI) in Drosophila simulans is related to infection of the germ line by a rickettsial endosymbiont (genus Wolbachia). Wolbachia were transferred by microinjection of egg cytoplasm into uninfected eggs of both D. simulans and D. melanogaster to generate infected populations. Transinfected strains of D. melanogaster with lower densities of Wolbachia than the naturally infected D. simulans strain did not express high levels of CI. However, transinfected D. melanogaster egg cytoplasm, transferred back into D. simulans, generated infected populations that expressed CI at levels near those of the naturally infected strain. A transinfected D. melanogaster line selected for increased levels of CI expression also displayed increased symbiont densities. These data suggest that a threshold level of infection is required for normal expression of CI and that host factors help determine the density of the symbiont in the host.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT ENTOMOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			O'Neill, Scott/R-9560-2019; Karr, Timothy L/G-1693-2011; O'Neill, Scott L/B-3568-2009	O'Neill, Scott/0000-0002-4131-3615; O'Neill, Scott L/0000-0002-4131-3615				ASHBURNER M, 1989, LABORATORY MANUAL, P228; BOYLE LA, UNPUB; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, IN PRESS GENETICS; FRENCH WL, 1978, GENETICS, V88, P447; HOFFMAN AA, 1992, GENETICS, V132, P713; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOFFMANN AA, 1988, ENTOMOL EXP APPL, V48, P61, DOI 10.1007/BF00343386; JOST E, CAN J GENET CYTOL, V13, P237; KARR TL, UNPUB; NIGRO L, 1991, HEREDITY, V66, P41, DOI 10.1038/hdy.1991.5; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V250, P91, DOI 10.1098/rspb.1992.0135; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; STEVENS L, 1990, GENETICS, V124, P367	18	262	279	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1796	1799		10.1126/science.8511587	http://dx.doi.org/10.1126/science.8511587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511587				2022-12-28	WOS:A1993LH20500047
J	GU, H; ZOU, YR; RAJEWSKY, K				GU, H; ZOU, YR; RAJEWSKY, K			INDEPENDENT CONTROL OF IMMUNOGLOBULIN SWITCH RECOMBINATION AT INDIVIDUAL SWITCH REGIONS EVIDENCED THROUGH CRE-IOXP-MEDIATED GENE TARGETING	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; EMBRYONIC STEM-CELLS; HEAVY-CHAIN GENES; B-CELLS; CIRCULAR DNA; LYMPHOID-CELLS; IGH LOCI; SEQUENCE; MOUSE; EXPRESSION	We have employed a method based on the Cre-IoxP recombination system of bacteriophage Pl to generate a mouse strain in which the J(H) segments and the intron enhancer in the IgH locus are deleted. By analysis of immunoglobulin isotype switch recombination in heterozygous mutant B cells activated by lipopolysaccharide plus interleukin-4, we show that, on the mutant chromosome, switch recombination at the mu gene switch region is strongly suppressed, whereas the switch region of the gamma1 gene is efficiently rearranged. These data demonstrate an independent control of switch recombination at individual switch regions and suggest that, in the process of switch recombination, the alignment of the recombining strands occurs independently of and probably after the introduction of double-strand breaks into the switch regions involved.			GU, H (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, W-5000 COLOGNE 41, GERMANY.							AKIRA S, 1984, EMBO J, V3, P677, DOI 10.1002/j.1460-2075.1984.tb01866.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CORY S, 1980, NATURE, V285, P450, DOI 10.1038/285450a0; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GRITZMACHER CA, 1989, CRIT REV IMMUNOL, V9, P173; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; Honjo T., 1989, Immunoglobulin genes., P123; HONJO T, 1978, P NATL ACAD SCI USA, V75, P2140, DOI 10.1073/pnas.75.5.2140; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HUMMEL M, 1987, J IMMUNOL, V138, P3539; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; LEUNG H, 1992, P NATL ACAD SCI USA, V89, P4154, DOI 10.1073/pnas.89.9.4154; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; RABBITTS TH, 1980, NATURE, V283, P351, DOI 10.1038/283351a0; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; Sambrook J, 1989, MOL CLONING LABORATO; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAUER B, 1990, New Biologist, V2, P441; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZER J, 1984, CURR TOP MICROBIOL, V113, P109; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; SZUREK P, 1985, J IMMUNOL, V135, P620; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x	56	795	884	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1155	1164		10.1016/0092-8674(93)90644-6	http://dx.doi.org/10.1016/0092-8674(93)90644-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513499				2022-12-28	WOS:A1993LH54800011
J	PECULIS, BA; STEITZ, JA				PECULIS, BA; STEITZ, JA			DISRUPTION OF U8 NUCLEOLAR SNRNA INHIBITS 5.8S AND 28S RIBOSOMAL-RNA PROCESSING IN THE XENOPUS-OOCYTE	CELL			English	Article							SMALL NUCLEAR-RNA; PRE-RIBOSOMAL-RNA; EXTERNAL TRANSCRIBED SPACER; U3 SNRNA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; LAEVIS OOCYTES; YEAST; FIBRILLARIN	The nucleoli of vertebrate cells contain several snRNPs, of which only one, U3, has been assigned a role in rRNA processing. We present the primary sequence of Xenopus U8, a fibrillarin-associated nucleolar snRNA, and examine its expression through oocyte development. Antisense deoxyoligonucleotides were microinjected into Xenopus oocytes to deplete the endogenous pool of U8 RNA. Analysis of the mature rRNAs and rRNA intermediates that accumulate in the U8-depleted oocytes indicate that the U8 snRNP is essential for correct maturation of the 5.8S and 28S rRNAs at both their 5' and 3' ends. U8 is therefore a nucleolar snRNA implicated in a nucleolytic rRNA processing step other than 18S maturation. Evidence for a long-lived 5.8S rRNA intermediate (12S) in Xenopus is also presented.			PECULIS, BA (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536, USA.				NIGMS NIH HHS [GM26154, GM14529-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026154, F32GM014529, R01GM026154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW C, 1976, MOL GEN GENET, V144, P29, DOI 10.1007/BF00277300; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BOWMAN LH, 1983, MOL CELL BIOL, V3, P1501, DOI 10.1128/MCB.3.8.1501; CAIZERGUESFERRER M, 1991, DEVELOPMENT, V112, P317; Davidson E. H., 1976, GENE ACTIVITY EARLY; DAWID IB, 1976, CELL, V8, P443, DOI 10.1016/0092-8674(76)90157-4; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GORENSTEIN C, 1977, MOL GEN GENET, V157, P327, DOI 10.1007/BF00268670; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JEPPESEN C, 1988, NUCLEIC ACIDS RES, V16, P2127, DOI 10.1093/nar/16.5.2127; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1985, EUR J BIOCHEM, V152, P259, DOI 10.1111/j.1432-1033.1985.tb09192.x; KRAINER AR, 1988, NUCLEIC ACIDS RES, V16, P9415, DOI 10.1093/nar/16.20.9415; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIU J, 1990, NUCLEIC ACIDS RES, V18, P6565, DOI 10.1093/nar/18.22.6565; LONG EO, 1980, J MOL BIOL, V138, P873, DOI 10.1016/0022-2836(80)90070-4; LUND E, 1987, GENE DEV, V1, P39, DOI 10.1101/gad.1.1.39; Maniatis T., 1982, MOL CLONING; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MAXWELL ES, 1986, P NATL ACAD SCI USA, V83, P7261, DOI 10.1073/pnas.83.19.7261; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; RAZIUDDIN R D L, 1989, Molecular and Cellular Biology, V9, P1667; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; REDDY R, 1979, J BIOL CHEM, V254, P1097; REDDY R, 1985, J BIOL CHEM, V260, P930; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; ROSBASH M, 1974, J MOL BIOL, V85, P87, DOI 10.1016/0022-2836(74)90131-4; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SHASTRY BS, 1984, J BIOL CHEM, V259, P1373; SHUMARD CM, 1990, MOL CELL BIOL, V10, P3868, DOI 10.1128/MCB.10.8.3868; Silberklang M, 1979, Methods Enzymol, V59, P58; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1993, IN PRESS GENES DEV, V7; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P4847, DOI 10.1093/nar/9.19.4847; WISE JA, 1980, CELL, V22, P109, DOI 10.1016/0092-8674(80)90159-2; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	56	217	219	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1233	1245		10.1016/0092-8674(93)90651-6	http://dx.doi.org/10.1016/0092-8674(93)90651-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513505				2022-12-28	WOS:A1993LH54800018
J	ADES, AE; DAVISON, CF; HOLLAND, FJ; GIBB, DM; HUDSON, CN; NICHOLL, A; GOLDBERG, D; PECKHAM, CS				ADES, AE; DAVISON, CF; HOLLAND, FJ; GIBB, DM; HUDSON, CN; NICHOLL, A; GOLDBERG, D; PECKHAM, CS			VERTICALLY TRANSMITTED HIV-INFECTION IN THE BRITISH-ISLES	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; AIDS	Objective-To describe the epidemiology of vertically acquired HIV infection in the British Isles, the level of underreporting, the vertical transmission rate, and clinical spectrum of paediatric AIDS. Design--Confidential, linked registers based on reporting from obstetricians and paediatricians; anonymous unlinked neonatal HIV serosurveys. Setting-British Isles. Subjects-Children born to mothers with HIV infection. Main outcome measures-Trends in HIV infection and vertical transmission rate. Results-In Scotland and the Irish Republic, where most maternal HIV infection is related to drug misuse, the annual number of reports of children born to infected mothers has fallen since 1989. In England and Wales nearly half of maternal infections have been acquired overseas, and the number of children born to these women, and to women who became infected in Britain, is increasing. In south east England the proportion of live births to women whose infection was identified before delivery was only 17% (50/287), compared with 68% (26/38) in Scotland. The vertical transmission rate was 13.7% (23/168), and 23% of infected children developed AIDS in the first year of life. 41% (38/92) of children born to infected mothers who were ascertained after delivery were breast fed, compared with 5% (12/236) of those ascertained before delivery. Conclusions-The incidence of vertically transmitted HIV infection is increasing in England and Wales. More extensive antenatal testing would enable infected women to be counselled against breast feeding, which could prevent a substantial proportion of vertical transmission in some areas, and would increase opportunities for early diagnosis and treatment of infected children.	ST BARTHOLOMEWS HOSP,DEPT OBSTET & GYNAECOL,LONDON EC1A 7BE,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,CTR AIDS,LONDON NW9 5EQ,ENGLAND; RUCHILL HOSP,COMMUNICABLE DIS SCOTLAND UNIT,GLASGOW G20 9NB,SCOTLAND	University of London; Queen Mary University London; Public Health England	ADES, AE (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,DIV PUBL HLTH,LONDON WC1N 1EH,ENGLAND.			Gibb, Diana/0000-0002-9738-5490				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; ADES AE, 1992, AIDS, P1031; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; DAVISON CF, 1989, LANCET, V2, P1442; DAVISON CF, 1993, AIDS CARE, V5, P135, DOI 10.1080/09540129308258593; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; HALL SM, 1990, ARCH DIS CHILD, V65, P807, DOI 10.1136/adc.65.7.807; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; JONES DS, 1992, PEDIATRICS, V89, P123; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; Lynn R, 1992, Commun Dis Rep CDR Rev, V2, pR145; ROUZIOUX C, 1992, 8TH INT C AIDS AMST; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TAPPIN DM, 1991, LANCET, V337, P1565; THOMAS P, 1992, PEDIATR INFECT DIS J, V11, P34, DOI 10.1097/00006454-199201000-00009; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; 1993, 9305 COMM DIS UN COM; 1993, COMMUNICABLE DISEASE, V3, P20; 1992, AIDS SCOTLAND, V7, P1; 1991, LANCET, V337, P253; 1992, NATIONAL STUDY HIV P; 1987, MMWR, V15, P225	26	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1296	1299		10.1136/bmj.306.6888.1296	http://dx.doi.org/10.1136/bmj.306.6888.1296			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518568	Green Published			2022-12-28	WOS:A1993LC72200018
J	Caron, H; vanSluis, P; deKraker, J; Bokkerink, J; Egeler, M; Laureys, G; Slater, R; Westerveld, A; Voute, PA; Versteeg, R				Caron, H; vanSluis, P; deKraker, J; Bokkerink, J; Egeler, M; Laureys, G; Slater, R; Westerveld, A; Voute, PA; Versteeg, R			Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CELLULAR DNA CONTENT; NEURO-BLASTOMA; CHILDHOOD NEUROBLASTOMA; MYC; HETEROZYGOSITY; ONCOGENE; TUMOR	Background. Neuroblastoma is a childhood tumor derived from cells of the neural crest, with a widely variable outcome. Differences in the behavior and prognosis of the tumor suggest that neuroblastoma can be divided into several biologic subgroups. We evaluated the most frequent genetic abnormalities in neuroblastoma to determine their prognostic value. Methods. We used Southern blot analysis to study the allelic loss of chromosomes 1p, 4p, 11q, and 14q, the duplication of chromosome 17q, and the amplification of the N-myc oncogene in 89 neuroblastomas. We also determined the nuclear DNA content of the tumor cells. Results. Allelic loss of chromosome 1p, N-myc amplification, and extra copies of chromosome 17q were significantly associated with unfavorable outcomes. In a multivariate analysis, loss of chromosome Ip was the most powerful prognostic factor. It provided strong prognostic information when it was included in multivariate models containing the prognostic factors of age and stage or serum ferritin level and stage. Among the patients with stage I, II, or IVS disease, the mean (+/-SD) three-year event-free survival was 100 percent in those without allelic loss of chromosome Ip and 34 +/- 15 percent in those with such loss; the rates of three-year event-free survival among the patients with stage III and stage IV disease were 53 +/- 10 percent and 0 percent, respectively. Conclusions. The loss of chromosome 1p is a strong prognostic factor in patients with neuroblastoma, independently of age and stage. It reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable. More intensive therapy may be considered in these patients. Patients in stages III and IV with allelic loss of chromosome 1p have a very poor outlook, whereas those without such loss are at moderate risk. (C) 1996, Massachusetts Medical Society.	UNIV AMSTERDAM, ACAD MED CTR, INST HUMAN GENET, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV NIJMEGEN, CTR PEDIAT ONCOL SE NETHERLANDS, NIJMEGEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, SOPHIA KINDERZIEKENHUIS, ROTTERDAM, NETHERLANDS; STATE UNIV GHENT HOSP, INST HUMAN GENET, GHENT, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen; Erasmus University Rotterdam; Ghent University; Ghent University Hospital	Caron, H (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, EMMA KINDERZIEKENHUIS, DEPT PEDIAT ONCOL & HEMATOL, POB 22700, 1100 DE AMSTERDAM, NETHERLANDS.		laureys, genevieve/AAG-2390-2021; Bokkerink, J.P.M./L-4210-2015; Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388				AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; BERTHOLD F, 1992, AM J PEDIAT HEMATOL, V14, P207; BOURHIS J, 1991, CANCER RES, V51, P33; CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; CARON H, 1994, AM J HUM GENET, V55, P341; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CARON H, 1993, NAT GENET, V4, P431, DOI 10.1038/ng0893-431a; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1992, CANCER RES, V52, P1780; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; JOSHI VV, 1992, CANCER-AM CANCER SOC, V69, P2197, DOI 10.1002/1097-0142(19920415)69:8<2197::AID-CNCR2820690829>3.0.CO;2-X; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SHUSTER JJ, 1992, AM J CLIN ONCOL-CANC, V15, P295, DOI 10.1097/00000421-199208000-00004; SILBER JH, 1991, CANCER RES, V51, P1426; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VOUTE PA, 1992, CANCER CHILDREN CLIN	25	327	331	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					225	230		10.1056/NEJM199601253340404	http://dx.doi.org/10.1056/NEJM199601253340404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8531999	Green Published			2022-12-28	WOS:A1996TQ75500004
J	Massy, ZA; Keane, WF; Kasiske, BL				Massy, ZA; Keane, WF; Kasiske, BL			Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?	LANCET			English	Article							FAMILIAL HYPERCHOLESTEROLEMIA; PRAVASTATIN; LOVASTATIN; CHOLESTYRAMINE; INVIVO		UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55415	University of Minnesota System; University of Minnesota Twin Cities	Massy, ZA (corresponding author), HENNEPIN CTY MED CTR,DEPT MED,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.							CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CORSINI A, 1991, PHARMACOL RES, V23, P173, DOI 10.1016/S1043-6618(05)80119-7; DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166; ELMBERGER PG, 1991, J LIPID RES, V32, P935; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOTTO AM, 1995, CIRCULATION, V92, P646, DOI 10.1161/01.CIR.92.3.646; ILLINGWORTH DR, 1994, LANCET, V343, P1554, DOI 10.1016/S0140-6736(94)92945-9; Kasiske B. L., 1992, Journal of the American Society of Nephrology, V3, P843; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; NEUMAN A, 1995, J INVEST MED, V43, P269; ODONNELL MP, 1993, J CLIN INVEST, V91, P83, DOI 10.1172/JCI116204; PAN HY, 1990, J CLIN PHARMACOL, V30, P1128, DOI 10.1002/j.1552-4604.1990.tb01856.x; PAPPU AS, 1989, J LAB CLIN MED, V114, P554; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; SOMA MR, 1993, ARTERIOSCLER THROMB, V13, P571, DOI 10.1161/01.ATV.13.4.571; SUMI S, 1994, PANCREAS, V9, P657, DOI 10.1097/00006676-199409000-00018	18	153	159	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					102	103		10.1016/S0140-6736(96)90217-2	http://dx.doi.org/10.1016/S0140-6736(96)90217-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538301				2022-12-28	WOS:A1996TP28100016
J	Scarabin, PY; Billaud, E; PluBureau, G; Agher, R				Scarabin, PY; Billaud, E; PluBureau, G; Agher, R			HRT and ACE activity in postmenopausal women	LANCET			English	Letter							ANGIOTENSIN-CONVERTING ENZYME		HOP BROUSSAIS,SERV PHARMACOL,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Scarabin, PY (corresponding author), HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE.							BONITHONKOPP C, 1994, CIRCULATION, V89, P952, DOI 10.1161/01.CIR.89.3.952; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					122	122		10.1016/S0140-6736(96)90248-2	http://dx.doi.org/10.1016/S0140-6736(96)90248-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538318				2022-12-28	WOS:A1996TP28100050
J	Dewji, NN; Singer, SJ				Dewji, NN; Singer, SJ			Genetic clues to Alzheimer's disease	SCIENCE			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; TYROSINE-KINASE RECEPTOR; BETA-PEPTIDE; CELL-CELL; SEVENLESS; EXPRESSION; DROSOPHILA; ADHESION; LIGAND; BRIDE		UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Dewji, NN (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CRAS P, 1990, AM J PATHOL, V137, P241; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187	19	45	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					159	160		10.1126/science.271.5246.159	http://dx.doi.org/10.1126/science.271.5246.159			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539612				2022-12-28	WOS:A1996TP36400026
J	Strollo, PJ; Rogers, RM				Strollo, PJ; Rogers, RM			Current concepts: Obstructive sleep apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITIVE AIRWAY PRESSURE; EXCESSIVE DAYTIME SLEEPINESS; RESPIRATORY MOTOR-ACTIVITY; NASAL CPAP; PROTRIPTYLINE; TRACHEOSTOMY; EXPERIENCE; DEPRESSION; MORTALITY; RECOVERY				Strollo, PJ (corresponding author), UNIV PITTSBURGH,SCH MED,DIV PULM ALLERGY & CRIT CARE MED,440 SCAIFE HALL,3550 TERRACE ST,PITTSBURGH,PA 15261, USA.		Strollo, Patrick J/L-7062-2016					BERRY RB, 1991, CHEST, V99, P339, DOI 10.1378/chest.99.2.339; BONORA M, 1985, AM REV RESPIR DIS, V131, P41; BONORA M, 1984, AM REV RESPIR DIS, V130, P156; BONSIGNORE MR, 1994, EUR RESPIR J, V7, P786, DOI 10.1183/09031936.94.07040786; CARTWRIGHT R, 1991, SLEEP, V14, P546, DOI 10.1093/sleep/14.6.546; CLARK GT, 1993, AM REV RESPIR DIS, V147, P624, DOI 10.1164/ajrccm/147.3.624; COLT HG, 1991, CHEST, V100, P1542, DOI 10.1378/chest.100.6.1542; CONWAY WA, 1981, JAMA-J AM MED ASSOC, V246, P347, DOI 10.1001/jama.246.4.347; DAVIES RJO, 1990, EUR RESPIR J, V3, P509; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; EDINGER JD, 1993, SLEEP, V16, P678; EVELOFF SE, 1994, AM J RESP CRIT CARE, V149, P905, DOI 10.1164/ajrccm.149.4.8143054; FERBER R, 1994, SLEEP, V17, P378, DOI 10.1093/sleep/17.4.378; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; FLETCHER EC, 1990, CHEST, V98, P1497, DOI 10.1378/chest.98.6.1497; FLETCHER EC, 1995, AM J MED, V98, P118, DOI 10.1016/S0002-9343(99)80395-7; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; GUILLEMINAULT C, 1981, ARCH INTERN MED, V141, P985, DOI 10.1001/archinte.141.8.985; GUILLEMINAULT C, 1993, CHEST, V104, P781, DOI 10.1378/chest.104.3.781; HANZEL DA, 1991, CHEST, V100, P416, DOI 10.1378/chest.100.2.416; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HUDGEL DW, 1992, CHEST, V101, P541, DOI 10.1378/chest.101.2.541; JOHNSON NT, 1994, CHEST, V105, P278, DOI 10.1378/chest.105.1.278; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; LAMPHERE J, 1989, CHEST, V96, P1364, DOI 10.1378/chest.96.6.1364; LEVINSON PD, 1991, ARCH INTERN MED, V151, P455, DOI 10.1001/archinte.151.3.455; MATHUR R, 1995, ANN INTERN MED, V122, P174, DOI 10.7326/0003-4819-122-3-199502010-00003; NEILLY JB, 1992, J APPL PHYSIOL, V72, P100, DOI 10.1152/jappl.1992.72.1.100; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; PARTINEN M, 1988, CHEST, V93, P1199, DOI 10.1378/chest.93.6.1199; PROSISE GL, 1994, CHEST, V106, P180, DOI 10.1378/chest.106.1.180; RAJAGOPAL KR, 1984, ANN INTERN MED, V101, P491, DOI 10.7326/0003-4819-101-4-491; REEVESHOCHE MK, 1995, AM J RESP CRIT CARE, V151, P443, DOI 10.1164/ajrccm.151.2.7842204; RILEY RW, 1993, OTOLARYNG HEAD NECK, V108, P117, DOI 10.1177/019459989310800203; ROSEN RC, 1993, SLEEP, V16, P249, DOI 10.1093/sleep/16.3.249; SANDERS MH, 1993, AM REV RESPIR DIS, V147, P1169, DOI 10.1164/ajrccm/147.5.1169; SANDERS MH, 1990, CHEST, V98, P317, DOI 10.1378/chest.98.2.317; SANDERS MH, 1994, CHEST, V106, P774, DOI 10.1378/chest.106.3.774; SCHWAB RJ, IN PRESS AM J RESPIR; SHEPARD JW, 1990, MAYO CLIN PROC, V65, P1260, DOI 10.1016/S0025-6196(12)62750-5; SHEPARD JW, 1990, AM REV RESPIR DIS, V141, P1350, DOI 10.1164/ajrccm/141.5_Pt_1.1350; SHEPARD JW, 1991, SLEEP, V14, P361, DOI 10.1093/sleep/14.4.361; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; STILLER RA, 1994, CHEST, V105, P1306, DOI 10.1378/chest.105.5.1306; SULLIVAN CE, 1981, LANCET, V1, P862; SULLIVAN CE, 1985, CLIN CHEST MED, V6, P633; WOODSON BT, 1991, LARYNGOSCOPE, V101, P1318, DOI 10.1002/lary.5541011211; Yamashiro Y., 1994, CLIN PULM MED, V1, P250; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1990, INT CLASSIFICATION S, P52; 1994, SLEEP, V17, P744; 1994, AM J RESPIRR CRIT CA, V150, P1738	54	446	460	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					99	104		10.1056/NEJM199601113340207	http://dx.doi.org/10.1056/NEJM199601113340207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531966				2022-12-28	WOS:A1996TP36300007
J	Pharoah, P				Pharoah, P			Bed-sharing and sudden infant death	LANCET			English	Editorial Material							HONG-KONG				Pharoah, P (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; DAVIES DP, 1985, LANCET, V2, P1346; GRANTLEY M, 1993, BRIT MED J, V306, P16; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; 1995, COMBINED ORAL CONTRA	7	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					2	2		10.1016/S0140-6736(96)91547-0	http://dx.doi.org/10.1016/S0140-6736(96)91547-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531543				2022-12-28	WOS:A1996TN76200002
J	Simmons, AH; Michal, CA; Jelinski, LW				Simmons, AH; Michal, CA; Jelinski, LW			Molecular orientation and two-component nature of the crystalline fraction of spider dragline silk	SCIENCE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; LEAST-SQUARES ALGORITHM; L-ALANINE; RELAXATION; BEHAVIOR; FIBERS; SPIN	The molecular origin of the exceptional mechanical properties of spider silk is unclear. This paper presents solid-state H-2 nuclear magnetic resonance data from unoriented, oriented, and supercontracted fibers, indicating that the crystalline fraction of dragline silk consists of two types of alanine-rich regions, one that is highly oriented and one that is poorly oriented and less densely packed. A new model for the molecular-level structure of individual silk molecules and their arrangement in the fibers is proposed. These data suggest that it will be necessary to control the secondary structure of individual polymer molecules in order to obtain optimum properties in bio-inspired polymers.	CORNELL UNIV,CTR ADV TECHNOL BIOTECHNOL,ITHACA,NY 14853	Cornell University			Michal, Carl/G-5288-2012	Michal, Carl/0000-0002-5764-3221				AKASAKA K, 1983, J CHEM PHYS, V78, P3567, DOI 10.1063/1.445183; BATCHELDER LS, 1983, J AM CHEM SOC, V105, P2228, DOI 10.1021/ja00346a021; BLOOM M, 1980, CAN J PHYS, V58, P1510, DOI 10.1139/p80-196; CANDELAS GC, 1981, J EXP ZOOL, V216, P1, DOI 10.1002/jez.1402160102; Cunniff P.M., 1994, POLYM ADVAN TECHNOL, V5, P401; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DENNIS JE, 1981, ACM T MATH SOFTWARE, V7, P348, DOI 10.1145/355958.355965; DENNIS JE, 1981, ACM T MATH SOFTWARE, V7, P369, DOI 10.1145/355958.355966; DONG ZY, 1991, ARCH BIOCHEM BIOPHYS, V284, P53, DOI 10.1016/0003-9861(91)90262-H; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; GRUBB DP, UNPUB; JACKSON C, 1995, MACROMOLECULES, V28, P5975, DOI 10.1021/ma00121a042; Lehninger A., 1993, PRINCIPLES BIOCH; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; LOTZ B, 1974, J MOL BIOL, V87, P193, DOI 10.1016/0022-2836(74)90143-0; MELLO CM, 1994, ACS SYM SER, V554, P67; SCHAEFER DJ, 1995, MACROMOLECULES, V28, P1152, DOI 10.1021/ma00108a050; SIMMONS A, 1994, MACROMOLECULES, V27, P5235, DOI 10.1021/ma00096a060; STAUFFER SL, 1994, J ARACHNOL, V22, P5; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018; THIEL BL, 1994, BIOPOLYMERS, V34, P1089, DOI 10.1002/bip.360340812; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; WORK RW, 1982, J ARACHNOL, V10, P1; WORK RW, 1985, J EXP BIOL, V118, P379; WORK RW, 1982, TEXT RES J, V52, P349, DOI 10.1177/004051758205200508; WORK RW, 1977, TEXT RES J, V47, P650, DOI 10.1177/004051757704701003; XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120; [No title captured]	28	514	533	8	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					84	87		10.1126/science.271.5245.84	http://dx.doi.org/10.1126/science.271.5245.84			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539605				2022-12-28	WOS:A1996TP02200049
J	WOOSTER, R; BIGNELL, G; LANCASTER, J; SWIFT, S; SEAL, S; MANGION, J; COLLINS, N; GREGORY, S; GUMBS, C; MICKLEM, G; BARFOOT, R; HAMOUDI, R; PATEL, S; RICE, C; BIGGS, P; HASHIM, Y; SMITH, A; CONNOR, F; ARASON, A; GUDMUNDSSON, J; FICENEC, D; KELSELL, D; FORD, D; TONIN, P; BISHOP, DT; SPURR, NK; PONDER, BAJ; EELES, R; PETO, J; DEVILEE, P; CORNELISSE, C; LYNCH, H; NAROD, S; LENOIR, G; EGILSSON, V; BARKADOTTIR, RB; EASTON, DF; BENTLEY, DR; FUTREAL, PA; ASHWORTH, A; STRATTON, MR				WOOSTER, R; BIGNELL, G; LANCASTER, J; SWIFT, S; SEAL, S; MANGION, J; COLLINS, N; GREGORY, S; GUMBS, C; MICKLEM, G; BARFOOT, R; HAMOUDI, R; PATEL, S; RICE, C; BIGGS, P; HASHIM, Y; SMITH, A; CONNOR, F; ARASON, A; GUDMUNDSSON, J; FICENEC, D; KELSELL, D; FORD, D; TONIN, P; BISHOP, DT; SPURR, NK; PONDER, BAJ; EELES, R; PETO, J; DEVILEE, P; CORNELISSE, C; LYNCH, H; NAROD, S; LENOIR, G; EGILSSON, V; BARKADOTTIR, RB; EASTON, DF; BENTLEY, DR; FUTREAL, PA; ASHWORTH, A; STRATTON, MR			IDENTIFICATION OF THE BREAST-CANCER SUSCEPTIBILITY GENE BRCA2	NATURE			English	Article								IN Western Europe and the United States approximately 1 in 12 women develop breast cancer. A small proportion of breast cancer cases, in particular those arising at a young age, are attributable to a highly penetrant, autosomal dominant predisposition to the disease. The breast cancer susceptibility gene, BRCA2, was recently localized to chromosome 13q12-q13. Here we report the identification of a gene in which we have detected six different germline mutations in breast cancer families that are likely to be due to BRCA2. Each mutation causes serious disruption to the open reading frame of the transcriptional unit. The results indicate that this is the BRCA2 gene.	INST CANC RES,HADDOW LABS,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,HADDOW LABS,CRC CTR CELL & MOLEC BIOL,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; SANGER CTR,HINXTON CB10 1RQ,CAMBS,ENGLAND; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV GYNECOL ONCOL,DURHAM,NC 27710; UNIV HOSP ICELAND,CELL BIOL LAB,IS-121 REYKJAVIK,ICELAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,DIV HUMAN GENET,MONTREAL,PQ H3G 1A4,CANADA; IMPERIAL CANC RES FUND,GENET EPIDEMIOL LAB,LEEDS LS2 9LU,W YORKSHIRE,ENGLAND; ADDENBROOKES HOSP,CRC HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; LEIDEN UNIV,DEPT HUMAN GENET & PATHOL,2300 RA LEIDEN,NETHERLANDS; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED & PUBL HLTH,OMAHA,NE 68178; INT AGCY RES CANC,F-69372 LYON 08,FRANCE; UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,CRC GENET EPIDEMIOL GRP,CAMBRIDGE CB2 2SR,ENGLAND; WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA; WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Wellcome Trust Sanger Institute; Duke University; Duke University; Duke University; Landspitali National University Hospital; McGill University; McGill University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Leiden University; Leiden University - Excl LUMC; Creighton University; World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge; University of Toronto; University Toronto Affiliates; Womens College Hospital; Washington University (WUSTL)	WOOSTER, R (corresponding author), INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Narod, Steven A/AAA-6112-2022; Kelsell, David P/F-8767-2011; DEVILEE, PETER/ABR-2140-2022; Biggs, Patrick Jon/H-3355-2014	Biggs, Patrick Jon/0000-0002-0285-4101; Arason, Adalgeir/0000-0003-0480-886X; Bishop, Tim/0000-0002-8752-8785; Micklem, Gos/0000-0002-6883-6168; Kelsell, David/0000-0002-9910-7144; Gregory, Simon/0000-0002-7805-1743; Hamoudi, Rifat/0000-0002-1402-0868	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; EASTON DF, 1993, AM J HUM GENET, V52, P678; GAYPAY G, 1994, NAT GENET, V7, P246; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; NEHLS M, 1994, ONCOGENE, V9, P2169; SCHUTTE M, 1995, CANCER RES, V55, P4570; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	13	2616	2694	1	166	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					789	792		10.1038/378789a0	http://dx.doi.org/10.1038/378789a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524414				2022-12-28	WOS:A1995TL41900029
J	BEATO, M; HERRLICH, P; SCHUTZ, G				BEATO, M; HERRLICH, P; SCHUTZ, G			STEROID-HORMONE RECEPTORS - MANY ACTORS IN SEARCH OF A PLOT	CELL			English	Review							TRANSCRIPTION FACTORS; GLUCOCORTICOID RECEPTOR; GENE; PROTEIN; INVIVO; FINGER		FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,D-76021 KARLSRUHE,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; German Cancer Research Center (DKFZ)	BEATO, M (corresponding author), UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY.		Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BERKOFLINT Y, 1994, EMBO J, V13, P546; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUIOCHONMANTEL A, 1995, IN PRESS MOL ENDOCRI; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LI Q, 1995, MOL CELL BIOL, V15, P4375; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; ONATE SA, 1995, SCIENCE, V270, P1354; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REIK A, 1994, MOL ENDOCRINOL, V8, P490, DOI 10.1210/me.8.4.490; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TRUSS M, 1994, P NATL ACAD SCI USA, V91, P11333, DOI 10.1073/pnas.91.24.11333; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YAMAMOTO KR, 1993, TRANSCRIPTIONAL REGU, P3; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	66	1539	1580	1	41	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					851	857		10.1016/0092-8674(95)90201-5	http://dx.doi.org/10.1016/0092-8674(95)90201-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521509	Bronze			2022-12-28	WOS:A1995TK74500004
J	SAUER, F; HANSEN, SK; TJIAN, R				SAUER, F; HANSEN, SK; TJIAN, R			DNA-TEMPLATE AND ACTIVATOR-COACTIVATOR REQUIREMENTS FOR TRANSCRIPTIONAL SYNERGISM BY DROSOPHILA BICOID	SCIENCE			English	Article							GRADIENT MORPHOGEN; PROTEIN; CLONING; EMBRYO	The template and coactivator requirements for synergistic transcription directed by a single activator, Bicoid (BCD), bound to multiple sites have been determined. Mutagenesis studies in combination with protein binding experiments and reconstituted transcription reactions identified two independent activation domains of BCD that target different coactivator subunits (TAF(II)110 and TAF(II)60) of the basal transcription factor IID (TFIID). The presence of both coactivators is required for BCD to recruit the TATA binding protein (TBP)-TAF complex to the promoter and direct synergistic activation of transcription. Thus, contact between multiple activation domains of BCD and different targets within the TFIID complex can mediate transcriptional synergism.			SAUER, F (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, UNPUB; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; ZAWEL L, 1992, CURR OPIN CELL BIOL, V4	30	75	76	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1825	1828		10.1126/science.270.5243.1825	http://dx.doi.org/10.1126/science.270.5243.1825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525377				2022-12-28	WOS:A1995TK47600047
J	ZHOU, JM; LOH, YT; BRESSAN, RA; MARTIN, GB				ZHOU, JM; LOH, YT; BRESSAN, RA; MARTIN, GB			THE TOMATO GENE PTI1 ENCODES A SERINE/THREONINE KINASE THAT IS PHOSPHORYLATED BY PTO AND IS INVOLVED IN THE HYPERSENSITIVE RESPONSE	CELL			English	Article							PROTEIN-KINASE; ARABIDOPSIS-THALIANA; DISEASE RESISTANCE; PURIFICATION; ACTIVATION; CLONING	The Pto gene encodes a serine/threonine kinase that confers resistance to bacterial speck disease in tomato. Using the yeast two-hybrid system, we identified a second serine/threonine kinase, Pto-interacting 1 (Pti1), that physically interacts with Pto. Cross-phosphorylation assays revealed that Pto specifically phosphorylates Pti1 and that Pti1 does not phosphorylate Pto. Fen, another serine/threonine kinase from tomato that is closely related to Pto, was unable to phosphorylate Pti1 and was not phosphorylated by Pti1. Expression of a Pti1 transgene in tobacco plants enhanced the hypersensitive response to a P. syringae pv. tabaci strain carrying the avirulence gene avrPto. These findings indicate that Pti1 is involved in a Pto-mediated signaling pathway, probably by acting as a component downstream of Pto in a phosphorylation cascade.	PURDUE UNIV, DEPT AGRON, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT HORT, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Zhou, Jian-Min/A-3140-2013; Martin, Gregory B/F-6262-2011	Zhou, Jian-Min/0000-0002-9943-2975; Martin, Gregory B/0000-0003-0044-6830; Loh, Ying-Tsu/0000-0003-0833-4622; Bressan, Ray/0000-0002-8754-606X				BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CHOI KY, 1994, CELL, V78, P499; Cutt J. R., 1992, Genes involved in plant defense., P209; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DESPRES C, 1995, PLANT CELL, V7, P589, DOI 10.1105/tpc.7.5.589; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DWYER SC, 1995, IN PRESS BIOCH BIOPH; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Goodman R. N., 1994, HYPERSENSITIVE REACT; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Keen N. T., 1993, Biotechnology in plant disease control., P65; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MARTIN GB, 1995, IN PRESS PLANT MICRO, V1; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MORAN TV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P9, DOI 10.1016/0167-4781(93)90031-8; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; REYNOLDS A, 1989, CURRENT PROTOCOLS MO; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; ROMMENS CMT, 1995, PLANT CELL, V7, P1537, DOI 10.1105/tpc.7.10.1537; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Sambrook J, 1989, MOL CLONING LABORATO; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; THILMONY RL, 1995, PLANT CELL, V7, P1529, DOI 10.1105/tpc.7.10.1529; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; YU LM, 1993, PLANT J, V3, P805, DOI 10.1111/j.1365-313X.1993.00805.x	55	320	359	4	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					925	935		10.1016/0092-8674(95)90208-2	http://dx.doi.org/10.1016/0092-8674(95)90208-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521516	Bronze			2022-12-28	WOS:A1995TK74500011
J	PILLANS, P				PILLANS, P			BRONCHOSPASM ASSOCIATED WITH CISAPRIDE	BRITISH MEDICAL JOURNAL			English	Letter											PILLANS, P (corresponding author), UNIV OTAGO,SCH MED,DUNEDIN,NEW ZEALAND.		Pillans, Peter/G-8719-2013					MCCALLUM RW, 1991, AM J GASTROENTEROL, V86, P135; NOLAN P, 1990, LANCET, V336, P1443, DOI 10.1016/0140-6736(90)93140-K	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1472	1472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520336				2022-12-28	WOS:A1995TJ04400027
J	VOSS, M; KNOTTENBELT, JD; PEDEN, MM				VOSS, M; KNOTTENBELT, JD; PEDEN, MM			PATIENTS WHO REATTEND AFTER HEAD-INJURY - A HIGH-RISK GROUP	BRITISH MEDICAL JOURNAL			English	Article							TRAUMA	Objective-To assess risk factors for important neurosurgical effects in patients who reattend after head injury. Design-Retrospective study. Subject -606 patients who reattended a trauma unit after minor head injury. Main outcome measures-Intracranial abnormality detected on computed tomography or the need for neurosurgical intervention. Results-Five patients died: two from unrelated causes and three from raised intracranial pressure. On multiple regression analysis the only significant predictor for both abnormality on computed tomography (14.4% of reattenders) and the need for operation (5% of reattenders) was vault fracture seen on the skull radiograph (P<10(-6)); predictors for abnormal computed tomogram were a Glasgow coma scale score <15 at either first or second attendance (P<0.0001) and convulsion at second attendance (P<0.05); predictive for operation only was penetrating injury of the skull (P<10(-6)). On contingency table analysis these associations were confirmed. In addition significant associations with both abnormality on computed tomography and operation were focal neurological abnormality, weakness, or speech disturbance. Amnesia or loss of consciousness at the time of initial injury, personality change, and seizures were significantly associated only with abnormality on computed tomography. Headache, dizziness, nausea, and vomiting were common in reattenders but were found to have no independent significance. Conclusions-All patients who reattend after head injury should undergo computed tomography as at least 14% of scans can be expected to yield positive results. Where this facility is not available patients with predictors for operation should be urgently referred for neurosurgical opinion. Other patients can be readmitted and need referral only if symptoms persist despite symptomatic treatment or there is neurological deterioration while under observation. These patients are a high risk group and should be treated seriously.	GROOTE SCHUUR HOSP,TRAUMA UNIT,CAPE TOWN,SOUTH AFRICA; S AFRICAN MRC,CAPE TOWN,SOUTH AFRICA	University of Cape Town; South African Medical Research Council				Mary, Margaret/0000-0003-0872-9851				DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; GUSTAFFSON T, 1985, EPISTAT STATISTICAL; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; JONES RK, 1974, SURG NEUROL, V2, P101; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; 1990, SAS USERS GUIDE STAT; 1984, BRIT MED J, V288, P983	11	37	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1395	1398		10.1136/bmj.311.7017.1395	http://dx.doi.org/10.1136/bmj.311.7017.1395			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520273	Green Published			2022-12-28	WOS:A1995TG90200017
J	LEHN, JM				LEHN, JM			SUPRAMOLECULAR CHEMISTRY	SCIENCE			English	Article							MOLECULAR DEVICES; PERSPECTIVES; ORGANIZATION; RECOGNITION; COMPLEXES; LECTURE		UNIV STRASBOURG 1, F-67070 STRASBOURG, FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	LEHN, JM (corresponding author), COLL FRANCE, F-75231 PARIS 05, FRANCE.							AHLERS M, 1990, ANGEW CHEM INT EDIT, V29, P1269, DOI 10.1002/anie.199012691; Balzani V., 1991, SUPRAMOLECULAR PHOTO; BERNSTEIN J, IN PRESS STRUCTURE C; COLLET A, 1987, TETRAHEDRON, V43, P5725, DOI 10.1016/S0040-4020(01)87780-2; CONSTABLE EC, 1992, TETRAHEDRON, V48, P10013, DOI 10.1016/S0040-4020(01)89035-9; CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P1009, DOI 10.1002/anie.198810093; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; Diederich F., 1991, CYCLOPHANES; DIETRICHBUCHECKER C, 1990, TETRAHEDRON, V46, P503, DOI 10.1016/S0040-4020(01)85433-8; FAGAN PJ, 1992, SCI AM, V267, P48, DOI 10.1038/scientificamerican0792-48; Gokel G. W., 1991, CROWN ETHERS CRYPTAN; GUTSCHE CD, 1987, CALIXARENES, V43, P5725; KUNITAKE T, 1992, ANGEW CHEM INT EDIT, V31, P709, DOI 10.1002/anie.199207091; LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LEHN JM, 1978, PURE APPL CHEM, V50, P871, DOI 10.1351/pac197850090871; LEHN JM, 1985, SCIENCE, V227, P849, DOI 10.1126/science.227.4689.849; Lehn JM., 1973, STRUCT BONDING BERLI, V16, P1, DOI DOI 10.1017/BFB0004364; LINDSEY JS, 1991, NEW J CHEM, V15, P153; ORGEL LF, 1992, NATURE, V358, P2032; Ovchinnikov Y.A., 1974, MEMBRANE ACTIVE COMP; PEDERSEN CJ, 1988, ANGEW CHEM INT EDIT, V27, P1021, DOI 10.1002/anie.198810211; PHILP D, 1991, SYNLETT, P445; Rebek Julius Jr., 1992, Journal of Molecular Recognition, V5, P83, DOI 10.1002/jmr.300050302; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; SEEL C, 1992, ANGEW CHEM INT EDIT, V31, P528, DOI 10.1002/anie.199205281; SEEL C, 1993, TOP CURR CHEM, V165; TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381; VONKIEDROWSKI G, 1992, NACHR CHEM TECH LAB, V40, P578; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191	30	630	642	6	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1993	260	5115					1762	1763		10.1126/science.8511582	http://dx.doi.org/10.1126/science.8511582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511582				2022-12-28	WOS:A1993LH20500034
J	CONNOLLY, AM; SALMON, RL; LERVY, B; WILLIAMS, DH				CONNOLLY, AM; SALMON, RL; LERVY, B; WILLIAMS, DH			WHAT ARE THE COMPLICATIONS OF INFLUENZA AND CAN THEY BE PREVENTED - EXPERIENCE FROM THE 1989 EPIDEMIC OF H3N2 INFLUENZA-A IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-In an epidemic: to measure the incidence and risk of complications of influenza; to determine the effect of pre-existing disease on complications; to estimate vaccine uptake and efficacy. Design-Case-control study. Setting-Primary care: two group practices. Subjects-342 of the 395 cases of clinically diagnosed influenza reported to the general practice surveillance of infectious diseases scheme of the Public Health Laboratory Service during the 1989 epidemic, and 342 age and sex matched controls. Interventions-Examination of records. Main outcome measures-Documented recognised complications; hospital admission; previous vaccination. Results-Of 15 recognised complications, bronchitis was the commonest (rate 190.1/1000 cases) and significantly commoner in cases (summary odds ratio 9.7) after adjusting for higher consultation rates (mean 6.1 per annum v 4.2 among controls; p<0.0001). No deaths were recorded. The risk of bronchitis complicating influenza was higher in patients with pre-existing illnesses regarded as an indication for vaccination (odds ratio 3.3; p<0.0001). Observed vaccination efficacy in those with pre-existing illnesses and in elderly subjects was high (63% and 77% respectively) but uptake was low (4.5% and 6.1% respectively). Conclusions-Bronchitis complicates about one fifth of all cases of influenza presenting to general practitioners. Patients with pre-existing illnesses regarded as an indication for vaccination are particularly at risk. Vaccine uptake is extremely low, precluding an unequivocal demonstration of a protective effect.	PHLS,CTR COMMUNICABLE DIS SURVEILLANCE,WELSH UNIT,CARDIFF CF4 3QX,WALES; LLYS MEDDYG,THE SURGERY,SWANSEA SA6 6HU,WALES; EGLWYSBACH SURG,PONTYPRIDD CF37 2AA,M GLAM,WALES									Ashley J., 1991, Population Trends, P16; CAMPOSHILHO BSN, 1988, MULTLR MICROCOMPUTER; CATE TR, 1987, AM J MED, V82, P15, DOI 10.1016/0002-9343(87)90555-9; DAN BB, 1987, JAMA-J AM MED ASSOC, V257, P1094, DOI 10.1001/jama.257.8.1094; DEAN AD, 1990, EPI INFOR VERSION 5; FLEMING DM, 1990, BRIT J GEN PRACT, V40, P495; FLEMING DM, 1988, J ROY COLL GEN PRACT, V38, P159; GARDNER MJ, 1989, STATISTICS CONFIDENC; GRIST N, 1989, PRACTITIONER, V233, P56; HALL CB, 1986, PRACTICAL APPROACH I; MILLER DL, 1969, J HYG-CAMB, V67, P559, DOI 10.1017/S0022172400042005; NAGINGTON J, 1983, OXFORD TXB MED, V1; NICHOLSON KG, 1990, BRIT MED J, V301, P617, DOI 10.1136/bmj.301.6753.617; Palmer S R, 1991, CDR (Lond Engl Rev), V1, pR25; PALMER SR, 1990, MMWR-MORBID MORTAL W, V39, P913; SCHAFFNER W, 1987, AM J MED, V82, P61, DOI 10.1016/0002-9343(87)90566-3; SHANN F, 1990, LANCET, V335, P898, DOI 10.1016/0140-6736(90)90489-R; STUARTHA.CH, 1966, BRIT MED J, V1, P217, DOI 10.1136/bmj.1.5481.217; STUARTHA.CH, 1966, BRIT MED J, V1, P149, DOI 10.1136/bmj.1.5480.149; 1990, CMO909 CHIEF MED OFF	20	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1452	1454		10.1136/bmj.306.6890.1452	http://dx.doi.org/10.1136/bmj.306.6890.1452			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518643	Green Published, Bronze			2022-12-28	WOS:A1993LE93500020
J	SMITH, GD; SONG, FJ; SHELDON, TA				SMITH, GD; SONG, FJ; SHELDON, TA			CHOLESTEROL-LOWERING AND MORTALITY - THE IMPORTANCE OF CONSIDERING INITIAL LEVEL OF RISK	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; SECONDARY PREVENTION; CLINICAL-TRIALS; SERUM-CHOLESTEROL; MEN; HYPERCHOLESTEROLEMIA; LOVASTATIN; REDUCTION; THERAPY; DIET	Objective-To investigate the level of risk of death from coronary heart disease above which cholesterol lowering treatment produces net benefits. Design-Meta-analysis of results of randomised controlled trials of cholesterol lowering treatments. Methods-Published and unpublished data from all identified randomised controlled trials of cholesterol lowering treatments with six months or more follow up and with at least one death were included in the meta-analysis. The analyses were stratified by the rate of death from coronary heart disease in the control arms of the trials. Main outcome measures-Death from all causes, from coronary heart disease, and from causes other than coronary heart disease. Results-In the pooled analysis, net benefit in terms of total mortality from cholesterol lowering was seen only for trials including patients at very high initial risk of coronary heart disease (odds ratio 0.74; 95% confidence interval 0.60 to 0.92). In a medium risk group no net effect was seen, and in the low risk group there were adverse treatment effects (1.22; 1.06 to 1.42). In a weighted regression analysis a significant (p<0.001) trend of increasing benefit with increasing initial risk of coronary heart disease was shown. Raised mortality from causes other than coronary heart disease was seen in trials of drug treatment (1.21; 1.05 to 1.39) but not in the trials of non-drug treatments (1.02; 0.88 to 1.19). Cumulative meta-analysis showed that these results seem to have been stable as new trials appeared. Conclusion-Currently evaluated cholesterol lowering drugs seem to produce mortality benefits in only a small proportion of patients at very high risk of death from coronary heart disease. Population cholestrol screening could waste resources and even result in net harm in substantial groups of patients. Overall risk of coronary heart disease should be the main focus of clinical guidelines, and a cautious approach to the use of cholesterol lowering drugs should be advocated. Future trials should aim to clarify the level of risk above which treatment is of net benefit.	UNIV LEEDS, NUFFIELD INST HLTH, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; UNIV YORK, CTR HLTH ECON, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Leeds; University of York - UK	SMITH, GD (corresponding author), UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, SCOTLAND.		Sheldon, Trevor/AAK-7088-2021; Davey Smith, George/A-7407-2013; Song, Fujian/B-3516-2013	Sheldon, Trevor/0000-0002-7479-5913; Davey Smith, George/0000-0002-1407-8314; 				ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BARSOTTI A, 1993, ECHOCARDIOGRAPHY 199; BASINSKI A, 1989, JAMA-J AM MED ASSOC, V261, P2953, DOI 10.1001/jama.1989.03420200042020; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BETTERIDGE DJ, 1992, BRIT J HOSP MED, V47, P643; BETTERIDGE DJ, IN PRESS POSTGRAD ME; BETTERIDGE DJ, 1993, ISSUES HYPERLIPIDAEM, V4, P1; BETTERIDGE J, 1992, CARDIOLOGY PRACT MAY, P4; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRADFORD RH, 1990, AM J CARDIOL, V66, pB44, DOI 10.1016/0002-9149(90)90440-C; BRAND R, 1992, STAT MED, V11, P2077, DOI 10.1002/sim.4780111605; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BURR ML, 1989, LANCET, V2, P757; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COLLINS R, 1992, BRIT MED J, V304, P1689, DOI 10.1136/bmj.304.6843.1689; CRIQUI MH, 1991, ANN INTERN MED, V115, P973, DOI 10.7326/0003-4819-115-12-973; DAYTON S, 1969, CIRCULATION, V40, pII1; DEBONT AJ, 1981, DIABETOLOGIA, V21, P529, DOI 10.1007/BF00281543; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEWAR HA, 1972, BRIT MED J, V1, P506, DOI 10.1136/bmj.1.5798.506-a; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; DWYER JH, 1993, CIRCULATION, V87, P703; EDERER F, 1971, LANCET, V2, P203; FAIL PS, 1992, CLIN RES, V40, pA400; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLD P, 1992, CHOLESTEROL CORONARY; GOLDSTEIN MR, 1992, LANCET, V340, P127, DOI 10.1016/0140-6736(92)90461-B; GREEN KG, 1989, INT J EPIDEMIOL, V18, P355, DOI 10.1093/ije/18.2.355; GROSS L, 1973, J AM GERIATR SOC, V21, P552, DOI 10.1111/j.1532-5415.1973.tb01662.x; HARROLD BP, 1969, DIABETES, V18, P285, DOI 10.2337/diab.18.5.285; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HOLME I, 1993, BRIT HEART J, V69, pS42; HOUTSMUL.AJ, 1968, OPHTHALMOLOGICA, V156, P2, DOI 10.1159/000305357; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Leren P, 1966, Acta Med Scand Suppl, V466, P1; MACMAHON S, 1992, AUST NZ J MED, V22, P580, DOI 10.1111/j.1445-5994.1992.tb00481.x; MAGNANI HN, 1992, SCRIPS 1991 HYPOLIPA; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCAUGHAN D, 1981, ARCH INTERN MED, V141, P1428, DOI 10.1001/archinte.141.11.1428; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P607; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1961, LANCET, V2, P499; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEARCE ML, 1971, LANCET, V1, P464; PETO R, 1985, CIRCULATION, V72, P451; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Rose G., 1992, STRATEGY PREVENTIVE; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SCHMIDT JG, 1992, BRIT MED J, V305, P1226, DOI 10.1136/bmj.305.6863.1226-b; SCHOCH HK, 1968, ADV EXP MED BIOL, V4, P405; SHELDON TA, 1993, LANCET, V341, P100, DOI 10.1016/0140-6736(93)92569-F; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1992, BRIT MED J, V304, P913, DOI 10.1136/bmj.304.6831.913-a; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; SULLIVAN J, 1993, GP              0312, P12; TOBERT JA, 1992, BRIT MED J, V304, P713, DOI 10.1136/bmj.304.6828.713; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; YUSUF S, 1987, ATHEROSCLEROSIS, P389; 1971, BMJ, V4, P775; 1971, BMJ, V4, P767; 1992, METABOLISM CARDIOVAS, V2, P113; 1987, BR HEAT J, V57, P188	90	295	302	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1993	306	6889					1367	1373		10.1136/bmj.306.6889.1367	http://dx.doi.org/10.1136/bmj.306.6889.1367			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518602	Green Published, Bronze			2022-12-28	WOS:A1993LD82900017
J	Bailey, JE				Bailey, JE			Asklepios: Ancient hero of medical caring	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Western culture's demands of integrity, sacrifice, and compassion from its physician healers have roots in the mythic traditions of ancient Greece. By understanding these traditions, modern physicians can better understand their patients' expectations and the high expectations physicians often have for themselves. The mythic figure Asklepios was the focus of Greek and Roman medical tradition from approximately 1500 BC to 500 AD. As a physician-hero, Asklepios exemplified the ideal physician and the pitfalls he or she may face. With the progressive deification of Asklepios and the spread of his worship first in Greece and then in the Roman empire, Asklepios became generally recognized as the god of healing and served as an object of supplication, particularly for the poor and disregarded. Asklepian traditions for medical service provide historical insight into the role of modern physicians and their obligations to care for the underserved.			Bailey, JE (corresponding author), UNIV TENNESSEE, DEPT MED, 842 JEFFERSON AVE, ROOM A607, MEMPHIS, TN 38103 USA.							AELIANUS, 1945, ASCLEPIUS COLLECTION, V1, P164; APOLLODORUS, 1945, ASCLEPIUS COLLECTION, V1, P7; Aristides Aelius, 1973, ARISTIDES; ARISTOTLE, 1945, ASCLEPIUS COLLECTION, V1, P104; EDELSTEIN EJ, 1945, ASCLEPIUS COLLECTION, V2, P7; EDELSTEIN EJ, 1945, ASCLEPIUS COLLECTION, V2, P43; EDELSTEIN EJ, 1945, ASCLEPIUS COLLECTION, V2, P45; EDELSTEIN EJ, 1945, ASCLEPIUS COLLECTION, V2, P108; FARNELL LR, 1921, GREEK HERO CULTS IDE, P271; FARNELL LR, 1930, WORKS PINDAR, P96; FARNELL LR, 1921, GREEK HERO CULTS IDE, P248; FRAZER JG, 1921, APOLLODORUS, P22; GALEN, 1945, ASCLEPIUS COLLECTION, V1, P263; HERONDAS, 1945, ASCLEPIUS COLLECTION, V1, P272; HESIOD, 1920, HOMERIC HYMNS HOMERI, P440; HESIOD, 1920, HOMEIC HYMNS HOMERIC, P210; HESIOD, 1920, HOMERIC HYMNS HOMERI, V5, P440; HIPPOCRATES, 1923, PRECEPTS, V5, P319; HOMER, 1960, ILIAD, V194, P167; HOMER, 1925, ODYSSEY, V383, P179; HOMER, 1960, ILIAD, V514, P519; JONES WH, 1923, HIPPOCRATES, P44; JONSEN AR, 1990, NEW MED OLD ETHICS, P19; JULIAN, 1923, WORKS EMPEROR JULIAN, P258; JUSTIN, 1909, WRITINGS J MARTYR AT, P25; KERENYI, 1956, BOLLINGEN SERIES, V65, P7; KERENYI C, 1956, BOLLINGEN SERIES, V65, P17; KIRCHNER J, 1945, COLLECTION INTERPRET, P374; NULAND SB, 1988, DOCTORS BIOGRAPHY ME, P38; Oliver JH, 1939, B HIST MED, V7, P315; OVID, 1984, METAMORPHOSES, V5, P105; OVID, 1984, METAMORPHOSES, V628, P408; OVID, 1984, METAMORPHOSES, V531, P403; PAUSANIAS, 1918, DESCRIPTIO GRAECIAE, V26, P387; PAUSANIAS, 1918, DESCRIPTIO GRAECIAE, V27, P390; PHILODEMUS, 1927, LYRA GRAECA, P266; PINDAR, 1924, ODES PYTHIAE INCLUDI, V1, P191; PINDAR, 1924, ODES PYTHIAE, V7, P189; PLATO, 1938, PHAEDRUS, P549; PLATO, 1926, LAWS CE, V720, P13; PLATO, 1938, PHAEDRUS, P548; PLATO, 1953, REPUBLIC, P281; SCHEER E, 1945, ASCLEPIUS COLLECTION, V48, P125; SUETONIUS, 1979, DEIFIED CLAUDIUS LIV, V2, P50; TATIAN, 1867, WRITINGS TATIAN THEO, P27; TEMKIN O, 1977, DOUBLE FACE JANUS OT, P140; TEMKIN O, 1991, HIPPOCRATES WORLD PA, P80; TERTULLIANUS, 1931, APOLOGETICUS, P75; THEODORETUS, 1945, ASCLEPIUS COLLECTION, V1, P118; THUCYDIDES, 1972, PELOPONNESIAN WAR, V47, P151; WALTON A, 1894, CORNELL STUDIES CLAS, P24; WALTON A, 1994, CORNELL STUDIES CLAS, P3	52	35	35	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					257	263		10.7326/0003-4819-124-2-199601150-00011	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	TQ016	8534003				2022-12-28	WOS:A1996TQ01600011
J	Iglehart, JK				Iglehart, JK			Health policy report - Managed care and mental health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ARONS BS, 1994, HEALTH AFFAIR, V13, P192, DOI 10.1377/hlthaff.13.1.192; AUERBACH S, 1995, WASHINGTON POST 1020, pB1; BATTAGLIOLA M, 1994, BUSINESS HLTH    JUN, P53; CALLAHAN JJ, 1995, HEALTH AFFAIR, V14, P173, DOI 10.1377/hlthaff.14.3.173; CHRISTIANSON JB, 1995, HEALTH AFFAIR, V14, P160, DOI 10.1377/hlthaff.14.3.160; CHRISTIANSON JB, 1994, HOSP COMMUNITY PSYCH, V45, P898; England M J, 1993, New Dir Ment Health Serv, P5; ESSOCK SM, 1995, HEALTH AFFAIR, V14, P34, DOI 10.1377/hlthaff.14.3.34; FELDMAN S, 1992, MANAGED MENTAL HLTH; FRANK RG, 1995, HEALTH AFFAIR, V14, P50, DOI 10.1377/hlthaff.14.3.50; FRANK RG, 1995, HEALTH AFFAIR, V14, P102, DOI 10.1377/hlthaff.14.3.102; FRANK RG, 1995, MILBANK Q, V73, P19; GOTTLIEB M, 1995, NY TIMES        1004, pA1; HYMOWITZ C, 1995, WALL STREET J   1221, pA1; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KOYANAGI C, 1995, HEALTH AFFAIR, V14, P124, DOI 10.1377/hlthaff.14.3.124; MECHANIC D, 1995, MILBANK Q, V73, P19, DOI 10.2307/3350312; Meyer R E, 1993, Acad Psychiatry, V17, P149, DOI 10.1007/BF03341518; MEYER RE, 1995, HEALTH AFFAIR, V14, P65, DOI 10.1377/hlthaff.14.3.65; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; NORQUIST G, 1991, ARCH GEN PSYCHIAT, V48, P475; OSS M, 1995, OPEN MINDS       MAR, P12; PANZARINO P, 1995, BEHAVIORAL  HEAL MAY, P49; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; SABIN JE, 1994, HASTINGS CENT REP, V24, P5, DOI 10.2307/3563458; STRUMWASSER I, 1991, MED CARE, V29, pAS77; 1995, MEDICAID MANAGED CAR; 1995, MANAGING MANAGED CAR; 1995, 1995 LEAD C WASH	31	94	94	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					131	135		10.1056/NEJM199601113340221	http://dx.doi.org/10.1056/NEJM199601113340221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP363	8531959				2022-12-28	WOS:A1996TP36300031
J	Laine, C; Davidoff, F				Laine, C; Davidoff, F			The patient physician relationship - Patient-centered medicine - A professional evolution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SURVEY; CARE; QUALITY; LIFE; OUTCOMES; SATISFACTION; POPULATION; FEEDBACK; CANCER; STATE		THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV INTERNAL MED,PHILADELPHIA,PA 19107; AMER COLL PHYSICIANS,ANNALS INTERNAL MED,PHILADELPHIA,PA 19106	Jefferson University; American College of Physicians	Laine, C (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CTR RES MED EDUC & HLTH CARE,1025 WALNUT ST,ROOM 119,PHILADELPHIA,PA 19107, USA.							American Board of Internal Medicine (ABIM), 1983, ANN INTERN MED, V99, P720; ANNAS GJ, 1994, NEW ENGL J MED, V330, P223, DOI 10.1056/NEJM199401203300324; ANNAS GJ, 1975, RIGHTS HOSPITAL PATI; BATALDEN PB, 1990, INT J HLTH CARE QUAL, V3, P7; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; BOSK CL, 1980, NEW ENGL J MED, V303, P71, DOI 10.1056/NEJM198007103030203; BREWSTER A, 1993, NEW ENGL J MED, V329, P1971, DOI 10.1056/NEJM199312233292622; BRODY DS, 1980, J MED EDUC, V55, P34; Bursztajn HJ, 1981, MED CHOICES MED CHAN; Casper G. R., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P8; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COPE DW, 1986, J GEN INTERN MED, V1, P394, DOI 10.1007/BF02596425; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DELBANCO TL, 1991, ANN INTERN MED, V116, P228; Donabedian A, 1970, Hospitals, V44, P131; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; FITZPATRICK R, 1993, MEASUREMENT PATIENTS; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GERTEIS M, 1993, PATIENTS EYES, P1; GRANT KD, 1992, AM SURGEON, V58, P146; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; Hippocrates, 1923, HIPPOCRATES, V2, P297; HOLMES OW, 1883, MED ESSAYS, P338; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KAPLAN SH, 1989, PROVIDING QUALITY CA; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KATZ J, 1984, SILENT WORLD DOCTOR, P85; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LERNER AM, 1992, J PSYCHIAT LAW, V20, P191; LIGHT D, 1979, J HEALTH SOC BEHAV, V20, P310, DOI 10.2307/2955407; MALONEY TW, 1991, HLTH AFF MILLWOOD, V4, P268; MATTHEWS DA, 1987, AM J MED, V83, P938, DOI 10.1016/0002-9343(87)90655-3; MAZUR DJ, 1988, J GEN INTERN MED, V3, P370, DOI 10.1007/BF02595796; MCCLOSKEY E, 1991, KENNEDY I ETHICS J, V2, P163; MILLER LJ, 1980, JAMA-J AM MED ASSOC, V244, P2100, DOI 10.1001/jama.244.18.2100; MIYAJI NT, 1993, SOC SCI MED, V36, P249, DOI 10.1016/0277-9536(93)90008-R; NASH DB, 1993, ACAD MED, V68, pS19, DOI 10.1097/00001888-199302000-00024; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; O'Brien M K, 1992, Med Care Rev, V49, P435, DOI 10.1177/002570879204900403; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; PATRICK DL, 1990, ANNU REV PUBL HEALTH, V11, P165; PELLEGRINO ED, 1992, JAMA-J AM MED ASSOC, V268, P1734, DOI 10.1001/jama.268.13.1734; PUTILO AB, 1991, HASTINGS CTR REP S5, V21, pS13; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; REISER SJ, 1993, JAMA-J AM MED ASSOC, V269, P1012, DOI 10.1001/jama.269.8.1012; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SLACK WV, 1977, LANCET, V2, P240; SPITZER WO, 1987, J CHRON DIS, V40, P465, DOI 10.1016/0021-9681(87)90002-6; Staff of The Benjamin Rose Hospital, 1959, J CHRON DIS, V9, P55, DOI DOI 10.1016/0021-9681(59)90137-7; Stewart A, 1992, MEASURING FUNCTION W; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; VICKERY DM, 1988, MED CARE, V26, P580, DOI 10.1097/00005650-198806000-00006; WACHTEL T, 1992, ANN INTERN MED, V116, P961; Waitzkin H., 1991, POLITICS MED ENCOUNT; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1988, OTAH386 US C OFF TEC, P231; WEAVER MJ, 1993, J GEN INTERN MED, V8, P135, DOI 10.1007/BF02599758; Weinstein MC, 1980, CLIN DECISION ANAL	68	586	593	6	51	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					152	156		10.1001/jama.275.2.152	http://dx.doi.org/10.1001/jama.275.2.152			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TN280	8531314				2022-12-28	WOS:A1996TN28000035
J	Winstanley, P				Winstanley, P			Pyronaridine: A promising drug for Africa?	LANCET			English	Editorial Material											Winstanley, P (corresponding author), UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							FU S, 1991, PARASITOL TODAY, V7, P310, DOI 10.1016/0169-4758(91)90267-R; MAGGS JL, 1988, BIOCHEM PHARMACOL, V37, P303, DOI 10.1016/0006-2952(88)90733-2; 1995, WHO12TH PROGR REP	3	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					2	3		10.1016/S0140-6736(96)91548-2	http://dx.doi.org/10.1016/S0140-6736(96)91548-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531544				2022-12-28	WOS:A1996TN76200003
J	Tallal, P; Miller, SL; Bedi, G; Byma, G; Wang, XQ; Nagarajan, SS; Schreiner, C; Jenkins, WM; Merzenich, MM				Tallal, P; Miller, SL; Bedi, G; Byma, G; Wang, XQ; Nagarajan, SS; Schreiner, C; Jenkins, WM; Merzenich, MM			Language comprehension in language-learning impaired children improved with acoustically modified speech	SCIENCE			English	Article							DEVELOPMENTAL APHASIA; READING DISABILITIES; AUDITORY-PERCEPTION; PREVALENCE; DELAY; RETARDATION; DISORDERS; INFANTS; YOUNG	A speech processing algorithm was developed to create more salient versions of the rapidly changing elements in the acoustic waveform of speech that have been shown to be deficiently processed by language-learning impaired (LLI) children. LLI children received extensive daily training, over a 4-week period, with listening exercises in which all speech was translated into this synthetic form. They also received daily training with computer ''games'' designed to adaptively drive improvements in temporal processing thresholds, Significant improvements in speech discrimination and language comprehension abilities were demonstrated in two independent groups of LLI children.	UNIV CALIF SAN FRANCISCO, WM KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, COLEMAN LAB, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tallal, P (corresponding author), RUTGERS STATE UNIV, CTR MOLEC & BEHAV NEUROSCI, NEWARK, NJ 07102 USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NINDS NIH HHS [R01 NS010414] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		[Anonymous], 1982, ANN DYSLEXIA, DOI DOI 10.1007/BF02647960; [Anonymous], 1991, WECHSLER INTELLIGENC; BEITCHMAN JH, 1986, J SPEECH HEAR DISORD, V51, P98, DOI 10.1044/jshd.5102.98; BENASICH AA, 1993, ANN NY ACAD SCI, V682, P312, DOI 10.1111/j.1749-6632.1993.tb22978.x; BISHOP DVM, 1990, J CHILD PSYCHOL PSYC, V31, P1027, DOI 10.1111/j.1469-7610.1990.tb00844.x; CATTS HW, 1993, J SPEECH HEAR RES, V36, P948, DOI 10.1044/jshr.3605.948; CURTISS S, 1992, J SPEECH HEAR RES, V35, P373, DOI 10.1044/jshr.3502.373; CURTISS S, UNPUB CURTISS YAMADA; DiSimoni F., 1978, TOKEN TEST CHILDREN; Eimas P. D., 1987, CATEGORICAL PERCEPTI, P161; Goldman R, 2015, GOLDMAN FRISTOE TEST; Goldman R., 1974, GOLDMAN FRISTOE WOOD; GORDONSALANT S, 1993, J SPEECH HEAR RES, V36, P1276, DOI 10.1044/jshr.3606.1276; HENDERSON JL, 1995, 61ST BIENN M SOC RES; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LANGHANS T, 1982, 1982 P IEEE INT C AC, P156; LEONARD LB, 1989, APPL PSYCHOLINGUIST, V10, P179, DOI 10.1017/S0142716400008511; LIBERMAN IY, 1974, J EXP CHILD PSYCHOL, V18, P201, DOI 10.1016/0022-0965(74)90101-5; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Merzenich MM., 1995, MATURATIONAL WINDOWS, P247; PORTNOFF MR, 1981, IEEE T ACOUST SPEECH, V29, P374, DOI 10.1109/TASSP.1981.1163581; RISSMAN M, 1990, J SPEECH LANGUAGE PA, V14, P49; SCARBOROUGH HS, 1990, CHILD DEV, V61, P1728, DOI 10.1111/j.1467-8624.1990.tb03562.x; SILVA PA, 1980, DEV MED CHILD NEUROL, V22, P768; Stark R., 1988, LANGUAGE SPEECH READ; STARK RE, 1984, ANN DYSLEXIA, V34, P49, DOI 10.1007/BF02663613; STEINSCHNEIDER M, 1990, BRAIN RES, V519, P158, DOI 10.1016/0006-8993(90)90074-L; STEVENSON J, 1976, DEV MED CHILD NEUROL, V18, P431; TALLAL P, 1978, BRAIN LANG, V5, P13, DOI 10.1016/0093-934X(78)90003-2; TALLAL P, 1973, NEUROPSYCHOLOGIA, V11, P389, DOI 10.1016/0028-3932(73)90025-0; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; TALLAL P, 1973, NATURE, V241, P468, DOI 10.1038/241468a0; TALLAL P, 1975, NEUROPSYCHOLOGIA, V13, P69, DOI 10.1016/0028-3932(75)90049-4; TALLAL P, 1985, BRAIN LANG, V25, P314, DOI 10.1016/0093-934X(85)90087-2; TALLAL P, 1974, NEUROPSYCHOLOGIA, V12, P83, DOI 10.1016/0028-3932(74)90030-X; TALLAL P, 1985, NEUROPSYCHOLOGIA, V23, P527, DOI 10.1016/0028-3932(85)90006-5; TALLAL P, 1994, UNPUB COMPUTERIZED V; Tallal P., 1980, NONSPEECH LANGUAGE C, P449; TORGESEN JK, 1994, J LEARN DISABIL, V27, P276, DOI 10.1177/002221949402700503; WILLIAMS DM, 1980, J OTOLARYNGOL S, V7, P5; 1988, JAN P NAT C LEARN DI	41	830	873	1	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					81	84		10.1126/science.271.5245.81	http://dx.doi.org/10.1126/science.271.5245.81			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP022	8539604				2022-12-28	WOS:A1996TP02200048
J	Schmitt, HJ; vonKonig, CHW; Neiss, A; Bogaerts, H; Bock, HL; SchulteWissermann, H; Gahr, M; Schult, R; Folkens, JU; Rauh, W; Clemens, R				Schmitt, HJ; vonKonig, CHW; Neiss, A; Bogaerts, H; Bock, HL; SchulteWissermann, H; Gahr, M; Schult, R; Folkens, JU; Rauh, W; Clemens, R			Efficacy of acellular pertussis vaccine in early childhood after household exposure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the efficacy of a three-dose primary vaccination with a diphtheria-tetanus tricomponent acellular pertussis vaccine against ''typical'' pertussis, defined as a spasmodic cough of 21 days or longer with confirmation of Bordetella pertussis infection by culture or serology. Design.-Passive monitoring for suspected first household (index) cases of typical pertussis in six areas in Germany comprising 22 505 children vaccinated with study vaccine at 3, 4, and 5 months of age. Blinded, prospective follow-up of household contacts of index cases for incidence and progression of pertussis. Setting.-Six areas in Germany with a high incidence of pertussis, Subjects.-Four hundred fifty-three households with index cases comprising 360 evaluable contacts eligible for analysis of vaccine efficacy. Main Outcome Measure.-Vaccine efficacy from attack rates of pertussis in household contacts classified by vaccination status. Results.-Of the 173 nonvaccinated household contacts, 96 developed typical pertussis, compared with seven of 112 contacts vaccinated with acellular pertussis vaccine. Vaccine efficacy was consequently calculated to be 88.7% (95% confidence interval, 76.6% to 94.6%). Protection did not wane until at least the time recommended for booster vaccination. None of the analyzed potential confounding factors-age, socioeconomic status, erythromycin treatment, household composition, center effect, and selection bias-influenced study results in favor of the vaccine. Conclusions.-Under conditions of intense household exposure, primary vaccination with acellular vaccine protected against pertussis until at least the time recommended for booster vaccination, The vaccine can be expected to be equally or more effective in settings with lower infectious pressure.	UNIV MAINZ,CHILDRENS HOSP,W-6500 MAINZ,GERMANY; MUNICIPAL HOSP KREFELD,INST HYG & LAB MED,KREFELD,GERMANY; MUNICIPAL HOSP KREFELD,CHILDRENS HOSP,KREFELD,GERMANY; TECH UNIV MUNICH,INST MED STAT & EPIDEMIOL,W-8000 MUNICH,GERMANY; SMITHKLINE BEECHAM BIOL,RIXENSART,BELGIUM; UNIV GOTTINGEN,CHILDRENS HOSP,W-3400 GOTTINGEN,GERMANY; PEDIATRICIANS FLENSBURG,FLENSBURG,GERMANY; CHILDRENS HOSP OFFENBURG,OFFENBURG,GERMANY; MUTTERHAUS BORROMAERINNEN,CHILDRENS HOSP,TRIER,GERMANY	Johannes Gutenberg University of Mainz; Technical University of Munich; GlaxoSmithKline; University of Gottingen				Clemens, Ralf/0000-0003-4685-4207				[Anonymous], 1988, LANCET, Vi, P955; AOYAMA T, 1985, J PEDIATR, V107, P80; BROOME CV, 1981, J PEDIATR-US, V98, P362, DOI 10.1016/S0022-3476(81)80696-8; BURSTYN DG, 1983, INFECT IMMUN, V41, P1150, DOI 10.1128/IAI.41.3.1150-1156.1983; DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1995, PEDIATRICS, V96, P548; FINE PEM, 1987, REV INFECT DIS, V9, P866; KIMURA M, 1988, Acta Paediatrica Japonica, V30, P143; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P446, DOI 10.1001/jama.274.6.446; MERTSOLA J, 1983, J PEDIATR-US, V103, P359, DOI 10.1016/S0022-3476(83)80403-X; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; MULLER AS, 1984, WHO EPIGAG84WP11 DOC; ONEILL RT, 1988, STAT MED, V7, P1279, DOI 10.1002/sim.4780071208; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SCHMITZ M, 1994, MONATSSCHR KINDERH, V142, P41; SPRAUER MA, 1992, AM J DIS CHILD, V146, P177, DOI 10.1001/archpedi.1992.02160140043018; STORSAETER J, 1992, AM J DIS CHILD, V146, P167, DOI 10.1001/archpedi.1992.02160140033016; STORSAETER J, 1992, VACCINE, V10, P142, DOI 10.1016/0264-410X(92)90002-2; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; 1991, 1991 WHO M CAS DEF P, P4	22	221	229	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					37	41		10.1001/jama.275.1.37	http://dx.doi.org/10.1001/jama.275.1.37			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531284				2022-12-28	WOS:A1996TM23800019
J	Gillies, JD; LeSouef, PN				Gillies, JD; LeSouef, PN			The mark 2 human genome: A word of advice from us down here	BRITISH MEDICAL JOURNAL			English	Article									UNIV WESTERN AUSTRALIA,DEPT PAEDIAT,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia	Gillies, JD (corresponding author), ANGLESEA CLIN,POB 228,HAMILTON,NEW ZEALAND.		Le Souef, Peter N/H-5256-2014						0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1669	1676		10.1136/bmj.311.7021.1669	http://dx.doi.org/10.1136/bmj.311.7021.1669			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541754	Green Published			2022-12-28	WOS:A1995TL94200013
J	Weisse, ME; Eberly, B; Person, DA				Weisse, ME; Eberly, B; Person, DA			Wine as a digestive aid: Comparative antimicrobial effects of bismuth salicylate and red and white wine	BRITISH MEDICAL JOURNAL			English	Article							SUBSALICYLATE	Objective-To test whether red and white wines are as potent as bismuth salicylate against the bacteria responsible for traveller's diarrhoea to try to explain wine's legendary reputation as a digestive aid. Design-Red and white wine, bismuth salicylate, two solutions containing ethanol (diluted absolute ethanol and tequila), and sterilised water were tested against suspensions of salmonella, shigella, and Escherichia coli to determine relative antibacterial activity. Suspensions of 10(7) colony forming units of shigella, salmonella, and E coli were added to the test solutions and plated on standard nutrient agar at 0, 10, 20, 30, 60, and 120 minutes and 24 hours. Dilutions of wine and bismuth salicylate were then tested with E coli as the test bacterium, and the experiment repeated. Main outcome measures-Exposure times necessary for eradication of organisms for the different solutions; decreases in colony counts at the different exposure times for dilutions of wine and bismuth salicylates. Results-Undiluted wine and bismuth salicylate were both effective in reducing the number of viable organisms (by 10(5)-10(6) colony forming units) after 20-30 minutes. Dilutions of wine were much more effective in decreasing colony counts than were similar dilutions of bismuth salicylate. Conclusion-The antibacterial property of wine is largely responsible for wine's reputation as a digestive aid.	TRIPLER ARMY MED CTR,DEPT PAEDIAT,HONOLULU,HI 96859; TRIPLER ARMY MED CTR,DEPT PATHOL,HONOLULU,HI 96859; TRIPLER ARMY MED CTR,MICROBIOL LAB,HONOLULU,HI 96859	United States Department of Defense; United States Army; United States Department of Defense; United States Army; United States Department of Defense; United States Army			Weisse, Martin/AAW-7050-2021					BLOCK E, 1985, SCI AM, V252, P1114; COMICK NA, 1990, REV INFECTIOUS DI S1, V12, pS9; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; DUPONT HL, 1980, JAMA-J AM MED ASSOC, V243, P237, DOI 10.1001/jama.243.3.237; DURANT W, 1939, LIFE GREECE, P45; ERICSSON CD, 1990, REV INFECT DIS, V12, pS16; HAJNAL F, 1990, GASTROENTEROLOGY, V98, P191, DOI 10.1016/0016-5085(90)91309-T; MAJNO G, 1975, HEALING HAND MAN WOU, P186; MANHART MD, 1990, REV INFECT DIS, V12, pS11; MASQUELIER MJ, 1953, B SOC PHARM BORDEAUX, V91, P24; PICKLEMAN J, 1990, AM SURGEON, V56, P395; QUENNELL M, 1954, EVERYDAY THINGS ANCI, P80; SHETH NK, 1988, AM J GASTROENTEROL, V83, P658; SINGER MV, 1988, SCAND J GASTROENTERO, V23, P11, DOI 10.3109/00365528809099126; SOX TE, 1989, ANTIMICROB AGENTS CH, V33, P2075, DOI 10.1128/AAC.33.12.2075; STEFFEN R, 1986, ANTIMICROB AGENTS CH, V29, P625, DOI 10.1128/AAC.29.4.625; WOOD LV, 1983, APPL ENVIRON MICROB, V46, P328, DOI 10.1128/AEM.46.2.328-332.1983	17	84	89	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1657	1660		10.1136/bmj.311.7021.1657	http://dx.doi.org/10.1136/bmj.311.7021.1657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541747	Green Published			2022-12-28	WOS:A1995TL94200006
J	Wilson, ME				Wilson, ME			Infectious diseases: An ecological perspective	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL-CHANGES		HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	Wilson, ME (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							[Anonymous], 1993, MANAGING GLOBAL GENE; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; Chivian E., 1993, CRITICAL CONDITION H; Crosby A., 1989, AM FORGOTTEN PANDEMI; Crosby A., 1972, COLUMBIAN EXCHANGE B; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; ELTON CS, 1972, ECOLOGY INVASIONS AN; FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857; GRIST NR, 1993, LANCET, V339, P1363; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; HOMERDIXON TF, 1991, INT SECURITY, V16, P76, DOI 10.2307/2539061; KOHN MA, 1995, J INFECT DIS, V172, P246, DOI 10.1093/infdis/172.1.246; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Lederberg J., 1992, EMERGING INFECTIONS; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCCARTHY SA, 1994, APPL ENVIRON MICROB, V60, P2597, DOI 10.1128/AEM.60.7.2597-2601.1994; McMichael A J, 1993, PLANETARY OVERLOAD G; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; MOORE PS, 1989, LANCET, V2, P260; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; RAEBURN P, 1995, LAST HARVEST GENETIC; REEVES WC, 1995, J MED ENTOMOL, V31, P323; ROOT TL, 1995, SCIENCE, V269, P334, DOI 10.1126/science.269.5222.334; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227; Snow J., 1849, MODE COMMUNICATION C; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; TESH RB, 1994, DISEASE EVOLUTION GL; TICKELL C, 1993, PARASITOLOGY, V106, pS5, DOI 10.1017/S0031182000086078; Toole M. J., 1994, MED GLOBAL SURVIVAL, V1, P200; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; Weiner J., 1994, BEAK FINCH STORY EVO; WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/eid0102.950201; WILSON ME, 1995, EPIDEMIOLOGY, V6, P458, DOI 10.1097/00001648-199507000-00027; WILSON ME, 1994, DISEASE EVOLUTION GL; WINKELSTEIN W, 1995, AM J EPIDEMIOL, V142, pS3, DOI 10.1093/aje/142.Supplement_9.S3; 1995, WHO1995 WORLD HLTH R; 1991, MMWR-MORBID MORTAL W, V40, P838; 1993, 1993 WORLD DEV REP; 1995, MMWR-MORBID MORTAL W, V44, P468; 1995, MMWR-MORBID MORTAL W, V44, P243; IN PRESS POLICY MAKE; 1995, MMWR-MORBID MORTAL W, V44, P237; 1995, LANCET, V345, P339; 1995, MMWR-MORBID MORTAL W, V44, P475	48	66	70	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1681	1684		10.1136/bmj.311.7021.1681	http://dx.doi.org/10.1136/bmj.311.7021.1681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541756	Green Published			2022-12-28	WOS:A1995TL94200016
J	BEZPROZVANNY, I; SCHELLER, RH; TSIEN, RW				BEZPROZVANNY, I; SCHELLER, RH; TSIEN, RW			FUNCTIONAL IMPACT OF SYNTAXIN ON GATING OF N-TYPE AND Q-TYPE CALCIUM CHANNELS	NATURE			English	Article							EXPRESSION; SUBUNIT; DOCKING; BRAIN; CDNA	RAPID and reliable synaptic transmission depends upon the close proximity of voltage-gated calcium channels and neurotransmitter-containing vesicles in the presynaptic terminal(1). Although it is clear that a local Ca2+ rise conveys the crucial signal from Ca2+ channels to the exocytotic mechanism(2), little is known about whether communication ever proceeds in the opposite direction, from the release machinery to Ca2+ channels(3,4). To look for such signalling, we examined the interaction of various types of voltage-gated Ca2+ channels with syntaxin, a presynaptic membrane protein of relative molecular mass 35,000 (refs 5-7) which may play a key part in synaptic vesicle docking and fusions and which interacts strongly with N-type Ca2+ channels(5,6,9-12). Here we report that co-expression of syntaxin 1A with N-type channels in Xenopus oocytes sharply decreases the availability of these channels. This is due to the stabilization of channel inactivation rather than to a simple block or lack of channel expression, because it is overcome by strong hyperpolarization. Deletion of syntaxin's carboxy-terminal transmembrane domain abolishes its functional effect on Ca2+ channels. Syntaxin produced a similar effect on Q-type Ca2+ channels encoded by alpha(1A) (refs 13-15) but not on L-type Ca2+-channels. Thus, the syntaxin effect is specific for Ca2+ channel types that participate in fast transmitter release in the mammalian central nervous system (ref. 16 and therein). We hypothesize that, in addition to acting as a vesicle-docking site, syntaxin may influence presynaptic Ca2+ channels, opposing Ca2+ entry where it is not advantageous, but allowing it at release sites where synaptic vesicles have become docked and/or ready for fusion.	STANFORD UNIV, MED CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, BECKMAN CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; RUSSIAN ACAD SCI, INST CYTOL, ST PETERSBURG 194064, RUSSIA	Stanford University; Howard Hughes Medical Institute; Stanford University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Katz B., 1969, RELEASE NEURAL TRANS; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SMIMOVA T, 1995, NEUROSCIENCE, V68, P125; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WHEELER DB, 1994, SCIENCE, V266, P830, DOI 10.1126/science.266.5186.830; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	30	363	372	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	1995	378	6557					623	626		10.1038/378623a0	http://dx.doi.org/10.1038/378623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524397				2022-12-28	WOS:A1995TJ22100079
J	EVANS, MR				EVANS, MR			IS TUBERCULOSIS TAKEN SERIOUSLY IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							BCG VACCINATION; ENGLAND; WALES; SCHOOLCHILDREN; IMMUNIZATION; POLICY; AUDIT	Tuberculosis has been the subject of much concern in recent years. Notifications have increased, inadequacies in surveillance revealed, and policies for BCG immunisation and screening of immigrants questioned. Until recently the disease was given low priority in the United Kingdom. There is no overall strategic framework for tackling tuberculosis, and fears have been expressed about the future of local tuberculosis control programmes in the new market economy of the NHS. An action plan for tuberculosis within the context of a national programme is urgently required. Only then will a major impact on the incidence of the disease be seen.			EVANS, MR (corresponding author), S GLAMORGAN HLTH AUTHOR,DEPT PUBL HLTH,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				AHMED S, 1992, J PUBLIC HEALTH MED, V14, P389, DOI 10.1093/oxfordjournals.pubmed.a042778; [Anonymous], 1994, TUBER LUNG DIS, V75, P179; BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; BROWN JS, 1995, BRIT MED J, V310, P974, DOI 10.1136/bmj.310.6985.974; Citron KM, 1995, OUT SHADOW DETECTING; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DAVIES PDO, 1993, BRIT MED J, V307, P59, DOI 10.1136/bmj.307.6895.59-b; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; DIPERRI G, 1989, LANCET, V2, P1502; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; HARDIE RM, 1993, BRIT MED J, V307, P1539, DOI 10.1136/bmj.307.6918.1539; HAYWARD AC, 1995, COMM DIS RESP CDR RE, V5, P29; HICKMAN M, 1992, BRIT MED J, V304, P1567, DOI 10.1136/bmj.304.6841.1567-c; HUSSAIN SF, 1992, BRIT MED J, V304, P1213, DOI 10.1136/bmj.304.6836.1213; ISEMAN MD, 1995, NEW ENGL J MED, V332, P1094, DOI 10.1056/NEJM199504203321611; JOSEPH CA, 1992, BRIT MED J, V305, P495, DOI 10.1136/bmj.305.6852.495; KENT RJ, 1994, BRIT MED J, V309, P639, DOI 10.1136/bmj.309.6955.639; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; ORMEROD LP, 1994, THORAX, V49, P1085, DOI 10.1136/thx.49.11.1085; ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; SELBY CD, 1993, RESPIR MED, V83, P353; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; STOKER N, 1994, BRIT MED J, V309, P1178, DOI 10.1136/bmj.309.6963.1178; SUTHERLAND I, 1989, J EPIDEMIOL COMMUN H, V43, P15, DOI 10.1136/jech.43.1.15; SUTHERLAND I, 1987, TUBERCLE, V68, P81, DOI 10.1016/0041-3879(87)90023-7; WATBURTON ARE, 1993, COMM DIS REP CDR REV, V3, P175; 1990, MMWR-MORBID MORTAL W, V39, P1; 1989, MMWR S5, V38, P1; 1989, MMWR-MORBID MORTAL W, V38, P313; 1994, THORAX, V49, P1193; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, LOCAL STRATEGIES HLT; 1992, HLTH NATION; 1992, IMMUNISATION INFECTI; 1994, REGISTRAR GENERAL MB; 1985, BRIT MED J, V291, P658; 1993, COMM DIS REP CDR WKL, V3, P1; 1990, MMWR-MORBID MORTAL W, V39, P8; 1990, THORAX, V45, P403; 1992, THORAX, V47, P770; 1980, BRIT MED J, V281, P895; 1992, BRIT MED J, V304, P1231; 1993, MMWR-MORBID MORTAL W, V42, P1; 1989, MMWR-MORBID MORTAL W, V38, P236; 1992, MMWR-MORBID MORTAL W, V41, P1	47	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1483	1485		10.1136/bmj.311.7018.1483	http://dx.doi.org/10.1136/bmj.311.7018.1483			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520341	Green Published			2022-12-28	WOS:A1995TJ04400031
J	ZHONG, T; ARNDT, KT				ZHONG, T; ARNDT, KT			THE YEAST SIS1-PROTEIN, A DNAJ HOMOLOG, IS REQUIRED FOR THE INITIATION OF TRANSLATION	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; 2 GENES; MUTANTS; REPLICATION; RNA; BACTERIOPHAGE; BIOSYNTHESIS; BINDING	The S. cerevisiae SIS1 gene is essential and encodes a heat shock protein with similarity to the bacterial DnaJ protein. At the nonpermissive temperature, temperature-sensitive sis1 strains rapidly accumulate 80S ribosomes and have decreased amounts of polysomes. Certain alterations in 60S ribosomal subunits can suppress the temperature-sensitive phenotype of sis1 strains and prevent the accumulation of 80S ribosomes and the loss of polysomes normally seen under conditions of reduced SIS1 function. Analysis of sucrose gradients for SIS1 protein shows that a large fraction of SIS1 is associated with 40S ribosomal subunits and the smaller polysomes. These and other results indicate that SIS1 is required for the normal initiation of translation. Because DnaJ has been shown to mediate the dissociation of several protein complexes, the requirement of SIS1 in the initiation of translation might be for mediating the dissociation of a specific protein complex of the translation machinery.	SUNY,GRAD PROGRAM GENET,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	ZHONG, T (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045179] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREVALO SG, 1990, NUCLEIC ACIDS RES, V18, P1447, DOI 10.1093/nar/18.6.1447; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; ITIKAWA H, 1986, J BIOCHEM, V99, P1719, DOI 10.1093/oxfordjournals.jbchem.a135648; KEIERLEBER C, 1986, MOL CELL BIOL, V6, P4419, DOI 10.1128/MCB.6.12.4419; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MUNROE D, 1990, RIBOSOME, P299; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OHKI M, 1987, J BACTERIOL, V169, P1917, DOI 10.1128/jb.169.5.1917-1922.1987; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SHERMAN F, 1989, METHODS YEAST GENETI; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V167, P1377, DOI 10.1016/0006-291X(90)90675-D; WADA M, 1982, JPN J GENET, V57, P407, DOI 10.1266/jjg.57.407; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	38	134	141	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1175	1186		10.1016/0092-8674(93)90646-8	http://dx.doi.org/10.1016/0092-8674(93)90646-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513501				2022-12-28	WOS:A1993LH54800013
J	JENKINSON, C; COULTER, A; WRIGHT, L				JENKINSON, C; COULTER, A; WRIGHT, L			SHORT FORM-36 (SF-36) HEALTH SURVEY QUESTIONNAIRE - NORMATIVE DATA FOR ADULTS OF WORKING AGE	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGISTS; PROFILE; TOOL	Objectives-To gain population norms for the short form 36 health survey questionnaire (SF36) in a large community sample and to explore the questionnaire's internal consistency and validity. Design-Postal survey by using a booklet containing the SF36 and several other items concerned with lifestyles and illness. Setting-The sample was drawn from computerised registers of the family health services authorities for Berkshire, Buckinghamshire, Northamptonshire, and Oxfordshire. Sample-13042 randomly selected subjects aged 18-64 years. Main outcome measures-Scores for the eight health dimensions of the SF36. Results-The survey achieved a response rate of 72% (n=9332). Internal consistency of the different dimensions of the questionnaire was high. Normative data broken down by age, sex, and social class were consistent with those from previous studies. Conclusions-The SF36 is a potentially valuable tool in medical research. The normative data provided here may further facilitate its validation and use.			JENKINSON, C (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bowling A., 1991, MEASURING HLTH REV Q; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Carmines E. G., 1979, RELIABILITY VALIDITY, DOI DOI 10.4135/9781412985642; CARRHILL RA, 1991, BRIT MED J, V303, P699, DOI 10.1136/bmj.303.6804.699; Fitzpatrick R, 1992, Qual Health Care, V1, P89, DOI 10.1136/qshc.1.2.89; GEIGLE R, 1990, INQUIRY-J HEALTH CAR, V27, P7; Helmstadter G. C., 1964, PRINCIPLES PSYCHOL M; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; Hunt SM, 1986, MEASURING HLTH STATU; KIND P, 1987, SOC SCI MED, V25, P905, DOI 10.1016/0277-9536(87)90260-7; McDowell I, 1987, MEASURING HLTH GUIDE; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Stewart AL, 1992, MEASURING FUNCTIONIN; STEWART AL, 1992, MEASURIING FUNCTIONI; Ware J, 1980, CONCEPTUALISATION ME, V1; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILKIN D, 1992, MEASURES NEED OUTCOM; WRIGHT L, 1992, HLTH LIFESTYLES OXFO; ZIEBLAND S, 1992, QUAL HEALTH CARE, V1, P141; 1990, PSYCHOMETRIKA, V2; 1992, RAND 36 ITEM HLTH SU	22	1207	1232	4	59	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1437	1440		10.1136/bmj.306.6890.1437	http://dx.doi.org/10.1136/bmj.306.6890.1437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE935	8518639	Green Published, Bronze			2022-12-28	WOS:A1993LE93500015
J	GRIFFIN, DK; WILTON, LJ; HANDYSIDE, AH; ATKINSON, GHG; WINSTON, RML; DELHANTY, JDA				GRIFFIN, DK; WILTON, LJ; HANDYSIDE, AH; ATKINSON, GHG; WINSTON, RML; DELHANTY, JDA			DIAGNOSIS OF SEX IN PREIMPLANTATION EMBRYOS BY FLUORESCENT INSITU HYBRIDIZATION	BRITISH MEDICAL JOURNAL			English	Article							DNA AMPLIFICATION		UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,LONDON NW1 2HE,ENGLAND; ZOOL SOC LONDON,INST ZOOL,LONDON NW1 4RY,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0NN,ENGLAND	University of London; University College London; Zoological Society of London; Imperial College London								GRIFFIN DK, 1992, HUM GENET, V89, P18, DOI 10.1007/BF00207035; Handyside A.H., 1993, PREIMPLANTATION DIAG, P239; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0	4	48	50	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1382	1382		10.1136/bmj.306.6889.1382	http://dx.doi.org/10.1136/bmj.306.6889.1382			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518605	Green Published, Bronze			2022-12-28	WOS:A1993LD82900022
J	Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW				Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW			Legalizing assisted suicide - Views of physicians in Oregon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; LIFE; DEPRESSION; ATTITUDES; AID	Background. Since the Oregon Death with Dignity Act was passed in November 1994, physicians in Oregon have faced the prospect of legalized physician-assisted suicide. We studied the attitudes and current practices of Oregon physicians in relation to assisted suicide. Methods. From March to June 1995, we conducted a cross-sectional mailed survey of all physicians who might be eligible to prescribe a lethal dose of medication if the Oregon law is upheld, Physicians were asked to complete and return a confidential 56-item questionnaire. Results. Of the 3944 eligible physicians who received the questionnaire, 2761 (70 percent) responded. Sixty percent of the respondents thought physician-assisted suicide should be legal in some cases, and nearly half (46 percent) might be willing to prescribe a lethal dose of medication if it were legal to do so; 31 percent of the respondents would be unwilling to do so on moral grounds. Twenty-one percent of the respondents have previously received requests for assisted suicide, and 7 percent have complied. Half the respondents were not sure what to prescribe for this purpose, and 83 percent cited financial pressure as a possible reason for such requests. The respondents also expressed concern about complications of suicide attempts and doubts about their ability to predict survival at six months accurately. Conclusions. Oregon physicians have a more favorable attitude toward legalized physician-assisted suicide, are more willing to participate, and are currently participating in greater numbers than other surveyed groups of physicians in the United States. A sizable minority of physicians in Oregon objects to legalization and participation on moral grounds. Regardless of their attitudes, physicians had a number of reservations about the practical applications of the act. (C) 1996, Massachusetts Medical Society.	OREGON HLTH SCI UNIV,SCH MED,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT EMERGENCY MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH NURSING,RES OFF,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,CTR BIOMED INFORMAT COMMUN,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Lee, MA (corresponding author), OREGON HLTH SCI UNIV,CTR ETH HLTH CARE L101,PORTLAND,OR 97201, USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CROSBY C, 1992, INTERNIST, V31, P10; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GATES V, 1995, OREGON HLTH PLAN REP, P71; HEILIG S, 1989, SF MED, V61, P24; KEISLING P, 1995, OREGON BLUE BOOK, P296; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KOENIG HG, 1988, ARCH INTERN MED, V148, P1929, DOI 10.1001/archinte.148.9.1929; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; MEIER D, 1993, SURVEY END LIFE PRAC; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1995, ACAD MED, V70, P583; 1995, J AM GERIATR SOC, V42, P579; 1994, POISITON STATEMENT A; 1994, OREGON VOTERS PAMPHL; 1991, INITATIVE 119 WSMA M	29	208	208	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					310	315		10.1056/NEJM199602013340507	http://dx.doi.org/10.1056/NEJM199602013340507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532028				2022-12-28	WOS:A1996TV69500007
J	Hanauer, SB; Sninsky, CA; Robinson, M; Powers, BJ; McHattie, JD; Mayle, JE; Elson, CO; DeMicco, MP; Butt, JH; Pruitt, RE; Bozdech, JM; Safdi, MA; Gurney, MS; Fixelle, AM; Levin, AI; Smoots, J; Wolf, DC				Hanauer, SB; Sninsky, CA; Robinson, M; Powers, BJ; McHattie, JD; Mayle, JE; Elson, CO; DeMicco, MP; Butt, JH; Pruitt, RE; Bozdech, JM; Safdi, MA; Gurney, MS; Fixelle, AM; Levin, AI; Smoots, J; Wolf, DC			An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						colitis, ulcerative; mesalamine; sulfasalazine; polymers; absorption	INFLAMMATORY BOWEL-DISEASE; 5-AMINO SALICYLIC-ACID; 5-AMINOSALICYLIC ACID; SULFASALAZINE; SULPHASALAZINE; REMISSION; RELEASE; SALICYLAZOSULFAPYRIDINE; METABOLISM; MESALAZINE	Objective: To compare the safety and efficacy of a pH-sensitive, polymer-coated oral formulation of mesalamine (Asacol, Procter & Gamble Pharmaceuticals, Cincinnati, Ohio) with those of placebo in maintaining remission in patients with ulcerative colitis. Design: Multicenter, double-blind, placebo-controlled, randomized clinical trial. Setting: Eight private practices, five university-based medical centers, and four hospitals or clinics. Patients: 264 patients with ulcerative colitis that had been maintained in remission for at least 1 month while the patients were receiving stable doses of sulfasalazine or any oral mesalamine product. Intervention: Coated mesalamine at oral dosages of 0.8 g/d or 1.6 g/d or matching placebo for 6 months. Measurements: Treatment success, defined as maintenance of remission after 6 months, and treatment failure, defined as relapse during the study (as indicated by proctosigmoidoscopy at 1, 3, or 6 months of treatment) or withdrawal due to adverse events. Safety was assessed on the basis of laboratory analyses and patient- and investigator-noted adverse events. Results: 189 patients were compliant with the protocol for 6 months or stopped receiving therapy because of relapse or adverse events. Of these 189 patients, 25 of the 63 patients (39.7%) in the placebo group had treatment success compared with 40 of the 68 patients (58.8% [95% CI, 46.4% to 71.3%]) in the group receiving mesalamine, 0.8 g/d (P = 0.036) and 38 of the 58 patients (65.5% [CI, 52.4% to 78.6%]) in the group receiving mesalamine, 1.6 g/d (P = 0.006). In the intention-to-treat analysis of all patients, 42 of the 87 patients (48.3%) in the placebo group had treatment success compared with 57 of the 90 patients (63.3% [CI, 52.8% to 73.8%]) in the group receiving mesalamine, 0.8 gld (P = 0.050) and 61 of the 87 patients (70.1% [CI, 59.9% to 80.3%]) in the group receiving mesalamine, 1.6 g/d (P = 0.005). Age, sex, and race were not found to predict treatment success or failure. The mesalamine tablet was well tolerated, and no clinically significant changes were seen in hematologic, hepatic, or renal laboratory profiles. Conclusion: Coated mesalamine at oral dosages of 0.8 g/d and 1.6 g/d is safe and effective in maintaining remission in patients with quiescent ulcerative colitis.	UNIV FLORIDA, GAINESVILLE, FL USA; UNIV OKLAHOMA, COLL MED, OKLAHOMA CITY, OK USA; CLEVELAND CLIN, CLEVELAND, OH 44106 USA; PORTLAND CLIN, PORTLAND, OR USA; WESTERN CLIN, TACOMA, WA USA; EMORY UNIV, ATLANTA, GA 30322 USA; ARAPAHOE GASTROENTEROL, ENGLEWOOD, CO 80210 USA; PASQUA HOSP, GASTROINTESTINAL UNIT, REGINA, SK S4T 1A5, CANADA; MICHIGAN STATE UNIV, GASTROENTEROL SERV, INGHAM MED PROFESS CTR, LANSING, MI 48910 USA; UNIV ALABAMA, DIV GASTROENTEROL, BIRMINGHAM, AL 35294 USA; ASSOCIATED GASTROENTEROL MED GRP, ANAHEIM, CA 92801 USA; UNIV MISSOURI, SCH MED, HARRY S TRUMAN MEM VET HOSP, COLUMBIA, MO 65201 USA; NASHVILLE MED RES INST, NASHVILLE, TN 37205 USA; GREATER CINCINNATI GASTROENTEROL ASSOCIATES, CINCINNATI, OH 45219 USA; EASTSIDE DIGEST DIS CLIN, KIRKLAND, WA 98034 USA	State University System of Florida; University of Florida; University of Oklahoma System; University of Oklahoma Health Sciences Center; Cleveland Clinic Foundation; Emory University; University of Saskatchewan; Michigan State University; University of Alabama System; University of Alabama Birmingham; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital	Hanauer, SB (corresponding author), UNIV CHICAGO HOSP, DIV GASTROENTEROL, 5841 S MARYLAND AVE, BOX 400, CHICAGO, IL 60637 USA.							AZADKHAN AK, 1977, LANCET, V2, P892; BACHRACH WH, 1988, AM J GASTROENTEROL, V83, P487; BARON JH, 1962, LANCET, V1, P1094; CALDER IC, 1972, BMJ-BRIT MED J, V1, P152, DOI 10.1136/bmj.1.5793.152; DAS KM, 1973, NEW ENGL J MED, V289, P491, DOI 10.1056/NEJM197309062891001; DEW MJ, 1982, BRIT J CLIN PHARMACO, V14, P405, DOI 10.1111/j.1365-2125.1982.tb01999.x; DEW MJ, 1983, BRIT MED J, V287, P23, DOI 10.1136/bmj.287.6384.23; DEW MJ, 1983, LANCET, V2, P801; DEW MJ, 1982, BMJ-BRIT MED J, V285, P1012, DOI 10.1136/bmj.285.6347.1012; DEW MJ, 1983, BRIT J CLIN PHARMACO, V16, P185, DOI 10.1111/j.1365-2125.1983.tb04983.x; DICK AP, 1964, GUT, V5, P437, DOI 10.1136/gut.5.5.437; DISSANAYAKE AS, 1973, GUT, V14, P923, DOI 10.1136/gut.14.12.923; DONALD IP, 1985, POSTGRAD MED J, V61, P1047, DOI 10.1136/pgmj.61.722.1047; GIONCHETTI P, 1990, GASTROENTEROLOGY, V98, P251, DOI 10.1016/0016-5085(90)91334-3; KHAN AKA, 1980, GUT, V21, P232; KIRSNER JB, 1980, INFLAMMATORY BOWEL D; KLOTZ U, 1980, NEW ENGL J MED, V303, P1499, DOI 10.1056/NEJM198012253032602; MISIEWICZ JJ, 1965, LANCET, V1, P185; MULDER CJJ, 1988, GASTROENTEROLOGY, V95, P1449, DOI 10.1016/S0016-5085(88)80061-1; NIELSEN OH, 1983, BRIT J CLIN PHARMACO, V16, P738; PEPPERCORN MA, 1972, J PHARMACOL EXP THER, V181, P555; PEPPERCORN MA, 1990, ANN INTERN MED, V112, P50, DOI 10.7326/0003-4819-112-1-50; PORRO GB, 1989, GUT, V30, pA1467; RIIS P, 1973, SCAND J GASTROENTERO, V8, P71; RILEY SA, 1988, GASTROENTEROLOGY, V94, P1383, DOI 10.1016/0016-5085(88)90677-4; RUTGEERTS P, 1989, ALIMENT PHARM THERAP, V3, P183; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SNINSKY CA, 1991, ANN INTERN MED, V115, P350, DOI 10.7326/0003-4819-115-5-350; TAFFET SL, 1983, DIGEST DIS SCI, V28, P833, DOI 10.1007/BF01296907; VANHEES PAM, 1980, GUT, V21, P632, DOI 10.1136/gut.21.7.632	30	126	128	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					204	+		10.7326/0003-4819-124-2-199601150-00003	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533995				2022-12-28	WOS:A1996TQ01600003
J	Tautz, D				Tautz, D			Selector genes, polymorphisms, and evolution	SCIENCE			English	Editorial Material											Tautz, D (corresponding author), UNIV MUNICH,INST ZOOL,LUISENSTR 14,D-80333 MUNICH,GERMANY.		Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; GARCIABELLIDO A, 1975, CELL PATTERNING, P181; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MACKAY TFC, 1995, TRENDS GENET, V11, P464, DOI 10.1016/S0168-9525(00)89154-4; WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091	6	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					160	161		10.1126/science.271.5246.160	http://dx.doi.org/10.1126/science.271.5246.160			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539613				2022-12-28	WOS:A1996TP36400027
J	Squier, HA				Squier, HA			Haying	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					99	99						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531322				2022-12-28	WOS:A1996TN28000008
J	Graham, I				Graham, I			I believe therefore I practise	LANCET			English	Editorial Material											Graham, I (corresponding author), OTTAWA CIVIC HOSP,LOEB MED RES INST,CLIN EPIDEMIOL UNIT,OTTAWA,ON,CANADA.		Graham, Ian D./ABD-5259-2021	Graham, Ian D./0000-0002-3669-1216				DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; KLEIN MC, 1995, CAN MED ASSOC J, V153, P769; Klein MC., 1992, ONLINE J CURR CLIN T, V1, P25, DOI [10.1097/00006254-199404000-00008, DOI 10.1097/00006254-199404000-00008]; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; SCHULZ KF, 1995, CAN MED ASSOC J, V153, P783	6	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					4	5		10.1016/S0140-6736(96)91550-0	http://dx.doi.org/10.1016/S0140-6736(96)91550-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531551	Bronze			2022-12-28	WOS:A1996TN76200005
J	Ringwald, P; Bickii, J; Basco, L				Ringwald, P; Bickii, J; Basco, L			Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa	LANCET			English	Article							PLASMODIUM-FALCIPARUM; INVITRO ACTIVITY; CAMEROON; RESISTANT; DRUG	Background The spread of chloroquine resistance poses a serious problem in Africa, where falciparum malaria transmission is the highest in the world. Pyronaridine, an acridine derivative, has been used successfully to treat malaria in China for over 20 years. We compared the efficacy of pyronaridine and chloroquine in African adult patients with acute uncomplicated falciparum malaria in Yaounde, Cameroon, where chloroquine resistance is well established. Methods 96 patients were randomly assigned treatment with chioroquine 25 mg/kg or pyronaridine 32 mg/kg, both orally and divided over 3 days. Patients were followed up for at least 14 days on an outpatient basis. Analysis was by on-active-treatment. Findings After losses from follow-up (11) or because of self-medication with quinine (four), 41 patients treated with chloroquine and 40 treated with pyronaridine were analysed. Parasite clearance during the 14-day follow-up with chioroquine and pyronaridine was 44% and 100%, respectively. All patients treated with pyronaridine were afebrile by day 3, and parasitaemia cleared by day 4. No serious drug-related side-effects were noted in pyronaridine-treated patients. Interpretation Pyronaridine was rapidly effective and well-tolerated in African patients with acute, uncomplicated falciparum malaria and may represent an alternative drug against chloroquine-resistant malaria.	CNRS, CTR GENET MOLEC, GIF SUR YVETTE, FRANCE; ORG COOPERAT & COORDINAT LUTTE CONTRE ENDEMIESAFRI, LAB RECH PALUDISME, YAOUNDE, CAMEROON; ORSTOM, INST FRANCAIS RECH SCI DEV COOPERAT, F-75010 PARIS, FRANCE; HOP BICHAT CLAUDE BERNARD, PARASITOL LAB, F-75877 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut de Recherche pour le Developpement (IRD); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite								AJAYI AA, 1991, EUR J CLIN PHARMACOL, V41, P383, DOI 10.1007/BF00314973; [Anonymous], 1986, CHEMOTHERAPY MALARIA; BASCO LK, 1992, ANN TROP MED PARASIT, V86, P447, DOI 10.1080/00034983.1992.11812693; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P1; CHEN C, 1992, T ROY SOC TROP MED H, V86, P7, DOI 10.1016/0035-9203(92)90414-8; CHILDS GE, 1988, AM J TROP MED HYG, V38, P24, DOI 10.4269/ajtmh.1988.38.24; FADAT G, 1993, ANTIMICROB AGENTS CH, V37, P1955, DOI 10.1128/AAC.37.9.1955; FU S, 1991, PARASITOL TODAY, V7, P310, DOI 10.1016/0169-4758(91)90267-R; LAPIERRE J, 1982, NOUV PRESSE MED, V11, P673; LOUIS JP, 1992, TROP MED PARASITOL, V43, P118; MOUNT DL, 1989, B WORLD HEALTH ORGAN, V67, P295; NEVILL CG, 1994, E AFR MED J, V71, P167; ODUOLA AMJ, 1989, T ROY SOC TROP MED H, V83, P308, DOI 10.1016/0035-9203(89)90482-3; PETERS W, 1992, ANN TROP MED PARASIT, V86, P455, DOI 10.1080/00034983.1992.11812694; PINICHPONGSE S, 1982, B WORLD HEALTH ORGAN, V60, P907; RINGWALD P, 1995, ANN SOC BELG MED TR, V75, P141; WERNSDORFER WH, 1991, PHARMACOL THERAPEUT, V50, P95, DOI 10.1016/0163-7258(91)90074-V; [No title captured]; 1994, WHOMAL941070 DIV CON; 1990, WHO TECH REP SER, V805	20	109	109	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					24	28		10.1016/S0140-6736(96)91558-5	http://dx.doi.org/10.1016/S0140-6736(96)91558-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531545	Bronze			2022-12-28	WOS:A1996TN76200013
J	Furukawa, K; Barger, SW; Blalock, EM; Mattson, MP				Furukawa, K; Barger, SW; Blalock, EM; Mattson, MP			Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein	NATURE			English	Article							POTASSIUM CHANNEL; ALZHEIMERS-DISEASE; RAT; MODULATION; GENE	THE Alzheimer's beta-amyloid precursor protein (beta-APP) is widely expressed in neural cells, and in neurons secreted forms of beta-APP (sAPPs) are released from membrane-spanning holo-beta APP in an activity-dependent manner(1,2). Secreted APPs can modulate neurite outgrowth, synaptogenesis, synaptic plasticity and cell survival(3,9); a signal transduction mechanism of sAPPs may involve modulation of intracellular calcium levels ([Ca2+](i))(4,10). Here we use whole-cell perforated patch and single-channel patch-clamp analysis of hippocampal neurons to demonstrate that sAPPs suppress action potentials and hyperpolarize neurons by activating high-conductance, charybdotoxin-sensitive K+ channels. Activation of K+ channels by sAPPs was mimicked by a cyclic GMP analogue and sodium nitroprusside and blocked by an antagonist of cGMP-dependent kinase and a phosphatase inhibitor, suggesting that the effect is mediated by cGMP and protein dephosphorylation. Calcium imaging studies indicate that activation of K+ channels mediates the ability of sAPPs to decrease [Ca-2](i). Modulation of neuronal excitability may be a major mechanism by which beta-APP regulates developmental and synaptic plasticity in the nervous system.	UNIV KENTUCKY,SANDERS BROWN RES CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT PHARMACOL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky			Mattson, Mark P/F-6038-2012	Barger, Steven/0000-0001-6049-6480				AKON DL, 1991, BRAIN RES REV, V16, P193; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BARGER SW, 1995, BIOCHEM J, V311, P45, DOI 10.1042/bj3110045; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CRITZ SD, 1992, J NEUROPHYSIOL, V68, P1079, DOI 10.1152/jn.1992.68.4.1079; EGAN TM, 1993, J NEUROPHYSIOL, V69, P1433, DOI 10.1152/jn.1993.69.5.1433; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; Firestein Stuart, 1994, Seminars in Cell Biology, V5, P39, DOI 10.1006/scel.1994.1006; HAYDON PG, 1995, TRENDS NEUROSCI, V18, P196, DOI 10.1016/0166-2236(95)93901-9; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; Sperelakis N, 1994, Adv Pharmacol, V26, P217, DOI 10.1016/S1054-3589(08)60056-3; WAKAMORI M, 1993, J PHYSIOL-LONDON, V463, P585, DOI 10.1113/jphysiol.1993.sp019612; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0	29	289	294	2	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					74	78		10.1038/379074a0	http://dx.doi.org/10.1038/379074a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538744				2022-12-28	WOS:A1996TN21600058
J	SEO, S; OKAMOTO, N; SETO, H; ISHIZUKA, K; SANO, H; OHASHI, Y				SEO, S; OKAMOTO, N; SETO, H; ISHIZUKA, K; SANO, H; OHASHI, Y			TOBACCO MAP KINASE - A POSSIBLE MEDIATOR IN WOUND SIGNAL-TRANSDUCTION PATHWAYS	SCIENCE			English	Article							PATHOGENESIS-RELATED PROTEINS; INHIBITOR-INDUCING FACTOR; JASMONIC ACID; GENE-EXPRESSION; ACQUIRED-RESISTANCE; VIRUS-INFECTION; SALICYLIC-ACID; PHOSPHORYLATION; PLANTS; INDUCTION	A complementary DNA encoding a mitogen-activated protein (MAP) kinase homolog has been isolated from tobacco plants. Transcripts of the corresponding gene were not observed in healthy tobacco leaves but began to accumulate 1 minute after mechanical wounding. In tobacco plants transformed with the cloned complementary DNA, trans inactivation of the endogenous homologous gene occurred, and both production of wound-induced jasmonic acid and accumulation of wound-inducible gene transcripts were inhibited. In contrast, the levels of salicylic acid and transcripts for pathogen-inducible, acidic pathogenesis-related proteins were increased upon wounding. These results indicate that this MAP kinase is part of the initial response of higher plants to mechanical wounding.	NATL INST AGROBIOL RESOURCES,DEPT MOLEC BIOL,TSUKUBA,IBARAKI 305,JAPAN; NARA INST SCI & TECHNOL,IKOMA,NARA 63001,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; TOAGOUSEI CORP LTD,TSUKUBA INST,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	National Institute of Agrobiological Sciences - Japan; Nara Institute of Science & Technology; RIKEN; RIKEN; University of Tsukuba				Seo, Shigemi/0000-0003-4940-288X				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALANDIN T, 1995, PLANT MOL BIOL, V27, P1197, DOI 10.1007/BF00020893; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; EYAL Y, 1992, PLANT MOL BIOL, V19, P589, DOI 10.1007/BF00026785; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; FARMER EE, 1989, P NATL ACAD SCI USA, V86, P1539, DOI 10.1073/pnas.86.5.1539; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAHLBROCK K, 1995, P NATL ACAD SCI USA, V92, P4150, DOI 10.1073/pnas.92.10.4150; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINTHORST HJM, 1990, P NATL ACAD SCI USA, V87, P8756, DOI 10.1073/pnas.87.22.8756; MACKINTOSH C, 1994, PLANT J, V5, P137, DOI 10.1046/j.1365-313X.1994.5010137.x; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MALAMY J, 1992, PLANT J, V2, P642; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MATSUOKA M, 1987, PLANT PHYSIOL, V85, P942, DOI 10.1104/pp.85.4.942; MATZKE M, 1993, ANNU REV PLANT PHYS, V44, P53, DOI 10.1146/annurev.pp.44.060193.000413; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; NAGY F, 1988, PLANT MOL BIOL MANUA; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NOJIRI H, 1992, PLANT CELL PHYSIOL, V33, P1225; OHSHIMA M, 1990, PLANT CELL, V2, P95, DOI 10.1105/tpc.2.2.95; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sambrook J, 1989, MOL CLONING LABORATO; SANO H, 1995, P NATL ACAD SCI USA, V92, P4138, DOI 10.1073/pnas.92.10.4138; SANO H, 1994, P NATL ACAD SCI USA, V91, P10556, DOI 10.1073/pnas.91.22.10556; SANO H, 1994, P NATL ACAD SCI USA, V91, P2582, DOI 10.1073/pnas.91.7.2582; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; URANO T, 1994, MOL GEN GENET, V244, P331; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; XU Y, 1994, PLANT CELL, V6, P1077, DOI 10.1105/tpc.6.8.1077	58	433	464	2	29	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1988	1992		10.1126/science.270.5244.1988	http://dx.doi.org/10.1126/science.270.5244.1988			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533090				2022-12-28	WOS:A1995TL42000041
J	MANIAK, M; RAUCHENBERGER, R; ALBRECHT, R; MURPHY, J; GERISCH, G				MANIAK, M; RAUCHENBERGER, R; ALBRECHT, R; MURPHY, J; GERISCH, G			CORONIN INVOLVED IN PHAGOCYTOSIS - DYNAMICS OF PARTICLE-INDUCED RELOCALIZATION VISUALIZED BY A GREEN FLUORESCENT PROTEIN TAG	CELL			English	Article							ACTIN-BINDING-PROTEIN; DICTYOSTELIUM-DISCOIDEUM; ALPHA-ACTININ; MONOCLONAL-ANTIBODIES; MYOSIN-I; CELLS; MUTANTS; LACKING; GENE; EXPRESSION	Coronin is a protein involved in cell locomotion and cytokinesis of Dictyostelium discoideum. Here we show that coronin is strongly enriched in phagocytic cups formed in response to particle attachment. A fusion of coronin with green fluorescent protein (GFP) accumulates in the cups within less than 1 min upon attachment of a particle and is gradually released from the phagosome within 1 min after engulfment is completed, Phagocytic cup formation competes with leading edge formation and can be interrupted at any stage, When the cup regresses, coronin dissociates from the site of accumulation, TRITC-labeled yeast cells have been used to assay phagocytosis quantitatively in wild-type and coronin-null cells, In the mutant, the rate of uptake is reduced to about one third, which shows that coronin contributes to the efficiency of phagocytosis to about the same extent as it improves the speed of cell locomotion.			MANIAK, M (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.			Maniak, Markus/0000-0001-6442-5372				ASHWORTH JM, 1970, BIOCHEM J, V119, P175, DOI 10.1042/bj1190175; BOF M, 1992, J CELL SCI, V101, P139; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; CLAVIEZ M, 1986, J CELL SCI, V86, P69; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; FURUKAWA R, 1994, CELL MOTIL CYTOSKEL, V29, P46, DOI 10.1002/cm.970290105; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Gerisch G., 1960, Roux Archiv fuer Entwicklungsmechanik Organismen, V152, P632; GERISCH G, 1964, ENCY CINEMATOGRAPHIC, P237; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HANAICHI T, 1986, J ELECTRON MICROSC, V35, P304; HANAKAM F, 1995, J BIOL CHEM, V270, P596, DOI 10.1074/jbc.270.2.596; HARWOOD AJ, 1990, NUCLEIC ACIDS RES, V18, P4292, DOI 10.1093/nar/18.14.4292; Hed J, 1986, Methods Enzymol, V132, P198; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HUMBEL BM, 1992, SCANNING MICROSCOPY, V6, P817; JAY PY, 1992, NATURE, V356, P438, DOI 10.1038/356438a0; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; LUTZ DA, 1993, ANAL BIOCHEM, V214, P205, DOI 10.1006/abio.1993.1478; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; PETERSON MD, 1994, J EUKARYOT MICROBIOL, V41, P852; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHLEICHER M, 1988, J CELL SCI, V90, P59; Segall JE, 1989, CURR OPIN CELL BIOL, V1, P44, DOI 10.1016/S0955-0674(89)80035-3; STEMPAK JG, 1964, J CELL BIOL, V22, P697, DOI 10.1083/jcb.22.3.697; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; VOSSKUHLER C, 1993, J EUKARYOT MICROBIOL, V40, P556; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	42	313	320	0	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					915	924		10.1016/0092-8674(95)90207-4	http://dx.doi.org/10.1016/0092-8674(95)90207-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521515	Bronze			2022-12-28	WOS:A1995TK74500010
J	SUNDARAM, M; HAN, M				SUNDARAM, M; HAN, M			THE C-ELEGANS KSR-1 GENE ENCODES A NOVEL RAF-RELATED KINASE INVOLVED IN RAS-MEDIATED SIGNAL-TRANSDUCTION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VULVAL CELL LINEAGES; PROTEIN; INDUCTION; LET-60; IDENTIFICATION; MUTANTS; FATES; PHOSPHORYLATION; EXPRESSION	Vulval induction in C. elegans is controlled by a highly conserved signaling pathway similar to the RTK-Ras-MAPK cascade in mammals. By screening for suppressors of the Multivulva phenotype caused by an activated let-60 ras allele, we isolated mutations in a gene, ksr-1, that acts as a positive modifier of vulval induction and is required for at least two other let-60 ras-mediated processes. Although ksr-1 mutations do not perturb vulval induction in an otherwise wild-type background, they have very strong effects on vulval induction in genetic backgrounds where Ras pathway activity is constitutively activated or compromised, suggesting that ksr-1 activity is required for maximal stimulation of vulval fates by the Ras pathway. Genetic epistasis analysis suggests that ksr-1 acts downstream of or in parallel to let-60 ras. We cloned ksr-1 and have shown that it encodes a novel putative protein kinase related to the Raf family of Ser/Thr kinases.			SUNDARAM, M (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.			Sundaram, Meera/0000-0002-2940-8750	NIGMS NIH HHS [R01 GM47869] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047869] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BEITEL G, 1996, IN PRESS GENES DEV; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BRENNER S, 1974, GENETICS, V77, P71; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; COX GN, 1980, GENETICS, V95, P317; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HODGKIN J, 1979, GENETICS, V91, P67; HOSONO R, 1982, J EXP ZOOL, V224, P135, DOI 10.1002/jez.1402240203; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENEELY PM, 1984, GENETICS, V106, P29; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742	72	243	264	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					889	901		10.1016/0092-8674(95)90205-8	http://dx.doi.org/10.1016/0092-8674(95)90205-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521513	Bronze			2022-12-28	WOS:A1995TK74500008
J	VANESSEN, D; KIKUTANI, H; GRAY, D				VANESSEN, D; KIKUTANI, H; GRAY, D			CD40 LIGAND-TRANSDUCED CO-STIMULATION OF T-CELLS IN THE DEVELOPMENT OF HELPER FUNCTION	NATURE			English	Article							X-LINKED IMMUNODEFICIENCY; HYPER-IGM; B-CELLS; MONOCLONAL-ANTIBODIES; DEFECTIVE EXPRESSION; B7/BB1; SIGNAL	MICE that lack either CD40(1,2) (expressed on B cells) or CD40 ligand(3,4) (expressed on activated T cells) are able neither to make IgG, IgA or IgE antibody responses, nor to generate germinal centres (the sites of formation of memory B cells), It has been assumed that these lesions were the result of an absence of signals to B cells through CD40. Here we show that the failure to signal T cells through CD40 ligand is an important contributory cause. Administration of soluble CD40 in vivo to CD40 knockout mice, restoring the missing signal through CD40 ligand, initiates germinal centre formation, Furthermore, T cells primed in the absence of CD40 (in CD40 knockout mice) are unable to help normal B cells to class switch or to form germinal centres (GC). These results indicate that cc-stimulation of T cells through CD40 ligand causes their differentiation into cells that help B cells to make mature antibody responses and to generate memory populations.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,DIV IMMUNOL,OSAKA 565,JAPAN	Imperial College London; Osaka University			Kikutani, Hitoshi/C-9525-2009; Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934; van Essen, Dominic/0000-0002-7225-1138				ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BUHLMANN JE, 1995, IMMUNITY, V2, P645; CATIGLI E, 1994, P NATL ACAD SCI USA, V9, P12135; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; Gray D, 1994, Semin Immunol, V6, P303, DOI 10.1006/smim.1994.1039; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; GRAY D, 1986, EUR J IMMUNOL, V16, P641, DOI 10.1002/eji.1830160609; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOSCO MH, 1992, J IMMUNOL, V148, P2331; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LENSCHOW DJ, 1994, J IMMUNOL, V153, P1990; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RONCHESE F, 1993, J EXP MED, V177, P679, DOI 10.1084/jem.177.3.679; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	369	376	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					620	623		10.1038/378620a0	http://dx.doi.org/10.1038/378620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524396				2022-12-28	WOS:A1995TJ22100078
J	ETEMADMOGHADAM, B; GUO, S; KEMPHUES, KJ				ETEMADMOGHADAM, B; GUO, S; KEMPHUES, KJ			ASYMMETRICALLY DISTRIBUTED PAR-3 PROTEIN CONTRIBUTES TO CELL POLARITY AND SPINDLE ALIGNMENT IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CYTOPLASMIC LOCALIZATION; SPLICED LEADER; GENE; EMBRYOGENESIS; MICROFILAMENTS; SEGREGATION; MUTATIONS; YEAST; ESTABLISHMENT	The par-3 gene is required for establishing polarity in early C. elegans embryos. Embryos from par-3 homozygous mothers show defects in segregation of cytoplasmic determinants and in positioning of the early cleavage spindles. We report here that the PAR-3 protein is asymmetrically distributed at the periphery of the zygote and asymmetrically dividing blastomeres of the germline lineage. The PAR-3 distribution is roughly the reciprocal of PAR-1, another protein required-for establishing embryonic polarity in C. elegans. Analysis of the distribution of PAR-3 and PAR-1 in other par mutants reveals that par-2 activity is required for proper localization of PAR-3 and that PAR-3 is required for proper localization of PAR-1. In addition, the distribution of the PAR-3 protein correlates with differences in cleavage spindle orientation and suggests a mechanism by which PAR-3 contributes to control of cleavage pattern.			ETEMADMOGHADAM, B (corresponding author), CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027689] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27689] Funding Source: Medline; NIGMS NIH HHS [GM07617] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENG NN, 1995, GENETICS, V139, P549; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; GOODNER B, 1993, PLANT CELL, V5, P1471; GUETHHALLONET C, 1992, TRENDS GENET, V8, P274, DOI 10.1016/0168-9525(92)90134-P; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HOLY J, 1991, J CELL SCI, V98, P423; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KEMPHUES KJ, 1989, FRONTIERS MOL BIOL G; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MAINS PE, 1990, GENETICS, V126, P593; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORTON DG, 1992, GENETICS, V130, P771; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; Nigon V., 1960, B BIOL FR BELG, V94, P132; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRIESS JR, 1994, CURR OPIN GENET DEV, V4, P563, DOI 10.1016/0959-437X(94)90073-C; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; ROSE LS, 1995, DEV BIOL, V168, P479, DOI 10.1006/dbio.1995.1096; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Schierenberg E., 1992, Seminars in Developmental Biology, V3, P25; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; WADDLE JA, 1994, DEVELOPMENT, V120, P2317; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1	49	328	342	0	28	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					743	752		10.1016/0092-8674(95)90187-6	http://dx.doi.org/10.1016/0092-8674(95)90187-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521491	hybrid			2022-12-28	WOS:A1995TH94800011
J	POLYAKOV, A; SEVERINOVA, E; DARST, SA				POLYAKOV, A; SEVERINOVA, E; DARST, SA			3-DIMENSIONAL STRUCTURE OF ESCHERICHIA-COLI CORE RNA-POLYMERASE - PROMOTER-BINDING AND ELONGATION CONFORMATIONS OF THE ENZYME	CELL			English	Article							LAC UV5 PROMOTER; OPEN COMPLEX-FORMATION; LAMBDA-PR PROMOTER; RIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; DUPLEX DNA	The structure of E, coli core RNA polymerase (RNAP) has been determined to similar to 23 Angstrom resolution by three-dimensional reconstruction from electron micrographs of flattened helical crystals. The structure reveals extensive conformational changes when compared with the previously determined E. coli RNAP holoenzyme structure, but resembles the yeast RNAPII structure, While each of these structures contains a thumb-like projection surrounding a channel 25 Angstrom in diameter, the E. coli RNAP holoenzyme thumb defines a deep but open groove on the molecule, whereas the thumb of E. coli core and yeast RNAPII form part of a ring that surrounds the channel. This may define promoter-binding and elongation conformations of RNAP, as E. coli holoenzyme recognizes promoter sites on double-stranded DNA, while both E. coli core and yeast RNAPII are elongating forms of the polymerase and ate incapable of promoter recognition.			POLYAKOV, A (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ALYAR SE, 1994, J BIOL CHEM, V269, P13179; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BONNER G, 1994, J BIOL CHEM, V269, P25129; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BRISSON A, 1984, J CELL BIOL, V99, P1202, DOI 10.1083/jcb.99.4.1202; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAMBERLIN MJ, 1993, HARVEY LECT, V88, P1; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1988, J MOL BIOL, V203, P269, DOI 10.1016/0022-2836(88)90107-6; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)80223-H; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hessler D, 1992, Neuroimage, V1, P55, DOI 10.1016/1053-8119(92)90007-A; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KENSLER RW, 1982, J MUSCLE RES CELL M, V3, P349, DOI 10.1007/BF00713042; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg RD, 1991, CURR OPIN STRUC BIOL, V1, P642, DOI 10.1016/S0959-440X(05)80090-9; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NEFF NF, 1980, BIOCHEMISTRY-US, V19, P3005, DOI 10.1021/bi00554a027; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PARK CS, 1982, J BIOL CHEM, V257, P6950; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; ROSENBERG S, 1982, J MOL BIOL, V155, P31, DOI 10.1016/0022-2836(82)90490-9; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WELLINGTON SR, 1991, BIOCHEM BIOPH RES CO, V179, P1107, DOI 10.1016/0006-291X(91)91934-5; WU FYH, 1976, BIOCHEMISTRY-US, V15, P3254, DOI 10.1021/bi00660a014; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	77	157	159	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					365	373		10.1016/0092-8674(95)90114-0	http://dx.doi.org/10.1016/0092-8674(95)90114-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521466	Bronze			2022-12-28	WOS:A1995TC97700006
J	VERSCHUEREN, KHG; SELJEE, F; ROZEBOOM, HJ; KALK, KH; DIJKSTRA, BW				VERSCHUEREN, KHG; SELJEE, F; ROZEBOOM, HJ; KALK, KH; DIJKSTRA, BW			CRYSTALLOGRAPHIC ANALYSIS OF THE CATALYTIC MECHANISM OF HALOALKANE DEHALOGENASE	NATURE			English	Article							XANTHOBACTER-AUTOTROPHICUS GJ10; ALPHA-HELIX DIPOLE; X-RAY-DIFFRACTION; HALOGENATED ALKANES; ENZYME INTERMEDIATE; SERINE PROTEINASE; CRYSTAL; ACETYLCHOLINESTERASE; PURIFICATION; DEGRADATION	Crystal structures of haloalkane dehalogenase were determined in the presence of the substrate 1,2-dichloroethane. At pH 5 and 4-degrees-C, substrate is bound in the active site without being converted; warming to room temperature causes the substrate's carbon-chlorine bond to be broken, producing a chloride ion with concomitant alkylation of the active-site residue Asp124. At pH 6 and room temperature the alkylated enzyme is hydrolysed by a water molecule activated by the His289-Asp260 pair in the active site. These results show that catalysis by the dehalogenase proceeds by a two-step mechanism involving an ester intermediate covalently bound at Asp124.	UNIV GRONINGEN,BIOSON RES INST,NIJENBORGH 4,9747 AG GRONINGEN,NETHERLANDS; UNIV GRONINGEN,BIOPHYS CHEM LAB,9747 AG GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen			Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477				DOUGLAS KT, 1976, J AM CHEM SOC, V98, P8231, DOI 10.1021/ja00441a057; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FROEDE HC, 1984, J BIOL CHEM, V259, P1010; HAJDU J, 1987, NATURE, V329, P178, DOI 10.1038/329178a0; HAMILTON WC, 1965, ACTA CRYSTALLOGR, V18, P129, DOI 10.1107/S0365110X65000233; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JANSSEN DB, 1988, EUR J BIOCHEM, V171, P67, DOI 10.1111/j.1432-1033.1988.tb13759.x; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEUNING S, 1985, J BACTERIOL, V163, P635, DOI 10.1128/JB.163.2.635-639.1985; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROZEBOOM HJ, 1988, J MOL BIOL, V200, P611, DOI 10.1016/0022-2836(88)90548-7; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VERSCHUEREN KHG, IN PRESS J MOL BIOL	27	412	417	3	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					693	698		10.1038/363693a0	http://dx.doi.org/10.1038/363693a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515812	Green Submitted			2022-12-28	WOS:A1993LJ33900047
J	VANHAM, SM; VANALPHEN, L; MOOI, FR; VANPUTTEN, JPM				VANHAM, SM; VANALPHEN, L; MOOI, FR; VANPUTTEN, JPM			PHASE VARIATION OF HAEMOPHILUS-INFLUENZAE FIMBRIAE - TRANSCRIPTIONAL CONTROL OF 2 DIVERGENT GENES THROUGH A VARIABLE COMBINED PROMOTER REGION	CELL			English	Article							NONTYPABLE HAEMOPHILUS-INFLUENZAE; OROPHARYNGEAL EPITHELIAL-CELLS; HEMOPHILUS-INFLUENZAE; ESCHERICHIA-COLI; PILIN GENE; RNA-POLYMERASE; MESSENGER-RNA; FRAMESHIFT MUTATION; ANTIGENIC VARIATION; HUMAN-ERYTHROCYTES	The expression of H. influenzae fimbriae is subject to reversible phase variation between three expression levels. This phenomenon is controlled at the transcriptional level of two divergently orientated genes, hifA and hifB, encoding the major fimbrial subunit and the fimbrial chaperone, respectively. The hifA and hifB promoter regions were found to be clustered through an almost complete divergent overlap with a variable DNA backbone of repetitive TA units. Variation in the number of units changes the normally strictly constrained spacing between the -35 and -10 sequences and controls the bidirectional transcription initiation, thus forming a novel mechanism directing multiple gene transcription.	UNIV AMSTERDAM,DEPT MED MICROBIOL,1105 AZ AMSTERDAM,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,3720 BA BILTHOVEN,NETHERLANDS	University of Amsterdam; Netherlands National Institute for Public Health & the Environment	VANHAM, SM (corresponding author), MAX PLANCK INST BIOL,INFEKT BIOL ABT,SPEMANNSTR 34,W-7400 TUBINGEN,GERMANY.			van Putten, Jos/0000-0002-4126-8172				ARMES LG, 1990, J PROTEIN CHEM, V9, P45, DOI 10.1007/BF01024983; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; BAKKER D, 1991, MOL MICROBIOL, V5, P875, DOI 10.1111/j.1365-2958.1991.tb00761.x; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRINTON CC, 1989, PEDIATR INFECT DIS J, V8, pS54; COLEMAN T, 1991, INFECT IMMUN, V59, P1716, DOI 10.1128/IAI.59.5.1716-1722.1991; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; EISENSTEIN BI, 1981, SCIENCE, V214, P337, DOI 10.1126/science.6116279; FARLEY MM, 1990, J INFECT DIS, V161, P274, DOI 10.1093/infdis/161.2.274; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILSDORF JR, 1990, INFECT IMMUN, V58, P1065, DOI 10.1128/IAI.58.4.1065-1072.1990; GUERINA NG, 1982, J INFECT DIS, V146, P564, DOI 10.1093/infdis/146.4.564; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KAR S, 1990, INFECT IMMUN, V58, P903, DOI 10.1128/IAI.58.4.903-908.1990; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LANGERMANN S, 1990, MOL MICROBIOL, V4, P221, DOI 10.1111/j.1365-2958.1990.tb00589.x; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MANDECKI W, 1982, NUCLEIC ACIDS RES, V10, P903, DOI 10.1093/nar/10.3.903; MASON EO, 1985, INFECT IMMUN, V49, P98, DOI 10.1128/IAI.49.1.98-103.1985; MEYER TF, 1990, ANNU REV MICROBIOL, V44, P451; MOOI FR, 1983, J BACTERIOL, V154, P41, DOI 10.1128/JB.154.1.41-49.1983; NIEUWKOOP AJ, 1984, J BACTERIOL, V159, P934, DOI 10.1128/JB.159.3.934-939.1984; PETERSEN C, 1992, MOL MICROBIOL, V6, P277, DOI 10.1111/j.1365-2958.1992.tb01469.x; PETERSEN C, 1991, J BACTERIOL, V173, P2167, DOI 10.1128/JB.173.7.2167-2172.1991; PETERSON ML, 1985, J MOL BIOL, V185, P525, DOI 10.1016/0022-2836(85)90069-5; PICHICHERO ME, 1982, LANCET, V2, P960; READ RC, 1991, J INFECT DIS, V163, P549, DOI 10.1093/infdis/163.3.549; REZNIKOFF WS, 1986, RNA POLYM REGULATION, P105; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SMITH HO, 1981, ANNU REV BIOCHEM, V50, P41, DOI 10.1146/annurev.bi.50.070181.000353; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; STREISINGER G, 1985, GENETICS, V109, P633; TRAVERS AA, 1983, CELL, V35, P265, DOI 10.1016/0092-8674(83)90229-5; TURK DC, 1985, J MED MICROBIOL, V18, P1; VANALPHEN L, 1991, INFECT IMMUN, V59, P4473, DOI 10.1128/IAI.59.12.4473-4477.1991; VANALPHEN L, 1986, FEMS MICROBIOL LETT, V37, P69, DOI 10.1016/0378-1097(86)90218-1; VANALPHEN L, 1983, J INFECT DIS, V148, P75, DOI 10.1093/infdis/148.1.75; VANALPHEN L, 1988, INFECT IMMUN, V56, P1800, DOI 10.1128/IAI.56.7.1800-1806.1988; VANHAM SM, 1989, EMBO J, V8, P3535, DOI 10.1002/j.1460-2075.1989.tb08519.x; WEBER A, 1991, INFECT IMMUN, V59, P4724, DOI 10.1128/IAI.59.12.4724-4728.1991; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; WILLEMS R, 1990, EMBO J, V9, P2803, DOI 10.1002/j.1460-2075.1990.tb07468.x; YOGEV D, 1991, EMBO J, V10, P4069, DOI 10.1002/j.1460-2075.1991.tb04983.x	54	144	146	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1187	1196		10.1016/0092-8674(93)90647-9	http://dx.doi.org/10.1016/0092-8674(93)90647-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513502				2022-12-28	WOS:A1993LH54800014
J	WOODWARD, MN; GRIFFITHS, DM				WOODWARD, MN; GRIFFITHS, DM			USE OF DIPSTICKS FOR ROUTINE ANALYSIS OF URINE FROM CHILDREN WITH ACUTE ABDOMINAL-PAIN	BRITISH MEDICAL JOURNAL			English	Article							TRACT INFECTION		SOUTHAMPTON GEN HOSP,WESSEX REG CTR PAEDIAT SURG,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; LEJEUNE B, 1991, J CLIN PATHOL, V44, P1029, DOI 10.1136/jcp.44.12.1029; SHAW KN, 1991, J PEDIATR-US, V118, P733, DOI 10.1016/S0022-3476(05)80035-6; STEVENS M, 1989, MED LAB SCI, V46, P194; WIGGELINKHUIZEN J, 1988, S AFR MED J, V74, P224	5	25	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1512	1512		10.1136/bmj.306.6891.1512	http://dx.doi.org/10.1136/bmj.306.6891.1512			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518679	Green Published, Bronze			2022-12-28	WOS:A1993LF94000025
J	HARPER, PS				HARPER, PS			RESEARCH SAMPLES FROM FAMILIES WITH GENETIC-DISEASES - A PROPOSED CODE OF CONDUCT	BRITISH MEDICAL JOURNAL			English	Article							HUNTINGTONS-DISEASE; DIAGNOSIS	Research on samples from families with genetic disease underlies many of the major advances that are occurring in medical genetics. But ethical and practical problems may arise when samples from relatives who are healthy but at risk are included in such studies. In particular, new molecular tests for specific gene mutations may result in the detection of a genetic defect in relatives who had neither expected this possibility nor given specific consent to such testing. Family members at risk should not be included in such studies unless strictly necessary, and in such cases specific consent should be obtained and information should be given about the implications of an abnormal result of a test. This is particularly important when stored samples from previous studies without such implications are being reused and is also relevant to the genetic testing of samples taken primarily for epidemiological studies of disorders when only a small proportion of cases is thought to be genetic in origin. There is a need for guidelines to protect both subjects and investigators in a field which is spreading rapidly and involving many clinical and laboratory research workers previously unfamiliar with genetic testing.			HARPER, PS (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							[Anonymous], 1989, REV GUIDANCE RES USE; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; FIRTH MA, 1983, BRIT MED J, V286, P700, DOI 10.1136/bmj.286.6366.700; HARPER PS, 1992, J ROY COLL PHYS LOND, V26, P184; MORRIS MJ, 1989, LANCET, V2, P601; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; YATES JRW, 1989, J MED GENET, V26, P245, DOI 10.1136/jmg.26.4.245; 1992, RESPONSIBILITY INVES; 1984, COMMITTEE INQUIRY HU; 1992, BIBLIO ETHICAL LEGAL; 1991, ETHICAL ISSUES CLIN; 1992, COMMITTEE ETHICS GEN	14	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1391	1394		10.1136/bmj.306.6889.1391	http://dx.doi.org/10.1136/bmj.306.6889.1391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518608	Green Published, Bronze			2022-12-28	WOS:A1993LD82900025
J	Simcic, KJ; Moreno, AJ				Simcic, KJ; Moreno, AJ			Paget's disease of bone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Simcic, KJ (corresponding author), WILLIAM BEAUMONT ARMY MED CTR,EL PASO,TX 79920, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					161	161		10.1056/NEJM199601183340306	http://dx.doi.org/10.1056/NEJM199601183340306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531972				2022-12-28	WOS:A1996TQ01700006
J	Palevsky, PM; Bhagrath, R; Greenberg, A				Palevsky, PM; Bhagrath, R; Greenberg, A			Hypernatremia in hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypernatremia; hospitalization; sodium; fluid therapy; water-electrolyte balance	HYPONATREMIA; DEHYDRATION	Objective: To determine the incidence, clinical characteristics, and outcome for general medical-surgical hospital patients with hypernatremia. Design: A prospective cohort study. Setting: A 942-bed urban university hospital. Patients: All patients who developed a serum sodium concentration of 150 mmol/L or greater during a 3-month observation period. Measurements: Daily fluid balance, mental status, and serum and urine electrolytes and osmolality. Results: 103 patients were identified. Eighteen patients were hypernatremic on hospital admission, and 85 developed hypernatremia during hospitalization. Patients who developed hypernatremia during hospitalization were younger than patients who developed hypernatremia before hospital admission (mean age +/- SD, 58.9 +/- 19.2 years compared with 76.6 +/- 16.6 years; P < 0.01) but did not differ in age from the patients of the general hospitalized population. Eighty-nine percent of patients who developed hypernatremia during hospitalization had urine concentrating defects, primarily as the result of the use of diuretics or of solute diuresis, whereas only 50% of patients who were hypernatremic on admission could be shown to have concentrating defects (P < 0.01). Fifty-five percent of all hypernatremic patients had increased insensible water losses, and 35% had increased enteral water losses. Eighty-six percent of patients with hospital-acquired hypernatremia lacked free access to water, 74% had enteral water intake of less than 1 L/d, and 94% received less than 1 L of intravenous electrolyte-free water per day during the development of hypernatremia. No supplemental electrolyte-free water was prescribed during the first 24 hours of hypernatremia in 49% of patients. The duration of hypernatremia was shorter in patients who were hypernatremic on admission (median duration, 3 days) than in patients with hospital-acquired hypernatremia (median duration, 5 days; P < 0.05). Mortality was 41% for all patients, but hypernatremia was judged to have contributed to mortality in only 16% of patients. Conclusions: Although the development of hypernatremia before hospital admission occurs primarily in geriatric patients, hospital-acquired hypernatremia was more common in our cohort and had an age distribution similar to that of the general hospitalized population. Hospital-acquired hypernatremia was primarily iatrogenic, resulting from inadequate and inappropriate prescription of fluids to patients with predictably increased water losses and impaired thirst or restricted free water intake or both. Treatment of hypernatremia is often inadequate or delayed. Efforts to manage hypernatremia better and altogether avoid hospital-acquired hypernatremia should focus on both physician education and the development of hospital systems to prevent errors in fluid prescription.	VET AFFAIRS MED CTR, MED SERV, PITTSBURGH, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Palevsky, PM (corresponding author), UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, A919 SCAIFE HALL, 3550 TERRACE ST, PITTSBURGH, PA 15261 USA.		Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400; Greenberg, Arthur/0000-0002-2838-8401				ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; BECK LH, 1987, ANN INTERN MED, V107, P768, DOI 10.7326/0003-4819-107-5-768; BRENNAN J, 1990, J CRIT ILLNESS, V5, P330; DAGGETT P, 1979, BRIT MED J, V1, P1177, DOI 10.1136/bmj.1.6172.1177; FITZSIMONS JT, 1976, KIDNEY INT, V10, P3, DOI 10.1038/ki.1976.74; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HIMMELSTEIN DU, 1983, J AM GERIATR SOC, V31, P466, DOI 10.1111/j.1532-5415.1983.tb05118.x; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LONG CA, 1991, POSTGRAD MED J, V67, P643, DOI 10.1136/pgmj.67.789.643; MACDONALD NJ, 1989, BRIT MED J, V299, P1426, DOI 10.1136/bmj.299.6713.1426; MAHOWALD JM, 1981, J AM GERIATR SOC, V29, P177, DOI 10.1111/j.1532-5415.1981.tb01761.x; PALEVSKY PM, 1992, CURRENT THERAPY NEPH; Plum F, 1966, DIAGNOSIS STUPOR COM, V1st; SNYDER NA, 1987, ANN INTERN MED, V107, P309, DOI 10.7326/0003-4819-107-2-309; TIERNEY WM, 1986, J GEN INTERN MED, V1, P380, DOI 10.1007/BF02596422	16	213	227	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					197	+		10.7326/0003-4819-124-2-199601150-00002	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533994				2022-12-28	WOS:A1996TQ01600002
J	Breathnach, AS; Turnbull, PCB; Eykyn, SJ; Twort, CHC				Breathnach, AS; Turnbull, PCB; Eykyn, SJ; Twort, CHC			A labourer with a spot on his chest	LANCET			English	Article									ST THOMAS HOSP,DEPT MED,LONDON SE1 7EH,ENGLAND; CTR APPL MICROBIOL & RES,ANTHRAX SECT,PORTON DOWN,WILTS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Breathnach, AS (corresponding author), ST THOMAS HOSP,DEPT MICROBIOL,LONDON SE1 7EH,ENGLAND.							IDE CW, 1992, COMMUNICABLE DIS ENV, V21, P4	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					96	96		10.1016/S0140-6736(96)90214-7	http://dx.doi.org/10.1016/S0140-6736(96)90214-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538350				2022-12-28	WOS:A1996TP28100013
J	Celentano, DD; Nelson, KE; Suprasert, S; Eiumtrakul, S; Tulvatana, S; Kuntolbutra, S; Akarasewi, P; Matanasarawoot, A; Wright, NH; Sirisopana, N; Theetranont, C				Celentano, DD; Nelson, KE; Suprasert, S; Eiumtrakul, S; Tulvatana, S; Kuntolbutra, S; Akarasewi, P; Matanasarawoot, A; Wright, NH; Sirisopana, N; Theetranont, C			Risk factors for HIV-1 seroconversion among young men in northern Thailand	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROSEXUAL TRANSMISSION; INFECTION; AIDS; AFRICA; FEMALE; PROSTITUTES; TYPE-1; SPREAD; UGANDA	Objective.-To identify behavioral and sociodemographic risk factors for incident human immunodeficiency virus-1 (HIV-1) infection among healthy young men in northern Thailand. Design.-Men inducted into military service in northern Thailand in May and November 1991 were followed at 6-month intervals until discharge 2 years later. Trained nonmilitary interviewers identified risk factors for HIV-1 infection through interviews with the men. Setting.-Thirteen military bases in northern Thailand. Participants.-A total of 1932 seronegative men, aged 19 to 23 years (average age, 21 years) at enrollment, conscripted into the Royal Thai Army and Air Force from six upper-northern Thai provinces. Main Outcome Measures.-Human immunodeficiency virus-1 seroincidence as determined through enzyme-linked immunosorbent assay and verified by Western blot, and univariate and multivariate analyses of risk factors related to H1V-1 incidence. Results.-A total of 85 men seroconverted to HIV-1 over the period of observation, giving an incidence rate of 2.43 per 100 person-years. Factors strongly associated with HIV-1 seroconversion were frequency of visits to female commercial sex workers (CSWs), sex with men, and incident sexually transmitted diseases (STDs). High frequency of condom use showed a significant (P<.001) protective effect for HIV-1 incidence among men with a history of recent sex with female CSWs in univariate analysis, but a multivariate model demonstrated no difference in HIV-1 seroconversion rates by consistency of condom use. Multivariate analysis incorporating condom use showed that having sex with men (adjusted relative risk [RR], 2.59; 95% confidence interval [CI], 1.08 to 6.25), having sex with CSWs (adjusted RR ranged from 2.54 [95% CI, 1.81 to 3.58] to 2.74 [95% CI, 1.56 to 4.81]), and incident STDs (adjusted RR, 2.38 [95% CI, 1.31 to 4.32]) to be predictors of incident HIV-1 infection. Substance use was not associated with HIV-1 seroconversion rates in multivariate analysis. Conclusion.-The HIV-1 incidence in this cohort of young men appears to be primarily attributable to having sex with female CSWs. Condom use provided some protection, although nor in multivariate analysis; however, condom use has previously been shown likely to be useful in preventing HIV-1 transmission. Thus, programs to increase effective condom use in brothels are essential. Efforts to extend condom use to non-CSW partners are especially needed. More effective prevention and treatment of STDs may also be necessary to decrease HIV-1 infection in this population.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CHIANG MAI UNIV,DEPT FAMILY MED,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,OFF PRESIDENT,CHIANG MAI 50000,THAILAND; MINIST PUBL HLTH,ROYAL THAI AF,CHIANG MAI,THAILAND; MINIST PUBL HLTH,ROYAL THAI ARMY,CHIANG MAI,THAILAND; ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ; ARMED FORCES RES INST MED SCI,BANGKOK 10400,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University; Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	Celentano, DD (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,624 N BROADWAY,BALTIMORE,MD 21205, USA.							AKARASEWI P, 1991, 9TH NAT THAI SEM EP; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BEYRER C, 1995, AIDS, V9, P171, DOI 10.1097/00002030-199509020-00009; BROWN T, 1994, AIDS, V8, pS131; CAMERON DW, 1989, LANCET, V2, P403; CARAEL M, 1988, AIDS, V2, P201; CARR JK, 1994, J ACQ IMMUN DEF SYND, V7, P1270; CELENTANO DD, 1994, AIDS, V8, P533, DOI 10.1097/00002030-199404000-00018; CELENTANO DD, 1993, AIDS, V7, P1647, DOI 10.1097/00002030-199312000-00016; CONANT M, 1986, JAMA-J AM MED ASSOC, V255, P1706, DOI 10.1001/jama.1986.03370130062013; CONANT MA, 1984, SEX TRANSM DIS, V11, P94, DOI 10.1097/00007435-198404000-00009; CORWIN JA, 1991, 7TH INT C AIDS FLOR; DESJARLAIS D, 1991, 8TH INT C AIDS FLOR; ESTEBANEZ P, 1989, 5 INT C AIDS MONTR; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HARRISON L, 1990, 6TH INT C AIDS SAN F; HOOYKAAS C, 1989, 5 INT C AIDS MONTR; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; HUNTER DJ, 1993, EPIDEMIOLOGY, V4, P63, DOI 10.1097/00001648-199301000-00012; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; KUNANUSONT C, 1991, 7TH INT C AIDS FLOR; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LINDAN C, 1991, AIDS, V5, P993, DOI 10.1097/00002030-199108000-00011; MCKEGANEY NP, 1994, AIDS, V8, P1215, DOI 10.1097/00002030-199409000-00002; MEYER H, 1990, AM MED NEWS     0727; MOODIE R, 1993, AIDS, V7, P1543, DOI 10.1097/00002030-199312000-00001; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; NOPKESORN T, 1993, 9TH INT C AIDS 4 STD; NZILA N, 1990, 6TH INT C AIDS SAN F; PADIAN NS, 1987, REV INFECT DIS, V9, P947; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO; PICKERING H, 1992, SOC SCI MED, V34, P75, DOI 10.1016/0277-9536(92)90069-3; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P2094, DOI 10.1001/jama.254.15.2094; RODRIGUES LC, 1993, JAMA-J AM MED ASSOC, V269, P870; RODRIGUES LC, 1992, BRIT MED J, V305, P364, DOI 10.1136/bmj.305.6849.364-a; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; SAWANPANYALERT P, 1994, AIDS, V8, P825, DOI 10.1097/00002030-199406000-00016; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; SITTITRAI W, 1994, AIDS, V8, pS143; SWADDIWUDHIPONG W, 1990, SE ASIAN J TROP MED, V2, P447; THANPRASERTSUK S, 1991, 7TH INT C AIDS FLOR; THOMAS MR, 1990, 6TH INT C AIDS SAN F; UNGCHUSAK K, 1991, 7 INT C AIDS FLOR; UNGPHAKORN J, 1994, AIDS S2, V8, pS133; VANICHSENI S, 1990, 6TH INT C AIDS SAN F; VANLANDINGHAM MJ, 1992, 1992 ANN M POP ASS A; WANGROONGSARB Y, 1985, SE ASIAN J TROP MED, V16, P717; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; WENIGER BG, 1994, AIDS, V8, P1007, DOI 10.1097/00002030-199407000-00020; YU XF, 1995, J VIROL, V69, P4649, DOI 10.1128/JVI.69.8.4649-4655.1995; 1990, PRESENTATION FINDING	60	57	58	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					122	127		10.1001/jama.275.2.122	http://dx.doi.org/10.1001/jama.275.2.122			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531307				2022-12-28	WOS:A1996TN28000028
J	Moss, M; Bucher, B; Moore, FA; Moore, EE; Parsons, PE				Moss, M; Bucher, B; Moore, FA; Moore, EE; Parsons, PE			The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APACHE-II; TRAUMA; PROGNOSIS; MORTALITY; SYSTEM	Objective.-To determine the effect of a history of chronic alcohol abuse on the incidence of acute respiratory distress syndrome (ARDS) and in-hospital mortality. Design.-Prospective cohort study. Patients.-A total of 351 medical and surgical intensive care unit patients with one of seven at-risk diagnoses for the development of ARDS. Main Outcome Measures.-The development of ARDS and in-hospital mortality. Results.-Of the 351 patients enrolled in the study, the incidence of ARDS in patients with a history of alcohol abuse was significantly higher than in patients without a history of alcohol abuse (43% vs 22%) (P<.001; relative risk [RR], 1.98; 95% confidence interval [Cl], 1.32 to 2.85), in patients with sepsis, ARDS developed in 52% of the patients with a prior history of alcohol abuse compared with only 20% in patients without a history of alcohol abuse (P<.001; RR, 2.59; 95% Cl, 1.29 to 5.12). Fifty-one percent (52/102) of the patients who developed ARDS died compared with only 14% (36/249) of patients who did not develop ARDS (P<.001). In the subset of patients who developed ARDS, the in-hospital mortality rate was 65% in patients with a prior history of alcohol abuse. This mortality rate was significantly higher (P=.003) than the mortality rate in patients without a history of alcohol abuse (36%). Conclusions.-A prior history of chronic alcohol abuse significantly increases the risk of developing ARDS in critically ill patients with an identified at-risk diagnosis. Our results may be useful in the earlier and more accurate identification of patients at high risk for developing ARDS.	DENVER GEN HOSP,DEPT MED,DENVER,CO 80204; DENVER GEN HOSP,DEPT SURG,DENVER,CO 80204; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT BIOSTAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT SURG,DENVER,CO 80262	Denver Health Medical Center; Denver Health Medical Center; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001849, P50HL040784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40784, K08 HL01849] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLA AK, 1993, ADV EXP MED BIOL, V335, P165; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Capps JA, 1923, J AMER MED ASSOC, V80, P0750, DOI 10.1001/jama.1923.02640380014005; Doyle R. L., 1995, Journal of Investigative Medicine, V43, p143A; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; HALLENGREN B, 1978, ACTA MED SCAND, V204, P43; HANLEY ME, 1994, SEMIN RESP CRIT CARE, V15, P260; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; HUDSON LD, 1994, SEM RESP CRIT CARE M, V15, P254, DOI 10.1055/s-2007-1006371; HUDSON LD, 1982, CLIN CHEST MED, V3, P195; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KELSEY JL, 1986, METHODS OBSERVATIONA, P285; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MATUSCHAK GM, 1987, J CRIT CARE, V2, P162, DOI 10.1016/0883-9441(87)90003-7; MATUSCHAK GM, 1990, AM REV RESPIR DIS, V141, P1296, DOI 10.1164/ajrccm/141.5_Pt_1.1296; MCANENA OJ, 1992, J TRAUMA, V33, P504, DOI 10.1097/00005373-199210000-00003; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MOORE EE, 1981, J TRAUMA, V21, P439; MOSS M, 1995, CRIT CARE MED, V23, P1629, DOI 10.1097/00003246-199510000-00006; MOSS M, 1994, AM J RESP CRIT CARE, V149, pA417; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; RINALDO JE, 1986, CHEST, V90, P470, DOI 10.1378/chest.90.4.470; 1985, NATIONAL I ALCOHOL A	26	319	322	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					50	54		10.1001/jama.275.1.50	http://dx.doi.org/10.1001/jama.275.1.50			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TM238	8531287				2022-12-28	WOS:A1996TM23800022
J	BURATOWSKI, S				BURATOWSKI, S			MECHANISMS OF GENE ACTIVATION	SCIENCE			English	Editorial Material											BURATOWSKI, S (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SAUER F, 1995, SCIENCE, V270, P1782	11	19	20	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1773	1774		10.1126/science.270.5243.1773	http://dx.doi.org/10.1126/science.270.5243.1773			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525364				2022-12-28	WOS:A1995TK47600031
J	CORREABORDES, J; NURSE, P				CORREABORDES, J; NURSE, P			P25(RUM1) ORDERS S-PHASE AND MITOSIS BY ACTING AS AN INHIBITOR OF THE P34(CDC2) MITOTIC KINASE	CELL			English	Article							P34CDC2 PROTEIN-KINASE; FISSION YEAST; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ENCODES; CDC13; CDC2+	p25(rum1) from the fission yeast S. pombe is shown to act as a specific in vitro inhibitor of the p34(cdc2)/p56(cdc13) mitotic kinase. It is also shown that early G1 cells contain p25(rum1), which associates with and inhibits the mitotic kinase, and maintains p56(cdc13) miotic B cyclin at a low level, ensuring that these cells do not undergo a premature lethal entry into mitosis. A high level of p25(rum1) in G2 cells inhibits the p34(cdc2)/p56(cdc13) kinase that removes the block preventing a further S phase and leads to repeated rounds of DNA replication. Thus, the cyclin-dependent kinase inhibitor p25(rum1), acting on the p34(cdc2) mitotic kinase, plays an important role in ensuring the correct sequence of S phase and mitosis during the cell cycle.			CORREABORDES, J (corresponding author), IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Correa-Bordes, Jaime/H-5545-2015	Correa-Bordes, Jaime/0000-0002-1961-4761				ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BASI G, 1995, MOL CELL BIOL, V15, P2028; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CONNOLLY T, 1994, MOL CELL BIOL, V14, P768, DOI 10.1128/MCB.14.1.768; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; FISHER DL, 1996, IN PRESS EMBO J; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OBARAISHIHARA T, 1994, EMBO J, V13, P1863, DOI 10.1002/j.1460-2075.1994.tb06455.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4	45	175	177	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1001	1009		10.1016/0092-8674(95)90215-5	http://dx.doi.org/10.1016/0092-8674(95)90215-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521500	Bronze			2022-12-28	WOS:A1995TK74500018
J	SMEDLEY, SR; EISNER, T				SMEDLEY, SR; EISNER, T			SODIUM UPTAKE BY PUDDLING IN A MOTH	SCIENCE			English	Article							BUTTERFLIES	Male Lepidoptera commonly visit stands of water to drink, a behavior known as puddling. Males of the notodontid moth Gluphisia septentrionis routinely puddle for hours, imbibing hundreds of gut-loads and voiding the fluid as repetitive anal jets. Cationic analyses showed puddling to lead to systemic sodium gain, a potential benefit to Gluphisia, whose larval food plant is low in sodium. Male Gluphisia are specialized for puddling, possessing a wide oral slit and a highly expanded enteric surface. The acquired sodium is transferred to the female at mating, for eventual incorporation into the eggs. Sodium acquisition may be the primary function of puddling in Lepidoptera.			SMEDLEY, SR (corresponding author), CORNELL UNIV, NEUROBIOL & BEHAV SECT, SEELEY G MUDD HALL, ITHACA, NY 14853 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI002908] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 02908] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER P H, 1982, Journal of the Lepidopterists' Society, V36, P161; ADLER PH, 1982, CAN J ZOOL, V60, P322, DOI 10.1139/z82-043; ARMS K, 1974, SCIENCE, V185, P372, DOI 10.1126/science.185.4148.372; BOTKIN DB, 1973, P NATL ACAD SCI USA, V70, P2745, DOI 10.1073/pnas.70.10.2745; Denton D., 1984, HUNGER SALT ANTHR PH, V1st; Harvey W.R., 1980, P105; JONES RL, 1985, MINERAL LICKS; KRIZEK G O, 1989, Journal of Research on the Lepidoptera, V27, P143; LABARBERA M, 1982, AM SCI, V70, P54; LIKENS GE, 1970, YALE U SCH FORESTRY, V79; Mattson W.J., 1987, P105; McDowell LR, 1992, MINERALS ANIMAL HUMA; MENEELY GR, 1976, NUTR REV, V34, P225; MILLER JS, 1991, B AM MUS NAT HIST, P1; PHILLIPS JE, 1986, ADV INSECT PHYSIOL, V19, P329; PIVNICK KA, 1987, PHYSIOL ENTOMOL, V12, P461, DOI 10.1111/j.1365-3032.1987.tb00773.x; PLETSCHER DH, 1982, THESIS YALE U NEW HA; POULTON EB, 1917, P ENTOMOL SOC LONDON, V65, P77; REINTHAL WJ, 1963, J LEPID SOC, V17, P35; SMEDLEY SR, 1993, THESIS CORNELL U ITH; 1988, ICAP 61 OPERATORS MA	21	84	98	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1816	1818		10.1126/science.270.5243.1816	http://dx.doi.org/10.1126/science.270.5243.1816			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525374				2022-12-28	WOS:A1995TK47600044
J	AITCHISON, TC; SIREL, JM; WATT, DC; MACKIE, RM				AITCHISON, TC; SIREL, JM; WATT, DC; MACKIE, RM			PROGNOSTIC TREES TO AID PROGNOSIS IN PATIENTS WITH CUTANEOUS MALIGNANT-MELANOMA	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL	Objectives-To design user friendly guides to prognosis for patients who have had invasive primary cutaneous malignant melanomas surgically excised. Design--Adaptation of the classification tree method was used to derive prognostic trees for four different subgroups of malignant melanoma patients in whom known and possible prognostic variables interacted in different ways. Setting-Scotland. Subjects-Statistical modelling for prognostic trees was based on 1978 patients whose primary malignant melanoma was first diagnosed in 1979-86 for whom five year follow up and all relevant clinical pathological data were available, The resultant model was validated with 300 patients first diagnosed in 1987 for whom the same information was available. Main outcome measures--Actual and predicted rate of survival after diagnosis of primary cutaneous malignant melanoma. Results--The four subgroups of patients were men and women with ulcerated and non-ulcerated cutaneous primary melanomas. Validation of the model showed excellent agreement between actual status of patients in the relevant subgroups and their status as predicted by the model. Conclusions--The prognostic trees are simple to use and give more accurate prognosis for individual patients than is currently available from tumour thickness alone.	UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow; University of Glasgow								BALCH CM, 1992, CUTANEOUS MELANOMA, P165; Brieman L, 1984, CLASSIFICATION REGRE; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; EVERITT BS, 1989, STATISTICAL METHODS, P83; MACKIE RM, 1995, BRIT J CANCER, V71, P173, DOI 10.1038/bjc.1995.35; RIGEL DS, 1991, DERMATOL CLIN, V9, P631; VOSSAERT KA, 1992, J AM ACAD DERMATOL, V26, P429, DOI 10.1016/0190-9622(92)70068-Q	7	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1536	1539		10.1136/bmj.311.7019.1536	http://dx.doi.org/10.1136/bmj.311.7019.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520396	Green Published			2022-12-28	WOS:A1995TK21400023
J	HARRISON, MJ; VANBUUREN, ML				HARRISON, MJ; VANBUUREN, ML			A PHOSPHATE TRANSPORTER FROM THE MYCORRHIZAL FUNGUS GLOMUS VERSIFORME	NATURE			English	Article							DIRECT LINEAR PLOT; SACCHAROMYCES-CEREVISIAE; CONSTITUTIVE MUTATION; INORGANIC-PHOSPHATE; NUCLEOTIDE-SEQUENCE; PHOSPHORUS UPTAKE; PLANTS; ROOTS; PARAMETERS; HYPHAE	VESICULAR-arbuscular (A) mycorrhizal fungi form symbiotic associations with the roots of most terrestrial plants, including many agriculturally important crop species(1-3). The fungi colonize the cortex of the root to obtain carbon from their plant host, while assisting the plant with the uptake of phosphate and other mineral nutrients from the soil(2-5). This association is beneficial to the plant, because phosphate is essential for plant growth and development, especially during growth under nutrient-limiting conditions(2,6-8). Molecular genetic studies of these fungi and their interaction with plants have been limited owing to the obligate symbiotic nature of the VA fungi, so the molecular mechanisms underlying fungal-mediated uptake and translocation of phosphate from the soil to the plant remain unknown. Here we begin to investigate this process by identifying a complementary DNA that encodes a transmembrane phosphate transporter (GvPT) from Glomus versiforme, a VA mycorrhizal fungus. The function of the protein encoded by GvPT was confirmed by complementation of a yeast phosphate transport mutant. Expression of GvPT was localized to the external hyphae of G. versiforme during mycorrhizal associations, these being the initial site of phosphate uptake from the soil.			HARRISON, MJ (corresponding author), SAMUEL ROBERTS NOBLE FDN INC,DIV PLANT BIOL,2510 SAM NOBLE PKWY,ARDMORE,OK 73401, USA.							AMMERER G, 1983, METHOD ENZYMOL, V101, P192; Beever R. E., 1980, Advances in Botanical Research, V8, P127, DOI 10.1016/S0065-2296(08)60034-8; BERHE A, 1995, EUR J BIOCHEM, V227, P566, DOI 10.1111/j.1432-1033.1995.tb20426.x; Bethlenfalvay Gabor J., 1992, V54, P1; BRADY JF, 1989, COMPUT METH PROG BIO, V28, P271, DOI 10.1016/0169-2607(89)90160-0; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; ECKENRODE VK, 1985, J MOL EVOL, V21, P259, DOI 10.1007/BF02102358; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Harley J.L., 1983, MYCORRHIZAL SYMBIOSI; HARRISON MJ, 1994, PLANT J, V6, P9, DOI 10.1046/j.1365-313X.1994.6010009.x; JAKOBSEN I, 1992, NEW PHYTOL, V120, P371, DOI 10.1111/j.1469-8137.1992.tb01077.x; JEFFRIES P, 1987, CRC CR REV BIOTECHN, V5, P319, DOI 10.3109/07388558709079476; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; MANN BJ, 1989, GENE, V83, P281, DOI 10.1016/0378-1119(89)90114-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; PEARSON JN, 1993, NEW PHYTOL, V124, P489, DOI 10.1111/j.1469-8137.1993.tb03840.x; PEARSON JN, 1993, NEW PHYTOL, V124, P481, DOI 10.1111/j.1469-8137.1993.tb03839.x; PFLEGER FL, 1994, APS S SERIES; SANDERS FE, 1971, NATURE, V233, P278, DOI 10.1038/233278c0; SIMON L, 1992, APPL ENVIRON MICROB, V58, P291, DOI 10.1128/AEM.58.1.291-295.1992; SMITH SE, 1990, NEW PHYTOL, V114, P1, DOI 10.1111/j.1469-8137.1990.tb00370.x; SMITH SE, 1988, ANNU REV PLANT PHYS, V39, P221, DOI 10.1146/annurev.arplant.39.1.221; SMITH SSE, 1980, BIOL REV, V55, P475, DOI 10.1111/j.1469-185X.1980.tb00701.x; THOMSON BD, 1990, NEW PHYTOL, V116, P647, DOI 10.1111/j.1469-8137.1990.tb00550.x; TOHE A, 1974, J BACTERIOL, V120, P608, DOI 10.1128/JB.120.2.608-617.1974; UEDA Y, 1975, MOL GEN GENET, V136, P255, DOI 10.1007/BF00334020; VERSAW WK, 1995, GENE, V153, P135, DOI 10.1016/0378-1119(94)00814-9; [No title captured]	30	378	410	2	97	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					626	629		10.1038/378626a0	http://dx.doi.org/10.1038/378626a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524398				2022-12-28	WOS:A1995TJ22100080
J	ALMOND, JW				ALMOND, JW			WILL BOVINE SPONGIFORM ENCEPHALOPATHY TRANSMIT TO HUMANS	BMJ-BRITISH MEDICAL JOURNAL			English	Article											ALMOND, JW (corresponding author), UNIV READING, SCH ANIM & MICROBIAL SCI, READING RG6 2AH, BERKS, ENGLAND.							BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEARMOND SJ, 1993, BRIT MED BULL, V49, P725, DOI 10.1093/oxfordjournals.bmb.a072644; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; WILL RG, 1995, CJD SURVEILLANCE UNI, P4; WYATT JM, 1991, VET REC, V129, P233, DOI 10.1136/vr.129.11.233	12	20	20	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 25	1995	311	7017					1415	1416		10.1136/bmj.311.7017.1415a	http://dx.doi.org/10.1136/bmj.311.7017.1415a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520279	Green Published			2022-12-28	WOS:A1995TG90200028
J	GLISE, B; BOURBON, H; NOSELLI, S				GLISE, B; BOURBON, H; NOSELLI, S			HEMIPTEROUS ENCODES A NOVEL DROSOPHILA MAP KINASE KINASE, REQUIRED FOR EPITHELIAL-CELL SHEET MOVEMENT	CELL			English	Article							LARVAL CUTICLE; ZYGOTIC LOCI; X-CHROMOSOME; PROTEIN; MELANOGASTER; PATTERN; MORPHOGENESIS; PURIFICATION; PHENOTYPES; LIBRARIES	During Drosophila embryogenesis, a cell sheet movement, dorsal closure, allows establishment of the dorsal epidermis. In this morphogenetic process, lateral epithelia undergo a dramatic movement toward the dorsal midline. In the mutant hemipterous (hep), spreading of the epithelia is blocked; in genetically sensitized hep embryos, cell sheet movement can be arrested at any time, indicating hep requirement in maintaining this morphogenetic activity. Further, hep is required for expression in the dorsal epithelium edges of another dorsal closure gene, puckered, The HEP protein is homologous to the Jun kinase kinase (JNKK) group of mitogen-activated protein kinase kinases (MAPKKs), These data suggest that hep functions in a novel Drosophila MAPK pathway, controlling puckered expression and morphogenetic activity of the dorsal epidermis.			GLISE, B (corresponding author), CNRS,CTR DEV BIOL,UNITE MIXTE RECH 9925,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE.			Noselli, stephane/0000-0002-7296-324X; Glise, Bruno/0000-0001-9135-8822				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARIAS AM, 1993, DEV DROSOPHILA MELAN, V1, P517; ASHBUMER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHOU TB, 1992, GENETICS, V131, P643; COSTA M, 1993, DEV DROSOPHILA; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIAS MS, 1992, PEDIATR NEUROSURG, V18, P229, DOI 10.1159/000120670; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FEHON RG, 1994, DEVELOPMENT, V120, P545; FRISTROM D, 1988, TISSUE CELL, V20, P645, DOI 10.1016/0040-8166(88)90015-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LEPTIN M, 1994, CURR BIOL, V4, P709, DOI 10.1016/S0960-9822(00)00156-1; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; NOSELLI S, 1992, MOL CELL BIOL, V12, P724, DOI 10.1128/MCB.12.2.724; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; RAMAIN P, 1993, DEVELOPMENT, V149, P1277; RAY RP, 1991, DEVELOPMENT, V113, P35; RING JM, 1993, DEVELOPMENT S, V119, P251; SAMBROOK S, 1989, MOL CLONING LABORATO; SEGER R, 1992, J BIOL CHEM, V267, P14373; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TERRACOL R, 1994, GENETICS, V138, P165; Thummel CS, 1992, DROS INF SERV, V71, P150; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VALLE D, 1992, INSECT BIOCHEM MOLEC, V23, P457; Wieschaus E., 1986, P199; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WINICK J, 1993, DEVELOPMENT, V119, P1055; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	56	283	289	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					451	461		10.1016/0092-8674(95)90123-X	http://dx.doi.org/10.1016/0092-8674(95)90123-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521475	Bronze			2022-12-28	WOS:A1995TC97700015
J	LEHMANN, R				LEHMANN, R			CELL-CELL SIGNALING, MICROTUBULES, AND THE LOSS OF SYMMETRY IN THE DROSOPHILA OOCYTE	CELL			English	Review											LEHMANN, R (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST,DEPT BIOL,CAMBRIDGE,MA 02142, USA.							CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; GERHART J, 1989, DEVELOPMENT, V107, P37; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; MARGOLIS J, 1995, IN PRESS DEVELOPMENT; MORISATO D, 1995, IN PRESS ANN REV GEN, V29; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; RONGO C, 1996, IN PRESS TRENDS GENE; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; SCHUPBACH T, 1994, CURR OPIN GENET DEV, V4, P502, DOI 10.1016/0959-437X(94)90064-A; Spradling Allan C., 1993, P1; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0	15	44	44	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					353	356		10.1016/0092-8674(95)90111-6	http://dx.doi.org/10.1016/0092-8674(95)90111-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521463	Bronze			2022-12-28	WOS:A1995TC97700003
J	TENG, BB; BURANT, CF; DAVIDSON, NO				TENG, BB; BURANT, CF; DAVIDSON, NO			MOLECULAR-CLONING OF AN APOLIPOPROTEIN-B MESSENGER-RNA EDITING PROTEIN	SCIENCE			English	Article							SMALL-INTESTINE; CHANNELS; BINDING; TISSUE; SITE; RAT	Mammalian apolipoprotein B (apo B) exists in two forms, each the product of a single gene. The shorter form, apo B48, arises by posttranscriptional RNA editing whereby cytidine deamination produces a UAA termination codon. A full-length complementary DNA clone encoding an apo B messenger RNA editing protein (REPR) was isolated from rat small intestine. The 229-residue protein contains consensus phosphorylation sites and leucine zipper domains. HepG2 cell extracts acquire editing activity when mixed with REPR from oocyte extracts. REPR is essential for apo B messenger RNA editing, and the isolation and characterization of REPR may lead to the identification of other eukaryotic RNA editing proteins.	UNIV CHICAGO,DEPT MED,MC 4076,CHICAGO,IL 60637	University of Chicago			Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, K04HL002166, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO-4 HL-02166, HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; KAYANO T, 1990, J BIOL CHEM, V265, P13276; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; PEASE RJ, 1990, J BIOL CHEM, V265, P553; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SUMIKAWA K, 1984, EMBO J, V3, P2291, DOI 10.1002/j.1460-2075.1984.tb02128.x; TENG B, UNPUB; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1992, J BIOL CHEM, V267, P21265; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; WU JH, 1990, J BIOL CHEM, V265, P12312	29	502	523	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1816	1819		10.1126/science.8511591	http://dx.doi.org/10.1126/science.8511591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511591				2022-12-28	WOS:A1993LH20500054
J	SAHA, S; BRICKMAN, JM; LEHMING, N; PTASHNE, M				SAHA, S; BRICKMAN, JM; LEHMING, N; PTASHNE, M			NEW EUKARYOTIC TRANSCRIPTIONAL REPRESSORS	NATURE			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; YEAST; ACTIVATORS; DROSOPHILA; PROTEIN; INVITRO; DORSAL; INITIATION; SEQUENCES	TRANSCRIPTIONAL activating sequences have been described1 that are encoded by parts of the genome of Escherichia coli. These acidic peptides, fused to a DNA-binding fragment of the yeast transcriptional activator GAL4, activate transcription of a gene in a wide array of eukaryotes, provided that gene bears GAL4-binding sites nearby2-4. Here we describe an E. coli-encoded sequence that, when attached to the same DNA-binding fragment (GAL4(1-147)), converts that fragment into a repressor. Thus, as assayed in yeast or in vitro in yeast extracts, this molecule represses transcription when bound upstream of a variety of different activators. Two additional repressing regions that work when tethered upstream, a multiple mutant derivative of the original isolate and a synthetic peptide are, like the original isolate, highly basic. At least one activator can be inhibited by the mutant but not by the parental repressing region. These and other findings suggest that these repressing regions interact with and inhibit the activity of activating regions bound nearby on DNA.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University				Brickman, Joshua/0000-0003-1580-7491				DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KAMENS J, 1991, NEW BIOL, V3, P1005; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1992, GENETIC SWITCH GENE; RAY RP, 1991, DEVELOPMENT, V113, P35; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; van Holde KE., 1989, SPRINGER SERIES MOL; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	23	86	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					648	652		10.1038/363648a0	http://dx.doi.org/10.1038/363648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510759				2022-12-28	WOS:A1993LH13900062
J	Bisno, AL; Stevens, DL				Bisno, AL; Stevens, DL			Current concepts - Streptococcal infections of skin and soft tissues	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOXIC SHOCK SYNDROME; ACUTE RHEUMATIC-FEVER; TUMOR-NECROSIS-FACTOR; NECROTIZING FASCIITIS; PYOGENES; ERYTHROMYCIN; PENICILLIN; CELLULITIS; THERAPY; GLOMERULONEPHRITIS		UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL; VET AFFAIRS MED CTR,INFECT DIS SECT,BOISE,ID; UNIV WASHINGTON,SCH MED,SEATTLE,WA	University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	Bisno, AL (corresponding author), VET AFFAIRS MED CTR,MED SERV,1201 NW 16TH ST,MIAMI,FL 33125, USA.							BADDOUR LM, 1982, ANN INTERN MED, V97, P493, DOI 10.7326/0003-4819-97-4-493; BADDOUR LM, 1985, AM J MED, V79, P155, DOI 10.1016/0002-9343(85)90003-8; BARRY W, 1992, JAMA-J AM MED ASSOC, V267, P3315, DOI 10.1001/jama.267.24.3315; BINNICK AN, 1980, ARCH DERMATOL, V116, P798, DOI 10.1001/archderm.116.7.798; BISNO AL, 1970, NEW ENGL J MED, V283, P561, DOI 10.1056/NEJM197009102831103; BISNO AL, 1973, J LAB CLIN MED, V81, P410; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BISNO AL, 1987, INFECT IMMUN, V55, P753, DOI 10.1128/IAI.55.3.753-757.1987; CHAPNICK EK, 1992, CLIN INFECT DIS, V14, P1074, DOI 10.1093/clinids/14.5.1074; CHARTIER C, 1990, INT J DERMATOL, V29, P459, DOI 10.1111/j.1365-4362.1990.tb04833.x; CHELSOM J, 1994, LANCET, V344, P1111, DOI 10.1016/S0140-6736(94)90629-7; CRAVEN DE, 1986, J INFECT DIS, V153, P988, DOI 10.1093/infdis/153.5.988; DEMIDOVICH CW, 1990, AM J DIS CHILD, V144, P1313, DOI 10.1001/archpedi.1990.02150360037015; EAGLE H, 1952, AM J MED, V13, P389, DOI 10.1016/0002-9343(52)90293-3; Farley J D, 1990, Can Dis Wkly Rep, V16, P257; FAST DJ, 1989, INFECT IMMUN, V57, P291, DOI 10.1128/IAI.57.1.291-294.1989; FEINGOLD DS, 1993, SEMIN DERMATOL, V12, P331; GAWORZEWSKA E, 1988, EPIDEMIOL INFECT, V100, P257, DOI 10.1017/S095026880006739X; GEMMELL CG, 1981, J CLIN INVEST, V67, P1249, DOI 10.1172/JCI110152; HACKETT SP, 1992, J INFECT DIS, V165, P879, DOI 10.1093/infdis/165.5.879; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; HOOK EW, 1986, ARCH INTERN MED, V146, P295; IWASAKI M, 1993, FEBS LETT, V331, P187, DOI 10.1016/0014-5793(93)80323-M; KAPLAN EL, 1970, J CLIN INVEST, V49, P1405, DOI 10.1172/JCI106358; KAPLAN EL, 1976, J EXP MED, V144, P754, DOI 10.1084/jem.144.3.754; KIEHLBAUCH JA, 1994, ANN INTERN MED, V121, P90, DOI 10.7326/0003-4819-121-2-199407150-00002; KIM YB, 1972, STREPTOCOCCI STREPTO, P33; KOTB M, 1993, INFECT IMMUN, V61, P1194, DOI 10.1128/IAI.61.4.1194-1201.1993; LASCH EE, 1971, J INFECT DIS, V124, P141, DOI 10.1093/infdis/124.2.141; LENTNEK AL, 1990, ARCH INTERN MED, V150, P89, DOI 10.1001/archinte.150.1.89; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; Meleny FK, 1924, ARCH SURG-CHICAGO, V9, P317, DOI 10.1001/archsurg.1924.01120080083007; MERTZ PM, 1989, ARCH DERMATOL, V125, P1069, DOI 10.1001/archderm.125.8.1069; MOLLICK JA, 1993, J CLIN INVEST, V92, P710, DOI 10.1172/JCI116641; NORRBYTEGLUND A, 1994, INFECT IMMUN, V62, P5227, DOI 10.1128/IAI.62.12.5227-5233.1994; RISEMAN JA, 1990, SURGERY, V108, P847; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STAMENKOVIC I, 1984, NEW ENGL J MED, V310, P1689, DOI 10.1056/NEJM198406283102601; STEVENS DL, 1987, ANTIMICROB AGENTS CH, V31, P213, DOI 10.1128/AAC.31.2.213; STEVENS DL, 1995, CLIN INFECT DIS, V20, pS154, DOI 10.1093/clinids/20.Supplement_2.S154; STEVENS DL, 1994, PEDIATR INFECT DIS J, V13, P561, DOI 10.1097/00006454-199406000-00033; STEVENS DL, 1993, J INFECT DIS, V167, P1401, DOI 10.1093/infdis/167.6.1401; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; STEVENS DL, 1988, J INFECT DIS, V158, P23, DOI 10.1093/infdis/158.1.23; STEVENS DL, 1995, ATLAS INFECTIOUS DIS, V2; STEVENS DL, 1994, NEW ENGL J MED, V13, P561; SWARTZ MN, 1995, MANDELL DOUGLAS BENN, P909; SWARTZ MN, 1995, MYOSITIS PRINCIPLES, P929; YONG JM, 1994, LANCET, V343, P1427, DOI 10.1016/S0140-6736(94)92548-8; ZITTERGRUEN M, 1993, PEDIATR EMERG CARE, V9, P26, DOI 10.1097/00006565-199302000-00009; 1993, JAMA-J AM MED ASSOC, V269, P390	52	648	681	0	35	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					240	245		10.1056/NEJM199601253340407	http://dx.doi.org/10.1056/NEJM199601253340407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532002				2022-12-28	WOS:A1996TQ75500007
J	Vento, S; Cainelli, F; Mirandola, F; Cosco, L; DiPerri, G; Solbiati, M; Ferraro, T; Concia, E				Vento, S; Cainelli, F; Mirandola, F; Cosco, L; DiPerri, G; Solbiati, M; Ferraro, T; Concia, E			Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus	LANCET			English	Article							NON-B HEPATITIS; NON-A; IMMUNOSUPPRESSIVE THERAPY; RNA	Background Fulminant hepatitis on withdrawal of chemotherapy has boon described in chronic hepatitis B virus infection, but not in hepatitis C virus (HCV) infection. The relation beween HCV and immune response to this virus, and disease severity, has not been examined. We present two patients with HCV who developed fulminant liver failure after chemotherapy was stopped. Patients and findings Two patients with chronic HCV infection and malignant lymphoma received chemotherapy (cyclophosphamide, adriamycin, vincristine, bleomycin, etoposide, and prednisolone in patient 1; doxorubicin, bleomycin, vinblastine, and dacarbazine in patient 2), on withdrawal of which both developed fulminant hepatitis. Alanine aminotransferase (ALT) concentrations were greatly raised (6030 and 3870 IU/L in patients 1 and 2, respectively), and serum HCV-RNA was low in both patients when severe disease developed (10(2) genome equivalents per mL). Patient 1 died, and necropsy showed massive liver necrosis. Interpretation The findings suggest an immune-mediated mechanism for hepatocyte damage in HCV infection. Careful monitoring of ALT concentrations is necessary in such patients during and after chemotherapy.	A PUGLIESE HOSP,INFECT DIS UNIT,CATANZARO,ITALY		Vento, S (corresponding author), UNIV VERONA,DEPT INFECT DIS,VIA LOCCHI 12,I-37124 VERONA,ITALY.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062; Cainelli, Francesca/0000-0003-1838-3946				BIRD GLA, 1989, Q J MED, V73, P895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCK KM, 1986, ANN INTERN MED, V105, P546; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; DIENES HP, 1982, HEPATOLOGY, V2, P562; FAN FS, 1991, BONE MARROW TRANSPL, V8, P417; FONG TL, 1994, GASTROENTEROLOGY, V107, P196, DOI 10.1016/0016-5085(94)90077-9; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MANZINI P, 1995, HEPATOLOGY, V21, P328, DOI 10.1016/0270-9139(95)90088-8; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111	12	139	142	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					92	93		10.1016/S0140-6736(96)90212-3	http://dx.doi.org/10.1016/S0140-6736(96)90212-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538348				2022-12-28	WOS:A1996TP28100011
J	Billups, B; Attwell, D				Billups, B; Attwell, D			Modulation of non-vesicular glutamate release by pH	NATURE			English	Article							RAT-BRAIN; GLIAL-CELLS; TRANSPORTER; ASPARTATE; SALAMANDER; ISCHEMIA; RETINA; HIPPOCAMPUS; EXPRESSION; MEMBRANE	GLUTAMATE uptake into glial cells helps to keep the brain extracellular glutamate concentration, [glu](0), below levels that kill neurons. Uptake is powered(1-4) by the transmembrane gradients of Na+, K+ and pH. When the extracellular [K+] rises in brain ischaemia, uptake reverses, releasing glutamate into the extracellular space(5,6). Here we show, by monitoring glutamate transport electrically and detecting released glutamate with ion channels in neurons placed outside glial cells, that a raised [Hf] inhibits both forward and reversed glutamate uptake. No electroneutral reversed uptake was detected, contradicting the idea(7) that forward and reversed uptake differ fundamentally. Suppression of reversed uptake by the low pH occurring in ischaemia(8,9) will slow the Ca2+-independent release of glutamate(10) which can raise [glu], to a neurotoxic level(11,12), and will thus protect the brain during a transient loss of blood supply.			Billups, B (corresponding author), UCL, DEPT PHYSIOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Attwell, David/ABE-6750-2020	Billups, Brian/0000-0001-5378-2809	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Attwell David, 1994, Current Opinion in Neurobiology, V4, P353, DOI 10.1016/0959-4388(94)90096-5; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; ELIASOF S, 1993, J NEUROSCI, V13, P402; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; IKEDA M, 1989, NEUROSCI LETT, V96, P202, DOI 10.1016/0304-3940(89)90058-X; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; LORD RSA, 1990, AUST NZ J OPHTHALMOL, V18, P299, DOI 10.1111/j.1442-9071.1990.tb00624.x; MADL JE, 1993, J NEUROSCI, V13, P4429; MOBBS P, 1988, BRAIN RES, V460, P235, DOI 10.1016/0006-8993(88)90368-X; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NADEAU SE, 1994, J FAM PRACTICE, V38, P495; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; NEWMAN EA, 1984, J NEUROPHYSIOL, V51, P164, DOI 10.1152/jn.1984.51.1.164; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SCHWARTZ EA, 1993, NEURON, V10, P1141, DOI 10.1016/0896-6273(93)90062-V; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; YAMADA KA, 1993, J NEUROSCI, V13, P3904	30	128	132	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	1996	379	6561					171	174		10.1038/379171a0	http://dx.doi.org/10.1038/379171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538768				2022-12-28	WOS:A1996TP36000060
J	Pier, GB; Grout, M; Zaidi, TS; Olsen, JC; Johnson, LG; Yankaskas, JR; Goldberg, JB				Pier, GB; Grout, M; Zaidi, TS; Olsen, JC; Johnson, LG; Yankaskas, JR; Goldberg, JB			Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; AERUGINOSA STRAIN PAO; PSEUDOMONAS-AERUGINOSA; DEFECTIVE-MUTANTS; EPITHELIAL-CELLS; LIPOPOLYSACCHARIDE; SURFACE; LOCALIZATION; POLYSACCHARIDE	Cystic fibrosis (CF) patients are hypersusceptible to chronic Pseudomonas aeruginosa lung infections. Cultured human airway epithelial cells expressing the Delta F508 allele of the cystic fibrosis transmembrane conductance regulator (CFTR) were defective in uptake of P. aeruginosa compared with cells expressing the wild-type allele. Pseudomonas aeruginosa lipopolysaccharide (LPS)-core oligosaccharide was identified as the bacterial ligand for epithelial cell ingestion; exogenous oligosaccharide inhibited bacterial ingestion in a neonatal mouse model, resulting In Increased amounts of bacteria in the lungs. CFTR may contribute to a host-defense mechanism that is important for clearance of P. aeruginosa from the respiratory tract.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27599	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Pier, GB (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, R01HL058398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022806, R01AI035674] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42384, R01 HL058398] Funding Source: Medline; NIAID NIH HHS [AI35674, AI22806] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARONSON M, 1988, INFECT IMMUN, V56, P1615, DOI 10.1128/IAI.56.6.1615-1617.1988; BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; CERVIN MA, 1994, MICROB PATHOGENESIS, V17, P291, DOI 10.1006/mpat.1994.1075; COYNE MJ, 1994, J BACTERIOL, V176, P3500, DOI 10.1128/JB.176.12.3500-3507.1994; DALAL E, 1994, INFECT IMMUN, V62, P5505, DOI 10.1128/IAI.62.12.5505-5510.1994; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EVANS DJ, 1994, MOL MICROBIOL, V13, P427, DOI 10.1111/j.1365-2958.1994.tb00437.x; FLEISZIG SMJ, 1995, INFECT IMMUN, V63, P4072, DOI 10.1128/IAI.63.10.4072-4077.1995; GOLDBERG JB, 1992, P NATL ACAD SCI USA, V89, P10716, DOI 10.1073/pnas.89.22.10716; GROUT M, UNPUB; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JARRELL K, 1977, MICROBIOS, V19, P103; JEFFERY PK, 1988, SCANNING MICROSCOPY, V2, P553; KOVAL SF, 1977, J GEN MICROBIOL, V98, P387, DOI 10.1099/00221287-98-2-387; KROPINSKI AM, 1979, CAN J MICROBIOL, V25, P390, DOI 10.1139/m79-060; LAM J, 1980, INFECT IMMUN, V28, P546; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; NELSON JW, 1990, INFECT IMMUN, V58, P1489, DOI 10.1128/IAI.58.6.1489-1495.1990; OHMAN DE, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P28; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ORIKASA S, 1977, INVEST UROL, V15, P185; PENKETH A, 1983, AM REV RESPIR DIS, V127, P605, DOI 10.1164/arrd.1983.127.5.605; PIER GB, 1978, INFECT IMMUN, V22, P908, DOI 10.1128/IAI.22.3.908-918.1978; PIER GB, 1986, J CLIN MICROBIOL, V24, P189, DOI 10.1128/JCM.24.2.189-196.1986; PLOTKOWSKI MC, 1992, J MED MICROBIOL, V36, P104, DOI 10.1099/00222615-36-2-104; ROWE PSN, 1983, EUR J BIOCHEM, V132, P329, DOI 10.1111/j.1432-1033.1983.tb07366.x; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHWAN ET, 1995, MOL MICROBIOL, V15, P267, DOI 10.1111/j.1365-2958.1995.tb02241.x; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; ZAR H, 1995, J PEDIATR-US, V126, P230, DOI 10.1016/S0022-3476(95)70549-X	34	322	334	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					64	67		10.1126/science.271.5245.64	http://dx.doi.org/10.1126/science.271.5245.64			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539601	Green Submitted, Green Accepted			2022-12-28	WOS:A1996TP02200043
J	LOUKERIS, TG; LIVADARAS, I; ARCA, B; ZABALOU, S; SAVAKIS, C				LOUKERIS, TG; LIVADARAS, I; ARCA, B; ZABALOU, S; SAVAKIS, C			GENE-TRANSFER INTO THE MEDFLY, CERATITIS-CAPITATA, WITH A DROSOPHILA-HYDEI TRANSPOSABLE ELEMENT	SCIENCE			English	Article							MEDITERRANEAN FRUIT-FLY; TRANSFORMATION; GENOME	Exogenous functional DNA was introduced into the germline chromosomes of the Mediterranean fruit fly (medfly) Ceratitis capitata with a germline transformation system based on the transposable element Mines from Drosophila hydei. Transformants were identified as phenotypic revertants of a white-eyed mutation carried by the recipient strain. Clusters of transformants were detected among the progeny of 390 individuals screened for germline transformation. Five independent and phenotypically active integration events were identified, in each of which a single copy of the transposon was inserted into a different site of the medfly genome. Molecular analysis indicates that they represent transposase-mediated insertions of the transposon into medfly chromosomes.	FDN RES & TECHNOL HELLAS,INST MOLEC BIOL & BIOTECHNOL,GR-71110 CRETE,GREECE; UNIV CRETE,SCH MED,DIV BASIC MED SCI,CRETE,GREECE	Foundation for Research & Technology - Hellas (FORTH); University of Crete			Savakis, Babis/D-3633-2009; Arca, Bruno/C-8383-2012	Arca, Bruno/0000-0002-4029-0984				ARCA B, UNPUB; BLACKMAN RK, 1989, EMBO J, V8, P211, DOI 10.1002/j.1460-2075.1989.tb03366.x; CAREY JR, 1991, SCIENCE, V253, P1369, DOI 10.1126/science.1896848; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FRANZ G, 1991, NUCLEIC ACIDS RES, V19, P6646, DOI 10.1093/nar/19.23.6646; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; KNIPLING EF, 1959, SCIENCE, V130, P902, DOI 10.1126/science.130.3380.902; LIDHOLM DA, 1993, GENETICS, V134, P859; LIVADARAS I, UNPUB; LOUIS C, 1987, FRUITFLIES, P47; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, UNPUB; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MINTZAS AC, 1983, DEV BIOL, V95, P492, DOI 10.1016/0012-1606(83)90051-9; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; OBROCHTA DA, 1994, MOL GEN GENET, V244, P9, DOI 10.1007/BF00280181; Robertson H.M., 1993, Insect Molecular Biology, V2, P125, DOI 10.1111/j.1365-2583.1993.tb00132.x; ROBERTSON HM, 1995, ANNU REV ENTOMOL, V40, P333, DOI 10.1146/annurev.en.40.010195.002001; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; ZACHAROPOULOU A, 1992, CHROMOSOMA, V101, P448, DOI 10.1007/BF00582839; ZACHAROPOULOU A, 1990, GENOME, V33, P184, DOI 10.1139/g90-030; ZWIEBEL LJ, 1995, SCIENCE, V270, P2005, DOI 10.1126/science.270.5244.2005	22	241	269	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2002	2005		10.1126/science.270.5244.2002	http://dx.doi.org/10.1126/science.270.5244.2002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533094				2022-12-28	WOS:A1995TL42000045
J	COCCHI, F; DEVICO, AL; GARZINODEMO, A; ARYA, SK; GALLO, RC; LUSSO, P				COCCHI, F; DEVICO, AL; GARZINODEMO, A; ARYA, SK; GALLO, RC; LUSSO, P			IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS	SCIENCE			English	Article							VIRUS-REPLICATION; FUNCTIONAL EXPRESSION; PROGENITOR CELLS; BINDING-PROTEIN; LINE PF-382; INFECTION; MIGRATION; RECEPTORS; MONOCYTE; INVITRO	Evidence suggests that CD8(+) T lymphocytes are involved in the control of human immunodeficiency virus (HIV) infection in vivo, either by cytolytic mechanisms or by the release of HIV-suppressive factors (HIV-SF). The chemokines RANTES, MIP-1 alpha, and MIP-1 beta were identified as the major HIV-SF produced-by CD8(+) T cells. Two active proteins purified from the culture supernatant of an immortalized CD8(+) T cell clone revealed sequence identity with human RANTES and MIP-1 alpha. RANTES, MIP-1 alpha, and MIP-1 beta were released by both immortalized and primary CD8(+) T cells. HIV-SF activity produced by these cells was completely blocked by a combination of neutralizing antibodies against RANTES, MIP-1 alpha, and MIP-1 beta. Recombinant human RANTES, MIP-1 alpha, and MIP-1 beta induced a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). These data may have relevance for the prevention and therapy of AIDS.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; ADV BIOSCI LABS,KENSINGTON,MD 20852	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Garzino-Demo, Alfredo/0000-0002-4095-6950				ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BELLONE G, 1987, LEUKEMIA, V1, P603; BERTINI R, 1995, AIDS RES HUM RETROV, V11, P155, DOI 10.1089/aid.1995.11.155; Bolognesi D P, 1993, Semin Immunol, V5, P203, DOI 10.1006/smim.1993.1024; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BROXMEYER HE, 1990, BLOOD, V76, P1110; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CASTRO BA, 1991, CELL IMMUNOL, V132, P246, DOI 10.1016/0008-8749(91)90023-5; COCCHI F, UNPUB; CONLON K, 1995, EUR J IMMUNOL, V25, P751, DOI 10.1002/eji.1830250319; DEROSSI A, 1986, P NATL ACAD SCI USA, V83, P4297, DOI 10.1073/pnas.83.12.4297; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GARZINODEMO A, UNPUB; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; HEENEY JL, 1994, J EXP MED, V180, P769, DOI 10.1084/jem.180.2.769; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KANAGI M, 1988, J IMMUNOL, V119, P470; KUNA P, 1992, J IMMUNOL, V149, P636; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; LUSSO P, 1990, J VIROL, V64, P6134; LUSSO P, 1988, J EXP MED, V166, P1659; LUSSO P, UNPUB; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; PEGORARO L, 1985, JNCI-J NATL CANCER I, V75, P285; PUTKONEN P, 1994, J MED PRIMATOL, V23, P89, DOI 10.1111/j.1600-0684.1994.tb00107.x; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WANG JM, 1993, J IMMUNOL, V150, P3022; WHITTON JL, 1990, VIROLOGY, P369; WOLFE SD, 1989, FASEB J, V3, P2565; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570	48	2554	2714	0	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1811	1815		10.1126/science.270.5243.1811	http://dx.doi.org/10.1126/science.270.5243.1811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525373	Green Submitted			2022-12-28	WOS:A1995TK47600043
J	PFRIEGER, FW; BARRES, BA				PFRIEGER, FW; BARRES, BA			WHAT THE FLYS GLIA TELL THE FLYS BRAIN	CELL			English	Review							NERVOUS-SYSTEM; GROWTH CONES; GUIDANCE; PATHWAYS				PFRIEGER, FW (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,FAIRCHILD SCI BLDG,STANFORD,CA 94305, USA.		Pfrieger, Frank/AAX-3208-2020	Pfrieger, Frank/0000-0001-7085-1431				ANDERSON DJ, 1995, IN PRESS NEURON, V15; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BARRES BA, 1991, J NEUROSCI, V11, P3685; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; Goodman Corey S., 1993, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; HOSLI E, 1993, PROG NEUROBIOL, V40, P477, DOI 10.1016/0301-0082(93)90019-O; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; LEIN P, 1995, NEURON, V15, P597, DOI 10.1016/0896-6273(95)90148-5; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAMON CS, 1909, HISTOLOGIE SYSTEME N; TROPEA M, 1988, GLIA, V1, P380, DOI 10.1002/glia.440010605; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; XIONG WC, 1995, NEURON, V14, P581, DOI 10.1016/0896-6273(95)90314-3	19	58	60	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					671	674		10.1016/0092-8674(95)90178-7	http://dx.doi.org/10.1016/0092-8674(95)90178-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521482	Bronze			2022-12-28	WOS:A1995TH94800002
J	WERNER, MH; CLORE, GM; FISHER, CL; FISHER, RJ; TRINH, L; SHILOACH, J; GRONENBORN, AM				WERNER, MH; CLORE, GM; FISHER, CL; FISHER, RJ; TRINH, L; SHILOACH, J; GRONENBORN, AM			THE SOLUTION STRUCTURE OF THE HUMAN ETS1-DNA COMPLEX REVEALS A NOVEL MODE OF BINDING AND TRUE SIDE-CHAIN INTERCALATION	CELL			English	Article							SERUM RESPONSE ELEMENT; CO-CRYSTAL STRUCTURE; TATA-BOX COMPLEX; TRANSCRIPTION FACTORS; DNA COMPLEX; PROTEIN; MOTIF; RESOLUTION; SUGGESTS; PROGRAM	The solution structure of a 24.4 kDa specific complex of the DNA-binding domain (DBD) of the human ETS1 (hETS1) oncoprotein with a 17-mer DNA has been solved by NMR. The interaction of the hETS1 DBD with DNA reveals a surprising twist on the general features of helix-turn-helix (HTH)-DNA interactions, Major groove recognition involves the C-terminal two thirds of the HTH recognition helix, while minor groove recognition occurs via true intercalation of the side chain of Trp-28, which extends from the minor to the major groove. This results in a sharp kink of similar to 60 degrees and a widening of the minor groove over one-half turn of the DNA. The orientation of the HTH element of the hETS1 DBD with respect to the major groove is significantly rotated relative to other HTH proteins. These observations establish the ETS family of DNA-binding proteins as a distinct family of HTH proteins.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21701; NIDDKD,CELLULAR & DEV BIOL LAB,BIOTECHNOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	WERNER, MH (corresponding author), NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892, USA.		Fisher, Robert/B-1431-2009; Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A.T, 1993, XPLOR VERSION 31 SYS; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLORE GM, 1994, PROTEIN SCI, V3, P372; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1985, PROG NMR SPECTROSC, V17, P1; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEIERSTANGER BH, 1995, ANNU REV BIOPH BIOM, V24, P463, DOI 10.1146/annurev.bb.24.060195.002335; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P252; MAVROTHALASSITI.G, 1994, ONCOGENE, V9, P425; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P129; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; TIMMS MJ, 1994, MOL REPROD DEV, V39, P208; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	45	114	118	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					761	771		10.1016/0092-8674(95)90189-2	http://dx.doi.org/10.1016/0092-8674(95)90189-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521493	Bronze			2022-12-28	WOS:A1995TH94800013
J	SCHLESSINGER, J; LAX, I; LEMMON, M				SCHLESSINGER, J; LAX, I; LEMMON, M			REGULATION OF GROWTH-FACTOR ACTIVATION BY PROTEOGLYCANS - WHAT IS THE ROLE OF THE LOW-AFFINITY RECEPTORS	CELL			English	Review							DIFFUSION; HEPARIN; BINDING; LIGAND; CELLS				SCHLESSINGER, J (corresponding author), NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA.			Lemmon, Mark/0000-0002-3379-5319; NOIRI, Eisei/0000-0002-9515-7582				Adam G., 1968, STRUCTURAL CHEM MOL, P198; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MALI M, 1993, J BIOL CHEM, V268, P24215; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	20	433	445	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					357	360		10.1016/0092-8674(95)90112-4	http://dx.doi.org/10.1016/0092-8674(95)90112-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521464	hybrid			2022-12-28	WOS:A1995TC97700004
J	LUBAN, J; BOSSOLT, KL; FRANKE, EK; KALPANA, GV; GOFF, SP				LUBAN, J; BOSSOLT, KL; FRANKE, EK; KALPANA, GV; GOFF, SP			HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GAG PROTEIN BINDS TO CYCLOPHILIN-A AND CYCLOPHILIN-B	CELL			English	Article							MURINE LEUKEMIA VIRUSES; CYCLOSPORINE-A; HOMOLOG NINAA; BALB-C; HIV-1; GENE; MYRISTYLATION; IMMUNOPHILIN; INFECTIVITY; ACTIVATION	Retroviral Gag protein is capable of directing the assembly of virion particles independent of other retroviral elements and plays an important role early in the infection of a cell. Using the GAL4 two hybrid system, we screened a cDNA expression library and identified two host proteins, cyclophilins (CyPs) A and B, which interact specifically with the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein Pr55gag. Glutathione S-transferase-CyP fusion proteins bind tightly to Pr55gag in vitro, as well as to the HIV-1 capsid protein p24. Cyclosporin A efficiently disrupts the Gag-CyPA interaction and less efficiently disrupts the Gag-CyPB interaction. The Gag-CyP interaction may be important for the HIV-1 life cycle and may be relevant to the pathology caused by this immunosuppressive virus.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University	LUBAN, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.			Kalpana, Ganjam/0000-0003-4111-0604; Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000988, U01AI024845] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24845, AI 00988] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER D M, 1991, P182; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HEITMAN J, 1992, NEW BIOL, V4, P448; HOPKINS N, 1977, J VIROL, V21, P309, DOI 10.1128/JVI.21.1.309-318.1977; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HSU HW, 1985, VIROLOGY, V142, P211, DOI 10.1016/0042-6822(85)90435-0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KAUFMANN R, 1992, J ACQ IMMUN DEF SYND, V15, P760; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KRAUSSLICH HG, 1993, VIROLOGY, V192, P605, DOI 10.1006/viro.1993.1077; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; Lilly F., 1973, Advances in Cancer Research, V17, P231, DOI 10.1016/S0065-230X(08)60532-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUBAN J, 1993, IN PRESS J VIROL; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWARTZ O, 1992, AIDS RES HUM RETROV, V8, P545, DOI 10.1089/aid.1992.8.545; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021, DOI 10.1128/JVI.66.12.7021-7032.1992; STRATHERN J N, 1991, P319; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WAINBERG MA, 1988, BLOOD, V72, P1904; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; WEISS R, 1984, RNA TUMOR VIRUSES; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	65	683	724	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1067	1078		10.1016/0092-8674(93)90637-6	http://dx.doi.org/10.1016/0092-8674(93)90637-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513493				2022-12-28	WOS:A1993LH54800004
J	SWIFT, CG; SHAPIRO, CM				SWIFT, CG; SHAPIRO, CM			ABC OF SLEEP DISORDERS - SLEEP AND SLEEP PROBLEMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	SWIFT, CG (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT HLTH CARE ELDERLY,LONDON SE5 8RX,ENGLAND.							GREENBLATT DJ, 1977, CLIN PHARMACOL THER, V21, P355; KARACAN I, 1976, SOC SCI MED, V10, P239, DOI 10.1016/0037-7856(76)90006-8; SPIEGEL R, 1985, PRINCIPLES PRACTICE	3	35	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1468	1471		10.1136/bmj.306.6890.1468	http://dx.doi.org/10.1136/bmj.306.6890.1468			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE935	8518648	Green Published, Bronze			2022-12-28	WOS:A1993LE93500026
J	Reaven, GM; Lithell, H; Landsberg, L				Reaven, GM; Lithell, H; Landsberg, L			Mechanisms of disease - Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SYMPATHETIC NERVOUS-SYSTEM; HIGH BLOOD-PRESSURE; CORONARY-ARTERY DISEASE; LIPID-METABOLISM; LIPOPROTEIN METABOLISM; CHRONIC HYPERINSULINEMIA; MYOCARDIAL-INFARCTION; SKELETAL-MUSCLE; PLASMA-INSULIN; HEART-DISEASE		STANFORD UNIV, PALO ALTO, CA 94304 USA; UNIV UPPSALA, UPPSALA, SWEDEN; NORTHWESTERN UNIV, SCH MED, DEPT MED, CHICAGO, IL 60611 USA	Stanford University; Uppsala University; Northwestern University								ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; ANDERSON EA, 1993, HYPERTENSION, V21, P745; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; ANDERSSON PE, 1994, J HUM HYPERTENS, V8, P219; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BOHLEN HG, 1989, J HYPERTENS, V7, pS117; BRANDS MW, 1991, AM J PHYSIOL, V260, pR764, DOI 10.1152/ajpregu.1991.260.4.R764; CARRETTA R, 1989, J HYPERTENS, V7, pS196, DOI 10.1097/00004872-198900076-00094; CHRISTLIEB AR, 1985, HYPERTENSION, V7, P54; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DALLAGLIO E, 1991, AM J HYPERTENS, V4, P773, DOI 10.1093/ajh/4.9.773; FACCHINI F, 1992, AM J HYPERTENS, V5, P694, DOI 10.1093/ajh/5.10.694; FALKNER B, 1993, HYPERTENSION, V22, P18, DOI 10.1161/01.HYP.22.1.18; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FRIEDMAN G, 1986, BIOCHIM BIOPHYS ACTA, V877, P112, DOI 10.1016/0005-2760(86)90125-6; HAENNI A, 1994, METABOLISM, V43, P455, DOI 10.1016/0026-0495(94)90076-0; HALL JE, 1993, HYPERTENSION, V22, P292, DOI 10.1161/01.HYP.22.3.292; HALL JE, 1989, AM J HYPERTENS, V2, P171, DOI 10.1093/ajh/2.3.171; HALL JE, 1990, HYPERTENSION, V15, P519, DOI 10.1161/01.HYP.15.5.519; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HWANG IS, 1987, HYPERTENSION, V10, P512, DOI 10.1161/01.HYP.10.5.512; JULIUS S, 1993, HYPERTENSION, V21, P886, DOI 10.1161/01.HYP.21.6.886; JUNG RT, 1979, BRIT MED J, V1, P12, DOI 10.1136/bmj.1.6155.12; KAUFMAN LN, 1986, J CLIN INVEST, V77, P551, DOI 10.1172/JCI112336; KROTKIEWSKI M, 1979, METABOLISM, V28, P650, DOI 10.1016/0026-0495(79)90018-0; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LANDSBERG L, 1985, INT J OBESITY, V9, P63; LANDSBERG L, 1986, Q J MED, V61, P1081; LANDSBERG L, 1993, INT J OBESITY, V17, pS29; LANDSBERG L, 1984, CLIN ENDOCRINOL META, V13, P475, DOI 10.1016/S0300-595X(84)80034-1; LANDSBERG L, 1985, NEUROENDOCRINE PERSP, V4, P191; LEMBO G, 1994, AM J PHYSIOL, V266, pE242, DOI 10.1152/ajpendo.1994.266.2.E242; LIND L, 1995, J HUM HYPERTENS, V9, P137; LITHELL H, 1981, METABOLISM, V30, P1130, DOI 10.1016/0026-0495(81)90059-7; Lithell H, 1992, Blood Press, V1, P92, DOI 10.3109/08037059209077499; LITHELL H, 1982, J CARDIOVASC PHARM, V4, pS242; Lithell H, 1992, Blood Press, V1, P20, DOI 10.3109/08037059209065120; LUNDGREN H, 1988, BRIT MED J, V297, P1512, DOI 10.1136/bmj.297.6662.1512; MANICARDI V, 1986, J CLIN ENDOCR METAB, V62, P1302, DOI 10.1210/jcem-62-6-1302; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MYKKANEN L, 1993, DIABETOLOGIA, V36, pA212; OHARE JA, 1989, METABOLISM, V38, P322, DOI 10.1016/0026-0495(89)90118-2; PARKER DR, 1993, AM J CLIN NUTR, V58, P129, DOI 10.1093/ajcn/58.2.129; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1988, DIABETOLOGIA, V31, P415, DOI 10.1007/BF00271585; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; RANDEREE HA, 1992, DIABETES CARE, V15, P1258, DOI 10.2337/diacare.15.10.1258; Reaven G M, 1993, Heart Dis Stroke, V2, P44; REAVEN GM, 1991, AM J HYPERTENS, V4, P34, DOI 10.1093/ajh/4.1.34; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REAVEN GM, 1991, HYPERTENSION, V18, P630, DOI 10.1161/01.HYP.18.5.630; REAVEN GM, 1990, J INTERN MED, V228, P415, DOI 10.1111/j.1365-2796.1990.tb00256.x; REAVEN GM, 1984, HORM METAB RES, V16, P230, DOI 10.1055/s-2007-1014753; ROSE HG, 1986, HYPERTENSION, V8, P793, DOI 10.1161/01.HYP.8.9.793; ROSE HG, 1987, HYPERTENSION, V9, P421; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAMUELSSON O, 1994, J INTERN MED, V235, P217, DOI 10.1111/j.1365-2796.1994.tb01063.x; SAWICKI PT, 1992, DIABETOLOGIA, V35, P649, DOI 10.1007/BF00400257; SCHWARTZ JH, 1983, J CLIN INVEST, V72, P361, DOI 10.1172/JCI110976; SHAMISS A, 1992, AM J HYPERTENS, V5, P26, DOI 10.1093/ajh/5.1.26; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SHEU WHH, 1991, AM J HYPERTENS, V4, P199, DOI 10.1093/ajh/4.3.199; SHEU WHH, 1992, AM J HYPERTENS, V5, P444, DOI 10.1093/ajh/5.7.444; SHIEH SM, 1987, ATHEROSCLEROSIS, V67, P49, DOI 10.1016/0021-9150(87)90264-4; SHIEH SM, 1992, AM J HYPERTENS, V5, P827, DOI 10.1093/ajh/5.11.827; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SKOTT P, 1991, DIABETOLOGIA, V34, P275, DOI 10.1007/BF00405088; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; SUPIANO MA, 1992, AM J PHYSIOL, V263, pE935, DOI 10.1152/ajpendo.1992.263.5.E935; SWISLOCKI ALM, 1989, AM J MED, V86, P14, DOI 10.1016/0002-9343(89)90122-8; TAPPY L, 1991, INT J OBESITY, V15, P669; TEDDE R, 1989, AM J HYPERTENS, V2, P163, DOI 10.1093/ajh/2.3.163; TROISI RJ, 1991, HYPERTENSION, V17, P669, DOI 10.1161/01.HYP.17.5.669; TUCK ML, 1992, HYPERTENSION, V19, pI67, DOI 10.1161/01.HYP.19.1_Suppl.I67; VACCARO O, 1992, DIABETES CARE, V15, P1328, DOI 10.2337/diacare.15.10.1328; WARD KD, 1994, METABOLISM, V43, P509, DOI 10.1016/0026-0495(94)90085-X; WARD KD, 1994, INT J OBESITY, V18, P137; WARD KD, 1993, CLIN RES, V41, pA168; YOUNG JB, 1980, J CLIN INVEST, V65, P1086, DOI 10.1172/JCI109761; YOUNG JB, 1977, NATURE, V269, P615, DOI 10.1038/269615a0; YOUNG JB, 1977, SCIENCE, V196, P1473, DOI 10.1126/science.867049; YOUNG JB, 1982, J CLIN INVEST, V69, P1061, DOI 10.1172/JCI110541; ZAVARONI I, 1992, J INTERN MED, V231, P235, DOI 10.1111/j.1365-2796.1992.tb00529.x	87	825	859	2	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					374	381		10.1056/NEJM199602083340607	http://dx.doi.org/10.1056/NEJM199602083340607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538710				2022-12-28	WOS:A1996TT48700007
J	Felner, JM				Felner, JM			Nail in the aorta	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Felner, JM (corresponding author), EMORY UNIV,SCH MED,ATLANTA,GA 30303, USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					239	239		10.1056/NEJM199601253340406	http://dx.doi.org/10.1056/NEJM199601253340406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532001				2022-12-28	WOS:A1996TQ75500006
J	Brodie, MJ; Dichter, MA				Brodie, MJ; Dichter, MA			Drug therapy - Antiepileptic drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VOLTAGE-DEPENDENT LIMITATION; COMPLEX-PARTIAL SEIZURES; ACID HEPATIC FATALITIES; 1ST UNPROVOKED SEIZURE; TONIC CLONIC SEIZURES; MOUSE CENTRAL NEURONS; ANTI-EPILEPTIC DRUGS; VALPROIC-ACID; INTRACTABLE EPILEPSY; RELEASE CARBAMAZEPINE		UNIV PENN, SCH MED, DEPT NEUROL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	Brodie, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP, DEPT MED & THERAPEUT, EPILEPSY RES UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND.							[Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; [Anonymous], 1991, Lancet, V337, P1175; BEGHI E, 1986, DRUGS, V31, P249, DOI 10.2165/00003495-198631030-00003; BRODIE MJ, 1990, LANCET, V336, P350, DOI 10.1016/0140-6736(90)91886-F; BRODIE MJ, 1988, BRIT MED J, V296, P1110, DOI 10.1136/bmj.296.6629.1110; BRODIE MJ, 1992, EPILEPSIA, V33, pS13, DOI 10.1111/j.1528-1157.1992.tb05896.x; BRODIE MJ, 1990, LANCET, V336, P426, DOI 10.1016/0140-6736(90)91960-I; BROWNE TR, 1988, NEUROLOGY, V38, P1146, DOI 10.1212/WNL.38.7.1146; CHADWICK D, 1994, CNS DRUGS, V2, P423, DOI 10.2165/00023210-199402060-00003; CHADWICK D, 1990, LANCET, V336, P291, DOI 10.1016/0140-6736(90)91815-R; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; DEAN JC, 1989, ANTIEPILEPTIC DRUGS, P133; DELGADOESCUETA AV, 1992, NEUROLOGY, V42, P149; DICHTER MA, 1993, EPILEPSY RES, P9; DODSON WE, 1989, NEUROLOGY, V39, P1009, DOI 10.1212/WNL.39.8.1009; DREIFUSS FE, 1987, NEUROLOGY, V37, P379, DOI 10.1212/WNL.37.3.379; DREIFUSS FE, 1989, NEUROLOGY, V39, P201, DOI 10.1212/WNL.39.2.201; DULAC O, 1993, EPILEPSIA, V34, P585; DUNCAN JS, 1991, EPILEPSIA, V32, P101, DOI 10.1111/j.1528-1157.1991.tb05620.x; ENGEL J, 1993, SURGICAL TREATMENT E; GANNAWAY DJ, 1981, BRIT J CLIN PHARMACO, V12, P833, DOI 10.1111/j.1365-2125.1981.tb01316.x; GOULDEN KJ, 1987, NEUROLOGY, V37, P1392, DOI 10.1212/WNL.37.8.1392; Gowers WR, 1881, EPILEPSY OTHER CHRON; HARDEN CL, 1993, J EPILEPSY, V6, P91, DOI 10.1016/S0896-6974(05)80094-5; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HELLER AJ, 1995, J NEUROL NEUROSUR PS, V58, P44, DOI 10.1136/jnnp.58.1.44; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; LARKIN JG, 1992, BRIT J CLIN PHARMACO, V33, P111, DOI 10.1111/j.1365-2125.1992.tb04009.x; LINDHOUT D, 1984, EPILEPSIA, V25, P77, DOI 10.1111/j.1528-1157.1984.tb04158.x; LIPORACE JD, 1994, EPILEPSIA, V35, P1026, DOI 10.1111/j.1528-1157.1994.tb02549.x; MACDONALD RL, 1993, EPILEPSIA, V34, pS1, DOI 10.1111/j.1528-1157.1993.tb05918.x; MACPHEE GJA, 1987, EPILEPSIA, V28, P286, DOI 10.1111/j.1528-1157.1987.tb04220.x; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MATTSON RH, 1986, JAMA-J AM MED ASSOC, V256, P238, DOI 10.1001/jama.256.2.238; McKee P J, 1992, Seizure, V1, P275, DOI 10.1016/1059-1311(92)90037-2; MCKEE PJW, 1993, BRIT J CLIN PHARMACO, V36, P257, DOI 10.1111/j.1365-2125.1993.tb04226.x; MCKEE PJW, 1991, BRIT J CLIN PHARMACO, V32, P99, DOI 10.1111/j.1365-2125.1991.tb05619.x; MCLEAN MJ, 1986, J PHARMACOL EXP THER, V238, P727; MCLEAN MJ, 1986, J PHARMACOL EXP THER, V237, P1001; MOSLET U, 1992, ACTA NEUROL SCAND, V85, P39; NAITO H, 1987, ACTA NEUROL SCAND, V76, P58, DOI 10.1111/j.1600-0404.1987.tb03545.x; NAKANE Y, 1980, EPILEPSIA, V21, P663, DOI 10.1111/j.1528-1157.1980.tb04320.x; PATSALOS PN, 1993, J EPILEPSY, V6, P228, DOI 10.1016/0896-6974(93)90006-V; PATSALOS PN, 1993, DRUG SAFETY, V9, P156, DOI 10.2165/00002018-199309030-00003; PELLOCK JM, 1991, NEUROLOGY, V41, P961, DOI 10.1212/WNL.41.7.961; PENRY JK, 1993, PEDIATRIC EPILEPSY D, P315; PISANI F, 1990, J INT MED RES, V18, P1; PORTER RJ, 1977, NEUROLOGY, V27, P1006, DOI 10.1212/WNL.27.11.1006; PRICHARD JW, 1986, RECENT ADV EPILEPSY, P261; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; RICHENS A, 1994, J NEUROL NEUROSUR PS, V57, P682, DOI 10.1136/jnnp.57.6.682; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P223; ROSA FW, 1991, NEW ENGL J MED, V324, P674, DOI 10.1056/NEJM199103073241006; ROWAN AJ, 1983, ARCH NEUROL-CHICAGO, V40, P797, DOI 10.1001/archneur.1983.04050120047006; SCHMIDT D, 1982, J NEUROL NEUROSUR PS, V45, P1119, DOI 10.1136/jnnp.45.12.1119; SELZER ME, 1978, ANN NEUROL, V3, P202, DOI 10.1002/ana.410030304; SHINNAR S, 1985, NEW ENGL J MED, V313, P976, DOI 10.1056/NEJM198510173131603; SHINNAR S, 1990, PEDIATRICS, V85, P1076; SHINNAR S, 1994, ANN NEUROL, V35, P534, DOI 10.1002/ana.410350506; SHORVON SD, 1990, LANCET, V336, P93, DOI 10.1016/0140-6736(90)91603-8; SHUKLA S, 1984, AM J PSYCHIAT, V141, P1604; SPECHT U, 1989, EPILEPSIA, V30, P458, DOI 10.1111/j.1528-1157.1989.tb05326.x; THEODORE WH, 1983, ANN NEUROL, V13, P320, DOI 10.1002/ana.410130316; THEODORE WH, 1983, EPILEPSIA, V24, P336, DOI 10.1111/j.1528-1157.1983.tb04897.x; THOMSON AH, 1992, CLIN PHARMACOKINET, V23, P216, DOI 10.2165/00003088-199223030-00004; TRIGGS WJ, 1990, ARCH NEUROL-CHICAGO, V47, P1131, DOI 10.1001/archneur.1990.00530100101021; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; VERITY CM, 1995, DEV MED CHILD NEUROL, V37, P97; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x; WOO E, 1988, EPILEPSIA, V29, P129, DOI 10.1111/j.1528-1157.1988.tb04408.x; YAARI Y, 1977, ANN NEUROL, V1, P334, DOI 10.1002/ana.410010405; YERBY MS, 1990, J EPILEPSY, V3, P193, DOI 10.1016/0896-6974(90)90046-2; ZACCARA G, 1988, CLIN PHARMACOKINET, V15, P367, DOI 10.2165/00003088-198815060-00002; ZIELINSKI JJ, 1987, THER DRUG MONIT, V9, P21, DOI 10.1097/00007691-198703000-00004; 1995, PRACTICE HDB, P187; 1988, LANCET, V2, P1229; 1991, LANCET, V337, P1193; 1989, LANCET, V2, P595; 1992, FOLIC ACID PREVENTIO, P21; 1994, PHYSICIANS DESK REFE, P1773	83	402	415	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					168	175		10.1056/NEJM199601183340308	http://dx.doi.org/10.1056/NEJM199601183340308			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531974				2022-12-28	WOS:A1996TQ01700008
J	Godecke, I; Bonhoeffer, T				Godecke, I; Bonhoeffer, T			Development of identical orientation maps for two eyes without common visual experience	NATURE			English	Article							CROSS-CORRELATION; STRIATE CORTEX; ORGANIZATION; SELECTIVITY; POTENTIALS; DOMAINS; AREA-18; CELLS	IN the mammalian visual cortex, many neurons are driven binocularly and response properties such as orientation preference or spatial frequency tuning are virtually identical for the two eyes(1). A precise match of orientation is essential in order to detect disparity and is therefore a prerequisite for stereoscopic vision. It is not clear whether this match is accomplished by activity-dependent mechanisms together wit the common visual experience normally received by the eyes(2,3), or whether the visual system relies on other, perhaps even innate, cues to achieve this task(4-7). Here we test whether visual experience is responsible for the match in a reverse-suturing experiment in which kittens were raised so that both eyes were never able to see at the same time. A comparison of the layout of the two maps formed under these conditions showed them to be virtually identical. Considering that the two eyes never had common visual experience, this indicates that correlated visual input is not required for the alignment of orientation preference maps.	MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY	Max Planck Society			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; BARLOW HB, 1971, J PHYSIOL-LONDON, V218, P98; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; BONHOEFFER T, 1995, CHALLENGES PERSPECTI, P117; BRAASTAD BO, 1985, J NEUROPHYSIOL, V53, P1158, DOI 10.1152/jn.1985.53.5.1158; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CROOK JM, 1992, J NEUROSCI, V12, P1816; FERSTER D, 1986, J NEUROSCI, V6, P1284; FITZPATRICK D, 1993, SOC NEUR ABSTR, V19; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IMBERT M, 1975, EXP BRAIN RES, V22, P25; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306	25	127	128	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					251	254		10.1038/379251a0	http://dx.doi.org/10.1038/379251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538789				2022-12-28	WOS:A1996TQ16900045
J	Last, EC				Last, EC			For Corrie	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					271	272		10.7326/0003-4819-124-2-199601150-00016	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534008				2022-12-28	WOS:A1996TQ01600016
J	Shore, MF; Beigel, A				Shore, MF; Beigel, A			The challenges posed by managed behavioral health care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV ARIZONA, TUCSON, AZ 85721 USA	University of Arizona	Shore, MF (corresponding author), JOHN F KENNEDY SCH GOVT, CAMBRIDGE, MA 02138 USA.							HOLMES OW, 1861, CURRENTS COUNTER CUR, P7; Iglehart JK, 1996, NEW ENGL J MED, V334, P131, DOI 10.1056/NEJM199601113340221; MANDERSCHEID RW, 1990, DHHS ADM901708 PUBL, P14; SABIN JE, 1991, HOSP COMMUNITY PSYCH, V42, P605; SMITH ML, 1977, AM PSYCHOL, V32, P752, DOI 10.1037/0003-066X.32.9.752	5	33	33	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					116	118		10.1056/NEJM199601113340211	http://dx.doi.org/10.1056/NEJM199601113340211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP363	8531945				2022-12-28	WOS:A1996TP36300011
J	Heilbron, JL; Bynum, WF				Heilbron, JL; Bynum, WF			Eighteen-ninety-six and all that	NATURE			English	Editorial Material									WELLCOME INST HIST MED,LONDON NW1 2BE,ENGLAND	University of London; University College London	Heilbron, JL (corresponding author), UNIV CALIF BERKELEY,OFF HIST SCI & TECHNOL,BERKELEY,CA 94720, USA.							Agricola G., 1546, NATURA FOSSILIUM; AGRICOLA G, RE METALLICA; BOISREYMOND EH, IGNORAMUS IGNORABIMU; BOUGUER, TRAITE NAVIRE; DELAPLACE PS, SYSTEME MONDE; DELHOSPITAL GFA, 1696, ANAL INIFINIMENT PET; DEPARCIEUX A, ESSAI PROBABILITES H; DIDEROT D, PENSEES PHILOSOPHIQU; Hufeland C. W., 1796, MAKROBIOTIK ODER KUN; POGGENDORFF, BIOGRAPHISCH LIT HAN; RICCIOLI G, ASTRONOMIAE REFORMAT; WHISTON W, NEW THEORY EARTH DEV; WINKLER JH, STARKE ELEKTRISCHEN; 1946, NATURE, V158, P558	14	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					15	18		10.1038/379015a0	http://dx.doi.org/10.1038/379015a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538734				2022-12-28	WOS:A1996TN21600025
J	THUMMEL, CS				THUMMEL, CS			FROM EMBRYOGENESIS TO METAMORPHOSIS - THE REGULATION AND FUNCTION OF DROSOPHILA NUCLEAR RECEPTOR SUPERFAMILY MEMBERS	CELL			English	Review							RETINOID-X-RECEPTOR; ECDYSONE-INDUCIBLE GENE; EMBRYONIC TERMINI; ORPHAN RECEPTORS; ULTRASPIRACLE; PROTEIN; BINDING; HOMOLOG; ENCODES; FTZ-F1				THUMMEL, CS (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; AYER S, 1993, NUCLEIC ACIDS RES, V21, P1619, DOI 10.1093/nar/21.7.1619; BILDER D, 1995, GENETICS, V141, P1087; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; FISK GJ, 1995, P NATL ACAD SCI USA, V92, P10604, DOI 10.1073/pnas.92.23.10604; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HILL RJ, 1993, INSECT BIOCHEM MOLEC, V23, P99, DOI 10.1016/0965-1748(93)90087-9; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; HOSHIZAKI DK, 1994, DEVELOPMENT, V120, P2489; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U ST; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OHNO CK, 1994, MOL CELL BIOL, V14, P3166, DOI 10.1128/MCB.14.5.3166; OHNO CK, 1992, MECH DEVELOP, V40, P13; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PERRIMON N, 1985, GENETICS, V111, P23; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Richards Geoff, 1992, Current Biology, V2, P657, DOI 10.1016/0960-9822(92)90123-R; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Segraves William A., 1994, Seminars in Cell Biology, V5, P105, DOI 10.1006/scel.1994.1014; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; TALBOT WS, 1993, THESIS STANFORD U ST; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU RT, 1994, NATURE, V370, P375, DOI 10.1038/370375a0; ZELHOF AC, 1995, MOL CELL BIOL, V15, P6736; ZELHOF AC, 1995, P NATL ACAD SCI USA, V92, P10477, DOI 10.1073/pnas.92.23.10477; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	56	295	307	1	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					871	877		10.1016/0092-8674(95)90203-1	http://dx.doi.org/10.1016/0092-8674(95)90203-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521511	Bronze			2022-12-28	WOS:A1995TK74500006
J	MORITZ, M; BRAUNFELD, MB; SEDAT, JW; ALBERTS, B; AGARD, DA				MORITZ, M; BRAUNFELD, MB; SEDAT, JW; ALBERTS, B; AGARD, DA			MICROTUBULE NUCLEATION BY GAMMA-TUBULIN-CONTAINING RINGS IN THE CENTROSOME	NATURE			English	Article								THE microtubule cytoskeleton of animal cells does not assemble spontaneously, but instead requires the centrosome. This organelle consists of a pair of centrioles surrounded by a complex collection of proteins known as the pericentriolar material (PCM)(1). The PCM is required for microtubule nucleation(2). The minus, or slow-growing, ends of microtubules are embedded in the PCM and the plus, or fast-growing, ends project outwards into the cytoplasm during interphase, or into the spindle apparatus during mitosis. gamma-Tubulin is the only component of the PCM that is so far implicated in microtubule nucleation(3-6). Here we use immune-electron microscopic tomography to show that gamma-tubulin is localized in ring structures in the PCM of purified centrosomes without microtubules. When these centrosomes are used to nucleate microtubule growth, gamma-tubulin is localized at the minus ends of the microtubules. We conclude that microtubule-nucleating sites within the PCM are ring-shaped templates that contain multiple copies of gamma-tubulin.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	MORITZ, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,513 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.			Moritz, Michelle/0000-0003-3811-5623				EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FELIX MA, 1994, J CELL BIOL, V24, P19; FUNG JC, IN PRESS J STRUCT BI; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Koster A. J., 1993, MICROSC SOC AM B, V23, P176; KOSTER AJ, 1992, ULTRAMICROSCOPY, V46, P207, DOI 10.1016/0304-3991(92)90016-D; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TILNEY LG, 1973, J CELL BIOL, V59, P267, DOI 10.1083/jcb.59.2.267; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	13	431	437	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					638	640		10.1038/378638a0	http://dx.doi.org/10.1038/378638a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524401				2022-12-28	WOS:A1995TJ22100084
J	GERMAIN, RN; RINKER, AG				GERMAIN, RN; RINKER, AG			PEPTIDE BINDING INHIBITS PROTEIN AGGREGATION OF INVARIANT-CHAIN FREE CLASS-II DIMERS AND PROMOTES SURFACE EXPRESSION OF OCCUPIED MOLECULES	NATURE			English	Article							HLA-DR MOLECULES; HISTOCOMPATIBILITY ANTIGENS; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODIES; CELL LINE; IA; ASSOCIATION; RECOGNITION; GENE; H-2	EFFICIENT egress of major histocompatibility complex (MHC) class I molecules from the endoplasmic reticulum (ER) depends on peptide binding1-7. For MHC class II molecules, invariant chain (Ii) promotes ER exit of newly assembled, peptide-free dimers8-14. This raises the question of whether a mechanism exists elsewhere in the cell that dictates selective expression of peptide-associated class II molecules. We report here that dissociation of MHC class II-Ii complexes at low pH and physiological temperature leads to inclusion of empty class II in protein aggregates, and that this aggregation is specifically prevented by peptide binding. Combined with data showing that antigen exposure increases cell surface class II expression on living cells by a post-translational mechanism12, these results provide evidence for peptide-dependent intracellular editing of class II dimers, which limits surface expression of empty molecules unsuitable for antigen-specific T-cell activation.			GERMAIN, RN (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020					ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CLAESSONWELSH L, 1985, J IMMUNOL, V135, P3551; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	37	162	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					725	728		10.1038/363725a0	http://dx.doi.org/10.1038/363725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515815				2022-12-28	WOS:A1993LJ33900057
J	DEVEREUX, JA; JONES, DPH; DICKENSON, DL				DEVEREUX, JA; JONES, DPH; DICKENSON, DL			CAN CHILDREN WITHHOLD CONSENT TO TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA	A dilemma exists when a doctor is faced with a child or young person who refuses medically indicated treatment. The Gillick case had been interpreted by many to mean that a child of sufficient age and intelligence could validly consent or refuse consent to treatment. Recent decisions of the Court of Appeal on a child's refusal of medical treatment have clouded the issue and undermined the spirit of the Gillick decision and the Children Act 1989. It is now the case that a child patient whose competence is in doubt will be found rational if he or she accepts the proposal to treat but may be found incompetent if he or she disagrees. Practitioners are alerted to the anomalies now exhibited by the law on the issue of children's consent and refusal. The impact of the decisions from the perspectives of medicine, ethics, and the law are examined. Practitioners should review each case of child care carefully and in cases of doubt seek legal advice.	PK HOSP CHILDREN,OXFORD OX3 7LQ,ENGLAND; KEBLE COLL,OXFORD,ENGLAND; OPEN UNIV,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND	University of Oxford; Open University - UK								BLACK D, 1979, HLTH SOCIAL SER 0322, P208; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P57; CULVER M, 1982, PHILOS MED; DEEPROSE M, 1992, BMA NEWS REV, V18, P19; DICKINSON D, 1991, MORAL LUCK MED ETHIC, P109; Douglas G, 1992, Mod Law Rev, V55, P569, DOI 10.1111/j.1468-2230.1992.tb00934.x; Eekelaar J, 1986, OXFORD J LEGAL STUD, V6, P161; FAULDER C, 1985, WHOSE BODY IS IT TRO, P141; HSU LKG, 1988, PSYCHOL MED, V18, P807, DOI 10.1017/S0033291700009739; JONES DPH, 1991, ROYAL COLLEGE PSYCHI, P23; LOWE NV, 1986, WARDS COURT, P132; RE X, 1975, FAMILY DIVISION, P47; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; STEINHAUSEN HC, 1991, PSYCHOL MED, V21, P447, DOI 10.1017/S0033291700020559; 1992, LONGMAN PRACTITIONER, V5, P87; 1992, WEEKLY LAW REPORTS, V3, P758; 1991, WEEKLY LAW REPORTS, V3, P592	17	34	34	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1459	1461		10.1136/bmj.306.6890.1459	http://dx.doi.org/10.1136/bmj.306.6890.1459			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE935	8518645	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1993LE93500022
J	GARRATT, AM; RUTA, DA; ABDALLA, MI; BUCKINGHAM, JK; RUSSELL, IT				GARRATT, AM; RUTA, DA; ABDALLA, MI; BUCKINGHAM, JK; RUSSELL, IT			THE SF-36 HEALTH SURVEY QUESTIONNAIRE - AN OUTCOME MEASURE SUITABLE FOR ROUTINE USE WITHIN THE NHS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL OUTCOMES	Objective-To assess the validity, reliability, and acceptability of the short form 36 (SF36) health survey questionnaire (a shortened version of a battery of 149 health status questions) as a measure of patient outcome in a broad sample of patients suffering from four common clinical conditions. Design-Postal questionnaire, followed up by two reminders at two week intervals. Setting-Clinics and four training practices in north east Scotland. Subjects-Over 1700 patients aged 16-86 with one of four conditions-low back pain, menorrhagia, suspected peptic ulcer, or varicose veins-and a comparison sample of 900 members of the general population. Main outcome measures-The eight scales within the SF36 health profile. Results-The response rate exceeded 75% in the patient population (1310 respondents). The SF36 satisfied rigorous psychometric criteria for validity and internal consistency. Clinical validity was shown by the distinctive profiles generated for each condition, each of which differed from that in the general population in a predictable manner. Furthermore, SF36 scores were lower in referred patients than in patients not referred and were closely related to general practitioners' perceptions of severity. Conclusions-These results provide support for the SF36 as a potential measure of patient outcome within the NHS. The SF36 seems acceptable to patients, internally consistent, and a valid measure of the health status of a wide range of patients. Before it can be used in the new health service, however, its sensitivity to changes in health status over time must also be tested.	UNIV ABERDEEN, HLTH SERV RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND	University of Aberdeen	GARRATT, AM (corresponding author), UNIV ABERDEEN, DEPT PUBL HLTH, ABERDEEN AB9 2ZD, SCOTLAND.		Russell, Ian T/H-1181-2012; Ruta, Danny A/E-4472-2013	Ruta, Danny/0000-0002-2024-3267				ARMITAGE P, 1987, STATISTICAL METHODS; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Child D., 1990, ESSENTIALS FACTOR AN; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FRATER A, 1992, BRIT MED J, V304, P519, DOI 10.1136/bmj.304.6826.519; Garratt A M, 1993, Qual Health Care, V2, P5, DOI 10.1136/qshc.2.1.5; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Jolliffe IT., 2002, PRINCIPAL COMPONENT, DOI DOI 10.1007/B98835; KIND P, 1987, SOC SCI MED, V25, P905, DOI 10.1016/0277-9536(87)90260-7; Kline P., 1986, HDB TEST CONSTRUCTIO; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Roland M, 1992, HOSPITAL REFERRALS; Stewart A.L., 1992, MEASURING FUNCTIONIN; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STREINER GL, 1990, HLTH MEASUREMENT SCA; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; VICKREY BG, 1992, MED CARE, V30, P299, DOI 10.1097/00005650-199204000-00002; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 1989, WORKING PATIENTS	23	885	905	0	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	1993	306	6890					1440	1444		10.1136/bmj.306.6890.1440	http://dx.doi.org/10.1136/bmj.306.6890.1440			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518640	Bronze, Green Published			2022-12-28	WOS:A1993LE93500016
J	JARRETT, P; SHARP, C; MCLELLAND, J				JARRETT, P; SHARP, C; MCLELLAND, J			PROTECTION OF CHILDREN BY THEIR MOTHERS AGAINST SUNBURN	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA; EXPOSURE		SUNDERLAND ROYAL INFIRM,DEPT DERMATOL,SUNDERLAND SR2 7JE,ENGLAND	Sunderland Royal Hospital								GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; HOLMAN CD, 1984, JNCI-J NATL CANCER I, V73, P75; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199	5	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1448	1448		10.1136/bmj.306.6890.1448	http://dx.doi.org/10.1136/bmj.306.6890.1448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518641	Green Published, Bronze			2022-12-28	WOS:A1993LE93500018
J	Zahger, D; Milgalter, E				Zahger, D; Milgalter, E			A broken heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR FREE-WALL; RUPTURE; SUBACUTE		HADASSAH MED CTR,DEPT CARDIOTHORAC SURG,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center	Zahger, D (corresponding author), HADASSAH MED CTR,DEPT CARDIOL,EIN KEREM,POB 12000,IL-91120 JERUSALEM,ISRAEL.							BALAKUMARAN K, 1984, EUR HEART J, V5, P282, DOI 10.1093/oxfordjournals.eurheartj.a061653; ISSELBACHER EM, 1994, CIRCULATION, V90, P2375, DOI 10.1161/01.CIR.90.5.2375; KNOPF WD, 1987, AM J CARDIOL, V59, P1202, DOI 10.1016/0002-9149(87)90878-2; LOPEZSENDON J, 1992, J AM COLL CARDIOL, V19, P1145, DOI 10.1016/0735-1097(92)90315-E; OLIVA PB, 1993, J AM COLL CARDIOL, V22, P720, DOI 10.1016/0735-1097(93)90182-Z; PAPPAS PJ, 1991, CHEST, V99, P892, DOI 10.1378/chest.99.4.892; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1200; POHJOLASINTONEN S, 1989, AM HEART J, V117, P809, DOI 10.1016/0002-8703(89)90617-0; RAITT MH, 1993, AM HEART J, V126, P946, DOI 10.1016/0002-8703(93)90711-H; REDDY SG, 1989, AM J CARDIOL, V63, P906, DOI 10.1016/0002-9149(89)90137-9; RENKIN J, 1991, J AM COLL CARDIOL, V17, P280, DOI 10.1016/0735-1097(91)90739-V; WINDSOR HM, 1982, J THORAC CARDIOV SUR, V84, P755	12	10	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					319	321		10.1056/NEJM199602013340509	http://dx.doi.org/10.1056/NEJM199602013340509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532030				2022-12-28	WOS:A1996TV69500009
J	Cameron, A; Davis, KB; Green, G; Schaff, HV				Cameron, A; Davis, KB; Green, G; Schaff, HV			Coronary bypass surgery with internal-thoracic-artery grafts - Effects on survival over a 15-year period	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAMMARY-ARTERY; FOLLOW-UP; ATHEROSCLEROSIS; EXPERIENCE	Background. Aortocoronary bypass surgery has been performed most often with the patient's saphenous vein as the conduit. The internal-thoracic-artery graft, which has superior patency rates, has been shown to have clinical advantages, but it is not known how long these advantages persist. Methods. We identified all the patients in the registry of the Coronary Artery Surgery Study who had undergone first-time coronary-artery bypass grafting. Those with internal-thoracic-artery bypass grafts (749 patients) were compared with those with saphenous-vein bypass grafts only (4888 patients) with respect to survival over a 15-year follow-up period. Results. In a multivariate analysis to account for differences between the two groups, the presence of an internal-thoracic-artery graft was an independent predictor of improved survival and was associated with a relative risk of dying of 0.73 (95 percent confidence interval, 0.64 to 0.83). This improved survival was also observed in subgroups including patients 65 years of age or older, both men and women, and patients with impaired ventricular function. The survival curves of the two groups showed further separation over the years of follow-up, with a more marked downsloping after eight years in the curve for the group with saphenous-vein grafts only than in that for the group with internal-thoracic-artery grafts. Conclusions. As compared with saphenous-vein coronary bypass grafts, internal-thoracic-artery grafts conferred a survival advantage throughout a 15-year follow-up period. The survival advantage increased with time, suggesting that the initial selection of the conduit was a more important factor in survival than problems appearing long after surgery, such as the progression of coronary disease. (C) 1996, Massachusetts Medical Society.	COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP,DIV CARDIOTHORAC SURG,NEW YORK,NY 10025; COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; MAYO CLIN,ROCHESTER,MN	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Mayo Clinic	Cameron, A (corresponding author), COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP,DIV CARDIOL,1111 AMSTERDAM AVE,NEW YORK,NY 10025, USA.			Schaff, Hartzell/0000-0003-0994-027X				CAMERON A, 1988, CIRCULATION, V77, P815, DOI 10.1161/01.CIR.77.4.815; CAMERON A, 1986, CIRCULATION, V74, P30; CAMERON AAC, 1995, J AM COLL CARDIOL, V25, P188, DOI 10.1016/0735-1097(94)00332-K; CAMPEAU L, 1983, CIRCULATION, V68, P1; CHRISTAKIS GT, 1989, CIRCULATION, V80, P151; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; GALBUT DL, 1990, ANN THORAC SURG, V49, P195, DOI 10.1016/0003-4975(90)90138-V; HUDDLESTON CB, 1986, ANN THORAC SURG, V42, P543, DOI 10.1016/S0003-4975(10)60579-6; KAY HR, 1976, ANN THORAC SURG, V21, P504, DOI 10.1016/S0003-4975(10)63917-3; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; Principal Investigators of CASS and Associates, 1981, CIRCULATION S1, V63, pI1; REEN GE, 1994, ANN THORAC SURG, V58, P74; ZEFF RH, 1988, ANN THORAC SURG, V45, P533, DOI 10.1016/S0003-4975(10)64526-2; 1995, STAT STATISTICAL SOF, P554	15	648	689	1	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					216	219		10.1056/NEJM199601253340402	http://dx.doi.org/10.1056/NEJM199601253340402			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8531997	Bronze			2022-12-28	WOS:A1996TQ75500002
J	Brown, D				Brown, D			The 1990 Florida dental investigation: Theory and fact	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HIV TRANSMISSION	Controversy remains about the Centers for Disease Control and Prevention's (CDC) conclusion that a dentist in Florida transmitted human immunodeficiency virus to six of his patients in the late 1980s. The most vocal doubt has come from journalists affiliated with the television program 60 Minutes. Although unanswered questions about the case remain, the evidence continues to overwhelmingly support the CDC's theory. The criticism of the CDC investigation consists largely of assertions that contrary evidence theoretically might exist.			Brown, D (corresponding author), WASHINGTON POST, NATL STAFF, 1150 15TH ST NW, WASHINGTON, DC 20071 USA.							Barr S, 1996, ANN INTERN MED, V124, P250, DOI 10.7326/0003-4819-124-2-199601150-00009; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165	5	5	5	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					255	256		10.7326/0003-4819-124-2-199601150-00010	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534002				2022-12-28	WOS:A1996TQ01600010
J	Stewart, PM; Krozowski, ZS; Gupta, A; Milford, DV; Howie, AJ; Sheppard, MC; Whorwood, CB				Stewart, PM; Krozowski, ZS; Gupta, A; Milford, DV; Howie, AJ; Sheppard, MC; Whorwood, CB			Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene	LANCET			English	Article							CORTISOL; RECEPTOR; CARBENOXOLONE; LOCALIZATION; DEFICIENCY; LIQUORICE; DEFECTS	Background 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) catalyses the interconversion of hormonally active cortisol to inactive cortisone acid is vital for dictating specificity for the mineralocorticoid receptor. Thus, in patients with congenital deficiency of 11 beta-HSD (the syndrome of apparent mineralocorticoid excess, AME), cortisol acid not aldosterone acts as a mineralocorticoid, resulting in hypertension and hypokalaemia with suppression of the renin-angiotensin-aldosterone axis. Two isoforms of human 11 beta-HSD have been described, but it is the NAD-dependent type 2 isoform (11 beta-HSD2), first characterised in placental tissue, that is expressed in the mineralocorticoid target tissues, kidney and colon. We have analysed the 11 beta-HSD2 gene as a candidate gene in explaining the molecular basis of AME. Methods By exon-specific PCR-amplification of the 11 beta-HSD2 gene in a consanguineous kindred with AME, we found a point mutation (C1228T) in two affected siblings, and also in placental DNA obtained from a stillbirth pregnancy. Findings The mutation in exon 5 of the 11 beta-HSD2 gene resulted in a premature stop site at codon 374 instead of a normal arginine (R374X), with the deletion of 32 aminoacids from the C-terminus of the 11 beta-HSD2 enzyme protein. Both parents, who are phenotypically normal, are heterozygote for the C1228T mutation in keeping with an autosomal recessive form of inheritance. NAD-dependent 11 beta-HSD activity was severely attenuated in the stillbirth placenta compared with control placental tissue, and no 11 beta-HSD immunostaining was observed in this placenta with antisera derived against a C-terminal 11 beta-HSD2 peptide sequence. Interpretation AME is due to a mutation in the 11 beta-HSD2 gene, and is an example of human hypertension arising from a single gene defect.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT PATHOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; CHILDRENS HOSP,DEPT PAEDIAT NEPHROL,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND; BAKER MED RES INST,PRAHRAN,VIC,AUSTRALIA	University of Birmingham; Baker Heart and Diabetes Institute	Stewart, PM (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; DIMARTINONARDI J, 1987, CLIN ENDOCRINOL, V27, P49, DOI 10.1111/j.1365-2265.1987.tb00838.x; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; KITANAKA S, 1995, 77TH P ANN M END SOC, P2; KROZOWSKI Z, 1995, CYTOGENET CELL GENET, V71, P124, DOI 10.1159/000134089; KROZOWSKI Z, 1995, J CLIN ENDOCR METAB, V80, P2203, DOI 10.1210/jc.80.7.2203; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MILFORD DV, 1995, CLIN ENDOCRINOL, V43, P242; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; NIKKILA H, 1993, J CLIN ENDOCR METAB, V77, P687, DOI 10.1210/jc.77.3.687; SHACKLETON CHL, 1990, ENDOCRINE HYPERTENSI, P155; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SORO A, 1995, HYPERTENSION, V25, P67, DOI 10.1161/01.HYP.25.1.67; SOUNESS GW, 1989, ENDOCRINOLOGY, V124, P1588, DOI 10.1210/endo-124-3-1588; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STEWART PM, 1990, CLIN SCI, V78, P49, DOI 10.1042/cs0780049; STEWART PM, 1987, LANCET, V2, P821; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; WALKER BR, 1993, CLIN ENDOCRINOL, V39, P221, DOI 10.1111/j.1365-2265.1993.tb01778.x; WERDER E, 1974, RES STEROIDS, V6, P385; WHORWOOD CB, 1995, MOL CELL ENDOCRINOL, V110, pR7, DOI 10.1016/0303-7207(95)03546-J; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263	30	201	204	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					88	91		10.1016/S0140-6736(96)90211-1	http://dx.doi.org/10.1016/S0140-6736(96)90211-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538347				2022-12-28	WOS:A1996TP28100010
J	Manian, FA; Janssen, DA				Manian, FA; Janssen, DA			Curbside consultations - A closer look at a common practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Manian, FA (corresponding author), ST JOHNS MERCY MED CTR,DIV INFECT DIS,621 S NEW BALLAS RD,ST LOUIS,MO 63141, USA.							MAGNUSSEN CR, 1994, INFECT DIS CLIN PRAC, V1, P391; MANIAN FA, 1993, 31ST ANN M INF DIS S; MYERS JP, 1984, J INFECT DIS, V150, P797, DOI 10.1093/infdis/150.6.797; OLANS RN, 1994, INFECT DIS CLIN PRAC, V1, P394; WEINBERG AD, 1981, J MED EDUC, V56, P174; 1995, JAMA-J AM MED ASSOC, V273, P330	6	53	53	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					145	147						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531311				2022-12-28	WOS:A1996TN28000032
J	Forrester, J				Forrester, J			Postal diagnosis: Breaking the bad news in the 17th century	BRITISH MEDICAL JOURNAL			English	Note									SCOTTISH HOME & HLTH DEPT,EDINBURGH,MIDLOTHIAN,SCOTLAND									GALEN, 1979, CORPUS MEDICORUM GRA, V8, P1; GAVEY CJ, 1952, MANAGEMENT HOPELESS; HIPPOCRATES, 1923, HIPPOCRATES, V2, P1; HUTCHISON R, 1935, PROGNOSIS, V1; MACOPPE AK, 1795, APHORISMI MEDICO POL; MACOPPE AK, 1694, AORTAE POLYPO EPISTO, P85; OBOYLE C, 1991, MEDIEVAL PROGNOSIS A, P15; REISER SJ, 1978, MED REIGN TECHNOLOGY, P6; SCANAGATUS N, 1745, AK MACOPPE PRIMARIO; VONHALLER A, 1757, DISPUTATIONES AD MOR, V2, P681; WOODHAMSMITH C, 1950, F NIGHTINGALE, P171	11	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1694	1696		10.1136/bmj.311.7021.1694	http://dx.doi.org/10.1136/bmj.311.7021.1694			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541762	Green Published			2022-12-28	WOS:A1995TL94200023
J	HEINLEIN, M; EPEL, BL; PADGETT, HS; BEACHY, RN				HEINLEIN, M; EPEL, BL; PADGETT, HS; BEACHY, RN			INTERACTION OF TOBAMOVIRUS MOVEMENT PROTEINS WITH THE PLANT CYTOSKELETON	SCIENCE			English	Article							TOBACCO MOSAIC-VIRUS; CORTICAL ENDOPLASMIC-RETICULUM; BULB EPIDERMIS CELLS; HERPES-SIMPLEX VIRUS; TRANSGENIC PLANTS; BINDING-PROTEIN; BY-2 CELLS; MICROTUBULES; RNA; PLASMODESMATA	The movement protein of tobacco mosaic tobamovirus and related viruses is essential for the cell-to-cell spread of infection and, in part, determines the host range of the virus. Movement protein (MP) was fused with the jellyfish green fluorescent protein (GFP), and a modified virus that contained this MP:GFP fusion protein retained infectivity. In protoplasts and leaf tissues, the MP:GFP fusion protein was detected as long filaments shortly after infection. Double-labeling fluorescence microscopy suggests that the MP interacts and coaligns with microtubules. The distribution of the MP is disrupted by treatments that disrupt microtubules, but not by cytochalasin B, which disrupts filamentous F-actin. Microtubules may target the MP to plasmodesmata, the intercellular channels connect adjacent cells.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; TEL AVIV UNIV, DEPT BOT, IL-69978 TEL AVIV, ISRAEL; UNIV WASHINGTON, DIV BIOL & BIOMED SCI, ST LOUIS, MO 63110 USA	Scripps Research Institute; Tel Aviv University; Washington University (WUSTL)								AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; AKASHI T, 1990, PLANTA, V182, P363, DOI 10.1007/BF02411386; AKASHI T, 1991, J CELL SCI, V98, P169; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; DEMATOS APA, 1993, BIOL CELL, V78, P229, DOI 10.1016/0248-4900(93)90134-Z; DEOM CM, 1992, CELL, V69, P221, DOI 10.1016/0092-8674(92)90403-Y; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; DEOM CM, 1990, P NATL ACAD SCI USA, V87, P3284, DOI 10.1073/pnas.87.9.3284; EPEL BL, 1994, PLANT MOL BIOL, V26, P1343, DOI 10.1007/BF00016479; EPEL BL, IN PRESS GENE; HEINE UI, 1985, J GEN VIROL, V66, P275, DOI 10.1099/0022-1317-66-2-275; HEINLEIN M, UNPUB; HEPLER PK, 1982, PROTOPLASMA, V111, P121, DOI 10.1007/BF01282070; HEPLER PK, 1990, J CELL SCI, V96, P355; HOLT CA, 1991, VIROLOGY, V181, P109, DOI 10.1016/0042-6822(91)90475-Q; KARASEV AV, 1992, FEBS LETT, V304, P12, DOI 10.1016/0014-5793(92)80578-5; KATSUTA J, 1990, J CELL SCI, V95, P413; KNEBEL W, 1990, EUR J CELL BIOL, V52, P328; KRISTENSSON K, 1986, J GEN VIROL, V67, P2023, DOI 10.1099/0022-1317-67-9-2023; LANCELLE SA, 1987, PROTOPLASMA, V140, P141, DOI 10.1007/BF01273723; LICHTSCHEIDL IK, 1990, PROTOPLASMA, V155, P116, DOI 10.1007/BF01322621; LICHTSCHEIDL IK, 1990, PROTOPLASMA, V157, P203, DOI 10.1007/BF01322653; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LLOYD CW, 1980, PLANTA, V147, P500, DOI 10.1007/BF00380194; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; LYCKE E, 1987, J VIROL, V61, P2733, DOI 10.1128/JVI.61.9.2733-2741.1987; MAULE AJ, 1991, CRIT REV PLANT SCI, V9, P457, DOI 10.1080/07352689109382301; MOORE PJ, 1992, PROTOPLASMA, V170, P115, DOI 10.1007/BF01378787; NORRILD B, 1986, J GEN VIROL, V67, P97, DOI 10.1099/0022-1317-67-1-97; OPARKA KJ, 1994, PLANT CELL ENVIRON, V17, P163, DOI 10.1111/j.1365-3040.1994.tb00279.x; PADGETT HS, 1993, PLANT CELL, V5, P577, DOI 10.1105/tpc.5.5.577; QUADER H, 1987, EUR J CELL BIOL, V44, P17; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; STEARNS T, 1995, CURR BIOL, V5, P262, DOI 10.1016/S0960-9822(95)00056-X; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; TOMENIUS K, 1987, VIROLOGY, V160, P363, DOI 10.1016/0042-6822(87)90007-9; TOPP KS, 1994, J NEUROSCI, V14, P318; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; WATANABE Y, 1982, VIROLOGY, V120, P478, DOI 10.1016/0042-6822(82)90048-4; WATANABE Y, 1987, FEBS LETT, V219, P65, DOI 10.1016/0014-5793(87)81191-2; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WILLIAMSON RE, 1991, INT REV CYTOL, V129, P135; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377	49	340	359	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	1995	270	5244					1983	1985		10.1126/science.270.5244.1983	http://dx.doi.org/10.1126/science.270.5244.1983			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533089				2022-12-28	WOS:A1995TL42000039
J	GRAUSCHOPF, U; WINTHER, JR; KORBER, P; ZANDER, T; DALLINGER, P; BARDWELL, JCA				GRAUSCHOPF, U; WINTHER, JR; KORBER, P; ZANDER, T; DALLINGER, P; BARDWELL, JCA			WHY IS DSBA SUCH AN OXIDIZING DISULFIDE CATALYST	CELL			English	Article							BOND FORMATION INVIVO; ESCHERICHIA-COLI; ISOMERASE DSBA; REDOX PROPERTIES; ACTIVE-SITE; IN-VIVO; THIOREDOXIN	DsbA, a member of the thioredoxin family of disulfide oxidoreductases, acts in catalyzing disulfide bond formation by donating its disulfide to newly translocated proteins. We have found that the two central residues within the active site Cys-30-Pro-31-His-32-Cys-33 motif are critical in determining the exceptional oxidizing power of DsbA. Mutations that change these two residues can alter the equilibrium oxidation potential of DsbA by more than 1000-fold. A quantitative explanation for the very high redox potential of DsbA was found by measuring the pK(a) of a single residue, Cys-30. The pK(a) of Cys-80 varied dramatically from mutant to mutant and could accurately predict the oxidizing power of each DsbA mutant protein.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY	University of Regensburg			Winther, Jakob R./K-4451-2014; Korber, Philipp/AAN-7633-2021	Winther, Jakob R./0000-0001-6995-9154; Korber, Philipp/0000-0001-7526-6549				BARDWELL J, 1994, PHOSPHATE IN MICROORGANISMS, P270; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; FREEDMAN RB, 1994, CURR BIOL, V4, P933, DOI 10.1016/S0960-9822(00)00210-4; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GUILHOT C, 1995, IN PRESS P NATL ACAD; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MARTIN JL, 1993, J MOL BIOL, V230, P1097, DOI 10.1006/jmbi.1993.1226; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; WUNDERLICH M, 1994, THESIS U REGENSBURG; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	33	277	290	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					947	955		10.1016/0092-8674(95)90210-4	http://dx.doi.org/10.1016/0092-8674(95)90210-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521518	Bronze			2022-12-28	WOS:A1995TK74500013
J	SAUER, F; HANSEN, SK; TJIAN, R				SAUER, F; HANSEN, SK; TJIAN, R			MULTIPLE TAF(II)S DIRECTING SYNERGISTIC ACTIVATION OF TRANSCRIPTION	SCIENCE			English	Article							DROSOPHILA EMBRYO; PROTEIN; HUNCHBACK; PATTERN; BINDING; REPRESSION; SEQUENCES; KRUPPEL; DOMAIN; STRIPE	Coordinate activation of transcription by multiple enhancer binding factors is essential for the regulation of pattern formation during development of Drosophila melanogaster. Cell-free transcription reactions are described that recapitulate transcriptional synergism directed by the Drosophila developmental regulators Bicoid (BCD) and Hunchback (HB). Within the basal transcription factor complex TFIID, two specific targets, TAF(II)110 and TAF(II)60, served as coactivators to mediate transcriptional activation by these two enhancer binding proteins. A quadruple complex containing TATA binding protein (TBP), TAF(II)250, TAF(II)110, and TAF(II)60 mediated transcriptional synergism by BCD and HB, whereas triple TBP-TAF(II) complexes lacking one or the other target coactivator failed to support synergistic activation. Deoxyribonuclease I footprint protection experiments revealed that an integral step leading to transcriptional synergism involves the recruitment of TBP-TAF(II) complexes to the promoter by way of multivalent contacts between activators and selected TAF(II)s. Thus, the concerted action of multiple regulators with different coactivators helps to establish the pattern and level of segmentation gene transcription during Drosophila development.			SAUER, F (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CUTLER G, UNPUB; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HULSKAMP M, 1991, BIOESSAYS, V13, P261, DOI 10.1002/bies.950130602; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KERSZBERG M, 1994, P NATL ACAD SCI USA, V91, P5823, DOI 10.1073/pnas.91.13.5823; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; PANKRATZ MJ, 1993, DEVELOPMENT, V1, P167; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAUER F, UNPUB; SCHUPBACH T, 1994, CURR OPIN GENET DEV, V4, P502, DOI 10.1016/0959-437X(94)90064-A; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Small S, 1991, CURR OPIN GENET DEV, V1, P255, DOI 10.1016/S0959-437X(05)80079-6; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	51	169	171	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1783	1788		10.1126/science.270.5243.1783	http://dx.doi.org/10.1126/science.270.5243.1783			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525367				2022-12-28	WOS:A1995TK47600034
J	YUSEFZADEH, F; UCHIDA, KI; ROBERTS, D				YUSEFZADEH, F; UCHIDA, KI; ROBERTS, D			SHOCK-EXCITED OH MASER EMISSION OUTLINING THE GALACTIC-CENTER SUPERNOVA REMNANT G359.1-0.05	SCIENCE			English	Article							MOLECULAR CLOUDS; SHELL	A search using the Very Large Array was performed for 1720-megahertz OH maser line emission from a number of nonthermal radio continuum sources in the galactic center region. The 1720-megahertz transition has recently been noted for its potential as a tracer of shock activity. The most striking result was the detection of extended 1720-megahertz OH maser emission, as well as a number of compact OH maser features, along the interface between a large-scale continuum shell (G359.1-0.5) and its surrounding ring of high-velocity molecular gas. The morphological correlation among the neutral gas, the nonthermal shell, and the maser features provides strong support for the hypothesis that the 1720-megahertz maser line of OH arises from gas shocked by the impact of the expanding supernova remnant into the molecular material. However, the radial velocities of the molecular cloud surrounding G359.1-0.5 are more negative than that of the OH maser spots by more than 50 kilometers per second. Here it is suggested that only the low-radial-velocity component of the carbon monoxide material at the limb of the remnant satisfies the physical conditions required for collisional pumping of the OH 1720-megahertz line behind the expanding shock front.	MAX PLANCK INST RADIOASTRON,D-53121 BONN,GERMANY; UNIV ILLINOIS,DEPT ASTRON,CHAMPAIGN,IL 61801	Max Planck Society; University of Illinois System; University of Illinois Urbana-Champaign	YUSEFZADEH, F (corresponding author), NORTHWESTERN UNIV,DEPT PHYS & ASTRON,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.							BALLY J, 1988, ASTROPHYS J, V324, P223, DOI 10.1086/165891; ELITZUR M, 1976, ASTROPHYS J, V203, P124, DOI 10.1086/154054; FRAIL DA, 1994, ASTROPHYS J, V424, pL111, DOI 10.1086/187287; GRAY AD, 1991, NATURE, V353, P237, DOI 10.1038/353237a0; HOLLENBACH D, 1989, ASTROPHYS J, V342, P306, DOI 10.1086/167595; LISZT HS, 1985, ASTROPHYS J, V293, pL65, DOI 10.1086/184492; TURNER BE, 1982, ASTROPHYS J, V255, pL33, DOI 10.1086/183764; UCHIDA K, 1992, ASTRON J, V104, P1533, DOI 10.1086/116337; UCHIDA KI, 1992, ASTROPHYS J, V398, P128, DOI 10.1086/171842; WARDLE M, 1991, MON NOT R ASTRON SOC, V251, P119, DOI 10.1093/mnras/251.1.119; YUSEFZADEH F, 1984, NATURE, V310, P557, DOI 10.1038/310557a0	11	52	52	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1801	1804		10.1126/science.270.5243.1801	http://dx.doi.org/10.1126/science.270.5243.1801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525369				2022-12-28	WOS:A1995TK47600039
J	KISSINGER, CR; PARGE, HE; KNIGHTON, DR; LEWIS, CT; PELLETIER, LA; TEMPCZYK, A; KALISH, VJ; TUCKER, KD; SHOWALTER, RE; MOOMAW, EW; GASTINEL, LN; HABUKA, N; CHEN, XH; MALDONADO, F; BARKER, JE; BACQUET, R; VILLAFRANCA, JE				KISSINGER, CR; PARGE, HE; KNIGHTON, DR; LEWIS, CT; PELLETIER, LA; TEMPCZYK, A; KALISH, VJ; TUCKER, KD; SHOWALTER, RE; MOOMAW, EW; GASTINEL, LN; HABUKA, N; CHEN, XH; MALDONADO, F; BARKER, JE; BACQUET, R; VILLAFRANCA, JE			CRYSTAL-STRUCTURES OF HUMAN CALCINEURIN AND THE HUMAN FKBP12-FK506-CALCINEURIN COMPLEX	NATURE			English	Article							FKBP-FK506	CALCINEURIN (CaN) is a calcium- and calmodulin-dependent protein serine/threonine phosphatase which is critical for several important cellular processes, including T-cell activation(1). CaN is the target of the immunosuppressive drugs cyclosporin A and FK506, which inhibit CaN after forming complexes with cytoplasmic binding proteins (cyclophilin and FKBP12, respectively)(2). We report here the crystal structures of full-length human CaN at 2.1 Angstrom resolution and of the complex of human CaN with FKBP12-FK506 at 3.5 Angstrom resolution. In the native CaN structure, an autoinhibitory element binds at the Zn/Fe-containing active site. The metal-site geometry and active-site water structure suggest a catalytic mechanism involving nucleophilic attack on the substrate phosphate by a metal-activated water molecule. In the FKBP12-FK506-CaN complex, the auto-inhibitory element is displaced from the active site. The site of binding of FKBP12-FK506 appears to be shared by other non-competitive inhibitors of calcine-urin, including a natural anchoring protein.	AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121	Pfizer				Moomaw, Ellen/0000-0002-2341-1676				BABU YS, 1988, J MOL BIOL, V203, P191; BRUNGER A, 1993, X PLOR VERSION 3 1 M; BURROUGHS SE, 1994, BIOCHEMISTRY-US, V33, P10428, DOI 10.1021/bi00200a026; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUERINI D, 1992, J BIOL CHEM, V267, P22542; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS C, 1995, FASEB J, V9, pA1346; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1990, FASEB J, V4, pA2237; Qin K. -F., 1995, FASEB J, V9, pA1347; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, P1; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040	29	673	702	4	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					641	644		10.1038/378641a0	http://dx.doi.org/10.1038/378641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524402				2022-12-28	WOS:A1995TJ22100085
J	FRISCH, M; FRIIS, S; KJAER, SK; MELBYE, M				FRISCH, M; FRIIS, S; KJAER, SK; MELBYE, M			FALLING INCIDENCE OF PENIS CANCER IN AN UNCIRCUMCISED POPULATION (DENMARK 1943-90)	BRITISH MEDICAL JOURNAL			English	Article									DANISH CANC SOC,RES CTR,DIV CANC EPIDEMIOL,COPENHAGEN,DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Kjaer, Susanne/0000-0002-8347-1398; melbye, mads/0000-0001-8264-6785				GORDON A, 1993, BRIT MED J, V306, P1, DOI 10.1136/bmj.306.6869.1; Nomura A, 1982, CANCER EPIDEMIOL, P624; Remondino PC, 1891, HIST CIRCUMCISION; Wolbarst AL, 1932, LANCET, V1, P150; 1943, STATISTISK ARBOG, P32; 1991, STATISTISK ARBOG, P73	6	92	93	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1471	1471		10.1136/bmj.311.7018.1471	http://dx.doi.org/10.1136/bmj.311.7018.1471			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520335	Green Published			2022-12-28	WOS:A1995TJ04400024
J	ISOM, LL; RAGSDALE, DS; DEJONGH, KS; WESTENBROEK, RE; REBER, BFX; SCHEUER, T; CATTERALL, WA				ISOM, LL; RAGSDALE, DS; DEJONGH, KS; WESTENBROEK, RE; REBER, BFX; SCHEUER, T; CATTERALL, WA			STRUCTURE AND FUNCTION OF THE BETA-2 SUBUNIT OF BRAIN SODIUM-CHANNELS, A TRANSMEMBRANE GLYCOPROTEIN WITH A CAM MOTIF	CELL			English	Article							AMINO-ACID SEQUENCE; RAT-BRAIN; SKELETAL-MUSCLE; ALPHA-SUBUNIT; IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; NA+ CHANNELS; EXPRESSION; PROTEIN; NEURONS	Voltage-gated sodium channels in brain neurons are complexes of a pore-forming alpha subunit with smaller beta 1 and beta 2 subunits, cDNA cloning and sequencing showed that the beta 2 subunit is a 186 residue glycoprotein with an extracellular NH2-terminal domain containing an immunoglobulin-like fold with similarity to the neural cell adhesion molecule (CAM) contactin, a single transmembrane segment, and a small intracellular domain, Coexpression of beta 2 with alpha subunits in Xenopus oocytes increases functional expression, modulates gating, and causes up to a 4-fold increase in the capacitance of the oocyte, which results from an increase in the surface area of the plasma membrane microvilli. beta 2 subunits are unique among the auxiliary subunits of ion channels in combining channel modulation with a CAM motif and the ability to expand the cell membrane surface area. They may be important regulators of sodium channel expression and localization in neurons.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle				Isom, Lori/0000-0002-9479-6729	NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NINDS NIH HHS [NS 25704] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hille B., 1992, IONIC CHANNELS EXCIT; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JUNG M, 1993, GLIA, V9, P163, DOI 10.1002/glia.440090302; KELLY GM, 1991, METHOD CELL BIOL, V36, P389; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINSON SR, 1986, ANN NY ACAD SCI, V479, P162, DOI 10.1111/j.1749-6632.1986.tb15568.x; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; QU Y, 1995, IN PRESS J BIOL CHEM; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; REBER BFX, 1987, J BIOL CHEM, V262, P11369; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; VAUGHAN L, 1994, PERSPECT DEV NEUROBI, V2, P43; WESTENBROEK RE, 1992, J NEUROSCI, V12, P2259, DOI 10.1523/jneurosci.12-06-02259.1992; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOLLNER DA, 1988, NEURON, V1, P727, DOI 10.1016/0896-6273(88)90171-7; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D; ZINSCH AH, 1992, J CELL BIOL, V119, P203	44	386	396	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					433	442		10.1016/0092-8674(95)90121-3	http://dx.doi.org/10.1016/0092-8674(95)90121-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521473	Bronze			2022-12-28	WOS:A1995TC97700013
J	BRILLEDWARDS, P; GINSBERG, JS; JOHNSTON, M; HIRSH, J				BRILLEDWARDS, P; GINSBERG, JS; JOHNSTON, M; HIRSH, J			ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPARIN; PARTIAL THROMBOPLASTIN TIME; THROMBOEMBOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; ANTICOAGULANTS	PARTIAL THROMBOPLASTIN TIME; MOLECULAR-WEIGHT HEPARIN; CONTINUOUS INTRAVENOUS HEPARIN; PROXIMAL-VEIN THROMBOSIS; VENOUS THROMBOSIS; SUBCUTANEOUS HEPARIN; INITIAL TREATMENT; STANDARD HEPARIN; INVITRO; SAMPLE	Objective: To compare two methods of determining a therapeutic range of activated partial thromboplastin time (aPTT) results. Design: Cohort studies. Setting: Referral teaching hospital. Patients: Inpatients who received unfractionated heparin intravenously for venous thromboembolic disease. Measurements: A therapeutic range determined by aPTT ratios of 1.5 to 2.5 times the control value as compared with a therapeutic range determined by protamine titration heparin levels of 0.2 to 0.4 U/mL. Results: For all aPTT reagents studied, a ratio of 1.5 times the control value is much less than a minimum protamine titration heparin level of 0.2 U/mL. Various manufacturers' aPTT reagents and reagent lots from the same manufacturer show considerable variation in response to heparin and therefore have different therapeutic ranges. Conclusions: A different dose of heparin would be required to produce an aPTT ratio of 1.5 times the control value, depending on the reagent used. Establishing a therapeutic range for aPTT results using protamine titration heparin levels of 0.2 to 0.4 U/mL as a reference standard is practical and compensates for the variable response of aPTT reagents to heparin.	HAMILTON CIVIC HOSP, RES CTR, HAMILTON, ON, CANADA	McMaster University	BRILLEDWARDS, P (corresponding author), MCMASTER UNIV, MED CTR, 1200 MAIN ST W, HSC-3W12, HAMILTON L8N 3Z5, ONTARIO, CANADA.		ginsberg, jeffrey s/ABC-1065-2020					ANSELL J, 1991, AM J CLIN PATHOL, V95, P222, DOI 10.1093/ajcp/95.2.222; BAIN B, 1980, AM J CLIN PATHOL, V74, P668; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; BRANDT JT, 1981, AM J CLIN PATHOL, V76, P530; CHIU HM, 1977, BLOOD, V49, P171; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; GAWOSKI JM, 1987, ARCH PATHOL LAB MED, V111, P785; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; LENTZ SR, 1992, MANUAL MED THERAPEUT, P323; MOSER KM, 1991, HARRISONS PRINCIPLES, P1090; POLLER L, 1989, AM J CLIN PATHOL, V92, P124, DOI 10.1093/ajcp/92.1.124; POLLER L, 1989, RES CLIN LAB, V19, P363; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; REFN I, 1954, SCAND J CLIN LAB INV, V6, P284, DOI 10.3109/00365515409134865; SCIALLA SJ, 1985, AM J CLIN PATHOL, V84, P351, DOI 10.1093/ajcp/84.3.351; SHOJANIA AM, 1988, AM J CLIN PATHOL, V89, P19, DOI 10.1093/ajcp/89.1.19; SPECTOR I, 1967, JAMA-J AM MED ASSOC, V201, P75; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VANDENBESSELAAR AMHP, 1990, THROMB HAEMOSTASIS, V63, P16; WESSLER S, 1955, CIRCULATION, V12, P553, DOI 10.1161/01.CIR.12.4.553; ZANKE B, 1990, AM J CLIN PATHOL, V93, P684, DOI 10.1093/ajcp/93.5.684; ZUCKER S, 1969, J LAB CLIN MED, V73, P320; [No title captured]	28	263	267	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					104	109		10.7326/0003-4819-119-2-199307150-00002	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512158				2022-12-28	WOS:A1993LU90200002
J	CARLISLE, RD; JOHNSTONE, SP; PEARSON, JCG				CARLISLE, RD; JOHNSTONE, SP; PEARSON, JCG			RELATION BETWEEN NIGHT VISIT RATES AND DEPRIVATION MEASURES IN ONE GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							HOURS WORKLOAD; JARMAN INDEX; MORTALITY	Objective-To compare night visit rates in different electoral wards of one general practice with the Jarman and Townsend deprivation scores and unemployment rates. Design-Analysis of computerised workload data. Setting-General practice in centre of Mansfield, Nottinghamshire. Outcome measure-Visits made in 588 nights to the 11 998 patients on the practice list. Results-Night visit rates in 15 electoral wards varied from 19.6 to 55.3 visits per 1000 patients per year. The rates showed a significant association with the Townsend score (p=0.004) and the unemployment rate (p=0.03) but not with the jarman score (p=0.3). The Townsend score explained 49% of the variability; unemployment explained 31% and the jarman score explained 9%. Conclusions-Even in a general practice not eligible for deprivation payments there was a 2.8-fold variation in night visit rates between wards. In this practice the Townsend score was significantly better at predicting night visit rates than the Jarman score. This method of looking at internal variation in workloads in computerised practices could give more direct data on the relation between deprivation and general practice workload than has previously been available.	RANSOM HOSP,N NOTTINGHAMSHIRE HLTH AUTHOR,DEPT PUBL MED,RAINWORTH NG21 0ER,NOTTS,ENGLAND; QUEENS MED CTR,SCH PUBL HLTH,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	CARLISLE, RD (corresponding author), ROUNDWOOD SURG,MANSFIELD NG18 1QQ,NOTTS,ENGLAND.							BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CAMPBELL DA, 1991, BMJ-BRIT MED J, V303, P750, DOI 10.1136/bmj.303.6805.750; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; CARSTAIRS V, 1989, COMMUNITY MED, V11, P364; CHARLTON JRH, 1985, BRIT MED J, V290, P1714, DOI 10.1136/bmj.290.6483.1714; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LEAVEY R, 1985, BRIT MED J, V291, P709, DOI 10.1136/bmj.291.6497.709; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; SENIOR ML, 1991, BRIT MED J, V302, P661, DOI 10.1136/bmj.302.6777.661-b; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; Townsend P., 1986, INEQUALITIES HLTH NO; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; 1989, GENERAL PRACTICE NAT	17	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1383	1385		10.1136/bmj.306.6889.1383	http://dx.doi.org/10.1136/bmj.306.6889.1383			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518606	Green Published, Bronze			2022-12-28	WOS:A1993LD82900023
J	Greco, D; Salmaso, S; Mastrantonio, P; Giuliano, M; Tozzi, AE; Anemona, A; Atti, MLCD; Giammanco, A; Panei, P; Blackwelder, WC; Klein, DL; Wassilak, SGF; Stefanelli, P; Bottone, M; Sofia, T; Luzi, S; Bellomi, G; Cobianchi, F; Canganella, G; Meduri, F; Scuderi, G; Chiarini, A; Maggio, M; Taormina, S; Genovese, M; Moiraghi, A; Barale, A; DiTommaso, S; Malaspina, S; Vasile, E; Ferraro, P; DalLago, P; DeMarzi, L; Robino, L; Giraldo, E; Coppola, N; Materassi, P; Castellani, GT; Basso, F; Barbuti, S; Quarto, M; Lopalco, P; DOrazio, P; Sanguedolce, A				Greco, D; Salmaso, S; Mastrantonio, P; Giuliano, M; Tozzi, AE; Anemona, A; Atti, MLCD; Giammanco, A; Panei, P; Blackwelder, WC; Klein, DL; Wassilak, SGF; Stefanelli, P; Bottone, M; Sofia, T; Luzi, S; Bellomi, G; Cobianchi, F; Canganella, G; Meduri, F; Scuderi, G; Chiarini, A; Maggio, M; Taormina, S; Genovese, M; Moiraghi, A; Barale, A; DiTommaso, S; Malaspina, S; Vasile, E; Ferraro, P; DalLago, P; DeMarzi, L; Robino, L; Giraldo, E; Coppola, N; Materassi, P; Castellani, GT; Basso, F; Barbuti, S; Quarto, M; Lopalco, P; DOrazio, P; Sanguedolce, A			A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BORDETELLA-PERTUSSIS; ANTIBODY-RESPONSE; EFFICACY; EPIDEMIOLOGY; IMMUNIZATION; CHILDREN; TOXIN; PARAPERTUSSIS; EXPERIENCE; DIPHTHERIA	Background. Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods. We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing. Results. The efficacy of each vaccine, given in three doses, against pertussis was determined for 14,751 children over an average of 17 months, with cases included in the analysis if cough began 30 days or more after the completion of immunization. For both of the acellular DTP vaccines, the efficacy was 84 percent (95 percent confidence intervals, 76 to 89 percent for SmithKline DTP and 76 to 90 percent for Biocine DTP), whereas the efficacy of the whole-cell DTP vaccine was only 36 percent (95 percent confidence interval, 14 to 52 percent). The antibody responses were greater to the acellular vaccines than to the whole-cell vaccine. Local and systemic adverse events were significantly more frequent after the administration of the whole-cell vaccine. For the acellular vaccines, the frequency of adverse events was similar to that in the control (DT) group. Conclusions. The two acellular DTP vaccines we studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.	IST SUPER SANITA,LAB BACTERIOL & MED MYCOL,I-00161 ROME,ITALY; UNIV PALERMO,DEPT HYG & MICROBIOL,PALERMO,ITALY; NIAID,BETHESDA,MD 20892	Istituto Superiore di Sanita (ISS); University of Palermo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Greco, D (corresponding author), IST SUPER SANITA,EPIDEMIOL & BIOSTAT LAB,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Giuliano, Marina/V-8991-2017; Giammanco, Andrea/O-5017-2019; degli Atti, Marta Ciofi/K-4650-2018; Tozzi, Alberto Eugenio/F-9494-2012; Lopalco, Pier Luigi/AAB-7035-2019; STEFANELLI, PAOLA/B-8729-2016	Giuliano, Marina/0000-0003-2789-7797; Giammanco, Andrea/0000-0001-9640-8294; degli Atti, Marta Ciofi/0000-0001-6492-4497; Tozzi, Alberto Eugenio/0000-0002-6884-984X; Lopalco, Pier Luigi/0000-0002-3181-8054; STEFANELLI, PAOLA/0000-0003-1620-4385	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025138] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-25138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, B WORLD HEALTH ORGAN, V72, P885; [Anonymous], 1988, LANCET, Vi, P955; BAKER JD, 1992, J PEDIATR-US, V121, P523, DOI 10.1016/S0022-3476(05)81138-2; BINKIN NJ, 1992, PEDIATR INFECT DIS J, V11, P653; BLACKWELDER WC, 1993, STAT MED, V12, P691, DOI 10.1002/sim.4780120708; BLENNOW M, 1988, PEDIATRICS, V82, P293; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; CODY CL, 1981, PEDIATRICS, V68, P650; DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1995, PEDIATRICS, V96, P548; EDWARDS KM, 1993, J INFECT DIS, V168, P15, DOI 10.1093/infdis/168.1.15; EDWARDS KM, 1991, PEDIATRICS, V88, P1019; FINE PEM, 1987, REV INFECT DIS, V9, P866; GILLENIUS P, 1985, J BIOL STAND, V13, P61, DOI 10.1016/S0092-1157(85)80034-2; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HALLANDER HO, 1991, J INFECT DIS, V163, P1046, DOI 10.1093/infdis/163.5.1046; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; Howson CP, 1991, ADVERSE EFFECTS PERT; Johnson NL, 1969, DISTRIBUTIONS STAT D; KANAI K, 1980, JPN J MED SCI BIOL, V33, P107, DOI 10.7883/yoken1952.33.107; KAPLAN SL, 1994, J PEDIATR-US, V124, P323, DOI 10.1016/S0022-3476(94)70328-0; KIMURA M, 1990, PEDIATR INFECT DIS J, V9, P705, DOI 10.1097/00006454-199010000-00004; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LIESE JG, 1995, 35TH INT C ANT AG CH, P173; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MILLER DL, 1982, EPIDEMIOL REV, V4, P1; MIYAMURA K, 1974, J BIOL STAND, V2, P203, DOI 10.1016/0092-1157(74)90016-X; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; ODA M, 1984, J INFECT DIS, V150, P823, DOI 10.1093/infdis/150.6.823; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; PITZURRA M, 1983, B WORLD HEALTH ORGAN, V61, P331; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; SHAHIN RD, 1990, J EXP MED, V171, P63, DOI 10.1084/jem.171.1.63; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; VANDERZEE A, 1993, J CLIN MICROBIOL, V31, P2134, DOI 10.1128/JCM.31.8.2134-2140.1993; VANDERZEE A, 1993, J BACTERIOL, V175, P141, DOI 10.1128/JB.175.1.141-147.1993; 1988, LANCET, V1, P1238	40	561	578	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					341	348		10.1056/NEJM199602083340601	http://dx.doi.org/10.1056/NEJM199602083340601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538704				2022-12-28	WOS:A1996TT48700001
J	Akopian, AN; Sivilotti, L; Wood, JN				Akopian, AN; Sivilotti, L; Wood, JN			A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons	NATURE			English	Article							ROOT GANGLION NEURONS; NERVOUS-SYSTEM; RAT; CURRENTS; CELLS	DORSAL root ganglion sensory neurons associated with C-fibres, many of which are activated by tissue-damage, express an unusual voltage-gated sodium channel that is resistant to tetrodotoxin(1-9). We report here that we have identified a 1,957 aminoacid sodium channel in these cells that shows 65% identity with the rat cardiac tetrodotoxin-insensitive sodium channel(10), and is not expressed in other peripheral and central neurons, glia or non-neuronal tissues. In situ hybridization shows that the channel is expressed only by small-diameter sensory neurons in neonatal and adult dorsal root and trigeminal ganglia. The channel is resistant to tetrodotoxin when expressed in Xenopus oocytes. The electrophysiological and pharmacological properties of the expressed channel are similar to those described for the small-diameter sensory neuron tetrodotoxin-resistant sodium channels. As some noxious input into the spinal cord is resistant to tetrodotoxin(8,11,12), block of expression or function of such a C-fibre-restricted sodium channel may have a selective analgesic effect.	UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London			Sivilotti, Lucia/D-8919-2011	Sivilotti, Lucia/0000-0003-2510-8424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; BECKH S, 1990, FEBS LETT, V262, P317, DOI 10.1016/0014-5793(90)80218-8; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; CARRIER GO, 1992, PFLUG ARCH EUR J PHY, V421, P7, DOI 10.1007/BF00374726; CHABAL C, 1989, PAIN, V38, P333, DOI 10.1016/0304-3959(89)90220-0; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cohen S A, 1993, Int Rev Cytol, V137C, P55; DELBIANCO E, 1994, NEUROSCI LETT, V170, P163, DOI 10.1016/0304-3940(94)90264-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; JEFTINIJA S, 1994, BRAIN RES, V665, P69, DOI 10.1016/0006-8993(94)91153-3; JEFTINIJA S, 1994, BRAIN RES, V639, P125, DOI 10.1016/0006-8993(94)91772-8; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; Mandel G, 1993, Curr Opin Neurobiol, V3, P278, DOI 10.1016/0959-4388(93)90118-I; MATSUDA Y, 1978, BRAIN RES, V154, P69, DOI 10.1016/0006-8993(78)91052-1; MATZNER O, 1994, J NEUROPHYSIOL, V72, P349, DOI 10.1152/jn.1994.72.1.349; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; NOWYCKY M, 1993, SENSORY NEURONS, P97; OH YS, 1994, NEUROSCI LETT, V176, P119, DOI 10.1016/0304-3940(94)90885-0; RAJ PP, 1988, NEURAL BLOCKADE CLIN, P899; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROY ML, 1992, J NEUROSCI, V12, P2104; SATIN J, 1992, SCIENCE, V256, P1205; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; WILLIS WD, 1994, 7TH P WORLD C PAIN, P301	30	842	889	2	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					257	262		10.1038/379257a0	http://dx.doi.org/10.1038/379257a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538791				2022-12-28	WOS:A1996TQ16900047
J	Horton, R				Horton, R			A physician's life	LANCET			English	Editorial Material																		HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611	2	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					6	6		10.1016/S0140-6736(96)91552-4	http://dx.doi.org/10.1016/S0140-6736(96)91552-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531568				2022-12-28	WOS:A1996TN76200007
J	Thompson, WG				Thompson, WG			Things that go red in the urine; And others that don't	LANCET			English	Editorial Material											Thompson, WG (corresponding author), UNIV OTTAWA, DIV GASTROENTEROL, OTTAWA CIVIC HOSP, OTTAWA, ON, CANADA.							EASTWOOD MA, 1995, QJM-INT J MED, V88, P711; JARNEROT G, 1995, GASTROENTEROLOGY, V109, P449, DOI 10.1016/0016-5085(95)90332-1; RILEY SA, 1990, Q J MED, V75, P551; STROCCHI A, 1991, GUT, V32, P1498, DOI 10.1136/gut.32.12.1498; THOMPSON WG, 1989, GUT REACTIONS; WATSON WC, 1963, BMJ-BRIT MED J, P971, DOI 10.1136/bmj.2.5363.971	6	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					5	6						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531553				2022-12-28	WOS:A1996TN76200006
J	BETTS, L; JOSEY, JA; VEAL, JM; JORDAN, SR				BETTS, L; JOSEY, JA; VEAL, JM; JORDAN, SR			A NUCLEIC-ACID TRIPLE-HELIX FORMED BY A PEPTIDE NUCLEIC-ACID DNA COMPLEX	SCIENCE			English	Article							THYMINE-SUBSTITUTED POLYAMIDE; STRAND-DISPLACEMENT; BINDING; PNA	The crystal structure of a nucleic acid triplex reveals a helix, designated P-form, that differs from previously reported nucleic acid structures. The triplex consists of one polypurine DNA strand complexed to a polypyrimidine hairpin peptide nucleic acid (PNA) and was successfully designed to promote Watson-Crick and Hoogsteen base pairing. The P-form helix is underwound, with a base tilt similar to B-form DNA. The bases are displaced from the helix axis even more than in A-form DNA. Hydrogen bonds between the DNA backbone and the Hoogsteen PNA backbone explain the observation that polypyrimidine PNA sequences form highly stable 2:1 PNA-DNA complexes. This structure expands the number of known stable helical forms that nucleic acids can adopt.			BETTS, L (corresponding author), GLAXO WELLCOME,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.							ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BABCOCK MS, 1993, J BIOMOL STRUCT DYN, V11, P597, DOI 10.1080/07391102.1993.10508018; BROWN SC, 1994, SCIENCE, V265, P777, DOI 10.1126/science.7519361; BRUNGER AT, 1987, X PLOR MANUAL VERSIO; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRIFFITH MC, 1995, J AM CHEM SOC, V117, P831, DOI 10.1021/ja00107a033; HUNTER WN, 1989, BIOCHEMISTRY-US, V28, P2444, DOI 10.1021/bi00432a015; JONES AT, 1994, MANUAL VERSION 5 9 1; JOSEY JA, UNPUB; KIM SK, 1992, J AM CHEM SOC, V115, P6477; MACAYA R, 1992, J MOL BIOL, V225, P755, DOI 10.1016/0022-2836(92)90399-5; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1995, J MOL RECOGNIT, V7, P165; OTWINOWSKI Z, 1993, JAN P CCP4 STUD WEEK; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; RADHAKRISHNAN I, 1994, STRUCTURE, V2, P17, DOI 10.1016/S0969-2126(00)00005-8; Saenger W., 1984, PRINCIPLES NUCL ACID, P132; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063; VANMEERVELT L, 1995, NATURE, V374, P742, DOI 10.1038/374742a0; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; 1994, QUANTA 4 0	27	272	293	2	46	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1838	1841		10.1126/science.270.5243.1838	http://dx.doi.org/10.1126/science.270.5243.1838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525381				2022-12-28	WOS:A1995TK47600051
J	HUANG, HF; ZHU, LM; REID, BR; DROBNY, GP; HOPKINS, PB				HUANG, HF; ZHU, LM; REID, BR; DROBNY, GP; HOPKINS, PB			SOLUTION STRUCTURE OF A CISPLATIN-INDUCED DNA INTERSTRAND CROSS-LINK	SCIENCE			English	Article							DOUBLE HELICAL DNA; CIS-DIAMMINEDICHLOROPLATINUM(II); DUPLEX	The widely used antitumor drug cis-diamminedichloroplatinum(II) (cisplatin or cis-DDP) reacts with DNA, cross-linking two purine residues through the N7 atoms, which reside in the major groove in B-form DNA. The solution structure of the short duplex [d(CATAGCTATG)](2) cross-linked at the GC:GC site was determined by nuclear magnetic resonance (NMR). The deoxyguanosine-bridging cis-diammineplatinum(II) lies in the minor groove, and the complementary deoxycytidines are extrahelical. The double helix is locally reversed to a left-handed form, and the helix is unwound and bent toward the minor groove. These findings were independently confirmed by results from a phase-sensitive gel electrophoresis bending assay. The NMR structure differs markedly from previously proposed models but accounts for the chemical reactivity, the unwinding, and the bending of cis-DDP interstrand cross-linked DNA and may be important in the formation and repair of these cross-links in chromatin.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32681, GM45804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNHAM KJ, 1995, INORG CHEM, V34, P2826, DOI 10.1021/ic00115a008; CHOU SH, 1994, J MOL BIOL, V244, P259, DOI 10.1006/jmbi.1994.1727; CRIPPEN GM, 1981, DISTANCE GEOMETRY CO; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HOPKINS PB, 1991, TETRAHEDRON, V47, P2475, DOI 10.1016/S0040-4020(01)81782-8; HUANG HF, 1995, BIOORGAN MED CHEM, V3, P659, DOI 10.1016/0968-0896(95)00059-P; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; MALINGE JM, 1994, NUCLEIC ACIDS RES, V22, P3834, DOI 10.1093/nar/22.19.3834; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYET D, 1993, NUCLEIC ACIDS RES, V21, P5846, DOI 10.1093/nar/21.25.5846; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; Pratt WB, 1994, ANTI-CANCER DRUG, P133; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; RINK SM, 1995, BIOCHEMISTRY-US, V34, P1439, DOI 10.1021/bi00004a039; ROBERTS JJ, 1987, PHARMACOL THERAPEUT, V34, P215, DOI 10.1016/0163-7258(87)90012-X; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SIP M, 1992, BIOCHEMISTRY-US, V31, P2508, DOI 10.1021/bi00124a010; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; TOMSON AJ, 1974, RECENT RES CANCER, V48, P38; WANG AHJ, 1978, NATURE, V276, P471, DOI 10.1038/276471a0; WANG AHJ, 1981, SCIENCE, V211, P171, DOI 10.1126/science.7444458; YANG DZ, 1995, NAT STRUCT BIOL, V2, P577, DOI 10.1038/nsb0795-577; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; ZHU LM, 1995, J MAGN RESON SER B, V106, P227, DOI 10.1006/jmrb.1995.1038; ZHU LM, 1995, J MOL BIOL, V254, P623, DOI 10.1006/jmbi.1995.0643; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	32	289	294	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1842	1845		10.1126/science.270.5243.1842	http://dx.doi.org/10.1126/science.270.5243.1842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525382				2022-12-28	WOS:A1995TK47600052
J	YOSHIMOTO, T; BENDELAC, A; WATSON, C; HULI, J; PAUL, WE				YOSHIMOTO, T; BENDELAC, A; WATSON, C; HULI, J; PAUL, WE			ROLE OF NK1.1(+) T-CELLS IN A T(H)2 RESPONSE AND IN IMMUNOGLOBULIN-E PRODUCTION	SCIENCE			English	Article							MURINE IMMUNE-SYSTEM; POLYCLONAL ACTIVATION; LYMPHOKINE SECRETION; INTERLEUKIN-4; ANTIBODY; CD4+; CD1; GENERATION; INVIVO; FAMILY	Immune responses dominated by interleukin-4 (IL-4)-producing T helper type 2 (T(H)2) cells or by interferon gamma (IFN-gamma)-producing T helper type 1 (T(H)1) cells express distinctive protection against infection with different pathogens. Interleukin-4 promotes the differentiation of naive CD4(+) T cells into IL-4 producers and suppresses their development into IFN-gamma producers. CD1-specific splenic CD4(+)NK1.1(+) T cells, a numerically minor population, produced IL-4 promptly on in vivo stimulation. This T cell population was essential for the induction of IL-4-producing cells and for switching to immunoglobulin E, an IL-4-dependent event, in response to injection of antibodies to immunoglobulin D.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Princeton University			Yoshimoto, Tomohiro/E-2224-2014					ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; GOROFF DK, 1991, J IMMUNOL, V146, P18; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; SCHMITT D, 1986, IMMUNOL LETT, V12, P231, DOI 10.1016/0165-2478(86)90009-X; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SMALL TN, 1987, J IMMUNOL, V138, P2864; SWAIN SL, 1990, J IMMUNOL, V145, P3796; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	27	451	467	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1845	1847		10.1126/science.270.5243.1845	http://dx.doi.org/10.1126/science.270.5243.1845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525383				2022-12-28	WOS:A1995TK47600053
J	CUDMORE, S; COSSART, P; GRIFFITHS, G; WAY, M				CUDMORE, S; COSSART, P; GRIFFITHS, G; WAY, M			ACTIN-BASED MOTILITY OF VACCINIA VIRUS	NATURE			English	Article							LISTERIA-MONOCYTOGENES; RELEASE; GENE; PROTEIN; SPREAD; N1-ISONICOTINOYL-N2-3-METHYL-4-CHLOROBENZOYLHYDRAZINE; POLYMERIZATION; DISSEMINATION; CYTOSKELETON; SEQUENCE	THE role of the cytoskeleton during viral infection is poorly understood, Here we show, using a combination of mutant and drug studies, that the intracellular enveloped form of vaccinia virus is capable of inducing the formation of actin tails that are strikingly similar to those seen in Listeria, Shigella and Rickettsia infections, Analysis using,video microscopy reveals that single viral particles are propelled in vivo on the tip of actin tails, at a speed of 2.8 mu m min(-1). On contact with the cell surface, virus particles extend outwards on actin projections at a similar rate, to contact and infect neighbouring cells, Given the similarities between the motility of vaccinia virus and bacterial pathogens, we suggest that intracellular pathogens have developed a common mechanism to exploit the actin cytoskeleton as a means to facilitate their direct spread between cells.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69117 HEIDELBERG, GERMANY; INST PASTEUR, UNITE INTERACT BACTERIES CELLULES, F-75724 PARIS 15, FRANCE	European Molecular Biology Laboratory (EMBL); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Cudmore, Sally/N-7736-2014	Way, Michael/0000-0001-7207-2722; Cudmore, Sally/0000-0002-3131-7428				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BLASCO R, 1991, J VIROL, V65, P4598, DOI 10.1128/JVI.65.9.4598-4608.1991; BLASCO R, 1992, J VIROL, V66, P4170, DOI 10.1128/JVI.66.7.4170-4179.1992; COSSART P, 1995, CURR OPIN CELL BIOL, V7, P94, DOI 10.1016/0955-0674(95)80050-6; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOUIN E, 1995, INFECT IMMUN, V63, P2729, DOI 10.1128/IAI.63.7.2729-2737.1995; HEINZEN RA, 1993, INFECT IMMUN, V61, P1926, DOI 10.1128/IAI.61.5.1926-1935.1993; HERZOG M, 1994, CELL BIOL LABORATORY; HILLER G, 1982, J VIROL, V44, P647, DOI 10.1128/JVI.44.2.647-657.1982; HILLER G, 1979, VIROLOGY, V98, P142, DOI 10.1016/0042-6822(79)90533-6; HILLER G, 1981, J VIROL, V39, P903, DOI 10.1128/JVI.39.3.903-913.1981; HILLER G, 1981, EXP CELL RES, V132, P81, DOI 10.1016/0014-4827(81)90085-9; KATO N, 1969, J EXP MED, V129, P795, DOI 10.1084/jem.129.4.795; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KREMPIEN U, 1981, VIROLOGY, V113, P556, DOI 10.1016/0042-6822(81)90183-5; MARCHAND JB, 1995, J CELL BIOL, V130, P1; MORGAN C, 1976, VIROLOGY, V73, P43, DOI 10.1016/0042-6822(76)90059-3; PAYNE LG, 1982, ARCH VIROL, V74, P11, DOI 10.1007/BF01320778; PAYNE LG, 1979, J VIROL, V32, P614, DOI 10.1128/JVI.32.2.614-622.1979; PAYNE LG, 1980, J GEN VIROL, V50, P89, DOI 10.1099/0022-1317-50-1-89; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCHMUTZ C, 1991, J VIROL, V65, P3435, DOI 10.1128/JVI.65.7.3435-3442.1991; STOKES GV, 1976, J VIROL, V18, P636, DOI 10.1128/JVI.18.2.636-643.1976; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; [No title captured]	30	362	372	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					636	638		10.1038/378636a0	http://dx.doi.org/10.1038/378636a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524400	Bronze			2022-12-28	WOS:A1995TJ22100083
J	POSTE, G				POSTE, G			THE CASE FOR GENOMIC PATENTING	NATURE			English	Note											POSTE, G (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							ADAMS MD, 1995, NATURE S, V377; [Anonymous], 1995, HUMAN TISSUE ETHICAL; [Anonymous], 1995, INTELLECTUAL PROPERT; [Anonymous], 1992, INTELLECTUAL PROPERT; Bernstein T, 1994, RADON RENTAL HOUSING; BUTLER D, 1994, NATURE, V370, P4; COHEN J, 1995, SCIENCE, V268, P1715, DOI 10.1126/science.7792594; SCOTTRAM N, 1993, NATURE, V364, P666, DOI 10.1038/364666a0; SMITH GK, 1994, AM INTELLECT PROP LA, V22, P28; WARSHOFSKY F, 1994, PATENT WARS; WILLIAMSON AR, 1994, NATURE, V372, P40; 1991, BIOTECHNOLOGY GLOBAL, P203; 1995, NATURE, V374, P750; 1995, NATURE, V374, P391; 1993, REALISING OUR POTENT; 1995, HUGO STATEMENT PATEN; 1994, PATENTING HUMAN GENE; 1995, FED REGISTER, V60, P12771; [No title captured]; 1994, NATURE, V371, P270; 1995, EPLC9 PHARM LAW REP; 1995, HUMAN GENETICS SCI I, V1; 1994, GENETIC SCREENING ET	23	22	22	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					534	536		10.1038/378534a0	http://dx.doi.org/10.1038/378534a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524376				2022-12-28	WOS:A1995TJ22100022
J	GRELL, M; DOUNI, E; WAJANT, H; LOHDEN, M; CLAUSS, M; MAXEINER, B; GEORGOPOULOS, S; LESSLAUER, W; KOLLIAS, G; PFIZENMAIER, K; SCHEURICH, P				GRELL, M; DOUNI, E; WAJANT, H; LOHDEN, M; CLAUSS, M; MAXEINER, B; GEORGOPOULOS, S; LESSLAUER, W; KOLLIAS, G; PFIZENMAIER, K; SCHEURICH, P			THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR	CELL			English	Article							FACTOR TNF RECEPTOR; HUMAN-ENDOTHELIAL-CELLS; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; IDENTIFICATION; RESPONSES; MICE; SIGNAL; 55-KDA	The 60 kDa tumor necrosis factor receptor (TNFR(60)) is regarded as the major signal transducer of TNF-induced cellular responses, whereas the signal capacity and role of the 80 kDa TNFR (TNFR(80)) remain largely undefined, We show here that the transmembrane form of TNF is superior to soluble TNF in activating TNFR(80) in various systems such as T cell activation, thymocyte proliferation, and granulocyte/macrophage colony-stimulating factor production, Intriguingly, activation of TNFR(80) by membrane TNF can lead to qualitatively different TNF responses such as rendering resistant tumor cells sensitive to TNF-mediated cytotoxicity. This study demonstrates that the diversity of TNF effects can be controlled through the differential sensitivity of TNFR(80) for the two forms of TNF and suggests an important physiological role for TNFR(80) in local inflammatory responses.	HELLEN INST PASTEUR,MOLEC GENET LAB,GR-11521 ATHENS,GREECE; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4002 BASEL,SWITZERLAND; MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCKHOFF INST,D-61231 BAD NAUHEIM,GERMANY	Roche Holding; Max Planck Society	GRELL, M (corresponding author), UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY.		Kollias, George/A-7079-2012; Wajant, Harald/A-3020-2017	Kollias, George/0000-0003-1867-3150; Wajant, Harald/0000-0002-2005-3949; Clauss, Matthias/0000-0001-5180-3899; DOUNI, ELENI/0000-0003-0004-5121				ADOLF RA, 1994, EPIDERMAL GROWTH FAC, P63; ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1994, J IMMUNOL, V153, P1963; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LOPEZCEPERO M, 1994, J IMMUNOL, V152, P3333; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MENEGAZZI R, 1994, BLOOD, V84, P287; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PORTEU F, 1994, J BIOL CHEM, V269, P2834; PROBERT L, 1993, J IMMUNOL, V151, P1894; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SCHEURICH P, 1992, TUMOR NECROSIS FACTO, V4, P52; SCHMID E, 1995, J INTERF CYTOK RES, V15, P819, DOI 10.1089/jir.1995.15.819; SCHMIDT EF, 1995, BLOOD, V86, P123; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015	43	1101	1154	3	21	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					793	802		10.1016/0092-8674(95)90192-2	http://dx.doi.org/10.1016/0092-8674(95)90192-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521496	Bronze			2022-12-28	WOS:A1995TH94800016
J	KLIEWER, SA; LENHARD, JM; WILLSON, TM; PATEL, I; MORRIS, DC; LEHMANN, JM				KLIEWER, SA; LENHARD, JM; WILLSON, TM; PATEL, I; MORRIS, DC; LEHMANN, JM			A PROSTAGLANDIN J(2) METABOLITE BINDS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AND PROMOTES ADIPOCYTE DIFFERENTIATION	CELL			English	Article							9-CIS RETINOIC ACID; ARACHIDONIC-ACID; D SYNTHETASE; FATTY-ACIDS; X RECEPTOR; RAT; MECHANISMS; TISSUES; 9-DEOXY-DELTA-9,DELTA-12-13,14-DIHYDROPROSTAGLANDIN-D2; BIOSYNTHESIS	Prostaglandins (PGs) of the J(2) series form in vivo and exert effects on a variety of biological processes. While most PGs mediate their effects through G protein-coupled receptors, the mechanism of action for the J(2) series of PGs remains unclear. Here, we report that PGJ(2) and its derivatives are efficacious activators of peroxisome proliferator-activated receptors alpha and gamma (PPAR alpha and PPAR gamma, respectively), orphan nuclear receptors implicated in lipid homeostasis and adipocyte differentiation. The PGJ(2) metabolite 15-deoxy-Delta(12,14)-PGJ(2) binds directly to PPAR gamma and promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes. These data provide strong evidence that a fatty acid metabolite can function as an adipogenic agent through direct interactions with PPAR gamma and, furthermore, suggest a novel mechanism of action for PGs of the J(2) series.	GLAXO INC,RES INST,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT BIOL MOLEC,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT MOLEC PHARMACOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	KLIEWER, SA (corresponding author), GLAXO INC,RES INST,DEPT CELL BIOL,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.		feinstein, doug/M-9414-2019					AXELROD L, 1981, DIABETES, V30, P163, DOI 10.2337/diabetes.30.2.163; BANNER CD, 1993, J LIPID RES, V34, P1583; BRAISSANT O, IN PRESS ENDOCRINOLO; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHIABRANDO C, 1984, BIOCHIM BIOPHYS ACTA, V794, P292, DOI 10.1016/0005-2760(84)90158-9; CHRIST EJ, 1970, BIOCHIM BIOPHYS ACTA, V218, P296, DOI 10.1016/0005-2760(70)90148-7; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GAO G, 1990, J BIOL CHEM, V265, P2431; GASKINS HR, 1989, J NUTR, V119, P458, DOI 10.1093/jn/119.3.458; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Greene M. E., 1995, Gene Expression, V4, P281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KOJIMA A, 1980, PROSTAGLANDINS, V20, P171, DOI 10.1016/0090-6980(80)90016-7; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; NOWAK J, 1979, ACTA PHYSIOL SCAND, V106, P307, DOI 10.1111/j.1748-1716.1979.tb06403.x; SHIMIZU T, 1979, J BIOL CHEM, V254, P5222; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; URADE Y, 1989, J IMMUNOL, V143, P2982	38	1815	1865	0	34	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					813	819		10.1016/0092-8674(95)90194-9	http://dx.doi.org/10.1016/0092-8674(95)90194-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521498	Bronze			2022-12-28	WOS:A1995TH94800018
J	KUNKEL, MT; PERALTA, EG				KUNKEL, MT; PERALTA, EG			IDENTIFICATION OF DOMAINS CONFERRING G-PROTEIN REGULATION ON INWARD RECTIFIER POTASSIUM CHANNELS	CELL			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; K+-CHANNEL; CLONING	Cardiac m2 muscarinic acetylcholine receptors reduce heart rate by coupling to heterotrimeric (alpha beta gamma) guanine nucleotide-binding (G) proteins that activate I-KaCh, an inward rectifier K+ channel (IRK), Activation of the GIRK subunit of I-KaCh requires G(beta gamma) subunits; however, the structural basis of channel regulation is unknown. To determine which sequences confer G(beta gamma) regulation upon IRKs, we generated chimeric proteins composed of GIRK and RB-IRK2, a related, G protein-insensitive channel, Importantly, a chimeric channel containing the hydrophobic pore region of RB-IRK2 joined to the amino and carboxyl termini of GIRK exhibited voltage- and receptor-dependent activation in Xenopus oocytes, Furthermore, carboxy-terminal sequences specific to this chimera and GIRK bound G(beta gamma) subunits in vitro. Thus, G(beta gamma), may regulate IRKs by interacting with sequences adjacent to the putative channel pore.			KUNKEL, MT (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.							BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	24	132	132	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					443	449		10.1016/0092-8674(95)90122-1	http://dx.doi.org/10.1016/0092-8674(95)90122-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521474	Bronze			2022-12-28	WOS:A1995TC97700014
J	OSKI, FA				OSKI, FA			IRON-DEFICIENCY IN INFANCY AND CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PSYCHOMOTOR DEVELOPMENT; ABSORPTION; ANEMIA; THERAPY; MILK; PERFORMANCE; CAPACITY; VOLUME; RATS; AGE				OSKI, FA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS CHILDRENS CTR, DEPT PEDIAT, 601 N WOLFE ST, BALTIMORE, MD 21205 USA.							[Anonymous], 1976, PEDIATRICS, V58, P765; AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; BALLIN A, 1992, AM J DIS CHILD, V146, P803, DOI 10.1001/archpedi.1992.02160190035015; BENSHACHAR D, 1986, INT J DEV NEUROSCI, V4, P81, DOI 10.1016/0736-5748(86)90019-5; BESSMAN JD, 1983, AM J CLIN PATHOL, V80, P322, DOI 10.1093/ajcp/80.3.322; BESSMAN JD, 1979, BLOOD, V53, P288, DOI 10.1182/blood.V53.2.288.288; CHARLTON RW, 1983, ANNU REV MED, V34, P55, DOI 10.1146/annurev.me.34.020183.000415; COHEN AR, 1981, PEDIATRICS, V67, P904; DALLMAN PR, 1990, ACTA PAEDIATR SCAND, P28; DERMAN DP, 1980, SCAND J HAEMATOL, V25, P193; GRONER JA, 1986, J ADOLESCENT HEALTH, V7, P44, DOI 10.1016/S0197-0070(86)80094-8; KLEINMAN RE, 1992, PEDIATRICS, V89, P1105; LANE M, 1983, IRON NUTRITION REVIS, P31; LOZOFF, 1988, PEDIATRICS, V81, P683; LOZOFF B, 1987, PEDIATRICS, V79, P981; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MCMILLAN JA, 1977, PEDIATRICS, V60, P896; MONZON CM, 1987, CLIN PEDIATR, V26, P632, DOI 10.1177/000992288702601203; OSKI FA, 1983, PEDIATRICS, V71, P877; PATTON WN, 1991, CLIN LAB HAEMATOL, V13, P153; PICCIANO MF, 1980, AM J CLIN NUTR, V33, P746, DOI 10.1093/ajcn/33.4.746; Reeves JD, 1981, IRON NUTRITION REVIS, P114; ROWLAND TW, 1988, AM J DIS CHILD, V142, P165, DOI 10.1001/archpedi.1988.02150020067030; SAARINEN UM, 1977, J PEDIATR-US, V91, P36, DOI 10.1016/S0022-3476(77)80439-3; TUNNESSEN WW, 1987, J PEDIATR-US, V111, P813, DOI 10.1016/S0022-3476(87)80193-2; van Zeben D, 1990, Eur J Haematol, V44, P106; WALTER T, 1989, PEDIATRICS, V84, P7; WIDDOWSON EM, 1951, ARCH DIS CHILD, V26, P205, DOI 10.1136/adc.26.127.205; YEHUDA S, 1986, PHARMACOL BIOCHEM BE, V25, P141, DOI 10.1016/0091-3057(86)90244-3; YIP R, 1984, AM J CLIN NUTR, V39, P427, DOI 10.1093/ajcn/39.3.427; YIP R, 1987, PEDIATRICS, V80, P330; 1986, MMWR MORB MORTAL WKL, V35, P565; 1985, PEDIATRIC NUTRITION, P213	33	311	326	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					190	193						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL460	8515791				2022-12-28	WOS:A1993LL46000008
J	PARKER, LL; WALTER, SA; YOUNG, PG; PIWNICAWORMS, H				PARKER, LL; WALTER, SA; YOUNG, PG; PIWNICAWORMS, H			PHOSPHORYLATION AND INACTIVATION OF THE MITOTIC INHIBITOR WEE1 BY THE NIM1/CDR1 KINASE	NATURE			English	Article							TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; DEPHOSPHORYLATION; INDUCER; FISSION	THE G2-M phase transition in eukaryotes is regulated by the synergistic and opposing activities of a cascade of distinct protein kinases and phosphatases. This cascade converges on Cdc2, a serine/threonine protein kinase required for entry into mitosis (reviewed in ref. 1). In the fission yeast Schizosacckaromyces pombe, inactivation of the Cdc2/cyclin B complex is achieved by phosphorylation of tyrosine 15 by Wee1 (refs 2, 3). The action of the Wee1 kinase is opposed by the action of the Cdc25 phosphatase, which dephosphorylates Cdc2 on tyrosine 15, thereby activating the Cdc2/cyclin B complex4-9. Much less is known about the regulatory signals upstream of cdc25 and wee1. Genetics indicate that the mitotic inducer nim1/cdr1 acts upstream of wee1, possibly as a negative regulator of wee1 (refs 10, 11). To characterize the nim1/cdr1 protein (Nim1), we have overproduced it in both bacterial and baculoviral expression systems. We report that Nim1 possesses intrinsic serine-kinase, threonine-kinase and tyrosine-kinase activities. Co-expression of the Nim1 and Wee1 kinases in insect cells results in the phosphorylation of Wee1 and therefore a shift in its electrophoretic mobility on SDS-polyacrylamide gels. When Weel is phosphorylated, its ability to phosphorylate Cdc2 on tyrosine 15 is inhibited; treatment with phosphatase restores this kinase activity. Furthermore, purified bacterially produced Nim1 kinase directly phosphorylates and inactivates Weel in vitro. These results show that nim1/cdr1 functions as a positive regulator of mitosis by directly phosphorylating and inactivating the mitotic inhibitor Wee1.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Harvard University; Harvard Medical School; Queens University - Canada	PARKER, LL (corresponding author), BETH ISRAEL HOSP,BLDG D2,ROOM 143,200 LONGWOOD AVE,BOSTON,MA 02215, USA.		Piwnica-Worms, Helen/C-5214-2012					FEILOTTER H, 1991, GENETICS, V127, P309; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	14	135	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					736	738		10.1038/363736a0	http://dx.doi.org/10.1038/363736a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515817				2022-12-28	WOS:A1993LJ33900060
J	YUDKIN, JS				YUDKIN, JS			HOW CAN WE BEST PROLONG LIFE - BENEFITS OF CORONARY RISK FACTOR REDUCTION IN NONDIABETIC AND DIABETIC SUBJECTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; BLOOD-PRESSURE; CHOLESTEROL REDUCTION; EPIDEMIOLOGIC CONTEXT; MORTALITY; HYPERTENSION; TRIALS; HYPERCHOLESTEROLEMIA; EXPECTANCY; MELLITUS	Objective-To compare the theoretical benefits of different approaches to reduce risk factors for coronary heart disease in subjects at risk. Design-The results of findings from meta-analyses of intervention studies on cause specific mortality and of observational studies on smokers and ex-smokers were applied to observational data on 10 year cause specific mortality derived from the multiple risk factor intervention trial. Lifetable analyses were used to estimate gains in life expectancy. Subjects-Diabetic and non-diabetic men initially 35-57 years of age. Main outcome measures-10 year mortality from coronary heart disease, 10 year total mortality, man years of intervention to prevent one death and one death from coronary heart disease, gain in life expectancy, and drug costs per year of additional life in diabetic and non-diabetic men of 45. Results-In non-diabetic men a 10 year mortality from coronary heart disease of 14.4 per 1000 would be reduced by a mean of 0.58, 0.82, 2.64, and 2.74 per 1000 by antihypertensive treatment, lowering cholesterol concentration, taking aspirin, and stopping smoking respectively; a 10 year total mortality of 44.1 per 1000 would fall by a mean of 1.06, 5.16, and 8.65 per 1000 with antihypertensive and aspirin treatment and stopping smoking respectively and increased by a mean of 0.07 per 1000 with the lowering of cholesterol concentration. In diabetic men the reductions in mortality from coronary heart disease would be between three and five times greater, and total mortality would show mean reductions of 5.81, 0.56, 16.17, and 20.84 per 1000 respectively, with all interventions of significant benefit except the lowering of cholesterol concentration. Between 2400 and 3800 man years of pharmacological intervention were calculated as being necessary to prevent one death from coronary heart disease in a non-diabetic man, and between 800 and 1200 man years in a diabetic man. The loss of life expectancy associated with smoking and hypertension is greater than that accruing from hypercholesterolaemia, but stopping smoking would prolong life by a mean of around four years in a 45 year old non-diabetic man and three years in a diabetic man, whereas aspirin and antihypertensive treatment would provide approximately one year of additional life expectancy in both categories. Conclusions-Studies to date have shown little impact of drugs that lower cholesterol concentration and blood pressure on either coronary heart disease or total mortality. Although new treatments for hypercholesterolaemia and hypertension might help prevent coronary heart disease, other approaches to reduce the burden of premature death are required.			YUDKIN, JS (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT MED, GREAT NO BLDG, LONDON N19 5NF, ENGLAND.		Yudkin, John S/C-1988-2008					[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1985, PREV MED, V14, P312; [Anonymous], 1988, BRIT MED J, V296, P320; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; JARRETT RJ, 1985, ACTA ENDOCRINOL-COP, V110, P21; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PARVING HH, 1991, DIABETES CARE, V14, P260, DOI 10.2337/diacare.14.3.260; PETO R, 1985, CIRCULATION, V72, P451; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; ROSE G, 1982, J EPIDEMIOL COMMUN H, V36, P102, DOI 10.1136/jech.36.2.102; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; ROTHENBERG R, 1992, J CLIN EPIDEMIOL, V45, P21, DOI 10.1016/0895-4356(92)90184-O; SMITH GD, 1992, BMJ-BRIT MED J, V304, P43; STAMLER J, 1987, CARDIOLOGY, P1; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; TURNER RC, 1991, DIABETIC MED S1, V8, pA41; WARRAM JH, 1991, ARCH INTERN MED, V151, P1350, DOI 10.1001/archinte.151.7.1350; YUDKIN JS, 1991, BMJ-BRIT MED J, V303, P730, DOI 10.1136/bmj.303.6805.730; 1984, LANCET, V1, P899; 1991, BRIT NATIONAL FORMUL; 1990, DHHS CDC908416 PUBL; 1991, INTERIM LIFE TABLES	34	125	125	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	1993	306	6888					1313	1318		10.1136/bmj.306.6888.1313	http://dx.doi.org/10.1136/bmj.306.6888.1313			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518573	Green Published, Bronze			2022-12-28	WOS:A1993LC72200025
J	Gans, RO; Feld, LG				Gans, RO; Feld, LG			Membranoproliferative glomerulonephritis type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHILDRENS HOSP BUFFALO,BUFFALO,NY 14222		Gans, RO (corresponding author), SUNY BUFFALO,BUFFALO,NY 14214, USA.			Gans, Reinold/0000-0001-5481-2387					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					367	367		10.1056/NEJM199602083340605	http://dx.doi.org/10.1056/NEJM199602083340605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538708				2022-12-28	WOS:A1996TT48700005
J	Goulmy, E; Schipper, R; Pool, J; Blokland, E; Falkenburg, JHF; Vossen, J; Gratwohl, A; Vogelsang, GB; vanHouwelingen, HC; vanRood, JJ				Goulmy, E; Schipper, R; Pool, J; Blokland, E; Falkenburg, JHF; Vossen, J; Gratwohl, A; Vogelsang, GB; vanHouwelingen, HC; vanRood, JJ			Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE DISTRIBUTION; LYMPHOCYTES; TOLERANCE; LEUKEMIA; CELLS	Background. Graft-versus-host disease (GVHD) can be a major complication of allogeneic bone marrow transplantation even when the donor and recipient are siblings and share identical major histocompatibility antigens. The explanation may be a mismatch of minor histocompatibility antigens. We previously characterized five minor histocompatibility antigens, HA-1, 2, 3, 4, and 5, that are recognized by T cells in association with the major histocompatibility antigens HLA-A1 and A2. Methods. We collected peripheral-blood leukocytes from 148 bone marrow recipients and their sibling donors, who were genotypically HLA identical. Fifty pairs were positive for HLA-A1, 117 were positive for HLA-A2, and 19 were positive for both. The pairs were typed with cytotoxic-T-cell clones specific for minor histocompatibility antigens HA-1, 2, 3, 4, and 5. Results. Mismatches of HA-3 were equally distributed among recipients in whom GVHD developed and those in whom it did not. By contrast, a mismatch of only HA-1 was significantly correlated with GVHD of grade II or higher (odds ratio, infinity; P = 0.02) in adults. One or more mismatches of HA-1, 2, 4, and 5 were also significantly associated with GVHD (odds ratio, infinity; P = 0.006) in adults. These associations were not observed in children. Conclusions. A mismatch of minor histocompatibility antigen HA-1 can cause GVHD in adult recipients of allogeneic bone marrow from HLA-identical donors. Prospective HA-1 typing may improve donor selection and identify recipients who are at high risk for GVHD. (C) 1996, Massachusetts Medical Society.	UNIV LEIDEN HOSP,DEPT HEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT PEDIAT,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT MED STAT,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,EUROPDONOR FDN,2300 RC LEIDEN,NETHERLANDS; KANTONSSPITAL,DIV HEMATOL,DEPT RES,CH-4031 BASEL,SWITZERLAND; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Kantonsspital Aarau AG (KSA); University of Basel; Johns Hopkins University; Johns Hopkins Medicine	Goulmy, E (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHEMATOL & BLOOD BANK,2300 RC LEIDEN,NETHERLANDS.		van houwelingen, hans c/C-1872-2008	van houwelingen, hans c/0000-0002-0494-4637				ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BEATTY PG, 1990, GRAFT VERSUS HOST DI, V12, P415; BORTIN MM, 1991, TRANSPLANT P, V23, P61; BRESOW NE, 1980, IARC SCI PUBLICATION, V32; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1992, INT IMMUNOL, V4, P53, DOI 10.1093/intimm/4.1.53; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; ELKINS WL, 1987, BONE MARROW TRANSPL, V1, P397; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; GOULMY E, 1982, HLA TYPING METHODOLO, V2, P105; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; IRSCHICK EU, 1992, BLOOD, V79, P1622; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; NIEDERWIESER D, 1993, BLOOD, V81, P2200; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; TSOI MS, 1983, TRANSPLANT P, V15, P1484; TSOI MS, 1980, J IMMUNOL, V125, P2258; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; VANLOCHEM E, IN PRESS TRANSPLANT; VOSSEN JM, 1990, GRAFT VERSUS HOST DI, V12, P403; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; 1989, BONE MARROW TRANSPL, V4, P221	28	445	458	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					281	285		10.1056/NEJM199602013340501	http://dx.doi.org/10.1056/NEJM199602013340501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532022				2022-12-28	WOS:A1996TV69500001
J	Lang, IM; Kneussl, MP				Lang, IM; Kneussl, MP			Dilatation of the pulmonary arteries in primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Lang, IM (corresponding author), UNIV VIENNA,WAEHRINGER GUERTEL 18,A-1090 VIENNA,AUSTRIA.		Winter, Max P/E-8456-2011	Lang, Irene/0000-0003-0485-2692					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					302	302		10.1056/NEJM199602013340505	http://dx.doi.org/10.1056/NEJM199602013340505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532026				2022-12-28	WOS:A1996TV69500005
J	Allison, JE; Tekawa, IS; Ransom, LJ; Adrain, AL				Allison, JE; Tekawa, IS; Ransom, LJ; Adrain, AL			A comparison of fecal occult-blood tests for colorectal-cancer screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SENSITIVITY; HEMOCCULT; NEOPLASIA; SIGMOIDOSCOPY; SPECIFICITY; MORTALITY; ADENOMAS	Background. Hemoccult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting colorectal neoplasms in asymptomatic patients at average risk, In such patients, the performance characteristics of screening tests developed to improve on Hemoccult II are not known. Methods. A set of three fecal occult-blood tests - Hemoccult II; Hemoccult II Sensa, a more sensitive guaiac test; and HemeSelect, an immunochemical test for human hemoglobin - was mailed to all patients 50 years of age or older who were scheduled for personal health appraisals at the Kaiser Permanente Medical Center in Oakland, California. The performance of each test and of a combination test (HemeSelect to confirm positive Hemoccult II Sensa results) was evaluated by identifying screened patients who had colorectal neoplasms (carcinoma or a polyp greater than or equal to 1 cm in diameter) in the two years after screening, Results. Of the 10,702 eligible patients, 8104 (75.7 percent) had at least one interpretable sample and were screened on the basis of at least one test; 96 percent of these patients had complete two-year follow-up. The sensitivity of the tests for detecting carcinoma was lowest with Hemoccult II (37.1 percent; 95 percent confidence interval, 19.7 to 54.6 percent), intermediate with the combination test (65.6 percent; 95 percent confidence interval, 47.6 to 83.6 percent) and with HemeSelect (68.8 percent; 95 percent confidence interval, 51.1 to 86.4 percent), and highest with Hemoccult II Sensa (79.4 percent; 95 percent confidence interval, 64.3 to 94.5 percent), The specificity for detecting carcinoma was 86.7 percent with Hemoccult II Sensa, 94.4 percent with HemeSelect, 97.3 percent with the combination test, and 97.7 percent with Hemoccult II. HemeSelect and the combination test detected more colorectal carcinomas and polyps than Hemoccult II, with only slight increases in the number of colonoscopies needed. Conclusions. HemeSelect and a combination test in which HemeSelect is used to confirm positive Hemoccult II Sensa results improve on Hemoccult II in screening patients for colorectal carcinoma.	KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA 94611	Kaiser Permanente	Allison, JE (corresponding author), KAISER PERMANENTE MED CTR,DEPT MED,280 W MACARTHUR BLVD,OAKLAND,CA 94611, USA.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; ALLISON J E, 1992, Gastroenterology, V102, pA340; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ALLISON JE, 1993, GASTROENTEROLOGY, V104, pA384; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; Fleiss JL, 1981, STAT METHODS RATES P; FOUTCH PG, 1985, GASTROENTEROLOGY, V88, P1386; LANCE P, 1993, GASTROENTEROLOGY, V104, P1852, DOI 10.1016/0016-5085(93)90669-4; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; SELBY JV, 1993, JAMA-J AM MED ASSOC, V269, P1294, DOI 10.1001/jama.269.10.1294; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; UNO Y, 1995, GASTROINTEST ENDOSC, V41, P460, DOI 10.1016/S0016-5107(05)80004-5; WINAWER SJ, 1982, GASTROENTEROLOGY, V82, P986; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311	21	473	492	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					155	159		10.1056/NEJM199601183340304	http://dx.doi.org/10.1056/NEJM199601183340304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531970	Bronze			2022-12-28	WOS:A1996TQ01700004
J	Finger, EB; Puri, KD; Alon, R; Lawrence, MB; vonAndrian, UH; Springer, TA				Finger, EB; Puri, KD; Alon, R; Lawrence, MB; vonAndrian, UH; Springer, TA			Adhesion through L-selectin requires a threshold hydrodynamic shear	NATURE			English	Article							NODE HOMING RECEPTOR; HUMAN NEUTROPHILS; LECAM-1; IDENTIFICATION; LEUKOCYTES; SURFACE; GMP-140; MAC-1; RATES; FLOW	SELECTINS are cell adhesion molecules that bind carbohydrate ligands and promote interaction between leukocytes and the vessel wall in vascular shear flow(1,2). Selectin-ligand bonds have high mechanical strength, allowing initial tethering to the vessel wall through one or few bonds, and have fast on and off rates, permitting rolling in response to hydrodynamic drag(3). The L-selectin molecule on leukocytes binds to peripheral node addressin on high endothelial venules of lymph nodes to mediate leukocyte rolling(4,5) and binds to a ligand on neutrophils to mediate rolling of leukocytes over one another(6). Here we describe a surprising mechanism for regulation of these interactions, both in vitro and in vivo. Shear above a critical threshold is required to promote and maintain rolling interactions through L-selectin, but not through E-selectin, P-selectin or VCAM-1. The shear threshold requirement for L-selectin may be physiologically important in low shear to prevent inappropriate aggregation of leukocytes and interaction with the vessel wall.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV VIRGINIA,DEPT BIOMED ENGN,CHARLOTTESVILLE,VA 22903	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Virginia			Finger, Erik/AFP-0406-2022; ALON, RONEN/GRX-6987-2022; von Andrian, Ulrich H/A-5775-2008	Finger, Erik/0000-0003-3899-6985; Alon, Ronen/0000-0001-9161-6369				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J IMMUNOL, V154, P5356; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; ROCHON YP, 1994, J IMMUNOL, V152, P1385; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SPRINGER TA, 1995, TRAFFIC SIGNALS ROLL; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	29	392	403	3	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					266	269		10.1038/379266a0	http://dx.doi.org/10.1038/379266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538793				2022-12-28	WOS:A1996TQ16900049
J	Orwoll, ES; Bauer, DC; Vogt, TM; Fox, KM				Orwoll, ES; Bauer, DC; Vogt, TM; Fox, KM			Axial bone mass in older women	ANNALS OF INTERNAL MEDICINE			English	Article						bone density; body weight; estrogen replacement; therapy; exercise; calcium	HIP FRACTURE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; CIGARETTE-SMOKING; PROXIMAL FEMUR; RISK-FACTORS; FAT MASS; OSTEOPOROSIS; THIAZIDE	Objective: To determine the anthropometric, historical, and lifestyle factors associated with bone mineral density (BMD) of the spine and proximal femur in older women. Design: Cross-sectional analyses. Setting: Four clinical centers in Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania. Participants: 7963 ambulatory, nonblack women 65 years of age or older. Measurements: Medical history was obtained by questionnaire and interview, and physical and anthropometric data were obtained by examination. Lumbar spine and proximal femoral BMDs were measured using dual-energy x-ray absorptiometry. Results: The multivariable models could predict 21% and 25% of the difference between participants in BMD at the femoral neck and lumbar spine, respectively. Weight was most highly associated with BMD. Postmenopausal estrogen use and other indicators of total estrogen exposure were strongly associated with increased BMD. Use of diuretics (both thiazide and nonthiazide), activity levels and muscle strength, alcohol intake, and dietary calcium intake were associated with higher BMD. A family history of osteoporotic fracture was strongly associated with low BMD. European ancestry and blond hair, childbirth or breast feeding, a history of hyperthyroidism, and progestin use were not associated with axial BMD. Conclusions: Weight is strongly associated with BMD, Estrogen exposure, physical activity, and calcium intake are also positively associated with BMD, whereas a family history of osteoporosis is associated with reduced BMD. These associations suggest ways to better identify risk for fracture.	KAISER PERMANENTE CTR HLTH RES, PORTLAND, OR 97227 USA; UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, SAN FRANCISCO, CA 94105 USA; UNIV MARYLAND, DEPT EPIDEMIOL & PREVENT MED, BALTIMORE, MD 21201 USA	Kaiser Permanente; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	Orwoll, ES (corresponding author), VET AFFAIRS MED CTR, MED SERV 111, BONE & MINERAL RES UNIT, POB 1034, PORTLAND, OR 97207 USA.			Orwoll, Eric/0000-0002-8520-7355	NIAMS NIH HHS [R01-AR35582] Funding Source: Medline; NIA NIH HHS [R01-AG053904, R01-AG605407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BARRETTCONNOR E, 1994, JAMA-J AM MED ASSOC, V271, P280, DOI 10.1001/jama.271.4.280; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DAWSONHUGHES B, 1993, BONE MINER, V21, P41, DOI 10.1016/S0169-6009(08)80119-5; ENSRUD KE, 1996, IN PRESS J BONE MINE; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GLAUBER HS, 1995, J CLIN ENDOCR METAB, V80, P1118, DOI 10.1210/jc.80.4.1118; GRIFFIN MG, 1991, J CLIN ENDOCR METAB, V73, P1164, DOI 10.1210/jcem-73-6-1164; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; HALL TJ, 1994, CALCIFIED TISSUE INT, V55, P266, DOI 10.1007/BF00310404; HAYES WC, 1991, RADIOL CLIN N AM, V29, P1; HEANEY RP, 1989, AM J CLIN NUTR, V50, P1182, DOI 10.1093/ajcn/50.5.1182; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HOLBROOK TL, 1993, BMJ-BRIT MED J, V306, P1506, DOI 10.1136/bmj.306.6891.1506; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KLEIN KB, 1987, GASTROENTEROLOGY, V92, P608, DOI 10.1016/0016-5085(87)90008-4; KRALL EA, 1991, J BONE MINER RES, V6, P331; KROGER H, 1994, CALCIFIED TISSUE INT, V55, P1, DOI 10.1007/BF00310160; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LAITINEN K, 1991, CALCIFIED TISSUE INT, V49, pS70, DOI 10.1007/BF02555094; LIEL Y, 1988, J CLIN ENDOCR METAB, V66, P1247, DOI 10.1210/jcem-66-6-1247; MARCUS R, 1994, J BONE MINER RES, V9, P1467, DOI 10.1002/jbmr.5650090920; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MENKES A, 1993, J APPL PHYSIOL, V74, P2478, DOI 10.1152/jappl.1993.74.5.2478; NEVITT MC, 1994, RHEUM DIS CLIN N AM, V20, P535; NGUYEN TV, 1994, J BONE MINER RES, V9, P1339; NORRIS RJ, 1992, BONE, V13, pS11, DOI 10.1016/8756-3282(92)90190-8; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RAY WA, 1989, LANCET, V1, P687; REID IR, 1992, J CLIN ENDOCR METAB, V75, P779, DOI 10.1210/jc.75.3.779; REID IR, 1992, J CLIN ENDOCR METAB, V75, P45, DOI 10.1210/jc.75.1.45; ROSS P, 1995, BONE, V16, P325, DOI 10.1016/8756-3282(94)00045-X; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; SCHAPIRA D, 1990, SEMIN ARTHRITIS RHEU, V19, P371, DOI 10.1016/0049-0172(90)90074-P; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SOROKO SB, 1994, J BONE MINER RES, V9, P761; STEIGER P, 1992, J BONE MINER RES, V7, P625; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605	49	179	185	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					187	+		10.7326/0003-4819-124-2-199601150-00001	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533993				2022-12-28	WOS:A1996TQ01600001
J	Prat, F; Amouyal, G; Amouyal, P; Pelletier, G; Fritsch, J; Choury, AD; Buffet, C; Etienne, JP				Prat, F; Amouyal, G; Amouyal, P; Pelletier, G; Fritsch, J; Choury, AD; Buffet, C; Etienne, JP			Prospective controlled study of endoscopic ultrasonography and endoscopic retrograde cholangiography in patients with suspected common-bileduct lithiasis	LANCET			English	Article							SPHINCTEROTOMY; CHOLANGIOPANCREATOGRAPHY; CHOLEDOCHOLITHIASIS; ULTRASOUND; DIAGNOSIS; CALCULI	Background Endoscopic sphincterotomy is sometimes done unnecessarily in patients with suspected choledocholithiasis. Our aims were to assess the diagnostic accuracy of endoscopic ultrasonography and endoscopic retrograde cholangiography (ERC) and to find out whether endoscopic ultrasonography may help to prevent unnecessary sphincterotomy or surgical explorations. Methods We recruited 119 patients aged 70.4 (SD 16.1) years with strongly suspected choledocholithiasis who presented to our endoscopy unit between January, 1994, and January, 1995. During the same spell of sedation or within 2 h of each other, endoscopic ultrasonography and ERC were carried out by investigators unaware of the patient's history. Endoscopic sphincterotomy with instrumental exploration was then done as the gold standard for the presence or the absence of stones. Findings 78 (66%) patients had choledocholithiasis; 17 (14%) had other bileduct diseases; 24 (20%) had a clear bileduct or did not require an invasive endoscopic procedure. The sensitivity of endoscopic ultrasonography was 93%, specificity 97%, positive predictive value 98%, and negative predictive value 88%. The corresponding values for ERC were 89%, 100%, 100%, and 83%. There were five false-negative cases by endoscopic ultrasonography (of which three were also negative with ERC) and one false-positive. The morbidity rate was 4.1%. Interpretation We conclude that endoscopic ultrasonography is at least as sensitive as ERC. Endoscopic ultrasonography may prevent inappropriate invasive explorations of the common bileduct.			Prat, F (corresponding author), HOP BICETRE,SERV MALAD FOIE & APPAREIL DIGESTIF,F-94275 LE KREMLIN BICETR,FRANCE.							ACOSTA JM, 1977, AM J DIG DIS, V22, P168, DOI 10.1007/BF01072962; AMOUYAL P, 1989, LANCET, V2, P1195; AMOUYAL P, 1994, GASTROENTEROLOGY, V106, P1062, DOI 10.1016/0016-5085(94)90768-4; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BUSCAIL L, 1992, DIGEST DIS SCI, V37, P116, DOI 10.1007/BF01308353; CATALANO MF, 1994, GASTROENTEROLOGY, V40, pP103; COTTON PB, 1984, GUT, V25, P587, DOI 10.1136/gut.25.6.587; COTTON PB, 1977, GUT, V18, P316, DOI 10.1136/gut.18.4.316; DAVIDSON BR, 1988, GUT, V29, P114, DOI 10.1136/gut.29.1.114; EDMUNDOWICZ SA, 1992, ENDOSCOPY, V24, P774, DOI 10.1055/s-2007-1010581; ERICKSON RA, 1995, GASTROENTEROLOGY, V109, P252, DOI 10.1016/0016-5085(95)90292-9; GERBER A, 1986, SURG GYNECOL OBSTET, V163, P363; GLENN F, 1974, ANN SURG, V179, P528, DOI 10.1097/00000658-197405000-00003; HAUERJENSEN M, 1985, ANN SURG, V202, P64, DOI 10.1097/00000658-198507000-00010; LAI ECS, 1992, NEW ENGL J MED, V326, P1582, DOI 10.1056/NEJM199206113262401; LINDSELL DRM, 1990, LANCET, V335, P390, DOI 10.1016/0140-6736(90)90217-S; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; NEUHAUS H, 1992, ENDOSCOPY, V24, P745, DOI 10.1055/s-2007-1010576; PASQUALE MD, 1989, ARCH SURG-CHICAGO, V124, P1041; ROSCH T, 1993, GASTROINTEST ENDOSC, V39, P341; SHIMIZU S, 1994, ENDOSCOPY, V26, P88, DOI 10.1055/s-2007-1008935; SIEGEL JH, 1988, AM J GASTROENTEROL, V11, P1255; THORNTON JR, 1992, GUT, V33, P1559, DOI 10.1136/gut.33.11.1559; VAIRA D, 1989, LANCET, V2, P431; 1994, GASTROENTEROLOGY, V40, pP65	25	232	240	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					75	79		10.1016/S0140-6736(96)90208-1	http://dx.doi.org/10.1016/S0140-6736(96)90208-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538344				2022-12-28	WOS:A1996TP28100007
J	Sherin, JE; Shiromani, PJ; McCarley, RW; Saper, CB				Sherin, JE; Shiromani, PJ; McCarley, RW; Saper, CB			Activation of ventrolateral preoptic neurons during sleep	SCIENCE			English	Article							FOS-LIKE IMMUNOREACTIVITY; RAT-BRAIN; C-FOS; BASAL FOREBRAIN; POSTERIOR HYPOTHALAMUS; WAKING DISCHARGE; UNIT-ACTIVITY; CAT; AREA; MICROINJECTION	The rostral hypothalamus and adjacent basal forebrain participate in the generation of sleep, but the neuronal circuitry involved in this process remains poorly characterized. Immunocytochemistry was used to identify the FOS protein, an immediate-early gene product, in a group of ventrolateral preoptic neurons that is specifically activated during deep. The retrograde tracer cholera toxin B, in combination with FOS immunocytochemistry, was used to show that sleep-activated ventrolateral preoptic neurons innervate the tuberomammillary nucleus, a posterior hypothalamic cell group thought to participate in the modulation of arousal. This monosynaptic pathway in the hypothalamus may play a key role in determining sleep-wake states.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, BROCKTON VET ADM HOSP, SCH MED, DEPT PSYCHIAT, BROCKTON, MA 02401 USA; UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; University of Chicago			Shenton, Martha/V-8780-2019; Saper, Clifford/L-3815-2019; McCarley, Robert W/N-5562-2014	McCarley, Robert W/0000-0001-5705-7495	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030140, R01NS022835] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10709] Funding Source: Medline; NINDS NIH HHS [NS30140, NS22835] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAM MN, IN PRESS AM J PHYSL; BENTIVOGLIO M, 1993, SLEEP RES, V22, P475; BOBERLY AA, 1985, BRAIN MECHANISMS SLE, P35; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P327; DETARI L, 1984, ELECTROEN CLIN NEURO, V58, P362, DOI 10.1016/0013-4694(84)90062-2; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; ELMQUIST JK, 1993, ENDOCRINOLOGY, V133, P3054, DOI 10.1210/en.133.6.3054; ERICSON H, 1991, J COMP NEUROL, V305, P462, DOI 10.1002/cne.903050309; FINDLAY ALR, 1969, J PHYSIOL-LONDON, V201, P237, DOI 10.1113/jphysiol.1969.sp008753; GARCIAARRARAS JE, 1983, J NEUROPHYSIOL, V49, P528, DOI 10.1152/jn.1983.49.2.528; GRASSIZUCCONI G, 1994, J PHYSIOLOGY-PARIS, V88, P91, DOI 10.1016/0928-4257(94)90096-5; GRASSIZUCCONI G, 1993, SLEEP RES, V22, P478; GRITTI I, 1994, J COMP NEUROL, V339, P251, DOI 10.1002/cne.903390206; HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173, DOI 10.1006/frne.1993.1006; KAADA BR, 1951, ACTA PHYSL SCAND, V24, P200; KAITIN KI, 1984, EXP NEUROL, V83, P347, DOI 10.1016/0014-4886(84)90103-1; KONONEN J, 1990, NEUROSCI LETT, V120, P105, DOI 10.1016/0304-3940(90)90179-D; KOYAMA Y, 1994, BRAIN RES BULL, V33, P367, DOI 10.1016/0361-9230(94)90278-X; KRILOWICZ BL, 1994, BRAIN RES, V668, P30, DOI 10.1016/0006-8993(94)90507-X; LIN JS, 1988, NEUROPHARMACOLOGY, V27, P111, DOI 10.1016/0028-3908(88)90159-1; LIN JS, 1989, BRAIN RES, V479, P225, DOI 10.1016/0006-8993(89)91623-5; LUCAS EA, 1975, EXP NEUROL, V46, P368, DOI 10.1016/0014-4886(75)90142-9; MALLICK BN, 1983, EXP NEUROL, V81, P586, DOI 10.1016/0014-4886(83)90328-X; MATSUMURA H, 1994, P NATL ACAD SCI USA, V91, P11998, DOI 10.1073/pnas.91.25.11998; Mauthner L, 1890, WIEN MED WSCHR, V40, P961; MCGINTY D, 1994, BRAIN RES, V667, P273, DOI 10.1016/0006-8993(94)91506-7; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; MENDELSON WB, 1989, NEUROPSYCHOPHARMACOL, V2, P61, DOI 10.1016/0893-133X(89)90008-0; MONTI JM, 1993, LIFE SCI, V53, P1331, DOI 10.1016/0024-3205(93)90592-Q; NAUTA WJH, 1946, J NEUROPHYSIOL, V9, P285, DOI 10.1152/jn.1946.9.4.285; NITZ DN, 1995, SLEEP RES, V24, P12; OGAWA Y, 1988, BRAIN RES BULL, V20, P897, DOI 10.1016/0361-9230(88)90108-6; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; POMPEIANO M, 1994, J SLEEP RES, V3, P80, DOI 10.1111/j.1365-2869.1994.tb00111.x; ROBERTS WW, 1969, EXP NEUROL, V25, P282, DOI 10.1016/0014-4886(69)90051-X; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SALLANON M, 1989, NEUROSCIENCE, V32, P669, DOI 10.1016/0306-4522(89)90289-3; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SENBA E, 1985, J NEUROSCI, V5, P3393; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHERIN JE, 1993, SOC NEUR ABSTR, V19, P31; SHERIN JE, UNPUB; SHIROMANI PJ, 1995, MOL BRAIN RES, V29, P163, DOI 10.1016/0169-328X(94)00242-7; Snedecor GW., 1989, STAT METHODS, P177; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERMAN MB, 1962, EXP NEUROL, V6, P91, DOI 10.1016/0014-4886(62)90080-8; Sterman MB, 1985, BRAIN MECHANISMS SLE, P277; SWETT CP, 1968, ARCH ITAL BIOL, V106, P283; SZYMUSIAK R, 1989, BRAIN RES BULL, V23, P111, DOI 10.1016/0361-9230(89)90169-X; SZYMUSIAK R, 1989, BRAIN RES, V498, P355, DOI 10.1016/0006-8993(89)91116-5; SZYMUSIAK R, 1986, BRAIN RES, V370, P82, DOI 10.1016/0006-8993(86)91107-8; SZYMUSIAK R, 1986, EXP NEUROL, V94, P598, DOI 10.1016/0014-4886(86)90240-2; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; VANHULZEN ZJM, 1980, PHYSIOL BEHAV, V25, P807, DOI 10.1016/0031-9384(80)90298-X; VANNIMERCIER G, 1984, CR ACAD SCI III-VIE, V298, P195; WATANABE T, 1983, NEUROSCI LETT, V39, P249, DOI 10.1016/0304-3940(83)90308-7; WILCOX BJ, 1982, NEUROSCI LETT, V29, P105, DOI 10.1016/0304-3940(82)90337-8; YANG OZ, 1994, SOC NEUR ABSTR, V20, P346	59	721	755	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					216	219		10.1126/science.271.5246.216	http://dx.doi.org/10.1126/science.271.5246.216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539624				2022-12-28	WOS:A1996TP36400046
J	Kusumoto, FM; Goldschlager, N				Kusumoto, FM; Goldschlager, N			Medical progress: Cardiac pacing	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGESTIVE-HEART-FAILURE; SICK SINUS SYNDROME; DUAL-CHAMBER; MINUTE VENTILATION; CLINICAL-EXPERIENCE; PACEMAKER SYNDROME; 2 SENSORS; SYNCOPE; DISEASE; CARDIOMYOPATHY		UNIV CALIF SAN FRANCISCO, DEPT MED, DIV CARDIOL, SAN FRANCISCO, CA USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Kusumoto, FM (corresponding author), LOVELACE MED CTR, DEPT MED, DIV CARDIOL, ELECTROPHYSIOL & PACING SERV, 5400 GIBSON BLVD SE, ALBUQUERQUE, NM 87108 USA.							ALICANDRI C, 1978, AM J CARDIOL, V42, P137, DOI 10.1016/0002-9149(78)90998-0; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; ALT E, 1987, CHEST, V92, P247, DOI 10.1378/chest.92.2.247; ALT E, 1988, PACE, V11, P1119, DOI 10.1111/j.1540-8159.1988.tb03963.x; AURICCHIO A, 1993, PACE, V16, P2034, DOI 10.1111/j.1540-8159.1993.tb00997.x; AUSUBEL K, 1985, ANN INTERN MED, V103, P420, DOI 10.7326/0003-4819-103-3-420; BATEY RL, 1990, PACE, V13, P646, DOI 10.1111/j.1540-8159.1990.tb02082.x; BENDITT DG, 1994, ANN INTERN MED, V121, P960, DOI 10.7326/0003-4819-121-12-199412150-00010; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BRIGNOLE M, 1991, AM J CARDIOL, V68, P1032, DOI 10.1016/0002-9149(91)90491-3; BUCKINGHAM TA, 1991, PACE, V14, P1437, DOI 10.1111/j.1540-8159.1991.tb04060.x; Byrd Charles L., 1992, Cardiology Clinics, V10, P735; CHARDACK WM, 1960, SURGERY, V48, P643; ELLENBOGEN KAS, 1992, CARIAC PACING; ELMQUIST R, 1960, 2ND P INT C MED EL E; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; Furman S, 1993, PRACTICE CARDIAC PAC; GREENBERG B, 1979, AM HEART J, V98, P742, DOI 10.1016/0002-8703(79)90473-3; GRIFFIN JC, 1992, CARDIOL CLIN, V10, P561; HAAS JM, 1974, AM J CARDIOL, V33, P295, DOI 10.1016/0002-9149(74)90293-8; HARTZLER GO, 1977, AM J CARDIOL, V40, P232, DOI 10.1016/0002-9149(77)90013-3; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JOSEPHSON ME, 1995, J AM COLL CARDIOL, V25, P23, DOI 10.1016/0735-1097(95)96220-S; JUTZY RV, 1989, J ELECTROPHYSIOL, V3, P194; KARLOF I, 1975, ACTA MED SCAND, V197, P195; KRUSE I, 1982, CIRCULATION, V65, P846, DOI 10.1161/01.CIR.65.5.846; KULBERTUS H, 1969, BRIT HEART J, V31, P435; LANDMAN MAJ, 1990, PACE, V13, P1615, DOI 10.1111/j.1540-8159.1990.tb06863.x; LAU CP, 1992, PACE, V15, P1177, DOI 10.1111/j.1540-8159.1992.tb03121.x; LAU CP, 1992, PACE, V15, P1504, DOI 10.1111/j.1540-8159.1992.tb02924.x; LAU CP, 1988, PACE, V11, P141, DOI 10.1111/j.1540-8159.1988.tb04535.x; LAU CP, 1989, PACE, V12, P321, DOI 10.1111/j.1540-8159.1989.tb02665.x; LEE MT, 1990, PACE, V13, P1852, DOI 10.1111/j.1540-8159.1990.tb06902.x; LONGO E, 1990, PACE, V13, P927, DOI 10.1111/j.1540-8159.1990.tb02130.x; LUDMER PL, 1984, NEW ENGL J MED, V311, P1671, DOI 10.1056/NEJM198412273112605; MCDONALD KM, 1991, AM J CARDIOL, V68, P108, DOI 10.1016/0002-9149(91)90721-V; MOND HG, 1993, PACE, V16, P2168, DOI 10.1111/j.1540-8159.1993.tb01022.x; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; PARSONNET V, 1974, AM J CARDIOL, V34, P487; REYNOLDS DW, 1983, J AM COLL CARDIOL, V1, P636; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; ROSSI P, 1988, PACE, V11, P1267, DOI 10.1111/j.1540-8159.1988.tb03987.x; SCHEINMAN MM, 1982, AM J CARDIOL, V50, P1316, DOI 10.1016/0002-9149(82)90469-6; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; SULKE N, 1991, J AM COLL CARDIOL, V17, P696, DOI 10.1016/S0735-1097(10)80186-X; SUTTON R, 1986, PACE, V9, P1110, DOI 10.1111/j.1540-8159.1986.tb06678.x; Sutton R., 1989, PACE, V12, P1260, DOI DOI 10.1111/J.1540-8159.1989.TB01982.X; VANERIO G, 1991, PACE, V14, P1815, DOI 10.1111/j.1540-8159.1991.tb02772.x; ZOLL PM, 1960, CIRCULATION, V22, P341, DOI 10.1161/01.CIR.22.3.341	53	106	123	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					89	98		10.1056/NEJM199601113340206	http://dx.doi.org/10.1056/NEJM199601113340206			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531965				2022-12-28	WOS:A1996TP36300006
J	Sobol, RW; Horton, JK; Kuhn, R; Gu, H; Singhal, RK; Prasad, R; Rajewsky, K; Wilson, SH				Sobol, RW; Horton, JK; Kuhn, R; Gu, H; Singhal, RK; Prasad, R; Rajewsky, K; Wilson, SH			Requirement of mammalian DNA polymerase-beta in base-excision repair	NATURE			English	Article							CELLS; AGENTS	SYNTHESIS Of DNA by DNA polymerase-beta is distributive on single-stranded DNA templates, but short DNA gaps with a 5' PO4 in the gap are filled processively to completion(1,2). In vitro studies have suggested a role of beta-polymerase in different types of DNA repair(3-9). However, the significance of these studies to the in vivo role of beta-polymerase has remained unclear. Because genetic studies are essential for determining the physiological role of a gene, we established embryonic fibroblast cell lines homozygous for a deletion mutation in the gene encoding DNA polymerase-beta. Extracts from these cell lines were found to be defective in uracil-initiated base-excision repair. The beta-polymerase-deleted cells are normal in viability and growth characteristics, although they exhibit increased sensitivity to monofunctional DNA-alkylating agents, but not to other DNA-damaging agents. Both the deficiency in base-excision repair and hypersensitivity to DNA-alkylating agents are rescued following stable transfection with a wild-type beta-polymerase minitransgene. These studies demonstrate that beta-polymerase functions specifically in base-excision repair in vivo.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne	Sobol, RW (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,CELL BIOL LAB,GALVESTON,TX 77555, USA.		Kühn, Ralf/U-1278-2017; Sobol, Robert W./E-4125-2013; Wilson, Samuel H/E-6644-2019	Kühn, Ralf/0000-0003-1694-9803; Sobol, Robert W./0000-0001-7385-3563; Wilson, Samuel H/0000-0002-1702-5293; Rajewsky, Klaus/0000-0002-6633-6370				BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; KOMBERG A, 1991, DNA REPLICATION; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P211; KRIEGLER M, 1995, CURRENT PROTOCOLS MO; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; PRASAD R, 1994, J BIOL CHEM, V269, P18096; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P49; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	17	748	770	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					183	186		10.1038/379183a0	http://dx.doi.org/10.1038/379183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538772				2022-12-28	WOS:A1996TP36000064
J	Merzenich, MM; Jenkins, WM; Johnston, P; Schreiner, C; Miller, SL; Tallal, P				Merzenich, MM; Jenkins, WM; Johnston, P; Schreiner, C; Miller, SL; Tallal, P			Temporal processing deficits of language-learning impaired children ameliorated by training	SCIENCE			English	Article							DEVELOPMENTAL DYSLEXIA; PERCEPTION; DISCRIMINATION; PERFORMANCE; APHASIA; TASK	Children with language-based learning impairments (LLIs) have major deficits in their recognition of some rapidly successive phonetic elements and nonspeech sound stimuli. In the current study, LLI children were engaged in adaptive training exercises mounted as computer ''games'' designed to drive improvements in their ''temporal processing'' skills. With 8 to 16 hours of training during a 20-day period, LLI children improved markedly in their abilities to recognize brief and fast sequences of nonspeech and speech stimuli.	UNIV CALIF SAN FRANCISCO, COLEMAN LAB, SAN FRANCISCO, CA 94143 USA; RUTGERS STATE UNIV, CTR MOLEC & BEHAV NEUROSCI, NEWARK, NJ 07102 USA	University of California System; University of California San Francisco; Rutgers State University Newark; Rutgers State University New Brunswick	Merzenich, MM (corresponding author), UNIV CALIF SAN FRANCISCO, WM KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NINDS NIH HHS [R01 NS010414] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; [Anonymous], 1982, ANN DYSLEXIA, DOI DOI 10.1007/BF02647960; BEITEL R, 1995, NEUR ABSTR, V21, P1180; BENESCISH AA, 1993, TEMPORALINFORMATION, P312; BENESCISH AA, IN PRESS INFANT BEHA; BERTINI G, 1995, NEUR ABSTR, V21, P276; BYL NN, IN PRESS J NEUROL; DUARA R, 1991, ARCH NEUROL-CHICAGO, V48, P410, DOI 10.1001/archneur.1991.00530160078018; FLYNN JM, 1992, J LEARN DISABIL, V25, P133, DOI 10.1177/002221949202500207; GALABURDA A, 1993, ANN NY ACAD SCI, V682, P70, DOI 10.1111/j.1749-6632.1993.tb22960.x; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; GALABURDA AM, 1993, NEUROL CLIN, V11, P161, DOI 10.1016/S0733-8619(18)30175-0; HAGMAN JO, 1992, ARCH NEUROL-CHICAGO, V49, P734, DOI 10.1001/archneur.1992.00530310082015; JERNIGAN TL, 1991, ARCH NEUROL-CHICAGO, V48, P539, DOI 10.1001/archneur.1991.00530170103028; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KLATT DH, 1980, J ACOUST SOC AM, V67, P971, DOI 10.1121/1.383940; KUSCH A, 1993, NEUROPSYCHOLOGIA, V31, P811; LARSEN JP, 1990, BRAIN LANG, V39, P289, DOI 10.1016/0093-934X(90)90015-9; LEWIS BA, 1993, BEHAV GENET, V23, P291, DOI 10.1007/BF01082469; LEWIS BA, 1992, J LEARN DISABIL, V25, P486; MERZENICH M. M., 1994, MEMORY CONCEPTS, P437; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; MERZENICH MM, 1993, ANN NY ACAD SCI, V682, P1; Merzenich MM., 1995, MATURATIONAL WINDOWS, P247; MERZENICH MM, IN PRESS MIND BRAIN; NAAS R, 1994, CURR OPIN NEUROL, V7, P179; PENNINGTON BF, 1995, J CHILD NEUROL, V10, pS69, DOI 10.1177/08830738950100S114; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TALLAL P, 1973, NATURE, V241, P468, DOI 10.1038/241468a0; TALLAL P, 1991, BRAIN LANG, V41, P81, DOI 10.1016/0093-934X(91)90112-E; TALLAL P, 1975, NEUROPSYCHOLOGIA, V13, P69, DOI 10.1016/0028-3932(75)90049-4; TALLAL P, 1985, BRAIN LANG, V25, P314, DOI 10.1016/0093-934X(85)90087-2; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; Tallal P., 1980, NONSPEECH LANGUAGE C, P449; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; 1978, TOKEN TEST CHILDREN	39	694	734	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					77	81		10.1126/science.271.5245.77	http://dx.doi.org/10.1126/science.271.5245.77			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP022	8539603				2022-12-28	WOS:A1996TP02200047
J	Chittajallu, R; Vignes, M; Dev, KK; Barnes, JM; Collingridge, GL; Henley, JM				Chittajallu, R; Vignes, M; Dev, KK; Barnes, JM; Collingridge, GL; Henley, JM			Regulation of glutamate release by presynaptic kainate receptors in the hippocampus	NATURE			English	Article							NEURONS; RAT; AMPA; 2,3-BENZODIAZEPINE; DESENSITIZATION; CYCLOTHIAZIDE; TRANSMISSION; ACTIVATION; ANTAGONIST; CHANNELS	MOST reported actions of kainate are mediated by AMPA (alpha-amino-3-hydroxy-5-methyl 3-isosazolepropionate) receptors(1,2). Here we report that, unlike AMPA which stimulates, kainate elicits a dose-dependent decrease in L-glutamate release from rat hippocampal synaptosomes and also depresses glutamatergic synaptic transmission. Brief exposure to kainate inhibited Ca2+-dependent [H-3]L-glutamate release by up to 80%. Inhibition was reversed by kainate antagonists but not by the AMPA-selective noncompetitive antagonist 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3- benzodiazepine (GYKI 52466)(3-7). A corresponding reversible kainate-evoked depression of NMDA (N-methyl-D-aspartate) receptor-mediated excitatory postsynaptic currents (e.p.s.cs) was observed when AMPA receptors were blocked by GYKI 52466. The synaptic depression was preceded by a brief period of enhanced release and a small inward current was also observed. The effects of kainate were unaffected by metabotropic glutamate (mGlu), GABA(A), GABA(B), glycine and adenosine receptor antagonists. These results indicate that glutamate release can be modulated directly by kainate autoreceptors.	UNIV BRISTOL,SCH MED SCI,DEPT ANAT,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Bristol; University of Birmingham			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Vignes, Michel/AAA-7693-2019; Chittajallu, Ramesh/AAX-3749-2020; Henley, Jeremy M/A-2776-2009	Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966; Chittajallu, Ramesh/0000-0002-9794-0052; Henley, Jeremy/0000-0003-3589-8335; Dev, Kumlesh/0000-0003-4274-9119	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGRAWAL SG, 1986, BRIT J PHARMACOL, V87, P345, DOI 10.1111/j.1476-5381.1986.tb10823.x; BAHN S, 1994, J NEUROSCI, V14, P5525; BARNES JM, 1994, BRIT J PHARMACOL, V113, P339, DOI 10.1111/j.1476-5381.1994.tb16902.x; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; COLLINGRIDGE G, 1994, NMDA RECEPTOR; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; JOHANSEN TH, 1993, EUR J PHARM-MOLEC PH, V246, P195, DOI 10.1016/0922-4106(93)90031-4; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; MALVA JO, 1995, NEUROSCI LETT, V185, P83, DOI 10.1016/0304-3940(94)11230-G; MARTIN D, 1991, J NEUROCHEM, V56, P1647, DOI 10.1111/j.1471-4159.1991.tb02063.x; NISTRI A, 1991, J PHYSIOL-LONDON, V435, P465, DOI 10.1113/jphysiol.1991.sp018519; PALMER AJ, 1993, EUR J PHARM-MOLEC PH, V244, P193, DOI 10.1016/0922-4106(93)90027-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; RENARD A, 1995, NEUROPHARMACOLOGY, V34, P335, DOI 10.1016/0028-3908(94)00165-O; RUANO D, 1995, J NEURON, V14, P1009; SAWADA S, 1985, EXP BRAIN RES, V60, P323; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; TAMAWA I, 1990, AMINO ACIDS CHEM BIO, P538; VERDOORN TA, 1994, EUR J PHARM-MOLEC PH, V269, P43, DOI 10.1016/0922-4106(94)90024-8; WONG LA, 1993, MOL PHARMACOL, V44, P504; ZEMAN S, 1992, BRIT J PHARMACOL, V106, P367, DOI 10.1111/j.1476-5381.1992.tb14342.x; ZHOU M, 1995, J NEUROCHEM, V64, P1556; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	30	338	342	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					78	81		10.1038/379078a0	http://dx.doi.org/10.1038/379078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538745				2022-12-28	WOS:A1996TN21600059
J	Sidel, VW				Sidel, VW			The international arms trade and its impact on health	BRITISH MEDICAL JOURNAL			English	Article									INT PHYSICIANS PREVENT NUCL WAR,CAMBRIDGE,MA		Sidel, VW (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,111 E 210TH ST,BRONX,NY 10467, USA.							AMITAI Y, 1992, JAMA-J AM MED ASSOC, V268, P630, DOI 10.1001/jama.268.5.630; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; Bloom S., 1994, HIDDEN CASUALTIES EN; Brauer Jurgen, 1993, EC ISSUES DISARMAMEN; Brzezinski Z., 1993, OUT CONTROL; Cahill K. M., 1995, CLEARING FIELDS SOLU; Grant James P., 1995, STATE WORLDS CHILDRE; GUTHKITTS G, 1995, ECAAR NEWSNETWORK, V7, P2; HARTUNG WD, 1994, WEAPONS ALL; Hu Howard, 1992, PLUTONIUM DEADLY GOL; LEANING J, 1993, CRITICAL CONDITION H; MACGRATH R, 1994, LANDMINES LEGACY CON; MAKHIJANI A, 1995, NUCLEAR WASTELANDS; PERRY WJ, 1994, GLOBAL ENGAGEMENT CO, P235; Physicians for Human Rights, 1992, HIDDEN ENEMIES LAND; RHODES R, 1988, JAMA-J AM MED ASSOC, V260, P686, DOI 10.1001/jama.260.5.686; Robbins A., 1991, RADIOACTIVE HEAVEN E; SIDEL VW, 1962, NEW ENGL J MED, V266, P1137, DOI 10.1056/NEJM196205312662205; SIDEL VW, 1988, LANCET, V2, P442; Sidel VW, 1993, PSR Q, V3, P18; SIDEL VW, 1995, ENCY BIOETHICS, P2544; SIVARD R, 1993, WORLD MILITARY SOCIA; STOTT R, 1994, MED GLOBAL SURVIVAL, V1, P92; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; WESTING AH, 1977, WEAPONS MASS DESTRUC; Westing Arthur H., 1980, WARFARE FRAGILE WORL; WILSON N, 1995, MED GLOBAL SURVIVAL, V2, P115; 1995, PHYSICIANS HUMAN AUG, P14; 1983, MED EFFECTS NUCLEAR; 1991, LANDMINES CAMBODIA C; 1995, DISARMAMENT UNFINISH; 1995, CONVENTIONAL ARMS TR; 1994, 1994 HUM DEV REP, P54; 1994, DISARMAMENT RESPONDI; 1962, NEW ENGL J MED, V266, P1126; 1995, SIPRI YB 1995; 1995, BLINDING LASER WEAPO, P7; 1995, WORLD MILITARY EXPEN; 1993, LANDMINES DEADLY LEG; 1994, HIDDEN KILLERS GLOBA	40	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1677	1680		10.1136/bmj.311.7021.1677	http://dx.doi.org/10.1136/bmj.311.7021.1677			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541755	Green Published			2022-12-28	WOS:A1995TL94200015
J	ASHBURNER, M				ASHBURNER, M			MEDFLY TRANSFORMED - OFFICIAL	SCIENCE			English	Editorial Material											ASHBURNER, M (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.							ARKINSON PW, COMMUNICATION; Benedict M. Q., 1994, Insect Molecular Biology, V3, P247, DOI 10.1111/j.1365-2583.1994.tb00173.x; CAREY JR, 1991, SCIENCE, V253, P1369, DOI 10.1126/science.1896848; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; French-Constant R. H., 1993, Proceedings of the National Academy of Sciences of the United States of America, V90, P1957; HENDRICHS J, 1995, J APPL ENTOMOL, V119, P371, DOI 10.1111/j.1439-0418.1995.tb01303.x; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P22; MATZSUBARA T, UNPUB; OBROCHTA DA, IN PRESS GENETICS; RUBIN GM, 1983, SCIENCE, V218, P348; RULL JA, 1995, FRUIT FLY PESTS WORL; ZWIEBEL LJ, 1995, SCIENCE, V270, P2005, DOI 10.1126/science.270.5244.2005	13	10	12	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1941	1942		10.1126/science.270.5244.1941	http://dx.doi.org/10.1126/science.270.5244.1941			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533084				2022-12-28	WOS:A1995TL42000026
J	NAGELE, R; FREEMAN, T; MCMORROW, L; LEE, HY				NAGELE, R; FREEMAN, T; MCMORROW, L; LEE, HY			PRECISE SPATIAL POSITIONING OF CHROMOSOMES DURING PROMETAPHASE - EVIDENCE FOR CHROMOSOMAL ORDER	SCIENCE			English	Article							INSITU HYBRIDIZATION; CELL-CYCLE; INTERPHASE NUCLEUS; CONFOCAL MICROSCOPY; TUMOR-CELLS; CENTROMERES; DOMAINS; METAPHASE; TELOMERES; MOVEMENT	The relative locations of several chromosomes within wheel-shaped prometaphase chromosome rosettes of human fibroblasts and HeLa cells were determined with fluorescence hybridization. Homologs were consistently positioned on opposite sides of the rosette, which suggests that chromosomes are separated into two haploid sets, each derived from one parent. The relative locations of chromosomes on the rosette were mapped by dual hybridizations. The data suggest that the chromosome orders within the two haploid sets are antiparallel. This chromosome arrangement in human cells appears to be both independent of cell type- and species-specific and may influence chromosome topology throughout the cell cycle.	THOMAS JEFFERSON UNIV,DEPT LAB SCI,PHILADELPHIA,PA 19107; RUTGERS STATE UNIV,DEPT BIOL,CAMDEN,NJ 08102	Jefferson University; Rutgers State University Camden; Rutgers State University New Brunswick	NAGELE, R (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT BIOL MOLEC,STRATFORD,NJ 08084, USA.			Freeman, Theresa/0000-0002-5959-5884				BARTHOLDI MF, 1991, J CELL SCI, V99, P255; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FREEMAN T, UNPUB; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAAF T, 1989, HUM GENET, V81, P137, DOI 10.1007/BF00293889; HAAF T, 1991, EXP CELL RES, V182, P325; HADLACZKY G, 1986, EXP CELL RES, V167, P1, DOI 10.1016/0014-4827(86)90199-0; HILLIKER AJ, 1989, EXP CELL RES, V185, P297, DOI 10.1016/0014-4827(89)90301-7; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HULSPAS R, 1992, CELL BIOL INT REP, V16, P739, DOI 10.1016/S0309-1651(05)80018-9; JANEVSKI J, 1995, EXP CELL RES, V217, P227, DOI 10.1006/excr.1995.1082; JORDAN MA, 1992, J CELL SCI, V102, P401; LANDEGENT J, 1988, P NATL ACAD SCI USA, V85, P9138; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MANUELIDIS L, 1985, ANN NY ACAD SCI, V450, P205, DOI 10.1111/j.1749-6632.1985.tb21494.x; MANUELIDIS L, 1984, P NATL ACAD SCI-BIOL, V81, P3123, DOI 10.1073/pnas.81.10.3123; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; MANUELIDIS L, 1988, CHROMOSOMA, V96, P397, DOI 10.1007/BF00303033; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; POPP S, 1990, EXP CELL RES, V189, P1, DOI 10.1016/0014-4827(90)90249-A; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; VANDEKKEN H, 1990, CYTOMETRY, V11, P570, DOI 10.1002/cyto.990110503; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068	24	127	130	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1831	1835		10.1126/science.270.5243.1831	http://dx.doi.org/10.1126/science.270.5243.1831			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525379				2022-12-28	WOS:A1995TK47600049
J	PATAPOUTIAN, A; WOLD, BJ; WAGNER, RA				PATAPOUTIAN, A; WOLD, BJ; WAGNER, RA			EVIDENCE FOR DEVELOPMENTALLY PROGRAMMED TRANSDIFFERENTIATION IN MOUSE ESOPHAGEAL MUSCLE	SCIENCE			English	Article							MYOD	Transdifferentiation is a relatively rare phenomenon in which cells of one differentiated type and function switch to a second discrete identity. In vertebrate embryos, smooth muscle and skeletal muscle are distinct tissues that arise from separate compartments of the mesoderm. The musculature of the mouse esophagus was found to undergo a conversion from smooth muscle in the fetus to skeletal muscle during early postnatal development. The switch from smooth to skeletal muscle features the transitory appearance of individual cells expressing a mixed phenotype, which suggests that this conversion is a result of programmed transdifferentiation.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NIAMS NIH HHS [AR40708] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DJ, 1989, TRENDS GENET, V5, P175; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BROCKES JP, 1994, TRENDS GENET, V10, P169, DOI 10.1016/0168-9525(94)90094-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; COLES HSR, 1993, DEVELOPMENT, V118, P777; DUBOND JL, 1993, DIFFERENTIATION, V55, P1; HITCHCOCK PF, 1992, TRENDS NEUROSCI, V15, P103, DOI 10.1016/0166-2236(92)90020-9; LANDIS SC, 1990, TRENDS NEUROSCI, V8, P344; MINER JH, 1992, DEVELOPMENT, V114, P853; Okada T.S, 1991, TRANSDIFFERENTIATION; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; Prosser C. L., 1973, Comparative animal physiology,, P719; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VOLPE P, 1993, DEV BIOL, V159, P441, DOI 10.1006/dbio.1993.1254; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	17	131	136	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1818	1821		10.1126/science.270.5243.1818	http://dx.doi.org/10.1126/science.270.5243.1818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525375				2022-12-28	WOS:A1995TK47600045
J	WALL, MA; COLEMAN, DE; LEE, E; INIGUEZLLUHI, JA; POSNER, BA; GILMAN, AG; SPRANG, SR				WALL, MA; COLEMAN, DE; LEE, E; INIGUEZLLUHI, JA; POSNER, BA; GILMAN, AG; SPRANG, SR			THE STRUCTURE OF THE G-PROTEIN HETEROTRIMER G(I-ALPHA-1)BETA(1)GAMMA(2)	CELL			English	Article							BETA-GAMMA; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURES; SUBUNITS; ALPHA; IDENTIFICATION; MECHANISM; RECEPTORS	The crystallographic structure of the G protein heterotrimer G(i alpha 1)(GDP)beta 1(1 gamma 2) (at 2.3 Angstrom) reveals two nonoverlapping regions of contact between alpha and beta, an extended interface between beta and nearly all of gamma, and limited interaction of alpha with gamma. The major alpha/beta interface covers switch II of alpha, and GTP-induced rearrangement of switch II causes subunit dissociation during signaling. Alterations in GDP binding in the heterotrimer (compared with alpha-GDP) explain stabilization of the inactive conformation of alpha by beta gamma. Repeated WD motifs in beta form a circularized sevenfold beta propeller. The conserved cores of these motifs are a scaffold for display of their more variable linkers on the exterior face of each propeller blade.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WALL, MA (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.			Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIAHIGUERA I, 1996, IN PRESS J BIOL CHEM; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HEPLER JR, 1995, IN PRESS J BIOL CHEM; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1993, O VERSION 5 9; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1994, ENZYMOL, V237, P146; LESK AM, 1986, PROTEIN ENG, V1, P77, DOI 10.1093/protein/1.1.77; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; XIA ZX, 1992, J BIOL CHEM, V267, P22289; 1994, ACTA CRYSTALLOGR, V50, P760	58	973	991	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1047	1058		10.1016/0092-8674(95)90220-1	http://dx.doi.org/10.1016/0092-8674(95)90220-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521505	Bronze			2022-12-28	WOS:A1995TK74500023
J	STEWARTBROWN, S; SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H				STEWARTBROWN, S; SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H			THE EFFECTS OF FUNDHOLDING IN GENERAL-PRACTICE ON PRESCRIBING HABITS 3 YEARS AFTER INTRODUCTION OF THE SCHEME	BRITISH MEDICAL JOURNAL			English	Article							COSTS	Objective--To observe changes in prescribing practice that occurred after the introduction of fundholding in first wave practices and to contrast these with changes occurring in similar non-fundholding practices. Design--Prospective observational study. Setting--Oxford region fundholding study. Subjects--Eight first wave fundholding practices and five practices that were not interested in fundholding in 1990-1, which were similar in terms of practice size, training status, locality, and urban rural mix. Three of the fundholding and none of the non-fundholding practices were dispensing practices. Main outcome measures--Changes in prescribing practice as measured by net cost per prescribing unit, cost per item, number of items prescribed, and substitution rates for generic drugs three years after the introduction of fundholding. Data for fundholding practices were analysed separately according to whether they were dispensing or non-dispensing practices. Results--Prescribing costs rose by a third or more in all types of practice. The patterns of change observed in this cohort after one year of fundholding were reversed. No evidence existed that fundholding had controlled prescribing costs among non-dispensing fundholders; costs among dispensing fundholders rose least, but the differences were small compared with the overall increase in costs. Conclusions--Early reports of the effectiveness of fundholding in curbing prescribing costs have not been confirmed in this longer term study.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE UNIT,OXFORD OX3 7LF,ENGLAND; KINGS FUND CTR,LONDON W1M 0AN,ENGLAND	University of Oxford	STEWARTBROWN, S (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; CHEW R, 1992, COMPENDIUM HLTH STAT; COULTER A, IN PRESS EUROPEAN J; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1993, EFFECTIVE HLTH CARE, V5	7	67	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1543	1547		10.1136/bmj.311.7019.1543	http://dx.doi.org/10.1136/bmj.311.7019.1543			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520399	Green Published			2022-12-28	WOS:A1995TK21400027
J	FEDER, G; GRIFFITHS, C; HIGHTON, C; ELDRIDGE, S; SPENCE, M; SOUTHGATE, L				FEDER, G; GRIFFITHS, C; HIGHTON, C; ELDRIDGE, S; SPENCE, M; SOUTHGATE, L			DO CLINICAL GUIDELINES INTRODUCED WITH PRACTICE-BASED EDUCATION IMPROVE CARE OF ASTHMATIC AND DIABETIC-PATIENTS - A RANDOMIZED CONTROLLED TRIAL IN GENERAL PRACTICES IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether locally developed guidelines on asthma and diabetes disseminated through practice based education improve quality of care in non-training, inner city general practices. Design-Randomised controlled trial with each practice receiving one set of guidelines but providing data on the management of both conditions. Subjects-24 inner city, non-training general practices. Setting-East London. Main outcome measures-Recording of key variables in patient records (asthma: peak flow rate, review of inhaler technique, review of asthma symptoms, prophylaxis, occupation, and smoking habit; diabetes: blood glucose concentration, glycaemic control, funduscopy, feet examination, weight, and smoking habit); size of practice disease registers; prescribing in asthma; and use of structured consultation ''prompts.'' Results-In practices receiving diabetes guidelines, significant improvements in recording were seen for all seven diabetes variables. Both groups of practices showed improved recording of review of inhaler technique, smoking habit, and review of asthma symptoms. In practices receiving asthma guidelines, further improvement was seen only in recording of review of inhaler technique and quality of prescribing in asthma. Sizes of disease registers were unchanged. The use of structured prompts was associated with improved recording of four of seven variables on diabetes and all six variables on asthma. Conclusions-Local guidelines disseminated via practice based education improve the management of diabetes and possibly of asthma in inner city, nontraining practices. The use of simple prompts may enhance this improvement.	UNIV LONDON,UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	FEDER, G (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON HOSP,COLL MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON EC1M 6BQ,ENGLAND.		Eldridge, Sandy/AAF-8139-2019	Eldridge, Sandy/0000-0002-7055-2754; Feder, Gene/0000-0002-7890-3926				BENETT IJ, 1994, DIABETIC MED, V11, P489, DOI 10.1111/j.1464-5491.1994.tb00312.x; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; FINLAY R, 1991, HLTH TRENDS, V23, P104; GRAFFY J, 1994, BRIT MED J, V38, P391; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; INKLEYLEITCH G, 1993, COLLABORATIVE DEV PL; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; Jones K, 1992, Qual Health Care, V1, P110, DOI 10.1136/qshc.1.2.110; Krans HMJ, 1992, DIABETES CARE RES EU; MITMAN BS, 1992, QUALITY REV B, V18, P413; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; OXMAN AD, 1994, NO MAGIC BULLETS SYS; PARNELL SJ, 1993, BRIT J GEN PRACT, V43, P65; PATCHETT P, 1994, BRIT MED J, V308, P1225, DOI 10.1136/bmj.308.6938.1225; PRINGLE M, 1994, OUTCOMES CLIN PRACTI, P135; RETHANS JJ, 1994, BRIT J GEN PRACT, V44, P153; SOUMERAI SB, 1985, JAMA-J AM MED ASSOC, V263, P549; WARREN R, 1992, LIST DISCREPANCY MOR; 1994, MONITORING ASTHMA; 1995, RCGP26 ROYAL COLL GE; 1993, MONITORING DIABETES; 1994, EFFECTIVE HLTH CARE, V8, P1; 1995, ELCHA1994 95 E LOND; 1994, POPULATION OUTCOME I; 1990, BRIT MED J, V301, P651; 1991, HACKNEY ASTHMA GUIDE; 1992, BRIT MED J, V304, P1480	29	159	159	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1473	1478		10.1136/bmj.311.7018.1473	http://dx.doi.org/10.1136/bmj.311.7018.1473			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520339	Green Published			2022-12-28	WOS:A1995TJ04400028
J	MONTGOMERY, HE; MCINTYRE, CW; ALMOND, MK; DAVIES, K; PUMPHREY, CW; BENNETT, D				MONTGOMERY, HE; MCINTYRE, CW; ALMOND, MK; DAVIES, K; PUMPHREY, CW; BENNETT, D			RHABDOMYOLYSIS AND MULTIPLE SYSTEM ORGAN FAILURE WITH STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter							MYOCARDIAL-INFARCTION		SO GEN HOSP, RENAL UNIT, WESTCLIFF ON THE SEA, ESSEX, ENGLAND; HAMMERSMITH HOSP, DEPT RHEUMATOL, LONDON W12 0NN, ENGLAND; ST GEORGE HOSP, CARDIOL UNIT, LONDON SW17, ENGLAND; ST GEORGE HOSP, INTENS CARE UNIT, LONDON SW17, ENGLAND	Imperial College London; St Georges University London; St Georges University London	MONTGOMERY, HE (corresponding author), UCL HOSP, HATTER INST CARDIOVASC RES, LONDON WC1E 6AU, ENGLAND.		Montgomery, Hugh/L-1229-2019; McIntyre, Christopher W/O-8927-2014; Montgomery, Hugh/C-2592-2008	Montgomery, Hugh/0000-0001-8797-5019				DAVIES KA, 1990, CLIN EXP IMMUNOL, V80, P83; DICKINSON RJ, 1991, BRIT MED J, V302, P111; LYNCH M, 1993, CLIN EXP IMMUNOL, V94, P279; QUEEN M, 1990, AM J CARDIOL, V65, P1042, DOI 10.1016/0002-9149(90)91014-W; TIO RA, 1992, AM J CARDIOL, V70, P1632, DOI 10.1016/0002-9149(92)90477-G	5	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1472	1472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520338				2022-12-28	WOS:A1995TJ04400025
J	PATEL, V; MUKHERJEE, JJ; BESSER, M; MEDBAK, S; DICKINSON, J; DONIACH, I; RAINE, A; SOMERVILLE, K; WEETMAN, A				PATEL, V; MUKHERJEE, JJ; BESSER, M; MEDBAK, S; DICKINSON, J; DONIACH, I; RAINE, A; SOMERVILLE, K; WEETMAN, A			GRAND-ROUNDS - ST-BARTHOLOMEWS-HOSPITAL - A LUMP IN THE CHEST - A COMMON PROBLEM IN AN UNUSUAL SETTING	BMJ-BRITISH MEDICAL JOURNAL			English	Discussion							DRUG-INDUCED AGRANULOCYTOSIS; ECTOPIC THYROID-TISSUE; GRAVES-DISEASE; SUBSTERNAL GOITER; SODIUM IPODATE; HYPERTHYROIDISM; THERAPY; CSF; THYROTOXICOSIS; METHIMAZOLE		UNIV SHEFFIELD, NO GEN HOSP, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	Northern General Hospital; University of Sheffield	PATEL, V (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, DEPT ENDOCRINOL, LONDON EC1A 7BE, ENGLAND.							ALLEN MD, 1983, SURGERY, V94, P969; ARMSTRONG P, 1983, CRITICAL PROBLEMS DI; BARZILAI D, 1966, ISRAEL J MED SCI, V2, P453; BURCH HB, 1993, ENDOCRIN METAB CLIN, V22, P263, DOI 10.1016/S0889-8529(18)30165-8; BURGI H, 1976, J CLIN ENDOCR METAB, V43, P1203; DEBRUIN TWA, 1994, LANCET, V343, P1160; DORIA E, 1989, CHEST, V96, P424, DOI 10.1378/chest.96.2.424; FALOR WH, 1963, SURG GYNECOL OBSTET, V117, P604; FEELY J, 1980, J CLIN ENDOCR METAB, V51, P658, DOI 10.1210/jcem-51-3-658; FRADKIN JE, 1983, MEDICINE, V62, P1; FUKATA S, 1993, LANCET, V342, P1495, DOI 10.1016/0140-6736(93)92980-8; HALL TS, 1988, ANN THORAC SURG, V46, P684, DOI 10.1016/S0003-4975(10)64734-0; HELLMAN R, 1977, NEW ENGL J MED, V297, P671; KATLIC MR, 1985, AM J SURG, V149, P283, DOI 10.1016/S0002-9610(85)80086-6; KATLIC MR, 1985, ANN THORAC SURG, V39, P391, DOI 10.1016/S0003-4975(10)62645-8; KAUFMAN DW, 1988, BRIT MED J, V297, P262; KENNEDY RL, 1989, CLIN CHEM, V35, P1882; Lahey FH, 1931, ANN SURG, V93, P1026, DOI 10.1097/00000658-193105000-00008; LAHEY FH, 1945, SURG CLIN N AM, V25, P609; MARTIN FIR, 1993, AM J MED, V95, P78, DOI 10.1016/0002-9343(93)90235-H; MARTINO E, 1991, J ENDOCRINOL INVEST, V14, P847, DOI 10.1007/BF03347940; OKSTAD S, 1986, J OTOLARYNGOL, V15, P52; PATTON WN, 1992, BRIT J HAEMATOL, V80, P564, DOI 10.1111/j.1365-2141.1992.tb04578.x; PERRILD H, 1983, CLIN ENDOCRINOL, V18, P139, DOI 10.1111/j.1365-2265.1983.tb03196.x; REICHERT LJM, 1989, BRIT MED J, V298, P1547, DOI 10.1136/bmj.298.6687.1547; REINWEIN D, 1993, J CLIN ENDOCR METAB, V76, P1516; ROTI E, 1985, CLIN ENDOCRINOL, V22, P489, DOI 10.1111/j.1365-2265.1985.tb00148.x; RUCHTI C, 1987, AM J CLIN PATHOL, V87, P776, DOI 10.1093/ajcp/87.6.776; Salvatori M, 1993, J Nucl Biol Med, V37, P69; SCHOU M, 1976, ANNU REV PHARMACOL, V16, P231, DOI 10.1146/annurev.pa.16.040176.001311; STROHSCHNEIDER T, 1993, CHIRURG, V64, P751; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TAMAI H, 1993, J CLIN ENDOCR METAB, V77, P1356, DOI 10.1210/jc.77.5.1356; TORANALLERAND CD, 1986, WERNERS THYROID, P7; WILLIAMS ED, 1989, J PATHOL, V159, P135, DOI 10.1002/path.1711590208; WU SY, 1978, J CLIN ENDOCR METAB, V46, P691, DOI 10.1210/jcem-46-4-691; 1970, BRIT MED J, V4, P386; 1993, CURRENT PROBLEMS PHA, V198, P10	38	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	1995	311	7018					1491	1494						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520344				2022-12-28	WOS:A1995TJ04400035
J	DAI, JW; SHEETZ, MP				DAI, JW; SHEETZ, MP			AXON MEMBRANE FLOWS FROM THE GROWTH CONE TO THE CELL BODY	CELL			English	Article							PLASMA-MEMBRANE; LIPID FLOW; MOVEMENTS; TRANSPORT; GLYCOPROTEINS; ENDOCYTOSIS; LOCOMOTION; PROTEINS; NEURONS; FORCE	During the growth of axons, the surface area of the neuron increases dramatically. Membrane addition as well as exchange could contribute to rapid membrane dynamics or flow. Using diffusing latex beads to monitor membrane flow, we find that axonal membrane flows rapidly (7 mu m/min) from growth cone to cell body during axon growth and that flow is inhibited by brefeldin A. To power this flow, there is a membrane tension gradient from growth cone to cell body that could draw the membrane over the axon at that rate. Further, when an artificial flow is induced to the center of the axon by use of laser tweezers, the primary source of the membrane is from the growth cone. We suggest that during neuron growth, there is excess membrane added at the growth cone in chick dorsal root ganglia (DRGs) that undergoes endocytosis at the cell body, thereby creating a flow that can rapidly alter the content of the axon membrane.			DAI, JW (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							BERK DA, 1992, BIOPHYS J, V61, P9, DOI 10.1016/S0006-3495(92)81811-8; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; BRETSCHER MS, 1984, SCIENCE, V224, P681, DOI 10.1126/science.6719108; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; DAI J, 1995, IN PRESS COLD SPRING, V60; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GRIFFIN JW, 1981, J CELL BIOL, V88, P205, DOI 10.1083/jcb.88.1.205; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; HOCHMUTH RM, 1995, IN PRESS BIOPHYS J; ISHIHARA A, 1993, BIOPHYS J, V65, P1754, DOI 10.1016/S0006-3495(93)81231-1; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LEE GM, 1991, P NATL ACAD SCI USA, V88, P6274, DOI 10.1073/pnas.88.14.6274; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; MARTENSON C, 1993, NATURE, V366, P66, DOI 10.1038/366066a0; OKABE S, 1993, J CELL BIOL, V120, P1177, DOI 10.1083/jcb.120.5.1177; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; PFENNINGER KH, 1981, J CELL BIOL, V89, P547, DOI 10.1083/jcb.89.3.547; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SCHNAPP BJ, 1988, CELL MOTIL CYTOSKEL, V10, P47, DOI 10.1002/cm.970100109; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SHEETZ MP, 1990, CELL, V61, P231, DOI 10.1016/0092-8674(90)90804-N; SMITH RS, 1994, J NEUROCHEM, V62, P1698; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; WAUGH RE, 1987, BIOPHYS J, V52, P391, DOI 10.1016/S0006-3495(87)83227-7	34	97	99	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					693	701						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521486				2022-12-28	WOS:A1995TH94800006
J	ANTONINI, A; STRYKER, MP				ANTONINI, A; STRYKER, MP			RAPID REMODELING OF AXONAL ARBORS IN THE VISUAL-CORTEX	SCIENCE			English	Article							BRIEF MONOCULAR DEPRIVATION; UNILATERAL EYE CLOSURE; KITTEN STRIATE CORTEX; SENSITIVE PERIOD; DEPRIVED CATS; REVERSAL; INNERVATION; BICUCULLINE; AMBLYOPIA; RECOVERY	If vision in one eye is blurred or occluded during a critical period in postnatal development, neurons in the visual cortex lose their responses to stimulation through that eye within a few days. Anatomical changes in the nerve terminals that provide input to the visual cortex have previously been observed only after weeks of deprivation, suggesting that synapses become physiologically ineffective before the branches on which they sit are withdrawn. Reconstruction of single geniculocortical axonal arbors in the cat after either brief or prolonged monocular occlusion revealed striking axonal rearrangements in both instances. Rapid withdrawal of the branches of deprived-eye arbors suggests that axonal branches bearing synapses respond quickly to changing patterns of neuronal activity.			ANTONINI, A (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,WM KECK FDN CTR INTEGRAT NEUROSCI,BOX 0444,SAN FRANCISCO,CA 94143, USA.		Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807; Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [IT32 EY07120-01, EY02874, R01 EY002874, T32 EY007120] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002874, T32EY007120, R37EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONINI A, IN PRESS J NEUROSCI; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BURCHFIEL JL, 1981, BRAIN RES, V206, P479, DOI 10.1016/0006-8993(81)90551-5; DUFFY FH, 1976, NATURE, V260, P256, DOI 10.1038/260256a0; FERSTER D, 1978, J COMP NEUROL, V182, P923, DOI 10.1002/cne.901820510; FRIEDLANDER MJ, 1989, J PHYSIOL-LONDON, V416, P183, DOI 10.1113/jphysiol.1989.sp017756; FRIEDLANDER MJ, 1991, J NEUROSCI, V11, P3268; GAREY LJ, 1974, BRAIN RES, V66, P165, DOI 10.1016/0006-8993(74)90086-9; GERFEN CR, 1984, BRAIN RES, V290, P219, DOI 10.1016/0006-8993(84)90940-5; HENDRY SHC, 1988, J NEUROSCI, V8, P1225; HENDRY SHC, 1990, J NEUROSCI, V10, P2438; HENDRY SHC, 1988, NEURON, V1, P701, DOI 10.1016/0896-6273(88)90169-9; Hubel D H, 1976, Cold Spring Harb Symp Quant Biol, V40, P581; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; JONES EG, 1990, J EXP BIOL, V153, P155; MALACH R, 1984, J NEUROPHYSIOL, V51, P538, DOI 10.1152/jn.1984.51.3.538; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MITZDORF U, 1980, J PHYSIOL-LONDON, V304, P203, DOI 10.1113/jphysiol.1980.sp013320; MOVSHON JA, 1977, J NEUROPHYSIOL, V40, P1255, DOI 10.1152/jn.1977.40.6.1255; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; NEUROTRACE AP, 1988, SOC NEUR ABSTR, V14, P550; OLSON CR, 1978, J NEUROPHYSIOL, V41, P65, DOI 10.1152/jn.1978.41.1.65; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; ROSEN KM, 1992, P NATL ACAD SCI USA, V89, P5437, DOI 10.1073/pnas.89.12.5437; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHERMAN SM, 1972, J NEUROPHYSIOL, V35, P532, DOI 10.1152/jn.1972.35.4.532; SPEAR PD, 1980, J NEUROPHYSIOL, V43, P559, DOI 10.1152/jn.1980.43.3.559; TIEMAN SB, 1984, J COMP NEUROL, V222, P166, DOI 10.1002/cne.902220203; VANSLUYTERS RC, 1978, J PHYSIOL-LONDON, V284, P1; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WORLEY PF, 1990, COLD SH Q B, V55, P213, DOI 10.1101/SQB.1990.055.01.023	33	392	398	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1819	1821		10.1126/science.8511592	http://dx.doi.org/10.1126/science.8511592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511592				2022-12-28	WOS:A1993LH20500055
J	CROZAT, A; AMAN, P; MANDAHL, N; RON, D				CROZAT, A; AMAN, P; MANDAHL, N; RON, D			FUSION OF CHOP TO A NOVEL RNA-BINDING PROTEIN IN HUMAN MYXOID LIPOSARCOMA	NATURE			English	Article							SINGLE GENE; EXPRESSION; SEQUENCE; DOMAIN; CELLS	HUMAN myxoid liposarcomas contain a characteristic chromosomal translocation, t(12;16)(q13;p11)1,2, that is associated with a structural rearrangement of the gene encoding CHOP 3, a growth arrest and DNA-damage inducible member of the C/EBP family of transcription factors4,5 residing on 12q13.1 6. Using a CHOP-specific complementary probe and antiserum we report here the presence of an abnormal CHOP transcript and protein in these tumours. Cloning of the translocation-associated CHOP gene product revealed a fusion between CHOP and a gene provisionally named TLS (translocated in liposarcoma). TLS is a novel nuclear RNA-binding protein with extensive sequence similarity to EWS7, the product of a gene commonly translocated in Ewing's sarcoma. In TLS-CHOP the RNA-binding domain of TLS is replaced by the DNA-binding and leucine zipper dimerization domain of CHOP. Targeting of a conserved effector domain of RNA-binding proteins to DNA may play a role in tumour formation.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN	New York University; New York University; Lund University; Skane University Hospital	CROZAT, A (corresponding author), NYU MED CTR,DEPT MED,NEW YORK,NY 10016, USA.			Aman, Pierre/0000-0002-1482-8875; Crozat, Anne/0000-0002-2539-8479; Ron, David/0000-0002-3014-5636				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P271; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, IN PRESS MOL CELL BI; CRETIN C, 1990, PLANT MOL BIOL, V15, P783, DOI 10.1007/BF00016128; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SREEKANTIAIAH S, 1992, CANCER, V69, P2484; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P291, DOI 10.1016/0165-4608(86)90011-7	18	740	761	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					640	644		10.1038/363640a0	http://dx.doi.org/10.1038/363640a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510758				2022-12-28	WOS:A1993LH13900060
J	SOUTHALL, DP; CRONIN, BC; HARTMANN, H; HARRISONSEWELL, C; SAMUELS, MP				SOUTHALL, DP; CRONIN, BC; HARTMANN, H; HARRISONSEWELL, C; SAMUELS, MP			INVASIVE PROCEDURES IN CHILDREN RECEIVING INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article							PAIN				SOUTHALL, DP (corresponding author), N STAFFORDSHIRE HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; HARPIN VA, 1983, ARCH DIS CHILD, V58, P226, DOI 10.1136/adc.58.3.226; McGrath PJ., 1987, PAIN CHILDREN ADOLES; TOHILL J, 1990, LANCET, V336, P569, DOI 10.1016/0140-6736(90)92127-4	5	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1512	1513		10.1136/bmj.306.6891.1512-a	http://dx.doi.org/10.1136/bmj.306.6891.1512-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518680	Green Published, Bronze			2022-12-28	WOS:A1993LF94000026
J	GRUER, L; CAMERON, J; ELLIOTT, L				GRUER, L; CAMERON, J; ELLIOTT, L			BUILDING A CITY WIDE SERVICE FOR EXCHANGING NEEDLES AND SYRINGES	BRITISH MEDICAL JOURNAL			English	Article							DRUG-ABUSERS; INFECTION	How best can injecting drug misusers obtain clean injecting equipment in a city where drug injecting is widespread? An exchange service for needles and syringes throughout Glasgow has been established in health centres and clinics in the evening. Over the past four years seven new exchanges have been opened and over 2700 injecting drug misusers have attended. Attendances rose from under 1000 in 1988 to 28000 in 1992. The exchanges also provide a wide range of other health and social services. Public hostility to the exchanges has abated. During the same period equipment sharing in the city diminished and the observed prevalence of HIV among injecting drug misusers stabilised at around 1%.			GRUER, L (corresponding author), RUCHILL HOSP,CTR HIV & ADDICT RESOURCE,GLASGOW G20 9NB,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				[Anonymous], 1988, AIDS DRUG MISUSE 1; BARDSLEY J, 1990, CAN J PUBLIC HEALTH, V81, P39; DONOGHOE MC, 1991, DRUGLINK, V1, P8; ELLIOTT L, IN PRESS ADDICTION; FOLLETT EAC, 1986, LANCET, V1, P446; FRISCHER M, 1992, INT J STD AIDS, V3, P288, DOI 10.1177/095646249200300412; FRISCHER M, 1991, INT J EPIDEMIOL, V20, P21; FRISCHER M, 1992, ANSWER AIDS NEWS S, V13, P1; GRUER LD, 1991, INT J STD AIDS, V2, P356, DOI 10.1177/095646249100200509; Hart G, 1989, AIDS Care, V1, P125, DOI 10.1080/09540128908260247; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; HAW S, 1991, ANSWER AIDS NEWS S, V31, P1; MCKEGANEY N, 1992, BMJ-BRIT MED J, V305, P801, DOI 10.1136/bmj.305.6857.801; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; SCOTT RN, 1992, BRIT MED J, V304, P1630, DOI 10.1136/bmj.304.6842.1630; SMITSON GB, 1988, BMJ, V286, P1717; Stimson GV, 1988, INJECTING EQUIPMENT; 1992, 1991 92 GREAT GLASGL	18	33	33	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1394	1397		10.1136/bmj.306.6889.1394	http://dx.doi.org/10.1136/bmj.306.6889.1394			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518609	Green Published, Bronze			2022-12-28	WOS:A1993LD82900026
J	KERR, DNS; JONES, SAM; EASMON, CSF				KERR, DNS; JONES, SAM; EASMON, CSF			CONTINUING MEDICAL-EDUCATION - EXPERIENCE AND OPINIONS OF CONSULTANTS	BRITISH MEDICAL JOURNAL			English	Article								The right of consultants to study leave and expenses is not binding on trusts and has been eroded in directly managed units. Complaints led to a survey of consultants in North West Thames region. This showed that most consultants use their own time and money to maintain their knowledge by buying and consulting journals and textbooks, attending local meetings, and using their annual leave for study, but they feel the need for study leave to attend meetings of specialist societies and courses. Leave is usually granted readily but without cover provided by a locum and with a very limited contribution to expenses. To maintain quality of medical care both the right and obligation to take study leave should be contractual.			KERR, DNS (corresponding author), NW THAMES REG HLTH AUTHOR,PUBL HLTH DIRECTORATE,LONDON W2 3QR,ENGLAND.							CALMAN KC, 1992, SPECIALIST MED TRAIN; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; GRANT J, 1992, STUDY FORMAL OPPORTU; 1992, 3RD REPORT; 1991, WORKING PATIENTS POS; 1992, CONTINUING MED ED TR; 1991, UPTAKE COSTS STUDY L; 1991, REPORT CONTINUING ME; 1986, HOSPITAL MED DENTAL; 1991, 1990 91 CVCP AC AUD	10	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1398	1402		10.1136/bmj.306.6889.1398	http://dx.doi.org/10.1136/bmj.306.6889.1398			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518610	Bronze, Green Published			2022-12-28	WOS:A1993LD82900027
J	BURKE, P; CHIVERS, A; CLEMENTS, J; DAWES, M; EASTWOOD, I; EBBS, D; GODLEE, R; HARRINGTON, R; KEARLEY, K; MACLENNAN, N; MANT, D; MURRAY, J; NICHOLS, M; VANOSS, H; STERN, D; STEVENS, R; THURSTON, D; WILSON, R; WOOD, S; AGNEW, K; BARTLETT, M; HODGEMAN, J; LINDSEY, K; TISSIER, J; DOBBIE, W; FOWLER, G; FULLER, A; JONES, L; THOROGOOD, M; YUDKIN, P				BURKE, P; CHIVERS, A; CLEMENTS, J; DAWES, M; EASTWOOD, I; EBBS, D; GODLEE, R; HARRINGTON, R; KEARLEY, K; MACLENNAN, N; MANT, D; MURRAY, J; NICHOLS, M; VANOSS, H; STERN, D; STEVENS, R; THURSTON, D; WILSON, R; WOOD, S; AGNEW, K; BARTLETT, M; HODGEMAN, J; LINDSEY, K; TISSIER, J; DOBBIE, W; FOWLER, G; FULLER, A; JONES, L; THOROGOOD, M; YUDKIN, P			EFFECTIVENESS OF A NICOTINE PATCH IN HELPING PEOPLE STOP SMOKING - RESULTS OF A RANDOMIZED TRIAL IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the effectiveness of 12 weeks' treatment with a 24 hour transdermal nicotine patch in helping heavy smokers to stop smoking; also to assess the value of a specially written support booklet about smoking cessation and patch use compared with a simple advice pamphlet. Design-Double blind placebo controlled randomised trial with a 2 x 2 factorial design. Setting-19 general practices in Oxfordshire. Subjects-1686 heavy smokers aged 25-64 (mean cigarette consumption 24/day; mean duration of smoking 25 years). Main outcome measure-Sustained cessation for the last four weeks of the 12 week treatment period, confirmed by saliva cotinine estimation (226/262 cases; 86.3%) or expired carbon monoxide concentration (36/262; 13.7%). Patients lost to follow up (155/1686; 9%) were assumed to have continued to smoke. Results-Cessation was confirmed in 163 patients (19.4%) using the nicotine patch and '' patients (11.7%) using the placebo patch (difference 7.6% (95% confidence interval 4.2% to 11.1%); p < 0.0001). There was no significant advantage in using the more detailed written support material. The most important adverse effect of the patch was local skin irritation, which occurred in 15.8% (133/842) and 5.1% (43/844) of patients using the nicotine and placebo patches respectively, was graded as severe in 4.8% (40) and 1.1% (nine), and was stated as a reason for withdrawal from the trial in 9.5% (80) and 2.8% (24). Conclusion-Nicotine patches are effective in a general practice setting with nursing support, but the extent to which this effect is sustained cannot be assessed until the results of longer term follow up are known.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,ICRF,GEN PRACTICE RES GRP,OXFORD,ENGLAND	University of Oxford			Mant, David CA/C-7763-2009	Dawes, Martin/0000-0003-3624-2477				ABELIN T, 1989, LANCET, V1, P7; Abelin T, 1991, SMOKING CARDIOVASCUL, P35; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; JAMROZIK K, 1984, BRIT MED J, V289, P794, DOI 10.1136/bmj.289.6448.794; JARVIS MJ, 1980, BRIT MED J, V281, P484, DOI 10.1136/bmj.281.6238.484; JARVIS MJ, 1990, WHY CHILDREN SOMKE, P5; LAM W, 1985, LANCET, V1, P27; RUSSELL MAH, 1974, J ROY STAT SOC A STA, V137, P313, DOI 10.2307/2344953; STEELE C, 1990, SMOKERS QUIT PLAN; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; Tonnesen P, 1992, J SMOKING RELATED DI, V3, P241; 1991, JAMA-J AM MED ASSOC, V266, P3133	12	85	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1304	1308						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518571				2022-12-28	WOS:A1993LC72200022
J	Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL; Caro, JF				Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL; Caro, JF			Serum immunoreactive leptin concentrations in normal-weight and obese humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Leptin, the product of the ob gene, is a hormone secreted by adipocytes, Animals with mutations in the ob gene are obese and lose weight when given leptin, but little is known about the physiologic actions of leptin in humans. Methods. Using a newly developed radioimmunoassay, we measured serum concentrations of leptin in 136 normal-weight subjects and 139 obese subjects (body-mass index, greater than or equal to 27.3 for men and greater than or equal to 27.8 for women; the body-mass index was defined as the weight in kilograms divided by the square of the height in meters). The measurements were repeated in seven obese subjects after weight loss and during maintenance of the lower weight. The ob messenger RNA (mRNA) content of adipocytes was determined in 27 normal-weight and 27 obese subjects. Results. The mean (+/-SD) serum leptin concentrations were 31.3+/-24.1 ng per milliliter in the obese subjects and 7.5+/-9.3 ng per milliliter in the normal-weight subjects (P < 0.001). There was a strong positive correlation between serum leptin concentrations and the percentage of body fat (r = 0.85, P < 0.001). The ob mRNA content of adipocytes was about twice as high in the obese subjects as in the normal-weight subjects (P = 0.005) and was correlated with the percentage of body fat (r = 0.68, P < 0.001) in the 54 subjects in whom it was measured. In the seven obese subjects studied after weight loss, both serum leptin concentrations and ob mRNA content of adipocytes declined, but these measures increased again during the maintenance of the lower weight. Conclusions. Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production. (C) 1996, Massachusetts Medical Society.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT CLIN PHARMACOL,BIOSTAT SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT SURG,PHILADELPHIA,PA 19107; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Jefferson University; Jefferson University; Jefferson University; Eli Lilly	Considine, RV (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV ENDOCRINOL & METAB,1025 WALNUT ST,813 COLL BLDG,PHILADELPHIA,PA 19107, USA.		sheng, jian/E-9474-2012		NIDDK NIH HHS [R01 DK45592] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045592] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; JEBB SA, 1993, INT J OBESITY, V17, P611; KOLACZYNSKI JW, 1994, INT J OBESITY, V18, P161; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NIH Technology Assessment Conference Panel, 1992, ANN INTERN MED, V116, P942; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	5081	5248	4	283	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					292	295		10.1056/NEJM199602013340503	http://dx.doi.org/10.1056/NEJM199602013340503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532024	Bronze			2022-12-28	WOS:A1996TV69500003
J	Ryan, CJ; Kaye, M				Ryan, CJ; Kaye, M			Euthanasia in Australia - The Northern Territory rights of the terminally ill act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV SYDNEY,SYDNEY,NSW 2000,AUSTRALIA	University of Sydney	Ryan, CJ (corresponding author), WESTMEAD HOSP,SYDNEY,NSW 2145,AUSTRALIA.		Ryan, Christopher/B-4095-2010	Kaye, Miranda/0000-0003-4484-1904; Ryan, Christopher/0000-0003-2158-9427				BATTIN MP, 1994, LEAST WORST DEATH, P123; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; GLOVER J, 1988, CAUSING DEATH SAVING, P188; Griffiths John, 1994, Med Law Int, V1, P137; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; OGILVIE AD, 1994, BRIT MED J, V309, P492, DOI 10.1136/bmj.309.6953.492; Ryan CJ, 1995, AUST NZ J PSYCHIAT, V29, P580, DOI 10.3109/00048679509064970; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1995, NO TERRITORY RIGHTS	11	46	46	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					326	328		10.1056/NEJM199602013340512	http://dx.doi.org/10.1056/NEJM199602013340512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532033				2022-12-28	WOS:A1996TV69500012
J	Slotnick, RN; Abuhamad, AZ				Slotnick, RN; Abuhamad, AZ			Prognostic implications of fetal echogenic bowel	LANCET			English	Article							DENSITOMETRY; DISEASE	Background An increased frequency of hyperechogenic bowel on ultrasound has been reported in fetuses with cystic fibrosis (CF) and trisomy-21. However, the diagnostic application of this observation has been hampered by the absence of a means of measuring echogenicity. Methods We devised an ultrasonic grading system in which echogenicity was quantified by linear gain reduction and comparison with fetal iliac crest. From 7400 second-trimester ultrasound referrals, 145 patients were identified as having a fetus with abnormally echogenic bowel. They were offered genetic counselling, parental and (if appropriate) CF carrier testing, and amniocentesis for karyotype and CF status if parents were informative. Follow-up was to 4 months of age. Findings Of 40 fetuses with mild increase in bowel sonodensity (grade 1), none had CF or aneuploidy. Of 81 patients identified with a moderate increase (grade 2), 2 had trisomy 21 and 2 had CF. And of 24 pregnancies with a pronounced increase (grade 3), 5 had CF and 6 had trisomy-21. Interpretation Parental CF carrier testing and amniocentesis to identify aneuploidy or fetal CF status has a high positive ascertainment rate in fetuses with echogenic bowel grades 2 and 3.			Slotnick, RN (corresponding author), EASTERN VIRGINIA MED SCH,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,NORFOLK,VA 23507, USA.							BEAUDET AL, 1990, NEW ENGL J MED, V323, P70; BLICKSTEIN I, 1994, J ULTRAS MED, V13, P675, DOI 10.7863/jum.1994.13.9.675; BLICKSTEIN I, 1993, J ULTRAS MED, V12, P567; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CASPI B, 1992, GYNECOL OBSTET INVES, V33, P26, DOI 10.1159/000294842; CASPI B, 1988, PRENATAL DIAG, V8, P379, DOI 10.1002/pd.1970080508; CHALUBINSKI K, 1992, PRENATAL DIAG, V12, P631, DOI 10.1002/pd.1970120802; DICKE JM, 1992, OBSTET GYNECOL, V80, P778; FOROUZAN I, 1992, OBSTET GYNECOL, V80, P535; NYBERG DA, 1990, OBSTET GYNECOL, V76, P370; NYBERG DA, 1993, RADIOLOGY, V188, P527, DOI 10.1148/radiology.188.2.8327709; PLATT JF, 1988, AM J ROENTGENOL, V151, P317, DOI 10.2214/ajr.151.2.317; SCIOSCIA AL, 1992, AM J OBSTET GYNECOL, V167, P889, DOI 10.1016/S0002-9378(12)80007-X; WEINER CP, 1993, AM J OBSTET GYNECOL, V68, P6	14	94	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					85	87		10.1016/S0140-6736(96)90210-X	http://dx.doi.org/10.1016/S0140-6736(96)90210-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538346				2022-12-28	WOS:A1996TP28100009
J	Enomoto, N; Sakuma, I; Asahina, Y; Kurosaki, M; Murakami, T; Yamamoto, C; Ogura, Y; Izumi, N; Marumo, F; Sato, C				Enomoto, N; Sakuma, I; Asahina, Y; Kurosaki, M; Murakami, T; Yamamoto, C; Ogura, Y; Izumi, N; Marumo, F; Sato, C			Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NON-B HEPATITIS; NON-A; MOLECULAR-CLONING; GENOME; RNA; GENOTYPES; THERAPY; PRIMERS; SERUM	Background. A region associated with sensitivity to interferon has been identified in the nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) genotype Ib. The region spans amino acid residues 2209 to 2248 (NS5A2209-2248) Of HCV-J, a strain of HCV-lb whose complete genomic sequence has been identified. We examined whether the NS5A2209-2248 sequence present before therapy could be used as a predictor of the response to interferon therapy in patients with chronic HCV-lb infection. Methods. We retrospectively analyzed 84 patients with chronic HCV-lb infection who had received interferon alfa (total dose, 516 million to 880 million units) for six months. Pretreatment serum samples were analyzed. The amino acid sequence of NS5A2209-2248 was determined by direct sequencing of the HCV genome amplified by the polymerase chain reaction (PCR) and was compared with the established sequence for HCV-J. Results. A complete response, as evidenced by the absence of HCV RNA in serum on nested reverse-transcription PCR for six months after therapy, did not occur in any of the 30 patients whose NS5A2209-2248 sequences were identical to that of HCV-J (wild type). Five of 38 patients (13 percent) with 1 to 3 changes in NS5A2209-2248 (intermediate type) had complete responses, as did all 16 patients with 4 to II amino acid substitutions (mutant type), indicating that the mutant type was significantly associated with a complete response (P<0.001). Although baseline serum HCV RNA levels, as measured by a branched-chain DNA assay, were lower in patients with the mutant type of NS5A2209-2248 than in those with the other types (P<0.001), multivariate analyses revealed that the number of amino acid substitutions in NS5A2209-2248 was the only variable associated with an independent effect on the outcome of interferon therapy (odds ratio, 5.3; 95 percent confidence interval, 1.6 to 18; P=0.007). Conclusions. In patients with chronic HCV-lb infection, there is a substantial correlation between responses to interferon and mutations in the NS5A gene.	TOKYO MED & DENT UNIV,FAC MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC MED,DIV HLTH SCI,TOKYO 113,JAPAN; MUSASHIMO RED CROSS HOSP,DEPT INTERNAL MED,TOKYO,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)			Yang, Chen/G-1379-2010					CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DAVIS GL, 1990, J HEPATOL, V11, pS72, DOI 10.1016/0168-8278(90)90168-Q; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; ENOMOTO N, 1994, J GEN VIROL, V75, P1361, DOI 10.1099/0022-1317-75-6-1361; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; HINO K, 1994, J MED VIROL, V42, P299, DOI 10.1002/jmv.1890420318; HOOFNAGLE JH, 1994, ADV INTERNAL MED, V39, P241; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; MITA E, 1994, DIGEST DIS SCI, V39, P977, DOI 10.1007/BF02087547; NAKAO T, 1991, J GEN VIROL, V72, P2105, DOI 10.1099/0022-1317-72-9-2105; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; SAKAMOTO N, 1994, J HEPATOL, V20, P593, DOI 10.1016/S0168-8278(05)80345-9; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1002/hep.1840210243; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TAKADA N, 1992, J HEPATOL, V14, P435; TANAKA T, 1992, VIRUS RES, V23, P39; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; VANDERPOEL CL, 1994, LANCET, V344, P1475, DOI 10.1016/S0140-6736(94)90293-3; VANDOORN LJ, 1994, J MED VIROL, V43, P345, DOI 10.1002/jmv.1890430406; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	34	885	921	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					77	81		10.1056/NEJM199601113340203	http://dx.doi.org/10.1056/NEJM199601113340203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531962				2022-12-28	WOS:A1996TP36300003
J	Baxt, WG; Skora, J				Baxt, WG; Skora, J			Prospective validation of artificial neural network trained to identify acute myocardial infarction	LANCET			English	Article							CLINICAL-PREDICTION RULES; CHEST PAIN; STREPTOCOCCAL PHARYNGITIS; DIAGNOSIS; EMERGENCY	Background Artificial neural networks apply non-linear statistics to pattern recognition problems. One such problem is acute myocardial infarction (AMI), a diagnosis which, in a patient presenting as an emergency, can be difficult to confirm. We report here a prospective comparison of the diagnostic accuracy of a network and that of physicians, on the same patients with suspected AMI. Methods Emergency department physicians who evaluated 1070 patients 18 years or older presenting to the emergency department of a teaching hospital in California, USA with anterior chest pain indicated whether they thought these patients had sustained a myocardial infarction. The network analysed the patient data collected by the physicians during their evaluations and also generated a diagnosis. Findings The physicians had a diagnostic sensitivity and specificity for myocardial infarction of 73.3% (95% confidence interval 63.3-83.3%) and 81.1% (78.7-83.5%), respectively, while the network had a diagnostic sensitivity and specificity of 96.0% (91.2-100%) and 96.0% (94.8-97.2%), respectively. Only 7% of patients had had an AMI, a low frequency but typical for anterior chest pain. Interpretation The application of non-linear neural computational analysis via an artificial neural network to the clinical diagnosis of myocardial infarction appears to have significant potential.	UNIV CALIF SAN DIEGO, DEPT EMERGENCY MED, MED CTR, SAN DIEGO, CA USA	University of California System; University of California San Diego								Bat WG, 1990, NEURAL COMPUT, V2, P480, DOI 10.1162/neco.1990.2.4.480; BAXT WG, 1995, NEURAL COMPUT, V7, P624, DOI 10.1162/neco.1995.7.3.624; BAXT WG, 1994, MED DECIS MAKING, V14, P217, DOI 10.1177/0272989X9401400303; BAXT WG, 1992, NEURAL COMPUT, V4, P772, DOI 10.1162/neco.1992.4.5.772; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; Baxt WG, 1993, NEURAL COMPUT APPL, V1, P176, DOI [10.1007/BF01414944, DOI 10.1007/BF01414944]; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; BOUNDS DG, 1990, NEURAL NETWORKS, V3, P583, DOI 10.1016/0893-6080(90)90008-9; BRANNEN AL, 1989, ARCH INTERN MED, V149, P1083, DOI 10.1001/archinte.149.5.1083; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; EBERHART RC, 1991, 4TH P ANN IEEE S COM, P298; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HARRISON RF, 1991, P INT JOINT C NEURAL, V1, P1; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; McClelland J. L., 1988, EXPLORATIONS PARALLE, P121; MULSANT GH, 12TH P ANN S COMP AP, P245; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; SEBALD AV, 1989, IMAGES 21ST CENTURY, V66, P2034; SMITH JW, 12TH P ANN S COMP AP, P261; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEINGARTEN SR, 1989, AM J MED, V87, P494, DOI 10.1016/S0002-9343(89)80603-5; White H., 1989, AI EXPERT, V4, P48; WIGTON RS, 1986, ARCH INTERN MED, V146, P81, DOI 10.1001/archinte.146.1.81; Yoon Y. O., 1989, J NEURAL NETWORK SUM, P43; YOUNG MJ, 1987, ARCH INTERN MED, V147, P1219, DOI 10.1001/archinte.147.7.1219	28	163	165	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					12	15		10.1016/S0140-6736(96)91555-X	http://dx.doi.org/10.1016/S0140-6736(96)91555-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531540	hybrid			2022-12-28	WOS:A1996TN76200010
J	Zinner, E				Zinner, E			Stardust in the laboratory	SCIENCE			English	Editorial Material							INTERSTELLAR GRAINS; METEORITES; GRAPHITE		WASHINGTON UNIV,DEPT PHYS,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT EARTH & PLANETARY SCI,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)	Zinner, E (corresponding author), WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,ST LOUIS,MO 63130, USA.							ALEXANDER CMO, 1993, GEOCHIM COSMOCHIM AC, V57, P2869, DOI 10.1016/0016-7037(93)90395-D; AMARI S, 1990, NATURE, V345, P238, DOI 10.1038/345238a0; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; BERNATOWICZ T, UNPUB; BOOTHROYD AI, 1994, ASTROPHYS J, V430, pL77, DOI 10.1086/187442; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; CAMERON AGW, 1995, ASTROPHYS J, V447, pL53, DOI 10.1086/309554; CAMERON AGW, 1957, 1CRL41 AT EN CAN REP; EBISUZAKI T, 1989, ASTROPHYS J, V344, pL65, DOI 10.1086/185532; GALLINO R, 1994, ASTROPHYS J, V430, P858, DOI 10.1086/174457; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; NITTLER L, 1995, NUCLEI COSMOS, V3, P585; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; NITTLER LR, 1995, ASTROPHYS J, V453, pL25, DOI 10.1086/309743; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; SRINIVASAN G, 1994, ASTROPHYS J, V431, pL67, DOI 10.1086/187474; WASSERBURG GJ, 1995, ASTROPHYS J, V440, pL101, DOI 10.1086/187771; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; ZINNER E, 1995, LUNAR PLANET SCI, V26, P1561; ZINNER E, 1995, NUCLEI COSMOS, V3, P567	24	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					41	42		10.1126/science.271.5245.41	http://dx.doi.org/10.1126/science.271.5245.41			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539598				2022-12-28	WOS:A1996TP02200034
J	Hunt, JF; Weaver, AJ; Landry, SJ; Gierasch, L; Deisenhofer, J				Hunt, JF; Weaver, AJ; Landry, SJ; Gierasch, L; Deisenhofer, J			The crystal structure of the GroES co-chaperonin at 2.8 angstrom resolution	NATURE			English	Article							PROTEIN STRUCTURES; SURFACE; COOPERATIVITY; HYDROLYSIS; INTERFACES; BINDING; CYCLE	The GroES heptamer forms a dome, approximately 75 Angstrom in diameter and 30 Angstrom high, with an 8 Angstrom orifice in the centre of its roof. The 'mobile loop' segment, previously identified as a GroEL binding determinant, is disordered in the crystal structure in six subunits; the single well-ordered copy extends from the bottom outer rim of the GroES dome, suggesting that the cavity within the dome is continuous with the polypeptide binding chamber of GroEL in the chaperonin complex.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hunt, JF (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.		Landry, Samuel/AAK-5778-2020; Gierasch, Lila M/D-1494-2009	Landry, Samuel/0000-0002-4082-0543; 				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Drenth J, 1994, PRINCIPLES PROTEIN X; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1994, CURR BIOL, V2, P1125; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LORIMER GH, 1994, STRUCTURE, V2, P1125, DOI 10.1016/S0969-2126(94)00114-6; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MERNITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Seale JW, 1995, J BIOL CHEM, V270, P30268, DOI 10.1074/jbc.270.51.30268; STEIGERMANN W, 1991, INT UNION CRYSTALLOG, V5, P115; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; ZONDLO J, 1995, BIOCHEMISTRY-US, V34, P10334, DOI 10.1021/bi00033a003	53	388	394	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					37	45		10.1038/379037a0	http://dx.doi.org/10.1038/379037a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538739				2022-12-28	WOS:A1996TN21600047
J	BUSCIGLIO, J; YANKNER, BA				BUSCIGLIO, J; YANKNER, BA			APOPTOSIS AND INCREASED GENERATION OF REACTIVE OXYGEN SPECIES IN DOWNS-SYNDROME NEURONS IN-VITRO	NATURE			English	Article							ALZHEIMER-DISEASE; CEREBRAL-CORTEX; HUMAN-FETUS; CELLS; GOLGI; DEATH; BRAIN	DOWN'S syndrome (DS) or trisomy 21 is the most common genetic cause of mental retardation(1). Development of the DS brain is associated with decreased neuronal number and abnormal neuronal differentiation(2-7), and adults with DS develop Alzheimer's disease(8,9). The cause of the neurodegenerative process in DS is unknown. Here we report that cortical neurons from fetal DS and age-matched normal brain differentiate normally in culture, but DS neurons subsequently degenerate and undergo apoptosis whereas normal neurons remain viable. Degeneration of DS neurons is prevented by treatment with free-radical scavengers or catalase. Furthermore, DS neurons exhibit a three- to fourfold increase in intracellular reactive oxygen species and elevated levels of lipid peroxidation that precede neuronal death. These results suggest that DS neurons have a defect in the metabolism of reactive oxygen species that causes neuronal apoptosis. This defect may contribute to mental retardation early in life and predispose to Alzheimer's disease in adults.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital								BASS DA, 1983, J IMMUNOL, V130, P1910; BECKER L, 1991, PROG CLIN BIOL RES, V373, P133; BROOKSBANK BWL, 1984, DEV BRAIN RES, V16, P37, DOI 10.1016/0165-3806(84)90060-9; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSCIGLIO J, 1993, J NEUROCHEM, V61, P1565, DOI 10.1111/j.1471-4159.1993.tb13658.x; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; COLON EJ, 1972, NEUROPADIATRIE, V3, P362, DOI 10.1055/s-0028-1091775; COYLE JT, 1986, BRAIN RES BULL, V16, P773, DOI 10.1016/0361-9230(86)90074-2; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KEDZIORA J, 1988, FREE RADICAL BIO MED, V4, P317, DOI 10.1016/0891-5849(88)90052-4; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; LAI F, 1989, ARCH NEUROL-CHICAGO, V46, P849, DOI 10.1001/archneur.1989.00520440031017; MANN DMA, 1988, MECH AGEING DEV, V43, P99, DOI 10.1016/0047-6374(88)90041-3; MARINPAD.M, 1972, BRAIN RES, V44, P625, DOI 10.1016/0006-8993(72)90324-1; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; PETIT TL, 1984, EXP NEUROL, V83, P13, DOI 10.1016/0014-4886(84)90041-4; ROSS MH, 1984, NEUROLOGY, V34, P909, DOI 10.1212/WNL.34.7.909; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; TAKASHIMA S, 1981, BRAIN RES, V225, P1, DOI 10.1016/0006-8993(81)90314-0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; [No title captured]	26	610	623	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					776	779		10.1038/378776a0	http://dx.doi.org/10.1038/378776a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524410				2022-12-28	WOS:A1995TL41900025
J	WAGNER, J; LERNER, RA; BARBAS, CF				WAGNER, J; LERNER, RA; BARBAS, CF			EFFICIENT ALDOLASE CATALYTIC ANTIBODIES THAT USE THE ENAMINE MECHANISM OF NATURAL ENZYMES	SCIENCE			English	Article							LEWIS ACID; DEOXYRIBOSE-5-PHOSPHATE ALDOLASE; ACYCLIC STEREOSELECTION; CHIRAL ALDEHYDES; CONDENSATION; ADDITIONS	Antibodies that catalyze the aldol reaction, a basic carbon-carbon bond-forming reaction, have been generated. The mechanism for antibody catalysis of this reaction mimics that used by natural class I aldolase enzymes. Immunization with a reactive compound covalently trapped a Lys residue in the binding pocket of the antibody by formation of a stable vinylogous amide. The reaction mechanism for the formation of the covalent antibody-hapten complex was recruited to catalyze the aldol reaction. The antibodies use the epsilon-amino group of Lys to form an enamine with ketone substrates and use this enamine as a nascent carbon nucleophile to attack the second substrate, an aldehyde, to form a new carbon-carbon bond. The antibodies control the diastereofacial selectivity of the reaction in both Cram-Felkin and anti-Cram-Felkin directions.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NCI NIH HHS [CA27489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACH T, 1994, ANGEW CHEM INT EDIT, V33, P417, DOI 10.1002/anie.199404171; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1990, J AM CHEM SOC, V112, P2013, DOI 10.1021/ja00161a064; Bednarski M. D., 1991, COMPREHENSIVE ORGANI, V2, P455; CARREIRA EM, 1995, J AM CHEM SOC, V117, P3649, DOI 10.1021/ja00117a049; CHEN LR, 1992, J AM CHEM SOC, V114, P741, DOI 10.1021/ja00028a050; CHEREST M, 1968, TETRAHEDRON LETT, P2199; CRAM DJ, 1952, J AM CHEM SOC, V74, P5828, DOI 10.1021/ja01143a007; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; EVANS DA, 1988, SCIENCE, V240, P420, DOI 10.1126/science.3358127; EVANS DA, 1982, TOP STEREOCHEM, V13, P1, DOI DOI 10.1002/9780470147221.CHL; FURUTA K, 1991, J AM CHEM SOC, V113, P1041, DOI 10.1021/ja00003a047; GIJSEN HJM, 1995, J AM CHEM SOC, V117, P2947, DOI 10.1021/ja00115a038; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; Heathcock C. H., 1990, ALDRICHIM ACTA, V23, P99; HEATHCOCK CH, 1983, J AM CHEM SOC, V105, P1667, DOI 10.1021/ja00344a050; HEATHCOCK CH, 1981, SCIENCE, V214, P395, DOI 10.1126/science.214.4519.395; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JEFREY T, 1984, J CHEM SOC CHEM COMM, P1287; KOBAYASHI S, 1993, TETRAHEDRON, V49, P1761, DOI 10.1016/S0040-4020(01)80533-0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LODGE EP, 1987, J AM CHEM SOC, V109, P3353, DOI 10.1021/ja00245a027; MASAMUNE S, 1985, ANGEW CHEM INT EDIT, V24, P1, DOI 10.1002/anie.198500013; MORIYASU M, 1986, J CHEM SOC PERK T 2, P515, DOI 10.1039/p29860000515; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PATERSON I, 1992, PURE APPL CHEM, V64, P1821, DOI 10.1351/pac199264121821; PRETSCH E, 1989, TABLES SPECTRAL DATA, pU20; REYMOND JL, 1995, TETRAHEDRON LETT, V36, P2575, DOI 10.1016/0040-4039(95)00343-B; RUTTER WJ, 1964, FED PROC, V23, P1248; TAGAKI W, 1968, BIOCHEMISTRY-US, V7, P905, DOI 10.1021/bi00843a004; Trost B. M., 1993, COMPREHENSIVE ORGANI, V2, p[133, 181], DOI DOI 10.1016/B978-0-08-052349-1.00027-5; WIRSCHING P, IN PRESS SCIENCE; WONG CH, 1995, J AM CHEM SOC, V117, P3333, DOI 10.1021/ja00117a003; WONG CH, 1994, ENZYMES SYNTHETIC OR; ZIMMERMAN HE, 1957, J AM CHEM SOC, V79, P1920, DOI 10.1021/ja01565a041; [No title captured]	39	392	405	0	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1797	1800		10.1126/science.270.5243.1797	http://dx.doi.org/10.1126/science.270.5243.1797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	TK476	8525368				2022-12-28	WOS:A1995TK47600038
J	PALLEN, M				PALLEN, M			GUIDE TO THE INTERNET .2. ELECTRONIC MAIL	BRITISH MEDICAL JOURNAL			English	Article								Electronic mail (email) has many advantages over other forms of communication: it is easy to use, free of charge, fast, and delivers information in a digital format. As a text only medium, email is usually less formal in style than conventional correspondence and may contain acronyms and other features, such as smileys, that are peculiar to the Internet. Email client programs that run on your own microcomputer render email powerful and easy to use. With suitable encoding methods, email can be used to send any kind of computer file, including pictures, sounds, programs, and movies. Numerous biomedical electronic mailing lists and other Internet services are accessible by email.			PALLEN, M (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED MICROBIOL,LONDON EC1A 7BE,ENGLAND.		Pallen, Mark J./E-7619-2011	Pallen, Mark/0000-0003-1807-3657				Angell D., 1994, ELEMENTS E MAIL STYL; FRIDSMA DB, 1994, P ANN S COMPUT APPL, V18, P15; LETTERIE GS, 1994, OBSTET GYNECOL, V84, P137; Lyness A L, 1992, J Nurs Educ, V31, P331; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; SANDERSON DW, 1994, SMILEYS; SANDS DZ, 1993, P ANN S COMPUT APPL, V17, P306; Singarella T, 1993, J Med Syst, V17, P69, DOI 10.1007/BF00996784; SPROULL L, 1995, SCI AM, V6, P128; STAGGERS N, 1989, J NURS ADMIN, V19, P31	10	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1487	1490		10.1136/bmj.311.7018.1487	http://dx.doi.org/10.1136/bmj.311.7018.1487			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520343	Green Published			2022-12-28	WOS:A1995TJ04400034
J	WU, CY; KEIVENS, VM; OTOOLE, TE; MCDONALD, JA; GINSBERG, MH				WU, CY; KEIVENS, VM; OTOOLE, TE; MCDONALD, JA; GINSBERG, MH			INTEGRIN ACTIVATION AND CYTOSKELETAL INTERACTION ARE ESSENTIAL FOR THE ASSEMBLY OF A FIBRONECTIN MATRIX	CELL			English	Article							STIMULATED HUMAN-PLATELETS; IIB-IIIA COMPLEX; MONOCLONAL-ANTIBODIES; PLASMA FIBRONECTIN; CYTOPLASMIC DOMAIN; CELL-ADHESION; GPIIB-IIIA; EXTRACELLULAR-MATRIX; FIBRINOGEN RECEPTOR; AFFINITY MODULATION	Fibronectin (Fn) matrices are vital to vertebrate development and wound healing and modulate tumorigenesis. We used a recombinant Fn-binding integrin, alpha(IIb)beta(3), to define rules for integrin-initiated Fn matrix formation. We report the following. First, multiple Fn-binding integrins can support matrix assembly; their activation state controls fibrillogenesis. Second, Fn binding to cells expressing an activated integrin is necessary but not sufficient for matrix assembly. Additional ''postoccupancy'' events involving the integrin beta, but not the alpha subunit, cytoplasmic domain are needed. Third, these postoccupancy events require an intact actin cytoskeleton. We propose a model for integrin involvement in Fn fibrillogenesis that reconciles previous paradoxes and suggests novel approaches to the therapeutic control of Fn matrix assembly.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	WU, CY (corresponding author), MAYO CLIN, DEPT BIOCHEM & MOLEC BIOL, 13400 E SHEA BLVD, SCOTTSDALE, AZ 85259 USA.		O'Toole, Timothy/I-4172-2013					AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALI IU, 1978, BIOCHIM BIOPHYS ACTA, V510, P140, DOI 10.1016/0005-2736(78)90136-0; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; AOTA S, 1994, J BIOL CHEM, V269, P24756; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BOUCAUT J-C, 1990, International Journal of Developmental Biology, V34, P139; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CLARK RAF, 1985, PLASMA FIBRONECTIN S, P197; CRITCHLEY DR, 1979, NATURE, V280, P498, DOI 10.1038/280498a0; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes R O, 1978, Ann N Y Acad Sci, V312, P317, DOI 10.1111/j.1749-6632.1978.tb16811.x; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KESKIOJA J, 1976, FEBS LETT, V71, P325, DOI 10.1016/0014-5793(76)80962-3; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WENNERBERG K, 1995, IN PRESS J CELL BIOL; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WOODS VL, 1984, BLOOD, V63, P368; WU CY, 1995, J CELL SCI, V108, P2511; WU CY, 1993, J BIOL CHEM, V268, P21883; YANG JT, 1993, DEVELOPMENT, V119, P1093; YIANNE J, 1993, J CELL BIOL, V122, P223; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447	72	304	311	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					715	724		10.1016/0092-8674(95)90184-1	http://dx.doi.org/10.1016/0092-8674(95)90184-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521488	Bronze			2022-12-28	WOS:A1995TH94800008
J	TSUJII, M; DUBOIS, RN				TSUJII, M; DUBOIS, RN			ALTERATIONS IN CELLULAR ADHESION AND APOPTOSIS IN EPITHELIAL-CELLS OVEREXPRESSING PROSTAGLANDIN-ENDOPEROXIDE-SYNTHASE-2	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUG; FAMILIAL ADENOMATOUS POLYPOSIS; E-CADHERIN EXPRESSION; COLON CARCINOGENESIS; RECTAL ADENOMAS; SODIUM-BUTYRATE; REDUCED RISK; ASPIRIN USE; CANCER; SULINDAC	Prostaglandin endoperoxide synthase 2, also referred to as cyclooxygenase 2 (COX-2), is a key enzyme in the conversion of arachidonic acid to prostaglandins and other eicosanoids. Rat intestinal epithelial (RIE) cells were permanently transfected with a COX-2 expression vector oriented in the sense (RIE-S) or antisense (RIE-AS) direction. The RIE-S cells expressed elevated COX-2 protein levels and demonstrated increased adhesion to extracellular matrix (ECM) proteins. E-cadherin was undetectable in RIE-S cells, but was elevated in parental RIE (RIE-P) and RIE-AS cells. RIE-S cells were resistant to butyrate-induced apoptosis, had elevated BCL2 protein expression, and reduced transforming growth factor beta 2 receptor levels. The phenotypic changes involving both increased adhesion to ECM and inhibition of apoptosis were reversed by sulindac sulfide (a COX inhibitor). These studies demonstrate that overexpression of COX-2 leads to phenotypic changes in intestinal epithelial cells that could enhance their tumorigenic potential.	VANDERBILT UNIV,MED CTR,VET AFFAIRS MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	TSUJII, M (corresponding author), VANDERBILT UNIV,MED CTR,VET AFFAIRS MED CTR,DEPT MED,NASHVILLE,TN 37232, USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47297-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BRONSTEIN JC, 1993, PROSTAGLANDINS, V46, P387, DOI 10.1016/0090-6980(93)90075-I; CARROLL KM, 1988, AM J PHYSIOL, V254, pG355, DOI 10.1152/ajpgi.1988.254.3.G355; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1047, DOI 10.1152/ajpgi.1992.262.6.G1047; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FU JY, 1990, J BIOL CHEM, V265, P16737; GENG Y, 1995, J IMMUNOL, V155, P796; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAGUE A, 1994, ONCOGENE, V9, P3367; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HODIN RA, 1994, AM J PHYSIOL, V266, pG83, DOI 10.1152/ajpgi.1994.266.1.G83; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KARGMAN SL, 1995, CANCER RES, V55, P2556; KLEIN T, 1994, BIOCHEM PHARMACOL, V48, P1605, DOI 10.1016/0006-2952(94)90205-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MARNETT LJ, 1992, CANCER RES, V52, P5575; MAYER B, 1993, CANCER RES, V53, P1690; MEADE EA, 1993, J BIOL CHEM, V268, P6610; OKA H, 1993, CANCER RES, V53, P1696; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1992, CARCINOGENESIS, V13, P1019, DOI 10.1093/carcin/13.6.1019; REDDY BS, 1987, CANCER RES, V47, P5340; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WINDE G, 1993, INT J COLORECTAL DIS, V8, P13, DOI 10.1007/BF00341270	54	2031	2155	0	63	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					493	501		10.1016/0092-8674(95)90127-2	http://dx.doi.org/10.1016/0092-8674(95)90127-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521479	Bronze			2022-12-28	WOS:A1995TC97700019
J	HE, ZG; BRINTON, BT; GREENBLATT, J; HASSELL, JA; INGLES, CJ				HE, ZG; BRINTON, BT; GREENBLATT, J; HASSELL, JA; INGLES, CJ			THE TRANSACTIVATOR PROTEIN-VP16 AND PROTEIN-GAL4 BIND REPLICATION FACTOR-A	CELL			English	Article							DNA-POLYMERASE-ALPHA; HERPES-SIMPLEX VIRUS; TRANSCRIPTIONAL ACTIVATION DOMAIN; ORIGIN AUXILIARY SEQUENCES; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; T-ANTIGEN; EUKARYOTIC TRANSCRIPTION; INVITRO REPLICATION; ESCHERICHIA-COLI	Many transcription factors can activate the initiation of DNA replication. We have used affinity chromatography to show that the acidic activation domains of the transcription factors VP16, GAL4, and p53 each bind selectively to human and yeast replication factor A (RPA). The binding is direct and to the largest subunit of the trimeric RPA complex, RPA-1. Mutations in VP16 that reduce the ability of GAL4-VP16 to activate polyomavirus DNA replication also compromise the binding of VP16 to RPA. We suggest that transcription factors may interact with RPA either to stabilize single-stranded DNA at a replication origin or to recruit DNA polymerase alpha to the replication initiation complex.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5S 1A1,ONTARIO,CANADA; MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON L8S 4K1,ONTARIO,CANADA	University of Toronto; McMaster University	HE, ZG (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA.							AOKI H, 1991, NUCLEIC ACIDS RES, V19, P6215, DOI 10.1093/nar/19.22.6215; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOSHER J, 1990, New Biologist, V2, P1083; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; Coulombe Benoit, 1992, Gene Expression, V2, P99; COUSENS DJ, 1989, EMBO J, V8, P237; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; GUTIERREZ C, 1990, MOL CELL BIOL, V10, P1719, DOI 10.1128/MCB.10.4.1719; HEINTZ N H, 1992, Current Opinion in Cell Biology, V4, P459, DOI 10.1016/0955-0674(92)90012-2; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOANG AT, 1992, MOL CELL BIOL, V12, P3087, DOI 10.1128/MCB.12.7.3087; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MELANDY T, 1993, J BIOL CHEM, V268, P3389; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOOS M, 1988, J BIOL CHEM, V263, P6005; MULLER WJ, 1988, MOL CELL BIOL, V8, P5000, DOI 10.1128/MCB.8.11.5000; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SETO YS, 1993, P NATL ACAD SCI USA, V90, P2865; SKELLY S, 1987, P NATL ACAD SCI USA, V84, P8365, DOI 10.1073/pnas.84.23.8365; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOPTA M, 1985, J BIOL CHEM, V260, P353; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; UMBRICHT CB, 1983, J BIOL CHEM, V268, P6131; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; VERRIJZER CP, 1992, NUCLEIC ACIDS RES, V20, P6369, DOI 10.1093/nar/20.23.6369; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	89	209	209	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1223	1232		10.1016/0092-8674(93)90650-F	http://dx.doi.org/10.1016/0092-8674(93)90650-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513504				2022-12-28	WOS:A1993LH54800017
J	Bennett, DA; Beckett, LA; Murray, AM; Shannon, KM; Goetz, CG; Pilgrim, DM; Evans, DA				Bennett, DA; Beckett, LA; Murray, AM; Shannon, KM; Goetz, CG; Pilgrim, DM; Evans, DA			Prevalence of Parkinsonian signs and associated mortality in a community population of older people	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARADIGM-BASED DIAGNOSIS; ALZHEIMERS-DISEASE; HETEROGENEOUS POPULATION; COGNITIVE FUNCTION; GAIT DISORDERS; DEATH; INDIVIDUALS; DEMENTIA; SYSTEM; RATES	Background. Older people frequently have signs of parkinsonism, but information about the prevalence of parkinsonism and mortality among those with the condition in the community is limited. Methods. A stratified random sample of 467 residents of East Boston, Massachusetts, 65 years of age or older, were given structured neurologic examinations. Using uniform, specified combinations of parkinsonian signs, we estimated the prevalence of four categories of signs - bradykinesia, gait disturbance, rigidity, and tremor - and of parkinsonism, defined as the presence of two or more categories. We did not study Parkinson's disease because it could not be distinguished from other conditions that carl cause parkinsonism. Proportional-hazards models were used to compare the risk of death among people with and those without parkinsonism. Results. One hundred fifty-nine persons had parkinsonism, 301 did not, and 7 could not be classified. The overall prevalence estimates were 14.9 percent for people 65 to 74 years of age, 29.5 percent for those 75 to 84, and 52.4 percent for those 85 and older. With a mean follow-up period of 9.2 years, 124 persons with parkinsonism (78 percent) and 146 persons without it (49 percent) died. Adjusted for age and sex, the overall risk of death among people with parkinsonism was 2.0 (95 percent confidence interval, 1.6 to 2.6) times that among people without it. Among people with parkinsonism, the presence of gait disturbance was associated with an increased risk of death. Conclusions. Parkinsonism is very common among people over the age of 65, and its prevalence increases markedly with age, Parkinsonism is associated with a twofold increase in the risk of death, which is strongly related to the presence of a gait disturbance.	RUSH UNIV,DEPT NEUROL SCI,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA	Rush University; Rush University	Bennett, DA (corresponding author), RUSH UNIV,RUSH INST AGING,1645 W JACKSON BLVD,SUITE 675,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [U01AG006789, N01AG012106, N01AG002107] Funding Source: NIH RePORTER; NIA NIH HHS [AG06789, N01-AG-1-2106, N01-AG-0-2107] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; BARBEAU A, 1973, J AM GERIATR SOC, V21, P145, DOI 10.1111/j.1532-5415.1973.tb00865.x; BECKETT LA, 1992, J CLIN EPIDEMIOL, V45, P393, DOI 10.1016/0895-4356(92)90040-T; BENSHLOMO Y, 1995, J NEUROL NEUROSUR PS, V58, P293, DOI 10.1136/jnnp.58.3.293; BONIFATI V, 1993, ACTA NEUROL SCAND, V87, P9; CALNE DB, 1991, ANN NEUROL, V30, P206, DOI 10.1002/ana.410300213; CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721; CORNONIHUNTLEY J, 1986, DHHS NIH862443 PUBL; COX DR, 1972, J R STAT SOC B, V34, P187; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; EBMEIER KP, 1990, SCOT MED J, V35, P173, DOI 10.1177/003693309003500605; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EVANS DA, 1991, AM J EPIDEMIOL, V134, P403, DOI 10.1093/oxfordjournals.aje.a116102; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; GIBB WRG, 1988, POSTGRAD MED J, V64, P345, DOI 10.1136/pgmj.64.751.345; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JOHNSON RA, 1982, APPLIED MULTIVARIATE; JONES MK, 1990, ANTHONYS 1991 INPATI; Katzman R., 1992, PRINCIPLES GERIATRIC, P18; KAYE JA, 1994, ARCH NEUROL-CHICAGO, V51, P1205, DOI 10.1001/archneur.1994.00540240049015; KOKMEN E, 1977, J GERONTOL, V32, P411, DOI 10.1093/geronj/32.4.411; KOLLER WC, 1992, NEUROLOGY, V42, P6; KURTZKE JF, 1990, NEUROLOGY, V40, P42, DOI 10.1212/WNL.40.1.42; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MARTINEZMARTIN P, 1988, PARKINSONS DIS MOVEM, P235; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORGANTE L, 1992, NEUROLOGY, V42, P1901; NEWMAN RP, 1985, NEUROLOGY, V35, P571, DOI 10.1212/WNL.35.4.571; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; ODENHEIMER G, 1994, ARCH NEUROL-CHICAGO, V51, P573, DOI 10.1001/archneur.1994.00540180051013; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POTVIN AR, 1980, J AM GERIATR SOC, V28, P1; QUINN NP, 1986, BRIT MED J, V293, P379, DOI 10.1136/bmj.293.6543.379; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; RAJPUT AH, 1991, NEUROLOGY, V41, P1298, DOI 10.1212/WNL.41.8.1298; RAJPUT AH, 1992, CAN J NEUROL SCI, V19, P103, DOI 10.1017/S0317167100041457; RICHARDS M, 1993, ANN NEUROL, V33, P267, DOI 10.1002/ana.410330307; SAWLE GV, 1994, ARCH NEUROL-CHICAGO, V51, P237, DOI 10.1001/archneur.1994.00540150027011; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; Skinner C.J., 1989, ANAL COMPLEX SURVEYS; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441; WEBSTER DD, 1968, MOD TREAT, V5, P257	44	497	504	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					71	76		10.1056/NEJM199601113340202	http://dx.doi.org/10.1056/NEJM199601113340202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531961				2022-12-28	WOS:A1996TP36300002
J	Copeland, JWR; Nasiadka, A; Dietrich, BH; Krause, HM				Copeland, JWR; Nasiadka, A; Dietrich, BH; Krause, HM			Patterning of the Drosophila embryo by a homeodomain-deleted Ftz polypeptide	NATURE			English	Article							FUSHI-TARAZU; DNA-BINDING; GENE; EXPRESSION; PROTEIN; SEGMENTATION; DOMAIN; ESTABLISHMENT; MAINTENANCE; ACTIVATION	HOMEODOMAIN proteins regulate diverse developmental processes in a wide range of organisms, yet bind in vitro to DNA sequences that are remarkably similar(1). This has raised the fundamental question of how target gene specificity is achieved in vivo. The Drosophila fushi tarazu protein (Ftz) contains a homeodomain(2) and is required for the formation of alternate segments(3). We have shown previously that a homeodomain-deleted Ftz polypeptide (Ftz Delta HD), incapable of binding DNA in vitro, could regulate endogenous ftz gene expression(4). Here we test Ftz Delta HD activities in a ftz mutant background and find that, surprisingly, Ftz Delta HD can directly regulate ftz-dependent segmentation, suggesting that it can control target gene expression through interactions with other proteins. A likely candidate is the pair-rule protein Paired (Prd). Ftz Delta HD bound directly to Prd in vitro and required Prd to repress wingless in vivo. These results emphasize the pivotal importance of protein-protein interactions in homeodomain protein function.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; DEPT MED & MOLEC GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto				Krause, Henry/0000-0002-6182-7074				ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; BAUMGARTNER S, 1991, MECH DEVELOP, V33, P1; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X	22	79	79	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					162	165		10.1038/379162a0	http://dx.doi.org/10.1038/379162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538765				2022-12-28	WOS:A1996TP36000057
J	Young, DAB				Young, DAB			Florence Nightingale's fever	BMJ-BRITISH MEDICAL JOURNAL			English	Note									WELLCOME FDN LTD, BECKENHAM, KENT, ENGLAND	GlaxoSmithKline								BUCHANAN TM, 1982, CECIL TXB MED, P1535; CHRISTIE AB, 1987, INFECT DIS, P1130; COOK E, 1913, LIFE F NIGHTINGALE; DALRYMPLECHAMPNEYS W, 1950, LANCET, V258, P429; DALRYMPLECHAMPNEYS W, 1950, LANCET, V258, P477; Evans AC, 1934, J AMER MED ASSOC, V103, P0665, DOI 10.1001/jama.1934.02750350029008; GANADO WALTER, 1965, SCOT MED J, V10, P451; Goldsmith Margaret, 1937, F NIGHTINGALE WOMAN; Hughes M.L., 1897, MEDITERRANEAN MALTA; Lawson G., 1968, SURGEON CRIMEA EXPER; LONGFORD E, 1981, EMINENT VICTORIAN WO, P85; LYONS RD, 1857, REPORTS COMMISSIONER, V3, P54; MARSTON JA, 1863, ARMY MED DEP REPORTS, V3, P486; MCHUGH PR, 1982, CECIL TXB MED, P1991; NELSONJONES A, 1951, LANCET, V260, P495; Pickering GW., 1974, CREATIVE MALADY ILLN; RAMSAY AM, 1967, INFECT DIS, P208; SMITH FB, 1982, F NIGHTINGALE REPUTA; Soyer Alexis, 1857, SOYERS CULINARY CAMP; SPINK WW, 1959, TXB MED, P226; Spink WW, 1956, NATURE BRUCELLOSIS; WOODHAMSMITH C, 1955, F NIGHTINGALE; 1903, LANCET, V2, P1184; [No title captured]	24	13	16	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	1995	311	7021					1697	1700		10.1136/bmj.311.7021.1697	http://dx.doi.org/10.1136/bmj.311.7021.1697			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541764	Green Published			2022-12-28	WOS:A1995TL94200025
J	CROSS, DAE; ALESSI, DR; COHEN, P; ANDJELKOVICH, M; HEMMINGS, BA				CROSS, DAE; ALESSI, DR; COHEN, P; ANDJELKOVICH, M; HEMMINGS, BA			INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY INSULIN-MEDIATED BY PROTEIN-KINASE-B	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; MOLECULAR-CLONING; PHOSPHORYLATION; IDENTIFICATION; SUBFAMILY	GLYCOGEN synthase kinase-3 (GSK3)(1) is implicated in the regulation of several physiological processes, including the control of glycogen(2) and protein(3) synthesis by insulin, modulation of the transcription factors AP-1 and CREB(4-6), the specification of cell fate in Drosophila(7) and dorsoventral patterning in Xenopus embryos(8). GSK3 is inhibited by serine phosphorylation in response to insulin or growth factors and in vitro by either MAP kinase-activated protein (MAPKAP) kinase-1 (also known as p90(rsk)) or p70 ribosomal S6 kinase (p70(S6k))(12,13). Here we show, however, that agents which prevent the activation of both MAPKAP kinase-1 and p70(S6k) by insulin in vivo do not block the phosphorylation and inhibition of GSK3. Another insulin-stimulated protein kinase inactivates GSK3 under these conditions, and Ne demonstrate that it is the product of the proto-oncogene protein kinase B (PKB, also known as Akt/RAC). Like the inhibition of GSK3 (refs 10, 14), the activation of PKB is prevented by inhibitors of phosphatidylinositol (PT) 3-kinase.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research	CROSS, DAE (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT LAB,DUNDEE DD1 4HN,SCOTLAND.			Alessi, Dario/0000-0002-2140-9185				AHMED NN, 1995, MOL CELL BIOL, V15, P2304; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DALTO Y, 1994, BIOCHEM J, V303, P27; DEGROOT RP, 1993, ONCOGENE, V8, P841; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOODE N, 1992, J BIOL CHEM, V267, P16878; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015	29	4199	4330	2	216	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					785	789		10.1038/378785a0	http://dx.doi.org/10.1038/378785a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524413				2022-12-28	WOS:A1995TL41900028
J	SHIMAMOTO, K				SHIMAMOTO, K			THE MOLECULAR-BIOLOGY OF RICE	SCIENCE			English	Editorial Material							PROTOPLASTS; RESISTANT; SYSTEM; PLANTS; INDICA				SHIMAMOTO, K (corresponding author), NARA INST SCI & TECHNOL,PLANT MOLEC GENET LAB,8916-5 TAKAYAMA,IKOMA,NARA 63001,JAPAN.							AHN S, 1993, P NATL ACAD SCI USA, V90, P7980, DOI 10.1073/pnas.90.17.7980; BENNETZEN JL, 1993, TRENDS GENET, V9, P259, DOI 10.1016/0168-9525(93)90001-X; CHRISTOU P, 1991, BIO-TECHNOL, V9, P957, DOI 10.1038/nbt1091-957; DATTA SK, 1990, BIO-TECHNOL, V8, P736, DOI 10.1038/nbt0890-736; DUNFORD RP, 1995, NUCLEIC ACIDS RES, V23, P2724, DOI 10.1093/nar/23.14.2724; FUJIMOTO H, 1993, BIO-TECHNOL, V11, P1151, DOI 10.1038/nbt1093-1151; HAYAKAWA T, 1992, P NATL ACAD SCI USA, V89, P9865, DOI 10.1073/pnas.89.20.9865; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HIROCHIKA H, UNPUB; HUBERT SH, 1990, P NATL ACAD SCI USA, V87, P4251; KILIAN A, 1995, NUCLEIC ACIDS RES, V23, P2729, DOI 10.1093/nar/23.14.2729; KURATA N, 1994, BIO-TECHNOL, V12, P276, DOI 10.1038/nbt0394-276; KURATA N, 1994, NAT GENET, V8, P365, DOI 10.1038/ng1294-365; KYOZUKA J, 1994, PLANT CELL, V6, P799, DOI 10.1105/tpc.6.6.799; LI LC, 1993, PLANT CELL REP, V12, P250, DOI 10.1007/BF00237129; LIN W, 1995, BIO-TECHNOL, V13, P686, DOI 10.1038/nbt0795-686; PATERSON AH, 1995, SCIENCE, V270, P1714; SHIELDS R, 1993, NATURE, V365, P297, DOI 10.1038/365297a0; SHIMAMOTO K, 1989, NATURE, V338, P274, DOI 10.1038/338274a0; Shimamoto Ko, 1994, Current Opinion in Biotechnology, V5, P158, DOI 10.1016/S0958-1669(05)80029-1; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x	22	28	32	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1772	1773		10.1126/science.270.5243.1772	http://dx.doi.org/10.1126/science.270.5243.1772			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525363				2022-12-28	WOS:A1995TK47600030
J	NISHITANI, H; NURSE, P				NISHITANI, H; NURSE, P			P65(CDC18) PLAYS A MAJOR ROLE CONTROLLING THE INITIATION OF DNA-REPLICATION IN FISSION YEAST	CELL			English	Article							CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; S-PHASE; MITOSIS; GENE; P34CDC2; RECOGNITION; ORIGINS; COMPLEX	A key problem in the cell cycle is understanding what brings about the initiation of DNA replication and how this is linked with global cell cycle controls. The fission yeast gene cdc18 is required for DNA replication and is transcriptionally activated by the cdc10/res1/res2 control acting at START in late G1. We show here that overexpressing cdc18 is able to bring about repeated rounds of DNA synthesis in the absence of mitosis and of continuing protein synthesis. The level of the cdc18-encoded protein p65(cdc18) is periodic in the cell cycle, peaking at the G1 to S phase transition, and p65(cdc18) is located in the nucleus when cdc18 is overexpressed. We propose that p65(cdc18) acts af the initiation of DNA replication and plays a major role in controlling the onset of S phase.			NISHITANI, H (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Nishitani, Hideo/0000-0001-5907-9380				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; SAZER S, 1990, J CELL SCI, V97, P509; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	37	236	241	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					397	405		10.1016/0092-8674(95)90117-5	http://dx.doi.org/10.1016/0092-8674(95)90117-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521469	Bronze			2022-12-28	WOS:A1995TC97700009
J	FELDMAN, AM; BRISTOW, MR; PARMLEY, WW; CARSON, PE; PEPINE, CJ; GILBERT, EM; STROBECK, JE; HENDRIX, GH; POWERS, ER; BAIN, RP; WHITE, BG				FELDMAN, AM; BRISTOW, MR; PARMLEY, WW; CARSON, PE; PEPINE, CJ; GILBERT, EM; STROBECK, JE; HENDRIX, GH; POWERS, ER; BAIN, RP; WHITE, BG			EFFECTS OF VESNARINONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE INOTROPIC AGENT; IDIOPATHIC DILATED CARDIOMYOPATHY; GUINEA-PIG; CARDIOTONIC AGENT; CLINICAL-TRIALS; ORAL MILRINONE; OPC-8212; ENOXIMONE; SURVIVAL; DISEASE	Background. Inotropic therapy, other than with digitalis glycosides, has had limited success in patients with chronic congestive heart failure. We investigated whether vesnarinone, a new positive inotropic agent, reduces morbidity and mortality and improves the quality of life of patients with symptomatic heart failure. Methods. Patients receiving concomitant therapy with digoxin (87 percent) and an angiotensin-converting-enzyme inhibitor (90 percent) who had ejection fractions of 30 percent or less were randomly assigned to receive double-blinded therapy with 60 mg of vesnarinone per day, 120 mg of vesnarinone per day, or placebo. After 253 patients had been enrolled, randomization to the 120-mg vesnarinone group had to be stopped because of a significant increase in early mortality in this group. Thereafter, patients were randomly assigned only to 60 mg of vesnarinone per day (a total of 239 patients) or placebo (a total of 238 patients). Results. Significantly fewer patients in the group receiving 60 mg of vesnarinone than in the group receiving placebo (26 vs. 50 patients; P = 0.003) died or had worsening heart failure during the six-month study period. The reduction in risk was 50 percent (95 percent confidence interval, 20 to 69 percent). Similarly, there was a 62 percent reduction (95 percent confidence interval, 28 to 80 percent) in the risk of dying from any cause among the patients receiving vesnarinone. Furthermore, quality of life improved to a greater extent in the vesnarinone group than in the placebo group over 12 weeks (P = 0.008). The principal side effect associated with vesnarinone was reversible neutropenia, which occurred in 2.5 percent of the patients. Conclusions. Six months of therapy with 60 mg of vesnarinone per day resulted in lower morbidity and mortality and improved the quality of life of patients with congestive heart failure. However, a higher dose of vesnarinone (120 mg per day) increased mortality, suggesting that this drug has a narrow therapeutic range; the long-term effects of vesnarinone are unknown.			FELDMAN, AM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,PETER BELFER CARDIAC LABS,RICHARD S ROSS RES BLDG,RM 835,BALTIMORE,MD 21205, USA.		bristow, michael r/G-7850-2011					ASANOI H, 1989, CLIN CARDIOL, V12, P133, DOI 10.1002/clc.4960120304; BERGNER M, 1984, ASSESSMENT QUALITY L, P152; COHN JN, 1989, NEW ENGL J MED, V320, P729, DOI 10.1056/NEJM198903163201109; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COLUCCI WS, 1986, NEW ENGL J MED, V314, P349, DOI 10.1056/NEJM198602063140605; Cox DR., 1970, ANAL BINARY DATA; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; EISNER DA, 1991, HEART CARDIOVASCULAR, P863; FELDMAN AM, 1988, AM HEART J, V116, P771, DOI 10.1016/0002-8703(88)90336-5; FELDMAN AM, 1991, AM J CARDIOL, V68, P1203, DOI 10.1016/0002-9149(91)90194-P; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; GOLDBERG AD, 1991, AM J CARDIOL, V68, P631, DOI 10.1016/0002-9149(91)90356-P; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; HORI M, 1986, JPN CIRC J, V50, P659, DOI 10.1253/jcj.50.659; IIJIMA T, 1987, J PHARMACOL EXP THER, V240, P657; INOUE M, 1986, Heart and Vessels, V2, P166, DOI 10.1007/BF02128143; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KUBO SH, 1992, CIRCULATION, V85, P942, DOI 10.1161/01.CIR.85.3.942; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LATHROP DA, 1989, EUR J PHARMACOL, V164, P487, DOI 10.1016/0014-2999(89)90256-2; LATHROP DA, 1985, EUR J PHARMACOL, V117, P391, DOI 10.1016/0014-2999(85)90016-0; LEE HR, 1991, J THORAC CARDIOV SUR, V102, P246; LEHMANN EL, 1975, NONPARAMETRICS; MARUYAMA Y, 1986, J CARDIOVASC PHARM, V8, P161, DOI 10.1097/00005344-198601000-00024; MASSIE B, 1985, CIRCULATION, V71, P963, DOI 10.1161/01.CIR.71.5.963; MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5; MEHTA C, 1991, STATXACT STATISTICAL; MOSS AJ, 1981, CIRCULATION, V64, P1150, DOI 10.1161/01.CIR.64.6.1150; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAPUNDALO ST, 1988, N-S ARCH PHARMACOL, V338, P692, DOI 10.1007/BF00165636; SASAYAMA S, 1986, Heart and Vessels, V2, P23, DOI 10.1007/BF02060240; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SMITH T W, 1988, New England Journal of Medicine, V318, P358; TAIRA N, 1984, ARZNEIMITTEL-FORSCH, V34-1, P347; TANDE PM, 1990, J CARDIOVASC PHARM, V16, P401, DOI 10.1097/00005344-199009000-00008; URETSKY BF, 1990, CIRCULATION, V82, P774, DOI 10.1161/01.CIR.82.3.774; WENGER NK, 1989, CARDIOLOGY, V76, P391, DOI 10.1159/000174523; YATANI A, 1989, J CARDIOVASC PHARM, V13, P812, DOI 10.1097/00005344-198906000-00002; 1990, LANCET, V336, P517; 1985, SAS USERS GUIDE STAT; 1991, NEW ENGL J MED, V325, P293; 1990, CARDIOVASC DRUG THER, V4, P419; 1988, JAMA-J AM MED ASSOC, V259, P539	45	384	391	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					149	155		10.1056/NEJM199307153290301	http://dx.doi.org/10.1056/NEJM199307153290301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL460	8515787	Bronze			2022-12-28	WOS:A1993LL46000001
J	Gustafsson, L; Hallander, HO; Olin, P; Reizenstein, E; Storsaeter, J				Gustafsson, L; Hallander, HO; Olin, P; Reizenstein, E; Storsaeter, J			A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BORDETELLA-PERTUSSIS; DIPHTHERIA; CHILDREN; TETANUS; INFANTS; INFECTIONS; EFFICACY	Background. Because of concern about safety and efficacy, no pertussis vaccine has been included in the vaccination program in Sweden since 1979, To provide data that might permit the reintroduction of a pertussis vaccine, we conducted a placebo-controlled trial of two acellular and one whole-cell pertussis vaccines. Methods. After informed consent was obtained, 9829 children born in 1992 were randomly assigned to receive one of four vaccines: a two-component acellular diphtheria-tetanus-pertussis (DTP) vaccine (2566 children), a five-component acellular DTP vaccine (2587 children), a whole-cell DTP vaccine licensed in the United States (2102 children), or (as a control) a vaccine containing diphtheria and tetanus toxoids (DT) alone (2574 children). The vaccines were given at 2, 4, and 6 months of age, and the children were then followed for signs of pertussis for an additional 2 years (to a mean age of 2 1/2 years). Results. The whole-cell vaccine was associated with significantly higher rates of protracted crying, cyanosis, fever, and local reactions than the other three vaccines. The rates of adverse events were similar for the acellular vaccines and the control DT vaccine. After three doses, the efficacy of the vaccines with respect to pertussis linked to a laboratory-confirmed case of pertussis or contact with an infected household member with paroxysmal cough for greater than or equal to 21 days was 58.9 percent for the two-component vaccine (95 percent confidence interval, 50.9 to 65.9 percent), 85.2 percent for the five-component vaccine (95 percent confidence interval, 80.6 to 88.8 percent), and 48.3 percent for the whole-cell vaccine (95 percent confidence interval, 37.0 to 57.6 percent). Conclusions. The five-component acellular pertussis vaccine we evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussis. The two-component acellular vaccine and the whole-cell vaccine were less efficacious.	SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN; SACHS CHILDRENS HOSP,STOCKHOLM,SWEDEN	Swedish Institute for Infectious Disease Control					NIAID NIH HHS [N01-AI-15125] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015125] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON EL, 1988, J INFECT DIS, V157, P731, DOI 10.1093/infdis/157.4.731; [Anonymous], 1988, LANCET, Vi, P955; BLUMBERG DA, 1991, J PEDIATR-US, V119, P194, DOI 10.1016/S0022-3476(05)80727-9; CHERRY J D, 1988, Pediatrics, V81, P939; CHERRY JD, 1992, VACCINE, V10, P1033, DOI 10.1016/0264-410X(92)90113-X; CODY CL, 1981, PEDIATRICS, V68, P650; DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1995, PEDIATRICS, V96, P548; EDWARDS KM, 1991, PEDIATRICS, V88, P1019; ENGLUND JA, 1992, J INFECT DIS, V166, P1436, DOI 10.1093/infdis/166.6.1436; FELDMAN S, 1992, J PEDIATR-US, V121, P857, DOI 10.1016/S0022-3476(05)80328-2; FELDMAN S, 1993, J PEDIATR, V123, P842; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GUSTAFSSON L, 1995, EFFICACY TRIAL ACELL, P20; HALLANDER HO, 1993, J CLIN MICROBIOL, V31, P50, DOI 10.1128/JCM.31.1.50-52.1993; HALLANDER HO, 1991, J INFECT DIS, V163, P1046, DOI 10.1093/infdis/163.5.1046; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MEADE BD, 1995, PEDIATRICS, V96, P570; MOXON ER, 1990, LANCET, V335, P1324, DOI 10.1016/0140-6736(90)91200-T; NOBLE GR, 1987, JAMA-J AM MED ASSOC, V257, P1351, DOI 10.1001/jama.257.10.1351; OLIN P, 1995, J HOSP INFECT, V30, P503, DOI 10.1016/0195-6701(95)90055-1; PETER G, 1994, 1994 RED BOOK REPORT, P355; REED GF, 1995, PEDIATRICS, V96, P600; REGAN J, 1977, J CLIN MICROBIOL, V6, P303; REIZENSTEIN E, 1993, DIAGN MICR INFEC DIS, V17, P185, DOI 10.1016/0732-8893(93)90094-N; REIZENSTEIN E, 1995, J IMMUNOL METHODS, V183, P279, DOI 10.1016/0022-1759(95)00067-K; SHAHIN RD, 1990, J EXP MED, V171, P63, DOI 10.1084/jem.171.1.63; STORSAETER J, 1988, PEDIATR INFECT DIS J, V7, P637, DOI 10.1097/00006454-198809000-00008; STORSAETER J, 1992, VACCINE, V10, P142, DOI 10.1016/0264-410X(92)90002-2; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; 1988, LANCET, V1, P1238; 1991, 1991 WHO M CAS DEF P, P4	32	570	642	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					349	355		10.1056/NEJM199602083340602	http://dx.doi.org/10.1056/NEJM199602083340602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538705				2022-12-28	WOS:A1996TT48700002
J	Thomas, P; Howarth, D				Thomas, P; Howarth, D			Paget's disease of bone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Thomas, P (corresponding author), JOHN HUNTER HOSP,NEWCASTLE,NSW 2310,AUSTRALIA.		Thomas, Paul A/K-7463-2012	Thomas, Paul A/0000-0002-2420-0950					0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					160	160		10.1056/NEJM199601183340305	http://dx.doi.org/10.1056/NEJM199601183340305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531971				2022-12-28	WOS:A1996TQ01700005
J	vanEssen, GG; Rensma, PL; deZeeuw, D; Sluiter, WJ; Scheffer, H; Apperloo, AJ; deJong, PE				vanEssen, GG; Rensma, PL; deZeeuw, D; Sluiter, WJ; Scheffer, H; Apperloo, AJ; deJong, PE			Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy	LANCET			English	Article							INSERTION DELETION POLYMORPHISM; CARDIOMYOPATHY	Background Polymorphism in the gene for angiotensin-converting enzyme (ACE), especially the DD genotype, is associated with risk for cardiovascular disease. Glomerulosclerosis has similarities to atherosclerosis, and we looked at ACE gene polymorphism in patients with kidney disease who were in a trial of long-term therapy with an ACE inhibitor or a beta-blocker. Methods 81 patients with non-diabetic renal disease had been entered into a randomised comparison of oral atenolol or enalapril to prevent progressive decline in renal function. The dose was titrated to a goal diastolic blood pressure of 10 mm Hg below baseline and/or below 95 mm Hg. The mean (SE) age was 50 (1) years, and the group included 49 men. Their renal function had been monitored over 3-4 years. We have looked at their ACE genotype, which we assessed with PCR. Findings 27 patients had the II genotype, 37 were ID, and 17 were DD. 11 patients were lost to follow-up over 1-3 years. The decline of glomerular filtration rate over the years was significantly steeper in the DD group than in the ID and the II groups (p=0.02; means -3.79, -1.37, and -1.12 mL/min per year, respectively). The DD patients treated with enalapril fared as equally a bad course as the DD patients treated with atenolol. Neither drug lowered the degree of proteinuria in the DD group. Interpretation Our data show that patients with the DD genotype are resistant to commonly advocated renoprotective therapy.	UNIV GRONINGEN HOSP,DIV NEPHROL,DEPT MED,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT MED GENET,9700 RB GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen			Scheffer, Hans/E-4644-2012; de Zeeuw, Dick/E-9080-2014	Scheffer, Hans/0000-0002-2986-0915; de Zeeuw, Dick/0000-0003-3434-7777				APPERLOO AJ, 1994, KIDNEY INT, V45, pS174; APPERLOO AJ, IN PRESS J AM SOC NE; DONKER AJM, 1977, NETH J MED, V20, P97; HARDEN PN, 1995, LANCET, V345, P1540, DOI 10.1016/S0140-6736(95)91088-3; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SHANMUGAM V, 1993, PCR METH APPL, V3, P120	11	168	169	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					94	95		10.1016/S0140-6736(96)90213-5	http://dx.doi.org/10.1016/S0140-6736(96)90213-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538349				2022-12-28	WOS:A1996TP28100012
J	Gabriel, K; Schneider, J; McClain, WH				Gabriel, K; Schneider, J; McClain, WH			Functional evidence for indirect recognition of G center dot U in tRNA(Ala) by alanyl-tRNA synthetase	SCIENCE			English	Article							TRANSFER-RNA; ESCHERICHIA-COLI; IDENTITY; SPECIFICITY; DETERMINES; END	The structural features of the G . U wobble pair in Escherichia coli alanine transfer RNA (tRNA(Ala)) that are associated with aminoacylation by alanyl-tRNA synthetase (AlaRS) were investigated in vivo for wild-type tRNA(Ala) and mutant tRNAs with G . U substitutions. tRNA(Ala) with G . U, C . A, or G . A gave similar amounts of charged tRNA(Ala) and supported viability of E. coli lacking chromosomal tRNA(Ala) genes. tRNA(Ala) With G . C was inactive. Recognition of G . U by AlaRS thus requires more than the functional groups on G . U in a regular helix and may involve detection of a helical distortion.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM42123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; ALLAIN FHT, 1995, NUCLEIC ACIDS RES, V23, P341, DOI 10.1093/nar/23.3.341; BLUM P, 1989, J BACTERIOL, V171, P538, DOI 10.1128/jb.171.1.538-546.1989; BRUN YV, 1990, J MOL BIOL, V214, P825, DOI 10.1016/0022-2836(90)90339-N; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; GABRIEL K, UNPUB; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LIMMER S, 1993, P NATL ACAD SCI USA, V90, P6199, DOI 10.1073/pnas.90.13.6199; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	21	106	106	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					195	197		10.1126/science.271.5246.195	http://dx.doi.org/10.1126/science.271.5246.195			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539617				2022-12-28	WOS:A1996TP36400039
J	Fine, MJ; Smith, MA; Carson, CA; Mutha, SS; Sankey, SS; Weissfeld, LA; Kapoor, WN				Fine, MJ; Smith, MA; Carson, CA; Mutha, SS; Sankey, SS; Weissfeld, LA; Kapoor, WN			Prognosis and outcomes of patients with community-acquired pneumonia - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BACTEREMIC PNEUMOCOCCAL PNEUMONIA; INTENSIVE-CARE TREATMENT; LEGIONNAIRES-DISEASE; REQUIRING HOSPITALIZATION; NURSING-HOME; MARROW TRANSPLANTATION; BACTERIAL PNEUMONIA; CLINICAL-FEATURES; ANTIBIOTIC ERA; ETIOLOGY	Objective.-To systematically review the medical literature on the prognosis and outcomes of patients with community-acquired pneumonia (CAP). Data Sources.-A MEDLINE literature search of English-language articles involving human subjects and manual reviews of article bibliographies were used to identify studies of prognosis in CAP. Study Selection.-Review of 4573 citations revealed 122 articles (127 unique study cohorts) that reported medical outcomes in adults with CAP. Data Extraction.-Qualitative assessments of studies' patient populations, designs, and patient outcomes were performed. Summary univariate odds ratios (ORs) and rate differences (RDs) and their associated 95% confidence intervals (CIs) were computed to estimate a summary effect size for the association of prognostic factors and mortality. Data Synthesis.-The overall mortality for the 33148 patients in all 127 study cohorts was 13.7%, ranging from 5.1% for the 2097 hospitalized and ambulatory patients (in six study cohorts) to 36.5% for the 788 intensive care unit patients (in 13 cohorts). Mortality varied by pneumonia etiology, ranging from less than 2% to greater than 30%. Eleven prognostic factors were significantly associated with mortality using both summary ORs and RDs: male sex (OR=1.3; 95% CI, 1.2 to 1.4), pleuritic chest pain (OR=0.5; 95% CI, 0.3 to 0.8), hypothermia (OR=5.0; 95% CI, 2.4 to 10.4), systolic hypotension (OR=4.8; 95% CI, 2.8 to 8.3), tachypnea (OR=2.9; 95% CI, 1.7 to 4.9), diabetes mellitus (OR=1.3; 95% CI, 1.1 to 1.5), neoplastic disease (OR=2.8; 95% CI, 2.4 to 3.1), neurologic disease (OR=4.6; 95% CI, 2.3 to 8.9), bacteremia (OR=2.8; 95% CI, 2.3 to 3.6), leukopenia (OR=2.5; 95% CI, 1.6 to 3.7), and multilobar radiographic pulmonary infiltrate (OR=3.1; 95% CI, 1.9 to 5.1). Assessments of other clinically relevant medical outcomes such as morbid complications (41 cohorts), symptoms resolution (seven cohorts), return to work or usual activities (five cohorts), or functional status (one cohort) were infrequently performed. Conclusions.-Mortality for patients hospitalized with CAP was high and was associated with characteristics of the study cohort, pneumonia etiology, and a variety of prognostic factors. Generalization of these findings to all patients with CAP should be made with caution because of insufficient published information on medical outcomes other than mortality in ambulatory patients.	UNIV PITTSBURGH, DEPT MED, DIV GEN INTERNAL MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT BIOSTAT, PITTSBURGH, PA USA; WASHINGTON UNIV, SCH MED, DIV GEN MED SCI, ST LOUIS, MO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)					AHRQ HHS [HS-06468] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADERAYE G, 1994, ETHIOPIAN MED J, V32, P115; ALI NJ, 1986, Q J MED, V58, P241; ALLEN SC, 1984, THORAX, V39, P612, DOI 10.1136/thx.39.8.612; ANDREWS BE, 1987, Q J MED, V62, P195; AUBERTIN J, 1987, INFECTION, V15, P328, DOI 10.1007/BF01647732; AUSINA V, 1988, EUR J CLIN MICROBIOL, V7, P343, DOI 10.1007/BF01962334; BARTLETT JG, 1979, AM REV RESPIR DIS, V119, P19; BASILIER.JL, 1968, AM J MED, V44, P580, DOI 10.1016/0002-9343(68)90058-2; BENEDETTI TJ, 1982, AM J OBSTET GYNECOL, V144, P413, DOI 10.1016/0002-9378(82)90246-0; BISNO AL, 1971, AM J MED SCI, V261, P251, DOI 10.1097/00000441-197105000-00004; BLANQUER J, 1991, THORAX, V46, P508, DOI 10.1136/thx.46.7.508; BOERNER DF, 1982, JAMA-J AM MED ASSOC, V247, P642, DOI 10.1001/jama.247.5.642; BOYD DHA, 1975, BRIT J DIS CHEST, V69, P259, DOI 10.1016/S0007-0971(75)80042-8; BRANCATI FL, 1993, LANCET, V342, P30, DOI 10.1016/0140-6736(93)91887-R; CAMERON EWJ, 1980, THORAX, V35, P340, DOI 10.1136/thx.35.5.340; CAMERON S, 1991, AUST NZ J MED, V21, P65, DOI 10.1111/j.1445-5994.1991.tb03007.x; CARPENTER JL, 1991, SOUTHERN MED J, V84, P299, DOI 10.1097/00007611-199103000-00004; CARSON CA, 1994, J GEN INTERN MED, V9, P13, DOI 10.1007/BF02599136; COHEN M A H, 1989, SMJ Singapore Medical Journal, V30, P141; Cohen S, 1969, J Med Soc N J, V66, P513; Cox DR., 1970, ANAL BINARY DATA; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIPOALA JA, 1977, NEW YORK STATE J MED, V77, P1259; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; DOUGLAS M, 1970, PAPUA NEW GUINEA MED, V13, P105; DOUGLAS RM, 1973, MED J AUSTRALIA, V1, P42, DOI 10.5694/j.1326-5377.1973.tb119602.x; DUROCHER A, 1988, INTENS CARE MED, V14, P39, DOI 10.1007/BF00254120; EBRIGHT JR, 1980, J AM GERIATR SOC, V28, P220, DOI 10.1111/j.1532-5415.1980.tb00523.x; EL-AMIN A M, 1978, Medical Journal of Zambia, V12, P42; ESPOSITO AL, 1984, ARCH INTERN MED, V144, P945, DOI 10.1001/archinte.144.5.945; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; FEDSON DS, 1982, JAMA-J AM MED ASSOC, V248, P1989; FEDULLO AJ, 1985, J GERONTOL, V40, P29, DOI 10.1093/geronj/40.1.29; FEKETY RF, 1971, AM REV RESPIR DIS, V104, P499; FELDMAN C, 1989, INTENS CARE MED, V15, P302; FINE MJ, 1990, AM J MED, V89, P713, DOI 10.1016/0002-9343(90)90211-U; FINE MJ, 1990, AM J MED, V88, pN1; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; FINE MJ, 1995, J GEN INTERN MED, V10, P359, DOI 10.1007/BF02599830; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; FINKELSTEIN MS, 1983, J AM GERIATR SOC, V31, P19, DOI 10.1111/j.1532-5415.1983.tb06283.x; Fleiss JL, 1981, STAT METHODS RATES P; FRASER DW, 1977, NEW ENGL J MED, V297, P1189, DOI 10.1056/NEJM197712012972201; GARB JL, 1978, JAMA-J AM MED ASSOC, V240, P2169; GRANADOS A, 1989, EUR RESPIR J, V2, P130; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; GREMILLION DH, 1981, AM J MED, V71, P539, DOI 10.1016/0002-9343(81)90203-5; HARPER C, 1989, J AM GERIATR SOC, V37, P867, DOI 10.1111/j.1532-5415.1989.tb02268.x; HELMS CM, 1984, AM J MED SCI, V288, P2, DOI 10.1097/00000441-198407000-00001; HELMS CM, 1979, ANN INTERN MED, V90, P543, DOI 10.7326/0003-4819-90-4-543; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; JAY SJ, 1975, NEW ENGL J MED, V293, P798, DOI 10.1056/NEJM197510162931604; JONG GM, 1995, CHEST, V107, P214, DOI 10.1378/chest.107.1.214; Kamat S R, 1979, J Postgrad Med, V25, P15; KARALUS NC, 1991, THORAX, V46, P413, DOI 10.1136/thx.46.6.413; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KIM TC, 1981, SOUTH MED J, V74, P1304, DOI 10.1097/00007611-198111000-00005; KINZEL T, 1988, EXP AGING RES, V14, P99, DOI 10.1080/03610738808259730; KNAUS WA, 1985, J CHRON DIS, V38, P295, DOI 10.1016/0021-9681(85)90075-X; KURASHI NY, 1992, THORAX, V47, P115, DOI 10.1136/thx.47.2.115; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAMBERT CC, 1990, ANN CLIN LAB SCI, V20, P140; LEVY M, 1988, CHEST, V93, P43, DOI 10.1378/chest.93.1.43; LIGHT RW, 1980, AM J MED, V69, P507, DOI 10.1016/0002-9343(80)90460-X; LIM I, 1989, MED J AUSTRALIA, V151, P87, DOI 10.5694/j.1326-5377.1989.tb101168.x; MACFARLANE JT, 1984, THORAX, V39, P28, DOI 10.1136/thx.39.1.28; MACFARLANE JT, 1982, LANCET, V2, P255; MACFARLANE JT, 1983, THORAX, V38, P231; Mandell L, 1993, Can J Infect Dis, V4, P25; MARRIE TJ, 1985, J AM GERIATR SOC, V33, P671, DOI 10.1111/j.1532-5415.1985.tb01775.x; MARRIE TJ, 1986, J AM GERIATR SOC, V34, P697, DOI 10.1111/j.1532-5415.1986.tb04300.x; MARRIE TJ, 1992, J INFECTION, V24, P247, DOI 10.1016/S0163-4453(05)80029-5; MARRIE TJ, 1988, CLIN INVEST MED, V11, P10; MARRIE TJ, 1987, ANN INTERN MED, V106, P507, DOI 10.7326/0003-4819-106-4-507; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; MAY HM, 1994, RESP MED, V88, P693, DOI 10.1016/S0954-6111(05)80069-1; MCNABB WR, 1984, J ROY SOC MED, V77, P550, DOI 10.1177/014107688407700705; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MEYERS JD, 1975, ANN INTERN MED, V82, P181, DOI 10.7326/0003-4819-82-2-181; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MEYERS JD, 1994, AM J RESP CRIT CARE, V149, P630; MOHAMED ARE, 1987, J INFECTION, V14, P31, DOI 10.1016/S0163-4453(87)90756-0; MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; MUFSON MA, 1967, AM J EPIDEMIOL, V86, P526, DOI 10.1093/oxfordjournals.aje.a120763; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505; Munda R, 1976, Proc Clin Dial Transplant Forum, V6, P1; NEIMAN PE, 1977, J INFECT DIS, V136, P754, DOI 10.1093/infdis/136.6.754; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; NOONE P, 1978, J ANTIMICROB CHEMOTH, V4, P83, DOI 10.1093/jac/4.suppl_C.83; NORDSTROM K, 1983, SCAND J INFECT DIS, V15, P43, DOI 10.3109/inf.1983.15.issue-1.08; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; ORTQVIST A, 1988, SCAND J INFECT DIS, V20, P451, DOI 10.3109/00365548809032486; ORTQVIST A, 1988, SCAND J INFECT DIS, V20, P163, DOI 10.3109/00365548809032433; OSEASOHN R, 1978, AM REV RESPIR DIS, V117, P1003; PACHON J, 1990, AM REV RESPIR DIS, V142, P369, DOI 10.1164/ajrccm/142.2.369; PETERS SG, 1987, AM J MED, V82, P73, DOI 10.1016/0002-9343(87)90380-9; POE RH, 1986, ARCH INTERN MED, V146, P1304, DOI 10.1001/archinte.146.7.1304; PROUT S, 1983, S AFR MED J, V64, P443; REE GH, 1982, PAPUA NEW GUINEA MED, V25, P223; RELLO J, 1993, CHEST, V103, P232, DOI 10.1378/chest.103.1.232; RICHEY SD, 1994, OBSTET GYNECOL, V84, P525; RUF B, 1989, EUR RESPIR J, V2, P257; RYTEL MW, 1986, DIAGN MICR INFEC DIS, V4, pS35, DOI 10.1016/S0732-8893(86)80041-4; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SCHWARZMANN SW, 1971, ARCH INTERN MED, V127, P1037, DOI 10.1001/archinte.127.6.1037; SEEDAT MA, 1993, Q J MED, V86, P669, DOI 10.1093/qjmed/86.10.669; SICKLES EA, 1973, ANN INTERN MED, V79, P528, DOI 10.7326/0003-4819-79-4-528; SMITH FE, 1981, W J MED, V136, P1; SOBRADILLO V, 1989, EUR RESPIR J, V2, P263; Sofowora E O, 1973, Niger Med J, V3, P144; SORENSEN J, 1989, SCAND J INFECT DIS, V21, P33, DOI 10.3109/00365548909035678; SORENSEN J, 1986, SCAND J INFECT DIS, V18, P329, DOI 10.3109/00365548609032344; STARCZEWSKI AR, 1988, AGE AGEING, V17, P181, DOI 10.1093/ageing/17.3.181; SULKAVA R, 1980, ANN CLIN RES, V12, P59; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; TUGWELL PX, 1981, CAN MED ASSOC J, V124, P869; VANEEDEN SF, 1988, S AFR MED J, V73, P77; VANEEDEN SF, 1990, CRIT CARE MED, V18, P1204, DOI 10.1097/00003246-199011000-00003; VENKATESAN P, 1990, THORAX, V45, P254, DOI 10.1136/thx.45.4.254; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; WEITZMAN S, 1983, ISRAEL J MED SCI, V19, P591; WHITE RJ, 1981, THORAX, V36, P566, DOI 10.1136/thx.36.8.566; WINTERBAUER RH, 1969, ANN INTERN MED, V70, P689, DOI 10.7326/0003-4819-70-4-689; WOODHEAD MA, 1987, BRIT J DIS CHEST, V81, P133, DOI 10.1016/0007-0971(87)90130-6; WOODHEAD MA, 1987, LANCET, V1, P671; WOODHEAD MA, 1991, RESP MED, V85, P313, DOI 10.1016/S0954-6111(06)80103-4; WOODHEAD MA, 1987, Q J MED, V64, P783; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; ZWEIG S, 1990, J FAM PRACTICE, V30, P153; 1992, RES MED, V86, P7	137	950	1021	1	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					134	141		10.1001/jama.275.2.134	http://dx.doi.org/10.1001/jama.275.2.134			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531309				2022-12-28	WOS:A1996TN28000030
J	Zitnan, D; Kingan, TG; Hermesman, JL; Adams, ME				Zitnan, D; Kingan, TG; Hermesman, JL; Adams, ME			Identification of ecdysis-triggering hormone from an epitracheal endocrine system	SCIENCE			English	Article							MANDUCA-SEXTA; ECLOSION HORMONE; MOTOR PATTERN; CARDIOACTIVE PEPTIDE; NEURAL ORGANIZATION; TOBACCO HORNWORM; NERVOUS-SYSTEM; METAMORPHOSIS; ANTIBODIES; DROSOPHILA	Developing insects repeatedly shed their cuticle by means of a stereotyped behavior called ecdysis, thought to be initiated by the brain peptide eclosion hormone. Here an ecdysis-triggering hormone, Mas-ETH, is described from the tobacco hornworm Manduca sexta. Mas-ETH contains 26 amino acids and is produced by a segmentally distributed endocrine system of epitracheal glands (EGs). The EGs undergo a marked reduction in volume, appearance, and immunohistochemical staining during ecdysis, at which time Mas-ETH is found in the hemolymph. Injection of EGs extract or synthetic Mas-ETH into pharate larvae, pupae,or adults initiates preecdysis within 2 to 10 minutes, followed by ecdysis. Sensitivity to injected Mas-ETH appears much earlier before ecdysis and occurs with shorter latency than that reported for eclosion hormone. The isolated central nervous system responds to Mas-ETH, but not to eclosion hormone, with patterned motor bursting corresponding to in vivo preecdysis and ecdysis. Mas-ETH may be an immediate blood-borne trigger for ecdysis through a direct action on the nervous system.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,AGR EXPT STN,RIVERSIDE,CA 92521; USDA ARS,INSECT NEUROBIOL & HORMONE LAB,BELTSVILLE,MD 20705; UNIV MARYLAND,DEPT BIOL SCI,BALTIMORE,MD 21228	University of California System; University of California Riverside; University of California System; University of California Riverside; United States Department of Agriculture (USDA); University System of Maryland; University of Maryland Baltimore			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113				AKAI H, 1992, Cytologia (Tokyo), V57, P195; COPENHAVER PF, 1982, J INSECT PHYSIOL, V28, P695, DOI 10.1016/0022-1910(82)90148-2; CURTIS AT, 1984, J INSECT PHYSIOL, V30, P597, DOI 10.1016/0022-1910(84)90043-X; EWER J, 1994, J NEUROSCI, V14, P7704; HEWES RS, 1991, J COMP PHYSIOL A, V168, P697; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Keilin D., 1944, PARASITOLOGY, V36, P1, DOI 10.1017/S0031182000011975; MASINOVSKY B, 1988, J COMP NEUROL, V273, P500, DOI 10.1002/cne.902730406; MILES CI, 1991, J COMP PHYSIOL A, V168, P179, DOI 10.1007/BF00218410; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; REYNOLDS SE, 1979, J EXP BIOL, V78, P77; Truman J.W., 1985, P381; TRUMAN JW, 1992, PROG BRAIN RES, V92, P361, DOI 10.1016/S0079-6123(08)61189-9; TRUMAN JW, 1978, J EXP BIOL, V74, P151; TRUMAN JW, 1980, J EXP BIOL, V88, P327; TRUMAN JW, 1994, INSECT NEUROCHEMISTRY AND NEUROPHYSIOLOGY 1993, P39; TRUMAN JW, 1983, NEURAL CONTROL RHYTH, V37, P223; WEEKS JC, 1984, J COMP PHYSIOL, V155, P407, DOI 10.1007/BF00610594; WEEKS JC, 1984, J COMP PHYSIOL, V155, P423, DOI 10.1007/BF00610595; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063; ZITNAN D, 1989, THESIS SLOVAK ACADEM; ZITNAN D, 1995, J COMP NEUROL, V355, P1; ZITNAN D, UNPUB	23	188	195	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					88	91						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539606				2022-12-28	WOS:A1996TP02200050
J	Hargarten, SW; Karlson, TA; OBrien, M; Hancock, J; Quebbeman, E				Hargarten, SW; Karlson, TA; OBrien, M; Hancock, J; Quebbeman, E			Characteristics of firearms involved in fatalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To document the types of firearms associated with firearm fatalities, and to determine the availability of information on firearm characteristics in existing data sources. Design.-Review of police, medical examiner, and crime laboratory records for all firearm homicides and review of medical examiner records for all suicides and unintentional and undetermined firearm fatalities. Setting.-City of Milwaukee, Wis, from 1990 through 1994. Population.-A total of 175 firearm suicides and 524 firearm homicides. Main Outcome Measures.-Source of data, circumstances and means of death; host demographic characteristics; firearm make, model, caliber, barrel length, and serial number. Results.-Handguns accounted for 468 (89%) of 524 firearm homicides and 124 (71%) of 175 firearm suicides. Handguns of .25 caliber accounted for 14% (n=63) of 438 firearm homicides and 12% (n=15) of all firearm suicides in which caliber was known. The Raven MP-25 was the single most commonly identified firearm and accounted for 10% (n=15) of 153 handgun homicide cases and 7% (n=7) of the 76 suicide cases in which the manufacturer of the firearm was identified. From all data sources combined, information on firearm type was available in 681 (97%) of 699 cases, caliber/gauge in 636 cases (91%), manufacturer/model in 309 cases (44%), and serial number in 276 cases (40%). Conclusions.-Inexpensive, short-barreled .25-caliber handguns were the most common weapon type associated with firearm homicides and suicides in Milwaukee during 1990 through 1994. Product-specific Information is a crucial part of planning appropriate injury countermeasures for firearms. in combination, police, crime laboratory, and medical examiner data can supply this information with modest changes in data collection procedures.	MED COLL WISCONSIN,DEPT GEN SURG,MILWAUKEE,WI 53226; UNIV WISCONSIN,CTR HLTH SYST RES & ANAL,MADISON,WI; WISCONSIN DEPT JUSTICE,OFF CONSUMER PROTECT,MADISON,WI	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Hargarten, SW (corresponding author), MED COLL WISCONSIN,DEPT EMERGENCY MED,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							BAKER S, 1992, INJURY FACT BOOK, P9; FREEDMAN A, 1992, WALL STREET J   0218, pA1; HARGARTEN S, 1994, WIS MED J        OCT, P521; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; WINTEMUTE G, 1993, JAMA-J AM MED ASSOC, V269, P2213, DOI 10.1001/jama.1993.03500170043026; Wintemute G., 1994, RING FIRE HANDGUN MA; Zane D F, 1991, Tex Med, V87, P63; 1992, FATAL ACCIDENT REPOR; 1983, ATF FORM 4590; 1994, 1994 BUYERS GUIDE SH, V38, P153; 1994, 1994 GUYERS GUIDE SH, V38, P145; 1994, MMWR-MORBID MORTAL W, V43, P3; 1994, 1994 BUYERS GUIDE SH, V38, P148; 1985, INJURY AM, P191; 1994, US DOT HS808169 US D	16	65	66	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					42	45		10.1001/jama.275.1.42	http://dx.doi.org/10.1001/jama.275.1.42			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531285				2022-12-28	WOS:A1996TM23800020
J	DOWNWARD, J				DOWNWARD, J			KSR - A NOVEL PLAYER IN THE RAS PATHWAY	CELL			English	Review							KINASE				DOWNWARD, J (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Downward, Julian/0000-0002-2331-4729				BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KORNFELD K, 1995, EMBO J, V14, P3136; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SOZERI O, 1992, ONCOGENE, V7, P2259; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAN M, 1994, NATURE, V372, P789	16	42	56	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					831	834		10.1016/0092-8674(95)90198-1	http://dx.doi.org/10.1016/0092-8674(95)90198-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521506	Bronze			2022-12-28	WOS:A1995TK74500001
J	FIELDS, BA; OBER, B; MALCHIODI, EL; LEBEDEVA, MI; BRADEN, BC; YSERN, X; KIM, JK; SHAO, XG; WARD, ES; MARIUZZA, RA				FIELDS, BA; OBER, B; MALCHIODI, EL; LEBEDEVA, MI; BRADEN, BC; YSERN, X; KIM, JK; SHAO, XG; WARD, ES; MARIUZZA, RA			CRYSTAL-STRUCTURE OF THE V-ALPHA DOMAIN OF A T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; 3-DIMENSIONAL STRUCTURE; MOLECULAR-STRUCTURE; VARIABLE PORTIONS; ENCEPHALOMYELITIS; RECOGNITION; ACTIVATION; CLONES; REI	The crystal structure of the V-alpha domain of a T cell antigen receptor (TCR) was determined at a resolution of 2.2 angstroms. This structure represents an immunoglobulin topology set different from those previously described. A switch in a polypeptide strand from one beta sheet to the other enables a pair of V-alpha homodimers to pack together to form a tetramer, such that the homodimers are parallel to each other and all hypervariable loops face in one direction. On the basis of the observed mode of V-alpha association, a model of an (alpha beta)(2) TCR tetramer can be positioned relative to the major histocompatibility complex class II (alpha beta)(2) tetramer with the third hypervariable loop of V-alpha over the amino-terminal portion of the antigenic peptide and the corresponding loop of V-beta over its carboxyl-terminal residues. TCR dimerization that is mediated by the alpha chain may contribute to the coupling of antigen recognition to signal transduction during T cell activation.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; UNIV TEXAS, SW MED CTR, CTR CANC IMMUNOBIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA; US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Food & Drug Administration (FDA)				Malchiodi, Emilio/0000-0001-7501-3330; Ward, E. Sally/0000-0003-3232-7238; Fields, Barry/0000-0003-0628-1328	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031592] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31592] Funding Source: Medline; NIGMS NIH HHS [GM52801] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; EPP O, 1974, EUR J BIOCHEM, V45, P513, DOI 10.1111/j.1432-1033.1974.tb03576.x; FIELDS BA, 1994, J MOL BIOL, V239, P339, DOI 10.1006/jmbi.1994.1373; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; GOODMAN S, 1995, J IMMUNOL, V155, P1210; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KAPPLER J, 1983, CELL, V34, P727, DOI 10.1016/0092-8674(83)90529-9; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; STEINMAN L, 1991, ADV IMMUNOL, V49, P357; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	35	180	181	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1821	1824		10.1126/science.270.5243.1821	http://dx.doi.org/10.1126/science.270.5243.1821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525376				2022-12-28	WOS:A1995TK47600046
J	HELLWALD, KH; PALUKAITIS, P				HELLWALD, KH; PALUKAITIS, P			VIRAL-RNA AS A POTENTIAL TARGET FOR 2 INDEPENDENT MECHANISMS OF REPLICASE-MEDIATED RESISTANCE AGAINST CUCUMBER MOSAIC-VIRUS	CELL			English	Article							NUCLEOTIDE-SEQUENCE; X INFECTION; PLANTS; PROTEIN; INVITRO; GENE; COMPLEMENTARY; TRANSCRIPTS; EXPRESSION; POLYMERASE	Transgenic tobacco showing replicase-mediated resistance against cucumber mosaic virus (CMV) can be infected by the strain K-CMV. By use of chimeric constructs between full-length cDNA clones of RNA2 of strains Fny-CMV and K-CMV, the existence of two independent mechanisms of replicase-mediated resistance against viral replication and movement of Fny-CMV was demonstrated in these plants. The data indicate that viral RNA may serve as the target for both mechanisms of resistance. A positive correlation was observed between the amount of K-CMV RNA2 sequence present in the chimeric constructs and the ability to overcome the inhibition of replication, whereas a sequence domain was delimited in K-CMV RNAS responsible for the ability of this strain to break resistance against virus movement.	CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853	Cornell University								AHLQUIST P, 1981, CELL, V23, P183, DOI 10.1016/0092-8674(81)90283-X; ANDERSON JM, 1992, P NATL ACAD SCI USA, V89, P8759, DOI 10.1073/pnas.89.18.8759; AUDY P, 1994, MOL PLANT MICROBE IN, V7, P15, DOI 10.1094/MPMI-7-0015; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BOCCARD F, 1992, GENE, V114, P223, DOI 10.1016/0378-1119(92)90578-D; BRAUN CJ, 1992, PLANT CELL, V4, P735, DOI 10.1105/tpc.4.6.735; BREDERODE FT, 1995, VIROLOGY, V207, P467, DOI 10.1006/viro.1995.1106; CAMERON FH, 1991, NUCLEIC ACIDS RES, V19, P469, DOI 10.1093/nar/19.3.469; CARR JP, 1994, VIROLOGY, V199, P439, DOI 10.1006/viro.1994.1142; CARR JP, 1993, SEMIN VIROL, V4, P339, DOI 10.1006/smvy.1993.1032; COOPER B, 1995, VIROLOGY, V206, P307, DOI 10.1016/S0042-6822(95)80046-8; COUTTS RHA, 1977, PLANT SCI LETT, V9, P45, DOI 10.1016/0304-4211(77)90009-8; DING SW, 1994, VIROLOGY, V198, P593, DOI 10.1006/viro.1994.1071; DING SW, 1995, J GEN VIROL, V76, P459, DOI 10.1099/0022-1317-76-2-459; DONSON J, 1993, MOL PLANT MICROBE IN, V6, P635, DOI 10.1094/MPMI-6-635; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; GALON A, 1994, VIROLOGY, V205, P280, DOI 10.1006/viro.1994.1644; GOLEMBOSKI DB, 1990, P NATL ACAD SCI USA, V87, P6311, DOI 10.1073/pnas.87.16.6311; HAYES RJ, 1990, J GEN VIROL, V71, P2503, DOI 10.1099/0022-1317-71-11-2503; HELLWALD KH, 1994, J GEN VIROL, V75, P2121, DOI 10.1099/0022-1317-75-8-2121; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOSHI RL, 1983, EMBO J, V2, P1123, DOI 10.1002/j.1460-2075.1983.tb01556.x; KAPLAN IB, 1995, VIROLOGY, V209, P188, DOI 10.1006/viro.1995.1242; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LONGSTAFF M, 1993, EMBO J, V12, P379, DOI 10.1002/j.1460-2075.1993.tb05669.x; MACFARLANE SA, 1992, P NATL ACAD SCI USA, V89, P5829, DOI 10.1073/pnas.89.13.5829; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; PALUKAITIS P, 1992, ADV VIRUS RES, V41, P281, DOI 10.1016/B978-0-12-394314-9.00013-0; PALUKAITIS P, 1994, METH MOL G, V4, P237; POGUE GP, 1992, J VIROL, V66, P674, DOI 10.1128/JVI.66.2.674-684.1992; POWELLABEL P, 1986, SCIENCE, V232, P738, DOI DOI 10.1126/SCIENCE.3457472; QUADT R, 1991, FEBS LETT, V279, P273, DOI 10.1016/0014-5793(91)80166-Z; REZAIAN MA, 1985, EUR J BIOCHEM, V150, P331, DOI 10.1111/j.1432-1033.1985.tb09025.x; RIZZO TM, 1990, MOL GEN GENET, V222, P249, DOI 10.1007/BF00633825; RIZZO TM, 1988, J GEN VIROL, V69, P1777, DOI 10.1099/0022-1317-69-8-1777; RUBINO L, 1993, MOL PLANT MICROBE IN, V6, P729, DOI 10.1094/MPMI-6-729; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; SUZUKI M, 1991, VIROLOGY, V183, P106, DOI 10.1016/0042-6822(91)90123-S; TRAYNOR P, 1991, J VIROL, V65, P2807, DOI 10.1128/JVI.65.6.2807-2815.1991; WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134; ZAITLIN M, 1994, VIROLOGY, V201, P200, DOI 10.1006/viro.1994.1286; ZHANG L, 1994, J GEN VIROL, V75, P3185, DOI 10.1099/0022-1317-75-11-3185	43	44	50	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					937	946		10.1016/0092-8674(95)90209-0	http://dx.doi.org/10.1016/0092-8674(95)90209-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521517	hybrid			2022-12-28	WOS:A1995TK74500012
J	MANGELSDORF, DJ; EVANS, RM				MANGELSDORF, DJ; EVANS, RM			THE RXR HETERODIMERS AND ORPHAN RECEPTORS	CELL			English	Review							9-CIS RETINOIC ACID; DNA-BINDING DOMAIN; STEROIDOGENIC FACTOR-I; THYROID-HORMONE; NUCLEAR RECEPTORS; X-RECEPTOR; RESPONSE ELEMENTS; PEROXISOME PROLIFERATOR; FATTY-ACIDS; GLUCOCORTICOID RECEPTOR		UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CONNEELY OM, 1994, MOL BIOL INTELLIGENC, P111; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FORMAN BM, 1995, IN PRESS CELL, V83; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P394; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATAHIRA M, 1992, BIOCHEMISTRY-US, V31, P6474, DOI 10.1021/bi00143a017; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KLIEWER SA, 1995, IN PRESS CELL, V83; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VOMBAUR E, IN PRESS EMBO J; WAGNER RL, 1995, IN PRESS NATURE; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEIGEL NL, 1994, MECH STEROID HORMONE, P93; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	80	2725	2842	2	125	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					841	850		10.1016/0092-8674(95)90200-7	http://dx.doi.org/10.1016/0092-8674(95)90200-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521508	Bronze			2022-12-28	WOS:A1995TK74500003
J	THERRIEN, M; CHANG, HC; SOLOMON, NM; KARIM, FD; WASSERMAN, DA; RUBIN, GM				THERRIEN, M; CHANG, HC; SOLOMON, NM; KARIM, FD; WASSERMAN, DA; RUBIN, GM			KSR, A NOVEL PROTEIN-KINASE REQUIRED FOR RAS SIGNAL-TRANSDUCTION	CELL			English	Article							TYROSINE KINASE; DROSOPHILA; EXPRESSION; ACTIVATION; PATTERN; CELLS	We have identified and characterized two genes in Drosophila whose products are required for activated RAS to signal with normal efficiency, but do not appear to effect signaling by activated RAF, One encodes the beta subunit of type I geranylgeranyl transferase, a prenylation enzyme essential for targeting RAS to the plasma membrane, The other encodes a protein kinase that we have named kinase suppressor of ras (ksr). By genetic criteria, we show that KSR functions in multiple receptor tyrosine kinase pathways. We have isolated mammalian homologs of KSR that, together with the Drosophila gene, define a novel class of kinases. Our results suggest that KSR is a general and evolutionarily conserved component of the RAS signaling pathway that acts between RAS and RAF.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	THERRIEN, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDI G, 1995, PROTEIN KINASE 1; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUBBARD SR, 1991, SCIENCE, V254, P1776; KARPEN GH, 1992, GENETICS, V132, P737; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XU T, 1993, DEVELOPMENT, V117, P1223	44	329	343	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					879	888		10.1016/0092-8674(95)90204-X	http://dx.doi.org/10.1016/0092-8674(95)90204-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521512	Bronze			2022-12-28	WOS:A1995TK74500007
J	ADAMS, CBT				ADAMS, CBT			OXDONS SYNDROME - THE INEVITABLE DISEASE OF THE NHS REFORMS	BRITISH MEDICAL JOURNAL			English	Article								The financial demise of Oxford's department of neurosurgery (OxDONS) was precipitated by the financial rules of the reformed NHS. In particular it was produced by the failure of ''resources to follow patients''; the requirement that ''prices have to follow costs''; and the use of private income for revenue expenditure, not capital expenditure. This process will eventually affect all hospital departments, but it affected the unit in Oxford sooner as it Started as ''efficient''--that is, underresourced--and has depended on income from extracontractual referrals and private work. Current NHS accounting rules act as a disincentive to private income being generated in NHS hospitals, and consultants should be aware of this.			ADAMS, CBT (corresponding author), RADCLIFFE INFIRM,NHS TRUST,DEPT NEUROL SURG,OXFORD OX2 6HE,ENGLAND.							JONSSON B, 1994, SPINE, V19, P2381; NYGAARD OP, 1994, ACTA NEUROCHIR, V128, P53, DOI 10.1007/BF01400653; WINYARD GP, 1981, BRIT MED J, V282, P498; 1993, SAFE NEUROSURGERY	4	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1559	1561		10.1136/bmj.311.7019.1559	http://dx.doi.org/10.1136/bmj.311.7019.1559			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520404	Green Published			2022-12-28	WOS:A1995TK21400033
J	LIP, GYH; WATSON, RDS				LIP, GYH; WATSON, RDS			ABC OF ATRIAL-FIBRILLATION - DIFFERENTIAL-DIAGNOSIS OF ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND; CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								ZIPES DP, 1992, HEART DISEASE TXB CA, P667	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1495	1498		10.1136/bmj.311.7018.1495	http://dx.doi.org/10.1136/bmj.311.7018.1495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520345	Green Published			2022-12-28	WOS:A1995TJ04400036
J	PAL, B; HUTCHINSON, A; BHATTACHARYA, A; RALSTON, A				PAL, B; HUTCHINSON, A; BHATTACHARYA, A; RALSTON, A			LESSON OF THE WEEK - CARDIAC-ARREST DUE TO SEVERE HYPERKALEMIA IN PATIENT TAKING NABUMETONE AND LOW-SALT DIET	BRITISH MEDICAL JOURNAL			English	Article							ANTI-INFLAMMATORY DRUGS; KIDNEY				PAL, B (corresponding author), WITHINGTON HOSP,MANCHESTER M20 2LR,LANCS,ENGLAND.							BOERS M, 1990, SEMIN ARTHRITIS RHEU, V20, P57, DOI 10.1016/0049-0172(90)90095-W; HYNECK ML, 1992, J RHEUMATOL, V19, P20; PAL B, 1985, ANN RHEUM DIS, V44, P212, DOI 10.1136/ard.44.3.212-b; REEVES WB, 1984, ARCH INTERN MED, V144, P1943, DOI 10.1001/archinte.144.10.1943; SEGASOTHY M, 1995, BRIT J RHEUMATOL, V34, P162; STILLMAN MT, 1984, MED CLIN N AM, V68, P371; SWALES JD, 1991, BMJ-BRIT MED J, V303, P1084, DOI 10.1136/bmj.303.6810.1084; WHELTON A, 1991, J CLIN PHARMACOL, V31, P588, DOI 10.1002/j.1552-4604.1991.tb03743.x	8	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1486	1487		10.1136/bmj.311.7018.1486	http://dx.doi.org/10.1136/bmj.311.7018.1486			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520342	Green Published			2022-12-28	WOS:A1995TJ04400033
J	PERNEGER, TV; SUDRE, P; LUNDGREN, JD; HIRSCHEL, B				PERNEGER, TV; SUDRE, P; LUNDGREN, JD; HIRSCHEL, B			DOES THE ONSET OF TUBERCULOSIS IN AIDS PREDICT SHORTER SURVIVAL - RESULTS OF A COHORT STUDY IN 17 EUROPEAN COUNTRIES OVER 13 YEARS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Objective-To assess the impact of tuberculosis on mortality in patients with AIDS. Design-Community based cohort study. Setting-52 centres in 17 countries (AIDS in Europe study). Subjects-5249 patients who were alive and free of tuberculosis one month after the diagnosis of AIDS, enrolled between 1979 and 1989, and followed up until 1992. Main outcome measures-Onset of clinically active tuberculosis or death, or both. Results-During a mean follow up period of 15 months 201 (4%) patients developed tuberculosis and 3889 (74%) died. Patients who developed tuberculosis survived significantly longer (median 22 months) than those who did not (median 16 months). This apparent survival advantage was due to patients who survived longer having more opportunity to develop tuberculosis (or any other disease). In models that took into account the time at which tuberculosis was diagnosed, the onset of tuberculosis was associated with a significant increase in mortality (adjusted relative hazard of death 1 . 34; 95% confidence interval 1 . 12 to 1 . 60). Conclusions-The onset of tuberculosis in patients with AIDS predicts a substantial increase in mortality. Whether this increased mortality is directly attributable to the tuberculosis remains uncertain. If the association is causal preventive chemotherapy and aggressive treatment of tuberculosis could improve survival in AIDS.	UNIV HOSP GENEVA, DIV INFECT DIS, GENEVA, SWITZERLAND; UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK	University of Geneva; University of Copenhagen	PERNEGER, TV (corresponding author), UNIV GENEVA, INST SOCIAL & PREVENT MED, CMU CASE POSTALE, CH-1211 GENEVA 4, SWITZERLAND.		Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; Collett D, 1994, MODELLING SURVIVAL D; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; HORSBURGH CR, 1993, AIDS, V7, pS109, DOI 10.1097/00002030-199301001-00014; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; 1987, MMWR-MORBID M      S, V36, P3	15	57	58	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	1995	311	7018					1468	1471		10.1136/bmj.311.7018.1468	http://dx.doi.org/10.1136/bmj.311.7018.1468			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520334	Green Published, Green Submitted			2022-12-28	WOS:A1995TJ04400023
J	GRIFF, IC; REED, RR				GRIFF, IC; REED, RR			THE GENETIC-BASIS FOR SPECIFIC ANOSMIA TO ISOVALERIC ACID IN THE MOUSE	CELL			English	Article							RECOMBINANT-INBRED STRAINS; ODORANT-BINDING PROTEIN; HUMAN COLOR-VISION; OLFACTORY EPITHELIUM; RECEPTOR EXPRESSION; MOLECULAR-GENETICS; CONGENIC STRAINS; LIGAND-BINDING; MICE; SENSITIVITY	The detection and discrimination of odorants in mammals is thought to be mediated by a family of 100-1000 seven transmembrane domain receptor proteins, although none of these putative olfactory receptors have been shown to bind individual odorants with high affinity. We have used a genetic approach to identify the genomic regions responsible for the differential ability of two inbred mouse strains to detect a single odorant, isovaleric acid. Results obtained with a behavioral assay were consistent with a limited number of genes conf erring the ability to detect isovaleric acid. One genetic location mapped to a 0.3 cM region between D4MIT37 and D4MIT156 on mouse chromosome 4. A second locus mapped to the distal end of mouse chromosome 6. The most likely cause of the behavior difference between the two strains of mice is the loss of the receptor protein or proteins responsible for recognizing isovaleric acid. High resolution genetic mapping provides a novel approach to the identification of genes critical for the detection of particular odorants.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University	GRIFF, IC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.		Reed, Russell/HGU-0528-2022					ABBOTT CM, 1993, MAMM GENOME, V4, pS58, DOI 10.1007/BF00360830; Amoore J. E., 1991, SMELL TASTE HLTH DIS, P655; AMOORE JE, 1967, NATURE, V214, P1095, DOI 10.1038/2141095a0; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BELKNAP JK, 1992, BEHAV GENET, V22, P81, DOI 10.1007/BF01066794; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAPELESS CG, 1992, BEHAV GENET, V22, P655, DOI 10.1007/BF01066636; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CUSCHIERI A, 1975, J ANAT, V119, P277; CUSCHIERI A, 1975, J ANAT, V119, P471; DEAR TN, 1991, EMBO J, V10, P2813, DOI 10.1002/j.1460-2075.1991.tb07830.x; Defranco Anthony L., 1993, P505; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; GROSSISSEROFF R, 1992, NEUROSCI LETT, V141, P115, DOI 10.1016/0304-3940(92)90347-A; HUBERT HB, 1980, SCIENCE, V208, P607, DOI 10.1126/science.7189296; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KISHIMOTO J, 1994, MOL BRAIN RES, V23, P33, DOI 10.1016/0169-328X(94)90208-9; KOSHIMOTO H, 1994, NEUROSCI LETT, V169, P73, DOI 10.1016/0304-3940(94)90359-X; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUSH IE, 1988, GENET RES, V52, P207, DOI 10.1017/S0016672300027671; LUSH IE, 1989, GENET RES, V53, P95, DOI 10.1017/S0016672300027968; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PATTERSON PM, 1948, J HERED, V39, P295, DOI 10.1093/oxfordjournals.jhered.a105774; PEVSNER J, 1990, J BIOL CHEM, V265, P6118; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PEVSNER J, 1988, P NATL ACAD SCI USA, V85, P2383, DOI 10.1073/pnas.85.7.2383; POURTIER L, 1990, BEHAV GENET, V20, P499, DOI 10.1007/BF01067716; PRICE S, 1977, NEUROSCI LETT, V4, P49, DOI 10.1016/0304-3940(77)90123-9; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; STROTMANN J, 1994, CELL TISSUE RES, V276, P429; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; WANG HW, 1993, SCIENCE, V260, P998, DOI 10.1126/science.8493539; WHISSELL.D, 1973, NATURE, V245, P157, DOI 10.1038/245157b0; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; WYSOCKI CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4899, DOI 10.1073/pnas.81.15.4899; WYSOCKI CJ, 1991, CHEM SENSES, V3, P331	53	53	57	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					407	414		10.1016/0092-8674(95)90118-3	http://dx.doi.org/10.1016/0092-8674(95)90118-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521470	Bronze			2022-12-28	WOS:A1995TC97700010
J	MICHAEL, WM; CHOI, MY; DREYFUSS, G				MICHAEL, WM; CHOI, MY; DREYFUSS, G			A NUCLEAR EXPORT SIGNAL IN HNRNP A1 - A SIGNAL-MEDIATED, TEMPERATURE-DEPENDENT NUCLEAR-PROTEIN EXPORT PATHWAY	CELL			English	Article							RNA-BINDING-PROTEINS; LOCATION SIGNALS; 2 STEPS; LARGE-T; TRANSLOCATION; NUCLEOPLASMIN; SEQUENCE; COMPLEX; IMPORT; PORE	Pre-mRNAs are associated with hnRNPs, and these proteins play important roles in the biogenesis of mRNAs, The hnRNP Al is one of the most abundant hnRNPs, and although localized primarily in the nucleoplasm, shuttles continuously between the nucleus and the cytoplasm, A 38 amino acid domain within Al, termed M9, which bears no resemblance to classical nuclear localization signal (NLS) sequences, localizes Al to the nucleus, Here we show that M9 is also a nuclear export signal; placing M9 on a protein that is otherwise restricted to the nucleus, the nucleoplasmin core domain (NPc), efficiently exports it to the cytoplasm in a temperature-dependent manner. In contrast, classical NLSs cannot promote the export of NPc. These findings demonstrate that there is a signal-dependent, temperature-sensitive nuclear export pathway and strengthen the suggestion that Al and other shuttling hnRNPs function as carriers for RNA during export to the cytoplasm.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	MICHAEL, WM (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		McDermott, Michael Francis/GZM-5330-2022; Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CULLEN BR, 1991, J VIROL, V65, P1053, DOI 10.1128/JVI.65.3.1053-1056.1991; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MEHLIN H, 1995, J CELL BIOL, V129, P1205, DOI 10.1083/jcb.129.5.1205; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1988, CELL, V64, P615; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZAPP ML, 1995, CURR OPIN GENET DEV, V5, P229, DOI 10.1016/0959-437X(95)80013-1	49	469	478	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					415	422						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521471				2022-12-28	WOS:A1995TC97700011
J	SHERR, CJ				SHERR, CJ			MAMMALIAN G(1)-CYCLINS	CELL			English	Review							HUMAN CYCLIN-A; CELL-CYCLE; PROMOTING FACTOR; DNA-REPLICATION; MESSENGER-RNA; PROTEIN; PHASE; GENE; ONCOGENE; KINASE				SHERR, CJ (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, HOWARD HUGHES MED INST, MEMPHIS, TN 38101 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, IN PRESS GENES DEV, V7; BIANCHI AB, 1993, IN PRESS ONCOGENE, V8; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COCKS BG, 1992, J BIOL CHEM, V267, P12307; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNA Z, 1993, IN PRESS ONCOGENE, V8; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1992, SCIENCE, V258, P424; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, 1993, IN PRESS ONCOGENE, V8; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	73	2104	2217	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1059	1065		10.1016/0092-8674(93)90636-5	http://dx.doi.org/10.1016/0092-8674(93)90636-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513492				2022-12-28	WOS:A1993LH54800003
J	SHAPIRO, CM; DEVINS, GM; HUSSAIN, MRG				SHAPIRO, CM; DEVINS, GM; HUSSAIN, MRG			ABC OF SLEEP DISORDERS - SLEEP PROBLEMS IN PATIENTS WITH MEDICAL ILLNESS	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,CLARKE INST PSYCHIAT,TORONTO M5T 1R8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	SHAPIRO, CM (corresponding author), UNIV TORONTO,TORONTO HOSP,TORONTO M5S 1A1,ONTARIO,CANADA.								0	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1532	1535		10.1136/bmj.306.6891.1532	http://dx.doi.org/10.1136/bmj.306.6891.1532			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518686	Green Published, Bronze			2022-12-28	WOS:A1993LF94000035
J	SMITH, J				SMITH, J			THE NEW NHS - THE 2ND YEAR - WEST-SUFFOLK - A NEW LANDSCAPE	BRITISH MEDICAL JOURNAL			English	Article																		SMITH J, 1992, BRIT MED J, V304, P1036, DOI 10.1136/bmj.304.6833.1036; SMITH J, 1991, BRIT MED J, V302, P641, DOI 10.1136/bmj.302.6777.641	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1524	1526		10.1136/bmj.306.6891.1524	http://dx.doi.org/10.1136/bmj.306.6891.1524			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518683	Bronze, Green Published			2022-12-28	WOS:A1993LF94000031
J	Fadic, R; Sunada, Y; Waclawik, AJ; Buck, S; Lewandoski, PJ; Campbell, KP; Lotz, BP				Fadic, R; Sunada, Y; Waclawik, AJ; Buck, S; Lewandoski, PJ; Campbell, KP; Lotz, BP			Brief report: Deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DILATED CARDIOMYOPATHY; FUKUYAMA-TYPE; PROTEINS; COMPLEX; MUSCLE; GENE; EXPRESSION; LOCUS		UNIV WISCONSIN, DEPT NEUROL, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI USA; UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Iowa; University of Iowa			Fadic, Ricardo/E-9488-2013	Campbell, Kevin/0000-0003-2066-5889				AZIBI K, 1993, HUM MOL GENET, V2, P1423; BORGEAT A, 1987, CLIN CARDIOL, V10, P127, DOI 10.1002/clc.4960100209; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CASAZZA F, 1988, J NEUROL, V235, P496, DOI 10.1007/BF00314256; DEVISSER M, 1992, MUSCLE NERVE, V15, P591, DOI 10.1002/mus.880150510; DONOFRIO PD, 1989, ARCH NEUROL-CHICAGO, V46, P705, DOI 10.1001/archneur.1989.00520420127038; DORSOGNA L, 1988, PEDIATR CARDIOL, V9, P205, DOI 10.1007/BF02078410; ENGEL AG, 1994, MYOLOGY, P822; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FARAH MG, 1980, AM J MED, V69, P248, DOI 10.1016/0002-9343(80)90385-X; FARDEAU M, 1993, CR ACAD SCI III-VIE, V316, P799; FUKUYAMA Y, 1981, BRAIN DEV-JPN, V3, P1; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HILLAIRE D, 1994, HUM MOL GENET, V3, P1657, DOI 10.1093/hmg/3.9.1657; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KUHN E, 1979, NEUROLOGY, V29, P1144, DOI 10.1212/WNL.29.8.1144; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; MATSUMURA K, 1993, AM J HUM GENET, V53, P409; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; McNally E. M., 1994, American Journal of Human Genetics, V55, pA135; MICHELS VV, 1993, J MED GENET, V30, P955, DOI 10.1136/jmg.30.11.955; MIZUNO Y, 1994, BIOCHEM BIOPH RES CO, V203, P979, DOI 10.1006/bbrc.1994.2278; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NONAKA I, 1982, MUSCLE NERVE, V5, P102, DOI 10.1002/mus.880050204; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PALMUCCI L, 1992, J NEUROL SCI, V111, P218, DOI 10.1016/0022-510X(92)90073-T; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SEWRY CA, 1994, NEUROMUSCULAR DISORD, V4, P121, DOI 10.1016/0960-8966(94)90003-5; SPECHT LA, 1993, MOL GENETIC BASIS NE, P613; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; TODA T, 1994, NAT GENET, V7, P113, DOI 10.1038/ng0594-113a; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; VRINTS C, 1983, ACTA CARDIOL, V38, P479; YOSHIDA K, 1993, MUSCLE NERVE, V16, P1161, DOI 10.1002/mus.880161104; ZATZ M, 1994, J NEUROL SCI, V123, P122, DOI 10.1016/0022-510X(94)90213-5	42	63	64	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					362	366		10.1056/NEJM199602083340604	http://dx.doi.org/10.1056/NEJM199602083340604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT487	8538707				2022-12-28	WOS:A1996TT48700004
J	Israelachvili, J; Wennerstrom, H				Israelachvili, J; Wennerstrom, H			Role of hydration and water structure in biological and colloidal interactions	NATURE			English	Review							AQUEOUS-ELECTROLYTE SOLUTIONS; ATOMIC FORCE MICROSCOPE; MICA SURFACES; DOUBLE-LAYER; PHOSPHATIDYLCHOLINE BILAYERS; HYDROPHOBIC INTERACTION; MOLECULAR-DYNAMICS; SOLVATION FORCES; LAMELLAR PHASES; CACL2 SOLUTIONS	The conventional explanation of why hydrophilic surfaces and macromolecules remain well separated in water is that they experience a monotonically repulsive hydration force owing to structuring of water molecules at the surfaces. A consideration of recent experimental and theoretical results suggests an alternative interpretation in which hydration forces are either attractive or oscillatory, and where repulsions have a totally different origin. Further experiments are needed to distinguish between these possibilities.	UNIV CALIF SANTA BARBARA, DEPT MAT, SANTA BARBARA, CA 93106 USA; LUND UNIV, CTR CHEM, S-22100 LUND, SWEDEN	University of California System; University of California Santa Barbara; Lund University	Israelachvili, J (corresponding author), UNIV CALIF SANTA BARBARA, DEPT CHEM ENGN, SANTA BARBARA, CA 93106 USA.		Zdilla, Michael J/B-4145-2011; Wunder, Stephanie L/B-5066-2012					Allen M.P., 1987, COMPUTER SIMULATION, DOI [10.2307/2938686, DOI 10.2307/2938686]; ATTARD P, 1988, CHEM PHYS LETT, V149, P206, DOI 10.1016/0009-2614(88)87223-3; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, pCH23; CHRISTENSON HK, 1985, CHEM PHYS LETT, V118, P455, DOI 10.1016/0009-2614(85)85331-8; CHRISTENSON HK, 1993, LANGMUIR, V9, P2448, DOI 10.1021/la00033a030; CHRISTENSON HK, 1986, J PHYS CHEM-US, V90, P4, DOI 10.1021/j100273a002; CHRISTENSON HK, 1988, J DISPER SCI TECHNOL, V9, P171, DOI 10.1080/01932698808943983; CHRISTENSON HK, 1992, MODERN APPROACHES WE, P29; CLAESSON P, 1984, J COLLOID INTERF SCI, V100, P250, DOI 10.1016/0021-9797(84)90433-8; COULSON CA, 1961, VALENCE, pCHR13; CURRY NA, 1971, J CHEM SOC A, P3725, DOI 10.1039/j19710003725; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; Derjaguin B. V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L; DERJAGUIN BV, 1973, NATURE, V244, P430, DOI 10.1038/244430a0; DERJAGUIN BV, 1986, FLUID INTERFACIAL PH, P633; DROSTHANSEN W, 1979, CELL ASS WATER; DUBOIS M, 1992, J CHEM PHYS, V96, P2278, DOI 10.1063/1.462078; DUCKER WA, 1991, NATURE, V353, P239, DOI 10.1038/353239a0; EVANS R, 1990, J PHYS-CONDENS MAT, V2, pSA15, DOI 10.1088/0953-8984/2/S/003; Franks F., 1981, POLYWATER; Franks F, 1972, WATER COMPREHENSIVE, V1-7; FRENS G, 1972, J COLLOID INTERF SCI, V38, P376, DOI 10.1016/0021-9797(72)90253-6; GEE ML, 1990, J CHEM SOC FARADAY T, V86, P4049, DOI 10.1039/ft9908604049; GRANFELDT MK, 1991, J PHYS CHEM-US, V95, P6351, DOI 10.1021/j100169a051; GRUEN DWR, 1983, J CHEM SOC FARAD T 2, V79, P225, DOI 10.1039/f29837900225; HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030; HANSEN WD, 1982, BIOPHYSICS WATER, P163; Hartley G. S., 1936, AQUEOUS SOLUTIONS PA, P60; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HENDERSON D, 1988, J COLLOID INTERF SCI, V121, P486, DOI 10.1016/0021-9797(88)90450-X; HENDERSON D, 1986, J COLLOID INTERF SCI, V114, P180, DOI 10.1016/0021-9797(86)90250-X; HOM RG, 1989, CHEM PHYS LETT, V162, P404; HUNTER RJ, 1989, F COLLOID SCI, V1; ILER K, 1979, CHEM SILICA, P628; Iler R. K., 1979, CHEM SILICA, P644; ILER RK, 1979, CHEM SILICA, P135; ILER RK, 1979, CHEM SILICA, P640; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; ISRAELACHVILI JN, 1985, CHEM SCRIPTA, V25, P7; ISRAELACHVILI JN, 1983, NATURE, V306, P249, DOI 10.1038/306249a0; ISRAELACHVILI JN, 1986, J COLLOID INTERF SCI, V110, P263, DOI 10.1016/0021-9797(86)90376-0; ISRAELACHVILI JN, 1992, J PHYS CHEM-US, V96, P520, DOI 10.1021/j100181a007; ISRAELACHVILI JN, 1982, BIOPHYSICS WATER, P183; JONSSON B, 1980, J PHYS CHEM-US, V84, P2179; KJELLANDER R, 1988, J PHYS CHEM-US, V92, P6489, DOI 10.1021/j100334a005; KJELLANDER R, 1990, J CHEM PHYS, V92, P4399, DOI 10.1063/1.457750; KJELLANDER R, 1985, CHEM PHYS LETT, V120, P393, DOI 10.1016/0009-2614(85)85626-8; KJELLANDER R, 1985, CHEM SCRIPTA, V25, P73; Langmuir I, 1938, J CHEM PHYS, V6, P873, DOI 10.1063/1.1750183; LEERMAKERS FAM, 1988, J CHEM PHYS, V89, P3264, DOI 10.1063/1.454931; LEIKIN S, 1993, ANNU REV PHYS CHEM, V44, P369, DOI 10.1146/annurev.pc.44.100193.002101; Lennard-Jones JE, 1928, T FARADAY SOC, V24, P0092, DOI 10.1039/tf9282400092; LIS LJ, 1982, BIOPHYS J, V37, P657; LUZAR A, 1987, J CHEM PHYS, V86, P2955, DOI 10.1063/1.452047; LYLE IG, 1986, CHEM PHYS LETT, V124, P432, DOI 10.1016/0009-2614(86)85048-5; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; MARCELJA S, 1976, CHEM PHYS LETT, V42, P129, DOI 10.1016/0009-2614(76)80567-2; MARCELJA S, 1990, LES HOUCH S, P99; MARRA J, 1985, BIOCHEMISTRY-US, V24, P4608, DOI 10.1021/bi00338a020; MARRA J, 1985, J COLLOID INTERF SCI, V107, P446, DOI 10.1016/0021-9797(85)90197-3; MARRA J, 1986, BIOPHYS J, V50, P815, DOI 10.1016/S0006-3495(86)83522-6; MARRA J, 1986, J PHYS CHEM-US, V90, P2145, DOI 10.1021/j100401a031; MARRA J, 1986, J COLLOID INTERF SCI, V109, P11, DOI 10.1016/0021-9797(86)90276-6; MARRINK SJ, 1993, LANGMUIR, V9, P3122, DOI 10.1021/la00035a062; MARSH D, 1989, BIOPHYS J, V55, P1093, DOI 10.1016/S0006-3495(89)82906-6; MCINTOSH TJ, 1989, BIOCHEMISTRY-US, V28, P7904, DOI 10.1021/bi00445a053; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P7325, DOI 10.1021/bi00397a020; MCINTOSH TJ, 1993, BIOCHEMISTRY-US, V32, P8374, DOI 10.1021/bi00083a042; MCINTOSH TJ, 1994, ANNU REV BIOPH BIOM, V23, P27, DOI 10.1146/annurev.bb.23.060194.000331; MEAGHER L, 1992, J COLLOID INTERF SCI, V152, P293, DOI 10.1016/0021-9797(92)90030-P; MYSELS KJ, 1992, LANGMUIR, V8, P3191, DOI 10.1021/la00048a055; PASHLEY RM, 1982, ADV COLLOID INTERFAC, V16, P57, DOI 10.1016/0001-8686(82)85006-9; PASHLEY RM, 1984, J COLLOID INTERF SCI, V101, P511, DOI 10.1016/0021-9797(84)90063-8; PERSSON PKT, 1985, BIOPHYS J, V47, P743, DOI 10.1016/S0006-3495(85)83974-6; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; SCHEUTJENS JMHM, 1985, MACROMOLECULES, V18, P1882, DOI 10.1021/ma00152a016; SCHIBY D, 1983, CHEM PHYS LETT, V95, P435, DOI 10.1016/0009-2614(83)80589-2; SERVUSS RM, 1989, J PHYS-PARIS, V50, P809, DOI 10.1051/jphys:01989005007080900; SHUBIN VE, 1993, J COLLOID INTERF SCI, V155, P108, DOI 10.1006/jcis.1993.1016; SMITH CA, 1992, BIOL MOL, pCH8; TANFORD C, 1980, HYDROPHOBIC EFFECT; TARAZONA P, 1985, MOL PHYS, V56, P557, DOI 10.1080/00268978500102521; TIDDY GJT, 1980, PHYS REP, V57, P1, DOI 10.1016/0370-1573(80)90041-1; Verwey E.J., 1948, THEORY STABILITY LYO; VIGIL G, 1994, J COLLOID INTERF SCI, V165, P367, DOI 10.1006/jcis.1994.1242; VOET D, 1990, BIOCHEMISTRY-US, P811; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0	88	1116	1125	10	417	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					219	225		10.1038/379219a0	http://dx.doi.org/10.1038/379219a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538786				2022-12-28	WOS:A1996TQ16900036
J	Trachtenberg, JT; Thompson, WJ				Trachtenberg, JT; Thompson, WJ			Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor	NATURE			English	Article							NERVOUS-SYSTEM; MOTOR UNITS; MUSCLE; IDENTIFICATION; BIRTH; DEATH	DENERVATED adult mammalian muscle fibres are reinnervated by regenerating axons and, in the case of partially denervated muscles, by sprouts extended from remaining, intact axons(1,3). Recent experiments suggest that Schwann cells (SCs) regulate these events, inducing and guiding axonal outgrowth through the processes they extend(4,5). In contrast to adults, reinnervation of denervated neonatal muscles is deficient and axonal sprouting is absent(6-9). In light of the proposed roles for SCs in these processes, we examined whether SCs in neonatal muscles exhibit altered responses to denervation. We report here that neonatal denervation leads to the rapid, apoptotic death of SCs at rat neuromuscular junctions. Injection of glial growth factor, a member of the neuregulin family of trophic factors present in developing sensory and motor neurons(10), prevents this apoptosis in vivo. These results provide further evidence for the importance of SCs in regulating nerve grow,vth and suggest that axon-Schwann cell trophic interactions play a role in the normal development of the neuromuscular system.			Trachtenberg, JT (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.							ASTROW SH, 1994, J NEUROBIOL, V25, P937, DOI 10.1002/neu.480250804; BETZ WJ, 1980, J PHYSIOL-LONDON, V303, P265, DOI 10.1113/jphysiol.1980.sp013284; BROWN MC, 1981, A REV NEUROSCI, V4, P57; DENNIS MJ, 1980, DEV BIOL, V74, P173, DOI 10.1016/0012-1606(80)90059-7; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCARDLE JJ, 1977, J PHYSIOL-LONDON, V271, P567, DOI 10.1113/jphysiol.1977.sp012015; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SON YJ, 1995, NEURON, V14, P125, DOI 10.1016/0896-6273(95)90246-5; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; THOMPSON W, 1977, NEUROSCIENCE, V2, P523, DOI 10.1016/0306-4522(77)90049-5; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNIG A, 1986, PROG NEUROBIOL, V27, P251, DOI 10.1016/0301-0082(86)90023-7	18	250	254	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					174	177		10.1038/379174a0	http://dx.doi.org/10.1038/379174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538769				2022-12-28	WOS:A1996TP36000061
J	Zabin, LS; Emerson, MR; Ringers, PA; Sedivy, V				Zabin, LS; Emerson, MR; Ringers, PA; Sedivy, V			Adolescents with negative pregnancy test results - An accessible at-risk group	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABORTION; CHILDBEARING	Objective.-To estimate nationally what percentage of young women receive negative pregnancy test results before becoming pregnant, to explore their fertility and test histories, and to estimate the potential for intervention at the time of a negative test result. Design.-A cross-sectional study in which young women presenting to clinics for pregnancy tests were asked to complete a self-administered questionnaire before test results were known that explored prior pregnancy tests, pregnancies, sexual and contraceptive histories, and childbearing attitudes. Setting.-Fifty-two clinics including hospital, health department, Planned Parenthood, and independent facilities. Participants.-A total of 2926 patients aged 17 years or younger requesting pregnancy tests at presentation. Results.-Among young women who had ever conceived, 34.2% had a prior negative pregnancy test result and 24.4% had a prior negative test result at a clinic. Almost three of five of the adolescent girls, including both those who had and those who had not-conceived, received a negative test result at a clinic before they ever became pregnant. By the age of 14 years, the probability of a negative test result was substantially greater than the chance of a positive test. Many presented for tests even though they were quite certain that they were not pregnant. Conclusions.-Adolescent girls with a negative pregnancy test result may be an appropriate target group for intervention. One fourth of adolescent girls who have a negative pregnancy test may be identified by the health care system on that occasion in time to prevent early childbearing.			Zabin, LS (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT POPULAT DYNAM,615 N WOLFE ST,BALTIMORE,MD 21205, USA.							BERGER DK, 1991, ADOLESCENCE, V26, P951; Chiang C., 1968, INTRO STOCHASTIC PRO; EVANS JR, 1976, FAM PLANN PERSPECT, V8, P192, DOI 10.2307/2134210; Hardy J. B., 1991, ADOLESCENT PREGNANCY; HATCHER RA, 1992, CONTRACEPTIVE TECHNO; HAYES CD, 1987, RISKING FUTURE ADOLE, P1; MARCY SA, 1983, RES NURS HEALTH, V6, P175, DOI 10.1002/nur.4770060405; MOSHER WD, 1988, FAM PLANN PERSPECT, V20, P33, DOI 10.2307/2135595; MOSHER WD, 1990, 184 NAT CTR HLTH STA; Schorr LB, 1988, OUR REACH BREAKING C; Zabin L S, 1993, J Res Adolesc, V3, P67, DOI 10.1207/s15327795jra0301_4; ZABIN LS, 1989, FAM PLANN PERSPECT, V21, P248, DOI 10.2307/2135377; ZABIN LS, 1990, J ADOLESCENT HEALTH, V11, P107, DOI 10.1016/0197-0070(90)90018-W; ZABIN LS, 1981, FAM PLANN PERSPECT, V13, P205, DOI 10.2307/2134551; ZABIN LS, 1994, FAM PLANN PERSPECT, V26, P212, DOI 10.2307/2135941; ZABIN LS, 1987, EVALUATION PREGNANCY	16	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					113	117		10.1001/jama.275.2.113	http://dx.doi.org/10.1001/jama.275.2.113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TN280	8531305				2022-12-28	WOS:A1996TN28000026
J	Nutt, DJ				Nutt, DJ			Addiction: Brain mechanisms and their treatment implications	LANCET			English	Article							ALCOHOL-WITHDRAWAL; DOPAMINE; COCAINE; ANTAGONISTS; ABUSE; DEPENDENCE; RECEPTORS; CLONIDINE; ETHANOL; DRUGS				Nutt, DJ (corresponding author), UNIV BRISTOL,PSYCHOPHARMACOL UNIT,SCH MED SCI,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.							ABOOD ME, 1992, TRENDS PHARMACOL SCI, V13, P201, DOI 10.1016/0165-6147(92)90064-D; ACETO MD, 1989, ARZNEIMITTEL-FORSCH, V39-1, P570; ACQUAS E, 1993, EUR J PHARMACOL, V230, P239, DOI 10.1016/0014-2999(93)90809-V; BARTENSTEIN PA, 1993, J NEUROL NEUROSUR PS, V56, P1295, DOI 10.1136/jnnp.56.12.1295; BENKELFAT C, 1991, ARCH GEN PSYCHIAT, V48, P383; BORG S, 1981, SCIENCE, V213, P1135, DOI 10.1126/science.7268421; BRUNNING J, 1986, ALCOHOL ALCOHOLISM, V21, P167; BUSTO U, 1994, CLIN PHARMACOL THER, V55, P451, DOI 10.1038/clpt.1994.55; COOLS AR, 1991, NEUROSCIENCE, V43, P419, DOI 10.1016/0306-4522(91)90304-7; COSTALL B, 1991, NEUROPEPTIDES, V19, P65, DOI 10.1016/0143-4179(91)90084-V; COWLEY DS, 1992, ALCOHOL CLIN EXP RES, V16, P1057, DOI 10.1111/j.1530-0277.1992.tb00699.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GLUE P, 1987, ALCOHOL ALCOHOLISM, V22, P161; GLUE P, 1990, BRIT J PSYCHIAT, V157, P491, DOI 10.1192/bjp.157.4.491; GOLD MS, 1978, LANCET, V2, P599; GOLDMAN D, 1995, NAT MED, V1, P624, DOI 10.1038/nm0795-624; HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301; HUNKELER W, 1981, NATURE, V290, P515; JUDSON BA, 1984, DRUG ALCOHOL DEPEN, V13, P357, DOI 10.1016/0376-8716(84)90003-6; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; LEWIS JW, 1985, DRUG ALCOHOL DEPEN, V14, P363, DOI 10.1016/0376-8716(85)90067-5; LITTLE HJ, 1991, PHARMACOL THERAPEUT, V50, P347, DOI 10.1016/0163-7258(91)90050-V; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P567; MALIZIA AL, 1955, GABA A RECEPTORS ANX, P115; MCDOUGLE CJ, 1994, ARCH GEN PSYCHIAT, V51, P713; MYERS RD, 1992, PHARMACOL BIOCHEM BE, V43, P661, DOI 10.1016/0091-3057(92)90392-S; NUTT DJ, 1994, BRIT MED BULL, V50, P5, DOI 10.1093/oxfordjournals.bmb.a072883; PERSSON A, 1989, Human Psychopharmacology, V4, P215, DOI 10.1002/hup.470040307; Pike V. W., 1993, Journal of Labelled Compounds and Radiopharmaceuticals, V32, P495; Pike Victor W., 1993, Journal of Psychopharmacology, V7, P139, DOI 10.1177/026988119300700202; PIKE VW, 1995, EUR J PHARMACOL, V283, pR1, DOI 10.1016/0014-2999(95)00438-Q; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROTHMAN RB, 1991, PHARMACOL BIOCHEM BE, V40, P387, DOI 10.1016/0091-3057(91)90570-R; RPATT JA, 1991, BIOL BASES DRUG TOLE, P1; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; SHAW GK, 1994, BRIT J PSYCHIAT, V165, P515, DOI 10.1192/bjp.165.4.515; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SPANAGEL R, 1990, J NEUROCHEM, V55, P1743; TIIHONEN J, 1995, NAT MED, V1, P654, DOI 10.1038/nm0795-654; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; VIRKKUNEN M, 1994, ARCH GEN PSYCHIAT, V51, P20; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WOODS SW, 1992, PSYCHIAT RES-NEUROIM, V45, P67, DOI 10.1016/0925-4927(92)90001-K	47	91	94	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					31	36		10.1016/S0140-6736(96)91561-5	http://dx.doi.org/10.1016/S0140-6736(96)91561-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TN762	8531549				2022-12-28	WOS:A1996TN76200016
J	YAMAGUCHI, K; SHIRAKABE, T; SHIBUYA, H; IRIE, K; OISHI, I; UENO, N; TANIGUCHI, T; NISHIDA, E; MATSUMOTO, K				YAMAGUCHI, K; SHIRAKABE, T; SHIBUYA, H; IRIE, K; OISHI, I; UENO, N; TANIGUCHI, T; NISHIDA, E; MATSUMOTO, K			IDENTIFICATION OF A MEMBER OF THE MAPKKK FAMILY AS A POTENTIAL MEDIATOR OF TGF-BETA SIGNAL-TRANSDUCTION	SCIENCE			English	Article							GROWTH-FACTOR-BETA; KINASE; GENE; EXPRESSION; CELLS; RAF	The mitogen-activated protein kinase (MAPK) pathway is a conserved beta eukaryotic signaling module that converts receptor signals into various outputs. MAPK is activated through phosphorylation by MAPK kinase (MAPKK), which is first activated by MAPKK kinase (MAPKKK). A genetic selection based on a MAPK pathway in yeast was used to identify a mouse protein kinase (TAK1) distinct from other members of the MAPKKK family. TAK1 was shown to participate in regulation of transcription by transforming growth factor-beta (TGF-beta). Furthermore, kinase activity of TAK1 was stimulated in response to TGF-beta and bone morphogenetic protein. These results suggest that TAK1 functions as a mediator in the signaling pathway of TGF-beta superfamily members.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Hokkaido University; Nagoya University; Kyoto University; Osaka University			Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349; Ueno, Naoto/0000-0002-8375-2317				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRAI R, COMMUNICATION; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; IRIE K, UNPUB; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SHIBUYA H, UNPUB; Shibuya K., UNPUB; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	28	1158	1201	2	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2008	2011		10.1126/science.270.5244.2008	http://dx.doi.org/10.1126/science.270.5244.2008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533096				2022-12-28	WOS:A1995TL42000047
J	BARTSCH, D; GHIRARDI, M; SKEHEL, PA; KARL, KA; HERDER, SP; CHEN, M; BAILEY, CH; KANDEL, ER				BARTSCH, D; GHIRARDI, M; SKEHEL, PA; KARL, KA; HERDER, SP; CHEN, M; BAILEY, CH; KANDEL, ER			APLYSIA CREB2 REPRESSES LONG-TERM FACILITATION - RELIEF OF REPRESSION CONVERTS TRANSIENT FACILITATION INTO LONG-TERM FUNCTIONAL AND STRUCTURAL-CHANGE	CELL			English	Article							DNA-BINDING PROTEINS; GILL-WITHDRAWAL REFLEX; GLUTATHIONE-S-TRANSFERASE; LEUCINE ZIPPER PROTEINS; CAMP RESPONSE ELEMENT; SENSORY NEURONS; TRANSCRIPTION FACTOR; BEHAVIORAL SENSITIZATION; SYNAPTIC FACILITATION; FUSION PROTEINS	The switch from short- to long-term facilitation induced by behavioral sensitization in Aplysia involves CREB-like proteins, as well as the immediate-early gene ApC/EBP. Using the bZIP domain of ApC/EBP in a two-hybrid system, we have cloned ApCREB2, a transcription factor constitutively expressed in sensory neurons that resembles human CREB2 and mouse ATF4. ApCREB2 represses ApCREB-1-mediated transcription in F9 cells. Injection of anti-ApCREB2 antibodies into Aplysia sensory neurons causes a single pulse of serotonin (5-HT), which induces only short-term facilitation lasting minutes, to evoke facilitation lasting more than 1 day. This facilitation has the properties of long-term facilitation: it requires transcription and translation, induces the growth of new synaptic connections, and occludes further facilitation by five pulses of 5-HT.	COLUMBIA UNIV COLL PHYS & SURG,COLL PHYSICIANS & SURGEONS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	BARTSCH, D (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.		ghirardi, mirella/AEQ-0420-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1979, J NEUROCYTOL, V8, P415, DOI 10.1007/BF01214801; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BROWN E, 1995, J HIST BEHAV SCI, V11, P342; BROWN R, 1977, COGNITION, V5, P73, DOI 10.1016/0010-0277(77)90018-X; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CAREW T J, 1971, International Journal of Neuroscience, V2, P79, DOI 10.3109/00207457109146995; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conway M.A., 1995, FLASHBULB MEMORIES; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEXNER JB, 1963, SCIENCE, V141, P57, DOI 10.1126/science.141.3575.57; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1988, ANTIBODIES; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; Luria A., 1968, MIND MNEMONIST; MA J, 1987, CELL, V57, P113; MCGAUGH JL, 1993, BEHAV BRAIN RES, V58, P81, DOI 10.1016/0166-4328(93)90092-5; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Neisser U., 1982, MEMORY OBSERVED REME, P43; NORBY PL, 1992, NUCLEIC ACIDS RES, V20, P6317, DOI 10.1093/nar/20.23.6317; PETERSEN RC, 1992, NEUROLOGY, V42, P396, DOI 10.1212/WNL.42.2.396; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PINSKER H, 1970, SCIENCE, V167, P1740, DOI 10.1126/science.167.3926.1740; PINSKER HM, 1973, SCIENCE, V182, P1039, DOI 10.1126/science.182.4116.1039; RAYPORT SG, 1986, J NEUROSCI, V6, P759; Sambrook J., 1989, MOL CLONING; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SKEHEL PA, 1994, GENE, V145, P231, DOI 10.1016/0378-1119(94)90011-6; Stratton GM, 1917, PSYCHOL REV, V24, P244, DOI 10.1037/h0070091; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	64	452	473	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					979	992		10.1016/0092-8674(95)90213-9	http://dx.doi.org/10.1016/0092-8674(95)90213-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521521	Bronze			2022-12-28	WOS:A1995TK74500016
J	CUCKLE, HS; RICHARDSON, GA; SHELDON, TA; QUIRKE, P				CUCKLE, HS; RICHARDSON, GA; SHELDON, TA; QUIRKE, P			COST-EFFECTIVENESS OF ANTENATAL SCREENING FOR CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; IDENTIFICATION; GENE; MUTATIONS; APPRAISAL	Objective-To estimate the cost effectiveness of different antenatal screening programmes for cystic fibrosis. Setting-Antenatal clinics and general practices in the United Kingdom. Design-Four components of the screening process were identified: information giving, DNA testing, genetic counselling, and prenatal diagnosis. The component costs were derived from the literature and from a pilot screening study in Yorkshire. The cost of a given screening programme was then obtained by summing the components according to the specific screening strategy adopted (sequential and couple), the proportion of carriers detected by the DNA test, and the uptake of screening. Baseline assumptions were made about the proportion with missing information on carrier status from previous pregnancies (20%), the proportion changing partners between pregnancies (20%), and the uptake of prenatal diagnosis (100%). Sensitivity analysis was performed by varying these assumptions. Main outcome measure-Cost per affected pregnancy detected. Results-Under the baseline assumptions sequential screening costs between pound 40000 and pound 90000 per affected pregnancy detected, depending on the carrier detection rate and uptake. Couple screening was more expensive, ranging from pound 46000 to pound 104000. From the sensitivity analysis a 10% change in the assumed proportion with missing information from a previous pregnancy alters the cost by pound 4000; a 10%, change in the proportion with new partners has a similar effect but only for couple screening; and cost will change directly in proportion to the uptake of prenatal diagnosis. Conclusions-While economic analysis cannot determine screening policy, the paper provides the NHS with the information on cost effectiveness needed to inform decisions on the introduction of a screening service for cystic fibrosis.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV LEEDS,CTR CANC RES,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of York - UK; University of York - UK; University of Leeds	CUCKLE, HS (corresponding author), UNIV LEEDS,RES SCH MED,CTR REPROD GROWTH & DEV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Quirke, Philip/AAI-1362-2019; Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913; Quirke, Philip/0000-0002-3597-5444				ASCH DA, 1993, AM J OBSTET GYNECOL, V168, P1; CHEADLE J, 1992, J MED GENET, V29, P642, DOI 10.1136/jmg.29.9.642; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; GARBER AM, 1991, MED CARE, V29, P473, DOI 10.1097/00005650-199105000-00007; GINSBERG G, 1994, HEALTH ECON, V3, P5, DOI 10.1002/hec.4730030104; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LIEU TA, 1994, OBSTET GYNECOL, V84, P903; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MIEDZYBRODZKA Z, 1995, J MED GENET, V32, P282, DOI 10.1136/jmg.32.4.282; MIEDZYBRODZKA ZH, 1994, J MED GENET, V31, P545, DOI 10.1136/jmg.31.7.545; MIEDZYBRODZKA ZH, 1995, BRIT MED J, V310, P353, DOI 10.1136/bmj.310.6976.353; MIEDZYBRODZKA ZH, 1993, J MED GENET, V30, P316, DOI 10.1136/jmg.30.4.316; MOONEY G, 1993, SOC SCI MED, V37, P873, DOI 10.1016/0277-9536(93)90140-Y; Piggott M, 1994, J Med Screen, V1, P45; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHACKLEY P, 1993, J PUBLIC HEALTH MED, V15, P175; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SUPER M, 1994, BRIT MED J, V308, P1462, DOI 10.1136/bmj.308.6942.1462; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; 1988, BRIT MED J, V297, P1599; 1995, NATIONAL POPULAT PP2, V19	27	46	47	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1460	1463		10.1136/bmj.311.7018.1460	http://dx.doi.org/10.1136/bmj.311.7018.1460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ044	8520332	Green Published			2022-12-28	WOS:A1995TJ04400020
J	REXACH, M; BLOBEL, G				REXACH, M; BLOBEL, G			PROTEIN IMPORT INTO NUCLEI - ASSOCIATION AND DISSOCIATION REACTIONS INVOLVING TRANSPORT SUBSTRATE, TRANSPORT FACTORS, AND NUCLEOPORINS	CELL			English	Article							PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; BINDING; TRANSLOCATION; LOCATION; RAN/TC4	The molecular dynamics of nuclear protein import were examined in a solution binding assay by testing for interactions between a protein containing a nuclear localization signal (NLS), the transport factors karyopherin alpha, karyopherin beta, and Ran, and FXFG or GLFG repeat regions of nucleoporins. We found that karyopherins alpha and beta cooperate to bind FXFG but not GLFG repeat regions. Binding of the NLS protein to karyopherin alpha was enhanced by karyopherin beta. Two novel reactions were discovered. First, incubation of a karyopherin heterodimer-NLS protein complex with an FXFG repeat region stimulated the dissociation of the NLS protein from the karyopherin heterodimer. Second, incubation of the karyopherin heterodimer with RanGTP (or with a Ran mutant that cannot hydrolyze GTP) led to the dissociation of karyopherin alpha from beta and to an association of Ran with karyopherin beta; RanGDP had no effect. We propose that movement of NLS proteins across the nuclear pore complex is a stochastic process that operates via repeated association-dissociation reactions.	HOWARD HUGHES MED RES INST, CELL BIOL LAB, NEW YORK, NY 10021 USA		REXACH, M (corresponding author), ROCKEFELLER UNIV, CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	38	671	676	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					683	692		10.1016/0092-8674(95)90181-7	http://dx.doi.org/10.1016/0092-8674(95)90181-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521485	Bronze			2022-12-28	WOS:A1995TH94800005
J	ISAACS, AJ; BRITTON, AR; MCPHERSON, K				ISAACS, AJ; BRITTON, AR; MCPHERSON, K			UTILIZATION OF HORMONE REPLACEMENT THERAPY BY WOMEN DOCTORS	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT; HEART-DISEASE; HRT	Objectives-To ascertain the prevalence and duration of use of hormone replacement therapy by menopausal women doctors. Design-Postal questionnaire. Setting-General practices in the United Kingdom. Subjects-Randomised stratified sample of women doctors who obtained full registration between 1952 and 1976, taken from the current principal list of the Medical Register. Main outcome measures- Prevalence and duration of use of hormone replacement therapy; menopausal status. Results-Overall, 45.7% (436/954) of women doctors aged between 45 and 65 years had ever used hormone replacement therapy. When the results from women still menstruating regularly were excluded, 55.2% (428) were ever users and 41.2% (319) current users. The cumulative probability of remaining on hormone replacement therapy was 0.707 at five years and 0.576 at 10 years. Conclusions-Women doctors have a higher prevalence of use of hormone replacement therapy than has been reported for other women in the United Kingdom, and most users seem to be taking hormone replacement therapy for more than five years. The results may become generalisable to the wider population as information on the potential benefits of hormone replacement therapy is disseminated.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUNKER JP, 1974, NEW ENGL J MED, V290, P1051, DOI 10.1056/NEJM197405092901905; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; COOPE J, 1991, LANCET, V337, P1162; DALY E, 1992, BRIT MED BULL, V48, P368, DOI 10.1093/oxfordjournals.bmb.a072552; DEAN AD, 1990, EPI INFO; DOLL R, 1980, BRIT MED J, V1, P967; DUGOWSON CE, 1987, WESTERN J MED, V146, P494; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FERGUSON KJ, 1989, ARCH INTERN MED, V49, P132; HAHN RG, 1989, AM J OBSTET GYNECOL, V161, P1854, DOI 10.1016/S0002-9378(89)80006-7; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JANNAUSCH ML, 1992, MATURITAS, V14, P161, DOI 10.1016/0378-5122(92)90111-G; MCPHERSON K, 1994, CORONARY HEART DISEA, P141; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; ROSENBERG L, 1993, AM J PUBLIC HEALTH, V3, P1670; ROSS RK, 1989, LANCET, V1, P505; SINCLAIR HK, 1993, BRIT J GEN PRACT, V43, P365; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317	26	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1399	1401		10.1136/bmj.311.7017.1399	http://dx.doi.org/10.1136/bmj.311.7017.1399			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520274	Green Published			2022-12-28	WOS:A1995TG90200020
J	CARNEY, PA; DIETRICH, AJ; FREEMAN, DH; MOTT, LA				CARNEY, PA; DIETRICH, AJ; FREEMAN, DH; MOTT, LA			THE PERIODIC HEALTH EXAMINATION PROVIDED TO ASYMPTOMATIC OLDER WOMEN - AN ASSESSMENT USING STANDARDIZED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY CARE; CLINICAL SKILLS; CANCER PREVENTION; CONTROLLED TRIAL; PHYSICIANS; PERFORMANCE; GUIDELINES; RESIDENTS; COMPETENCE; KNOWLEDGE	Objectives: To describe physical examination and cancer prevention services provided by primary care physicians in response to the request for a ''checkup'' by an asymptomatic 55-year-old woman seeking to establish ongoing care; to assess the effects of two interventions (education and office organization) intended to improve these services; and to assess the feasibility of using ''standardized'' patients to evaluate physician responses to such a request. Setting: Northern New England. Participants: Fifty-nine primary care physicians who were accepting new patients and were participating in a study of early detection and prevention of cancer. Design: Cross sectional; observations of patient visits. Interventions: Actresses trained to portray a specific patient role (''standardized'' or ''simulated'' patients) visited each physician once. Physicians were blinded to the simulated patients' true identities. Measurements: Actresses reported the components of the general physical examination and the cancer-related'' checkup.'' Most interactions were audiotaped. Results: Fourteen physical examination components were measured, ranging from assessment of vibratory sense (5%) to measurement of blood pressure (98%). Provision of 10 services recommended by the National Cancer Institute to standardized patients included 16% being advised to reduce dietary fat; 53% to do monthly breast self-examination; 74% to quit smoking; and 89% to obtain a mammogram. Physicians spent from 5 to 60 minutes with the patients. Two physicians did not charge, whereas others charged from $24 to $108. Study group assignment was not associated with statistical differences in provider performance. Two standardized patients (3%) were detected by physicians. Audiotapes were used to verify the actresses' ability to replicate their scenario (consistently repeat their performance) and to verify physician performance. Conclusions: Physician responses to an identical patient request varied widely in terms of time spent with the patient, the services provided, and the cost of the visit. Using standardized patients is a feasible method for assessing physician performance of the periodic health examination while controlling for case mix.	DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA; UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA	Dartmouth College; University of Texas System; University of Texas Medical Branch Galveston	CARNEY, PA (corresponding author), UNIV WASHINGTON, DEPT COMMUNITY HLTH CARE SYST, SM-24, SEATTLE, WA 98195 USA.				NCI NIH HHS [CA531521, CA46075, CA23108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046075, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AINSWORTH MA, 1991, JAMA-J AM MED ASSOC, V266, P1390, DOI 10.1001/jama.266.10.1390; BELCHER DW, 1990, ARCH INTERN MED, V150, P2533, DOI 10.1001/archinte.150.12.2533; BOWMAN JA, 1991, HEALTH SERV RES, V26, P97; BUTRUM RR, 1988, AM J CLIN NUTR, V48, P888, DOI 10.1093/ajcn/48.3.888; CALHOUN JG, 1987, J MED EDUC, V62, P754; CARNEY PA, 1992, J FAM PRACTICE, V35, P388; COLLIVER JA, 1989, TEACH LEARN MED, V1, P31; DIETRICH AJ, 1990, AM J PREV MED, V6, P346, DOI 10.1016/S0749-3797(18)30981-4; DIETRICH AJ, 1989, J FAM PRACTICE, V29, P319; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; FULLARD E, 1984, BRIT MED J, V289, P1585, DOI 10.1136/bmj.289.6458.1585; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HENKE CJ, 1991, MED CARE, V29, P799, DOI 10.1097/00005650-199108000-00012; HOPPE RB, 1990, J GEN INTERN MED, V5, P415, DOI 10.1007/BF02599430; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOVE R R, 1988, Cancer Bulletin (Houston), V40, P380; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; NORMAN GR, 1985, MED EDUC, V19, P344, DOI 10.1111/j.1365-2923.1985.tb01336.x; NORMAN GR, 1985, J MED EDUC, V60, P925; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; STILLMAN PL, 1990, ACAD MED, V65, P288, DOI 10.1097/00001888-199005000-00002; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STILLMAN PL, 1987, ARCH INTERN MED, V147, P1049, DOI 10.1001/archinte.147.6.1049; VU NV, 1987, J MED EDUC, V62, P1000; VU NV, 1987, ACAD MED, V65, pS29; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WILLIAMS RG, 1987, MED EDUC, V21, P482, DOI 10.1111/j.1365-2923.1987.tb01407.x; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; 1987, WORKING GUIDELINES E; 1990, CA-CANCER J CLIN, V40, P77; GUIDE CLIN PREVENTIV	35	48	48	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					129	135		10.7326/0003-4819-119-2-199307150-00007	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512162				2022-12-28	WOS:A1993LU90200007
J	NEDIVI, E; HEVRONI, D; NAOT, D; ISRAELI, D; CITRI, Y				NEDIVI, E; HEVRONI, D; NAOT, D; ISRAELI, D; CITRI, Y			NUMEROUS CANDIDATE PLASTICITY-RELATED GENES REVEALED BY DIFFERENTIAL CDNA CLONING	NATURE			English	Article							MOLECULAR-CLONING; STRESS PROTEINS; EXPRESSION; CELLS; ACID; PROENKEPHALIN; MECHANISMS; EXTRACTION; SEQUENCE; SEIZURE	PLASTICITY is a property of the nervous system that allows it to modify its response to an altered input. This capacity for change suggests that there are molecular mechanisms in neurons that can couple stimuli to long-term alterations in phenotype1-3. Neuronal excitation elicits rapid transcriptional activation of several immediate-early genes4, for example c-fos, c-jun and zif268. Many immediate-early genes encode transcription factors that control expression of downstream genes whose products are believed to bring about long-term plastic changes3,4. Here we use a highly sensitive differential complementary DNA cloning procedure to identify genes that may participate in long-term plasticity. We cloned 52 cDNAs of genes induced by the glutamate analogue kainate in the hippocampus dentate gyrus. The number of these candidate plasticity-related genes (CPGs) is estimated to be 500-1,000. One of the cloned CPGs (16C8), encoding a protease inhibitor, is induced by a stimulus producing long-term potentiation and during dentate gyrus development; a second, cpg1, is dependent on activation of the NMDA (N-methyl-D-aspartate) receptor for induction and encodes a new small, dentate-gyrus-specific protein. Seventeen of the cloned CPGs encode known proteins, including six suggesting that strong neuronal activation leads to de novo synthesis of vesicular and other synaptic components.			NEDIVI, E (corresponding author), WEIZMANN INST SCI,DEPT HORMONE RES,IL-76100 REHOVOT,ISRAEL.		Nedivi, Elly/ABC-9923-2021	Naot, Dorit/0000-0001-9498-2639; /0000-0002-1710-0767; Israeli, David/0000-0003-2762-2195				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ALTIN JG, 1993, NEUROTROPHIC FACTORS, P129; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GALL C, 1988, J NEUROSCI, V8, P1852; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEBB DO, 1949, ORG BEHAVIOR; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; MCNAMARA JO, 1988, TRENDS NEUROSCI, V11, P33, DOI 10.1016/0166-2236(88)90047-1; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORRIS BJ, 1988, P NATL ACAD SCI USA, V85, P3226, DOI 10.1073/pnas.85.9.3226; NAIM AC, 1992, CURR OPIN NEUROBIOL, V2, P296; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; Sambrook J, 1989, MOL CLONING LABORATO; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; UHL GR, 1986, IN SITU HYBRIDIZATIO; [No title captured]	38	429	456	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					718	722		10.1038/363718a0	http://dx.doi.org/10.1038/363718a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515813				2022-12-28	WOS:A1993LJ33900055
J	Blumenthal, D; Causino, N; Campbell, E; Louis, KS				Blumenthal, D; Causino, N; Campbell, E; Louis, KS			Relationships between academic institutions and industry in the life sciences - An industry survey	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIOTECHNOLOGY; UNIVERSITY	Background. Despite growing acceptance of relationships between academia and industry in the life sciences, systematic, up-to-date information about their extent and the consequences for the parties involved remains scarce. We attempted to collect information about the prevalence, magnitude, commercial benefits, and potential risks of such relationships by surveying a representative sample of life-science companies in the United States to determine their relationships with academic institutions. Methods. We collected data by telephone from May through September 1994 from senior executives of 210 life-science companies (of 306 companies surveyed; response rate, 69 percent). The sample contained all Fortune 500 companies in the fields of agriculture, chemicals, and pharmaceuticals; all international pharmaceutical companies with sales volumes similar to those of the Fortune 500 companies; and a random sample of non-fortune 500 companies in the life sciences drawn from multiple commercial and noncommercial directories. Both the survey instrument and the survey methods resembled those of our 1984 study of 106 biotechnology companies, allowing us to assess the evolution of relationships between academia and industry over the past decade. Results. Ninety percent of companies conducting life-science research in the United States had relationships involving the life sciences with an academic institution in 1994. Fifty-nine percent supported research in such institutions, providing an estimated $1.5 billion, or approximately 11.7 percent of all research-and-development funding received that year. The agreements with universities tended to be short-term and to involve small amounts, implying that most such relationships supported applied research or development. Over 60 percent of companies providing support for life-science research in universities had received patents, products, and sales as a result of those relationships. At the same time, the companies reported that their relationships with universities often included agreements to keep the results of research secret beyond the time needed to file a patent. From 1984 to 1994, the involvement of industry with academic institutions has increased, but the characteristics of the relationships have remained remarkably stable. Conclusions. After more than a decade of sustained interaction, universities and industries seem to have formed durable partnerships in the life sciences, although the relationships may pose greater threats to the openness of scientific communication than universities generally acknowledge. However, industrial support for university research is much smaller in amount than federal support, and companies are unlikely to be able to compensate for sizable federal cutbacks.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,HLTH POLICY RES & DEV UNIT,BOSTON,MA; UNIV MINNESOTA,COLL EDUC,MINNEAPOLIS,MN 55455	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities				Seashore, Karen/0000-0003-1070-0273	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000724, R55HG000724] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00724-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BLUMENTHAL D, 1994, HEALTH AFFAIR, V13, P176, DOI 10.1377/hlthaff.13.3.176; BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; BLUMENTHAL D, 1986, SCIENCE, V231, P242, DOI 10.1126/science.3941897; BLUMENTHAL D, 1992, JAMA-J AM MED ASSOC, V268, P3344, DOI 10.1001/jama.268.23.3344; DIBNER MD, 1991, BIOTECHNOLOGY GUIDE; ETZKOWITZ H, 1991, MINERVA, V29, P133, DOI 10.1007/BF01096406; MERVIS J, 1995, SCIENCE, V267, P780, DOI 10.1126/science.7846519; Rosenberg SA, 1996, NEW ENGL J MED, V334, P392, DOI 10.1056/NEJM199602083340610; WEBSTER A, 1992, SOCIOLOGY, V28, P123; 1985, NY TIMES        0128, pA14; 1993, NSB931 NAT SCI BOARD; 1994, FED REGISTER, V59, P55674; 1993, BIOSCAN WORLDWIDE BI; 1993, PHS NIH931261 DEP HL; 1993, SMALL BUSINESS INNOV; 1991, SMALL BUSINESS INNOV; 1988, PHS TECHNOLOGY TRANS; 1993, GENETIC ENG BIOTECHN	18	239	241	0	37	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	1996	334	6					368	373		10.1056/NEJM199602083340606	http://dx.doi.org/10.1056/NEJM199602083340606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT487	8538709				2022-12-28	WOS:A1996TT48700006
J	Ertem, G; Ferris, JP				Ertem, G; Ferris, JP			Synthesis of RNA oligomers on heterogeneous templates	NATURE			English	Article							5'-PHOSPHORIMIDAZOLIDE; RIBONUCLEOTIDES; MONTMORILLONITE; RIBOZYME; REPLICATION; ADENOSINE; MINERALS; CATALYST; MODEL; LIFE	THE concept of an RNA world(1,2) in the chemical origin of life is appealing, as nucleic acids are capable of both information storage and acting as templates that catalyse the synthesis of complementary molecules(3). Template-directed synthesis has been demonstrated for homogeneous oligonucleotides that, like natural nucleic acids, have 3',5' linkages between the nucleotide monomers(4-7). But it seems likely that prebiotic routes to RNA-like molecules would have produced heterogeneous molecules,vith various kinds of phosphodiester linkages and both linear and cyclic nucleotide chains. Here we show that such heterogeneity need be no obstacle to the templating of complementary molecules. Specifically, we show that heterogeneous oligocytidylates, formed by the montmorillonite clay-catalysed condensation of actuated monomers, can serve as templates for the synthesis of oligoguanylates. Furthermore, we show that oligocytidylates that are exclusively 2',5'-linked can also direct synthesis of oligoguanylates. Such heterogeneous templating reactions could have increased the diversity of the pool of protonucleic acids from which life ultimately emerged.			Ertem, G (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ATKINS RF, 1993, RNA WORLD; DOUDNA JA, 1993, BIOCHEMISTRY-US, V32, P2111, DOI 10.1021/bi00059a032; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; FERRIS JP, 1992, ORIGINS LIFE EVOL B, V22, P369, DOI 10.1007/BF01809373; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; FERRIS JP, 1993, ORIGINS LIFE EVOL B, V23, P229, DOI 10.1007/BF01581901; FERRIS JP, 1993, ORIGINS LIFE EVOL B, V23, P307, DOI 10.1007/BF01582081; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GRZESKOWIAK K, 1986, J MOL EVOL, V23, P287, DOI 10.1007/BF02100635; HOHN T, 1967, BIOCHIM BIOPHYS ACTA, V138, P466, DOI 10.1016/0005-2787(67)90543-6; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JUNG KE, 1994, J AM CHEM SOC, V116, P6059, DOI 10.1021/ja00093a001; KAWAMURA K, 1994, J AM CHEM SOC, V116, P7564, DOI 10.1021/ja00096a013; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P1685, DOI 10.1093/nar/20.7.1685; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; LOHRMANN R, 1980, SCIENCE, V208, P1464, DOI 10.1126/science.6247762; LOHRMANN R, 1982, J MOL EVOL, V18, P185, DOI 10.1007/BF01733045; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; PRABAHAR KJ, 1994, J AM CHEM SOC, V116, P10914, DOI 10.1021/ja00103a006; SAWAI H, 1976, J AM CHEM SOC, V98, P7037, DOI 10.1021/ja00438a050; SAWAI H, 1992, J CHEM SOC PERK T 1, P505, DOI 10.1039/p19920000505; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; STRIBLING R, 1991, J CHROMATOGR, V538, P474, DOI 10.1016/S0021-9673(01)88872-5	28	127	143	0	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					238	240		10.1038/379238a0	http://dx.doi.org/10.1038/379238a0			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538788				2022-12-28	WOS:A1996TQ16900040
J	ONeill, EM; Kaffman, A; Jolly, ER; OShea, EK				ONeill, EM; Kaffman, A; Jolly, ER; OShea, EK			Regulation of PHO4 nuclear localization by the PHO80-PHO85 cyclin-CDK complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; YEAST; PHOSPHORYLATION; SEQUENCES; PROMOTER	PHO4, a transcription factor required for induction of the PHO5 gene in response to phosphate starvation, is phosphorylated by the PHO80-PHO85 cyclin-CDK (cyclin-dependent kinase) complex when yeast are grown in phosphate-rich medium. PHO4 was shown to be concentrated in the nucleus when yeast were starved for phosphate and was predominantly cytoplasmic when yeast were grown in phosphate-rich medium. The sites of phosphorylation on PHO4 were identified, and phosphorylation was shown to be required for full repression of PHO5 transcription when yeast were grown in high phosphate. Thus, phosphorylation of PHO4 by PHO80-PHO85 turns off PHO5 transcription by regulating the nuclear localization of PHO4.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Jolly, Emmitt R/I-6646-2012	Jolly, Emmitt R/0000-0002-7141-2307				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; FISHER F, 1991, ONCOGENE, V6, P1099; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OCONNELL KF, 1992, GENETICS, V132, P63; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONEILL EM, UNPUB; OSHEA EK, UNPUB; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	20	274	279	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					209	212		10.1126/science.271.5246.209	http://dx.doi.org/10.1126/science.271.5246.209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539622				2022-12-28	WOS:A1996TP36400044
J	Debrah, K; Sherwin, RS; Murphy, J; Kerr, D				Debrah, K; Sherwin, RS; Murphy, J; Kerr, D			Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes	LANCET			English	Article							MILD HYPOGLYCEMIA; BLOOD-FLOW; HUMANS; IDDM	Background For the patient with diabetes, hypoglycaemia unawareness-ie, the warning signs of falling blood glucose are missing-is potentially dangerous. One study has suggested that, in healthy volunteers, caffeine might be a helpful treatment. Our study looked at two effects of caffeine ingestion (250 mg) on the brain-namely, a decrease in cerebral blood flow and an increase in brain glucose use-to see if the recognition of and physiological responses to hypoglycaemia were altered in patients with insulin-dependent diabetes mellitus (IDDM). Methods 12 patients were studied twice. A hyperinsulinaemic glucose clamp was used to maintain plasma glucose at 5 mmol/L for 90 min, followed by 60 min at 3.8 mmol/L, and then 2.8 mmol/L for a further hour. After 30 min at 5 mmol/L, patients consumed, in a double-blind, crossover design, 250 mg caffeine or matched placebo. We recorded middle cerebral artery velocity (V-MCA), counterregulatory hormone levels, and cognitive function, and patients recorded hypoglycaemia symptoms on a visual analogue scale. Results Caffeine caused an immediate and sustained fall in V-MCA of 10 cm/s, from 60 to 50 cm/s (95% Cl -5 to -15 cm/s; p<0.001). At a blood glucose of 3.8 mmol/L, plasma adrenaline levels were twice as high after caffeine than after placebo (difference 524 pmol/L). When glucose was lowered to 2.8 mmol/L, caffeine ingestion was associated with: greater awareness of hypoglycaemia in 9 patients, significantly more intense autonomic and neuroglycopenic symptoms, and higher levels of adrenaline, cortisol, and growth hormone. Cognitive function (latency of P-300 evoked potentials) deteriorated to the same extent in both studies at this glucose level. Interpretation The sustained fall in V-MCA and augmented sympathoadrenal and symptomatic responses during moderate hypoglycaemia suggest caffeine as a potentially useful treatment for diabetic patients who have difficulty recognising the onset of hypoglycaemia.	ROYAL BOURNEMOUTH HOSP, METAB UNIT, BOURNEMOUTH BH7 7DW, DORSET, ENGLAND; YALE UNIV, DIV ENDOCRINOL, SCH MED, NEW HAVEN, CT USA	Yale University					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020495, R01DK020495] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00125] Funding Source: Medline; NIDDK NIH HHS [DK 20495] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASLID R, 1984, J NEUROSURG, V57, P739; ALTORFER RM, 1981, ACTA ENDOCRINOL-COP, V98, P413, DOI 10.1530/acta.0.0980413; BOYLE PJ, 1994, P NATL ACAD SCI USA, V91, P9352, DOI 10.1073/pnas.91.20.9352; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517; COX DJ, 1987, DIABETES CARE, V10, P617, DOI 10.2337/diacare.10.5.617; COX DJ, 1994, DIABETES CARE, V17, P1, DOI 10.2337/diacare.17.1.1; CRANSTON I, 1994, LANCET, V344, P283, DOI 10.1016/S0140-6736(94)91336-6; CRYER PE, 1993, DIABETES ANN, V7, P317; DAGOGOJACK S, 1994, DIABETES, V43, P1426, DOI 10.2337/diabetes.43.12.1426; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DENARO CP, 1991, EUR J CLIN PHARMACOL, V40, P273, DOI 10.1007/BF00315208; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; KERR D, 1989, DIABETOLOGIA, V32, P249, DOI 10.1007/BF00285293; KERR D, 1991, DIABETIC MED, V8, P123, DOI 10.1111/j.1464-5491.1991.tb01557.x; KERR D, 1993, ANN INTERN MED, V119, P799, DOI 10.7326/0003-4819-119-8-199310150-00005; KERR D, 1993, DIABETOLOGIA, V36, P73, DOI 10.1007/BF00399097; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KONTOS HA, 1989, STROKE, V20, P1; MADDOCK RK, 1953, ARCH INTERN MED, V91, P695, DOI 10.1001/archinte.1953.00240180004001; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; POLICH J, 1986, ELECTROEN CLIN NEURO, V65, P236, DOI 10.1016/0168-5597(86)90059-6; PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKLARE DA, 1984, ELECTROEN CLIN NEURO, V59, P420, DOI 10.1016/0168-5597(84)90043-1; Sorteberg W., 1992, TRANSCRANIAL DOPPLER, P57	29	49	49	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					19	24		10.1016/S0140-6736(96)91557-3	http://dx.doi.org/10.1016/S0140-6736(96)91557-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531542				2022-12-28	WOS:A1996TN76200012
J	MANGELSDORF, DJ; THUMMEL, C; BEATO, M; HERRLICH, P; SCHUTZ, G; UMESONO, K; BLUMBERG, B; KASTNER, P; MARK, M; CHAMBON, P; EVANS, RM				MANGELSDORF, DJ; THUMMEL, C; BEATO, M; HERRLICH, P; SCHUTZ, G; UMESONO, K; BLUMBERG, B; KASTNER, P; MARK, M; CHAMBON, P; EVANS, RM			THE NUCLEAR RECEPTOR SUPERFAMILY - THE 2ND DECADE	CELL			English	Review							RETINOIC ACID; ERB-A; HORMONE RECEPTOR; THYROID-HORMONE; GENE ENCODES; CDNA; EXPRESSION; TRANSCRIPTION; SEQUENCE; PROTEIN		SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; FORSCHUNGSZENTRUM KARLSRUHE,D-76021 KARLSRUHE,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; ADV INST SCI & TECHNOL,GRAD SCH BIOL SCI,NARA 63001,JAPAN; SALK INST BIOL STUDIES,LA JOLLA,CA 92037; CTR NATL RECH SCI,INST GENET & BIOL MOLEC CELLULAIRE,INST NATL SANTE & RECH MED,F-67404 ILLKIRCH GRAFFENS,FRANCE	Howard Hughes Medical Institute; Salk Institute; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; German Cancer Research Center (DKFZ); Nara Institute of Science & Technology; Salk Institute; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Evans, Ronald/AAF-4001-2019; Beato, Miguel/B-5564-2015	Evans, Ronald/0000-0002-9986-5965; Beato, Miguel/0000-0002-2878-2222; Mangelsdorf, David/0000-0002-4355-0796	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GRONEMEYER H, 1995, IN PRESS PROTEIN PRO, V3; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Jensen E., 1966, STEROID DYNAMICS, P133; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	21	5803	6012	12	351	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					835	839		10.1016/0092-8674(95)90199-X	http://dx.doi.org/10.1016/0092-8674(95)90199-X			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521507	Green Accepted, Bronze			2022-12-28	WOS:A1995TK74500002
J	HADLEY, TR; GOLDMAN, H				HADLEY, TR; GOLDMAN, H			EFFECT OF RECENT HEALTH AND SOCIAL-SERVICE POLICY REFORMS ON BRITAIN MENTAL-HEALTH SYSTEM	BRITISH MEDICAL JOURNAL			English	Article								The introduction of new policies in health and social services in Britain has changed the way community care is provided to seriously mentally ill people. Britain is creating the same problems that have existed in the United States, whereby clinicians struggle to provide services in an environment with multiple payers and perverse incentives. A simple system in Britain has been replaced with complicated organisational and financial structures that require almost impossible feats by local health and social service staff to coordinate care for patients for whom continuity of care is critical for their survival in the community and their wellbeing. Seriously mentally ill people are in the middle of these complicated problems. The creation of a local mental health authority that could be held responsible for community care, as exists in some American states, may be one solution.	UNIV MARYLAND,DEPT PSYCHIAT,MENTAL HLTH POLICY STUDIES,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore	HADLEY, TR (corresponding author), UNIV PENN,CTR MENTAL HLTH POLICY & SERV RES,ROOM 717,3600 MARKET ST,PHILADELPHIA,PA 19104, USA.							GOLDMAN HH, 1992, HEALTH AFFAIR, V11, P51, DOI 10.1377/hlthaff.11.3.51; GOLDMAN HH, 1994, MILBANK Q, V72, P37, DOI 10.2307/3350337; HADLEY T, IN PRESS ADM POLICY; MUIJEN M, 1995, HLTH SERVICE J  0309; SCHLESINGER M, 1986, MILBANK Q, V64, P189, DOI 10.2307/3349970; SHEPHERD G, IN PRESS RESIDENTIAL; 1995, LANCET, V345, P399	7	10	10	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1556	1558		10.1136/bmj.311.7019.1556	http://dx.doi.org/10.1136/bmj.311.7019.1556			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK214	8520403	Green Published			2022-12-28	WOS:A1995TK21400031
J	SMITH, PJS				SMITH, PJS			NONINVASIVE ION PROBES - TOOLS FOR MEASURING TRANSMEMBRANE ION FLUX	NATURE			English	Article											SMITH, PJS (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.			Smith, Peter/0000-0003-4400-6853				Ammann D., 1986, ION SELECTIVE MICROE, V1, DOI [10.1007/978-3-642-52507-0, DOI 10.1007/978-3-642-52507-0]; DEMAREST JR, IN PRESS BIOL B, V189; JAFFE LF, 1976, J CELL BIOL, V33, P614; KEEFE D, IN PRESS BIOL B, V189; KOCHIAN LV, 1992, PLANTA, V188, P601, DOI 10.1007/BF00197055; KUHTREIBER WM, 1990, J CELL BIOL, V110, P1565, DOI 10.1083/jcb.110.5.1565; LAND SC, IN PRESS BIOL B, V189; MARCUS DC, 1994, BIOPHYS J, V66, P1939, DOI 10.1016/S0006-3495(94)80987-7; NUCCITELLI R, 1990, NONINVASIVE TECHNIQU; SCHEFFEY C, 1988, REV SCI INSTRUM, V59, P787, DOI 10.1063/1.1139830; SMITH PJS, 1994, METHOD CELL BIOL, V40, P115; SMITH PJS, IN PRESS, V189; YAMOAH E, 1994, BIOL BULL, V187, P270, DOI 10.1086/BBLv187n2p270	13	47	56	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					645	646		10.1038/378645a0	http://dx.doi.org/10.1038/378645a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524403				2022-12-28	WOS:A1995TJ22100089
J	SCHWACHA, A; KLECKNER, N				SCHWACHA, A; KLECKNER, N			IDENTIFICATION OF DOUBLE HOLLIDAY JUNCTIONS AS INTERMEDIATES IN MEIOTIC RECOMBINATION	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX-FORMATION; ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ENDONUCLEASE-VII; HETERODUPLEX DNA; REPAIR MODEL; YEAST; MEIOSIS	During meiosis, branched DNA molecules containing information from both parental chromosomes occur in vivo at loci where meiosis-specific double-stranded breaks occur. We demonstrate here that these joint molecules are recombination intermediates: they contain single strands that have undergone exchange of information. Moreover, these joint molecules are resolved into both parental and recombinant duplexes when treated in vitro with Holliday junction-resolving endonucleases RuvC or T4 endo VII. Taken together with previous observations, these results strongly suggest that joint molecules are double Holliday junctions.			SCHWACHA, A (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [R01-GM44794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BYERS B, 1994, CURR BIOL, V4, P448, DOI 10.1016/S0960-9822(00)00100-7; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; FAN QQ, 1995, MOL CELL BIOL, V15, P1679; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; FU TJ, 1994, J MOL BIOL, V236, P91, DOI 10.1006/jmbi.1994.1121; FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003; GAME JC, 1989, GENETICS, V123, P695; GOLDWAY M, 1993, GENETICS, V133, P159; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HABER JE, 1995, MICROB GENE TECH, V6, P204; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEENEY S, 1995, IN PRESS P NATL ACAD, V92; KEMPER B, 1984, COLD SPRING HARB SYM, V49, P815, DOI 10.1101/SQB.1984.049.01.092; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; MALONE RE, 1980, CURR GENET, V1, P241, DOI 10.1007/BF00390950; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NAG DK, 1990, GENETICS, V125, P753; OHTA K, 1994, EMBO J, V13, P5754, DOI 10.1002/j.1460-2075.1994.tb06913.x; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PORTER SE, 1993, GENETICS, V134, P5; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; SIGAL N, 1972, J MOL BIOL, V71, P789, DOI 10.1016/S0022-2836(72)80039-1; SOBELL HM, 1974, MOL MECHANISMS GENET, P433; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1987, GENETICS, V116, P501; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	55	389	395	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					783	791		10.1016/0092-8674(95)90191-4	http://dx.doi.org/10.1016/0092-8674(95)90191-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521495	Bronze			2022-12-28	WOS:A1995TH94800015
J	VASSYLYEV, DG; KASHIWAGI, T; MIKAMI, Y; ARIYOSHI, M; IWAI, S; OHTSUKA, E; MORIKAWA, K				VASSYLYEV, DG; KASHIWAGI, T; MIKAMI, Y; ARIYOSHI, M; IWAI, S; OHTSUKA, E; MORIKAWA, K			ATOMIC MODEL OF A PYRIMIDINE DIMER EXCISION-REPAIR ENZYME COMPLEXED WITH A DNA SUBSTRATE - STRUCTURAL BASIS FOR DAMAGED DNA RECOGNITION	CELL			English	Article							T4 ENDONUCLEASE-V; SITE-DIRECTED MUTAGENESIS; SYN THYMINE DIMER; CRYSTAL-STRUCTURE; CIS-SYN; DUPLEX D(GCGTTGCG).D(CGCAACGC); T4-ENDONUCLEASE-V; GLYCOSYLASE; PHOTODIMER; ACID	T4 endonuclease V is a DNA repair enzyme from bacteriophage T4 that catalyzes the first reaction step of the pyrimidine dimer-specific base excision repair pathway. The crystal structure of this enzyme complexed with a duplex DNA substrate, containing a thymine dimer, has been determined at 2.75 Angstrom resolution, The atomic structure of the complex reveals the unique conformation of the DNA duplex, which exhibits a sharp kink with a 60 degrees inclination at the central thymine dimer, The adenine base complementary to the 5' side of the thymine dimer is completely flipped out of the DNA duplex and trapped in a cavity on the protein surface. These structural features allow an understanding of the catalytic mechanism and implicate a general mechanism of how other repair enzymes recognize damaged DNA duplexes.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	VASSYLYEV, DG (corresponding author), PROT ENGN RES INST,6-2-3 FURUDEAI,SUITA,OSAKA 565,JAPAN.		Vassylyev, Dmitry/A-9005-2008	Ariyoshi, Mariko/0000-0002-1361-2642				BABCOCK MS, 1993, BIOMOL STRUCT DYN, V2, P597; BAKER D, 1993, ACTA CRYSTALLOGR D, V49, P429, DOI 10.1107/S0907444993004032; BRUNGER AT, 1993, XPLOR VERSION 31; CAMERMAN N, 1970, J AM CHEM SOC, V92, P2523, DOI 10.1021/ja00711a050; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; HAMILTON KK, 1992, NATURE, V356, P725, DOI 10.1038/356725a0; HORI N, 1992, J BIOL CHEM, V267, P15591; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; INAOKA T, 1989, J BIOL CHEM, V264, P2609; IWAI S, 1994, BIOCHEMISTRY-US, V33, P5581, DOI 10.1021/bi00184a029; IWAI S, 1995, BIOCHEMISTRY-US, V34, P4601, DOI 10.1021/bi00014a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAO JY, 1993, J BIOL CHEM, V268, P17787; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KEMMINK J, 1987, EUR J BIOCHEM, V162, P37, DOI 10.1111/j.1432-1033.1987.tb10538.x; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LATHAM KA, 1994, BIOCHEMISTRY-US, V33, P9024, DOI 10.1021/bi00196a021; LATHAM KA, 1995, J BACTERIOL, V177, P5166, DOI 10.1128/jb.177.17.5166-5168.1995; LATHAM KA, 1994, DNA DAMAGE, P181; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; MACMILLAN S, 1981, J VIROL, V40, P211; MANOHARAN M, 1988, J AM CHEM SOC, V11, P2690; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1993, CURR OPIN STRUC BIOL, V3, P17, DOI 10.1016/0959-440X(93)90196-R; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; MORIKAWA K, 1994, DNA DAMAGE, P198; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SARVA R, 1995, NATURE, V373, P487; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	51	245	246	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					773	782		10.1016/0092-8674(95)90190-6	http://dx.doi.org/10.1016/0092-8674(95)90190-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521494	Bronze			2022-12-28	WOS:A1995TH94800014
J	VANASPEREN, IA; DEROVER, CM; SCHIJVEN, JF; OETOMO, SB; SCHELLEKENS, JFP; VANLEEUWEN, NJ; COLLE, C; HAVELAAR, AH; KROMHOUT, D; SPRENGER, MWJ				VANASPEREN, IA; DEROVER, CM; SCHIJVEN, JF; OETOMO, SB; SCHELLEKENS, JFP; VANLEEUWEN, NJ; COLLE, C; HAVELAAR, AH; KROMHOUT, D; SPRENGER, MWJ			RISK OF OTITIS-EXTERNA AFTER SWIMMING IN RECREATIONAL FRESH-WATER LAKES CONTAINING PSEUDOMONAS-AERUGINOSA	BRITISH MEDICAL JOURNAL			English	Article							MORBIDITY; POLLUTION; QUALITY; BEACHES	Objective-To determine whether an outbreak of otitis externa was due to bathing in recreational fresh water lakes and to establish whether the outbreak was caused by Pseudomonas aeruginosa in the water. Design-Matched case-control study. Setting-The Achterhoek area, the Netherlands. Subjects-98 cases with otitis externa and 149 controls matched for age, sex, and place of residence. Main outcome measures-Odds ratios for type of swimming water and frequency of swimming; presence of P aeruginosa in ear swabs and fresh water lakes. Results-Otitis externa was strongly associated with swimming in recreational fresh water lakes in the previous two weeks (odds ratio 15.5 (95% confidence interval) 4.9 to 49.2) compared with non-swimming). The risk increased with the number of days of swimming, and subjects with recurrent ear disease had a greatly increased risk. The lakes met the Dutch bathing water standards and those set by the European Commission for faecal pollution in the summer of 1994, but P aeruginosa was isolated from all of them, as well as from the ear swabs of 78 (83%) of the cases and 3 (4%) of the controls. Conclusions-Even when current bathing water standards are met, swimming can be associated with a substantial risk of otitis externa because of exposure to P aeruginosa. People with recurrent ear disease should take special care when swimming in waters containing P aeruginosa.			VANASPEREN, IA (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT INFECT DIS EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Havelaar, Arie H./P-8495-2014; Kromhout, Daan/A-8566-2014	Havelaar, Arie H./0000-0002-6456-5460; Schijven, Jack/0000-0002-9327-1584				BALARAJAN R, 1991, BRIT MED J, V303, P1444, DOI 10.1136/bmj.303.6815.1444; BROEN A, 1994, CONCEPE STANDARD OTI; CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; CALDERON R, 1982, ARCH ENVIRON HEALTH, V37, P83; CHEUNG WHS, 1990, EPIDEMIOL INFECT, V105, P139, DOI 10.1017/S0950268800047737; CORBETT SJ, 1993, AM J PUBLIC HEALTH, V83, P1701, DOI 10.2105/AJPH.83.12.1701; Dufour A.P., 1984, EPA600184004; El Sharkawi F, 1982, B HIGH I PUB HLTH AL, V12, P337; FATTAL B, 1987, CHEMOSPHERE, V16, P565, DOI 10.1016/0045-6535(87)90268-2; Foulon G, 1983, REV FR SCI EAUX, V2, P127; HAVELAAR AH, 1985, CAN J MICROBIOL, V31, P686, DOI 10.1139/m85-130; HAVELAAR AH, 1984, H2O, V17, P367; KAY D, 1994, LANCET, V344, P905, DOI 10.1016/S0140-6736(94)92267-5; Lanyi B., 1978, METHOD MICROBIOL, V10, P93; LIGHTFOOT N, 1989, THESIS U TORONTO TOR; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; SENTURIA BH, 1980, DISEASES EXTERNAL CA; SEYFRIED P L, 1985, American Journal of Public Health, V75, P1068, DOI 10.2105/AJPH.75.9.1068; SEYFRIED PL, 1985, AM J PUBLIC HEALTH, V75, P1071, DOI 10.2105/AJPH.75.9.1071; SEYFRIED PL, 1984, CAN J PUBLIC HEALTH, V75, P83; SINGER DE, 1952, ANN OTO RHINOL LARYN, V61, P317, DOI 10.1177/000348945206100201; SPRINGER GL, 1985, ARCH ENVIRON HEALTH, V40, P202, DOI 10.1080/00039896.1985.10545918; STEVENSON AH, 1953, AM J PUBLIC HEALTH, V43, P529; 1994, COM94940006SYN COMM; 1985, EGRET EPIDEMIOLOGICA; 1989, STATISTICAL ANAL SYS; 1994, BILT, V91, P2	27	67	73	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1407	1410		10.1136/bmj.311.7017.1407	http://dx.doi.org/10.1136/bmj.311.7017.1407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520277	Green Published			2022-12-28	WOS:A1995TG90200024
J	VIJN, I; DASNEVES, L; VANKAMMEN, A; FRANSSEN, H; BISSELING, T				VIJN, I; DASNEVES, L; VANKAMMEN, A; FRANSSEN, H; BISSELING, T			NOD FACTORS AND NODULATION IN PLANTS	SCIENCE			English	Article											VIJN, I (corresponding author), AGR UNIV WAGENINGEN,DEPT MOLEC BIOL,DREIJENLAAN 3,6703 HA WAGENINGEN,NETHERLANDS.		Bisseling, Ton/A-2421-2013	Neves, Lucinda/0000-0002-2817-354X				DAVIS EO, 1988, MOL GEN GENET, V212, P531, DOI 10.1007/BF00330860; DEJONG A, IN PRESS PLANT CELL; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; FIRMIN J, COMMUNICATION; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; HORVATH B, IN PRESS PLANT J; Libbenga K.R., 1974, BIOL NITROGEN FIXATI, P430; LIE TA, 1971, PLANT SOIL, P117, DOI 10.1007/BF02661845; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; NICOLAOU KC, 1992, J AM CHEM SOC, V114, P8701, DOI 10.1021/ja00048a054; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; SMIT G, 1993, NEW HORIZONS NITROGE, P371; SPAINK HP, 1992, PLANT MOL BIOL, V20, P977, DOI 10.1007/BF00027167; YANG WC, 1993, PLANT J, V3, P573, DOI 10.1046/j.1365-313X.1993.03040573.x	14	80	81	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1764	1765		10.1126/science.8511583	http://dx.doi.org/10.1126/science.8511583			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511583				2022-12-28	WOS:A1993LH20500035
J	HOLBROOK, TL; BARRETTCONNOR, E				HOLBROOK, TL; BARRETTCONNOR, E			A PROSPECTIVE-STUDY OF ALCOHOL-CONSUMPTION AND BONE-MINERAL DENSITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; OSTEOPOROSIS; FRACTURES; DISEASE; MEN; INDICATORS; COMMUNITY; FEMUR; WOMEN	Objectives-To study the effects of alcohol consumption on bone mineral density in a defined population. Design-Prospective study of bone mineral density, measured during 1988-91, in a cohort who had given baseline data on alcohol intake in the previous week and in the previous 24 hours and other factors affecting bone mineral density during 1973-5. Setting-Rancho Bernardo, California. Subjects-182 men and 267 women aged 45 and over at baseline, half having been randomly selected and half having been chosen for hyperlipidaemia, who gave baseline information on alcohol intake in one week. Of these subjects, 142 men and 220 women gave information on alcohol intake in 24 hours. Main outcome measures-Bone mineral density of the radial shaft, ultradistal wrist, femoral neck, and lumbar spine. Results-Men and women were considered separately, and the tertiles of alcohol consumption were used to delineate low, medium, and high values of alcohol intake. With increasing alcohol intake in one week, bone mineral density (adjusted for age, body mass index, smoking, taking exercise, and oestrogen replacement therapy in women) increased significantly in the femoral neck of men (p<0.01) and the spine of women (p<0.01). With increasing alcohol intake in 24 hours, adjusted bone mineral density increased significantly in the radial shaft (p<0.05) and spine (p<0.001) of women. Similar, but not significant, patterns were seen at the other bone sites. Conclusions-Social drinking is associated with higher bone mineral density in men and women.			HOLBROOK, TL (corresponding author), UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, LA JOLLA, CA 92093 USA.				NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGUS RM, 1988, BONE MINER, V4, P265; BARRETTCONNOR E, 1982, AM J EPIDEMIOL, V115, P888, DOI 10.1093/oxfordjournals.aje.a113376; BJORNEBOE GEA, 1988, ALCOHOL CLIN EXP RES, V12, P229, DOI 10.1111/j.1530-0277.1988.tb00185.x; COOPER C, 1987, BMJ-BRIT MED J, V295, P13, DOI 10.1136/bmj.295.6589.13; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; GAVALER JS, 1991, ALCOHOL ALCOHOLISM, P327; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HALL ML, 1990, BRIT J RADIOL, V63, P266, DOI 10.1259/0007-1285-63-748-266; Hansen M A, 1991, Osteoporos Int, V1, P95; HARDING A, 1988, ORTHOPEDICS, V11, P279; HENRY RJ, 1960, AM J CLIN PATHOL, V34, P381; ISRAEL Y, 1980, ALCOHOL CLIN EXP RES, V4, P420, DOI 10.1111/j.1530-0277.1980.tb04842.x; JOHNELL O, 1984, INT ORTHOP, V7, P229; JOHNELL O, 1985, SCAND J SOC MED, V13, P95; JOHNSON RD, 1984, BRIT MED J, V288, P365, DOI 10.1136/bmj.288.6414.365; JONES BR, 1982, AM J CLIN NUTR, V35, P135, DOI 10.1093/ajcn/35.1.135; KRISTENSSON H, 1980, ACTA ORTHOP SCAND, V51, P205, DOI 10.3109/17453678008990787; LAITINEN K, 1990, ALCOHOL CLIN EXP RES, V14, P551, DOI 10.1111/j.1530-0277.1990.tb01198.x; LAITINEN K, 1991, CALCIFIED TISSUE INT, V49, pS70, DOI 10.1007/BF02555094; LAITINEN K, IN PRESS CALCIF TISS; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; RICO H, 1990, ALCOHOL ALCOHOLISM, V25, P345; SAVILLE PD, 1965, J BONE JOINT SURG AM, VA 47, P492, DOI 10.2106/00004623-196547030-00005; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924	25	196	200	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1993	306	6891					1506	1509		10.1136/bmj.306.6891.1506	http://dx.doi.org/10.1136/bmj.306.6891.1506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518677	Green Published, Bronze			2022-12-28	WOS:A1993LF94000023
J	PARIS, JAG; PLAYER, D				PARIS, JAG; PLAYER, D			CITIZENS ADVICE IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the introduction of citizens advice bureau sessions into general practice. Design-Prospective survey of 150 consecutive attenders. Setting-10 Practices in south Birmingham that volunteered to participate. Outcome measures-The social characteristics of the population attending, the problems presented, the social security and other payments obtained, and the health problems mentioned during the sessions. Results-Advice requested covered the whole range offered by the citizens advice bureaus. Thirty nine of 150 attenders obtained payments totalling 58300.58 Pounds for year 1991-2, of which 54929.58 Pounds was recurring. People mentioning health problems were significantly more likely to be entitled to unclaimed benefits. Conclusions-The provision of citizens advice bureau sessions in general practice is an effective way of providing advice on life problems and securing proper payment of benefits, particularly to patients with health problems. This service complements rather than detracts from other citizens advice bureau activities.	S BIRMINGHAM HLTH AUTHOR,BIRMINGHAM B15 3DP,ENGLAND									BUCKLE J, 1986, BRIT MED J, V293, P1077, DOI 10.1136/bmj.293.6554.1077; DEAN AG, 1991, EPPINFO501B WHO; ENNALS S, 1990, BRIT MED J, V301, P1321, DOI 10.1136/bmj.301.6764.1321; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; MARKS BE, 1988, BRIT MED J, V297, P1148, DOI 10.1136/bmj.297.6657.1148; MORRIS JN, 1990, LANCET, V336, P491, DOI 10.1016/0140-6736(90)92026-E; Townsend P., 1982, INEQUALITIES HLTH BL; Whitehead, 1987, HLTH DIVIDE; 1991, SUBJECT CLASSIFICATI; 1988, POVERTY BIRMINGHAM P	10	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1518	1520		10.1136/bmj.306.6891.1518	http://dx.doi.org/10.1136/bmj.306.6891.1518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518682	Green Published, Bronze			2022-12-28	WOS:A1993LF94000029
J	OBRIEN, JM; OBRIEN, SJ; GEDDES, AM; HEAP, BJ; MAYONWHITE, RT				OBRIEN, JM; OBRIEN, SJ; GEDDES, AM; HEAP, BJ; MAYONWHITE, RT			TEMPTING FATE - CONTROL OF COMMUNICABLE DISEASE IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Recent changes in the NHS have left many defects in the systems for the control of communicable diseases and infection and their surveillance and the management of outbreaks. Clear, explicit legislation is needed, placing the responsibilities on health authorities. New teams led by consultants need to be set up to investigate and manage outbreaks of communicable diseases of all types.	UNIV NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV BIRMINGHAM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NORWICH HLTH AUTHOR,NORWICH,NORFOLK,ENGLAND; OXFORDSHIRE HLTH AUTHOR,OXFORD,ENGLAND	Newcastle University - UK; University of Birmingham	OBRIEN, JM (corresponding author), E ANGLIAN REG HLTH AUTHOR,UNION LANE,CAMBRIDGE CB4 1RF,ENGLAND.			O'Brien, Sarah Jane/0000-0003-2896-8999				ACHESON ED, 1991, HLTH TRENDS, V23, P49; [Anonymous], 1989, CONSULTATION EPIDEMI; ASHLEY JSA, 1991, OXFORD TXB PUBLIC HL, V2; COOKE EM, 1990, LANCET, V336, P790, DOI 10.1016/0140-6736(90)93251-J; COWDEN JM, 1989, BRIT MED J, V299, P771, DOI 10.1136/bmj.299.6702.771; COYLE EF, 1988, LANCET, V2, P1295; DUCKWORTH GJ, 1991, BRIT MED J, V303, P483, DOI 10.1136/bmj.303.6801.483-a; GALBRAITH N S, 1987, Health and Hygiene, V8, P102; GALBRAITH NS, 1989, CONSULTANTS COMMUNIC; GODLEE F, 1991, BRIT MED J, V303, P1254, DOI 10.1136/bmj.303.6812.1254; GREENSHIELDS G, 1991, COMMUNICATION   0121; Harvey I, 1991, Health Trends, V23, P73; HAWARD RA, 1973, LANCET, V1, P873; HEAP BJ, 1992, BRIT MED J, V304, P726, DOI 10.1136/bmj.304.6829.726; HOOPER G, 1991, EUROPE HLTH INFLUENC; JONES S, 1991, 1991 REITH LECT LOND; PORTER JDH, 1992, BRIT MED J, V304, P1323, DOI 10.1136/bmj.304.6838.1323; RICHARDSON AJ, 1991, EPIDEMIOL INFECT, V107, P485, DOI 10.1017/S0950268800049189; ROBERTS A, 1992, TIMES           0805, P1; ROBERTS JA, 1989, BRIT MED J, V298, P1227, DOI 10.1136/bmj.298.6682.1227; Secretary of State for Social Services, 1988, PUBLIC HLTH ENGLAND; SKIRROW MB, 1977, BRIT MED J, V2, P9, DOI 10.1136/bmj.2.6078.9; VOSS S, 1992, BRIT MED J, V304, P755, DOI 10.1136/bmj.304.6829.755; 1991, DOH PL91CMO18 DEP HL; 1990, COMMUNICABLE DISEASE; 1990, MICROBIOLOGICAL SA 1; 1991, DOEDOH EL91123 DEP E; 1991, MED ROLE COMMUNICABL; [No title captured]; 1988, DOH HC8864 DEP HLTH; 1989, REV LAW INFECTIOUS D; 1989, SALMONELLA EGGS; 1990, MICROBIOLOGICAL SA 2; 1990, CRYPTOSPORIDIUM WATE; 1988, SI19881546; 1984, INFECTIOUS DISEASES	36	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1461	1464		10.1136/bmj.306.6890.1461	http://dx.doi.org/10.1136/bmj.306.6890.1461			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518646	Bronze, Green Published			2022-12-28	WOS:A1993LE93500023
J	CONROY, RM; OBRIEN, E; OMALLEY, K; ATKINS, N				CONROY, RM; OBRIEN, E; OMALLEY, K; ATKINS, N			MEASUREMENT ERROR IN THE HAWKSLEY RANDOM ZERO SPHYGMOMANOMETER - WHAT DAMAGE HAS BEEN DONE AND WHAT CAN WE LEARN	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; HYPERTENSION; INACCURACY; MORTALITY; STANDARD; MEN	The Hawksley random zero sphygmomanometer is used in all aspects of blood pressure research, from clinical trials to evaluation of new blood pressure recorders. It is designed to reduce observer bias in blood pressure measurement. The problem is that it also underestimates blood pressure. Furthermore, this was first reported more than two decades ago. In this paper Ronan Conroy and colleagues explore the consequences of using an inaccurate instrument for important research and why prestigious organisations like the World Health Organisation continue to use it.	BEAUMONT HOSP,BLOOD PRESSURE UNIT,DUBLIN 7,IRELAND		CONROY, RM (corresponding author), ROYAL COLL SURGEONS IRELAND,DEPT EPIDEMIOL,DUBLIN 2,IRELAND.		Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Atkins, Neil/0000-0002-9575-4686				BARNOWSKI T, 1988, PEDIATR RES, V23, P270; CANNER PL, 1991, AM J EPIDEMIOL, V134, P379, DOI 10.1093/oxfordjournals.aje.a116100; DEMAN SA, 1991, J HYPERTENS, V9, P109, DOI 10.1097/00004872-199102000-00002; EVANS JG, 1970, BRIT J PREV SOC MED, V24, P10; FITZGERALD DJ, 1982, BRIT MED J, V284, P18, DOI 10.1136/bmj.284.6308.18; FOUQUERAY B, 1988, ARCH MAL COEUR VAISS, V81, P231; GARROW JS, 1963, LANCET, V4, P1205; HOSIE GAC, 1985, BMJ, V291, P337; KEYS A, 1984, PREV MED, V13, P141, DOI 10.1016/0091-7435(84)90047-1; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI [10.1001/archinte.128.2.201, 10.1001/archinte.1971.00310200037002]; KEYS A, 1984, INT J EPIDEMIOL, V13, P428, DOI 10.1093/ije/13.4.428; KRONMAL RA, 1990, LANCET, V335, P360, DOI 10.1016/0140-6736(90)90652-L; LABARTHE DR, 1973, AM J CARDIOL, V32, P546, DOI 10.1016/S0002-9149(73)80046-3; LEPARSKI E, 1987, PROTOCOL GUIDELINES, P40; MAHESWARAN R, 1988, J MED ENG TECHNOL, V12, P160, DOI 10.3109/03091908809030175; OBRIEN E, 1990, LANCET, V336, P1465, DOI 10.1016/0140-6736(90)93177-Q; OBRIEN E, 1991, J HUM HYPERTENS, V5, P223; OGLESBY P, 1986, HYPERTENSION, V8, P733; ORNSTEIN S, 1988, J FAM PRACTICE, V26, P517; PARKER D, 1988, HYPERTENSION, V11, P269, DOI 10.1161/01.HYP.11.3.269; ROGERS S, 1948, J EPIDEMIOL COMMUNIT, V42, P321; SHELLEY E, 1991, IRISH J MED SCI, V160, P22, DOI 10.1007/BF02950438; SILMAN AJ, 1985, BRIT MED J, V290, P1781, DOI 10.1136/bmj.290.6484.1781; VANLOO JM, 1986, J HYPERTENS, V4, P631, DOI 10.1097/00004872-198610000-00017; VERDECCHIA P, 1988, INT J CLIN PHARM TH, V26, P570; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; WHINCUP PH, 1989, J HYPERTENS, V7, P845, DOI 10.1097/00004872-198910000-00010; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; WRIGHT BM, 1970, LANCET, V1, P337; 1980, LANCET, V1, P1261; [No title captured]; 1986, ACTA CARDIOL, V4, P283; 1988, J CLIN EPIDEMIOL, V41, P105	33	58	58	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1319	1322		10.1136/bmj.306.6888.1319	http://dx.doi.org/10.1136/bmj.306.6888.1319			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518574	Bronze, Green Published			2022-12-28	WOS:A1993LC72200028
J	Berger, JM; Gamblin, SJ; Harrison, SC; Wang, JC				Berger, JM; Gamblin, SJ; Harrison, SC; Wang, JC			Structure and mechanism of DNA topoisomerase II	NATURE			English	Article							GYRASE-B-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; PURIFICATION; COMPLEXES; HOMOLOGY; SEQUENCE; FRAGMENT	The crystal structure of a large fragment of yeast type II DNA topoisomerase reveals a heart-shaped dimeric protein with a large central hole. It provides a molecular model of the enzyme as an ATP-modulated clamp with two sets of jaws at opposite ends, connected by multiple joints. An enzyme with bound DNA can admit a second DNA duplex through one set of jaws, transport it through the cleaved first duplex, and expel it through the other set of jaws.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute				Gamblin, Steve/0000-0001-5331-639X				ADACHI T, 1984, NUCLEIC ACIDS RES, V12, P6389, DOI 10.1093/nar/12.16.6389; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Caron Paul R., 1994, V29B, P271; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COWTAN KA, 1994, CCP4 DENSITY MODIFIC; Gellert M, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 1, P391; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; Huang W M, 1994, Adv Pharmacol, V29A, P201; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MURZIN AG, 1994, CURR OPIN STRUC BIOL, V4, P441, DOI 10.1016/S0959-440X(94)90114-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; THOMAS W, 1991, GENETICS, V128, P703; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271	43	708	731	2	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					225	232		10.1038/379225a0	http://dx.doi.org/10.1038/379225a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538787				2022-12-28	WOS:A1996TQ16900037
J	Cropper, SJ; Derrington, AM				Cropper, SJ; Derrington, AM			Rapid colour-specific detection of motion in human vision	NATURE			English	Article							RHESUS-MONKEY; VISUAL-CORTEX; PERCEPTION; GRATINGS; MOVEMENT; STIMULI; MACAQUE; INPUT	THE human visual system is much better at analysing the motion of luminance (black and white) patterns than it is at analysing the motion of colour patterns(1-4), especially if the pattern is presented very briefly(5) or moves rapidly(6). We report here that observers reliably distinguish the direction of motion of a colour pattern presented for only 17 milliseconds, provided that the contrast is several times the threshold value (the contrast needed to detect the presence of the pattern). A control experiment, in which a static luminance 'mask' is added to the moving colour pattern, proves that discrimination of the direction of motion of these brief stimuli is colour-specific. The mask drastically impairs discrimination of the direction of motion of a luminance pattern, but it has little effect on a colour pattern. We conclude that the human visual system contains colour-specific motion-detection mechanisms that are capable of analysing very brief signals.	UNIV NOTTINGHAM,DEPT PSYCHOL,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham	Cropper, SJ (corresponding author), UNIV WALES COLL CARDIFF,SCH PSYCHOL,CARDIFF CF1 3YG,S GLAM,WALES.		Derrington, Andrew/A-4389-2009	Cropper, Simon James/0000-0002-3574-6414; Derrington, Andrew/0000-0001-9938-4638	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAVANAGH P, 1984, J OPT SOC AM A, V1, P893, DOI 10.1364/JOSAA.1.000893; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; CAVANAGH P, 1991, VISION RES, V31, P2109, DOI 10.1016/0042-6989(91)90169-6; CROPPER SJ, 1994, VISION RES, V34, P49, DOI 10.1016/0042-6989(94)90256-9; DERRINGTON AM, 1993, VISION RES, V33, P799, DOI 10.1016/0042-6989(93)90199-7; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DOBKINS KR, 1993, VISION RES, V33, P1019, DOI 10.1016/0042-6989(93)90238-R; GOREA A, 1993, VISION RES, V33, P2515, DOI 10.1016/0042-6989(93)90132-G; HAWKEN MJ, 1994, NATURE, V367, P268, DOI 10.1038/367268a0; KRAUSKOPF J, 1982, VISION RES, V22, P1123, DOI 10.1016/0042-6989(82)90077-3; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; MERRISON AFA, 1995, VISION RES, V35, P1459, DOI 10.1016/0042-6989(95)98725-O; MULLEN KT, 1992, VISION RES, V32, P483, DOI 10.1016/0042-6989(92)90240-J; RAMACHANDRAN VS, 1978, NATURE, V275, P55, DOI 10.1038/275055a0; SAITO H, 1989, EXP BRAIN RES, V75, P1; STROMEYER CF, 1995, J PHYSIOL-LONDON, V485, P221, DOI 10.1113/jphysiol.1995.sp020726; TROSCIANKO T, 1988, J OPT SOC AM A, V5, P871, DOI 10.1364/JOSAA.5.000871; ZEKI SM, 1978, J PHYSIOL-LONDON, V277, P273, DOI 10.1113/jphysiol.1978.sp012272; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	19	92	92	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					72	74		10.1038/379072a0	http://dx.doi.org/10.1038/379072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538743				2022-12-28	WOS:A1996TN21600057
J	Swire, J				Swire, J			The aftermath of disaster	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1688	1689		10.1136/bmj.311.7021.1688	http://dx.doi.org/10.1136/bmj.311.7021.1688			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541759	Green Published			2022-12-28	WOS:A1995TL94200019
J	CAMERON, AM; STEINER, JP; ROSKAMS, AJ; ALI, SM; RONNETT, GV; SNYDER, SH				CAMERON, AM; STEINER, JP; ROSKAMS, AJ; ALI, SM; RONNETT, GV; SNYDER, SH			CALCINEURIN ASSOCIATED WITH THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR-FKBP12 COMPLEX MODULATES CA2+ FLUX	CELL			English	Article							RECONSTITUTED LIPID VESICLES; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CALCIUM-RELEASE CHANNEL; TRISPHOSPHATE RECEPTOR; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; RYANODINE RECEPTOR; KINASE-C	The immunosuppressant drug FK506 binds to the immunophilin protein FKBP12 and inhibits its prolyl isomerase activity. Immunosuppresive actions, however, are mediated via an FK506-FKBP12 inhibition of the Ca2+-activated phosphatase calcineurin. Physiologic cellular roles for FKBP12 have remained unclear. FKBP12 is physically associated with the RyR and IP(3)R Ca2+ channels in the absence of FK506, with added FK506 disrupting these complexes, Dissociation of FKBP12 results in alteration of channel Ca2+ conductance in both cases. We now report that calcineurin is physiologically associated with the IP(3)R-FKBP12 and RyR-FKBP12 receptor complexes and that this interaction can be disrupted by FK506 or rapamycin, Calcineurin anchored to the IP(3)R via FKBP12 regulates the phosphorylation status of the receptor, resulting in a dynamic Ca2+-sensitive regulation of IP3-mediated Ca2+ flux.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	CAMERON, AM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010325, R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266] Funding Source: Medline; NIMH NIH HHS [MH 10325-03, MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEDA Y, 1994, J AM CHEM SOC, V116, P4143, DOI 10.1021/ja00088a086; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SHARP AH, 1993, J NEUROSCI, V13, P3051; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WALSH CT, 1992, J BIOL CHEM, V267, P13115; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1990, J BIOL CHEM, V265, P21419	56	445	453	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					463	472		10.1016/0092-8674(95)90124-8	http://dx.doi.org/10.1016/0092-8674(95)90124-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521476	Bronze			2022-12-28	WOS:A1995TC97700016
J	DEWITT, D; SMITH, WL				DEWITT, D; SMITH, WL			YES, BUT DO THEY STILL GET HEADACHES	CELL			English	Review											DEWITT, D (corresponding author), MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824, USA.							BIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P610; CHAN CC, 1994, CAN J PHYSL PHARM S1, V72, P266; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; KARGMAN SL, 1995, CANCER RES, V55, P2556; LANGENBACH R, 1995, CELL, V83; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MORHAM SG, 1995, CELL, V83; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; REDDY ST, 1994, J BIOL CHEM, V269, P15473; SANO H, 1995, CANCER RES, V55, P3785; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Tsujii M, 1995, CELL, V83, P493	16	148	152	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					345	348		10.1016/0092-8674(95)90109-4	http://dx.doi.org/10.1016/0092-8674(95)90109-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521461	Bronze			2022-12-28	WOS:A1995TC97700001
J	MIZUUCHI, M; BAKER, TA; MIZUUCHI, K				MIZUUCHI, M; BAKER, TA; MIZUUCHI, K			ASSEMBLY OF PHAGE-MU TRANSPOSOSOMES - COOPERATIVE TRANSITIONS ASSISTED BY PROTEIN AND DNA SCAFFOLDS	CELL			English	Article							STRAND TRANSFER-REACTION; BACTERIOPHAGE-MU; B-PROTEIN; TRANSPOSITIONAL ENHANCER; INVITRO TRANSPOSITION; TN7 TRANSPOSITION; ESCHERICHIA-COLI; RIBONUCLEASE-H; TARGET DNA; A-PROTEIN	Transposition of phage Mu takes place within higher order protein-DNA complexes called transpososomes. These complexes contain the two Mu genome ends synapsed by a tetramer of Mu transposase (MuA). Transpososome assembly is tightly controlled by multi pie protein and DNA sequence cofactors. We find that assembly can occur through two distinct pathways. One previously described pathway depends on an enhancer-like sequence element, the internal activation sequence (IAS). The second pathway depends on a MuB protein-target DNA complex. For both pathways, all four MuA monomers in the tetramer need to interact with an assembly-assisting element, either the IAS or MuB. However, once assembled, not all MuA monomers within the transpososome need to interact with MuB to capture MuB-bound target DNA. The multiple layers of control likely are used in vivo to ensure efficient rounds of DNA replication when needed, while minimizing unwanted transposition products.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	MIZUUCHI, M (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NIGMS NIH HHS [GM499224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; ALLISON RG, 1992, J BIOL CHEM, V267, P19963; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KUKOLJ G, 1991, NUCLEIC ACIDS RES, V19, P5949, DOI 10.1093/nar/19.21.5949; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; WU ZG, 1992, J BIOL CHEM, V267, P9552; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZOU A, 1991, J BIOL CHEM, V266, P20476	48	39	40	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					375	385		10.1016/0092-8674(95)90115-9	http://dx.doi.org/10.1016/0092-8674(95)90115-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521467	Bronze			2022-12-28	WOS:A1995TC97700007
J	ANDRES, DA; SEABRA, MC; BROWN, MS; ARMSTRONG, SA; SMELAND, TE; CREMERS, FPM; GOLDSTEIN, JL				ANDRES, DA; SEABRA, MC; BROWN, MS; ARMSTRONG, SA; SMELAND, TE; CREMERS, FPM; GOLDSTEIN, JL			CDNA CLONING OF COMPONENT-A OF RAB GERANYLGERANYL TRANSFERASE AND DEMONSTRATION OF ITS ROLE AS A RAB ESCORT PROTEIN	CELL			English	Article							GTP-BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; PEPTIDE-BINDING; FARNESYLTRANSFERASE; EXPRESSION; CHOROIDEREMIA; DISSOCIATION; PURIFICATION; DEPENDENCE	cDNA cloning of component A of rat Rab geranylgeranyl transferase confirms identity of the protein with the human choroideremia gene product and its resemblance to Rab3A guanine nucleotide dissociation inhibitor (GDI), which binds prenylated Rabs. In biochemical assays we demonstrate that component A binds unprenylated Rab1A, presents it to the catalytic component B, and remains bound to it after the geranylgeranyl transfer reaction. In the absence of detergents, the reaction terminates when all of component A is occupied with prenylated Rab. Detergents allow multiple rounds of catalysis, apparently by dissociating the component A-Rab complex and thus allowing recycling of component A. Within the cell, component A may be regenerated by transferring its prenylated Rab to a protein acceptor, such as Rab3A GDI. In view of its function in escorting Rab proteins during and presumably after the prenyl transfer reaction, we propose to rename component A as Rab escort protein (REP). A genetic defect in REP underlies human choroideremia, a disease of retinal degeneration.			ANDRES, DA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Cremers, Frans/A-5625-2014; Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Cremers, Frans/0000-0002-4954-5592; Seabra, Miguel C/0000-0002-6404-4892; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GMO8014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1993, IN PRESS J BIOL CHEM, V268; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CHIESA G, 1992, J BIOL CHEM, V267, P24369; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JAN, 1989, ANN HIST COMPUT, V11, P159; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SAMBROOK J, 1989, MOL CLONIG LABORATOR; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	36	282	290	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1091	1099		10.1016/0092-8674(93)90639-8	http://dx.doi.org/10.1016/0092-8674(93)90639-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513495				2022-12-28	WOS:A1993LH54800006
J	JARRETT, JT; LANSBURY, PT				JARRETT, JT; LANSBURY, PT			SEEDING ONE-DIMENSIONAL CRYSTALLIZATION OF AMYLOID - A PATHOGENIC MECHANISM IN ALZHEIMERS-DISEASE AND SCRAPIE	CELL			English	Review							BIOLOGY				JARRETT, JT (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.			Jarrett, Joseph/0000-0002-3737-7464				Asakura S, 1970, Adv Biophys, V1, P99; Baker H. F., 1992, Neurodegeneration, V1, P3; BAKER HF, 1993, 7TH P INT STUD GROUP, P315; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CASPAR DLD, 1980, BIOPHYS J, V32, P101; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; NIEWOLD TA, 1987, LAB INVEST, V56, P544; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, NEW ENGL J MED, V310, P661, DOI 10.1056/NEJM198403083101021; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760	30	1900	1958	2	163	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1055	1058		10.1016/0092-8674(93)90635-4	http://dx.doi.org/10.1016/0092-8674(93)90635-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513491				2022-12-28	WOS:A1993LH54800002
J	IRVINE, HD; LAMONT, DW; HOLE, DJ; GILLIS, CR				IRVINE, HD; LAMONT, DW; HOLE, DJ; GILLIS, CR			ASBESTOS AND LUNG-CANCER IN GLASGOW AND THE WEST OF SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; HEALTH; MESOTHELIOMA; EXPOSURE	Objective-To quantify the relation between lung cancer and exposure to asbestos in men in west Scotland and to estimate the proportion of lung cancer which may be attributed to exposure to asbestos. Design-An ecological correlation study of the incidence of lung cancer in men and past asbestos exposure. The unit of analysis was the postcode sector. Correction was made for past cigarette smoking, air pollution, and deprivation. Setting-The region covered by the west of Scotland cancer registry, containing 2.72 million people and including Glasgow and the lower reaches of the River Clyde, where shipbuilding was once a major industry. Subjects-All men diagnosed with lung cancer between 1975 and 1984 whose residence at the time of registration was within the west of Scotland. Main outcome measure-The population attributable risk for asbestos related lung cancer. Results-An estimated 5.7% (95% confidence interval 2.3 to 9.11%) of all lung cancers in men registered in the west of Scotland during the period 1975-84 were asbestos related, amounting to 1081 cases. Conclusions-A considerable proportion of cases of lung cancer in men in Glasgow and the west of Scotland from 1975 to 1984 were asbestos related. Most of these may not have been considered for compensation by the Department of Social Security. Given the very small annual number of recorded cases of asbestosis this condition is probably not a prerequisite for the development of asbestos related lung cancer. A heightened awareness of the increasing incidence of asbestos related neoplasms and their more thorough investigation are recommended.			IRVINE, HD (corresponding author), RUCHILL HOSP, GREATER GLASGOW HLTH BOARD, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW G20 9NB, SCOTLAND.							[Anonymous], 1965, ANN NY ACAD SCI, V132, P745; BRIDBORD K, 1981, BANBURY REPORT, V9, P701; Carstairs V., 1991, DEPRIVATION HLTH SCO; DANIEL FB, 1983, ENVIRON HEALTH PERSP, V53, P163, DOI 10.2307/3429629; DOLL R, 1989, IARC SCI PUBL, V90, P511; DOLL R, 1981, CAUSES CANC, P1238; DORWARD AJ, 1981, BRIT J DIS CHEST, V75, P397, DOI 10.1016/0007-0971(81)90027-9; ENTERLINE PE, 1981, BANBURY REPORT, V9, P19; FRASER RG, 1989, DIAGNOSIS DISEASES C, V2; FULTON M, 1988, EUR J CLIN NUTR, V42, P797; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; GILLIS CR, 1990, J SOC OCCUP MED, V40, P5; Hammond E C, 1979, Ann N Y Acad Sci, V330, P473, DOI 10.1111/j.1749-6632.1979.tb18749.x; HIGGINSON J, 1980, PREV MED, V9, P180, DOI 10.1016/0091-7435(80)90073-0; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HUGHES JM, 1991, BRIT J IND MED, V48, P229; KIPEN HM, 1987, BRIT J IND MED, V44, P96; MANCUSO TF, 1963, ARCH ENVIRON HEALTH, V6, P210, DOI 10.1080/00039896.1963.10663384; MARTISCHNIG KM, 1977, BRIT MED J, V1, P746, DOI 10.1136/bmj.1.6063.746; MUIR CS, 1987, IARC SCI PUBLICATION, V88; MURRAY R, 1990, BRIT J IND MED, V47, P361; Parkes W.R., 1982, OCCUPATIONAL LUNG DI; PETO J, 1981, BANBURY REPORT, V9, P51; Peto J., 1985, ASBESTOS EFFECTS HLT; ROGGLI VL, 1986, BRIT J IND MED, V43, P18; SEATON A, 1988, CROFTON DOUGLASS RES; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; SELIKOFF IJ, 1964, JAMA-J AM MED ASSOC, V188, P22; SLUISCREMER GK, 1980, CHEST, V78, P380, DOI 10.1378/chest.78.2_Supplement.380; STJERNSWARD J, 1988, LUNG CANCER, V4, P11; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; WARNOCK ML, 1986, CHEST, V89, P20, DOI 10.1378/chest.89.1.20; 1989, SOCIAL SECURITY STAT; 1951, 1951 CENSUS SCOTLAND; 1991, HLTH SAFETY STATISTI, V99, P72; 1976, NATIONAL SURVEY AIR, V5; 1988, WORLD HLTH STATISTIC, V41, P115	37	37	37	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1993	306	6891					1503	1506		10.1136/bmj.306.6891.1503	http://dx.doi.org/10.1136/bmj.306.6891.1503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518676	Green Published, Bronze			2022-12-28	WOS:A1993LF94000022
J	Celermajer, DS; Adams, MR; Clarkson, P; Robinson, J; McCredie, R; Donald, A; Deanfield, JE				Celermajer, DS; Adams, MR; Clarkson, P; Robinson, J; McCredie, R; Donald, A; Deanfield, JE			Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; RISK; ATHEROSCLEROSIS; CHILDREN; CHOLESTEROL; LIPOPROTEIN; RABBITS; SMOKERS; INVIVO	Background. Passive smoking has been linked to an increased risk of dying from atherosclerotic heart disease. Since endothelial dysfunction is an early feature of atherogenesis and occurs in young adults who actively smoke cigarettes, we hypothesized that passive smoking might also be associated with endothelial damage in healthy young-adult nonsmokers. Methods. We studied 78 healthy subjects (39 male and 39 female) 15 to 30 years of age (mean +/-SD, 22+/-4): 26 control subjects who had never smoked or had regular exposure to environmental tobacco smoke, 26 who had never smoked but had been exposed to environmental tobacco smoke for at least one hour dally for three or more years, and 26 active smokers. Using ultrasonography, we measured the brachial-artery diameter under base-line conditions, during reactive hyperemia (with flow increase causing endothelium-dependent dilatation), and after sublingual administration of nitroglycerin (an endothelium-independent dilater). Results. Flow-mediated dilatation was observed in all control subjects (8.2+/-3.1 percent; range, 2.1 to 16.7) but was significantly impaired in the passive smokers (3.1+/-2.7 percent; range, 0 to 9; P<0.001 for the comparison with the controls) and in the active smokers (4.4+/-3.1 percent; range, 0 to 10; P<0.001 for the comparison with the controls; P=0.48 for the comparison with the passive smokers). In the passive smokers, there was an inverse relation between the intensity of exposure to tobacco smoke and flow-mediated dilatation (r=-0.67, P<0.001). In contrast, dilatation induced by nitroglycerin was similar in all groups. Conclusions. Passive smoking is associated with dose-related impairment of endothelium-dependent dilatation in healthy young adults, suggesting early arterial damage.	HEART RES INST, SYDNEY, NSW, AUSTRALIA; HOSP SICK CHILDREN, CARDIOTHORAC UNIT, LONDON WC1N 3JH, ENGLAND	University of Sydney; Heart Research Institute; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Celermajer, DS (corresponding author), ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA.		Deanfield, John E/C-5178-2008	Deanfield, John/0000-0001-8806-6052; Robinson, Jacqui/0000-0001-6671-5437				ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; BROWN RE, 1993, CIRCULATION, V88, P260; BURGHUBER OC, 1986, CHEST, V90, P34, DOI 10.1378/chest.90.1.34; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHAUVEAU M, 1985, CARDIOVASC RES, V19, P700, DOI 10.1093/cvr/19.11.700; COLLEY JRT, 1974, LANCET, V2, P1031; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; DAVIS JW, 1990, J VASC MED BIOL, V2, P289; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FELDMAN J, 1991, PEDIATRICS, V88, P259; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HOGG RV, 1978, INTRO MATH STATISTIC; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; JENDRYCZKO A, 1993, NEOPLASMA, V40, P199; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LIEBERMAN EH, 1994, CIRCULATION, V90, P138; MOORE S, 1973, LAB INVEST, V29, P478; MOSKOWITZ WB, 1990, CIRCULATION, V81, P586, DOI 10.1161/01.CIR.81.2.586; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RAIJ L, 1994, CIRCULATION, V90, P575; REPACE JL, 1985, ENVIRON INT, V11, P3, DOI 10.1016/0160-4120(85)90098-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SINZINGER H, 1989, WIEN KLIN WOCHENSCHR, V101, P694; SORENSEN KE, 1995, BRIT HEART J, V74, P247; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; SUN YP, 1994, CIRCULATION, V90, P459; TAYLOR AE, 1992, CIRCULATION, V86, P699, DOI 10.1161/01.CIR.86.2.699; TEIRSTEIN PS, 1993, J AM COLL CARDIOL, V21, P590, DOI 10.1016/0735-1097(93)90089-J; WELLS AJ, 1988, ENVIRON INT, V14, P249; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x; ZHU BQ, 1993, J AM COLL CARDIOL, V21, P225, DOI 10.1016/0735-1097(93)90741-I; 1983, DHHS PHS8450204 PUBL	40	754	785	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					150	154		10.1056/NEJM199601183340303	http://dx.doi.org/10.1056/NEJM199601183340303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531969				2022-12-28	WOS:A1996TQ01700003
J	Bernstein, AL; LeventhalRochon, JL				Bernstein, AL; LeventhalRochon, JL			Neurotoxicity related to the use topical tretinoin (retin-A)	ANNALS OF INTERNAL MEDICINE			English	Article							VITAMIN-A; TOXICITY		KAISER PERMANENTE MED CTR, HAYWARD, CA USA	Kaiser Permanente								BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; BIESALSKI HK, 1989, TOXICOLOGY, V57, P117, DOI 10.1016/0300-483X(89)90161-3; BIGBY M, 1988, J AM ACAD DERMATOL, V18, P543, DOI 10.1016/S0190-9622(88)70078-X; CHREN M-M, 1990, P1572; GEUBEL AP, 1991, GASTROENTEROLOGY, V100, P1701, DOI 10.1016/0016-5085(91)90672-8; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; HATOFF DE, 1982, GASTROENTEROLOGY, V82, P124; MARCUS R, 1990, P1553; MOSKOWITZ Y, 1993, ANN OPHTHALMOL, V25, P306; RESTAK RM, 1972, J NERV MENT DIS, V155, P72, DOI 10.1097/00005053-197207000-00008; SMITH FR, 1976, NEW ENGL J MED, V294, P805, DOI 10.1056/NEJM197604082941503; SNODGRASS SR, 1992, MOL NEUROBIOL, V6, P41, DOI 10.1007/BF02935566; SPECTOR RH, 1984, NEUROLOGY, V34, P1509, DOI 10.1212/WNL.34.11.1509; VAHLQUIST A, 1992, J AM ACAD DERMATOL, V27, pS29, DOI 10.1016/S0190-9622(08)80257-5; 1990, RETIN A TRETINOIN PA	15	6	6	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					227	228		10.7326/0003-4819-124-2-199601150-00006	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533998				2022-12-28	WOS:A1996TQ01600006
J	Gill, JB; Cairns, JA; Roberts, RS; Costantini, L; Sealey, BJ; Fallen, EF; Tomlinson, CW; Gent, M				Gill, JB; Cairns, JA; Roberts, RS; Costantini, L; Sealey, BJ; Fallen, EF; Tomlinson, CW; Gent, M			Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXERCISE TEST; SILENT ISCHEMIA; UNSTABLE ANGINA; FOLLOW-UP; RISK; DEATH	Background, After an acute myocardial infarction, it is important to determine the risk of a subsequent coronary event, We studied the prognostic value of myocardial ischemia detected by ambulatory electrocardiographic (EGG) monitoring in patients who had recently had an acute myocardial infarction. Methods. Five to seven days after acute myocardial infarction, 406 patients underwent 48-hour ambulatory ECG monitoring, with submaximal exercise testing before discharge and measurement of the left ventricular ejection fraction within 28 days after infarction. Death, nonfatal myocardial infarction, and admission to the hospital because of unstable angina were the principal end points recorded during the one-year follow-up period. Results. The overall incidence of myocardial ischemia detected by ambulatory ECG monitoring was 23.4 percent, The mortality rates at one year were 11.6 percent among the patients with ischemia and 3.9 percent among those without ischemia (P=0.009); 3.9 percent among the patients with a positive exercise test, 3.0 percent among those with a negative exercise test, and 16.4 percent among those in whom an exercise test was not performed (P<0.001); and 3.6 percent among the patients with an ejection fraction greater than 50 percent, 3.5 percent among those with an ejection fraction between 35 and 50 percent, and 18.2 percent among those with an ejection fraction below 35 percent (P=0.001), Using multiple logistic regression, we found that no diagnostic test performed after myocardial infarction provided additional prognostic information beyond that provided by the standard clinical variables used to predict the risk of death. When nonfatal myocardial infarction and admission to the hospital because of unstable angina were also included as outcome variables, ambulatory monitoring for ischemia was the only test that contributed significantly to the model. For the patients with ischemia detected by ambulatory monitoring, as compared with those who did not have evidence of ischemia, the odds ratio was 2.3 (95 percent confidence interval, 1.2 to 4.5) for death or nonfatal myocardial infarction (P=0.009) and 2.8 (95 percent confidence interval, 1.6 to 4.8) for death, nonfatal myocardial infarction, or admission to the hospital because of unstable angina (P<0.001). Conclusions. Myocardial ischemia detected by ambulatory ECG monitoring is common early after acute myocardial infarction and provides prognostic information beyond that available from standard clinical information.	MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA	McMaster University; McMaster University			Cairns, John/AAI-8744-2021					BONADUCE D, 1991, EUR HEART J, V12, P186, DOI 10.1093/oxfordjournals.eurheartj.a059867; CHAITMAN BR, 1993, AM J CARDIOL, V71, P131, DOI 10.1016/0002-9149(93)90727-T; CURRIE P, 1993, AM J CARDIOL, V71, P773, DOI 10.1016/0002-9149(93)90822-T; DAVIDSON DM, 1980, CIRCULATION, V61, P236, DOI 10.1161/01.CIR.61.2.236; DEBELDER M, 1990, BRIT HEART J, V63, P145; DEEDWANIA PC, 1991, AM J CARDIOL, V68, P1279, DOI 10.1016/0002-9149(91)90231-9; FLEISS JL, 1981, STATISTICAL METHODS, P25; FRIEDMAN LM, 1982, FUNDAMENTALS CLIN TR, P180; FROELICHER VF, 1987, AM J MED, V83, P1045, DOI 10.1016/0002-9343(87)90940-5; GOTTLIEB SO, 1988, JAMA-J AM MED ASSOC, V259, P1030, DOI 10.1001/jama.259.7.1030; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P756, DOI 10.1016/S0735-1097(87)80267-X; JERECZEK M, 1993, AM J CARDIOL, V72, P8, DOI 10.1016/0002-9149(93)90210-4; JUNEAU M, 1992, J AM COLL CARDIOL, V20, P927, DOI 10.1016/0735-1097(92)90195-S; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P512; LANGER A, 1992, J AM COLL CARDIOL, V20, P1313, DOI 10.1016/0735-1097(92)90242-F; MICKLEY H, 1993, AM J CARDIOL, V71, P139, DOI 10.1016/0002-9149(93)90728-U; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; OUYANG P, 1990, AM J CARDIOL, V65, P267, DOI 10.1016/0002-9149(90)90285-9; PETRETTA M, 1992, AM J CARDIOL, V69, P579, DOI 10.1016/0002-9149(92)90145-O; RABY KE, 1990, AM J CARDIOL, V66, P1309, DOI 10.1016/0002-9149(90)91159-4; SAMI M, 1979, CIRCULATION, V60, P1238, DOI 10.1161/01.CIR.60.6.1238; SOLIMENE MC, 1993, INT J CARDIOL, V38, P41, DOI 10.1016/0167-5273(93)90202-R; STARLING MR, 1980, AM J CARDIOL, V46, P909, DOI 10.1016/0002-9149(80)90344-6; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; WELD FM, 1981, CIRCULATION, V64, P306, DOI 10.1161/01.CIR.64.2.306; WILLIAMS WL, 1984, J AM COLL CARDIOL, V4, P477, DOI 10.1016/S0735-1097(84)80090-X; 1983, NEW ENGL J MED, V309, P331	28	86	89	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					65	70		10.1056/NEJM199601113340201	http://dx.doi.org/10.1056/NEJM199601113340201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531960	Bronze			2022-12-28	WOS:A1996TP36300001
J	Winawer, SJ; Zauber, AG; Gerdes, H; OBrien, MJ; Gottlieb, LS; Sternberg, SS; Bond, JH; Waye, JD; Schapiro, M; Panish, JF; Kurtz, RC; Shike, M; Ackroyd, FM; Stewart, ET; Skolnick, M; Bishop, DT; Lightdale, CJ; Edelman, M; Fleisher, M; Ho, MN; Diaz, B; Lapidus, J; Padern, RA; Mandelman, M; Nazario, H; Colon, H; Kadvan, P; Miller, C; Szporn, A; Herpes, R; Khilnani, M; Ansel, H; Ewing, S; Dobson, T; Hogan, W; Helm, J; Komorowski, R; McLaughlin, E; Greenen, J; Venu, R; Jonson, GK; DeBoer, N; Hedberg, S; Shellito, P; Hall, D; Dickersin, G; Horton, N; Sherman, J; Hamlin, JA; Geller, S; Kojimoto, M; Auslander, M; Kasimian, D; Kussin, L; Scoggins, C; Magrath, C				Winawer, SJ; Zauber, AG; Gerdes, H; OBrien, MJ; Gottlieb, LS; Sternberg, SS; Bond, JH; Waye, JD; Schapiro, M; Panish, JF; Kurtz, RC; Shike, M; Ackroyd, FM; Stewart, ET; Skolnick, M; Bishop, DT; Lightdale, CJ; Edelman, M; Fleisher, M; Ho, MN; Diaz, B; Lapidus, J; Padern, RA; Mandelman, M; Nazario, H; Colon, H; Kadvan, P; Miller, C; Szporn, A; Herpes, R; Khilnani, M; Ansel, H; Ewing, S; Dobson, T; Hogan, W; Helm, J; Komorowski, R; McLaughlin, E; Greenen, J; Venu, R; Jonson, GK; DeBoer, N; Hedberg, S; Shellito, P; Hall, D; Dickersin, G; Horton, N; Sherman, J; Hamlin, JA; Geller, S; Kojimoto, M; Auslander, M; Kasimian, D; Kussin, L; Scoggins, C; Magrath, C			Risk of colorectal cancer in the families of patients with adenomatous polyps	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLON-CANCER; NATIONAL POLYP; HISTORY; RECTUM; SURVEILLANCE; INHERITANCE; RELATIVES; MORTALITY; FREQUENCY; HOMOLOG	Background. The adenoma-adenocarcinoma sequence in colorectal cancer suggests an increased risk of colorectal cancer in the families of patients with adenomatous polyps. Methods. A random sample of participants in the National Polyp Study who had newly diagnosed adenomatous polyps were interviewed for information on the history of colorectal cancer in their parents and siblings, The risk of colorectal cancer in family members was analyzed according to the characteristics of the patients with adenomas and in comparison with a sample of patients' spouses, who served as controls. Results. Among the patients with adenomas, 1199 provided information on whether they had a family history of colorectal cancer. After the exclusion of families for which information was incomplete and of 48 patients who had been referred for colonoscopy solely because they had a family history of colorectal cancer, there were 1031 patients with adenomas, 1865 parents, 2381 siblings, and 1411 spouse controls. The relative risk of colorectal cancer, adjusted for the year of birth and sex, was 1.78 for the parents and siblings of the patients with adenomas as compared with the spouse controls (95 percent confidence interval, 1.18 to 2.67). The relative risk for siblings of patients in whom adenomas were diagnosed before 60 years of age was 2.59 (95 percent confidence interval, 1.46 to 4.58), as compared with the siblings of patients who were 60 or older at the time of diagnosis and after adjustment for the sibling's year of birth and sex and a parental history of colorectal cancer. The risk increased with decreasing age at the time of the diagnosis of adenoma (P for trend <0.001). The relative risk for the siblings of patients who had a parent with colorectal cancer, as compared with those who had no parent with cancer, was 3.25 (95 percent confidence interval, 1.92 to 5.52), after adjustment for the sibling's year of birth and sex and the patient's age at diagnosis. Conclusions. Siblings and parents of patients with adenomatous polyps are at increased risk for colorectal cancer, particularly when the adenoma is diagnosed before the age of 60 or - in the case of siblings - when a parent has had colorectal cancer.	BOSTON CITY HOSP,MALLORY INST PATHOL,BOSTON,MA; VET AFFAIRS MED CTR,MINNEAPOLIS,MN; MT SINAI HOSP,NEW YORK,NY; VALLEY PRESBYTERIAN HOSP,VAN NUYS,CA; CEDARS SINAI MED CTR,LOS ANGELES,CA; MASSACHUSETTS GEN HOSP,BOSTON,MA; MILWAUKEE CTY MED CTR,MILWAUKEE,WI; UNIV UTAH,SALT LAKE CITY,UT; IMPERIAL CANC RES FUND,LEEDS,W YORKSHIRE,ENGLAND	Boston Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Icahn School of Medicine at Mount Sinai; Cedars Sinai Medical Center; Harvard University; Massachusetts General Hospital; Utah System of Higher Education; University of Utah	Winawer, SJ (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT MED,SERV GASTROENTEROL & NUTR,NATL POLYP STUDY HEADQUARTERS,NEW YORK,NY 10021, USA.		O'Brien, Michael J/R-7179-2019	Bishop, Tim/0000-0002-8752-8785; O'Brien, Michael J/0000-0003-1124-3537	NATIONAL CANCER INSTITUTE [R01CA046940] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46940] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN J, 1995, AM J EPIDEMIOL, V141, P863, DOI 10.1093/oxfordjournals.aje.a117522; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BISHOP DT, 1990, CANCER SURV, V9, P585; BOND JH, 1994, ANN INTERN MED, V120, P347, DOI 10.7326/0003-4819-120-4-199402150-00032; BOND JH, 1993, ANN INTERN MED, V119, P836, DOI 10.7326/0003-4819-119-8-199310150-00010; BONELLI L, 1988, INT J CANCER, V41, P513; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P2378; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; DEVESA SS, 1987, J NATL CANCER I, V79, P701; DUNCAN JL, 1982, GUT, V23, P169, DOI 10.1136/gut.23.2.169; EASTON D, 1990, CANCER SURV, V9, P395; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GERDES H, 1993, CANCER RES, V53, P279; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; GUILLEM JG, 1988, AM J GASTROENTEROL, V83, P271; HALL NR, 1994, BRIT J SURG, V81, P1485, DOI 10.1002/bjs.1800811029; HORM JW, 1985, NIH8511837 PUBL; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; MACKLIN MT, 1960, J NATL CANCER I, V24, P551, DOI 10.1093/jnci/24.3.551; MAIRE P, 1984, GASTROEN CLIN BIOL, V8, P22; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MORSON BC, 1974, CANCER, V34, P845, DOI 10.1002/1097-0142(197409)34:3+<845::AID-CNCR2820340710>3.0.CO;2-H; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; RIES LAG, 1990, NIH902789 PUBL; ROZEN P, 1987, CANCER, V60, P248, DOI 10.1002/1097-0142(19870715)60:2<248::AID-CNCR2820600223>3.0.CO;2-G; SLATTERY ML, 1994, J NATL CANCER I, V86, P1618, DOI 10.1093/jnci/86.21.1618; SLATTERY ML, 1994, J NATL CANCER I, V86, P1802; SONDERGAARD JO, 1991, INT J CANCER, V47, P202, DOI 10.1002/ijc.2910470207; STEPHENSON BM, 1991, BRIT J SURG, V78, P1162, DOI 10.1002/bjs.1800781005; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1995, B WORLD HEALTH ORGAN, V73, P7; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WOOLF CM, 1958, AM J HUM GENET, V10, P42	44	238	243	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					82	87		10.1056/NEJM199601113340204	http://dx.doi.org/10.1056/NEJM199601113340204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531963				2022-12-28	WOS:A1996TP36300004
J	Pini, P				Pini, P			Addiction	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					6	6		10.1016/S0140-6736(96)91553-6	http://dx.doi.org/10.1016/S0140-6736(96)91553-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531569	Bronze			2022-12-28	WOS:A1996TN76200008
J	Scragg, RKR; Mitchell, EA; Stewart, AW; Ford, RPK; Taylor, BJ; Hassall, IB; Williams, SM; Thompson, JMD				Scragg, RKR; Mitchell, EA; Stewart, AW; Ford, RPK; Taylor, BJ; Hassall, IB; Williams, SM; Thompson, JMD			Infant room-sharing and prone sleep position in sudden infant death syndrome	LANCET			English	Article							HONG-KONG	Background There is evidence that the risk of sudden infant death syndrome is lower among ethnic groups in which parents generally share a room with the infant for sleeping. We investigated whether the presence of other family members in the infant's sleeping room affects the risk of the sudden infant death syndrome. Methods The case-control study covered a region with 78% of all births in New Zealand during 1987-90. Home interviews were completed with parents of 393 (81.0% of total) babies who died from the sudden infant death syndrome aged 28 days to 1 year and 1592 (88.4% of total) controls, selected from all hospital births in the study region. Findings The relative risk of sudden infant death for sharing the room with one or more adults compared with not sharing was 0.19 (95% Cl 0.08-0.45) for sharing at night during the last 2 weeks and 0.27 (0.17-0.41) for sharing in the last sleep, after control for other confounders. Sharing the room with one or more children did not affect the relative risk (1.25 [0.86-1.82] for sharing during last 2 weeks; 1.29 [0.85-1.94] for sharing in last sleep). There was a significant interaction (p=0.033) between not sharing the room with an adult and prone sleep position in the last sleep. Compared with infants sharing the room with an adult and not prone, the multivariate relative risk was 16.99 (10.43-27.69) for infants not sharing with an adult and prone, 3.28 (2.06-5.23) for infants sharing the room and prone, and 2.60 (1.58-4.30) for infants not sharing the room and not prone. The interaction between adult room-sharing and prone sleep position suggests that both exposures may affect the risk of sudden infant death syndrome through a common mechanism. Interpretation We recommend that infants sleep in the same bedroom as their parents at night to reduce the risk of sudden infant death syndrome.	UNIV AUCKLAND, DEPT PAEDIAT, AUCKLAND, NEW ZEALAND; UNIV OTAGO, DEPT PAEDIAT & CHILD HLTH, DUNEDIN, NEW ZEALAND; UNIV OTAGO, DEPT PREVENT & SOCIAL MED, DUNEDIN, NEW ZEALAND; HEALTHLINK S, COMMUNITY PAEDIAT UNIT, CHRISTCHURCH, NEW ZEALAND; INDEPENDENT CHILDRENS ADVOCATE, AUCKLAND, NEW ZEALAND	University of Auckland; University of Otago; University of Otago	Scragg, RKR (corresponding author), UNIV AUCKLAND, DEPT COMMUNITY HLTH, PRIVATE BAG 92019, AUCKLAND, NEW ZEALAND.		Taylor, Barry j/G-1410-2010; Williams, Sheila/L-4028-2019	Scragg, Robert/0000-0003-0013-2620; Taylor, Barry/0000-0002-6450-8677				BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BEGG NC, 1970, NZ CHILD HIS FAMILY, P98; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; DAVIES DP, 1985, LANCET, V2, P1346; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; Farooqi S, 1993, Paediatr Perinat Epidemiol, V7, P245; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KING FT, 1931, FEEDING CARE BABY, P64; Leach P., 1980, BABY CHILD, P93; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MALCOLM G, 1994, J PAEDIATR CHILD H, V30, P45, DOI 10.1111/j.1440-1754.1994.tb00565.x; McKenna J J, 1986, Med Anthropol, V10, P9; MCKENNA JJ, 1993, SLEEP, V16, P263, DOI 10.1093/sleep/16.3.263; Mitchell E. A., 1995, P266; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; Spock B, 1985, BABY CHILD CARE, P219; WILLIAMS SM, IN PRESS PAEDIATR PE	25	67	68	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					7	12		10.1016/S0140-6736(96)91554-8	http://dx.doi.org/10.1016/S0140-6736(96)91554-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531589	Bronze			2022-12-28	WOS:A1996TN76200009
J	Graeber, TG; Osmanian, C; Jacks, T; Housman, DE; Koch, CJ; Lowe, SW; Giaccia, AJ				Graeber, TG; Osmanian, C; Jacks, T; Housman, DE; Koch, CJ; Lowe, SW; Giaccia, AJ			Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours	NATURE			English	Article							CANCER; BCL-2; P53	APOPTOSIS is a genetically encoded programme of cell death that can be activated under physiological conditions(1,2) and may be an important safeguard against tumour development(3-6). Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours(7,8). Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as less of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.	STANFORD UNIV,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; UNIV PENN,PHILADELPHIA,PA 19104; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Stanford University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Cold Spring Harbor Laboratory				Graeber, Thomas/0000-0001-8574-9181				BAKER SJ, 1990, CANCER RES, V50, P7717; BARDEESY N, 1995, CANCER RES, V55, P215; BECLI A, 1995, CANCER RES, V55, P1811; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOCKEL M, 1993, GYNECOL ONCOL, V51, P141, DOI 10.1006/gyno.1993.1262; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LORD EM, 1993, CANCER RES, V53, P5721; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, IN PRESS CURR OPIN O; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SIRICROPE FA, 1995, CANCER RES, V55, P237; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaupel P., 1995, TUMOR OXYGENATION, P219; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	30	2053	2112	1	116	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					88	91		10.1038/379088a0	http://dx.doi.org/10.1038/379088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538748				2022-12-28	WOS:A1996TN21600062
J	Groves, KE				Groves, KE			How I'd like to be treated if I was terminally ill	BRITISH MEDICAL JOURNAL			English	Article											Groves, KE (corresponding author), QUEENSCOURT HOSPICE,SOUTHPORT PR8 6RE,MERSEYSIDE,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1690	1691		10.1136/bmj.311.7021.1690	http://dx.doi.org/10.1136/bmj.311.7021.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541760	Green Published			2022-12-28	WOS:A1995TL94200020
J	ZAMBRYSKI, P				ZAMBRYSKI, P			PLASMODESMATA - PLANT CHANNELS FOR MOLECULES ON THE MOVE	SCIENCE			English	Editorial Material							CELLS				ZAMBRYSKI, P (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT BIOL,KOSHLAND HALL,BERKELEY,CA 94720, USA.							CITOVSKY V, 1993, ANNU REV MICROBIOL, V47, P167, DOI 10.1146/annurev.mi.47.100193.001123; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; FISCHER DB, 1992, PLANT PHYSIOL, V100, P1433; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; HAKE S, 1986, NATURE, V320, P621, DOI 10.1038/320621a0; HEINLEIN M, 1995, SCIENCE, V270, P1983, DOI 10.1126/science.270.5244.1983; JACKSON D, 1994, DEVELOPMENT, V120, P405; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; LUCAS WJ, 1995, CURR OPIN CELL BIOL, V7, P673, DOI 10.1016/0955-0674(95)80109-X; MCLEAN EG, IN PRESS PLANT CELL; NAKAMURA S, 1993, PLANT CELL PHYSIOL, V34, P927; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; OPARKA KJ, 1995, J EXP BOT, V46, P187, DOI 10.1093/jxb/46.2.187; SINHA N, 1990, DEV BIOL, V141, P203, DOI 10.1016/0012-1606(90)90115-Y; SMITH LG, 1992, DEVELOPMENT, V116, P21; TILNEY LG, 1990, DEVELOPMENT, V110, P1209; TURNER A, 1994, J CELL SCI, V107, P3351; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; WAIGMANN E, 1994, CURR BIOL, V4, P713, DOI 10.1016/S0960-9822(00)00157-3; WAIGMANN E, IN PRESS PLANT CELL, V7; WHITE RG, 1994, PROTOPLASMA, V180, P169, DOI 10.1007/BF01507853	23	39	40	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1943	1944		10.1126/science.270.5244.1943	http://dx.doi.org/10.1126/science.270.5244.1943			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533085				2022-12-28	WOS:A1995TL42000028
J	KUJALA, UM; TAIMELA, S; ANTTIPOIKA, I; ORAVA, S; TUOMINEN, R; MYLLYNEN, P				KUJALA, UM; TAIMELA, S; ANTTIPOIKA, I; ORAVA, S; TUOMINEN, R; MYLLYNEN, P			ACUTE INJURIES IN SOCCER, ICE HOCKEY, VOLLEYBALL, BASKETBALL, JUDO, AND KARATE - ANALYSIS OF NATIONAL REGISTRY DATA	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; SPORTS; RATES	Objective-To determine the acute injury profile in each of six sports and compare the injury rates between the sports. Design-Analysis of national sports injury insurance registry data. Setting-Finland during 1987-98. Subjects-621 691 person years of exposure among participants in soccer, ice hockey, volleyball, basketball, judo, or karate. Main outcome measures-Acute sports injuries requiring medical treatment and reported to the insurance company on structured forms by the patients and their doctors. Results-54186 sports injuries were recorded. Injury rates were low in athletes aged under IS, while 20-24 year olds had the highest rates. Differences in injury rates between the sports were minor in this adult age group. Overall injury rates were higher in sports entailing more frequent and powerful body contact. Each sport had a specific injury profile. Fractures and dental injuries were most common in ice hockey and karate and least frequent in volleyball. Knee injuries were the most common cause of permanent disability. Conclusions-Based on the defined injury profiles in the different sports it is recommended that sports specific preventive measures should be employed to decrease the number of violent contacts between athletes, including improved game rules supported by careful refereeing. To prevent dental injuries the wearing of mouth guards should be encouraged, especially in ice hockey, karate, and basketball.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT ORTHOPAED & TRAUMATOL,SF-00260 HELSINKI,FINLAND	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	KUJALA, UM (corresponding author), UNIV HELSINKI,INST BIOMED,SPORTS & EXERCISE MED UNIT,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,SF-00250 HELSINKI,FINLAND.		Kujala, Urho/AAP-2547-2020	Kujala, Urho/0000-0002-9262-1992; Taimela, Simo/0000-0001-6755-2983				BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; BAXTERJONES A, 1993, ARCH DIS CHILD, V68, P130, DOI 10.1136/adc.68.1.130; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; DELOES M, 1990, INT J SPORTS MED, V11, P66, DOI 10.1055/s-2007-1024765; DELOES M, 1988, INT J SPORTS MED, V9, P461, DOI 10.1055/s-2007-1025052; EKSTRAND J, 1983, AM J SPORT MED, V11, P116, DOI 10.1177/036354658301100302; EKSTRAND J, 1983, INT J SPORTS MED, V4, P124, DOI 10.1055/s-2008-1026025; FENTEM P, 1994, BRIT MED J, V308, P1291, DOI 10.1136/bmj.308.6939.1291; HAYES D, 1978, CAN J APPL SPORT SCI, V3, P61; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Johnson R J, 1982, Clin Sports Med, V1, P181; KUJALA UM, 1994, BRIT MED J, V308, P231, DOI 10.1136/bmj.308.6923.231; KUJALA UM, 1988, SPORTS MED, V6, P197, DOI 10.2165/00007256-198806040-00002; KUJALA UM, 1995, INT J SPORTS MED, V16, P122, DOI 10.1055/s-2007-972977; MCLATCHIE GR, 1980, J TRAUMA, V20, P956, DOI 10.1097/00005373-198011000-00009; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SAMA S, 1993, MED SCI SPORTS EXERC, V25, P237; SANDELIN J, 1987, INT J SPORTS MED, V8, P61; SIM FH, 1987, AM J SPORTS MED, V15, P86; TATOR CH, 1991, CAN J SURG, V34, P63; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; WALTER SD, 1985, SPORTS MED, V2, P47, DOI 10.2165/00007256-198502010-00005; WATSON AWS, 1993, AM J SPORT MED, V21, P137, DOI 10.1177/036354659302100123; 1985, SPORTS INJURIES 1976	26	206	215	1	55	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1465	1468		10.1136/bmj.311.7018.1465	http://dx.doi.org/10.1136/bmj.311.7018.1465			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520333	Green Published			2022-12-28	WOS:A1995TJ04400022
J	MALLABIABARRENA, A; MALHOTRA, V				MALLABIABARRENA, A; MALHOTRA, V			VESICLE BIOGENESIS - THE COAT CONNECTION	CELL			English	Review							CLATHRIN				MALLABIABARRENA, A (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; CLEEVES A, 1991, CELL, V64, P789; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; GIMENO RE, 1995, J CELL BIOL, V131, P325, DOI 10.1083/jcb.131.2.325; HAY JC, 1995, NATURE, V374, P172; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Singer S J, 1992, Trends Cell Biol, V2, P69, DOI 10.1016/0962-8924(92)90060-Z; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; WHITNEY JA, 1995, CELL, V83; YEUNG T, 1995, IN PRESS J CELL BIOL	20	19	19	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					667	669		10.1016/0092-8674(95)90177-9	http://dx.doi.org/10.1016/0092-8674(95)90177-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521481	Bronze			2022-12-28	WOS:A1995TH94800001
J	BUCK, LB				BUCK, LB			UNRAVELING CHEMOSENSORY DIVERSITY	CELL			English	Review							NEMATODE CAENORHABDITIS-ELEGANS; OLFACTORY EPITHELIUM; C-ELEGANS; NEURONS; ORGANIZATION; CHEMOTAXIS; EXPRESSION; SYSTEM				BUCK, LB (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WYSOCKI CJ, 1989, NEURAL CONTROL REPRO, P545	17	19	20	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					349	352		10.1016/0092-8674(95)90110-8	http://dx.doi.org/10.1016/0092-8674(95)90110-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521462	Bronze			2022-12-28	WOS:A1995TC97700002
J	MCBLANE, JF; VANGENT, DC; RAMSDEN, DA; ROMEO, C; CUOMO, CA; GELLERT, M; OETTINGER, MA				MCBLANE, JF; VANGENT, DC; RAMSDEN, DA; ROMEO, C; CUOMO, CA; GELLERT, M; OETTINGER, MA			CLEAVAGE AT A V(D)J RECOMBINATION SIGNAL REQUIRES ONLY RAG1 AND RAG2 PROTEINS AND OCCURS IN 2 STEPS	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; BROKEN DNA-MOLECULES; MOUSE THYMOCYTES; STRAND TRANSFER; MECHANISM; REARRANGEMENT; EXPRESSION; GENES; MICE	Formation of double-strand breaks at recombination signal sequences is an early step in V(D)J recombination. Here we show that purified RAG1 and RAGS proteins are sufficient to carry out this reaction. The cleavage reaction can be divided into two distinct steps. First, a nick is introduced at the 5' end of the signal sequence, The other strand is then broken, resulting in a hairpin structure at the coding end and a blunt, 5'-phosphorylated signal end. The hairpin is made as a direct consequence of the cleavage mechanism. Nicking and hairpin formation each require the presence of a signal sequence and both RAG proteins.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	MCBLANE, JF (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Cuomo, Christina/L-2222-2019	Cuomo, Christina/0000-0002-5778-960X; Ramsden, Dale/0000-0003-1575-4748	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Ausubel FM, 1988, MOL REPROD DEV; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; GELLERT M, 1992, ANNU REV GENET, V22, P425; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KALLENBACH S, 1992, RES IMMUNOL, V143, P873, DOI 10.1016/0923-2494(92)80110-7; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDEN DA, 1995, IN PRESS GENES DEV, V9; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	32	560	570	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					387	395		10.1016/0092-8674(95)90116-7	http://dx.doi.org/10.1016/0092-8674(95)90116-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521468	Bronze, Green Submitted			2022-12-28	WOS:A1995TC97700008
J	Bunsey, M; Eichenbaum, H				Bunsey, M; Eichenbaum, H			Conservation of hippocampal memory function in rats and humans	NATURE			English	Article							RHESUS-MONKEYS; ASSOCIATION; SYMMETRY; AMNESIA; LESIONS; PIGEONS	THE hippocampus is critical to declarative memory in humans(1). This kind of memory involves associations among items or events that can be accessed flexibly to guide memory expression in various and even new situations(2-4). In animals, there has been controversy about whether the hippocampus is specialized for spatial memory(5,6) or whether it mediates a general memory function(3,4), as it does in humans. To address this issue we trained normal rats and rats with hippocampal damage on non-spatial stimulus-stimulus associations, then probed the nature of their memory representations. We report here that normal rats demonstrated two forms of flexible memory expression, transitivity, the ability to judge inferentially across stimulus pairs that share a common element, and symmetry, the ability to associate paired elements presented in the reverse of training order. Rats with neurotoxic damage limited to the hippocampus demonstrated neither form of flexible expression, indicating that non-spatial declarative processing depends specifically on the hippocampus in animals as it does in humans.,			Bunsey, M (corresponding author), SUNY STONY BROOK,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794, USA.							BUNSEY M, IN PRESS HIPPOCAMPUS; CHO YH, 1995, BEHAV BRAIN RES, V67, P91, DOI 10.1016/0166-4328(94)00109-S; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DAMATO MR, 1985, J EXP ANAL BEHAV, V44, P35, DOI 10.1901/jeab.1985.44-35; DAVIDSON TL, 1993, BEHAV NEUROSCI, V107, P227, DOI 10.1037/0735-7044.107.2.227; Dickinson A., 1980, CONT ANIMAL LEARNING; DOUGLAS RJ, 1966, NEUROPSYCHOLOGIA, V4, P197, DOI 10.1016/0028-3932(66)90028-5; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; EICHENBAUM H, 1990, J NEUROSCI, V10, P331; GAFFAN D, 1994, EXP BRAIN RES, V99, P411; HUNT ME, 1994, PSYCHOBIOLOGY, V22, P186; James W, 1918, PRINCIPLES PSYCHOL; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; KIMBLE DP, 1968, PSYCHOL BULL, V70, P285, DOI 10.1037/h0026470; MCGONIGLE BO, 1977, NATURE, V267, P694, DOI 10.1038/267694a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moscovitch Morris, 1994, P269; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Musen G., 1993, NEUROPSYCHOLOGY, V7, P119, DOI DOI 10.1037/0894-4105.7.2.119; NADEL L, 1995, HIPPOCAMPUS, V5, P232, DOI 10.1002/hipo.450050309; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; SIDMAN M, 1982, J EXP ANAL BEHAV, V37, P23, DOI 10.1901/jeab.1982.37-23; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TERRACE HS, 1993, PSYCHOL SCI, V4, P162, DOI 10.1111/j.1467-9280.1993.tb00481.x; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WEISKRANTZ L, 1975, HIPPOCAMPUS, V2, P411; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1995, HIPPOCAMPUS, V5, P235, DOI 10.1002/hipo.450050310; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	33	470	479	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					255	257		10.1038/379255a0	http://dx.doi.org/10.1038/379255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ169	8538790				2022-12-28	WOS:A1996TQ16900046
J	Mukhin, LM; Koscheev, AP; Dikov, YP; Huth, J; Wanke, H				Mukhin, LM; Koscheev, AP; Dikov, YP; Huth, J; Wanke, H			Experimental simulations of the photodecomposition of carbonates and sulphates on Mars	NATURE			English	Article							MARTIAN ATMOSPHERE	THERE is indirect spectroscopic evidence for the presence of sulphates and carbonates on the martian surface(1-5), and such minerals are also found in SNC meteorites(6), which are thought to be of martian origin. But although carbonates are expected to be abundant in the martian regolith(7-9), attempts to detect them directly have been unsuccessful(10,11). Here we report laboratory studies of the decomposition of calcium carbonate and magnesium sulphate under ultraviolet irradiation, which mimic the conditions under which photodecomposition of surface minerals by solar ultraviolet light might occur on Mars. We find that, even for a low abundance(6) of carbonate minerals in the martian regolith, the rate of CO2 release due to photodecomposition is higher than the rate of CO2 loss from the atmosphere by solar-wind-induced sputtering processes(12-15), making this profess a potential net source of atmospheric CO2 over time. SO2 is also released from the sulphate, albeit more slowly. The rate of carbonate degradation is high enough to explain the apparent absence of these compounds at the martian surface.	INST SPACE RES,MOSCOW,RUSSIA; KARPOV INST PHYS CHEM,ACT PARTICLE ABSORPT LAB,MOSCOW 103064,RUSSIA; RUSSIAN ACAD SCI,INST ORE DEPOSIT PETROG MINERAL & GEOCHEM,MOSCOW 109017,RUSSIA; MAX PLANCK INST CHEM,ABT KOSMOCHEM,D-55122 MAINZ,GERMANY	Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences; Karpov Institute of Physical Chemistry; Russian Academy of Sciences; Max Planck Society	Mukhin, LM (corresponding author), EMBASSY RUSSIAN FEDERAT,2650 WISCONSIN AVE NW,WASHINGTON,DC 20007, USA.							BANIN A., 2000, MARS, P594; BELL JF, 1994, ICARUS, V111, P106, DOI 10.1006/icar.1994.1136; BIERMANN K, 1977, J GEOPHYS RES, V82, P4641; BLANEY DL, 1989, J GEOPHYS RES-SOLID, V94, P10159, DOI 10.1029/JB094iB08p10159; BLANEY DL, 1995, J GEOPHYS RES-PLANET, V100, P14433, DOI 10.1029/95JE00224; CALVIN WM, 1994, J GEOPHYS RES-PLANET, V99, P14659, DOI 10.1029/94JE01090; CLARK BC, 1981, ICARUS, V45, P370, DOI 10.1016/0019-1035(81)90041-5; Fanale F.P., 1992, MARS, P1135; GOODING JL, 1991, METEORITICS, V26, P135, DOI 10.1111/j.1945-5100.1991.tb01029.x; GREELEY R, 1982, J GEOPHYS RES, V87, P9, DOI 10.1029/JB087iB12p10009; Greeley R., 1992, MARS, P730; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; MOUNT GH, 1983, J GEOPHYS RES-OCEANS, V88, P5403, DOI 10.1029/JC088iC09p05403; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; WEBER MJ, 1986, HDB LASER SCI TECHNO, V4, P224; [No title captured]	23	38	38	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					141	143		10.1038/379141a0	http://dx.doi.org/10.1038/379141a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538763				2022-12-28	WOS:A1996TP36000050
J	Roelke, M; Parsonnet, V				Roelke, M; Parsonnet, V			Fracture of a retentin wire in an atrial J pacemaker lead	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Roelke, M (corresponding author), BETH ISRAEL MED CTR,NEWARK,NJ 07112, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					88	88		10.1056/NEJM199601113340205	http://dx.doi.org/10.1056/NEJM199601113340205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531964				2022-12-28	WOS:A1996TP36300005
J	Mahon, FX; Faberes, C; Reiffers, J				Mahon, FX; Faberes, C; Reiffers, J			Response to IFN alpha in myelogenous leukaemia	LANCET			English	Letter									CHU BORDEAUX,SERV MALAD SANG,HOP HAUT LEVEQUE,F-33604 PESSAC,FRANCE	CHU Bordeaux								HOROWITZ MM, 1992, BLOOD, V79, P2771; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KUMA, 1995, LANCET          1014, P984; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; OHNISHI K, 1995, BLOOD, V86, P906	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1996	347	8993					57	58		10.1016/S0140-6736(96)91588-3	http://dx.doi.org/10.1016/S0140-6736(96)91588-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531561				2022-12-28	WOS:A1996TN76200044
J	FERMULLER, C; ALOIMONOS, Y				FERMULLER, C; ALOIMONOS, Y			DIRECT PERCEPTION OF 3-DIMENSIONAL MOTION FROM PATTERNS OF VISUAL-MOTION	SCIENCE			English	Article							OPTIC FLOW; FIELD	Measurements of retinal motion along a set of predetermined orientations on the retina of a moving system give rise to global patterns. Because the form and location of these patterns depend purely on three-dimensional (3D) motion, the effects of 3D motion and scene structure on image motion can be globally separated. The patterns are founded on easily derivable image measurements that depend only on the sign of image motion and do not require information about optical flow. The computational theory presented here explains how the self-motion of a system can be estimated by locating these patterns.	UNIV MARYLAND,CTR AUTOMAT RES,DEPT COMP SCI,COMP VIS LAB,COLLEGE PK,MD 20742; UNIV MARYLAND,INST ADV COMP STUDIES,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park			Aloimonos, Yiannis/AAI-2969-2020	Aloimonos, Yiannis/0000-0002-8152-4281				Aloimonos J., 1984, Proceedings of the Workshop on Computer Vision: Representation and Control, P72; ALOIMONOS Y, 1991, SCIENCE, V253, P1181; ALOIMONOS Y, 1993, INTEGRATION VISUAL M; ANCONA N, 1995, INT J COMPUT VISION, V14, P131, DOI 10.1007/BF01418979; BRODSKY T, 1995, CARTR780 U MAR CTR A; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; FAUGERAS OD, 1990, INT J COMPUT VISION, V4, P225, DOI 10.1007/BF00054997; FERMULLER C, 1995, INT J COMPUT VISION, V15, P7, DOI 10.1007/BF01450848; FERMULLER C, 1993, INT J COMPUT VISION, V11, P165, DOI 10.1007/BF01469227; FERMULLER C, 1993, ACTIVE PERCEPTION, P103; FERMULLER C, IN PRESS VISUAL NAVI; FERMULLER C, 1994, CARTR732 U MAR CTR A; FERMULLER C, 1995, INT J COMPUT VISION, V114, P147; Gibson J.J., 1986, ECOLOGICAL APPROACH; Horn B. K. P., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3), P2; KOENDERINK JJ, 1986, VISION RES, V26, P161, DOI 10.1016/0042-6989(86)90078-7; LONGUETHIGGINS HC, 1984, P ROY SOC LOND B BIO, V208, P385; NELSON RC, 1989, IEEE T PATTERN ANAL, V11, P1102, DOI 10.1109/34.42840; POGGIO T, 1973, KYBERNETIK, V13, P223, DOI 10.1007/BF00274887; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; Reichardt W., 1961, S PRINC SENS COMM, P303; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; TSAI RY, 1984, IEEE T PATTERN ANAL, V6, P13, DOI 10.1109/TPAMI.1984.4767471; Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VERRI A, 1989, IEEE T PATTERN ANAL, V11, P490, DOI 10.1109/34.24781	27	52	54	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1973	1976		10.1126/science.270.5244.1973	http://dx.doi.org/10.1126/science.270.5244.1973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533087				2022-12-28	WOS:A1995TL42000036
J	QUELLE, DE; ZINDY, F; ASHMUN, RA; SHERR, CJ				QUELLE, DE; ZINDY, F; ASHMUN, RA; SHERR, CJ			ALTERNATIVE READING FRAMES OF THE INK4A TUMOR-SUPPRESSOR GENE ENCODE 2 UNRELATED PROTEINS CAPABLE OF INDUCING CELL-CYCLE ARREST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHASE; DNA	The INK4a (MTS1, CDKN2) gene encodes an inhibitor (p16(INK4a)) Of the cyclin D-dependent kinases CDK4 and CDK6 that blocks them from phosphorylating the retinoblastoma protein (pRB) and prevents exit from the G1 phase of the cell cycle. Deletions and mutations involving INK4a occur frequently in cancers, implying that p16(INK4a), like pRB, suppresses tumor formation. An unrelated protein (p19(ARF)) arises in major part from an alternative reading frame of the mouse INK4a gene, and its ectopic expression in the nucleus of rodent fibroblasts induces G1 and G2 phase arrest. Economical reutilization of coding sequences in this manner is practically without precedent in mammalian genomes, and the unitary inheritance of p16(INK4a) and p19(ARF) may underlie their dual requirement in cell cycle control.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES S, 1994, ONCOGENE, V9, P1633; BOLES E, 1994, MOL GEN GENET, V243, P363, DOI 10.1007/BF00280465; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; LAMB RA, 1991, TRENDS GENET, V7, P261, DOI 10.1016/0168-9525(91)90162-J; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STONE S, 1995, CANCER RES, V55, P2988; TAM SW, 1994, ONCOGENE, V9, P2663; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHANG SY, 1994, CANCER RES, V54, P5050	49	1254	1290	1	36	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 15	1995	83	6					993	1000						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521522				2022-12-28	WOS:A1995TK74500017
J	GREWAL, IS; XU, JC; FLAVELL, RA				GREWAL, IS; XU, JC; FLAVELL, RA			IMPAIRMENT OF ANTIGEN-SPECIFIC T-CELL PRIMING IN MICE LACKING CD40 LIGAND	NATURE			English	Article							HYPER-IGM SYNDROME	LACK of functional expression of CD40 ligand (CD40L) on T cells results in hyper-IgM syndrome (HIGM1), a human immunodeficiency associated with a severely impaired humoral immune response that is consistent with defects in B-cell responses(1-3). Patients also succumb to recurrent opportunistic infections such as Pneumocystis carinii and a Cryptosporidial diarrhoea(4,5), suggesting that T-cell functions are also compromised in these individuals, but so far this has not been explained. We have previously shown that mice deficient for CD40L, like HIGM1 patients, show grossly abnormal humoral responses(6). Here we report that CD40L-deficient mice are defective in antigen-specific T-cell responses, Adoptively transferred antigen-specific CD4(+) T cells lacking CD40L failed to expand upon antigen challenge of the recipients, showing that expression of CD40L on T cells is required for in vivo priming of CD4(+) T cells and therefore for the initiation of specific T-cell immune responses.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Yale University	GREWAL, IS (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.			Grewal, Iqbal S/0000-0002-4775-055X				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; CONSTANT S, 1995, J IMMUNOL, V154, P4915; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; EPSTEIN MM, 1995, J EXP MED, V182, P915, DOI 10.1084/jem.182.4.915; FOY M, 1995, EUR J IMMUNOL, V25, P596; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; KEAMEY ER, 1994, IMMUNITY, V1, P327; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WU Y, 1995, CURR BIOL, V5, P1303, DOI 10.1016/S0960-9822(95)00257-0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	16	438	446	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					617	620		10.1038/378617a0	http://dx.doi.org/10.1038/378617a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524395				2022-12-28	WOS:A1995TJ22100077
J	BENDER, J; FINK, GR				BENDER, J; FINK, GR			EPIGENETIC CONTROL OF AN ENDOGENOUS GENE FAMILY IS REVEALED BY A NOVEL BLUE FLUORESCENT MUTANT OF ARABIDOPSIS	CELL			English	Article							AUXIN POLAR TRANSPORT; ASCOBOLUS-IMMERSUS; METHYLATION; THALIANA; LOCUS; MECHANISMS; EXPRESSION; NEUROSPORA; MUTATIONS; SEQUENCES	The Wassilewskija strain of Arabidopsis has four genes encoding the tryptophan enzyme phosphoribosylanthranilate isomerase (PAI) located at three unlinked sites, These four PAI genes are methylated over their regions of DNA homology, When PAI copy number is reduced by deletion of two tandemly arrayed genes (MePAI1-PAI4), a mutant with fluorescent, tryptophan-deficient phenotypes results, because the two remaining methylated PAI genes (MePAI2 and MePAI3) supply insufficient PAI activity, These two methylated genes can be inherited through meiosis, even when they are segregated away from each other in crosses to a strain with unmethylated PAI genes, However, the mutant phenotypes conferred by the methylated PAI genes are unstable, and mutant plants yield occasional revertant somatic sectors and progeny. Revertant lines display coordinately reduced methylation of both PAI2 and PAI3, implying that this hypomethylation acts in a concerted manner across the genome rather than at individual sites.	MIT, CAMBRIDGE, MA 02142 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Massachusetts Institute of Technology (MIT); Johns Hopkins University	BENDER, J (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.							ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Ausubel FM, 1988, MOL REPROD DEV; BANKS JA, 1988, GENE DEV, V2, P1364, DOI 10.1101/gad.2.11.1364; BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; BRUTNELL TP, 1994, GENETICS, V138, P213; DEHIO C, 1994, P NATL ACAD SCI USA, V91, P5538, DOI 10.1073/pnas.91.12.5538; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ERRAMPALLI D, 1991, PLANT CELL, V3, P149, DOI 10.1105/tpc.3.2.149; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HENIKOFF S, 1994, CELL, V77, P993; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; KILBY NJ, 1992, PLANT MOL BIOL, V20, P103, DOI 10.1007/BF00029153; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI JY, 1995, PLANT CELL, V7, P447, DOI 10.1105/tpc.7.4.447; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; MARTIENSSEN R, 1994, GENETICS, V136, P1157; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; PETERSON K, 1993, ANNU REV GENET, V27, P7, DOI 10.1146/annurev.ge.27.120193.000255; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; ROSE AB, 1992, PLANT PHYSIOL, V100, P582, DOI 10.1104/pp.100.2.582; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; STINARD PS, 1993, PLANT CELL, V5, P1555, DOI 10.1105/tpc.5.11.1555; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8	39	186	195	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					725	734		10.1016/0092-8674(95)90185-X	http://dx.doi.org/10.1016/0092-8674(95)90185-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521489	hybrid			2022-12-28	WOS:A1995TH94800009
J	BOOTMAN, MD; BERRIDGE, MJ				BOOTMAN, MD; BERRIDGE, MJ			THE ELEMENTAL PRINCIPLES OF CALCIUM SIGNALING	CELL			English	Review							INOSITOL TRISPHOSPHATE; MUSCLE; CURRENTS; RELEASE; CELLS				BOOTMAN, MD (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,BABRAHAM INST LAB MOLEC SIGNALLING,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, RYANODINE RECEPTORS, P119; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HARDIE RC, 1995, CELL CALCIUM, V16, P256; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MARRION NV, 1992, J PHYSIOL-LONDON, V445, P515, DOI 10.1113/jphysiol.1992.sp018937; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; SILVER RB, 1994, BIOL BULL-US, V187, P237, DOI 10.1086/BBLv187n2p237; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SUGIMORI M, 1994, BIOL BULL-US, V187, P300, DOI 10.2307/1542286; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; ZHOLOS AV, 1994, J PHYSIOL-LONDON, V481, P97, DOI 10.1113/jphysiol.1994.sp020421	25	388	394	2	21	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					675	678		10.1016/0092-8674(95)90179-5	http://dx.doi.org/10.1016/0092-8674(95)90179-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521483	Bronze			2022-12-28	WOS:A1995TH94800003
J	CHEN, JW; GALL, MA; DECKERT, M; JENSEN, JS; PARVING, HH				CHEN, JW; GALL, MA; DECKERT, M; JENSEN, JS; PARVING, HH			INCREASED SERUM CONCENTRATION OF VON-WILLEBRAND-FACTOR IN NON-INSULIN-DEPENDENT DIABETIC-PATIENTS WITH AND WITHOUT DIABETIC NEPHROPATHY	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; DISEASE		STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; UNIV COPENHAGEN,RIGSHOSP,COPENHAGEN CITY HEART STUDY,DK-2200 COPENHAGEN,DENMARK	Steno Diabetes Center; Rigshospitalet; University of Copenhagen								GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; JENSEN T, 1989, BRIT MED J, V298, P27, DOI 10.1136/bmj.298.6665.27-a; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003	5	39	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1405	1406		10.1136/bmj.311.7017.1405	http://dx.doi.org/10.1136/bmj.311.7017.1405			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520276	Green Published			2022-12-28	WOS:A1995TG90200022
J	ALVIR, JMJ; LIEBERMAN, JA; SAFFERMAN, AZ; SCHWIMMER, JL; SCHAAF, JA				ALVIR, JMJ; LIEBERMAN, JA; SAFFERMAN, AZ; SCHWIMMER, JL; SCHAAF, JA			CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHLORPROMAZINE; SCHIZOPHRENIA; DRUGS	Background. Clozapine is an atypical antipsychotic agent that is more effective than standard neuroleptic drugs in the treatment of patients with refractory schizophrenia. Unlike classic neuroleptic agents, clozapine is not associated with the development of acute extrapyramidal symptoms or tardive dyskinesia. The main factor limiting its use is the risk of potentially fatal agranulocytosis, estimated to occur in 1 to 2 percent of treated patients. After clozapine was approved by the Food and Drug Administration, it became available for marketing in the United States in February 1990 only as part of a special surveillance system (the Clozaril Patient Management System, or CPMS), in which a weekly white-cell count was required for the patient to receive a supply of the drug. Methods. We evaluated the CPMS data for February 1990 through April 1991 by survival analysis to determine the incidence of agranulocytosis and the effects of potential risk factors such as age and sex. Data were available for 11,555 patients who received clozapine during the period after marketing began. Results. Agranulocytosis developed in 73 patients, resulting in death from infectious complications in 2 patients. Episodes of agranulocytosis occurred in 61 patients within three months after they began treatment. The cumulative incidence of this side effect was 0.80 percent (95 percent confidence interval, 0.61 to 0.99) at 1 year and 0.91 percent (95 percent confidence interval, 0.62 to 1.20) at 1 1/2 years. The risk of agranulocytosis increased with age and was higher among women. Conclusions. The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count. The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PSYCHIAT,BRONX,NY 10461; SANDOZ PHARMACEUT CORP,E HANOVER,NJ	Yeshiva University; Albert Einstein College of Medicine; Novartis; Sandoz	ALVIR, JMJ (corresponding author), LONG ISL JEWISH MED CTR,HILLSIDE HOSP,DEPT PSYCHIAT,75-59 263RD ST,GLEN OAKS,NY 11004, USA.				NIMH NIH HHS [MH-41960, MH-00537] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH041960, P30MH041960] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMSLER HA, 1977, ACTA PSYCHIAT SCAND, V56, P241, DOI 10.1111/j.1600-0447.1977.tb00224.x; ANDERMAN B, 1977, EUR J CLIN PHARMACOL, V11, P199, DOI 10.1007/BF00606410; BARNAS C, 1992, J CLIN PSYCHIAT, V53, P245; BASTANI B, 1989, PSYCHOPHARMACOLOGY, V99, pS122, DOI 10.1007/BF00442576; BURKI HR, 1975, PHARMAKOPSYCH NEURO, V8, P115; CHIODO LA, 1983, J NEUROSCI, V3, P1067; de la Chapelle A, 1977, Hum Genet, V37, P183; FLEMING TR, 1991, COUNTING PROCESSES S; GERSON SL, 1992, LANCET, V340, P1097, DOI 10.1016/0140-6736(92)93116-5; GERSON SL, 1991, LANCET, V338, P262, DOI 10.1016/0140-6736(91)90410-Q; GRIFFITH RW, 1975, LANCET, V2, P657; HIPPIUS H, 1958, Arztl Wochensch, V13, P501; IDANPAANHEIKKILA J, 1975, LANCET, V2, P611; IDANPAANHEIKKILA J, 1977, EUR J CLIN PHARMACOL, V11, P193, DOI 10.1007/BF00606409; JUNGI WF, 1977, SCHWEIZ MED WSCHR, V107, P1861; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1981, PSYCHOPHARMACOLOGY, V73, P184, DOI 10.1007/BF00429215; LIEBERMAN J, 1986, CLIN NEUROPHARMACOL, V9, P140; LIEBERMAN JA, 1988, J CLIN PSYCHIAT, V49, P271; LIEBERMAN JA, 1990, ARCH GEN PSYCHIAT, V47, P945; LIEBERMAN JA, 1989, PSYCHOPHARMACOL BULL, V25, P57; Lieberman Jeffrey A., 1992, Psychiatric Quarterly (New York), V63, P51, DOI 10.1007/BF01064682; LJUNGBERG T, 1978, PSYCHOPHARMACOLOGY, V56, P239, DOI 10.1007/BF00432845; PISCIOTTA AV, 1992, J LAB CLIN MED, V119, P254; PISCIOTTA AV, 1969, J AMER MED ASSOC, V208, P1862, DOI 10.1001/jama.208.10.1862; Pisciotta AV, 1990, J CLIN PSYCHIATRY MO, V8, P22; SAYERS AC, 1975, PSYCHOPHARMACOLOGIA, V41, P97, DOI 10.1007/BF00421063; Schmutz J., 1982, CHRONICLES DRUG DISC, V1, P39; WEIDE R, 1992, BRIT J HAEMATOL, V80, P557, DOI 10.1111/j.1365-2141.1992.tb04574.x; 1991, SAS STAT SOFTWARE PH; 1989, SAS STAT USERS GUIDE, V2, P1027; 1989, CLOZARIL CLOZAPINE A	32	759	780	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					162	167		10.1056/NEJM199307153290303	http://dx.doi.org/10.1056/NEJM199307153290303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL460	8515788				2022-12-28	WOS:A1993LL46000003
J	BARONDESS, JA				BARONDESS, JA			THE FUTURE OF GENERALISM	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INTERNAL-MEDICINE; CARE; PHYSICIANS; SUBSPECIALISTS; PERSPECTIVE; POPULATION				BARONDESS, JA (corresponding author), NEW YORK ACAD MED, 2 E 103RD ST, NEW YORK, NY 10029 USA.							ANDERSEN RM, 1992, ANN INTERN MED, V117, P243, DOI 10.7326/0003-4819-117-3-243; BARONDESS JA, 1982, AM J MED, V73, P735, DOI 10.1016/0002-9343(82)90417-X; BERENSON R, 1992, JAMA-J AM MED ASSOC, V267, P687, DOI 10.1001/jama.267.5.687; BERENSON RA, 1992, NATIONAL PRIMARY CAR, P216; Boyer EL, 1990, SCHOLARSHIP RECONSID; BRAUNWALD E, 1991, ANN INTERN MED, V114, P76, DOI 10.7326/0003-4819-114-1-76; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; BROOK RH, 1991, ANN INTERN MED, V115, P486, DOI 10.7326/0003-4819-115-6-486; EBERT RH, 1993, TAKING CHARGE GRADUA; GLICKMAN R, 1992, ANN INTERN MED, V117, P259, DOI 10.7326/0003-4819-117-3-259; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; KARPF M, 1992, ANN INTERN MED, V116, P514, DOI 10.7326/0003-4819-116-6-514; KLETKE PR, 1987, ANN INTERN MED, V107, P93, DOI 10.7326/0003-4819-107-1-93; LEE P, 1992, NATIONAL PRIMARY CAR, P52; LEVEY GS, 1992, ANN INTERN MED, V116, P1046, DOI 10.7326/0003-4819-116-12-1046; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MURRAY FE, 1992, NATIONAL PRIMARY CAR, P213; NOLAN JP, 1992, ANN INTERN MED, V116, P1042, DOI 10.7326/0003-4819-116-12-1042; NUCKOLLS JG, 1992, ANN INTERN MED, V116, P1051, DOI 10.7326/0003-4819-116-12-1051; PETERSDORF RG, 1993, TAKING CHARGE GRADUA; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; SCHERR L, 1993, TAKING CHARGE GRADUA; SCHROEDER SA, 1992, NATIONAL PRIMARY CAR, P172; STARFIELD B, 1992, NATIONAL PRIMARY CAR, P24; STEIN JH, 1991, ANN INTERN MED, V114, P79, DOI 10.7326/0003-4819-114-1-79; VANSELOW NA, 1993, TAKING CHARGE GRADUA; WARING JP, 1991, J GEN INTERN MED, V6, P436, DOI 10.1007/BF02598166; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; WOODWELL DA, 1992, ADV DATA, V209, P1; 1978, MANPOWER POLICY PRIM; 1991, SURVEY HOUSE STAFF S, P67; 1993, TAKING CHARGE GRADUA; 1992, PHYSICIAN PAYMENT RE; 1966, GRADUATE ED PHYSICIA	36	50	50	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					153	160		10.7326/0003-4819-119-2-199307150-00010	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512164				2022-12-28	WOS:A1993LU90200010
J	ERARD, F; WILD, MT; GARCIASANZ, JA; LEGROS, G				ERARD, F; WILD, MT; GARCIASANZ, JA; LEGROS, G			SWITCH OF CD8 T-CELLS TO NONCYTOLYTIC CD8-CD4- CELLS THAT MAKE T(H)2 CYTOKINES AND HELP B-CELLS	SCIENCE			English	Article							INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTES; LEISHMANIASIS; GENERATION; PROFILES; INVITRO; SUBSETS; INVIVO; CLONES	CD8+ T cells are a major defense against viral infections and intracellular parasites. Their production of interferon-gamma (IFN-gamma) and their cytolytic activity are key elements in the immune response to these pathogens. Mature mouse CD8+ T cells that were activated in the presence of interleukin-4 (IL-4) developed into a CD8-CD4- population that was not cytolytic and did not produce IFN-gamma. However, these CD8- cells produced large amounts of IL-4, IL-5, and IL-10 and helped activate resting B cells. Thus, CD8 effector functions are potentially diverse and could be exploited by infectious agents that switch off host protective cytolytic responses.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		ERARD, F (corresponding author), CIBA GEIGY AG,DIV PHARMACEUT RES,DEPT ALLERGY IMMUNOL,CH-4002 BASEL,SWITZERLAND.		Le Gros, Graham/C-6725-2011; Garcia-Sanz, Jose A/E-7684-2011; Garcia-Sanz, Jose A./AAA-2956-2019	Garcia-Sanz, Jose A/0000-0002-1153-6025; Garcia-Sanz, Jose A./0000-0002-1153-6025; Le Gros, Graham/0000-0002-5721-0442				ABRAHAM VS, 1992, J IMMUNOL, V148, P3746; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; ERARD F, 1985, J EXP MED, V162, P1738, DOI 10.1084/jem.162.5.1738; ERARD F, 1985, J IMMUNOL, V134, P1644; GARCIASANZ JA, IN PRESS EUR J IMMUN; GEUERNE PA, 1983, J IMMUNOL, V130, P2225; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; KELSO A, 1984, J IMMUNOL, V132, P2924; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MARGOLICK JB, 1989, CLIN IMMUNOL IMMUNOP, V51, P348, DOI 10.1016/0090-1229(89)90033-0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; OWENS T, 1988, EUR J IMMUNOL, V18, P395, DOI 10.1002/eji.1830180312; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SHEARER GM, 1992, CHEM IMMUNOL, V54, P21; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TITUS RG, 1987, EUR J IMMUNOL, V17, P1429, DOI 10.1002/eji.1830171007; WHITE J, 1989, J IMMUNOL, V143, P1822; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	25	350	355	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1802	1805		10.1126/science.8511588	http://dx.doi.org/10.1126/science.8511588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511588				2022-12-28	WOS:A1993LH20500049
J	NADA, S; YAGI, T; TAKEDA, H; TOKUNAGA, T; NAKAGAWA, H; IKAWA, Y; OKADA, M; AIZAWA, S				NADA, S; YAGI, T; TAKEDA, H; TOKUNAGA, T; NAKAGAWA, H; IKAWA, Y; OKADA, M; AIZAWA, S			CONSTITUTIVE ACTIVATION OF SRC FAMILY KINASES IN MOUSE EMBRYOS THAT LACK CSK	CELL			English	Article							PROTEIN-TYROSINE KINASE; MONOCLONAL-ANTIBODIES; CARBOXY TERMINUS; PP60C-SRC; PHOSPHORYLATION; BINDING; CELLS; P60C-SRC; GENE; RNA	Csk is a novel cytoplasmic protein-tyrosine kinase that has been shown to inactivate members of the Src family of protein-tyrosine kinases in vitro. To examine the function of Csk in vivo, Csk-deficient mouse embryos were generated by gene targeting in embryonic stem cells. These embryos were developmentally arrested at the 10 to 12 somite stage and exhibited growth retardation and necrosis in the neural tissues. The kinase activity of p60c-src, p59fyn, and p53/56lyn in these embryos was greatly enhanced as an apparent consequence of enhanced specific activity. The increase in kinase activity was associated with an increase in tyrosine phosphorylation of several proteins, especially those around 85 and 120 kd. Thus, these results suggest that Csk indeed acts as an indispensable negative regulator of Src family kinases in vivo.	INST PHYS & CHEM RES,TSUKKUBA LIFE SCI CTR,GENE TECHNOL & SAFETY LAB,WAKO,SAITAMA 351,JAPAN; OSAKA UNIV,INST PROT RES,OSAKA,JAPAN	RIKEN; Osaka University	NADA, S (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,WAKO,SAITAMA 351,JAPAN.							AKEDA H, 1992, DIFFERENTIATION, V51, P121; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1989, ONCOGENE, V4, P295; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1993, ONCOGENE, V8, P117; MAEKAWA T, 1991, ONCOGENE, V6, P627; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKANO H, 1991, J NEUROCHEM, V56, P560, DOI 10.1111/j.1471-4159.1991.tb08186.x; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RUGH R, 1990, MOUSE ITS REPRODUCTI, P102; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; THEILERK, 1989, HOUSE MOUSE, P21; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	53	380	386	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1125	1135		10.1016/0092-8674(93)90642-4	http://dx.doi.org/10.1016/0092-8674(93)90642-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513497				2022-12-28	WOS:A1993LH54800009
J	JOHNSON, Z; HOWELL, F; MOLLOY, B				JOHNSON, Z; HOWELL, F; MOLLOY, B			COMMUNITY MOTHERS PROGRAM - RANDOMIZED CONTROLLED TRIAL OF NONPROFESSIONAL INTERVENTION IN PARENTING	BRITISH MEDICAL JOURNAL			English	Article								Objective-To see whether non-professional volunteer community mothers could deliver a child development programme to disadvantaged first time mothers for children aged up to 1 year. Design-Randomised controlled trial. Setting-A regional health authority in Dublin. Subjects-262 first time mothers who were delivered during six months in 1989 and who lived in a deprived area of Dublin; 30 experienced mothers from the same community recruited as community mothers. Interventions-All the first time mothers received standard support from the public health nurse. In addition, those in the intervention group received the services of a community mother, who was scheduled to visit monthly during the first year of the chlld's life. Results-232 (89%) first time mothers completed the study-127 in the intervention group, 105 controls. At the end of the study children in the intervention group were more likely to have received all of their primary immunisations, to be read to, and to be read to daily, played more cognitive games; and were exposed to more nursery rhymes. They were less likely to begin cows' milk before 26 weeks and to receive an inappropriate energy intake and in-appropriate amounts of animal protein, non-animal protein, wholefoods, vegetables, fruit, and milk. Mothers in the intervention group also had a better diet than controls. At the end of the study they were less likely to be tired, feel miserable, and want to stay indoors; had more positive feelings; and were less likely to display negative feelings. Conclusion-Non-professionals can deliver a health promotion programme on child development effectively. Whether they can do so as effectively as professionals requires further study.			JOHNSON, Z (corresponding author), DR STEEVENS HOSP,HLTH INFORMAT UNIT,EASTERN HLTH BOARD,COMMUNITY MOTHERS PROGRAMME,DUBLIN 8,IRELAND.							Barker W, 1990, Nurs Stand, V4, P43; BARKER W, 1987, 8 U BRIST EARL CHILD; Barker W, 1984, CHILD DEV PROGRAMME; BARKER W, 1987, 11 U BRIST CHILDH DE; BESHAROV DJ, 1987, PEDIATRICS, V79, P440; KOTELCHUCK M, 1987, PEDIATRICS, V79, P441; Percy P, 1986, Midwife Health Visit Community Nurse, V22, P235; 1985, TARGETS HLTH ALL; 1983, RECOMMENDED DIETARY	9	135	135	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1449	1452		10.1136/bmj.306.6890.1449	http://dx.doi.org/10.1136/bmj.306.6890.1449			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE935	8518642	Bronze, Green Published			2022-12-28	WOS:A1993LE93500019
J	MCMANUS, IC; VINCENT, CA; THOM, S; KIDD, J				MCMANUS, IC; VINCENT, CA; THOM, S; KIDD, J			HOW-TO-DO-IT - TEACHING COMMUNICATION-SKILLS TO CLINICAL STUDENTS	BRITISH MEDICAL JOURNAL			English	Article							INTERVIEWING SKILLS; MEDICAL-STUDENTS; SCHOOLS; TAUGHT	Seven years' experience in teaching communication skills to first year clinical students at St Mary's Hospital School of Medicine is described. The first component consists of a day during the introductory clinical course; this is divided into a lecture and small seminar groups and involves behavioural scientists and clinicians from many departments. The second component uses simulated patients and video feedback and takes place in small groups later in the year. Participation of the students through active critical discussion, role play, and interactive video feedback are important aspects in the success of the course. The methods have been refined through evaluation by students and tutors. This article aims to allow others, already running or considering such a course, to develop effective courses within the practical constraints of their own institutions.			MCMANUS, IC (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,LONDON W2 1PG,ENGLAND.		Vincent, Charles A/D-1134-2010	Vincent, Charles A/0000-0003-0270-0222; McManus, Ian/0000-0003-3510-4814				ALROY G, 1984, MED EDUC, V18, P85, DOI 10.1111/j.1365-2923.1984.tb00978.x; ENNIS M, 1990, BRIT MED J, V300, P1365, DOI 10.1136/bmj.300.6736.1365; EVANS BJ, 1991, MED EDUC, V25, P517, DOI 10.1111/j.1365-2923.1991.tb00105.x; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HARDEN RM, 1979, MED EDUC, V13, P41; HELFER RE, 1970, PEDIATRICS, V45, P623; KERR DNS, 1986, J ROY SOC MED, V79, P575, DOI 10.1177/014107688607901005; Ley P, 1989, HLTH PSYCHOL PROCESS, P74, DOI [10.1007/978-1-4899-3228-0_5, DOI 10.1007/978-1-4899-3228-0_5]; MAGUIRE GP, 1976, DEV EVALUATION TRAIN, P45; MAGUIRE P, 1990, BRIT J HOSP MED, V43, P215; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; MOSS F, 1992, MED EDUC, V26, P17, DOI 10.1111/j.1365-2923.1992.tb00116.x; MUMFORD E, 1971, INTERNS STUDENTS PHY; NOVACK D, 1989, PATIENT CENTRED INTE; POOLE AD, 1979, SOC SCI MED-MED SOC, VA13, P37, DOI 10.1016/0271-7123(79)90006-3; PREVEN DW, 1986, J MED EDUC, V61, P842; RICHARDS T, 1990, BRIT MED J, V301, P1407, DOI 10.1136/bmj.301.6766.1407; SANSONFISHER R, 1980, LANCET, V2, P523; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; VANDALEN J, 1989, MED EDUC, V23, P55; VINCENT CA, 1992, AUDIT ACCOUNTABILITY, P219; WAKEFORD R, 1983, DOCTOR PATIENT COMMU, P233; WEINMAN J, 1984, MED EDUC, V18, P164, DOI 10.1111/j.1365-2923.1984.tb00998.x; WHITEHOUSE CR, 1991, MED EDUC, V25, P311, DOI 10.1111/j.1365-2923.1991.tb00072.x; 1987, RECOMMENDATIONS GENE; 1987, REPORT WORKING PARTY; 1986, BMJ, V292, P768; 1992, COMPETENCE PREREGIST; 1992, COMMENTARY 2ND SURVE	29	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1322	1327		10.1136/bmj.306.6888.1322	http://dx.doi.org/10.1136/bmj.306.6888.1322			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518575	Green Published, Bronze			2022-12-28	WOS:A1993LC72200029
